



HAL
open science

Evaluation multi-échelle de toxines de venins comme agents antinociceptifs potentiels

Tânia C. Gonçalves

► **To cite this version:**

Tânia C. Gonçalves. Evaluation multi-échelle de toxines de venins comme agents antinociceptifs potentiels. Pharmacologie. Université Paris-Saclay, 2018. Français. NNT : 2018SACLS587. tel-04462483

HAL Id: tel-04462483

<https://hal.science/tel-04462483>

Submitted on 16 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Evaluation multi-échelle de toxines de venins comme agents antinociceptifs potentiels

Thèse de doctorat de l'Université Paris-Saclay
préparée à l'Université Paris-Sud

École doctorale n°569
Innovation thérapeutique : du fondamental à l'appliqué (ITFA)
Spécialité de doctorat: Sciences pharmacologiques

Thèse présentée et soutenue à Gif-sur-Yvette, le 19 décembre 2018, par

Tânia Cristina Gonçalves

Composition du Jury :

Hervé Daniel Professeur, Université Paris-Sud (Neuro-PSI)	Président
Eric Lingueglia Directeur de recherche, Université Côte d'Azur (IPMC)	Rapporteur
Christian Legros Professeur, Université d'Angers (Institut MITOVASC)	Rapporteur
Michel De Waard Directeur de recherche, Université de Nantes (Institut du thorax)	Examineur
Evelyne Benoit Chargée de recherche, Université Paris-Saclay (CNRS/CEA)	Examineur
Michel Partiseti Chercheur, SANOFI R & D (IDD-HCB)	Examineur
Denis Servent Chercheur, Université Paris-Saclay (CEA)	Directeur de thèse

A mon petit champion,





Cette thèse CIFRE n° 2015_0278, financée en partie par l'Association Nationale de la Recherche et de la Technologie (ANRT), a été réalisée en collaboration entre l'équipe "High Content Biology" de Michel Partiseti (Département "Integrated Drug Discovery", SANOFI R&D, Vitry-sur-Seine) et l'équipe "Toxines, récepteurs et canaux ioniques" de Denis Servent (Service d'Ingénierie moléculaire des protéines, Institut des Sciences du vivant Frédéric Joliot, CEA de Saclay).



Remerciements

Je voudrais tout d'abord remercier le Dr Michel Partiseti ainsi que le Dr Denis Servent de m'avoir choisie pour réaliser cette thèse CIFRE et de m'avoir donné cette opportunité au sein de leurs équipes respectives. Je voudrais aussi remercier les membres du jury d'avoir accepté d'évaluer ce travail. Je remercie le Dr Eric Lingueglia et le Dr Christian Legros d'avoir accepté d'être rapporteurs. Je remercie également le Dr Hervé Daniel et le Dr Michel De Waard d'avoir accepté de faire partie du jury.

Un merci au Dr Denis Servent, en tant que directeur de thèse, pour sa disponibilité, sa bienveillance, ses conseils ainsi que ses relectures constructives, pour tout le temps consacré à orienter ou recadrer certains aspects ainsi que pour son expertise en toxines peptidiques.

Je voudrais remercier aussi le Dr Michel Partiseti, en tant que co-encadrant, pour son œil critique sur le déroulement du projet, bien que par moment un peu dur. Je voudrais aussi remercier sa vision de la recherche innovatrice, non conformiste, sa volonté de simplifier les démarches administratives quand elles semblent vraiment inutiles et sa prise de position concernant ma place au sein du laboratoire.

Je voudrais remercier principalement le Dr Evelyne Benoit, en tant que co-encadrante, pour avoir été un guide tout au long de ces 3 années. Son dévouement aux étudiants est sans faille et sans limite ainsi que sa volonté de bien faire (à partir de 5h du matin, une possibilité pour l'étudiant insomniaque de la contacter si besoin). Merci pour l'expertise en électrophysiologie, pour avoir su me transmettre d'une façon limpide toutes les méthodologies d'analyses, de présentations et d'écriture. J'ai beaucoup appris...

Merci aussi à Rémy Bérout, président directeur général de SMARTOX, et Michel De Waard, co-fondateur de cette même société, d'avoir toujours été présents pour discuter de l'avancement du projet toxines-canaux sodium dans le cadre de la déconvolution des venins, ainsi que Patrick Jimonet de SANOFI qui a supervisé la mise en place du contrat entre SANOFI et SMARTOX.

Du côté de SANOFI :

Je voudrais tout d'abord remercier Rachid Boukaiba pour son accueil chaleureux au sein du laboratoire dès les premiers jours et son aide au quotidien en ce qui concerne les procédures internes à SANOFI ainsi que pour son implication dans le projet Na_v1.7-toxines, au même titre que Sophie Fouconnier. Ensuite, je voudrais remercier le Dr Jean-Marie Chambard et Laetitia Lucarain pour le travail



qu'ils ont abattu avant mon arrivée au laboratoire concernant la déconvolution de venins sur le même projet, ainsi que le Dr Andrees Bohme, Brigitte Schombert et Camille Sanson pour leur implication dans la partie "sûreté pharmacologique au niveau cardiaque". Je voudrais aussi remercier Cathy Cojean pour son aide dans la génération de lignées stables directement liées à mon projet de thèse.

Je voudrais aussi mentionner Philippe Boudeau, dernier "patch-clampeur" du laboratoire, qui a su me transmettre beaucoup de son savoir sur la technique mais aussi sur l'entreprise, avec ses nombreuses anecdotes qui reflétaient bien l'évolution de celle-ci au fil du temps. Une petite attention particulière à Anne-Julie Chevel, super camarade de bureau, toujours souriante et serviable. Sans oublier le Dr Pascal Roux, Eric Tagat et Sylvie Houtmann avec qui j'ai eu moins d'échanges sur le plan professionnel, mais qui étaient toujours très agréables à la pause-café. Au Dr Ouassila Habi, je voudrais juste dire "Ne change pas, la recherche pour avancer à besoin de jeunes personnes ultra-dynamiques et volontaires comme toi".

Au Dr Bruno Biton ainsi qu'à Pauline Cervello qui ont mis à disposition une partie de leur temps pour la transmission du savoir-faire concernant la culture des neurones des ganglions de la racine dorsale de souris.

Au Dr Veronique Ballet ainsi qu'à Thierry Carriot et Céline Chantoiseau pour m'avoir si gentiment accueillie dans leur laboratoire et m'avoir transmis toutes les informations nécessaires à l'avancement de mon projet concernant l'évaluation de la sécurité pharmacologique sur le système cardiovasculaire grâce aux expériences sur les fibres de Purkinje et le cœur isolé de lapin.

Au Dr Jean-Michel Itier ainsi qu'à Sandra Viale de s'être investis dans une partie de mon projet et m'avoir fourni des cardiomyocytes dérivées de cellules souches pluripotentes induites humaines. Je voudrais aussi souligner leur bonne volonté à partager avec moi leurs connaissances et leur savoir-faire en la matière.

Sans oublier de remercier le Dr Isabel Lefèvre pour la relecture de tous les manuscrits inclus dans cette thèse.

Un grand merci au Dr Rosalia Arrebola, responsable du laboratoire de « Simple Management », complémentaire d'"High Content Biology" de Michel Partiseti, de s'être souciée de moi sur le plan professionnel mais aussi personnel pendant tout le déroulement de ma thèse.

Du côté du CEA :

Je voudrais remercier le Dr Jordi Molgó pour son savoir, sa gentillesse, sa disponibilité et sa promptitude à répondre à tout type de question de façon claire et précise ainsi que pour l'aide fournie pour la préparation et l'enregistrement des héli-diaphragmes de souris. Merci aussi au Dr Muriel Amar pour son introduction au patch clamp manuel ainsi que pour les échanges que l'on a eu au laboratoire.

Au Dr Gilles Mourier et à Margot Vanden Driessche pour leur aide en synthèse peptidique ainsi qu'au Dr Lidia Ciccone d'avoir toujours répondu gentiment à mes questions, même les plus basiques, concernant l'étude ou la génération des structures 3D des toxines peptidiques.



Au Dr Nicolas Gilles, avec qui j'ai travaillé sur une des toxines antidouleur, au Dr Pascal Kessler, pour son humour décalé, au Dr Philippe Robin, pour sa gentillesse, et au Dr Romulo Araoz, pour sa convivialité quand il s'agit de nous préparer un apéro typiquement chilien.

Un petit clin d'œil à Christelle Carvalho, à Justyna Cyolek, au Dr Daad Saraf, au Dr Marcela Silva, à Manon Lancien, à Julia Boeri, à Fanny Noirmain, à Minh-Tuyet Nguyen, au Dr Pavel Shpak, au Dr Sarah Brégant et au dernier arrivé, le Dr Nicolo Tonali qui ont su égayer, évidemment par des discussions purement scientifiques, mes pauses cafés au quotidien. Sans oublier Evelyne Rabouille et Alexandra Aleixo, pour leur sourire et les aides précieuses pour tout ce qui concerne les procédures administratives.

Du côté des étudiants (BTS, Licence, Master et Doctorat) :

Je voudrais mentionner tous les stagiaires que j'ai vus défiler à SANOFI (Shanon Abergel, Pauline Ferlan, Manon Sirvin, Lise Bettoun, Eva Kirasic, Laura Chladni, Charlotte Saint-Omer et Julie Somkhit) mais aussi au CEA (Alexandre Sampaio, Amandine Gaudin, Claire Lamoise, Pierre-Emmanuel Girault-Sotias, Sarah Nadif, Hugo Dosquet, Steven Ascoët, Florian Blondel et Mickaël Susset) et qui, chacun par nos échanges, m'ont beaucoup apporté et permis de tenir le rythme assez mouvementé de ces trois dernières années.

Une mention spéciale à mes "frères de combat", Marc Ravatin, doctorant à SANOFI, ainsi que Steve Reynaud, doctorant au CEA, à qui je souhaite la meilleure réussite possible pour la suite de leur thèse. Je voudrais aussi mentionner la doctorante, à ce jour, déjà docteur, avec qui j'ai partagé le bureau pendant un peu plus de 2 ans, Laura Droctové, et qui a toujours eu les mots tout en douceur pour me rassurer à chaque fois qu'un obstacle pointait son nez. Merci à Nassim Mahtal, Aurélien Azam et Livia Tepshi, les doctorants du sous-sol, maintenant docteurs, toujours souriants et sympathiques ainsi que Monika Kaminska et Héloïse Cahuzac, les doctorantes du premier étage, avec qui j'ai partagé mes dernières angoisses et à qui je souhaite la meilleure continuation.

Du côté de ma famille :

Finalement, je voudrais dire un grand merci à ma famille, surtout à mes grands-parents qui ont participé à mon éducation étant jeune, à mes parents et mon frère qui, malgré leur méconnaissance concernant ce que je fais, me soutiennent et m'aident au quotidien, à mon fils pour sa patience, et enfin à mon conjoint qui me porte depuis le début dans la réalisation de ce projet.



Table des matières

Liste des abréviations.....	3
Préambule.....	7
Partie 1 - INTRODUCTION.....	9
1.1. Canaux cationiques dépendants du potentiel	11
1.1.1. Canaux sodium	14
1.1.2. Canaux potassium.....	19
1.1.3. Canaux calcium.....	23
1.1.4. Canalopathies.....	28
1.2. Toxines.....	34
1.2.1. Toxines et canaux ioniques	34
1.2.2. Toxines - Na _v - Modulations des propriétés biophysiques	35
1.2.3. Toxines – Canaux Na _v – Douleur.....	39
1.3. Nociception.....	42
1.3.1. Catégories de douleurs et épidémiologie	42
1.3.2. Arsenal thérapeutique.....	44
1.3.3. Publication n°1.....	49
1.4. Objectifs de la thèse	51
Partie 2 - RESULTATS et DISCUSSION	53
Avant-propos.....	55
2.1. De l'identification à la caractérisation fonctionnelle de la cyriotoxine-1a, une toxine issue du venin de l'araignée <i>Cyriopagopus schioedtei</i> ayant des propriétés antinociceptives	57
2.1.1. Contexte de l'étude	57
2.1.2. Publication n°2.....	58
2.1.3. Résumé des résultats obtenus	59
2.1.4. Conclusion.....	63
2.2. Relations "structure-activité" d'une toxine d'araignée <i>Phlogiellus</i> ciblant le sous-type Na _v 1.7 de canaux sodium.....	64
2.2.1. Contexte de l'étude	64
2.2.2. Publication n°3.....	66
2.2.3. Résumé des résultats obtenus	67
2.2.4. Conclusion.....	67
2.3. Mise en évidence d'un blocage de haute puissance du sous-type Na _v 1.6 de canaux sodium par le peptide d'araignée huwentoxine-IV, en utilisant des approches fonctionnelles multi-échelles.....	68
2.3.1. Contexte de l'étude	68
2.3.2. Publication n°4.....	69
2.3.3. Résumé des résultats obtenus	71
2.3.4. Conclusion.....	72
2.4. Profil de sélectivité original de la poécitoxine-1a de l'araignée <i>Poecilotheria subfusca</i> pour les sous-types humains de canaux ioniques dépendants du potentiel	73
2.4.1. Contexte de l'étude	73
2.4.2. Publication n°5.....	74
2.4.3. Résumé des résultats obtenus	75

2.4.4.	Conclusion.....	77
2.5.	Criblage à haut débit d'une banque de venins appartenant à SANOFI.....	79
2.5.1.	Contexte de l'étude	79
2.5.2.	Résultats obtenus	79
2.5.2.1.	Criblage primaire de la banque de venins.....	79
2.5.2.2.	Etude du venin de l'araignée <i>Selenotypus plumipes</i> (A5-x)	81
2.5.2.3.	Etude du venin de l'araignée <i>Phoneyusa celerieri</i> (B5-x).....	87
2.5.2.4.	Etude du venin du scorpion <i>Hottentotta gentili</i> (G4-x)	90
2.5.2.5.	Etude du venin du scorpion <i>Hottentotta jayakari</i> (H4-x).....	95
2.5.3.	Conclusion.....	95
Partie 3 - CONCLUSION et PERSPECTIVES		99
3.1.	Profils de sélectivité et applications potentielles des 4 toxines étudiées	101
3.2.	Limites et avantages d'un criblage à haut débit d'une banque contenant une quantité importante de venins.....	104
Liste des illustrations		107
Références bibliographiques.....		111
ANNEXES.....		123
A1.	Liste des publications, des participations à des congrès et des formations.....	125
A1.1.	Publications	125
A1.2.	Participations à des congrès.....	125
A1.3.	Formations	127
A2.	Publication n°6.....	128

Liste des abréviations

4-AP :	4-aminopyridine
AID :	Domaine d'interaction à la sous-unité $\alpha 1$ (" $\alpha 1$ -subunit Interacting Domain")
AINS :	Anti-inflammatoires non-stéroïdiens
AMM :	Autorisation de mise sur le marché
ASIC :	Canal senseur de protons ["Acid-Sensing (proton-gated) Ion Channel"]
CAM:	Protéines d'adhésion cellulaire ("Cell-Adhesion Molecules")
Canal CatSper :	"Cation channel of Sperm"
Canal Ca _v :	Canal calcium dépendant du potentiel
Canal CNG :	"Cyclic Nucleotide-Gated channel"
Canal HCN :	"Hyperpolarisation-activated, Cyclic Nucleotide-gated channel"
Canal K _{2p} :	Canal à domaine deux P ("Two P domain channel")
Canal Kir :	Canal potassium à rectification entrante
Canal K _v :	Canal potassium dépendant du potentiel
Canal Na _v :	Canal sodium dépendant du potentiel
Canal SOC:	"Store-Operated Calcium channel"
Canal TRP :	"Transient Receptor Potential channel"
CHO :	"Chinese hamster ovary"
CiPA :	"Comprehensive <i>in vitro</i> Proarrhythmia Assay"
Cryo-ME :	Cryo-microscopie électronique
CssII :	Toxine II du scorpion <i>Centruroides suffusus suffusus</i>
CTD :	Partie C-terminale ("Carboxy-Terminal Domain")
CyrTx-1a :	Cyriotoxine-1a
D :	Domaine
DRG :	Ganglion de la racine dorsale ("Dorsal root ganglion")
EC ₅₀ :	Concentration effective produisant 50% de l'effet
EF :	Main EF ("EF hand")
ENaC :	Canal sodium des cellules épithéliales ["Epithelial sodium (Na) Channel"]
ES :	Erreur standard
ESM :	Erreur standard de la moyenne
FDA :	"Food and Drug Administration"
GABA :	Acide γ -aminobutyrique
GPI :	Glycophosphatidylinositol
HEK :	"Human embryonic kidney"
hiPSC-CM :	Cardiomyocyte dérivé de cellules souches pluripotentes humaines
HMM :	Hidden Markov Model
HPLC :	Chromatographie en phase liquide haute pression (le terme "à haute performance" est aussi fréquemment utilisé)

HVA :	Canaux à haut seuil d'activation ("High Voltage Activated")
HwTx-IV :	Huwentoxine-IV
Ig :	Immunoglobuline
i.m. :	Intramusculaire
i.p. :	Intrapéritonéal
i.pl. :	Intrapleural
IASP :	Association internationale pour l'étude de la douleur (International Association for the Study of Pain)
IC ₅₀ :	Concentration inhibant de 50% la réponse
ICK :	Nœud de cystines inhibiteur ("Inhibitor cystine knot")
IFM :	Isoleucine-Phénylalanine-Méthionine
Ig :	Immunoglobuline
IP3 :	Inositol trisphosphate
IVA :	Canaux à seuil d'activation intermédiaire ("Intermediate Voltage Activated")
JzTx :	Jinghaotoxine
k _g :	Pente de la courbe de la conductance en fonction du potentiel de membrane
k _h :	Pente de la courbe d'inactivation stationnaire en fonction du potentiel de membrane
LqhIII :	Toxine III du scorpion <i>Leiurus quinquestriatus hebraeus</i>
LVA :	Canaux à bas seuil d'activation ("Low Voltage Activated")
MAPS :	Balayage positionnel multi-attributs ("Multi Attribute Positional Scan")
MS/MS :	Masse en tandem
NALCN :	Canal sodium de fuite ("Sodium Leak Channel")
NaSpTx-1 :	Famille 1 des toxines d'araignées inhibant les canaux Na _v
NaSpTx-2 :	Famille 2 des toxines d'araignées inhibant les canaux Na _v
NaSpTx-3 :	Famille 3 des toxines d'araignées inhibant les canaux Na _v
OAIP :	Peptide insecticide actif par voie orale ("Orally active insecticidal peptide")
OD1 :	Toxine 1 du scorpion <i>Odonthobuthus doriae</i>
OMS :	Organisation mondiale de la Santé
p :	Bras long du chromosome
PA :	Potentiel d'action
PD :	Pore du canal ("Pore Domain")
PDB :	Base de données des protéines ("Protein data bank")
PecTx-1a :	Poécitoxine-1a
PhITx-1 :	Phlotoxine-1
PKA :	Phosphokinase A
PKC :	Phosphokinase C
ProTx-II :	Protoxine-II
q :	Bras court du chromosome
SFETD :	Société française d'étude et de traitement de la douleur
SNC :	Système nerveux central
SNP :	Système nerveux périphérique

STX :	Saxitoxine
TEA :	Tétraéthylammonium
TPC :	Canal à deux pores ("Two-Pore Channel")
TTX :	Tétradotoxine
TTX-R :	Résistant à la tétradotoxine
TTX-S :	Sensible à la tétradotoxine
U2OS :	"Human bone osteosarcoma epithelium"
V _{P50%} :	Potentiel correspondant à une diminution de 50% de l'inactivation stationnaire
VSD :	Domaine senseur du potentiel membranaire ("Voltage Sensing Domain")
V _{T50%} :	Potentiel correspondant à une diminution de 50% de la conductance
ZAC :	Canal activable par le zinc ("Zinc-Activated Channel")

Acides aminés essentiels

Ala (A) :	Alanine	Leu (L) :	Leucine
Arg (R) :	Arginine	Lys (K) :	Lysine
Asn (N) :	Asparagine	Met (M) :	Méthionine
Asp (D) :	Aspartate	Phe (F) :	Phénylalanine
Cys (C) :	Cystéine	Pro (P) :	Proline
Gln (Q) :	Glutamine	Ser (S) :	Sérine
Glu (E) :	Glutamate	Thr (T) :	Thréonine
Gly (G) :	Glycine	Trp (W) :	Tryptophane
His (H) :	Histidine	Tyr (Y) :	Tyrosine
Ile (I) :	Isoleucine	Val (V) :	Valine

Acides aminés non naturels

1-Nal :	1-naphthylalanine
---------	-------------------

Préambule

Les travaux de recherche de ma thèse concernent l'évaluation multi-échelle de toxines de venins comme agents antinociceptifs potentiels. Ils ont été effectués dans le cadre d'une convention CIFRE associant l'équipe de Michel Partiseti (SANOFI) et celle de Denis Servent (CEA) pour lesquelles l'exploitation des venins comme source d'agents thérapeutiques potentiels est un sujet d'intérêt.

En effet, en décembre 2013, le groupe SANOFI a signé un partenariat de recherche avec Smartox Biotechnology, un partenariat rendu officiel le 6 février 2014 avec cette biotech grenobloise, spécialiste de l'exploitation des venins d'animaux, qui maîtrise la purification, le séquençage et la synthèse des peptides composant ces mélanges complexes. De son côté, l'équipe "High Content Biology" de Michel Partiseti (Département "Integrated Drug Discovery", SANOFI R&D, Vitry-sur-Seine) est experte dans le criblage à haut débit de librairie de ligands, comme des fractions et sous-fractions de venins, pour en extraire des molécules naturelles d'intérêt afin d'en évaluer les propriétés thérapeutiques. Quant aux axes de recherches développés par l'équipe "Toxines, récepteurs et canaux ioniques" de Denis Servent (Service d'Ingénierie moléculaire des protéines, Institut des sciences du vivant Frédéric Joliot, CEA de Saclay), ils visent, d'une part, à identifier de nouvelles toxines aux propriétés originales et, d'autre part, à caractériser fonctionnellement (par des approches multi-échelles in vitro, ex vivo et in vivo) et structuralement leur interaction avec les récepteurs et canaux ioniques, à modifier ces propriétés fonctionnelles par ingénierie et à exploiter ces ligands en tant qu'outils d'étude du fonctionnement de leurs cibles moléculaires ou pour leurs potentialités thérapeutiques.

Ce mémoire de thèse est organisé en trois parties:

La première partie, introductive, est un état des connaissances actuelles (i) sur les canaux ioniques (sodium, potassium et calcium), dépendants du potentiel de membrane, et des canalopathies associées, (ii) sur l'utilisation des toxines en tant que thérapeutiques, en mettant plus particulièrement en évidence les peptides de venin d'animaux potentiellement antalgiques, et (iii) sur la physiopathologie de la nociception. Cette partie se termine par une revue publiée sur le sujet dans "Frontiers in Pharmacology".

La seconde partie, intitulée "Résultats et Discussion", est structurée en 5 sous-parties portant sur les données obtenues suite au criblage à haut débit de deux banques de venins qui a permis l'identification et la caractérisation, par des approches fonctionnelles multi-échelles, de peptides dérivés de venins et ayant des propriétés potentiellement antinociceptives. Elles sont présentées sous

forme d'articles publiés ou en révision dans des journaux à comité de lecture, d'articles en préparation et de résultats non publiés.

La troisième et dernière partie de ce mémoire est consacrée aux conclusions générales et aux perspectives découlant du travail réalisé au cours de cette thèse.

Partie 1

INTRODUCTION

1.1. Canaux cationiques dépendants du potentiel

Actuellement, 2880 cibles moléculaires humaines ont été identifiées dont les principales classes sont les enzymes (1201, soit 42%), les transporteurs (509, soit 18%) et les récepteurs couplés aux protéines G (399, soit 14%). Parmi ces classes, les enzymes et les récepteurs couplés aux protéines G représentent 77% des cibles thérapeutiques actuelles. Les canaux ioniques, quant à eux, ne constituent que 7% des cibles thérapeutiques actuelles mais 10% des cibles moléculaires humaines (Figure 1-1).




Figure 1-1. Nombre de chaque classe de cibles moléculaires humaines et la part de chacune d'entre elle dans le panel thérapeutique actuel. Adapté de Harding et al. (2018) et de Hopkins & Groom (2002).

Parmi les canaux ioniques se trouvent les canaux activables par un ligand (81, soit 29%), par le potentiel de membrane (144, soit 52%) et les autres canaux ioniques (52, soit 19%). Les canaux activables par un ligand comprennent, notamment, les récepteurs sérotoninergiques (5-HT₃), de l'acide γ -aminobutyrique de type A (GABA_A), glycinergiques, ionotropiques du glutamate, purinergiques (P2X) et nicotiques de l'acétylcholine ainsi que certains canaux de la famille ENaC [pour "epithelial sodium (Na) channel"] tels que les canaux sodium activés par le FMRFamide. Les autres canaux ioniques incluent, notamment, d'autres canaux de la famille ENaC tels que les canaux senseurs de protons [ASIC pour "acid-sensing (proton-gated) ion channel"], les canaux chimiosensoriels répondant au sel ou encore les canaux mécanosensoriels responsables de la sensation tactile, les aquaporines, les connexines/pannexines, certains canaux chlore, les canaux SOC (pour "store-operated calcium"), les canaux Piezo et le canal sodium de fuite (NALCN ou "sodium leak channel"). Finalement, 8 groupes de canaux ioniques dépendants du potentiel sont dénombrés: les canaux calcium CatSper (pour "cation channel of sperm") et les canaux à deux pores (TPC pour "two-pore channel"), les canaux régulés par les nucléotides cycliques (comprenant les canaux CNG pour

"cyclic nucleotide-gated" et les canaux HCN pour "hyperpolarisation-activated, cyclic nucleotide-gated"), les canaux potassium [dont ceux activés par le calcium ou le sodium, ceux à rectification entrante, ceux à domaine deux P ("two P domain" ou K_{2P}) et ceux dépendants du potentiel], les canaux TRP (pour "transient receptor potential channels") ainsi que les canaux chlore ($ClC-x$), calcium, proton et sodium dépendants du potentiel (Alexander et al., 2017; [Figure 1-2](#)).




Figure 1-2. Représentation des relations entre les séquences d'acides aminés du pore formant le canal de la superfamille des canaux ioniques dépendants du potentiel de membrane (Yu & Catterall, 2004).

Les canaux cationiques (sodium, potassium et calcium) dépendants du potentiel (respectivement Na_v , K_v et Ca_v) sont des protéines transmembranaires qui confèrent aux cellules nerveuses la propriété d'excitabilité en participant à la génération et à la propagation du potentiel d'action (canaux Na_v et K_v) pour permettre *in fine* la libération des neurotransmetteurs (canaux Ca_v). Ces canaux, ou du moins certains d'entre eux, interviennent également dans la genèse des contractions musculaires, la fréquence des battements cardiaques, la sécrétion, la balance eau/électrolyte, la réponse immunitaire, la prolifération cellulaire.... Ils peuvent se trouver dans les trois états conformationnels principaux suivants (à l'exception de certains canaux K_v): l'état fermé (non conducteur), l'état activé (conducteur) et l'état inactivé (non conducteur), selon le sous-type de canal ionique considéré et en fonction du temps et du potentiel appliqué à la membrane plasmique ([Figure](#)

1-3A). La sous-unité principale, qui constitue le pore ionique du canal (sous-unité α), est souvent associée à des sous-unités auxiliaires qui en modifient les propriétés biophysiques et pharmacologiques (sous-unités β , δ , γ). Des modifications post-traductionnelles sur une des sous-unités constituant le canal ionique peuvent également contribuer à la modulation des propriétés fonctionnelles du pore. Au cours de ces dernières années, l'obtention de la structure tridimensionnelle des canaux ioniques, grâce à la cristallographie et à la cryo-microscopie électronique (Cryo-ME), a permis de mieux comprendre leur fonctionnement, les différences structurales associées à leurs différents états, ainsi que le mode d'interaction entre la sous-unité principale et les sous-unités auxiliaires (Figure 1-3B) (Payandeh et al., 2011; Payandeh & Minor, 2015; Wu et al., 2016; Shen et al., 2017; Yan et al., 2017; Matthies et al., 2018; Pan et al., 2018).




Figure 1-3. Bases chimiques de la signalisation électrique et propriétés d'ouverture et de fermeture des canaux cationiques dépendants du potentiel. (A) Principaux états biophysiques (fermé, activé et inactivé) des canaux ioniques en fonction du temps et du potentiel appliqué à la membrane plasmique. D'après Bourdain et al. (2005). (B) Représentation des canaux cationiques (Na_v , Ca_v et K_v) au niveau de la membrane lipidique, avec un milieu extracellulaire hautement concentré en ions sodium et calcium alors que le milieu intracellulaire est concentré en ions potassium. De la gauche vers la droite, le canal bactérien Na_vAb , le sous-type $Ca_v1.1$ de canal calcium de mammifère complexé à ses sous-unités auxiliaires, et la chimère de mammifère $K_v1.2/2.1$ complexée aux sous-unités β intracellulaires. D'après Catterall et al. (2017).

1.1.1. Canaux sodium

Les canaux Na_v sont composés d'une sous-unité α principale d'environ 220-260 kDa, liée de façon covalente ou non à des sous-unités β auxiliaires avoisinant les 33-36 kDa (stœchiométrie α/β non encore élucidée) (Isom et al., 2001; Catterall et al., 2007; Namadurai et al., 2015).

La sous-unité α est constituée de 4 domaines (DI-DIV) regroupant chacun 6 segments transmembranaires dont les 4 premiers (S1-S4) forment le domaine senseur du potentiel (VSD pour "Voltage Sensing Domain"). Le segment 4 chargé positivement (par la présence d'arginines) est le principal composant du VSD et les deux derniers (S5-S6), reliés par la boucle P, forment le pore du canal (PD pour "Pore Domain") (Figure 1-4A).




Figure 1-4. Structure architecturale des canaux Na_v (d'après Catterall & Swanson, 2015; Ahern et al., 2016; Tibbs et al., 2016; Pan et al., 2018). (A) Organisation transmembranaire du canal sodium avec la sous-unité α au centre constituée de 4 domaines transmembranaires (DI à DIV) à 6 segments entourée par les sous-unités β auxiliaires se liant soit par des ponts disulfures (matérialisés par le rectangle gris, $\beta 1$ ou $\beta 3$) ou bien soit des liaisons hydrogènes ($\beta 2$ ou $\beta 4$). Le segment 4 par la présence d'arginine (R) est le segment senseur du potentiel, en bleu le segment S5-S6 constitue le pore module. Le motif IFM permet l'inactivation rapide du courant en se fixant sur les points gris bleutés adjacents. Ces canaux sont phosphorylés par des PKA et PKC. (B) À gauche, structure obtenue en Cryo-ME (3,2 Å de résolution) du complexe musculaire humain $\text{Na}_v1.4/\beta 1$. Au milieu, vue schématique du dessus du canal Na_v eucaryotes dont la boucle extracellulaire S3b-S4 des parties VSD est colorée différemment en fonction du domaine. Les ions sodium passent par le pore, module formé par les parties PD de chaque domaine. À droite, vue supérieure du canal Na_vAb coloré de façon à mettre en évidence l'arrangement décalé, dit "domain-swapped", des parties VSD de chaque domaine par rapport à leur partie PD pour tous les canaux ioniques dépendants du potentiel.

Tableau 1-1. Matrice d'identité en pourcentage des sous-unités α des sous-types de Na_v humains. Les alignements de séquence multiple de haute qualité ont été réalisés grâce à CLUSTAL Oméga, version 1.2.3 (version Web).

Subtypes	hNa _v 1.1	hNa _v 1.2	hNa _v 1.3	hNa _v 1.4	hNa _v 1.5	hNa _v 1.6	hNa _v 1.7	hNa _v 1.8	hNa _v 1.9	hNa _v 1
hNa _v 1.1	100.00	86.65	83.23	61.50	59.53	74.12	75.88	53.57	44.56	31.69
hNa _v 1.2	86.65	100.00	87.02	63.02	60.46	74.89	77.11	54.22	45.35	
hNa _v 1.3	83.23	87.02	100.00	62.28	60.57	73.44	75.22	54.01	45.39	
hNa _v 1.4	61.50	63.02	62.28	100.00	58.02	60.32	60.33	52.58	46.53	
hNa _v 1.5	59.53	60.46	60.57	58.02	100.00	59.39	58.39	60.93	48.07	
hNa _v 1.6	74.12	74.89	73.44	60.32	59.39	100.00	69.69	53.51	44.90	
hNa _v 1.7	75.88	77.11	75.22	60.33	58.39	69.69	100.00	53.54	45.92	
hNa _v 1.8	53.57	54.22	54.01	52.58	60.93	53.51	53.54	100.00	48.44	
hNa _v 1.9	44.56	45.35	45.39	46.53	48.07	44.90	45.92	48.44	100.00	

UniprotKB entry identifiant (UEI) - Human (homo sapiens)

UEI	P35498	Q99250	Q9NY46	P35499	Q14524	Q9UQD0	Q15858	Q9Y5Y9	Q9UI33
Gene	SCN1A	SCN2A	SCN3A	SCN4A	SCN5A	SCN8A (MED)	SCN9A	SCN10A	SCN11A
Protein	hNav1.1	hNav1.2	hNav1.3	hNav1.4	hNav1.5	hNav1.6	hNav1.7	hNav1.8	hNav1.9

Au niveau de la structure tridimensionnelle, la partie VSD est positionnée en décalage par rapport à la partie PD d'un même domaine ("domain-swapped arrangement") (Figure 1-4B). En fonction du temps et du potentiel de membrane, les canaux Na_v peuvent être successivement dans les 3 états fonctionnels suivants: (i) l'état de repos (état fermé), (ii) l'état activé (état ouvert) et (iii) l'état inactivé (état fermé). L'inactivation du canal est due à une boucle intracellulaire, nommée "la boucle d'inactivation" ou "IFM" (pour "isoleucine-phénylalanine-méthionine"), située entre DIII et DIV qui bouche le pore (Figure 1-4A).

Il existe 9 sous-unités $\alpha 1$ à l'origine de 9 sous-types de canaux sodium ($\text{Na}_v1.1-1.9$) classés par leur sensibilité à la tétrodotoxine (TTX), une toxine extraite de certaines espèces de poissons, les tétrodons. Un dixième leur est associé, le canal Na_x qui, comme le canal sodium de fuite (NALCN pour "sodium leak channel"), n'est cependant pas dépendant du potentiel mais de la concentration d'ions sodium (Hiyama et al., 2002; Snutch & Monteil, 2007). Les gènes codant pour la sous-unité α des sous-types $\text{Na}_v1.1-1.3$ et 1.7 de canaux sodium sensibles à la tétrodotoxine (TTX-S) sont localisés sur le bras long du chromosome 2 (2q23-24 plus précisément) d'où leur fort pourcentage d'identité (75,22% à 87,02% d'identité de séquence entre eux). Le gène codant pour la sous-unité α des sous-types $\text{Na}_v1.4$ et $\text{Na}_v1.6$ de canaux sodium TTX-S sont localisés sur le bras long du chromosome 17 (17q23-25) et 12 (12q13), respectivement, avec un pourcentage d'identité moyen (60,33% et 74,90% avec les gènes des Na_v du chromosomes 2) alors que les gènes codant pour la sous-unité α des sous-types $\text{Na}_v1.5$ et $\text{Na}_v1.8-1.9$ de canaux sodium résistants à la tétrodotoxine (TTX-R) sont localisés sur le bras court du chromosome 3 (3p21-24) d'où un pauvre pourcentage d'identité (44,56% et 60,57% avec les gènes des Na_v du chromosomes 2) (Tableau 1-1). Il est à noter que des différences existent

sur le pourcentage d'identité des séquences citées ci-après et ceux de la littérature due à des versions de Clustal différentes. La version Clustal oméga étant plus récente, elle est plus rapide et en constante évolution. Elle peut aligner des centaines de milliers de séquences en quelques heures et possède une plus grande précision en raison de l'utilisation de méthodes d'alignements progressifs simples améliorées par le modèle probabiliste de Markov caché (HMM pour "Hidden Markov Model"). La version plus classique du logiciel, ClustalW, utilise la consistance des séquences par des méthodes basées sur les matrices (Catterall et al., 2005a).

Les sous-types de canaux sodium ont des profils d'expression tissulaire bien établis au niveau des cellules excitables musculaires et neuronales mais aussi des sites d'expression moins canoniques (Goldin, 2001; Trimmer & Rhodes, 2004; Brackenbury et al., 2012; Black & Waxman, 2013).

Le **Nav1.1**, codé par le gène SCN1A, est exprimé au niveau du système nerveux central (SNC) et périphérique (SNP) ainsi qu'au niveau des kératinocytes et des cellules cancéreuses de l'ovaire.

Le **Nav1.2**, codé par le gène SCN2A, est exprimé au niveau du SNC et SNP ainsi qu'au niveau des fibroblastes, des cellules β des îlots de Langerhans, des odontoblastes, des ostéoblastes et des cellules cancéreuses (du cervix utérin, du mésothéliome, de l'ovaire, de la prostate).

Le **Nav1.3**, codé par le gène SCN3A, est la forme fœtale des sous-unités α qui est exprimé au niveau du SNC et SNP en cas de lésion. Il est aussi retrouvé au niveau des fibroblastes, des cellules β des îlots de Langerhans et des cellules cancéreuses (de l'ovaire, de la prostate, du cancer du poumon à petite cellules).

Le **Nav1.4**, codé par le gène SCN4A, est exprimé au niveau du tissu musculaire squelettique, ainsi qu'au niveau des cellules endothéliales, des globules rouges et des cellules cancéreuses (du cervix utérin, de l'ovaire et de la prostate).

Le **Nav1.5**, codé par le gène SCN5A, est exprimé au niveau du tissu musculaire lisse cardiaque et squelettique fœtal ou dénervé ainsi qu'au niveau des cellules endothéliales, des globules rouges et des cellules cancéreuses (du cancer du sein, du colon, du lymphome, et du neuroblastome dont c'est le sous-type majoritaire, du cancer du poumon à petites cellules ou non à petites cellules et du cancer de l'ovaire).

Le **Nav1.6**, codé par le gène SCN8A, est exprimé au niveau du SNC et SNP ainsi qu'au niveau des fibroblastes, kératinocytes, macrophages, cellules endothéliales, et des cellules cancéreuses (du cancer du sein, du cervix utérin, du lymphome, du mélanome, du mésothéliome, du cancer du poumon non à petites cellules, du cancer de la prostate, du cancer du poumon à petites cellules).

Le **Nav1.7**, codé par le gène SCN9A, est exprimé au niveau du SNC et SNP ainsi qu'au niveau du tissu musculaire lisse, de la prostate, des progéniteurs érythroïdes, des fibroblastes, des cellules immunitaires et des cellules cancéreuses (du cancer du sein, du cervix utérin, du lymphome, du mésothéliome, du cancer du poumon non à petites cellules, du cancer de l'ovaire et du cancer de la prostate pour lequel le sous-type Nav1.7 est la forme prédominante).

Le **Nav1.8**, codé par le gène SCN10A, est exprimé au niveau du SNC et du SNP, ainsi qu'au niveau des cellules endothéliales, des fibroblastes, des kératinocytes et des lymphocytes T.

Le **Nav1.9**, codé par le gène SCN11A, est exprimé au niveau du SNC et SNP ainsi qu'au niveau des cellules endothéliales, des fibroblastes et des lymphocytes T mais aussi au niveau des cellules cancéreuses (de lymphome et du cancer du poumon à petites cellules).

Le **Na_x**, codé par le gène SCN7A, est un sous-type de canal sodium qui n'est pas dépendant du potentiel mais de la concentration extracellulaire de sodium (Hiyama et al., 2002). Il est exprimé au niveau du SNC et SNP ainsi qu'au niveau du poumon, de l'utérus et du cœur.

Les canaux Na_v sont sélectifs aux ions sodium mais aussi aux ions lithium. Les sous-types TTX-S ont des cinétiques d'activation et d'inactivation relativement rapides comparées à celles des sous-types TTX-R. De plus, les cinétiques d'activation et d'inactivation du sous-type TTX-R Nav1.9 sont particulièrement lentes comparées à celles des deux autres sous-types TTX-R Nav1.5 et 1.8. La dépendance vis-à-vis du potentiel de l'activation des sous-types TTX-S est similaire à celle du sous-type TTX-R Nav1.5 mais est déplacée vers des potentiels plus négatifs d'environ 15-30 mV comparée à celle du sous-type Nav1.8, et plus positifs d'environ 10-25 mV comparée à celle du sous-type Nav1.9. En revanche, la dépendance vis-à-vis du potentiel de l'inactivation des sous-types TTX-S est déplacée vers des potentiels plus positifs d'environ 10-20 mV comparée à celle du sous-type Nav1.5, et plus négatifs d'environ 15-30 mV comparée à celles des sous-types Nav1.8 et 1.9 ([Figure 1-5a](#); Deuis et al., 2017; Inserra et al., 2017). De ce fait, la superposition des courbes d'activation et d'inactivation en fonction du potentiel des sous-types TTX-R laisse apparaître une "fenêtre de courant" à des potentiels physiologiques (entre -70 et -40 mV) pour lesquels le courant est persistant, ce qui permet à la membrane d'atteindre la valeur "seuil" de déclenchement des potentiels d'action qui apparaissent donc de façon spontanée, comme cela est le cas au niveau cardiaque pour le sous-type Nav1.5 et au niveau neuronal pour le sous-type Nav1.8 ([Figure 1-5b et c](#)).

Les sous-unités β auxiliaires sont des protéines transmembranaires, membres de la famille des protéines d'adhésion cellulaire (CAM pour "cell-adhesion molecules") ayant un domaine extracellulaire de type immunoglobuline (Ig) et permettant, comme les protéines propres à cette

famille, l'interaction cellule-cellule (Figure 1-4a; Barbosa et al., 2015). Elles sont au nombre de 4. Les sous-unités $\beta 1$ et $\beta 3$, codées par les gènes SCN1B et SNC3B respectivement, se lient de façon covalente et les sous-unités $\beta 2$ et $\beta 4$, codées par les gènes SCN2B et SNC4B, se lient par des liaisons hydrogènes.




Figure 1-5. Propriétés biophysiques et implication dans la genèse du potentiel d'action neuronal ou cardiaque des différents sous-types de canaux sodium. (a, gauche) Courant sodium persistant TTX-R médié par le sous-type $\text{Na}_v1.9$ et, à des fins de comparaison, le courant sodium TTX-S médié par les sous-types $\text{Na}_v1.6$ et/ou $\text{Na}_v1.7$, enregistrés à partir des petits neurones de ganglions de la racine dorsale (DRG) d'une souris knock-out pour le gène codant le sous-type $\text{Na}_v1.8$ (absence du courant TTX-R lent médié par ce sous-type). Les courants ont été enregistrés au cours d'impulsions dépolarisantes de 100 ms à -30 ou -40 mV à partir d'un potentiel de maintien de -120 mV. Il est à noter l'activation et l'inactivation rapide du courant TTX-S par rapport à l'activation lente et l'inactivation très lente du $\text{Na}_v1.9$. (a, droite) Le sous-type $\text{Na}_v1.9$ s'active à des valeurs de potentiel plus négatives et s'inactive à des valeurs de potentiels plus positives que les sous-types TTX-S. En conséquence, il existe un "courant de fenêtre" persistant, médié par le sous-type $\text{Na}_v1.9$, dans la gamme de potentiels proche du potentiel membranaire de repos des neurones (-70 à -40 mV). D'après Dib-Hajj et al. (2015). (b) Sous-types de canaux Na_v impliqués dans le potentiel d'action (PA) neuronal sain. Les sous-types $\text{Na}_v1.7$ et 1.9 seraient des canaux sodium de "seuil" qui mèneraient le potentiel de repos au potentiel "seuil" avant que le sous-type $\text{Na}_v1.8$ ne permette le dépassement de cette valeur "seuil" et l'apparition d'un PA, les sous-types $\text{Na}_v1.1$, 1.6 et 1.7 ne jouant qu'un rôle mineur dans le PA. En cas de lésion, le sous-type $\text{Na}_v1.3$ prend le relais aux deux niveaux (d'après Rush et al., 2007). (c) Potentiel d'action cardiaque ventriculaire composé de 5 phases mettant en jeu le courant I_{Na^+} , médié par le sous-type $\text{Na}_v1.5$, contribuant principalement à la phase 0 et, en ne s'inactivant pas complètement, participant à maintenir le "plateau" (phase 2) du potentiel d'action avec le sous-type $\text{Ca}_v1.2$ de canal calcium (adapté de Nerbonne & Kass, 2005).

Excepté le SCN1B qui est localisé sur le chromosome 19, les autres le sont sur le chromosome 11. Ces unités β ont un grand impact sur les sous-unités α puisqu'elles favorisent leur expression, leur localisation subcellulaire et leur déplacement membranaire, et modulent fortement leurs propriétés biophysiques, *i.e.* cinétiques et dépendance vis-à-vis du potentiel de l'activation et de l'inactivation des canaux sodium, et pharmacologiques (Xie et al., 2016).

Tout comme les sous-unités α , les sous-unités β sont hautement exprimées de façon variable selon le type cellulaire au niveau du SNC, SNP ainsi qu'au niveau des muscles squelettiques et cardiaques mais aussi au niveau de cellules non-excitables comme les astrocytes, la glie radiale, les cellules vasculaires endothéliales et les cellules cancéreuses (du cancer du sein, du cervix utérin, du cancer du poumon non à petites cellules, de la prostate) (Brackenbury & Isom, 2011; Brackenbury et al., 2012; Winters et al., 2017). Par exemple, au niveau des neurones des ganglions de la racine dorsale (DRG pour "dorsal root ganglia"), l'expression des 4 sous-unités β est variable et modulera donc le message différemment (Lopez-Santiago et al., 2006; Ho et al., 2012) (Figure 1-6).




Figure 1-6. Influence des sous-unités β hautement exprimés au niveau des petits ou grands neurones de DRG sur le courant $\text{Na}_v1.7$. À gauche, taux d'expression des ARN messagers des 4 sous-unités β en fonction de la taille des neurones extraits des DRG et à droite, probabilité de courant $\text{Na}_v1.7$ spontané et persistant en fonction du potentiel imposé en la présence ou non des sous-unités $\beta1$ ou $\beta3$ (Ho et al., 2012).

Les sous-unités α de canaux sodium impliquées dans la douleur sont $\text{Na}_v1.1$, 1.3, 1.6, 1.7 et Na_x (Gonçalves et al., 2018a). Concernant les sous-unités β , malgré la forte expression des sous-unités $\beta2$ et $\beta3$, il semblerait que la sous-unité $\beta4$ par son association à $\text{Na}_v1.6$ jouerait un rôle crucial dans l'apparition des courants réurgents et serait donc plus impliquée dans la douleur pathologique chronique (Barbosa et al., 2015).

1.1.2. Canaux potassium

Les canaux K_v sont composés d'un tétramère de 4 sous-unités α associées à des sous-unités β , le ratio étant variable.

Les sous-unités α d'environ 50 à 135 kDa, formant le pore, s'assemblent en homotétramère (sous-types identiques) ou hétérotétramère (sous-types non identiques) et ressemblent chacune à un domaine du canal Na_v , regroupant 6 segments transmembranaires hydrophobes reliés entre eux par des boucles intra- et extracellulaires dont les 4 premiers (S1-S4) forment le VSD et sont senseurs du potentiel membranaire alors que les deux derniers (S5-S6), reliés par la boucle P, forment le pore du canal ([Figure 1-7](#)). Les segments du VSD sont arrangés en décalage par rapport aux segments du pore ("domain-swapped arrangement") comme décrit pour tous les canaux ioniques (Catterall et al., 2017). L'activation du canal est assurée par le segment 4 du VSD, chargé positivement, des 4 sous-unités α (par la présence d'arginines). La tétramérisation des 4 sous-unités α est consolidée par l'association de sous-unités β à leur partie N-terminale, ce qui modifie les propriétés du canal (Bahring et al., 2001). Il y a donc une grande diversité de complexes moléculaires ayant des propriétés biophysiques et pharmacologiques différentes.




Figure 1-7. Les sous-unités des canaux potassium dépendants du potentiel (Catterall et al., 2007). Le monomère α du canal K_v et les trois types de sous-unités β ($\text{K}_v\beta$, KChIP , minK). Les cylindres correspondent aux hélices α transmembranaires; en rouge, les segments S5-S6; en vert le segment S4; en bleu, les segments S1-S3). Les glycosylations protéiques sont annotées avec la lettre grecque suivante: ψ .

C'est une famille de 40 membres, classés en 12 sous-familles ($\text{K}_v1.x$ - $\text{K}_v12.x$), qui représente plus de 25% de la superfamille des canaux ioniques dépendants du potentiel (Catterall et al., 2007; Wulff et al., 2009; Alexander et al., 2017). La localisation chromosomique du gène qui encode chacune de ces 40 sous-unités ainsi que leur pattern d'expression témoignent d'une hétérogénéité des sous-unités α ([Tableau 1-2](#)). D'un point de vue électrophysiologique, on peut les classer aussi en 6 groupes, les canaux à rectification retardée qui s'inactivent lentement ou pas du tout ($\text{K}_v1.1-3$, $\text{K}_v1.5-8$, K_v2 , $\text{K}_v3;1-2$, $\text{K}_v7.1-5$, $\text{K}_v10.1$), les canaux potassium de type A qui s'inactivent rapidement ($\text{K}_v1.4$, $\text{K}_v3.3-4$, $\text{K}_v4.1-3$), les canaux à rectification sortante ($\text{K}_v10.2$), les canaux à rectification entrante ($\text{K}_v11.1-3$), les canaux s'activant lentement ($\text{K}_v12.1-3$) et les canaux « silencieux » ($\text{K}_v5.1$, $\text{K}_v6.1-4$, $\text{K}_v8.1-2$, $\text{K}_v9.1-3$). Ils sont impliqués dans la repolarisation de la membrane lors d'un potentiel d'action ([Figure 1-8](#)).

D'un point de vue pharmacologique, des substances inhibent les canaux potassium telles que l'ion tétraéthylammonium (TEA), la 4-aminopyridine (4-AP) ou encore certaines dendrotoxines. D'autres, telles que la régitabine (K_v7.1), l'activent.

Tableau 1-2. Site d'expression, nom et localisation chromosomique du gène des 40 sous-unités α des canaux potassium dépendants du potentiel. Adapté de Wulff et al. (2009).

Protein	Gene	Gene location	Expression
K _v 1.1	KCNA1	12p13	CNS (medulla, pons, cerebellum, midbrain, hippocampus, auditory nuclei), Node of Ranvier Kidney
K _v 1.2	KCNA2	1p13	CNS (pons, medulla, cerebellum, hippocampus, thalamus, cerebral cortex), spinal cord
K _v 1.3	KCNA3	1p13	T and B cells, macrophages, microglia, osteoclasts, platelets, CNS (prominent in olfactory bulb), testis
K _v 1.4	KCNA4	11p14	CNS (olfactory bulb, corpus striatum, hippocampus), heart, skeletal and smooth muscle, pancreatic islets
K _v 1.5	KCNA5	12p13	cardiac myocytes (IK _{Kr}), CNS (hippocampus, cortex, pituitary), microglia, Schwann cells, macrophages vascular smooth muscle
K _v 1.6	KCNA6	12p13	Spinal cord, CNS, oligodendrocyte progenitor cells, astrocytes, pulmonary artery smooth muscle
K _v 1.7	KCNA7	19p13	Heart, skeletal muscle, liver, lung, placenta, CNS
K _v 1.8	KCNA10	1p13	Kidney, CNS, heart, skeletal muscle
K _v 2.1	KCNB1	20q13	CNS (cerebral cortex, hippocampus, cerebellum), pancreatic beta cells, insulinomas, gastric cancer cell
K _v 2.2	KCNB2	8q21	CNS (olfactory bulb, cortex, hippocampus, cerebellum), pancreatic delta cells
K _v 3.1	KCNC1	11p15	CNS (cerebellum, substantia nigra, cortical and hippocampal interneurons, inferior colliculi, cochlear and vestibular nuclei), skeletal muscle, mouse CD8+ T cells
K _v 3.2	KCNC2	12q21	CNS (fast spiking GABAergic interneurons), pancreatic islets, Renshaw cells (spinal interneurons), pancreatic beta cells
K _v 3.3	KCNC3	19q13	CNS (brainstem, cerebellum, forebrain, Purkinje cells, motoneurons, auditory brainstem)
K _v 3.4	KCNC4	1p13	CNS (brainstem, hippocampal granule cells), skeletal muscle
K _v 4.1	KCND1	Xp11	CNS, heart, liver, kidney, thyroid gland, pancreas
K _v 4.2	KCND2	7q31	CNS (cerebellum, hippocampus, thalamus, forebrain, dorsal horn neurons), heart [rodents]
K _v 4.3	KCND3	1p13	Heart, CNS (cortex, cerebellum), atrial and ventricular myocytes (Ito) smooth muscle
K _v 5.1	KCNF1	2p25	-
K _v 6.1	KCNG1	20q13	-
K _v 6.2	KCNG2	18q23	-
K _v 6.3	KCNG3	2p21	-
K _v 6.4	KCNG4	16q24	-
K _v 7.1	KCNQ1	11p15	Heart, ear, skeletal muscle, liver, epithelia in kidney, lung, gastrointestinal tract
K _v 7.2	KCNQ2	20q13	CNS (hippocampus, cortex, thalamus, cerebellum, brain stem, nodes of Ranvier); sympathetic and dorsal root ganglia
K _v 7.3	KCNQ3	8q24	CNS (hippocampus, cortex, thalamus, cerebellum, brain stem), nodes of Ranvier; sympathetic and dorsal root ganglia
K _v 7.4	KCNQ4	1p34	Outer hair cells and neurons of auditory system, vascular smooth muscle
K _v 7.5	KCNQ5	6q13	CNS (hippocampus, cortex, thalamus), skeletal muscle, vascular smooth muscle
K _v 8.1	KCNV1	8q23	-
K _v 8.2	KCNV2	9p24	-
K _v 9.1	KCNS1	20q13	-
K _v 9.2	KCNS2	8q22	-
K _v 9.3	KCNS3	2p24	-
K _v 10.1	KCNH1, eag-1	1q32	CNS
K _v 10.2	KCNH5, eag-2	14q23	CNS, muscle, heart, placenta, lung, liver, kidney, pancreas
K _v 11.1	KCNH2, erg-1, HERG	7q36	Heart, CNS, endocrine cells, lymphocytes
K _v 11.2	KCNH6, erg-2	17q23	CNS, endocrine cells
K _v 11.3	KCNH7, erg-3	2q24	CNS
K _v 12.1	KCNH8, elk-1	3p24	CNS
K _v 12.2	KCNH3, elk-2	12q13	CNS
K _v 12.3	KCNH4, elk-3	17q21	CNS

Les complexes moléculaires de sous-unités α peuvent également être associés à divers types de sous-unités auxiliaires β (K_v β 1-3, KChIp1-4, minK1-5), ce qui permet de modifier leurs propriétés. De

plus, la sous-unité $\beta 1$ des canaux Na_v peut aussi moduler les propriétés biophysiques des sous-types $\text{K}_v 1.1, 1.2, 1.3, 1.6, 4.2$ et 7.2 (Nguyen et al., 2012; Marionneau et al., 2012).

Tout comme les sous-unités β des canaux calcium, les sous-unités auxiliaires $\text{K}_v\beta$ ($\approx 40-45$ kDa) des canaux potassium sont cytoplasmiques mais avec une séquence en acide aminés et une structure complètement différentes. Les sous-unités auxiliaires KChIp (≈ 30 kDa), sont membres de la famille des protéines régulatrices calciques neuronales, comme la calmoduline, et ont quatre motifs main EF ("EF hand").




Figure 1-8. Rôle des canaux potassium dépendants du potentiel. (a) Potentiel d'action (PA) axonal. La conductance potassium est responsable de la repolarisation et de l'hyperpolarisation du PA avec la fermeture des canaux Na_v . (http://ressources.unisciel.fr/physiologie/co/grain3b_1.html). **(b)** PA cardiaque ventriculaire. La conductance potassium générée par les courants I_{TO1} ($\text{K}_v 4.3$) et I_{TO2} ($\text{K}_v 1.4$), I_{Ks} ($\text{K}_v 7.1$), I_{Kr} ($\text{K}_v 11.1$), I_{Kur} ($\text{K}_v 1.5$) permet de rythmer correctement la repolarisation du PA cardiaque (adapté de Nerbonne et Kass, 2005).

Les sous-unités auxiliaires minK ($\approx 11-23$ kDa) sont des glycoprotéines avec un seul segment transmembranaire (Figure 1-7). Les sous-unités auxiliaires $\text{K}_v\beta 1-3$, codées par les gènes $\text{KCNA} 1-3$, sont localisées sur les chromosomes 3q25, 1p36 et 17p13 respectivement. Les sous-unités auxiliaires $\text{KChIp} 1-4$, codées par les gènes $\text{KCNI} 1-4$, sont localisées sur les chromosomes 5q35, 10q24, 2q11 et 4p15, respectivement. Quant aux sous-unités auxiliaires $\text{minK} 1-5$ codées par les gènes $\text{KCNE} 1-5$, elles sont localisées sur les chromosomes 21q22, 21q22, 11q13, 2q36 et Xq23, respectivement. Des mutations de cette sous-unité seraient à l'origine d'arythmies cardiaques graves telles que certaines formes du syndrome du QT long. Concernant leur fonctions respectives, l'association des sous-unités auxiliaires $\text{K}_v\beta$ aux sous-types $\text{K}_v 1$ conduit à la formation d'un second tétramère symétrique qui joue le rôle de porte d'inactivation au niveau de la face intracellulaire du canal. L'association des sous-unités auxiliaires KChIp aux sous-types $\text{K}_v 4$ résulte en une augmentation de leur expression au niveau de la membrane cellulaire et en une altération de leurs propriétés fonctionnelles. Quant aux sous-unités auxiliaires minK , ce sont des régulateurs fonctionnels importants des sous-types $\text{K}_v 7$, mais aussi $\text{K}_v 3, \text{K}_v 4, \text{K}_v 10$ et $\text{K}_v 11$.

Les sous-types de canaux K_v impliqués dans la douleur sont les sous-types $K_v1.4$, $K_v3.4$ et K_v4 , mais aussi les sous-types $K_v9.1/K_v2.1$, K_v7 et $K_v1.2$ dans le cadre de douleur due à des neuropathies traumatiques (Wang et al., 2017b; Zemel et al., 2018).

1.1.3. Canaux calcium

Les canaux Ca_v sont constitués de 5 sous-unités avec un ratio stœchiométrique: une sous-unité α_1 (190 kDa), une glycoprotéine composée d'un dimère de deux sous-unités α_2 et δ reliées par des ponts disulfures (170 kDa), une sous-unité β intracellulaire (55 kDa) et une sous-unité de glycoprotéine γ transmembranaire (33 kDa) (Figure 1-9).

La sous-unité α_1 des canaux Ca_v s'organise comme la sous-unité α_1 des canaux Na_v , soit 4 domaines divisés en 6 segments transmembranaires dont les 4 premiers (S1-S4) forment le VSD et les deux derniers (S5-S6), reliés par la boucle P, forment le pore du canal. L'arrangement des 2 parties de chaque domaine est en décalage. Cependant, elle possède une partie C-terminale beaucoup plus longue que celle des canaux sodium dont la fonction reste inconnue et dont des variants d'épissage existent (Figure 1-2). Il en existe 10, divisées en trois superfamilles de canaux calcium, les canaux à haut seuil d'activation (HVA) Ca_v1 de type L ("long lasting"), les canaux Ca_v2 neuronaux à seuil intermédiaire d'activation (IVA) de types N, P/Q et R et les canaux à bas seuil d'activation (LVA) Ca_v3 de type T (pour "transient" ou "tiny") (Lory et al., 2006; Catterall et al., 2011; Zamponi et al., 2015).




Figure 1-9. Structure globale du sous-type $Ca_v1.1$ de canal calcium de lapin associé à ses 4 sous-unités auxiliaires à une résolution de 3.6 Å (Cryo-ME). Les groupements glycosyl sont indiqués en bâtonnets noirs sur la sous-unité $\alpha_2\delta$. La partie C-terminale (CTD pour "carboxy-terminal domain") forme un domaine globulaire avec la boucle DIII-IV, la sous-unité β_{1a} interagit avec le domaine d'interaction à la sous-unité α_1 (AID pour " α_1 -subunit Interacting Domain") qui est une extension du S6 du DI (Wu et al., 2016). Dans le coin en haut à gauche, une représentation schématique de la structure où sont mentionnés les sites de fixation du ziconotide et du prégabaline.

En plus du classement par leur fonction, les différents sous-types de canaux calcium peuvent être aussi classés en fonction de l'homologie de leur séquence. Il existe 4 sous-types appartenant à la superfamille Ca_v1 , $Ca_v1.1-1.4$ codés par des gènes localisés sur les chromosomes 1q32, 12p13, 3p14 et Xp11 respectivement, partageant un fort pourcentage d'identité entre eux (entre 54,51 et 63,66%). Les membres de la superfamille Ca_v2 , $Ca_v2.1-2.3$ codés par des gènes localisés sur les chromosomes 19p13, 9p34 et 1q25-q31 respectivement, partagent un fort pourcentage d'identité entre eux (entre 53,97 et 59,43%). Ceux de la superfamille Ca_v3 , $Ca_v3.1-3.3$ codés par des gènes localisés sur les chromosomes 17p22, 16p13 et 22q11 respectivement, présentent un pourcentage d'identité entre eux permettant de les classer ensemble (entre 48,60 et 51,08%). Les superfamilles Ca_v1 et Ca_v2 partagent environ 30% d'identité de séquence alors que la superfamille Ca_v3 possède environ 20% d'identité de séquence avec les deux autres superfamilles, tout comme les canaux Ca_v comparés aux canaux Na_v quelle que soit la superfamille étudiée (Tableau 1-3).

Tableau 1-3. Matrice d'identité en pourcentage des sous-unités α des sous-types de Ca_v humain. Les alignements de séquence multiple de haute qualité ont été réalisés grâce à CLUSTAL Oméga, version 1.2.3 (version Web). Les traits noirs délimitent les 3 superfamilles de canaux Ca_v .

Subtypes	hCav1.1	hCav1.2	hCav1.3	hCav1.4	hCav2.1	hCav2.2	hCav2.3	hCav3.1	hCav3.2	hCav3.3	hCav1, hCav2, hCav3
hCav1.1	100.00	54.99	55.08	54.51	31.31	32.85	32.57	19.77	20.28	21.55	7.54
hCav1.2	54.99	100.00	63.66	55.02	31.82	33.31	32.54	19.75	19.26	20.85	
hCav1.3	55.08	63.66	100.00	59.95	32.03	33.36	31.83	19.88	20.17	20.22	
hCav1.4	54.51	55.02	59.95	100.00	30.83	34.47	32.45	20.78	20.54	21.90	
hCav2.1	31.31	31.82	32.03	30.83	100.00	59.43	53.97	19.81	18.54	19.83	
hCav2.2	32.85	33.31	33.36	34.47	59.43	100.00	54.33	21.15	20.32	21.13	
hCav2.3	32.57	32.54	31.83	32.45	53.97	54.33	100.00	20.01	20.12	20.23	
hCav3.1	19.77	19.75	19.88	20.78	19.81	21.15	20.01	100.00	51.22	48.60	
hCav3.2	20.28	19.26	20.17	20.54	18.54	20.32	20.12	51.22	100.00	51.08	
hCav3.3	21.55	20.85	20.22	21.90	19.83	21.13	20.23	48.60	51.08	100.00	

UniprotKB entry identifiant (UEI) - Human (homo sapiens)

UEI	Q13698	Q13936	Q01668	O60840	O00555	Q00975	Q15878	O43497	O95180	Q9P0X4
Gene	CACNA1S	CACNA1C	CACNA1D	CACNA1F	CACNA1A	CACNA1B	CACNA1E	CACNA1G	CACNA1H	CACNA1I
Protein	hCav1.1	hCav1.2	hCav1.3	hCav1.4	hCav2.1	hCav2.2	hCav2.3	hCav3.1	hCav3.2	hCav3.3

Les sous-types de canaux calcium ont des profils d'expression tissulaire bien établis au niveau des cellules excitables musculaires et neuronales et une pharmacologie moléculaire bien définie (Catterall et al., 2005b; 2011; Sousa et al., 2013; Zamponi et al., 2015).

Le **Ca_v1.1**, de type L, codé par le gène CACNA1S, est exprimé au niveau du muscle squelettique et des tubules transverses plus particulièrement.

Le **Ca_v1.2**, de type L, codé par le gène CACNA1C, est exprimé au niveau des cardiomyocytes, des muscles lisses intestinaux et de la vessie, des cellules endocriniennes, des corps cellulaires de certains neurones ainsi qu'au niveau des dendrites proximales dans le SNC.

Le **Ca_v1.3**, de type L, codé par le gène CACNA1D, est exprimé au niveau des cellules endocriniennes, des corps cellulaires de certains neurones ainsi qu'au niveau des dendrites dans le SNC, au niveau des cardiomyocytes atriales et des cellules "pacemaker" et au niveau des cellulaires

ciliées cochléaires et vestibulaires.

Le **Ca_v1.4**, de type L, codé par le gène CACNA1F, s'exprime au niveau des bâtonnets rétiens et des cellules bipolaires, de la moelle épinière, de la glande surrénale et des mastocytes.

Le **Ca_v2.1**, de type P/Q, codé par le gène CACNA1A, s'exprime au niveau des dendrites et des terminaisons des neurones et des cellules neuroendocriniennes.

Le **Ca_v2.2**, de type N, codé par le gène CACNA1B, s'exprime au niveau des dendrites et des terminaisons des neurones et des cellules neuroendocriniennes.

Le **Ca_v2.3**, de type R, codé par le gène CACNA1E, s'exprime au niveau des dendrites et des corps cellulaires des neurones et des cardiomyocytes.

Le **Ca_v3.1**, de type T, codé par le gène CACNA1G, s'exprime au niveau des dendrites et des corps cellulaires des neurones du cervelet et du thalamus, ainsi que des cardiomyocytes et des muscles lisses.

Le **Ca_v3.2**, de type T, codé par le gène CACNA1H, s'exprime au niveau des dendrites et des corps cellulaires des neurones, des cardiomyocytes et des muscles lisses, du foie, du rein, du poumon et du pancréas.

Le **Ca_v3.3**, de type T, codé par le gène CACNA1I, s'exprime au niveau des dendrites et des corps cellulaires des neurones.

Les membres de la superfamille Ca_v1 (type L) initient la contraction, la sécrétion, la régulation de l'expression des gènes, l'intégration des entrées synaptiques dans les neurones et la transmission synaptique dans les cellules sensorielles spécialisées. Les membres de la superfamille Ca_v2 (types P/Q, N et R) sont principalement responsables de l'initiation de la transmission synaptique. Les membres de la superfamille Ca_v3 (type T) sont importants pour le déclenchement répétitif des potentiels d'action dans les cellules rythmiques telles que les cardiomyocytes et les neurones du thalamus ([Figure 1-10](#); Catterall et al., 2011).

Sur le plan pharmacologique, des petites molécules, telles que les dihydropyridines, ont permis d'identifier les membres de la superfamille Ca_v1 dans des systèmes natifs. De même, des toxines peptidiques de venins d'animaux, telles que l' ω -agatoxine IVA, l' ω -conotoxine GVIA et l' ω -théraphotoxine-Hg1a (SNX-482), ont permis d'identifier chaque sous-type de canaux Ca_v2. Concernant les membres de la superfamille Ca_v3, il n'y a pas vraiment de bloqueurs sélectifs qui ont permis leur découverte mais il existe des antagonistes tels que le mibéfradile et le pimozide ([Tableau 1-4](#); Catterall et al., 2005b; Sousa et al., 2013).

Bien que la sous-unité $\alpha 1$ soit responsable des principales caractéristiques électrophysiologiques et pharmacologiques, les sous-unités auxiliaires $\alpha 2\delta$, β et γ modulent les propriétés d'ouverture et de fermeture du canal.




Figure 1-10. Exemple de certaines fonctions des trois superfamilles de canaux calcium Ca_v . (a) Rôle des $Ca_v2.2$ dans la transmission synaptique. La région correspondant aux acides aminés 772-856 du sous-type $Ca_v2.2$, nommée "synprint" permet l'arrimage des vésicules à la membrane (Chai et al., 2017). (b) Au niveau du nœud sino-atrial, les canaux Ca_v1 et Ca_v3 sont mis en jeu dans la genèse du potentiel d'action (PA) sinusal. La phase ascendante 0 du PA met principalement en jeu les canaux Ca_v1 . Les canaux Ca_v3 et Na_v avec l'aide des canaux HCN (responsables du courant I_f) permettent au potentiel d'arriver au potentiel "seuil". Les canaux potassium sont responsables de la phase de repolarisation du PA (<https://www.cvphysiology.com/textbook>). (c) Le PA cardiaque met en jeu le sous-type de canaux Ca_v1 et Ca_v3 . Les canaux Ca_v1 , qui s'inactivent plus lentement que les canaux Ca_v3 , sont responsables du plateau du PA cardiaque (phase 2). Les canaux Ca_v3 , par leurs propriétés d'activation à des valeurs de potentiel plus négatives, permettent le déclenchement de celui-ci (phase 0-1). Adapté de Nerbonne et Kass (2005).

Quatre gènes CACNA2D1-4 principalement, localisés sur les sites chromosomiques 7q21, 3p21, 3p21-p14 et 12p13 codent respectivement pour les sous-unités auxiliaires $\alpha 2\delta$ -1, 2, 3 et 4 qui s'expriment de façon ubiquitaire dans les cellules, qu'elles soient excitables (musculaires et neuronales) ou non. On retrouve plus particulièrement dans les neurones les sous-types $\alpha 2\delta$ -2 et $\alpha 2\delta$ -3, le sous-type $\alpha 2\delta$ -4 étant exprimé plutôt au niveau des neurones rétiniens. La sous-unité $\alpha 2$ est une glycoprotéine extracellulaire et extrinsèque à la membrane attachée par des ponts disulfures à celle-ci par la sous-unité δ qui est ancrée à la membrane par un GPI (glycophosphatidylinositol). C'est sur les sous-types de cette sous-unité $\alpha 2\delta$ -1 et $\alpha 2\delta$ -2 que se fixent les anti-épileptiques gabapentine et prégabaline pour traiter les douleurs neuropathiques et certaines formes d'épilepsie. Des effets anxiolytiques et antipyrétiques dans un modèle rongeur sont aussi décrits (Field et al.,

2006; Lotarski et al., 2011, Lotarski et al., 2014).

Tableau 1-4. Caractéristiques physiologiques et pharmacologiques des canaux Ca_v . Adapté de Sousa et al. (2013). DHP: Dihydropyridine, PHA: Phénylalkylamine, BTZ: Benzithiazépine, Ni^{2+} :Nickel, Zn^{2+} :Zinc.

	Ca_v subtype	Current type	Antagonist class/Name		Ca_v subtype	Current type	Antagonist class/Name
HVA	$Ca_v1.1$	L	DHP, PHA, BTZ	IVA	$Ca_v2.1$	P/Q	ω -agatoxin IVA
	$Ca_v1.2$	L	DHP, PHA, BTZ		$Ca_v2.2$	N	ω -conotoxin CVID, GVIA MVIIA
	$Ca_v1.3$	L	DHP, PHA, BTZ		$Ca_v2.3$	R	ω -theraphotoxin-Hg1a (SNX-482)
	$Ca_v1.4$	L	DHP, PHA, BTZ	LVA	$Ca_v3.1$	T	Pimozide, mibefradil, TTA-P2, Ni^{2+} , Zn^{2+}
					$Ca_v3.2$	T	Kurtoxin, pimopzide, mibefradil, Z123212, TTA-P2, Ni^{2+} , Zn^{2+}
					$Ca_v3.3$	T	Pimozide, TTA-P2, Zn^{2+} , Ni^{2+} , mibefradil

Des mutations humaines sur $\alpha2\delta-1$ sont associées à des troubles cardiaques, incluant le syndrome Brugada et le syndrome du QT court (Templin et al., 2011; Bourdin et al., 2015). Une expression augmentée est observée dans les neurones de DRG lésés ou dans un modèle rongeur de douleur neuropathique, diminuant les effets des antagonistes des $Ca_v2.2$ (Luo et al., 2001; Luo et al., 2002). Il existe 4 sous-types de sous-unités β codés par 4 gènes situés sur les sites chromosomiques 17q12, 10p12, 12q13 et 2q23. Ce sont des sous-unités cytoplasmiques constituées d'hélices alpha qui se fixent sur la partie proximale de la boucle intracellulaire reliant le DI et le DII, sur une région de 18 acides aminés nommée AID (pour " $\alpha1$ -interaction domain"), domaine d'interaction avec la sous-unité $\alpha1$. Elles s'expriment de façon ubiquitaire et agit plutôt comme une chaperonne qui permet le bon repliement de la sous-unité $\alpha1$ et la protège ainsi de la dégradation en favorisant son arrimage à la membrane. L'interruption de l'interaction entre la sous-unité β et $\alpha1$ serait une bonne approche thérapeutique dans certaines conditions, par exemple de douleurs chroniques (Young et al., 1998). Des mutations de la sous-unité auxiliaire β seraient liées à des formes d'épilepsie et de dysfonctions cardiaques. La sous-unité γ est une glycoprotéine avec 4 segments transmembranaires, mise en évidence initialement sur le muscle squelettique, cependant des sous-types ont été récemment trouvés au niveau du cerveau. Sur un plan pharmacologique, la sous-unité γ n'a pas été clairement étudiée. Il semblerait que contrairement aux sous-unités auxiliaires $\alpha2\delta$ et β qui ont des effets synergétiques positifs sur la densité de courant des différents canaux calciques, la sous-unité γ aurait des effets négatifs sur le courant calcium (Sousa et al., 2013).

Les sous-unités $\alpha 1$ des canaux calcium dépendants du potentiel, impliquées dans la douleur sont $Ca_v2.2$, $Ca_v3.2$; les sous-unités auxiliaires $\alpha 2\delta-1$ et β le sont aussi (Saegusa et al., 2001; Sousa et al., 2013; François et al., 2014; Sekiguchi et al., 2018).

1.1.4. Canalopathies

Des mutations au niveau des canaux ioniques dépendants du potentiel sont souvent à l'origine de beaucoup de maladies génétiques que l'on nomme communément "canalopathies". Parmi ces canalopathies, beaucoup d'entre elles sont aussi référencées par Orphanet en Europe pour être associées à des maladies rares, maladies définies par son homogénéité clinique, indépendamment de son étiologie ou du nombre de gènes impliqués dont la prévalence (nombre de malades à un instant précis t) est inférieure à 1 personnes sur 2000 selon la commission européenne (http://europa.eu/rapid/press-release_IP-97-480_fr.htm). Cette prévalence des maladies rares est définie par chaque nation. Par exemple, aux USA, elle tombe à 1/1500 selon *rare Disease Act of 2002*.

Sous la forme de tableaux sont présentées les canalopathies et maladies orphelines humaines associées à chaque sous-type de canaux Na_v , K_v et Ca_v (Tableaux 1-5 à 1-10). Elles sont liées au site d'expression de chaque sous-type de canal ionique étudié, et sont résumées ci-dessous.

- ✓ Canalopathies affectant le SNC qui s'exprime par différentes formes d'épilepsie, d'ataxies, de migraines ainsi que les troubles neurodéveloppementaux (une multitude de mutations peuvent être mises en cause touchant les $Na_v1.1-3$, $Na_v1.6-8$, les $K_v2.1$, $K_v3.1$, $K_v3.3$, $K_v4.2-3$, $K_v7.2-3$, $K_v7.5$ et $K_v10.1$ ainsi que les $Ca_v2.1$, $Ca_v3.1-2$).
- ✓ Canalopathies affectant le SNP plus particulièrement le système sensoriel qui traite le message douloureux (un nombre non négligeable de mutations touchant principalement $Na_v1.7-9$).
- ✓ Canalopathies affectant les tissus musculaires squelettiques (les mutations touchent principalement $Na_v1.4$, $Ca_v1.1$ et $Ca_v2.2$).
- ✓ Canalopathies affectant les tissus cardiaques (les mutations touchent $Na_v1.5$, $K_v1.5$, $K_v4.3$, $K_v7.1$, $K_v11.1$, $Ca_v1.2$ et $Ca_v1.3$).
- ✓ Canalopathies affectant le système visuel ($K_v8.2$, $Ca_v1.4$).
- ✓ Canalopathies affectant le système auditif ($K_v7.4$).

Ce résumé met en évidence le rôle important joué par ces sous-types de canaux ioniques dans chacun des systèmes physiologiques où ils sont exprimés. D'un point de vue moins réducteur, des canalopathies acquises apparaissent par exemple suite à l'exposition aux xénobiotiques, substances étrangères au corps humain et le polluant (Imbrici et al., 2018).

Tableau 1-5. Canalopathies associées aux sous-types Na_v . Les informations ont été extraites de la base de données "UniprotKB".

$Na_v1.1$	Generalized epilepsy with febrile seizures plus 2 (GEFS+2) Epileptic encephalopathy, early infantile, 6 (EIEE6) Intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC) Migraine, familial hemiplegic, 3 (FHM3) Febrile seizures, familial, 3A (FEB3A) Neurodevelopmental disorders (autism)
$Na_v1.2$	Epileptic encephalopathy, early infantile, 11 (EIEE11) Seizures, benign familial infantile, 3 (BFIS3) Autism spectrum disorder (ASD)
$Na_v1.3$	Epilepsy, familial focal, with variable foci 4 (FFEVF4) Epileptic encephalopathy, early infantile, 62 (EIEE62)
$Na_v1.4$	Paramyotonia congenita of von Eulenburg (PMC) Periodic paralysis hypokalemic 2 (HOKPP2) Periodic paralysis hyperkalemic (HYPP) Periodic paralysis normokalemic (NKPP) Myotonia SCN4A-related (MYOSCN4A)
$Na_v1.5$	Progressive familial heart block 1A (PFHB1A) Long QT syndrome 3 (LQT3) Brugada syndrome 1 (BRGDA1) Sick sinus syndrome 1 (SSS1) Familial paroxysmal ventricular fibrillation 1 (VF1) Sudden infant death syndrome (SIDS) Atrial standstill 1 (ATRST1) Cardiomyopathy, dilated 1E (CMD1E) Atrial fibrillation, familial, 10 (ATFB10)
$Na_v1.6$	Cognitive impairment with or without cerebellar ataxia (CIAT) Epileptic encephalopathy, early infantile, 13 (EIEE13) Seizures, benign familial infantile, 5 (BFIS5)
$Na_v1.7$	Primary erythermalgia (PERYTHM) Indifference to pain, congenital, autosomal recessive (CIP) Paroxysmal extreme pain disorder (PEPD) Generalized epilepsy with febrile seizures plus 7 (GEFS+7) Febrile seizures, familial, 3B (FEB3B)
$Na_v1.8$	Episodic pain syndrome, familial, 2 (FEPS2)
$Na_v1.9$	Neuropathy, hereditary sensory and autonomic, 7 (HSAN7) Episodic pain syndrome, familial, 3 (FEPS3)

Tableau 1-6. Maladies orphelines associées aux sous-types Na_v. Les informations ont été extraites de la base de données "Orphanet".

Na_v1.1	Dravet syndrome Familial or sporadic hemiplegic migraine Generalized epilepsy with febrile seizures-plus Lennox-Gastaut syndrome Malignant migrating partial seizures of infancy
Na_v1.2	Benign familial infantile epilepsy Benign familial neonatal-infantile seizures Dravet syndrome Early infantile epileptic encephalopathy Generalized epilepsy with febrile seizures-plus West syndrome
Na_v1.3	-
Na_v1.4	Acetazolamide-responsive myotonia Hyperkalemic periodic paralysis Hypokalemic periodic paralysis Myotonia fluctuans Myotonia permanens Paramyotonia congenita of Von Eulenburg Postsynaptic congenital myasthenic syndromes
Na_v1.5	Atrial stand still Brugada syndrome Familial atrial fibrillation Familial isolated dilated cardiomyopathy Familial progressive cardiac conduction defect Familial sick sinus syndrome Idiopathic ventricular fibrillation, not Brugada type Romano-Ward syndrome
Na_v1.6	Early infantile epileptic encephalopathy
Na_v1.7	Channelopathy-associated congenital insensitivity to pain Dravet syndrome Erythromelalgia Generalized epilepsy with febrile seizures-plus Hereditary sensory and autonomic neuropathy type 2 Paroxysmal extreme pain disorder Primary erythermalgia Sodium channelopathy-related small fiber neuropathy
Na_v1.8	Channelopathy-associated congenital insensitivity to pain Paroxysmal extreme pain disorder Primary erythermalgia Sodium channelopathy-related small fiber neuropathy
Na_v1.9	Channelopathy-associated congenital insensitivity to pain Familial episodic pain syndrome with predominantly lower limb involvement Hereditary sensory and autonomic neuropathy type 7 Paroxysmal extreme pain disorder Primary erythermalgia Sodium channelopathy-related small fiber neuropathy

Tableau 1-7. Canalopathies associées aux sous-types K_v. Les informations ont été extraites de la base de données "UniprotKB".

K_v1.1	Episodic ataxia 1 (EA1) Myokymia isolated 1 (MK1)
K_v1.2	Epileptic encephalopathy, early infantile, 32 (EIEE32)
K_v1.3	-
K_v1.4	-
K_v1.5	Atrial fibrillation, familial, 7 (ATFB7)
K_v1.6	-
K_v1.7	-
K_v1.8	-
K_v2.1	Epileptic encephalopathy, early infantile, 26 (EIEE26)
K_v2.2	-
K_v3.1	Epilepsy, progressive myoclonic 7 (EPM7)
K_v3.2	-
K_v3.3	Spinocerebellar ataxia 13 (SCA13)
K_v3.4	-
K_v4.1	-
K_v4.2	Temporal lobe epilepsy ASD and epilepsy
K_v4.3	Spinocerebellar ataxia 19 (SCA19) Brugada syndrome 9 (BRGDA9)
K_v5.1	-
K_v6.1	-
K_v6.2	-
K_v6.3	-
K_v6.4	-
K_v7.1	Long QT syndrome 1 (LQT1) Jervell and Lange-Nielsen syndrome 1 (JLNS1) Atrial fibrillation, familial, 3 (ATFB3) Short QT syndrome 2 (SQT2) Diabetes mellitus, non-insulin-dependent (NIDDM)
K_v7.2	Seizures, benign familial neonatal 1 (BFNS1) Epileptic encephalopathy, early infantile, 7 (EIEE7)
K_v7.3	Seizures, benign familial neonatal 2 (BFNS2)
K_v7.4	Deafness, autosomal dominant, 2A (DFNA2A)
K_v7.5	Mental retardation, autosomal dominant 46 (MRD46)
K_v8.1	-
K_v8.2	Cone dystrophy retinal 3B (RCD3B)
K_v9.1	-
K_v9.2	-
K_v9.3	-
K_v10.1	Temple-Baraitser syndrome (TMBTS) Zimmermann-Laband syndrome 1 (ZLS1)
K_v10.2	-
K_v11.1	Long QT syndrome 2 (LQT2) Short QT syndrome 1 (SQT1)
K_v11.2	-
K_v11.3	-
K_v12.1	-
K_v12.2	-
K_v12.3	-

Tableau 1-8. Maladies orphelines associées aux sous-types Kv. Les informations ont été extraites de la base de données "Orphanet".

K_v1.1	Episodic ataxia type 1 Hereditary continuous muscle fiber activity Isolated autosomal dominant hypomagnesemia, Glaudemans type
K_v1.2	-
K_v1.3	-
K_v1.4	-
K_v1.5	Familial atrial fibrillation
K_v1.6	-
K_v1.7	-
K_v1.8	-
K_v2.1	Early infantile epileptic encephalopathy
K_v2.2	-
K_v3.1	-
K_v3.2	-
K_v3.3	Spinocerebellar ataxia type 13
K_v3.4	-
K_v4.1	-
K_v4.2	Temporal lobe epilepsy ASD and epilepsy
K_v4.3	Brugada syndrome Spinocerebellar ataxia type 19/22
K_v5.1	-
K_v6.1	-
K_v6.2	-
K_v6.3	-
K_v6.4	-
K_v7.1	Familial atrial fibrillation Familial short QT syndrome Jervell and Lange-Nielsen syndrome Romano-Ward syndrome
K_v7.2	Benign familial infantile epilepsy Benign familial neonatal seizures Benign familial neonatal-infantile seizures Early infantile epileptic encephalopathy
K_v7.3	Benign familial infantile epilepsy Benign familial neonatal seizures Juvenile myoclonic epilepsy
K_v7.4	Autosomal dominant non-syndromic sensorineural deafness type DFNA
K_v7.5	-
K_v8.1	-
K_v8.2	Cone dystrophy with supernormal rod response
K_v9.1	-
K_v9.2	-
K_v9.3	-
K_v10.1	-
K_v10.2	-
K_v11.1	Familial short QT syndrome Romano-Ward syndrome
K_v11.2	-
K_v11.3	-
K_v12.1	-
K_v12.2	-
K_v12.3	-

Tableau 1-9. Canalopathies associées aux sous-types Ca_v. Les informations ont été extraites de la base de données "UniprotKB".

Ca_v1.1	Periodic paralysis hypokalemic 1 (HOKPP1) Malignant hyperthermia 5 (MHS5) Thyrotoxic periodic paralysis 1 (TTPP1)
Ca_v1.2	Timothy syndrome (TS) Brugada syndrome 3 (BRGDA3)
Ca_v1.3	Sinoatrial node dysfunction and deafness (SANDD) Primary aldosteronism, seizures, and neurologic abnormalities (PASNA)
Ca_v1.4	Night blindness, congenital stationary, 2A (CSNB2A) Cone-rod dystrophy, X-linked 3 (CORDX3) Aaland island eye disease (AIED)
Ca_v2.1	Spinocerebellar ataxia 6 (SCA6) Migraine, familial hemiplegic, 1 (FHM1) Episodic ataxia 2 (EA2) Epileptic encephalopathy, early infantile, 42 (EIEE42)
Ca_v2.2	Dystonia 23 (DYT23)
Ca_v2.3	-
Ca_v3.1	Spinocerebellar ataxia 42 (SCA42)
Ca_v3.2	Epilepsy, idiopathic generalized 6 (EIG6) Epilepsy, childhood absence 6 (ECA6) Hyperaldosteronism, familial, 4 (HALD4)
Ca_v3.3	-

Tableau 1-10. Maladies orphelines associées aux sous-types Ca_v. Les informations ont été extraites de la base de données "Orphanet".

Ca_v1.1	Hypokalemic periodic paralysis Malignant hyperthermia Periodic paralysis with transient compartment-like syndrome Thyrotoxic periodic paralysis
Ca_v1.2	Brugada syndrome Timothy syndrome
Ca_v1.3	Aldosterone-producing adenoma Aldosterone-producing adenoma with seizures and neurological abnormalities Sinoatrial node dysfunction and deafness
Ca_v1.4	Aland Islands eye disease Cone rod dystrophy Congenital stationary night blindness
Ca_v2.1	Alternating hemiplegia of childhood Benign paroxysmal torticollis of infancy Familial or sporadic hemiplegic migraine Familial paroxysmal ataxia Spinocerebellar ataxia type 6
Ca_v2.2	-
Ca_v2.3	-
Ca_v3.1	-
Ca_v3.2	Childhood absence epilepsy
Ca_v3.3	-

1.2. Toxines

Une toxine peut-être définie comme un poison, une substance telle qu'une petite molécule organique, un peptide ou une protéine, produit par l'activité métabolique d'un organisme vivant (bactérie, champignon vénéneux, plantes, algues, animaux venimeux), hautement toxique pour un ou plusieurs autres organismes vivants. On parle aussi de "biotoxines" car elles sont extraites d'organismes vivants. Selon la spécificité d'action, il y a des neurotoxines, myotoxines, des hémotoxines, des cytotoxines, des dermatotoxines, des hépatotoxines et des néphrotoxines. Ce n'est pas la substance qui est toxique mais la dose qui est ingérée ou injectée à l'organisme cible, d'où l'idée d'utiliser ces toxines comme médicaments dans une fenêtre thérapeutique non toxique.

Une partie non négligeable (11%) des médicaments, considérés comme basiques, essentiels à la pharmacopée par l'Organisation Mondiale de la Santé (OMS) et actuellement sur le marché, sont extraits des plantes et décrits comme plus efficaces et plus sûrs pour l'être humain (Veeresham, 2012). Les métabolites secondaires des plantes, aussi nommés "toxines", font déjà partie de la pharmacopée. On retrouve, par exemple, les hétérosides cardiotoniques (digitaline, ouabaine) qui ont des effets tonocardiaques comme leur nom l'indique, les alcaloïdes tropaniques (atropine, hyoscyamine, scopolamine) qui provoquent des effets musculaires relaxants, les opioïdes (morphine, codéine, thébaïne, narcotine) et la capsaïcine associés à des effets antalgiques, le quinquina et l'artémisinine à des effets antipaludiques, les dérivés de la cocaïne (xylocaïne, novocaïne...) induisant des effets anesthésiques et la vinblastine et le paclitaxel des effets antitumoraux (Sevenet, 2006; Veeresham, 2012). Explorer d'autres sources de molécules à potentiel thérapeutique pourrait permettre de mettre en évidence d'autres classes de molécules avec des activités nouvelles. C'est dans ce cadre que l'étude des venins d'animaux, source d'une immense diversité de toxines pouvant élargir potentiellement le panel thérapeutique actuel, devient opportune.

1.2.1. Toxines et canaux ioniques

Le venin est défini comme "une sécrétion, produite dans une glande spécialisée chez un animal et délivrée à une proie à l'aide d'un appareil inoculateur (crochet, harpon, dard...), qui contient des molécules qui perturbent les processus physiologiques normaux dans la victime de manière à faciliter l'alimentation ou la défense de l'animal producteur de venin". Les serpents, araignées, scorpions, cônes marins et anémones de mer représentent la majorité des organismes venimeux étudiés jusqu'à présent. D'autres (tels que les oursins, étoiles de mers, fourmis, centipèdes, abeilles, guêpes, moustiques, tiques, lézards...) ont été plus négligés. Cependant, chaque venin est unique de par la diversité des molécules qui le constituent et de par l'expression de ces molécules selon les saisons,

l'étape du développement de l'animal et le but à atteindre, *i.e.* prédation ou défense (Dutertre et al., 2014; Santana et al., 2017; Tobassum et al., 2018). Il ne faut donc pas négliger une espèce venimeuse par rapport à une autre car chacune présente un venin qui lui est propre.

Le venin est composé de sels inorganiques, de petites molécules organiques, ainsi que de protéines à haute masse moléculaire incluant les enzymes. Cependant, les peptides riches en cystéines (< 10 kDa) et les polypeptides (> 10 kDa) sont la classe de molécules les plus abondantes dans ces sécrétions venimeuses (King et al., 2008; Fry et al., 2009; Pennington et al., 2018). Parmi les différents composés des venins d'animaux, les peptides riches en cystéines se sont révélées être des ligands puissants des canaux Na_v , K_v et Ca_v . Les toxines peptidiques inhibant/modulant ces canaux sont principalement extraites de cônes, d'anémones de mer, d'araignées, de scorpions, de serpents (Figure 1-11; Gilchrist et al., 2014; Gandini et al., 2015; Norton & Chandy, 2017). Ces peptides sont de puissants outils permettant d'étudier les différents sous-types d'une même famille de canaux ioniques ayant des fonctions proches, des patterns d'expression proches et partageant un fort pourcentage d'identité de séquence. Par exemple, l'étude de certains sous-types ou certaines superfamilles de canaux calcium a été permise par la découverte de toxines peptidiques très sélectives d'un sous-type ou d'une superfamille donné (Tableau 1-11). Concernant les toxines peptidiques ciblant les canaux K_v ou Ca_v , certaines d'entre elles sont devenues des médicaments, comme par exemple l' ω -conotoxine-MVIIA (Prialt), antalgique dans le traitement de douleurs chroniques rebelles, ou sont en cours d'évaluation en phase clinique de phases I-II, comme la ShK-186 (Dalazatide) ainsi que d'autres analogues de la ShK (ShK-170 ou ShK-192) comme immunomodulateurs dans le traitement de maladies auto-immunes telles que la sclérose en plaques ou l'arthrite rhumatoïde. On remarque cependant une absence de représentation des toxines peptidiques ciblant les canaux Na_v (Tableau 1-12).

1.2.2. Toxines - Na_v - Modulations des propriétés biophysiques

Malgré l'absence de molécules peptidiques dérivées de venin ciblant les canaux Na_v sur le marché ou tout du moins en phase clinique, la mise en évidence de cette catégorie de molécules représente un axe de recherche important. Tout d'abord, les canaux Na_v représentent une cible thérapeutique de choix puisque de nombreux anti-arythmiques cardiaques de classe I (tels que la méxilitine, la flécaïne), anti-épileptiques (tels que le carbamazépine, l'oxcarbazépine), analgésiques locaux (tels que la lidocaïne) sont déjà sur le marché et ciblent spécifiquement ces canaux. De plus, la plupart des toxines dérivées des venins ciblent les canaux Na_v du fait de leur importance dans l'initiation du potentiel d'action (Kalia et al., 2015). Au niveau de ces canaux, elles se fixent sur

différents sites associés à des modifications de leurs propriétés biophysiques (de Lera Ruiz & Kraus, 2015; Israel et al., 2017).




Figure 1-11. Convergence observée de l'action des neurotoxines extraites de différentes espèces animales (Fry et al., 2009). Les principales cibles sont les canaux sodium, potassium et calcium dépendants du potentiel, ainsi que les récepteurs nicotiniques et muscariniques de l'acétylcholine.

Tableau 1-11. Exemples de toxines peptidiques ciblant les canaux Ca_v selon le type de famille (Gandini et al., 2015).

Selectivity	Toxin	Lenght	Source	Concentration
L-type	Calciseptine	60 aa	<i>Dendroaspis polylepis polylepis</i>	100 nM-2 μM
	FS-2	60 aa	<i>Dendroaspis polylepis polylepis</i>	100 nM-2 μM
	Calcicludine	60 aa	<i>Dendroaspis angusticeps</i>	1-10 nM
P/Q-type	ω-Agatoxin IVA	48 aa	<i>Agelenopsis aperta</i>	20 nM-1 μM
	ω-Agatoxin IVB	48 aa	<i>Agelenopsis aperta</i>	100-800 nM
P/Q & N-type	ω-Grammotoxin SIA	36 aa	<i>Grammostola spatulata</i>	50 -500 nM
	ω-PnTx3-3	34 aa	<i>Phoneutrica nigriventer</i>	60-100 nM
	Phonetoxin IIA	76 aa	<i>Phoneutrica nigriventer</i>	60-100 nM
N-type	ω-Conotoxin GVIA	27 aa	<i>Conus geographus</i>	100 nM-1 μM
	ω-Conotoxin MVIIA	25 aa	<i>Conus magus</i>	100 nM-2 μM
	ω-Conotoxin MVIIC	26 aa	<i>Conus magus</i>	50 nM-1 μM
	ω-Conotoxin CVID	27 aa	<i>Conus catus</i>	10-100 nM
R-type	SNX482	41 aa	<i>Hysteroocrates gigas</i>	10-100 nM
T-type	Kurtoxin	63 aa	<i>Parabuthus transvaalicus</i>	50 -500 nM
	ProTx-I	35 aa	<i>Thrixopelma pruriens</i>	10-100 nM
	ProTx-II	30 aa	<i>Thrixopelma pruriens</i>	10-500 nM

Le préfixe grec utilisé pour nommer les toxines ciblant les canaux Na_v donne déjà une indication sur les effets attendus de chacune d'entre elle: α , pour les toxines de scorpions ralentissant et inhibant une partie de l'inactivation et affectant la dépendance vis-à-vis du potentiel de la courbe d'inactivation; β , pour les toxines affectant la dépendance vis-à-vis du potentiel de la courbe d'activation; δ , pour les toxines ralentissant et inhibant une partie de l'inactivation; μ , pour les toxines bloquant le pore du canal (King et al., 2008).

Tableau 1-12. Pharmacologie des composés dérivés de venins d'animaux sélectionnés.
Adapté de King et al. (2011).

Protein or derivative	Source of venom protein	Molecular target	Indication	FDA approval	Company
Captopril [‡] (Capoten [®])	Pit viper (snake)	ACE	Hypertension	1981	Bristol-Myers Squibb
Eptifibatide [§] (Integrilin [®])	Pygmy rattlesnake	$\alpha_{IIb}\beta_3$ integrin receptor	Acute coronary syndromes	1998	Merck
Tirofiban [¶] (Aggrastat [®])	Saw-scaled viper (snake)	$\alpha_{IIb}\beta_3$ integrin receptor	Acute coronary syndromes	1999	Iroko Cardio and Merck (USA only)
Bivalirudin [#] (Angiomax [®])	Medicinal leech	Thrombin	Coagulation during surgery	2000	The Medicines Co.
Ziconotide ^{**} (Prialt [®])	Cone snail	$Ca_v2.2$ channel	Chronic pain	2004	Azur Pharma and Eisai (Europe)
Exenatide (Byetta [®])	Lizard (Gila monster)	GLP-1 receptor ^{††}	Type 2 diabetes	2005	Amylin and Eli Lilly
Batroxobin (Baquting)	Lancehead snake	Fibrinogen	Perioperative bleeding	Outside USA ^{§§}	Nuokang Biopharma

Protein or derivative	Source of venom protein	Molecular target	Indication	Trial Phase	Company
Xen2174 (χ -CTX MrlA)	Cone snail	Norepinephrine transporter	Postoperative pain	II	Xenome Ltd
BAY86-7548 (bombesin) [‡]	Fire-bellied toad	Gastrin-releasing peptide receptor	Prostate cancer imaging	I	Bayer
CNSB004 (Leconotide) [§]	Cone snail	$Ca_v2.2$ channel	Neuropathic pain	I	Relevare Pharmaceuticals
ShK-192	Sea anemone	$K_v1.3$ channel	Autoimmune disease	I (first quarter 2012)	Airmid
Tumor Paint (chlorotoxin) [¶]	Deathstalker scorpion	Annexin A2	Tumor marker for surgery	I	TransMolecular
Cenderitide (CD-NP) [#]	Eastern green mamba (snake)	Natriuretic peptide receptor	Congestive heart failure	II	Nile Therapeutics
RPI-MN (α -cobrotoxin) ^{**}	Cobra (snake)	nAChR	HIV	I	ReceptoPharm
RPI-78M (α -cobrotoxin) ^{††} Agkistrodon ^{§§} (agkisacutacin)	Cobra (snake) Sharp-nosed viper	nAChR Fibrin(ogen)	Multiple sclerosis Perioperative bleeding	I III	ReceptoPharm China Nuokang Bio-Pharmaceutical
Desmoteplase (rDSPA α 1) ^{¶¶}	Common vampire bat	Plasminogen	Acute ischemic stroke	III	H. Lundbeck A/S

Le **site 1** est formé par les quatre boucles P constituant le pore du canal [plus particulièrement, le filtre de sélectivité formé par les acides aminés D, E, K, A, et le vestibule extracellulaire (Penzotti et al., 1998). Il représente le site de fixation des toxines telles que la TTX, la saxitoxine (STX) et les μ -conotoxines dont le principal effet est l'obstruction du pore et, en conséquence, une inhibition du courant sodium en fonction du temps et du potentiel (Figures 1-12 et 1-13).

Le **site 2** est constitué par le segment S6 des domaines DI et DIV. Il permet la fixation des toxines telles que la batrachotoxine, la vératridine et l'antillatoxine qui entraînent une inhibition de l'inactivation (courant sodium maintenu en fonction du temps tout au long de l'impulsion dépolarisante) (Figure 1-12).

Le **site 3** est formé par la boucle reliant les segments S3-S4 du domaine DIV. Il représente le site de fixation des toxines α de scorpion qui ralentissent ou inhibent une partie de l'inactivation en empêchant le mouvement vers l'extérieur du segment S4, sans modifier la cinétique d'activation, et affectent la dépendance vis-à-vis du potentiel de la courbe d'inactivation avec des effets mineurs sur la dépendance vis-à-vis du potentiel de la courbe d'activation (Figures 1-12 et 1-13). Des toxines d'autres espèces (anémones de mer, cônes, araignées et serpents) présentent les mêmes effets sur le canal sodium. Cependant, le site de fixation n'est pas toujours le même.

Le **site 4** est formé des boucles extracellulaires reliant les segments S1-S2 et S3-S4 du domaine DII (Figure 1-12). Il représente le site de fixation des toxines β de scorpions et de certaines toxines d'araignées. Les toxines β de scorpions provoquent généralement un déplacement de la courbe d'activation vers des valeurs de potentiel plus négatives, ce qui résulte en une augmentation du pic de courant (Figure 1-13, exemple de la Css-IV). Les toxines d'araignées, quant à elles, produisent un déplacement de la courbe d'activation vers des valeurs de potentiel plus positives, ce qui provoque une diminution du pic du courant (Figure 1-13, exemple de la protoxine-II) mais ce n'est pas une caractéristique générale des théréphotoxines se fixant sur le site 4 (exemple de l'huwentoxine-IV).

Le **site 5** est formé du segment S6 du domaine DI et du segment S5 du domaine DIV. Il constitue le site de fixation des ciguatoxines et des brevéttoxines qui ralentissent ou inhibent une partie de l'inactivation des canaux sodium (Figure 1-12).

Le **site 6** est formé du segment S4 du domaine DIV et représente le site de fixation des μ O- et δ -conotoxines dont le principal effet est de bloquer les domaines senseurs du potentiel à l'état fermé sans affecter la dépendance du courant vis-à-vis du potentiel, ce qui se traduit par une diminution du pic du courant (Figures 1-12 et 1-13). Certaines toxines d'araignées présentent les mêmes effets sans que leur site de fixation ne soit connu.

Le **site des anesthésiques locaux** est formé des portions intracellulaires du segment 6 des domaines DI, DII et DIV du pore ouvert (Figure 1-12). C'est aussi le site de fixation principal de toutes les molécules citées précédemment et déjà sur le marché (telles que les anti-arythmiques, les antiépileptiques...). D'autres molécules, telles que la benzocaïne et la phénytoïne, peuvent inhiber le canal sodium en atteignant la cavité centrale du pore fermé *via* ses fenestrations latérales (Payandeh et al., 2011). L'action de l'ensemble de ces molécules dépend de l'état du canal et donc de sa fréquence d'ouverture et de fermeture.

Le **site 8, site des petites molécules des compagnies pharmaceutiques Icagen et Pfizer**, est beaucoup moins communément admis par la communauté scientifique. Il est dû à la découverte récente de cette classe de molécules dans le cadre de la recherche de nouvelles molécules antidouleur (McCormack et al., 2013; Sun et al., 2014) et est formé par des portions intracellulaires des segments 2 et 3 du domaine DIV (Figure 1-12). D'autres auteurs définissent le site 8 comme étant le segment 5 du domaine DII, cible de la conotoxine GVIIJ (Gajewiak et al., 2014).




Figure 1-12. Sites de fixation des différents types de toxines sur les canaux Na_v (Ahern et al., 2016). Outre les 6 sites identifiés pour les toxines (site 1-6), les sites de liaison des anesthésiques locaux (site AL) et des petites molécules d'Icagen et de Pfizer (site ICA/PF) sont aussi indiqués.

Parfois, il n'y a pas de corrélation entre les effets électrophysiologiques observés sur le courant sodium et le site de fixation défini après mutagenèse du canal, ce dernier prenant souvent le dessus lors de la classification du site de fixation d'une toxine donnée.

1.2.3. Toxines – Canaux Na_v – Douleur

Les toxines activatrices ou inhibitrices de canaux Na_v sont retrouvées dans les venins de toutes les espèces (araignées, guêpes, serpents, scorpions, cônes de mer, anémones de mer...). Elles sont utiles lorsque l'animal veut atteindre son but de prédation ou de défense en produisant, parmi les

premiers symptômes, la douleur chez la proie ou le prédateur. Cependant, il est admis que les toxines qui induisent la douleur sont mieux adaptées à des fins défensives alors que celles qui produisent une paralysie sont souvent supposées avoir évolué spécifiquement à des fins de prédation. En effet, certains des venins les plus douloureux, comme celui de l'abeille, de la guêpe, du poisson-pierre ou d'ornithorynque, ne sont utilisés qu'à des fins défensives ou de compétition (Jami et al., 2017).




Figure 1-13. Représentations schématiques des effets des toxines sur le courant sodium. Tracés de courant en fonction du temps (à gauche) et courbes courant-potentiel (I-V, à droite). Effets représentatifs d'une concentration maximale de toxine. Adapté d'Israel et al. (2017).

Les toxines activatrices de canaux Na_v (tout comme la vératridine) sont des outils pharmacologiques précieux qui peuvent être employées, par exemple, lors de criblages à haut débit

de molécules inhibitrices de ces canaux, basés sur l'utilisation de sondes fluorescentes (Klint et al., 2015). Cependant, Il y a deux inconvénients principaux à ces criblages basés sur les sondes fluorescentes: l'inefficacité des toxines activatrices sur un sous-type donné de canaux Na_v (exemple du sous-type $hNa_v1.8$ résistant à la vératridine) et l'échec de la mise en évidence de l'effet d'une molécule criblée à cause d'une compétition sur le site de fixation (Deuis et al., 2016a). Ces toxines activatrices ont également permis de décortiquer le rôle joué par chaque sous-type de Na_v dans la transmission du message douloureux comme, par exemple, le sous-type $Na_v1.1$ dont le rôle a été mis en évidence par la toxine Hm1a qui inhibe de façon sélective l'inactivation de ce sous-type (Osteen et al., 2016). Celles du sous-type $Na_v1.7$, cible d'intérêt pour traiter la douleur, ont permis de créer des modèles pour évaluer l'effet antalgique des toxines inhibant ce sous-type (Deuis et al., 2016b; Cardoso et al., 2017; Deuis et al., 2017; Sousa et al., 2017; Rahnama et al., 2017). Le modèle le plus couramment utilisé est le modèle rongeur de douleur induite par l'OD1, une toxine α de scorpion ayant des effets mixtes α/β (Meng et al., 2015). Selon le sous-type Na_v étudié en rapport avec la douleur, il existe un panel non négligeable de toxines activatrices de ces sous-types, avec une sélectivité plus ou moins importante (Tableau 1-13; Jami et al., 2017).

Tableau 1-13. Exemples des principales toxines produisant la douleur *via* l'activation de certains sous-types de canaux Na_v (Jami et al., 2017).

Venom Peptide	Species	Pharmacological Target(s)	Pain Phenotype (Route)
δ -theraphotoxin-Hm1a	<i>Heteroscodra maculata</i>	$Na_v1.1$	Spontaneous pain (i.pl.), mechanical allodynia (i.pl.)
OD1	<i>Odontobuthus doriae</i>	$Na_v1.7$	Spontaneous pain (i.pl.)
Cn2	<i>Centruroides noxius</i>	$Na_v1.6$	Spontaneous pain (i.pl.), mechanical allodynia (i.pl.)
δ -conotoxin SuVIA	<i>Conus suturatus</i>	$Na_v1.3, Na_v1.4, Na_v1.6, Na_v1.7$	Spontaneous pain (i.pl.)
α -scorpion toxin CvIV4	<i>Centruroides vittatus</i>	$Na_v1.2, Na_v1.3, Na_v1.4, Na_v1.7$	Spontaneous pain (i.pl.)

Les toxines inhibitrices de canaux Na_v , en rapport avec la douleur, ont été très étudiées principalement pour les développer comme nouvelles classes de traitement antalgique avec moins d'effets secondaires que les opioïdes utilisés dans le cadre de douleurs chroniques récidivantes. Tous les sous-types de canaux Na_v présents sur les premiers neurones senseurs de la douleur, et transmettant le message au SNC, sont potentiellement des cibles antinociceptives intéressantes. Dans ce sens, le sous-type le plus criblé est le $Na_v1.7$ et les toxines les plus étudiées sont celles d'araignées ayant un réarrangement des ponts disulfures sous forme de nœud de cystines inhibiteur (ICK pour "inhibitor cystine knot") (Figure 1-14; Vetter et al., 2017), comme cela est développé dans la Publication n°1.




Figure 1-14. Toxines d'araignées à trois ponts disulfures réarrangés en structure ICK (Saez et al., 2010). La connectivité des ponts disulfures est C1-CIV, CII-CV, CIII-CVI. Exemple de l' ω -héxatoxine-Hv1a, une toxine d'araignée de 37 acides aminés.

1.3. Nociception

La douleur a été définie officiellement par l'association internationale pour l'étude de la douleur (IASP pour "International Association for the Study of Pain") en 1979 comme "une expérience sensorielle et émotionnelle désagréable, associée à une lésion tissulaire réelle ou potentielle, ou décrite dans ces termes". La douleur est une sensation subjective, très difficile à quantifier et à qualifier autant par le patient que par les professionnels de la santé, surtout qu'elle n'est pas toujours associée à une lésion.

1.3.1. Catégories de douleurs et épidémiologie

Il existe deux catégories de douleur selon la durée: (1) les douleurs aiguës, souvent intenses et brèves, servant de signal d'alarme permettant de maintenir l'intégrité du corps et (2) les douleurs chroniques, aussi nommées douleurs pathologiques, récurrentes maintenues depuis plus de trois mois, qui deviennent une maladie à part entière (Figure 1-15).



Figure 1-15. Les différentes étapes de la douleur chronique (Crofford et al., 2015). De gauche à droite, portrait des émotions négatives et de l'aspect intrusif de la douleur. La composante émotionnelle empêche les professionnels d'évaluer objectivement la douleur chronique et les symptômes somatiques associés qui peuvent-être prédits par des facteurs déterminés lors d'études épidémiologiques telles que des traumatismes ou abus subits dans l'enfance, une éducation pauvre, un isolement social, de la dépression et de l'anxiété.

Il existe trois catégories de douleur selon le processus physiopathologique mis en jeu. Les douleurs inflammatoires, les douleurs neuropathiques et les douleurs mixtes. Il y a donc une lésion due à une dérégulation des phénomènes inflammatoires et/ou une atteinte du SNC ou du SNP. Les douleurs neuropathiques entraînent souvent un trouble de la sensibilité locale (hypoesthésie ou anesthésie complète au toucher ou à la piqûre) associé à des allodynies ou des hyperesthésies (Figure 1-16). Il existe une quatrième catégorie dont les processus physiopathologiques sont encore mal connus, les douleurs dysfonctionnelles. Celles-ci ne sont dues à aucun des deux systèmes précédemment décrits, une altération des systèmes centraux modulateurs de la douleur en étant probablement la cause.




Figure 1-16. Zoom sur deux manifestations cliniques de la douleur (Bridges et al., 2001; Rostaing-Rigattieri & Guerin, 2014). (A) L'hyperalgie est une réponse exagérée à un stimulus qui normalement est douloureux (B) L'allodynie est une douleur causée par un stimulus qui normalement ne produit pas de douleur. Elle peut être tactile ou mécanique à l'effleurement cutané (allodynie dite "dynamique") ou à la pression (allodynie dite "statique") ou encore thermique, à la chaleur non nociceptive (< 42 °C) ou au froid non nociceptif (> 10 °C).

Le trajet de l'information douloureuse (que l'on nomme "nociception") est largement décrit dans la [Publication n°1](#) (cf. "Primary sensory neurons as front door for pain"). Bien qu'une personne sur dix souffre de douleur dans le monde, d'après l'IASP (Goldberg and McGee, 2011), une étude réalisée en France a permis de montrer que les douleurs chroniques touchent 20% des français dont ¼ ayant des douleurs neuropathiques avec une fréquence accrue chez les femmes, les personnes de 50-64 ans, les travailleurs manuels et les patients habitant en zone rurale (Bouhassira et al., 2008). La douleur chronique/pathologique est souvent accompagnée d'émotions négatives déclenchant une dépression (anxiété et pensées suicidaires). Elle altère inévitablement la qualité de vie entraînant souvent des arrêts de travail. La prise en charge de celle-ci a un coût socio-économique important d'où la nécessité de trouver des solutions globales à la maîtrise de la sensation douloureuse.

1.3.2. Arsenal thérapeutique

Des traitements non pharmacologiques existent tels que l'acupuncture, la relaxation, la sophrologie ou la stimulation électronique médullaire. Cependant, les traitements pharmacologiques sont le plus utilisés au quotidien. Les douleurs inflammatoires, tout comme les douleurs aiguës, sont aujourd'hui bien prises en charge grâce au paracétamol, à l'aspirine, aux anti-inflammatoires non-stéroïdiens (AINS) ou encore à la morphine et ses dérivés pour les douleurs les plus rebelles. Ceci étant, les effets secondaires sont non négligeables (troubles gastriques et rénaux, tolérance et dépendance à la morphine...), surtout s'il s'agit d'une utilisation prolongée, voire chronique. Bien que les douleurs neuropathiques répondent à certains opioïdes, les traitements les plus adéquates sont les antidépresseurs et les anti-épileptiques, qui présentent moins d'effets indésirables.

Trois paliers d'antalgiques, devant être prescrits en fonction de l'intensité de la douleur, ont été établis à la disposition des médecins par l'OMS et l'IASP. Cependant, l'IASP préconise, d'emblée, la prescription d'opioïdes pour toute douleur d'intensité supérieure à 6/10 sur l'échelle visuelle analogique (Tableau 1-14).

- ✓ Les antalgiques du Palier I, pour les douleurs légères et modérées: l'aspirine, le paracétamol et les anti-inflammatoires non stéroïdiens, comme par exemple l'ibuprofène. Ils sont parfois appelés "antalgiques périphériques" ou "non morphiniques" et ont la puissance antalgique la plus faible.
- ✓ Les antalgiques du Palier II, pour les douleurs plus importantes: la codéine, la nalbuphine, le tramadol ou des associations de médicaments de Paliers 1 et 2. Ils sont dits "centraux" ou "morphiniques faibles" car ils sont actifs sur la perception de la douleur au niveau cérébral.
- ✓ Les antalgiques du Palier III, pour les douleurs très intenses: la morphine. Malgré des réticences à prescrire la morphine qui ont longtemps empêché les médecins de calmer les douleurs les plus fortes, il a été prouvé que ce composé ne rend pas toxicomane quand il est utilisé pour traiter la douleur de façon contrôlée. La morphine peut être donnée en sirop, en comprimé ou par injection. Dans certains cas, une pompe d'analgésie contrôlée permet au patient de s'administrer lui-même la quantité dont il a besoin (selon un maximum fixé par le médecin).

Cependant, seulement la moitié de patients sous traitement ressentent un soulagement de la douleur chronique et plus de 70% ne sont pas correctement traités, d'où la nécessité de trouver d'autres solutions d'après les spécialistes de la Société française d'étude et de traitement de la douleur (SFETD).

Tableau 1-14. Famille d'antalgiques (Palier I à III) à prescrire selon l'intensité de la douleur (de faible à sévère).

Famille	Dénomination Commune Internationale (DCI)
Palier I Antalgiques non opioïdes	Paracétamol
	Acide acétylsalicylique
	Ibuprofène
	Kétoprofène
	Néfopam
Palier II Antalgiques opioïdes faibles	Codéine
	Codéine + Paracétamol
	Tramadol
	Tramadol + Paracétamol
Palier III Antalgiques opioïdes	Morphine
	Fentanyl
	Oxycodone
	Buprénorphine
	Nalbuphine

Par conséquent, l'arsenal thérapeutique doit être élargi (*i*) en étudiant et élucidant davantage les mécanismes d'action des traitements existants, (*ii*) en améliorant leur spécificité en favorisant, par exemple, une voie de signalisation intracellulaire (Manglik et al., 2016; Villanueva, 2017), (*iii*) en les rendant plus puissants et mieux tolérés par couplage à une deuxième molécule procurant des effets antidouleur potentiels synergiques (Emery et al., 2016; Deuis et al., 2017), ou (*iv*) en réfléchissant à la voie d'administration de molécules déjà connues afin d'optimiser leur pouvoir antalgique (Hagen et al., 2017; Mattei et al., 2018).

Cet arsenal peut-être aussi élargi en cherchant de nouvelles classes de molécules naturelles que l'on peut extraire du règne végétal ou animal. Une source originale de molécules ayant des propriétés antalgiques provient des venins d'animaux et ciblent les canaux ioniques. Par exemple, la mambalgine du mamba noir, la crotalpine du crotale et certaines α -conotoxines de cônes marins (Vc1.1 et RegIA4) ciblent les ASICs, les canaux TRPs et les récepteurs nicotiniques de l'acétylcholine, et sont en cours de développement (Callaghan et al., 2008; King, 2011; Diochot et al., 2012; Bressan et al., 2016; Zambelli et al., 2016; Safavi-Hemami et al., 2018). Sans oublier de mentionner l'effet du venin d'abeille dilué qui atténuerait l'apparition d'allodynies, dans le cadre de douleurs neuropathiques, en diminuant l'expression des canaux TRPV1, TRPA1 et TRPM8 et de c-Fos au niveau des neurones de DRG (Koh et al., 2014).

Cependant, les canaux Na_v , K_v et Ca_v , qui régulent l'excitabilité membranaire, la genèse et la propagation des potentiels d'action axonaux, peuvent être la cible d'inhibiteurs ou d'activateurs qui ramèneront à la normale tous les paramètres d'excitabilité en cas de pathologie, et plus

particulièrement en cas de douleur (Figure 1-17). En effet, le ziconotide (ω -conotoxine MVIIA inhibant le sous-type $Ca_v2.2$ de canal calcium) est la seule toxine commercialisée par Neurex (une filiale d'Elan Pharmaceuticals) jusqu'à aujourd'hui, malgré une fenêtre d'utilisation thérapeutique très restreinte, *i.e.* uniquement pour des douleurs rebelles ne répondant plus à aucun traitement pharmacologique standard, et une voie d'administration intrathécale. Le ziconotide a une puissance remarquable dans les modèles animaux de douleur persistante et neuropathique. En particulier, chez un modèle de rat de douleur post-opératoire, ce composé a une puissance plus élevée et une activité plus longue que la morphine (Molinski et al., 2009). Cependant, chez l'homme, le ziconotide présente des effets secondaires (tels que des troubles de la mémoire, des épisodes confusionnels, des troubles de l'humeur ou des nausées) qui peuvent être limités par un titrage très progressif du composé administré par voie intrathécale (Raffaelli et al., 2011; Dupoirion et al., 2012). Le ziconotide reste malgré tout efficace pour traiter les douleurs chroniques cancéreuses et celles associées au SIDA, résistantes aux autres antalgiques (Staats et al., 2004).




Figure 1-17. Effets théoriques des inhibiteurs/activateurs des canaux Na_v , Ca_v et K_v en cas d'activité neuronale altérée (adapté de Wulff et al., 2009). Les inhibiteurs de K_v ou activateurs de Na_v et Ca_v devraient restaurer le déclenchement normal des potentiels d'action, altéré dans certaines pathologies telles que la dépression ou le dysfonctionnement cognitif. En contrepartie, les activateurs de K_v ou inhibiteurs de Na_v et Ca_v devraient restaurer le déclenchement normal des potentiels d'action, altéré dans certaines pathologies telles que l'épilepsie et la douleur.

Le développement de l' ω -conotoxine CVID, ciblant le sous-type $Ca_v2.2$ de canal calcium, ainsi que celui de la toxine Ssm6a de centipède, inhibant le sous-type $Na_v1.7$ de canal sodium, n'ont pas

abouti car la première avait une activité trop proche de celle du ziconotide et la forme synthétique de la deuxième n'avait plus d'activité (Wang et al., 2016; Zambelli et al., 2016). D'autres toxines sont en court d'exploration dans l'axe thérapeutique douleur, comme la Ph β 1 α extraite du venin *Phoneutria nigriventer* inhibant le sous-type Ca_v2.2 (Rigo et al., 2017).

Dans cette optique, nous avons cherché de nouvelles molécules extraites de venins d'animaux, en criblant les fractions et sous-fractions de ces venins sur le sous-type Na_v1.7 de canal sodium, une cible antinociceptive de choix qui a été génétiquement validée (Tableaux 1-5 et 1-6).

Concernant les canalopathies liées à une absence de douleur, le mécanisme qui relie les mutants nuls murin et humain du sous-type Na_v1.7 et la voie des opioïdes endogènes a été largement étudié récemment. Chez le mutant nul murin ainsi que chez les patients présentant une insensibilité congénitale à la douleur, la naloxone, un antagoniste des opioïdes, peut réverser l'analgésie associée à la perte d'expression de Na_v1.7, démontrant ainsi une augmentation des effets dus aux opioïdes endogènes dans les deux cas. Le lien entre l'absence du sous-type Na_v1.7 et la balance "douleur en faveur de la voie antinociceptive (opioïdes)" serait une diminution du sodium intracellulaire qui agirait comme un messenger secondaire pour activer la transcription des gènes des pré-pro-enképhalines (Figure 1-18; Minett et al., 2015; Insensee et al., 2017). L'utilisation d'antagonistes sélectifs du sous-type Na_v1.7 semble non applicable d'un point de vue pharmacologique car, pour obtenir un effet sur la voie antinociception (opioïdes) équivalent à celui chez les patients atteints d'insensibilité congénitale à la douleur (CIP), il faudrait une inhibition de 100% de la cible sur l'ensemble des neurones de DRG transmettant la douleur, sans produire d'effets secondaires, ce qui n'a pas encore été réalisé par de petites molécules, telles que la TTX, à des concentrations acceptables. Malgré cela, les recherches s'orientent vers un effet similaire avec des molécules qui ne passent pas la barrière hémato encéphalique (Emery et al., 2016). Une alternative invasive, et peu contrôlée, serait la thérapie génique neutralisant les ARN messagers du gène codant Na_v1.7. Il faudrait cependant trouver un système d'expression réversible, inductible par une molécule prise par le patient, qui ciblerait uniquement l'expression du sous-type Na_v1.7 au niveau des neurones de DRG impliqués dans la douleur, sans effet secondaire (Emery et al., 2016). La solution semble donc être la combinaison d'antagonistes sélectifs du sous-type Na_v1.7, en association avec des inhibiteurs des enképhalines ou des opioïdes à faibles doses, qui peut entraîner une analgésie sans effet secondaire (Emery et al., 2016). L'action synergique entre certaines toxines peptidiques de venins d'animaux (telles que la PhITx-1 et la Pn3a) et les opioïdes (ou les inhibiteurs des enképhalines) a déjà été mise en évidence pour produire une analgésie (Brevet WO 2015036734 A1, 2015; Emery et al., 2016; Deuis et al., 2017).




Figure 2-18. Régulation synergique de la signalisation pro- et antinociceptive chez des souris déficientes en $Na_V1.7$ (Isensee et al., 2017). Le déficit en $Nav1.7$ entraîne une réduction des récepteurs couplés aux protéines G (RCPG) sérotoninergiques ($5-HT_4$), due à diminution de l'expression des gènes et de la sous-unité RIIb (et probablement aussi de la sous-unité catalytique) de la PKA-II. Ainsi, l'entrée pronociceptive dans les neurones sensoriels (en rouge) est fortement réduite. Simultanément, l'entrée antinociceptive (en vert) est augmentée en raison de l'activité accrue des RCPG des opioïdes et de l'expression accrue du gène codant le précurseur des peptides opioïdes endogènes (enképhalines). Cette régulation synergique déplace la balance vers la signalisation antinociceptive et contribue ainsi au phénotype indolore chez les souris déficientes en $Nav1.7$. MOR, récepteurs mu des opioïdes; Penk, précurseur de la met-enkephaline; DAMGO, agoniste spécifique des MOR; NTX, naltrexone, antagoniste des MOR; AC, adénylate cyclase.

Actuellement, aucune toxine inhibant spécifiquement le sous-type $Na_V1.7$ n'est en essai clinique ou commercialisée (King, 2011; Zambelli et al., 2016). La Publication n°1 est une revue bibliographique qui vise à mettre en évidence comment des toxines d'araignée ciblant le sous-type $Na_V1.7$ dans les neurones de DRG peuvent être de puissants agents antidouleur.

1.3.3. Publication n°1

Frontiers in Pharmacology (2018) 9:1000. doi: 10.3389/fphar.2018.01000

“The Na_v1.7 channel subtype as an antinociceptive target for spider toxins in adult dorsal root ganglia neurons”

Tânia C. Gonçalves, Evelyne Benoit, Michel Partiseti & Denis Servent



The Na_v1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons

Tânia C. Gonçalves^{1,2}, Evelyne Benoit^{2,3}, Michel Partiseti¹ and Denis Servent^{2*}

¹ Sanofi R&D, Integrated Drug Discovery – High Content Biology, Paris, France, ² Service d'Ingénierie Moléculaire des Protéines, CEA de Saclay, Université Paris-Saclay, Gif-sur-Yvette, France, ³ Institut des Neurosciences Paris-Saclay, UMR CNRS/Université Paris-Sud 9197, Gif-sur-Yvette, France

OPEN ACCESS

Edited by:

Yuri N. Utkin,
Institute of Bioorganic Chemistry
(RAS), Russia

Reviewed by:

Sandrine Cestèle,
UMR7275 Institut de Pharmacologie
Moléculaire et Cellulaire (IPMC),
France

Maria Elena De Lima,
Universidade Federal de Minas
Gerais, Brazil

*Correspondence:

Denis Servent
denis.servent@cea.fr

Specialty section:

This article was submitted to
Pharmacology of Ion Channels
and Channelopathies,
a section of the journal
Frontiers in Pharmacology

Received: 22 June 2018

Accepted: 14 August 2018

Published: 04 September 2018

Citation:

Gonçalves TC, Benoit E, Partiseti M
and Servent D (2018) The Na_v1.7
Channel Subtype as an
Antinociceptive Target for Spider
Toxins in Adult Dorsal Root Ganglia
Neurons. *Front. Pharmacol.* 9:1000.
doi: 10.3389/fphar.2018.01000

Although necessary for human survival, pain may sometimes become pathologic if long-lasting and associated with alterations in its signaling pathway. Opioid painkillers are officially used to treat moderate to severe, and even mild, pain. However, the consequent strong and not so rare complications that occur, including addiction and overdose, combined with pain management costs, remain an important societal and economic concern. In this context, animal venom toxins represent an original source of antinociceptive peptides that mainly target ion channels (such as ASICs as well as TRP, Ca_v, K_v and Na_v channels) involved in pain transmission. The present review aims to highlight the Na_v1.7 channel subtype as an antinociceptive target for spider toxins in adult dorsal root ganglia neurons. It will detail (i) the characteristics of these primary sensory neurons, the first ones in contact with pain stimulus and conveying the nociceptive message, (ii) the electrophysiological properties of the different Na_v channel subtypes expressed in these neurons, with a particular attention on the Na_v1.7 subtype, an antinociceptive target of choice that has been validated by human genetic evidence, and (iii) the features of spider venom toxins, shaped of inhibitory cysteine knot motif, that present high affinity for the Na_v1.7 subtype associated with evidenced analgesic efficacy in animal models.

Keywords: voltage-gated sodium channels, Na_v1.7 channel subtype, spider toxins, pain, dorsal root ganglia neurons, electrophysiology

Abbreviations: ASIC, acid-sensitive ionic channel; BGB, blood-ganglia-barrier; BNB, blood-nerve-barrier; Ca_v channel, voltage-gated calcium channel; CNS, central nervous system; DRG, dorsal root ganglia; EC₅₀, effective concentration necessary for increasing the response by 50%; GDNF, glial cell line-derived neurotrophic factor; GMT, gating modifier toxin; GPCR, G-protein-coupled receptor; HnTx, hainantoxin; HwTx, huwentoxin; IC₅₀, effective concentration necessary for decreasing the response by 50%; iPSCs, induced pluripotent stem cells; JzTx, jingzhaotoxin; K_v channel, voltage-gated potassium channels; NaSpTx, spider Na_v channel toxins; NAT, natural antisense transcript; Na_v channel, voltage-gated sodium channel; NGF, nerve growth factor; PaurTx, Phrixotoxin; PcTx-1, psalmotoxin-1; PNS, peripheral nervous system; ProTx, protoxin; PSN, primary sensory neuron; PTM, post-translational modification; Ret, “rearranged during transfection” proto-oncogene; RUNX, Runt-related transcription factor; SSN, secondary sensory neuron; TRP channel, transient receptor potential channel; TSN, tertiary sensory neuron; TTX, tetrodotoxin.

INTRODUCTION

According to the International Association for the Study of Pain, at least 10% of the world's population suffer from pain since 1 over 10 adults has experienced or had (acute, chronic, intermittent or combined) pain with a median of suffering time around 7 years (Goldberg and McGee, 2011). The unpleasant sensation of pain is necessary to maintain the body integrity. However, it is often accompanied by long-term complications not only limited to comorbidities, as depression, but also including social and economic concerns as inability to work, social isolation and intrusive thoughts, leading to costs of more than 600 billion US dollars annually (Holmes, 2016). Pain care is thus a global public health priority whose management must be regulated in its totality by policies.

Nowadays, mild to moderate pain may be treated effectively with a combination of physical modalities (e.g., ice, rest and splints) and non-opioid analgesics (e.g., non-steroidal anti-inflammatory drugs, acetaminophen or other adjuvant medications). In contrast, the health system is pushed into its limits to treat debilitating chronic pain because the therapy is ineffective and/or associated with devastating effects. Indeed, management of chronic and severe pain, especially related to cancers or neuropathies, often requires opioids (Savage et al., 2008). Unfortunately, the opioid abuse and overdose often lead to death, which stimulates industries and academics to find an alternative with acceptable undesired effects (Negus, 2018).

In this context, the likely promising target for therapeutic treatment to fight pain and avoid central side-effects is the neuron located in the periphery dorsal root ganglia (DRG) which conveys pain from the skin and tendons to the central nervous system (CNS). The DRG neurons are well-known to express various families of transmembrane proteins, including ion channels, G-protein-coupled receptors (GPCRs) and gap junctions/pannexins (Pan et al., 2008; Spray and Hanani, 2017; Yekkirala et al., 2017). Among the ion channel family, the most extensively studied targets for pain treatment are voltage-gated calcium (Cav) and sodium (Nav) channels. In particular, it is well established that small molecules that target Nav channels attenuate chronic and debilitating pain in humans, as exemplified by tetrodotoxin (TTX). However, due to a lack of selectivity, pronounced side-effects have been described, such as nausea, dizziness, oral numbness and tingling, limiting thus the therapeutic development of this molecule (Hagen et al., 2017). During the last decade, the attraction of scientists for the Nav1.7 channel subtype has greatly increased, due to its validation by human genetic diseases as a pain target. Many studies have been reported in the literature to describe gating modulators or pore blockers that affect the functional properties of this subtype (Vetter et al., 2017). Therefore, the present review will focus on the fascinating spider venom toxins which represent an original source of proteins possessing complex structures associated with specific electrophysiological effects and prone to be more selective



for the Nav1.7 channel subtype mainly expressed in DRG neurons.

PRIMARY SENSORY NEURONS AS FRONT DOOR FOR PAIN

The cellular elements involved in pain transmission from the peripheral to the CNS are detailed in **Figure 1**. The noxious information is first detected by the nociceptors of peripheral and visceral tissue, and then conveyed by the dendrites of primary sensory neurons (PSNs). The nociceptors are located at the level of free nerve endings of A δ and C fibers of PSNs that respond to noxious stimuli and are widely found throughout skin and internal tissue. Three main types of pain receptors exist: the thermal, the mechanical and the polymodal receptors, activated by temperature, high pressure and mechanical, thermal or/and chemical stimuli, respectively (**Figure 1**, Box 1). The PSNs are pseudo-bipolar neurons which send their axons, components of dorsal roots, to the laminae I, II and V of the dorsal horn of spinal cord and establish synapses with the dendrites of secondary sensory neurons (SSNs) (**Figure 1**, Box 2). The SSNs, in turn, bring the noxious information to the hypothalamus and connect to tertiary sensory neurons (TSNs) whose cell bodies constitute, in part, the brain cortex (**Figure 1**, Box 3). At each CNS level, the information is integrated and modulated by different ascending/descending control systems such as the medullary control, named "gate control," and the diffuse inhibitory control including the noradrenergic and serotonergic pathways induced by nociception from the higher centers to the dorsal horn, giving the affective, sensory and cognitive dimensions to the human experience of pain (Porreca and Navratilova, 2017).

The neuron bodies of PSNs constitute the 31 pairs of DRG, coming out all along the spinal marrow: 8 cervical (C1-C7, note that the first cervical spinal nerve is born above C1 and the eighth one below C7), 12 thoracic (T1-T12), 5 lumbar (L1-L5), 5 sacral (S1-S5), and 1 coccygeal (Co) which is vestigial. The cranial sensory (trigeminal or Gasser's) ganglion (nerve V) conveys facial skin sensitivity, the spiral (or cochlear) and vestibular (or Scarpa's) ganglia (nerve VIII) serve the hearing and balance senses, respectively, and the geniculate ganglion (nerve VII) transfers facial sensations, with the contribution of the superior and inferior (or petrous) ganglia of glossopharyngeal nerve (nerve IX) and the superior (or jugular) and inferior (or nodose) ganglia of vagus nerve (nerve X).

Dorsal root ganglia present a rich capillary bed in cell body area (**Figure 2**), with the particularity of high fenestrations between two endothelial cells being permeable to low and high molecular weight compounds (Pettersson and Olsson, 1989; Parke and Whalen, 2002; Jimenez-Andrade et al., 2008; Berta et al., 2017). In contrast to the cell body area, the nerve fiber area wrapped by the epineural sheath, i.e., the dura mater continuum in peripheral nervous system (PNS), presents a blood-nerve barrier similar to the CNS blood-brain barrier (BNB), with a lot of tight junctions between cells that prevent the passage of unwanted drugs (Jimenez-Andrade et al., 2008; Liu et al., 2018).



Soma of PSNs relaying the sensory information are part of the DRG which also contain other different cell types such as glial cells, endothelial cells and macrophages. Two groups of DRG neurons may be distinguished using light and electronic microscopy: the small dark neurons (cross-sectional area $\leq 800 \mu\text{m}^2$ and diameter $\leq 30 \mu\text{m}$) composed of high threshold, slowly-conducting unmyelinated (C) and/or thinly myelinated (A δ) nerve fibers, and the large light neurons (cross-sectional area $> 800 \mu\text{m}^2$ and diameter $> 30 \mu\text{m}$) constituted of low threshold, fast-conducting thickly-myelinated

(A α and A β) nerve fibers (Elliott and Elliott, 1993; Taddese et al., 1995; Ho and O'Leary, 2011). The small DRG neurons that convey mainly pain message are subdivided into two groups: the non-peptidergic and the peptidergic neurons, depending on isolectin-IB4 labeling (Table 1). This subdivision of small neurons results from the expression level of runt-related transcription factor 1 (RUNX1), responsible for neuropeptide expression, regulated by the nerve growth factor (NGF) signaling during cell growth and differentiation (Luo et al., 2007). In adult DRG neurons, RUNX and neurogenin transcription factors regulate the expression of (i) glial cell line-derived neurotrophic factor (GDNF) and tyrosine kinase c-Ret co-receptors (allowing the GDNF-ligand expression required for cell post-natal survival and indicative of non-peptidergic neurons), and (ii) the tropomyosin receptor-kinase receptors (TrkA, B and C which bind NGF or brain-derived neurotrophic factor, neurotrophin-4 and neurotrophin-3, respectively). The expression of growth factor receptors is therefore of great help to better characterizing adult DRG neurons (Ernsberger, 2009). Although only the small DRG neurons which are not labeled by isolectin-IB4 are peptidergic, the high dense-core vesicles of large neurons may also contain peptides, depending on both the vesicle size and the nerve condition, i.e., normal or injured (Wiesenfeld-Hallin and Xu, 2001). The peptidergic neurons deliver not only substance P and calcitonin gene-related peptide, but also somatostatin, vasoactive intestinal peptide and cholecystokinin. When released

TABLE 1 | Characteristics of DRG neurons.

	Small neurons (diameter \leq 30 μ m)		Large neurons (diameter $>$ 30 μ m)	
	Unmyelinated C fibers or thinly myelinated A δ -fibers		Thickly-myelinated A α /A β fibers	
Isolectin-IB4 labeling	YES (non-peptidergic)	NO (peptidergic)	NO	
Distribution	33%	33%	33%	
Transcription factors (during neurons development)	Neurogenin 1 (determines neuron formation)		Neurogenin 2 (regulates neuron formation)	
	RUNX1 (maintained by NGF signaling, inhibits neuropeptide expression)	Reduction of RUNX1 and Mrgpr (due to NGF signaling decrease)	RUNX3 (inhibits TrkB expression and contributes to specification of TrkC-positive neurons)	
Growth factor receptors (adult neurons)	GDNF and c-Ret co-receptors			
	GDNF family receptor α -2	GDNF family receptor α -3		
	P2X3 (absence of TrkA receptors)	TrkA receptors	TrkB receptors	TrkC receptors
Main Neuropeptides	<ul style="list-style-type: none"> – Substance P, NKA – CGRP, Somatostatin – VIP, PACAP-27 and 28 (upregulated after nerve injury) – Galanin – Cholecystokinin (upregulated after nerve injury) 		<ul style="list-style-type: none"> – Substance P (upregulated after nerve injury) – CGRP – Neuropeptide Y (upregulated after nerve injury) 	
Neuronal cytoskeleton	Peripherin		NF200	
Cell adhesion molecules	Necl-1	Necl-1	Necl-1	

The table illustrates the characteristics of DRG neurons regarding isolectin IB4-labeling, growth factor receptors, transcription factors, main neuropeptides, neuronal cytoskeleton composition, and cell adhesion molecules. GDNF, glial cell line-derived neurotrophic factor; Trk, Tropomyosin receptor-kinase; P2X3, P2X purinergic receptor subunit 3; RUNX, Runt-related transcription factor; NGF, Nerve Growth Factor; Mrgpr, Mas-related G-protein coupled receptor; NKA, neurokinin A; CGRP, Calcitonin Gene-Related Peptide; VIP, Vasoactive Intestine Peptide; PACAP, Pituitary Adenylate Cyclase-Activating Polypeptide; NF, Neurofilament; Necl, Nectin-like molecule. The increased gradient of Necl-1 expression between small non-peptidergic, small peptidergic and large neurons are represented by an increasing size of letters.

in the CNS areas associated with pain transmission, these neuropeptides affect the expression pattern of SSNs, PSNs and peripheral organs (Moraes et al., 2014). The type of cytoskeleton neurofilaments present in DRG neurons is correlated with both the axonal diameter and the conduction velocity of action potential: intermediate neurofilament peripherin (57 kDa) is expressed in slowly-conducting unmyelinated (C) and/or thinly myelinated (A δ) nerve fibers whereas the heavy neurofilament NF200 (200 kDa) is expressed in fast-conducting thickly-myelinated (A α and A β) nerve fibers. The expression of the cell adhesion nectin-like molecule 1, interacting with the cytoskeleton, reflects the myelination level of nerve fibers (Ho and O'Leary, 2011).

Because of sequencing advances, a large scaled and more precise genetic characterization of DRG is now possible to better identifying the function and underlying mechanisms of each neuron. Therefore, an innovative approach to get rid of pain sensation, without affecting other physiological pain (or itch) pathways, would be to inhibit/remove only the population of DRG neurons that are responsible

for the noxious disturbance (Liem et al., 2016; Li et al., 2018).

ELECTROPHYSIOLOGICAL STUDIES OF DRG NEURONS *IN VITRO*

Different types of tissues or individual cells can be used to perform electrophysiological studies of DRG neurons *in vitro*, each of them offering advantages and disadvantages. Hence, the primary cell cultures of rodent models (rats or mice) provide freshly isolated DRG neurons, however dissociated using enzymatic treatments which may disturb, in some extent, their functioning and thus their electrophysiological recordings. However, the two enzymatic procedures needed to replat the cells (i.e., detach and again deposit them on glass-slides) 24 h after their dissociation, in order to slow down extensive neurite growth that could limit adequate electrophysiological recordings, represent an aggressive cell treatment but were reported to have no marked effect on the neuronal action potential (Caviedes et al.,

1990). In any case, a delay of 4–7 days between cell dissociation and recordings is primordial to obtain adequate membrane conditions for experiments. A more physiological alternative to avoid cell dissociation and thus enzymatic procedures is to use DRG explants, i.e., slices of DRG previously inserted in 2% agar. Under these conditions, neurons are kept in their native environment and their plasma membrane is not altered (Scholz et al., 1998; Scholz and Vogel, 2000). However, the maximal life-time of DRG explants, as that of primary cell cultures, is of about 2 weeks.

Another possibility is thus the use of immortalized DRG neurons which offer the advantage of being maintained in cultures for long periods of time by changing freshly-made medium daily. The principle consists in immortalizing DRG neurons from human fetuses or rodents by using a tetracycline-responsive *v-myc* oncogene (Sah et al., 1997; Raymon et al., 1999), a medium previously conditioned with the rat thyroid cell line UCHT1 (Allen et al., 2002), or telomerase reverse transcriptase expression vectors added in the medium (Chen et al., 2007). Immortalized DRG neurons may also be directly obtained from transgenic rats harboring the temperature-sensitive large T-antigen gene (Nishiya et al., 2011). Immortalized human DRG neurons became an advance 30 years ago because of human tissue short supply. This type of more homogeneous cell lines is of great interest for high throughput screening of antinociceptive compounds.

Recently, the development of the induced pluripotent stem cell (iPSC) technology opens up new perspectives in personalized medicine, drug discovery or cell therapy. In the context of pain studies, iPSCs, derived for example from mesenchymal cells of a patient with inherited pain disease, are dedifferentiated to acquire the neuronal phenotype (bipolar cells) with the appropriate external medium containing neural growth factors. Then, the cell cultures will allow performing electrophysiological studies and pharmacological validation of a drug directly on targets presenting the mutation responsible for the patient pain phenotype (Cao et al., 2016; Sommer, 2016; Yang Y. et al., 2018).

VOLTAGE-GATED SODIUM CHANNELS EXPRESSED IN DRG NEURONS

Nav channels are crucial transmembrane proteins for the communication of excitable cells in vertebrate and invertebrate organisms, due to their important role in action potential genesis and propagation. In terms of discovery, these channels are the founding members of a superfamily comprising more than 140 members grouped into eight families (voltage-gated Na, K and Ca channels, Ca-activated K channels, cyclic nucleotide-modulated ion channels, transient receptor potential (TRP) channel, inward-rectifying K channels and two-pore K channels) which, after the GPCRs, constitute the second largest group of signaling molecules encoded by the human genome (Yu and Catterall, 2004).

The fundamental functional features that allow Nav channels to perform their role in cellular electrical signaling include a high selective permeation of Na ions and a gating system whose

opening and closing are controlled by both the time and the membrane potential. Currently available data indicate that these channels consist of a pore-forming α -subunit (glycoprotein of 220–260 kDa) which is formed by four homologous domains (designated DI to DIV), each comprising six hydrophobic transmembrane α helices segments (designated S1–S6) connected by extra- and intra-cellular loops (Figure 3). The channel pore formation is attributed to the hairpin-like P loops connecting S5 and S6 segments (extracellular part of the pore) and to the S6 segments (intracellular part of the pore) of each domain. The channel activation (opening) is associated with the S4 segments of each domain, containing repeated motifs of positively charged amino acid residues (arginine) followed by two hydrophobic residues, which lead to the opening of the pore by moving outward under the influence of the membrane electric field to initiate protein conformational change. The channel inactivation (closing), meanwhile, is associated with the intracellular loop connecting DIII and DIV domains, including the isoleucine, phenylalanine and methionine (IFM) motif (Catterall, 2000; Goldin et al., 2000; Payandeh et al., 2011). Ten α -subunits of the mammalian Nav channel, referred as Nav1.1–1.10 (the first and second numbers indicating the gene subfamily and the specific channel isoform, respectively), have been identified so far. These subunits, which exhibit 40–70% sequence homology and closely related structures, can be distinguished according to their specific expression in tissues and their sensitivity to TTX, a well-known blocker of Nav channels (Table 2). The structure, functional characteristics and phylogenetic relationships of the various Nav channel subtypes have been largely detailed in the literature (Catterall, 2000; Goldin et al., 2000; Goldin, 2001, 2002; Catterall et al., 2005b, 2007).

The expression, pharmacology and functioning of Nav channels can be altered by post-translational modifications (PTMs) of α -subunits, such as acetylation, phosphorylation, glycosylation and palmitoylation that occur after translation of mRNAs into peptidic chains or during secretory pathways. These PTMs greatly contribute to the development of chronic pain syndromes and may also modulate the toxin sensitivity of Nav channels (Liu et al., 2012). In acquired, but not in inherited, pain syndromes, various signaling pathway activations may alter expression and functioning of Nav channels (Laedermann et al., 2015). In mammals, the α -subunit is associated with an auxiliary β -subunit (glycoprotein of 30–40 kDa), consisting of a single transmembrane α helices segment, a long N-terminal extracellular immunoglobulin type V domain and a short C-terminal intracellular domain (Figure 3), which may in particular modulate the channel functioning, regulate its trafficking and expression at the membrane surface and/or link it to cytoskeleton proteins (Catterall, 2000; Xie et al., 2016). Therefore, it is likely that the β -subunit type and presence or absence in overexpression systems, or even in native tissues, will have big impact on Nav channel readout during molecule screening experiments, in particular. Hence, the functional behavior of Nav1.8 subtype has been reported to be highly dependent on the type of β -subunit expressed under normal and disease conditions (Vijayaragavan et al., 2004). Among the four auxiliary β -subunits (β 1– β 4) identified so far, only β 2- and




FIGURE 3 | The voltage-gated sodium channel. Schematic representations of α -subunit and auxiliary β -subunit of Nav channels, in which cylinders are transmembrane α helices. In red: S5 and S6 pore-forming segments, in green: S4 voltage-sensor segment, and in blue: S1, S2, and S3 segments. IFM, isoleucine, phenylalanine and methionine residues. The orange loops in DII and DIV domains correspond to spider toxins binding sites (adapted from Catterall et al., 2007).

TABLE 2 | Expression in tissues and TTX sensitivity of Nav channel subtypes.

Nav subtype	Gene	Expression in tissues	TTX sensitivity
$\text{Nav}1.1$	SCN1A	<ul style="list-style-type: none"> – PNS (DRG) – CNS (hippocampus, neocortex, cerebellum, retinal ganglion, microglia) – Keratinocytes 	Yes
$\text{Nav}1.2$	SCN2A	<ul style="list-style-type: none"> – PNS (DRG; unmyelinated or pre-myelinated axons and dendrites) – CNS (hippocampus, neocortex; cerebellum, astrocytes) – Fibroblast, islet β-cells, odontoblasts, osteoblasts 	Yes
$\text{Nav}1.3$ (fetal)	SCN3A	<ul style="list-style-type: none"> – PNS (early postnatal periods, adult DRG when nerve injury or inflammation, Schwann cells) – CNS (hippocampus, neocortex) – Fibroblasts, islet β-cells 	Yes
$\text{Nav}1.4$	SCN4A	<ul style="list-style-type: none"> – Skeletal muscle 	Yes
$\text{Nav}1.5$	SCN5A	<ul style="list-style-type: none"> – Heart – Skeletal muscle (denervated or fetal) 	No
$\text{Nav}1.6$	SCN8A	<ul style="list-style-type: none"> – PNS (DRG, nodes of Ranvier of motoneurons, Schwann cells) – CNS (Purkinje, pyramidal and granule neurons, nodes of Ranvier and axon initial segment of axons, astrocytes, microglia) – Cancer cells, endothelial cells, fibroblasts, keratinocytes, macrophages 	Yes
$\text{Nav}1.7$	SCN9A	<ul style="list-style-type: none"> – PNS (DRG and sympathetic ganglion neurons, neuroendocrine cells) – CNS (olfactory sensory neurons) – Smooth myocytes – Prostate and breast tumor cells, human erythroid progenitor cells, fibroblasts, immune cells 	Yes
$\text{Nav}1.8$	SCN10A	<ul style="list-style-type: none"> – PNS (DRG) – CNS (Purkinje neurons, astrocytes, Müller glia) – Endothelial cells, fibroblasts, keratinocytes, T lymphocytes 	No
$\text{Nav}1.9$	SCN11A	<ul style="list-style-type: none"> – PNS (DRG) – CNS (hypothalamus, astrocytes, Müller glia) – Cancer cells, endothelial cells, fibroblasts, T lymphocytes 	No
$\text{Nav}1.10$ ($\text{Nav}1.x$, $\text{Nav}2.1-2.3$)	SCN7A	<ul style="list-style-type: none"> – Lung, uterus, heart – PNS (DRG, Schwann cells) – CNS (thalamus, hippocampus, cerebellum, median preoptic nucleus) 	No

The table illustrates the expression in tissues and sensitivity to TTX of Nav channel α -subunits (adapted from Goldin, 2001; Trimmer and Rhodes, 2004; Black and Waxman, 2013). TTX, tetrodotoxin; PNS, peripheral nervous system; DRG, dorsal root ganglia; CNS, central nervous system.

$\beta 4$ -subunit have been reported to be covalently linked, by their N-terminal domain, to Nav channel α -subunits (Namadurai et al., 2015). Recently, $\beta 4$ -subunit has been highlighted as a painkiller target because of its action of regulating fast resurgent Na currents in sensory neurons associated with pain disorders (Xie et al., 2013; Lewis and Raman, 2014; Barbosa et al., 2015).

Seven over the ten Nav channel subtypes (Nav1.1, 1.3, 1.6–1.10) which are expressed in DRG neurons are detailed in **Table 3**. All these subtypes are thus potentially involved in conveying noxious stimuli and may represent a target for pain treatment. Indeed, the Nav1.6–1.9 subtypes, as main actors of pain anatomical and physiological integrities, have been genetically proved to be linked to human pain disorders. However, the high expression of Nav1.7 subtype in DRG neurons (see **Figure 4**) and its multiple reported mutations inducing genetic-painful and painless disorders, largely documented in the literature, make this subtype one of the most promising target to alleviate pain. The contribution of Nav1.1 and 1.10 subtypes to pain message was evidenced by pharmacological approaches, and the Nav1.3 (fetal) subtype was reported to be overexpressed during injury-induced pain. It is worth noting that Nav1.2 is the only subtype that does not transmit pain message in the PNS, although present in DRG neurons. In the CNS, mutations in the sequence coding for this subtype have been reported to induce epileptogenic and/or neurodevelopmental disorders (Liao et al., 2010; Hackenberg et al., 2014; Ben-Shalom et al., 2017; Wolff et al., 2017).

Nav1.1, encoded by the SCN1A gene, is a TTX-sensitive, fast-activating and inactivating Nav channel. Its expression is located in the CNS, PNS (more precisely in DRG neurons) and keratinocytes (Trimmer and Rhodes, 2004; Black and Waxman, 2013). This subtype was recently reported as a potential pain target involved in neuropathic pain (Irritable Bowel Syndrome, visceral hypersensitivity) and in acute pain and mechanical allodynia, due to the correlation between its activity and pain behaviors in rodent models using the activating spider toxin Hm1a and the selective inhibitory small molecule ICA-121431 (Osteen et al., 2016, 2017; Salvatierra et al., 2018). The important function of Nav1.1 in the CNS is highlighted by more than 500 mutations in its coding sequence that cause epileptic syndromes (Febrile Seizure, Generalized Epilepsy with Febrile Seizures +, and Severe Myoclonic Epilepsy of Infancy also known as Dravet syndrome) (Catterall et al., 2010). Moreover, three of these mutations are also correlated to familial hemiplegic migraine, and several copy number variants have been linked to neurodevelopmental disorders such as intellectual disability, autism and psychiatric disease (Dichgans et al., 2005; Fry et al., 2016; Xiong et al., 2016).

Nav1.3, encoded by the SCN3A gene, is also a TTX-sensitive, fast-activating and inactivating Nav channel (Cummins et al., 2001). This fetal subtype is normally expressed in early postnatal periods. However, it is also expressed at very low levels in adult sensory primary afferents, and is rapidly upregulated in DRG after peripheral axotomy by sciatic nerve transection or chronic constriction (Waxman et al., 1994; Black et al., 1999; Dib-Hajj et al., 1999) or by tight ligation of the spinal nerve (Boucher et al., 2000; Kim et al., 2001), and in painful

diabetic neuropathy (Tan et al., 2015; Yang et al., 2016). Nav1.3 promotes the spontaneous ectopic discharge observed during nerve injury. In particular, its over-expression after spinal cord injury leads to rhythmic oscillatory burst firing, alternating with single spikes and silent periods, in second order dorsal horn sensory neurons, and to spindle wave firing mode in thalamus (ventral posterior lateral) neurons with identifiable peripheral receptive fields (Hains et al., 2003; Lai et al., 2003). The central neuropathic pain is also explained by Nav1.3 upregulation which induces neuronal hyperexcitability and alters the process of somatosensory information (Hains et al., 2003; Hains et al., 2005, 2006). Recently, loss-of-function of the SCN3A gene, resulting in reduced expression or deficient trafficking to the plasma membrane of the protein, was reported to contribute to increased seizure susceptibility (Lamar et al., 2017).


Nav1.6, encoded by the SCN8A gene, is a TTX-sensitive fast-activating and inactivating Nav channel expressed in the PNS (DRG neurons, nodes of Ranvier of motoneurons, Schwann cells), in the CNS (Purkinje, pyramidal and granule neurons, nodes of Ranvier and initial segment of axons, astrocytes, microglia) and in non-neuronal tissues such as cancer cells, endothelial cells, fibroblasts, keratinocytes and macrophages (Trimmer and Rhodes, 2004; Black and Waxman, 2013; Israel et al., 2017). This subtype is upregulated in various peripheral pain pathways including oxaliplatin-induced cold allodynia (Deuis et al., 2013), type-2 diabetic neuropathic pain (Ren et al., 2012) and inflammatory pain (Xie et al., 2013). The Nav1.6 α -subunit, covalently linked to the $\beta 4$ -subunit, can underlie excitatory, persistent and resurgent currents which induce repetitive firing and abnormal spontaneous activity of sensory neurons (Lewis and Raman, 2014; Barbosa et al., 2015; Xie et al., 2016). A Nav1.6-gene mutation resulting in gain-of-function has been reported to potentiate transient and resurgent Na currents, leading to increased excitability in trigeminal neurons, exacerbating thus the pathophysiology of vascular compression and contributing to idiopathic trigeminal neuralgia (Grasso et al., 2016; Tanaka et al., 2016). In contrast to Nav1.1 and 1.2, Nav1.6 is involved in seizure resistance (Makinson et al., 2014). The knock-down of Nav1.6 in the brain was shown to compensate the Nav1.1-gene mutation-induced imbalance of excitation over inhibition involved in epileptogenic disorders, which motivates the necessity to find specific Nav1.6 inhibitors to treat debilitating or fatal form of epilepsy such as the Dravet syndrome (Catterall, 2012; Anderson et al., 2017). Finally, more than ten human *de novo* mutations of Nav1.6 gene have been identified in patients with two types of CNS disorders, epileptic encephalopathy and intellectual disability (O'Brien and Meisler, 2013).

Nav1.7, encoded by the SCN9A gene, is a TTX-sensitive fast-activating and inactivating Nav channel. It is expressed in the somatosensory system (mainly in C- and A β -type DRG neurons) and in the sympathetic ganglion neurons (myenteric and visceral sensory neurons) of PNS, but only in the olfactory sensory neurons of CNS. This subtype is also present in smooth myocytes (Jo et al., 2004; Israel et al., 2017; Vetter et al., 2017), and in non-excitable cells such as prostate and breast tumor cells, human erythroid progenitor cells, fibroblasts and immune cells (Black and Waxman, 2013; Israel et al., 2017). This subtype is

TABLE 3 | Electrophysiological properties and disorders associated with Nav channel subtypes expressed in DRG neurons and involved in pain.

Nav subtype	Activation (m) and inactivation (h) gating properties ¹	Pain signs	Genetic pain disorders	Pain-unrelated disorders
	Time-dependence	Voltage-dependence		
Nav1.1	Fast (Tp = 1.23 ms)	V _{m0.5} = -20 mV V _{h0.5} = -52 mV	<ul style="list-style-type: none"> - Acute pain - Mechanical allodynia - Visceral hypersensitivity - Irritable Bowel syndrome 	<ul style="list-style-type: none"> - Epileptic syndromes - Familial hemiplegic migraine - Neurodevelopmental disorders
Nav1.3 (fetal)	Fast (Tp = 1.08 ms)	V _{m0.5} = -20 mV V _{h0.5} = -58 mV	<ul style="list-style-type: none"> - Painful nerve injury - Painful diabetic neuropathy - Central neuropathic pain 	<ul style="list-style-type: none"> - Increased seizure susceptibility
Nav1.6	Fast (Tp = 1.03 ms)	V _{m0.5} = -19 mV V _{h0.5} = -56 mV	<ul style="list-style-type: none"> - Oxaliplatin-induced cold allodynia - Painful diabetic neuropathy - Inflammatory pain <p>⇒ Resurgent/persistent currents</p>	<ul style="list-style-type: none"> - Painful neuropathy (idiopathic trigeminal neuralgia) - Seizure resistance - Epileptic encephalopathy - Intellectual disability - Cerebellar atrophy, behavioral deficits and ataxia
Nav1.7	Fast (Tp = 1.09 ms)	V _{m0.5} = -33 mV V _{h0.5} = -62 mV	<ul style="list-style-type: none"> - Painful diabetic neuropathy - Inflammatory pain - Acute noxious mechanosensation <p>⇒ Threshold current</p>	<ul style="list-style-type: none"> - Anosmia and hyposmia - Epileptic syndromes - Autism spectrum disorder - Irritating, itchy cough
Nav1.8	Slow (Tp = 1.06 ms)	V _{m0.5} = -6 mV V _{h0.5} = -35 mV	<ul style="list-style-type: none"> - Painful neuropathy (AIDS, diabetes, cancer) - Inflammatory pain - Maintenance of bone cancer pain <p>⇒ Persistent currents</p>	<ul style="list-style-type: none"> - Multiple sclerosis - Cardiac conduction abnormalities
Nav1.9	Very slow (Tp > > 1 ms)	V _{m0.5} = -48 mV V _{h0.5} = -31 mV	<ul style="list-style-type: none"> - Inflammation-induced hyperalgesia and peripheral sensitization - Inflammatory, heat and mechanical pain hypersensitivity - Maintenance of bone cancer pain - Perception of cold pain - Visceral pain <p>⇒ Threshold current</p>	<ul style="list-style-type: none"> - Hirschprung's disease (mega colon motility) - Bladder motility dysfunction - Essential tremor associated with familial episodic pain
Nav1.10 (Nav1.x, 2.1-2.3)		Na-dependence (threshold value = 150 mM)	<ul style="list-style-type: none"> - Bone cancer-related pain 	<ul style="list-style-type: none"> - Chronic hypernatremia - Epileptogenic process

¹Adapted from Deus et al. (2017a) and Inseira et al. (2017). Tp, time to peak current; V_{m0.5}, test-pulse voltage corresponding to 50% maximal activation; V_{h0.5}, pre-pulse voltage corresponding to 50% steady-state inactivation.



a threshold channel since it is involved in the action potential (i.e., pain message) triggering by regulating the resting membrane potential of DRG. The implication of Nav1.7 in neuropathic (diabetes) and inflammatory pain, as well as in acute noxious mechanosensation, has been explained by gene upregulation or variants (Dib-Hajj et al., 2013; Blesneac et al., 2018). In addition, multiple Nav1.7 genetic mutations have been linked to painless or painful phenotypes. Hence, congenital SCN9A loss-of-function mutations, such as congenital insensitivity to pain and type IID of hereditary sensory and autonomic neuropathy, can induce genetic diseases with a complete absence of pain. In contrast, the SCN9A gain-of-function mutations cause genetic painful neuropathies such as small fiber neuropathy, primary erythromelalgia and paroxysmal extreme pain disorder (de Lera Ruiz and Kraus, 2015; Vetter et al., 2017). The Nav1.7 expression in the CNS is responsible for anosmia and hyposmia, always linked to painless phenotypes, and epilepsy (presence of different variants in patients showing seizures and Dravet syndrome, and of two SCN9A mutations related to epilepsy phenotype), as well as to autism spectrum disorder (Dib-Hajj et al., 2013; Mulley et al., 2013; Rubinstein et al., 2018; Yang C. et al., 2018). Nav1.7 has also been reported to be the major Nav subtype in irritating, itchy cough conveyed by DRG neurons (Muroi and Udem, 2014; Sun et al., 2017).

Nav1.8, encoded by the SCN10A gene, is a TTX-resistant Nav channel that exhibits slow activation and inactivation, as well as rapid repriming kinetics in C- and A β -type DRG neurons. With its slow kinetics and high activation threshold, this subtype corresponds to 80–90% of the inward current necessary to the rising phase of action potentials (Renganathan et al., 2001; Patrick Harty and Waxman, 2007). It is ectopically expressed in the CNS Purkinje neurons during multiple sclerosis disorder, and becomes thus a target of choice to develop a treatment for this disorder (Han et al., 2016). Nav1.8 mRNAs were also detected and quantified in astrocytes, Müller glia, endothelial cells, fibroblasts, keratinocytes and T lymphocytes (Black and Waxman, 2013). This subtype has been reported to contribute to neuropathic pain, notably associated with acquired immunodeficiency syndrome, diabetes and cancer, as well as to inflammatory pain (Thakor et al., 2009; Qiu et al., 2012; Belkouch et al., 2014; Liu X. D. et al., 2014). Moreover, SCN10A gain-of-function mutations are associated, not only with the above mentioned neuropathic pain, but also with small fiber neuropathy and inherited erythromelalgia (Faber et al., 2012; Huang et al., 2016; Kist et al., 2016). Finally, genetic variations of SCN10A have been reported to correlate with cardiac conduction abnormalities in patients suffering from hypertrophic cardiomyopathy-like atrial fibrillation and Brugada

syndrome (Zimmer et al., 2014; Behr et al., 2015; Iio et al., 2015).

Nav1.9, encoded by the SCN11A gene, is a TTX-resistant Nav channel with very slow activation and inactivation kinetics. This subtype is also a threshold channel but exhibits different biophysical properties, compared with Nav1.7 subtype. Roughly 80% of small-diameter sensory DRG neurons but only a few large-diameter ones and trigeminal ganglia (including C-type nociceptive cells) were reported to express Nav1.9 mRNAs (Dib-Hajj et al., 1998). The expression pattern of this subtype is merely limited to the PNS, despite spots of expression in the CNS (hypothalamus, astrocytes, Müller glia), endothelial cells, fibroblasts, and T lymphocytes. It was also detected in some cancers such as lymphoma and small cell lung cancer (Black and Waxman, 2013; Israel et al., 2017). Nav1.9 plays a major role (i) in inflammatory, heat and mechanical pain hypersensitivity, as revealed in both (sub) acute and chronic inflammatory pain models, (ii) in the maintenance of bone cancer pain (with the Nav1.8 subtype), (iii) in the perception of cold pain under normal and pathological conditions, and (iv) in visceral pain (Lolignier et al., 2011; Qiu et al., 2012; Dib-Hajj et al., 2015; Lolignier et al., 2015; Hockley et al., 2016; Lolignier et al., 2016). More recently, multiple Nav1.9 genetic mutations were linked to painless or painful phenotypes, making this subtype the second target of interest (after the Nav1.7 subtype) to treat pain. Hence, on one hand, congenital SCN11A loss-of-function mutations, such as congenital insensitivity to pain and type VII of hereditary sensory and autonomic neuropathy, were reported to result in genetic diseases with a complete absence of pain (Leipold et al., 2013; Woods et al., 2015; Phatarakijvirund et al., 2016; Huang et al., 2017; King et al., 2017). On the other hand, the SCN11A gain-of-function mutations lead to genetic painful neuropathies such as small fiber neuropathy and rare inheritable pain disorders (Zhang et al., 2013; Huang et al., 2014; Han et al., 2015; Leipold et al., 2015; Kleggetveit et al., 2016; Okuda et al., 2016; Han et al., 2017). Finally, Nav1.9 expression has also been linked to the Hirschprung's disease (affecting the mega colon motility), and implicated in the development of inflammation-based bladder motility dysfunction and in essential tremor associated with familial episodic pain (Ritter et al., 2009; O'Donnell et al., 2016; Leng et al., 2017).

Nav1.10, encoded by the SCN7A gene and also named Nav1.x or Nav2.12.3 (according to the species), is an atypical subtype associated with leak currents and considered as descendant of Nav channel α 1-subunits despite, notably, a less than 50% sequence homology and marked discrepancies in S4 segments and the intracellular loop connecting DIII and DIV domains (Goldin et al., 2000; Yu and Catterall, 2003; Nehme et al., 2012). In addition and in contrast to other Nav channel subtypes, Nav1.10 is not activated by the membrane potential but is sensitive to extracellular concentration of Na ions with a threshold value of 150 mM (Hiyama et al., 2002). It is expressed in the lung, uterus and heart, in the PNS neurons (e.g., medium to large-sized DRG neurons, non-myelinating Schwann cells) and in the CNS (e.g., thalamus, hippocampus, cerebellum, median preoptic nucleus) (Fukuoka et al., 2008; Garcia-Villegas et al., 2009) In particular, this subtype is clearly present in the primary

regions implicated in hydromineral homeostasis, such as the subfornical organ, the vascular organ of the lamina terminalis and the median eminence which control the Na-intake behavior by changing neuronal excitability (Watanabe et al., 2006; King et al., 2015; Kinsman et al., 2017). It is involved in autoimmunity process causing chronic hypernatremia (Hiyama et al., 2010) and in epileptogenic process (Gorter et al., 2010). Recently, the inhibition or suppression of Nav1.10 was reported to reduce pain behaviors in a bone cancer-induced model by decreasing the excitability of DRG neurons (Ke et al., 2012).

Using electrophysiological studies of DRG neurons *in vitro* for drug-discovery research may be limited by the relative proportions of targeted Nav channel subtypes, as exemplified by the plant alkaloid paclitaxel whose effects differ between the models used (Chang et al., 2018). Indeed, the relative proportion of Nav channel subtypes varies between small- and large-diameter DRG neurons, the first one expressing more TTX-resistant and less TTX-sensitive subtypes than the second one in both rodent and human neurons (Djouhri et al., 2003; Zhang et al., 2017). In addition, the relative proportion of Nav subtypes varies according to the species studied. This is illustrated in **Figure 4** by the relative quantification of each Nav channel subtype mRNA in small-diameter DRG neurons, the most documented in the literature because of their interest to treat pain, in various mammalian species. As expected from their importance in pain process, Nav1.6–1.9 subtypes are relatively more expressed than Nav1.1–1.3 subtypes, and the expression of the pain-unrelated Nav1.4 and 1.5 subtypes, when detected, is extremely low and their function unknown (Ho et al., 2013).

The DRG neurons from rodent models are preferentially used for pain studies, compared with those from human, because they are rapidly available, easy to manipulate, cheap and exhibit well-conserved anatomical and physiological properties. However, adult mice and rat differ in their relative proportions of Nav subtypes: more than 50% of mouse DRG Nav subtypes are TTX-resistant (i.e., 45% of Nav1.8 and 12% of Nav1.9) whereas it is the opposite in rat DRG neurons (i.e., 15% of Nav1.1, 23% of Nav1.6 and 36% of Nav1.7) (Berta et al., 2008; Chang et al., 2018). Interestingly, the level of expression of Nav subtypes is greatly influenced by the age of mammal, i.e., the neuron maturation, as exemplified by the high expression of Nav1.9 subtype in pup rat DRG neurons which is replaced by Nav1.1 and 1.6 subtype expression in adult rat DRG neurons (Ho and O'Leary, 2011). PCR analysis of the seven Nav subtypes expressed in DRG neurons reveals that post-mortem human DRG neurons from healthy donors show relatively high expression of Nav1.7 (49%) and low expression of Nav1.8 (12%), whereas the mouse DRG neurons present high expression of Nav1.8 (45%) and low expression of Nav1.7 (18%), the adult rat DRG neurons having an intermediate expression of Nav1.7 (36%) and Nav1.8 (23%) (Chang et al., 2018).

The mammals closely related to human (i.e., adult monkey and pig) roughly conserve the Nav subtype expression pattern of post-mortem human DRG neurons, i.e., Nav1.7 \geq Nav1.9 \geq Nav1.8 (Raymond et al., 2004; Muroi and Udem, 2014). Although the adult post-mortem human DRG neurons obtained from healthy donors are valuable in

terms of physiology to estimate the relative proportions of Nav subtypes in living humans (Zhang et al., 2017; Chang et al., 2018), and even if some mammalian models seem closed to human, the message needs to be always shaded when extrapolated to human. Moreover, RT-PCR consists in averaging Nav subtype mRNAs present in nucleus of cell population, and does not represent strictly the level of functional Nav subtypes located in cell plasma membranes.

In several mammals DRG neurons, alternative splicing of Nav α -subunit genes has been detected, resulting in the expression of multiple proteins. However, the functional significance of this process has not been completely elucidated (Dietrich et al., 1998; Schirmeyer et al., 2014). Some variants seem to lead to subunits showing redundant or no obvious pharmacological and/or functional differences, compared with the wild-type subunit (Schirmeyer et al., 2014). However, different pharmacological and functional properties between variant and wild-type subunits are evidenced in the literature, such as their sensitivity to drugs/toxins (Dietrich et al., 1998; Tan et al., 2002; Thompson et al., 2011; Boullot et al., 2017), their functional specificity regarding tissue/cell localization (Song et al., 2004), and their involvement in membrane excitability *via* the regulation of translational repression (Lin and Baines, 2015). Some alternative splice events are unique to DRG neurons. Hence, significant changes in the splicing patterns of Scn8a and Scn9a genes were observed in a rat model of neuropathic pain, leading to down-regulation of all transcripts (Raymond et al., 2004). Moreover, four alternative splice variants of SCN9A gene were reported to be expressed in human DRG neurons. The difference between two of them at the exon 5 level (exons 5A and 5N) results in two different amino acid residues, located in the S3 segment of DI domain acid. One of them, negatively charged, may be involved in modifications of Nav channel activation and de-activation, impacting thus the paroxysmal extreme pain disorder disease phenotype (mutation I1461T). The two other alternative splice variants differ at the exon 11 level, leading to the presence (11L) or absence (11S) of an 11-amino acid sequence in the intracellular loop connecting DI and DII domains of Nav channels, an important region for protein kinase A regulation which will thus influence neuronal excitability and pain sensation (Chatelier et al., 2008; Jarecki et al., 2009). Recently, a (NAT) was reported to be a potential candidate gene for patients with inherited (primary erythromelalgia, paroxysmal extreme pain disorder, and painful small fiber neuropathy) or acquired chronic pain disorders linked to the SCN9A locus, taking into account that the sense gene must not contain mutations which lead to sense gene-NAT pairing. This is the first example of a new therapy based on increased native antisense mRNAs to treat chronic pain in humans (Koenig et al., 2015).


ANALGESIC SPIDER TOXINS TARGETING THE NAV1.7 CHANNEL SUBTYPE

Arachnids (araneae order) are the most diverse group of venomous animals with more than 46,000 extant species

subdivided in araneomorph (crossing fangs) and mygalomorph (parallel fangs) suborders. Theraphosidae, the most studied and represented family in Arachnoserver 3.0 database, belongs to the latter suborder, with approximately 470 species, a bit more than one quarter of all species (Pineda et al., 2018). Each spider venom contains from 100s to 1000s peptides (Escoubas, 2006), meaning that more than 10 million spider-venom peptides with an original sequence remain to be discovered since only approximately 0.01% of these toxins have been explored until now (Klint et al., 2012, 2015b). The major components of most spider venoms are small disulfide-rich peptide toxins (Saez et al., 2010).

Because of their major role in action potential genesis and propagation in CNS, PNS, heart, smooth and skeletal muscles, Nav channels are crucial for vital functions and are thus targeted by various groups of toxins that interact with at least six specific channel receptor-sites (Cestele and Catterall, 2000; Catterall et al., 2007; Gilchrist et al., 2014; Israel et al., 2017). Toxins that alter these channels may affect one or more of their three essential properties: activation, inactivation and ion selectivity. In that regard, toxins that have been isolated from different venomous animals (such as spiders, scorpions, cone snails, sea anemones and centipedes) may be classified as pore blockers and/or gating modifiers (Israel et al., 2017). The main source of the approximately 20 analgesic peptide toxins targeting the Nav1.7 subtype is the venoms of tarantula constitutive of the theraphosidae family (**Figure 5**) (Klint et al., 2015b; Vetter et al., 2017). It is worth nothing that this family also contains many Nav channel activators (Deuis et al., 2017b), such as Hm1a toxin which has been reported to induce a painful behavior when injected in rodents (Jami et al., 2017). A small amount of these toxins also target other ion channel types located at the level of DRG neurons and, thus, taking part into pain processing such as TRP channels A1 antagonized by Protoxin (ProTx)-I and Ph α 1 β , acid-sensitive ionic channel (ASIC)1a inhibited with high affinity by psalmotoxin (PcTx)-I, and N-type Cav channels targeted by Ph α 1 β , although with less potency than for TRPA1 (de Souza et al., 2013; Gui et al., 2014; Osmakov et al., 2014; Tonello et al., 2017).

Spider toxins targeting the Nav1.7 subtype with an IC₅₀ less than 500 nM are considered as analgesic toxin inhibitors (Klint et al., 2015a), and belong to the three first classes of spider Nav channel toxins (NaSpTx), based on their primary structure and disulfide framework (**Figure 5**). It is worth noting that this classification also includes spider toxins which target not only the Nav1.7 channel subtype but also other subtypes of ionic channels, as exemplified by the ω -TRTX-Gr2a toxin (GpTx-1) which was initially reported as a Cav3.1 subtype blocker after isolation from the Chilean tarantula, *Grammostola rosea*, venom (Ono et al., 2011). The NaSpTx peptides are gating modifier toxins (GMTs) because they alter channel gating by stabilizing voltage-sensors (mainly S3–S4 segments of DII domain) in a closed, or resting, configuration state (**Table 4**) (Klint et al., 2012). The Nav1.7 analgesic spider toxin inhibitors are shaped by inhibitory cystine knot (ICK) scaffold due to 6 cysteines, arranged into a ring composed of two disulfide-bridges crossed by a third one (Saez et al., 2010). These peptides share a conserved amphipathic surface profile characterized by a high proportion



of hydrophobic/aromatic amino acid residues, such as Trp, Tyr and Phe, surrounded by charged amino acids which constitute a dipole potential with negative (Asp and Glu) and positive (Lys and Arg) zones (Jung et al., 2005; Cai et al., 2015). Finding more selective GMTs than pore-blockers of Nav1.7 subtypes is likely because the voltage-sensors are more variable in terms of amino acid sequence than the pore region of Nav channels (Catterall et al., 2005a; Payandeh et al., 2011).

ProTx-III, ceratotoxin-1, GpTx-1, Cd1a, huwentoxin (HwTx)-IV, hainantoxin (HnTx)-IV, Hd1a, HnTx-III and HnTx-I are Nav1.7 potential analgesic peptide toxins, composed of 33–35 amino acid residues, that belong to NaSpTx-1 family, with nanomolar affinities (IC₅₀ between 2.1 and 440 nM) for this Nav subtype. According to their electrophysiological properties, these toxins act as pore blockers of the Nav1.7 subtype and, except for ProTx-III and ceratotoxin-1, induce

minor alterations (less than 5 mV) in the voltage-dependence of its activation and steady-state inactivation (Figure 5 and Table 4). Various mutants of ProTx-III and ceratotoxin-1 were produced, showing a 10–20-mV shift in the voltage-dependence of Nav1.7 activation without any change in its fast and steady-state inactivation (Bosmans et al., 2006; Cardoso et al., 2015), in agreement with their interaction with the receptor-site 4 of Nav channels (i.e., S3–S4 segments of DII domain). Models of docking toxins on Nav channels have been reported, placing toxin peptides in the cleft between the channel S1–S2 and S3–S4 transmembrane α-helices (Minassian et al., 2013; Cai et al., 2015; Murray et al., 2016). Even the main channel amino acid residues involved in toxin-channel interactions were located in the extracellular loop connecting S3 and S4 segments of DII domain, some residues of the extracellular loop connecting S1 and S2 segments of DII

domain helping to stabilize the toxin binding to the channel (Figure 3).

Pn3a, Dfla, ProTx-I, Phlo1b and jingzhaotoxin (JzTx)-34 are Nav1.7 potential analgesic peptide toxins, composed of 34–35 amino acid residues, belonging to the NaSpTx-2 family and having also nanomolar affinities (IC₅₀ between 0.9 and 610 nM) for this Nav subtype (Figure 5 and Table 4). This toxin family produces important alterations in the voltage-dependence of both activation (10–37-mV positive shifts) and steady-state inactivation (2.7–17.5-mV negative shifts). In addition, the fast inactivation of some TTX-sensitive Nav channels is also affected by some of these toxins. This is in agreement with the known toxin receptor-sites 3 (i.e., S3-S4 segments of DIV domain) and 4 of Nav channels (Deuis et al., 2017b).

ProTx-II, JzTx-V, GsAF1, GrTx-1 and Phlo2a are Nav1.7 potential analgesic peptide toxins from the NaSpTx-3 family, composed of 26–30 amino acid residues, and showing nanomolar affinities (IC₅₀ between 0.3 and 333 nM) for this Nav subtype (Figure 5 and Table 4). The toxin action consists in major alterations in the voltage-dependence of activation (10–31-mV positive shifts) with only minor modifications of the voltage-dependence of steady-state inactivation (up to 5-mV positive shifts). The channel binding sites of these toxins are the receptor-site 4 alone for JzTx-V or in addition with the receptor-site 3 for ProTx-II, those for the other toxins having not been reported (Smith et al., 2007; Moyer et al., 2018). As a consequence, the channel fast inactivation is altered by ProTx-II but not by JzTx-V.

Pn3a is the toxin that has been studied on the biggest panel of ionic channels and receptors reported so far (Deuis et al., 2017a), including all Nav channel subunits, some cardiosafety targets (such as K_V11.1 and Ca_V1.2 channel subtypes) and other transmembrane proteins expressed at the membrane of DRG neurons (K_V2.1, α 3- α 7 nAChR, Ca_V2.2 subtypes). In particular, this toxin was tested on human and rodent (mouse and rat) Nav1.7 subtypes, showing minor loss of potency (between 2 and 5 fold) for mouse and rat. These results are in agreement with the 93.0% (human *versus* mouse) and 92.8% (human *versus* rat) sequence identities between species [data obtained from high quality protein multiple sequence alignments using CLUSTAL Oméga version 1.2.3 (web version)]. The other toxins have not been screened exhaustively: mainly human Nav subtypes and cardiovascular targets, such as K_V11.1, Ca_V1.2 and Ca_V3.1 subtypes. Big efforts were engaged to decrease toxin potency for Nav1.4 and 1.5 subtypes to avoid neuromuscular and cardiac side-effects (Murray et al., 2016) or to directly find toxin possessing these characteristics (Xiao et al., 2008). Moreover, the interest to find analgesic toxins highly selective for Nav1.1 and 1.6 subtypes, or to improve the toxin selectivity for these two subtypes, decreased during the past years because of the consequent inhibition of action potential transmission *via* axonal nodes of Ranvier which leads to central and peripheral (at the level of neuromuscular junctions) side-effects. Hence, the HwTx-IV mutant m3-HwTx-IV, presenting an additional hydrophobic patch (Gly1-Gly4-Trp33) has a reinforced inhibitory potency for the Nav1.7 subtype while improving Nav1.1, 1.2 and 1.6 subtype

selectivity (Rahnama et al., 2017). Moreover, the ProTx-II mutant JNJ63955918/GP-ProTX-II (W7Q-W30L) presents a 14-fold decreased potency for the Nav1.7 subtype but an improved selectivity against Nav1.1, 1.2, 1.4, and 1.6 subtypes, thus avoiding side-effects such as seizures, arrhythmias and impaired motor functioning (Flinspach et al., 2017; Gonçalves et al., 2018). A new strategy was recently proposed to increase the selectivity among the off-target panel, consisting in finding antagonist antibodies specific of Nav1.7 subtype. The results obtained are controversial and need to be further confirmed (Lee et al., 2014; Liu et al., 2016). More recently, another approach was reported, using an antibody-drug conjugated: a potent Nav1.7 toxin inhibitor (a GpTx-1 analog), connected by a PEG-linker to an antibody, showed greater stability in plasma and a biodistribution restricted to the regions expressing Nav1.7 subtype, decreasing thus possible side-effect occurrence (Biswas et al., 2017).

Bilayer membranes that surrounded channel proteins seem to be important to stabilize the interactions between amphipathic GMTs and Nav channels. Toxins and their mutants brought a better understanding of the so-called trimolecular complex relations. Hence, the affinity of GMTs for bilayer membrane lipids highlighted the type of amino acid residues implicated in these interactions that could also impact the toxin selectivity for Nav channels (Deplazes et al., 2016; Henriques et al., 2016; Agwa et al., 2017, 2018; Zhang et al., 2018). Moreover, the pharmacological sensitivity of Nav channels for toxins may be modulated by PTMs on the Nav channel protein itself (Liu et al., 2012). Indeed, palmitoylation of rat Nav1.2 subtype was reported to modify the subtype sensitivity to phrixotoxin (PaurTx)-3 and ProTx-II, producing a 10-fold increased affinity by binding to simultaneously the voltage-sensor domain and the surrounding membrane, without affecting ProTx-I binding (Bosmans et al., 2011; Henriques et al., 2016). PTMs could thus be of major interest and have to be also considered as potential therapeutic targets.

GpTx-1, HwTx-IV, HnTx-IV, HnTx-III, Pn3a, JzTx-34, ProTx-II and JzTx-V were tested on rodent DRG neurons, revealing high affinity for TTX-sensitive Nav channels associated with high selectivity against TTX-resistant Nav channels in mouse and rat DRG neurons (Liu et al., 2002, 2013; Peng et al., 2002; Deuis et al., 2016, 2017a; Flinspach et al., 2017; Gonçalves et al., 2018; Moyer et al., 2018; Zeng et al., 2018). The action of HwTx-IV, meanwhile, is not equivalent on TTX-sensitive Nav channels of rat and mouse DRG neurons, the IC₅₀ being 4-fold lower in rat neurons likely due to the presence of high sensitive Nav subtypes that are poorly or not expressed in mouse DRG neurons (Peng et al., 2002; Gonçalves et al., 2018). Electrophysiological recordings under physiological conditions or quantification of altered expression of some proteins relevant in pain processing, in DRG neurons after toxin application, allowed characterizing the toxin potential analgesic effect at the cellular level. Hence, in DRG neurons, a JzTx-V mutant [CyA-JzTx-V (M6J)-E17X-I28G], i.e., AM-0422] and ProTx-II were reported to inhibit or diminish action potential firing induced by chemical (capsaicin) and mechanical stimulation, or to alter spinal nociceptive processing induced by burn injury, respectively (Moyer et al., 2018; Torres-Perez et al., 2018).

Acute pain is a physiological function associated with injury that is essential for human survival. This kind of pain is normally short-lasting (<3 months). Beyond this period of time and without real injury, pathologic chronic pain is considered to result from damage in the transmission pain system itself. Several bioassays are available to appraise acute or chronic pain using standard or specific rodent models. Hence, mechanical and thermal stimulation assays or global gait analysis are classical to evaluate acute pain. The manual or electronic von Frey filament (or paw pressure) test is commonly used to assess to mechanical pain, while tail flick or water immersion and hot/cold plate tests are dedicated to assess to thermal pain. In these tests, the pain is provoked by pressure or extreme temperature on healthy rodent models. The inflammatory (caused by subcutaneously injected formalin, carrageenan or Freund's adjuvant compound, or intraperitoneally injected acid acetic) and neuropathic (caused by nerve constriction or ligation injury, chemotherapy-induced neuropathy) chronic pain are usually evaluated with the above mentioned mechanical and thermal stimulation assays, associated to a global evaluation of animal behavior. However, under these conditions, the pathological pain transmission system induced by inflammatory proteins or nerve injury is evaluated (Bridges et al., 2001; Mogil, 2009).

Various analgesic toxins have been proposed as candidates to replace opioids, because of their well-known side-effects. Hence, HwTx-IV, HnTx-IV, Pn3a and ProTx-II were shown to decrease pain at the level of morphine relief, in a dose-depending manner, in neuropathic (mainly spared nerve injury and diabetic neuropathy) and all inflammatory pain models, revealing a real evidence of their analgesic potential as drugs (Liu et al., 2014a,b, Tanaka et al., 2015; Deuis et al., 2017a; Flinspach et al., 2017). Pn3a and the ProTx-II mutant JNJ63955918 were also described as being effective on acute thermal pain tests (Deuis et al., 2017a; Flinspach et al., 2017). Despite the large number of pain tests, a new and original pharmacological one was recently proposed. It consists in specifically inhibiting fast inactivation and increasing peak current associated to Nav1.7 subtype, by the local or systematical injection of OD1 scorpion toxin whose (EC₅₀) being in the nanomolar range (Deuis et al., 2016). This test has the advantages of being less invasive and more sensitive than neuropathic and inflammatory tests. Indeed, only a low amount of toxin candidate to be evaluated is necessary to relieve pain, as exemplified by GpTx-I, Cd1a, m3-HwTx-IV and Pn3a (Deuis et al., 2016; Cardoso et al., 2017; Rahnama et al., 2017; Sousa et al., 2017). However, the question of lack of physiological relevance of this test may be raised.

The best galenic form to make the patients compliant with their treatment is the pills for oral administration. However, in the pain tests, Nav1.7 potential analgesic peptide toxins are often administrated by peripheral routes, such as subcutaneous (intraplantar), intraperitoneal or intramuscular injection) or intrathecal route. ProTx-II and its mutant, despite being the best candidate toxins with the highest affinity and selectivity, are unable to pass through the BNB (see **Figure 2**) and inhibit action potential transmission along nerves, except if a disruption of the perineurial barrier occurs (Schmalhofer et al., 2008; Hackel et al.,

2012). After 24 h of intravenous infusion *in vivo*, ProTx-II can access DRG neurons but not sciatic nerves and CNS tissues (Liu et al., 2018). Thus, the fenestrations in Blood-Glangia-Barrier (BGB, see **Figure 2**) are the entry doors for large peptide toxins but their spreading to dorsal root of spinal cord and to distal nerve endings will depend on BNB. The intrathecal route is one possibility to bypass both the BBB and BNB, showing analgesic effects of ProTx-II in rodent pain tests with the risk of the post-lumbar puncture syndrome (headache down to the shoulders, nausea, vertigo and tinnitus) or the effects of the chemical compound itself if the injection is failed. The other possibility consists of toxin co-injection with hypertonic saline solution to disturb BNB (decrease claudin-1 mRNA, one protein responsible for tight-junction) and lead to toxin penetration (Hackel et al., 2012; Tanaka et al., 2015; Flinspach et al., 2017).

CONCLUSION

Venoms are usually associated with a lethal effect due to the presence in this complex mixture of toxins that have been selected during the evolution process to target crucial physiological systems of the preys. Nevertheless, due to their high affinity and selectivity profiles for specific receptors and ion channels involved in various pathophysiological processes, peptide toxins may be exploited as pharmacological tools and/or therapeutic drugs. Currently, six venom-derived drugs are used for the treatment of hypertension, acute coronary syndromes or diabetes, but the most promising therapeutic area is probably the pain and more precisely, the chronic pain. One peptide, isolated from cone snail venom, has been approved by FDA more than 14 years ago for the treatment of severe chronic pain (ziconotide), and several drug-leads, mainly issue from spider venoms, are actually in development. Among the various receptors and ion channels involved in pain transmission and which are targeted by venom peptides, the Nav1.7 subtype is one of the most promising due to its peripheral location in DRG neurons which in addition present facilitated permeability to high molecular weight drugs. Furthermore, human genetic diseases, associated with Nav1.7 mutations and leading to painless/painful phenotypes, validate this subtype as a pain target. Several spider toxins have been recently identified and characterized for their analgesic property due to their interactions with Nav1.7. Furthermore, their engineering was associated with the optimization of their pharmacological (affinity for Nav1.7 and selectivity profile) and biodistribution properties, reinforcing the potential of these venom-derived peptides as leads for therapeutic development. Finally, new paradigm used in the venom-peptide discovery, based on transcriptomic/proteomic technologies and on a toxin-driven approach, should increase the diversity of toxins identified and the rate of new drug lead discovery, more particularly for the treatment of chronic pain.

AUTHOR CONTRIBUTIONS

TG performed the major part of the bibliographic research and of the review writing. EB, MP, and DS critically read the review.

FUNDING

This research was funded by a collaborative grant (#153114) between Sanofi Research & Development (Chilly-Mazarin,

France) and the French Alternative Energies and Atomic Energy Commission (CEA, Gif sur Yvette, France). TG was supported by a doctoral CIFRE fellowship from Sanofi.

REFERENCES

- Agwa, A. J., Lawrence, N., Deplazes, E., Cheneval, O., Chen, R. M., Craik, D. J., et al. (2017). Spider peptide toxin HwTx-IV engineered to bind to lipid membranes has an increased inhibitory potency at human voltage-gated sodium channel hNav1.7. *Biochim. Biophys. Acta* 1859, 835–844. doi: 10.1016/j.bbame.2017.01.020
- Agwa, A. J., Peigneur, S., Chow, C. Y., Lawrence, N., Craik, D. J., Tytgat, J., et al. (2018). Gating modifier toxins isolated from spider venom: modulation of voltage-gated sodium channels and the role of lipid membranes. *J. Biol. Chem.* 293, 9041–9052. doi: 10.1074/jbc.RA118.002553
- Allen, D. D., Cardenas, A. M., Arriagada, C., Bennett, L. B., Garcia, C. J., Caviedes, R., et al. (2002). A dorsal root ganglia cell line derived from trisomy 16 fetal mice, a model for down syndrome. *Neuroreport* 13, 491–496. doi: 10.1097/00001756-200203250-00027
- Anderson, L. L., Hawkins, N. A., Thompson, C. H., Kearney, J. A., and George, A. L. Jr. (2017). Unexpected efficacy of a novel sodium channel modulator in dravet syndrome. *Sci. Rep.* 7:1682. doi: 10.1038/s41598-017-01851-9
- Barbosa, C., Tan, Z. Y., Wang, R., Xie, W., Strong, J. A., Patel, R. R., et al. (2015). Navbeta4 regulates fast resurgent sodium currents and excitability in sensory neurons. *Mol. Pain* 11:60. doi: 10.1186/s12990-015-0063-9
- Behr, E. R., Savio-Galimberti, E., Barc, J., Holst, A. G., Petropoulou, E., Prins, B. P., et al. (2015). Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. *Cardiovasc. Res.* 106, 520–529. doi: 10.1093/cvr/cvv042
- Belkouch, M., Dansereau, M. A., Tetreault, P., Biet, M., Beaudet, N., Dumaine, R., et al. (2014). Functional up-regulation of Nav1.8 sodium channel in Abeta afferent fibers subjected to chronic peripheral inflammation. *J. Neuroinflammation* 11:45. doi: 10.1186/1742-2094-11-45
- Ben-Shalom, R., Keeshen, C. M., Berrios, K. N., An, J. Y., Sanders, S. J., and Bender, K. J. (2017). Opposing effects on Nav1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures. *Biol. Psychiatry* 82, 224–232. doi: 10.1016/j.biopsych.2017.01.009
- Berta, T., Poirot, O., Pertin, M., Ji, R. R., Kellenberger, S., and Decosterd, I. (2008). Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. *Mol. Cell. Neurosci.* 37, 196–208. doi: 10.1016/j.mcn.2007.09.007
- Berta, T., Qadri, Y., Tan, P. H., and Ji, R. R. (2017). Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain. *Expert Opin. Ther. Targets* 21, 695–703. doi: 10.1080/14728222.2017.1328057
- Biswas, K., Nixey, T. E., Murray, J. K., Falsey, J. R., Yin, L., Liu, H., et al. (2017). Engineering antibody reactivity for efficient derivatization to generate Nav1.7 inhibitory GpTx-1 peptide-antibody conjugates. *ACS Chem. Biol.* 12, 2427–2435. doi: 10.1021/acscmbio.7b00542
- Black, J. A., Cummins, T. R., Plumpton, C., Chen, Y. H., Hormuzdiar, W., Clare, J. J., et al. (1999). Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. *J. Neurophysiol.* 82, 2776–2785. doi: 10.1152/jn.1999.82.5.2776
- Black, J. A., and Waxman, S. G. (2013). Noncanonical roles of voltage-gated sodium channels. *Neuron* 80, 280–291. doi: 10.1016/j.neuron.2013.09.012
- Blesneac, I., Themistocleous, A. C., Fratter, C., Conrad, L. J., Ramirez, J. D., Cox, J. J., et al. (2018). Rare Nav1.7 variants associated with painful diabetic peripheral neuropathy. *Pain* 159, 469–480. doi: 10.1097/j.pain.0000000000001116
- Bosmans, F., Milesu, M., and Swartz, K. J. (2011). Palmitoylation influences the function and pharmacology of sodium channels. *Proc. Natl. Acad. Sci. U.S.A.* 108, 20213–20218. doi: 10.1073/pnas.1108497108
- Bosmans, F., Rash, L., Zhu, S., Diochot, S., Lazdunski, M., Escoubas, P., et al. (2006). Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes. *Mol. Pharmacol.* 69, 419–429. doi: 10.1124/mol.105.015941
- Boucher, T. J., Okuse, K., Bennett, D. L., Munson, J. B., Wood, J. N., and McMahon, S. B. (2000). Potent analgesic effects of GDNF in neuropathic pain states. *Science* 290, 124–127. doi: 10.1126/science.290.5489.124
- Boullot, F., Castrec, J., Bidault, A., Dantas, N., Payton, L., Perrigault, M., et al. (2017). Molecular characterization of voltage-gated sodium channels and their relations with paralytic shellfish toxin bioaccumulation in the pacific oyster *Crassostrea gigas*. *Mar. Drugs* 15:E21. doi: 10.3390/md15010021
- Bridges, D., Thompson, S. W., and Rice, A. S. (2001). Mechanisms of neuropathic pain. *Br. J. Anaesth.* 87, 12–26. doi: 10.1093/bja/87.1.12
- Cai, T., Luo, J., Meng, E., Ding, J., Liang, S., Wang, S., et al. (2015). Mapping the interaction site for the tarantula toxin hainantoxin-IV (beta-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels. *Peptides* 68, 148–156. doi: 10.1016/j.peptides.2014.09.005
- Cao, L., McDonnell, A., Nitzsche, A., Alexandrou, A., Saintot, P. P., Loucif, A. J., et al. (2016). Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. *Sci. Transl. Med.* 8:335ra356. doi: 10.1126/scitranslmed.aad7653
- Cardoso, F. C., Dekan, Z., Rosengren, K. J., Erickson, A., Vetter, I., Deuis, J. R., et al. (2015). Identification and characterization of ProTx-III [mu-TRTX-Tp1a], a new voltage-gated sodium channel inhibitor from venom of the tarantula *Thrixopelma pruriens*. *Mol. Pharmacol.* 88, 291–303. doi: 10.1124/mol.115.098178
- Cardoso, F. C., Dekan, Z., Smith, J. J., Deuis, J. R., Vetter, I., Herzig, V., et al. (2017). Modulatory features of the novel spider toxin mu-TRTX-Df1a isolated from the venom of the spider *Davus fasciatus*. *Br. J. Pharmacol.* 174, 2528–2544. doi: 10.1111/bph.13865
- Catterall, W. A. (2000). From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. *Neuron* 26, 13–25. doi: 10.1016/S0896-6273(00)81133-2
- Catterall, W. A., Cestele, S., Yarov-Yarovoy, V., Yu, F. H., Konoki, K., and Scheuer, T. (2007). Voltage-gated ion channels and gating modifier toxins. *Toxicol.* 49, 124–141. doi: 10.1016/j.toxicol.2006.09.022
- Catterall, W. A., Goldin, A. L., and Waxman, S. G. (2005a). International union of pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. *Pharmacol. Rev.* 57, 397–409.
- Catterall, W. A., Perez-Reyes, E., Snutch, T. P., and Striessnig, J. (2005b). International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. *Pharmacol. Rev.* 57, 411–425.
- Catterall, W. A., Kalume, F., and Oakley, J. C. (2010). Nav1.1 channels and epilepsy. *J. Physiol.* 588, 1849–1859. doi: 10.1113/jphysiol.2010.187484
- Catterall, W. A. (2012). “Sodium channel mutations and epilepsy,” in *Jasper’s Basic Mechanisms of the Epilepsies*, eds J. Noebels, M. Avoli, M. Rogawski, R. Olsen, and A. Delgado-Escueta (Rockville, MD: Bethesda). doi: 10.1093/med/9780199746545.003.0052
- Caviedes, P., Ault, B., and Rapoport, S. I. (1990). Replating improves whole cell voltage clamp recording of human fetal dorsal root ganglion neurons. *J. Neurosci. Methods* 35, 57–61. doi: 10.1016/0165-0270(90)90094-V
- Cestele, S., and Catterall, W. A. (2000). Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. *Biochimie* 82, 883–892. doi: 10.1016/S0300-9084(00)01174-3
- Chang, W., Berta, T., Kim, Y. H., Lee, S., Lee, S. Y., and Ji, R. R. (2018). Expression and role of voltage-gated sodium channels in human dorsal root ganglion neurons with special focus on Nav1.7, Species Differences, and Regulation by Paclitaxel. *Neurosci. Bull.* 34, 4–12. doi: 10.1007/s12264-017-0132-3

- Chatelier, A., Dahllund, L., Eriksson, A., Krupp, J., and Chahine, M. (2008). Biophysical properties of human Na v1.7 splice variants and their regulation by protein kinase A. *J. Neurophysiol.* 99, 2241–2250. doi: 10.1152/jn.01350.2007
- Chen, W., Mi, R., Haughey, N., Oz, M., and Hoke, A. (2007). Immortalization and characterization of a nociceptive dorsal root ganglion sensory neuronal line. *J. Peripher. Nerv. Syst.* 12, 121–130. doi: 10.1111/j.1529-8027.2007.00131.x
- Cummins, T. R., Aglieco, F., Renganathan, M., Herzog, R. L., Dib-Hajj, S. D., and Waxman, S. G. (2001). Nav1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. *J. Neurosci.* 21, 5952–5961. doi: 10.1523/JNEUROSCI.21-16-05952.2001
- de Lera Ruiz, M., and Kraus, R. L. (2015). Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. *J. Med. Chem.* 58, 7093–7118. doi: 10.1021/jm501981g
- de Souza, A. H., Castro, C. J. Jr., Rigo, F. K., De Oliveira, S. M., Gomez, R. S., et al. (2013). An evaluation of the antinociceptive effects of Phalpal1beta, a neurotoxin from the spider *Phoneutria nigriventer*, and omega-conotoxin MVIIA, a cone snail *Conus magus* toxin, in rat model of inflammatory and neuropathic pain. *Cell. Mol. Neurobiol.* 33, 59–67. doi: 10.1007/s10571-012-9871-x
- Deplazes, E., Henriques, S. T., Smith, J. J., King, G. F., Craik, D. J., Mark, A. E., et al. (2016). Membrane-binding properties of gating modifier and pore-blocking toxins: membrane interaction is not a prerequisite for modification of channel gating. *Biochim. Biophys. Acta* 1858, 872–882. doi: 10.1016/j.bbame.2016.02.002
- Deuis, J. R., Dekan, Z., Wingerd, J. S., Smith, J. J., Munasinghe, N. R., Bhola, R. F., et al. (2017a). Pharmacological characterisation of the highly Nav1.7 selective spider venom peptide Pn3a. *Sci. Rep.* 7:40883. doi: 10.1038/srep40883
- Deuis, J. R., Mueller, A., Israel, M. R., and Vetter, I. (2017b). The pharmacology of voltage-gated sodium channel activators. *Neuropharmacology* 127, 87–108. doi: 10.1016/j.neuropharm.2017.04.014
- Deuis, J. R., Wingerd, J. S., Winter, Z., Durek, T., Dekan, Z., Sousa, S. R., et al. (2016). Analgesic effects of GpTx-1, PF-04856264 and CNV1014802 in a mouse model of Nav1.7-Mediated Pain. *Toxins* 8:E78. doi: 10.3390/toxins8030078
- Deuis, J. R., Zimmermann, K., Romanovsky, A. A., Possani, L. D., Cabot, P. J., Lewis, R. J., et al. (2013). An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. *Pain* 154, 1749–1757. doi: 10.1016/j.pain.2013.05.032
- Dib-Hajj, S. D., Black, J. A., and Waxman, S. G. (2015). Nav1.9: a sodium channel linked to human pain. *Nat. Rev. Neurosci.* 16, 511–519. doi: 10.1038/nrn3977
- Dib-Hajj, S. D., Fjell, J., Cummins, T. R., Zheng, Z., Fried, K., Lamotte, R., et al. (1999). Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. *Pain* 83, 591–600. doi: 10.1016/S0304-3959(99)00169-4
- Dib-Hajj, S. D., Tyrrell, L., Black, J. A., and Waxman, S. G. (1998). Na_v1, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. *Proc. Natl. Acad. Sci. U.S.A.* 95, 8963–8968. doi: 10.1073/pnas.95.15.8963
- Dib-Hajj, S. D., Yang, Y., Black, J. A., and Waxman, S. G. (2013). The Na(V)1.7 sodium channel: from molecule to man. *Nat. Rev. Neurosci.* 14, 49–62. doi: 10.1038/nrn3404
- Dichgans, M., Freilinger, T., Eckstein, G., Babini, E., Lorenz-Depiereux, B., Biskup, S., et al. (2005). Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. *Lancet* 366, 371–377. doi: 10.1016/S0140-6736(05)66786-4
- Dietrich, P. S., Mcgivern, J. G., Delgado, S. G., Koch, B. D., Eglén, R. M., Hunter, J. C., et al. (1998). Functional analysis of a voltage-gated sodium channel and its splice variant from rat dorsal root ganglia. *J. Neurochem.* 70, 2262–2272. doi: 10.1046/j.1471-4159.1998.70062262.x
- Djoughri, L., Newton, R., Levinson, S. R., Berry, C. M., Carruthers, B., and Lawson, S. N. (2003). Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav 1.7 (PN1) Na⁺ channel alpha subunit protein. *J. Physiol.* 546, 565–576. doi: 10.1111/jphysiol.2002.026559
- Elliott, A. A., and Elliott, J. R. (1993). Characterization of TTX-sensitive and TTX-resistant sodium currents in small cells from adult rat dorsal root ganglia. *J. Physiol.* 463, 39–56. doi: 10.1111/jphysiol.1993.sp019583
- Ernsberger, U. (2009). Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia. *Cell Tissue Res.* 336, 349–384. doi: 10.1007/s00441-009-0784-z
- Escoubas, P. (2006). Molecular diversification in spider venoms: a web of combinatorial peptide libraries. *Mol. Divers.* 10, 545–554. doi: 10.1007/s11030-006-9050-4
- Faber, C. G., Lauria, G., Merckies, I. S., Cheng, X., Han, C., Ahn, H. S., et al. (2012). Gain-of-function Nav1.8 mutations in painful neuropathy. *Proc. Natl. Acad. Sci. U.S.A.* 109, 19444–19449. doi: 10.1073/pnas.1216080109
- Flinspach, M., Xu, Q., Piekarz, A. D., Fellows, R., Hagan, R., Gibbs, A., et al. (2017). Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor. *Sci. Rep.* 7:39662. doi: 10.1038/srep39662
- Fry, A. E., Rees, E., Thompson, R., Mantripragada, K., Blake, P., Jones, G., et al. (2016). Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy. *BMC Med. Genet.* 17:34. doi: 10.1186/s12881-016-0294-2
- Fukuoka, T., Kobayashi, K., Yamanaka, H., Obata, K., Dai, Y., and Noguchi, K. (2008). Comparative study of the distribution of the alpha-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons. *J. Comp. Neurol.* 510, 188–206. doi: 10.1002/cne.21786
- García-Villegas, R., Lopez-Alvarez, L. E., Arni, S., Rosenbaum, T., and Morales, M. A. (2009). Identification and functional characterization of the promoter of the mouse sodium-activated sodium channel Na(x) gene (Scn7a). *J. Neurosci. Res.* 87, 2509–2519. doi: 10.1002/jnr.22069
- Gilchrist, J., Olivera, B. M., and Bosmans, F. (2014). Animal toxins influence voltage-gated sodium channel function. *Handb. Exp. Pharmacol.* 221, 203–229. doi: 10.1007/978-3-642-41588-3_10
- Goldberg, D. S., and McGee, S. J. (2011). Pain as a global public health priority. *BMC Public Health* 11:770. doi: 10.1186/1471-2458-11-770
- Goldin, A. L. (2001). Resurgence of sodium channel research. *Annu. Rev. Physiol.* 63, 871–894. doi: 10.1146/annurev.physiol.63.1.871
- Goldin, A. L. (2002). Evolution of voltage-gated Na(+) channels. *J. Exp. Biol.* 205, 575–584.
- Goldin, A. L., Barchi, R. L., Caldwell, J. H., Hofmann, F., Howe, J. R., Hunter, J. C., et al. (2000). Nomenclature of voltage-gated sodium channels. *Neuron* 28, 365–368. doi: 10.1016/S0896-6273(00)00116-1
- Gonçalves, T. C., Boukaiba, R., Molgo, J., Amar, M., Partiseti, M., Servent, D., et al. (2018). Direct evidence for high affinity blockade of Nav1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches. *Neuropharmacology* 133, 404–414. doi: 10.1016/j.neuropharm.2018.02.016
- Gorter, J. A., Zurolo, E., Iyer, A., Fluiter, K., Van Vliet, E. A., Baayen, J. C., et al. (2010). Induction of sodium channel Na(x) (SCN7A) expression in rat and human hippocampus in temporal lobe epilepsy. *Epilepsia* 51, 1791–1800. doi: 10.1111/j.1528-1167.2010.02678.x
- Grasso, G., Landi, A., and Alafaci, C. (2016). A novel pathophysiological mechanism contributing to trigeminal neuralgia. *Mol. Med.* doi: 10.2119/molmed.2016.00172 [Epub ahead of print]. doi: 10.2119/molmed.2016.00172
- Gui, J., Liu, B., Cao, G., Lipchik, A. M., Perez, M., Dekan, Z., et al. (2014). A tarantula-venom peptide antagonizes the TRPA1 nociceptor ion channel by binding to the S1-S4 gating domain. *Curr. Biol.* 24, 473–483. doi: 10.1016/j.cub.2014.01.013
- Hackel, D., Krug, S. M., Sauer, R. S., Mousa, S. A., Bocker, A., Pflucke, D., et al. (2012). Transient opening of the perineurial barrier for analgesic drug delivery. *Proc. Natl. Acad. Sci. U.S.A.* 109, E2018–E2027. doi: 10.1073/pnas.1120800109
- Hackenberg, A., Baumer, A., Sticht, H., Schmitt, B., Kroell-Seger, J., Wille, D., et al. (2014). Infantile epileptic encephalopathy, transient choreoathetotic movements, and hypersomnia due to a De Novo missense mutation in the SCN2A gene. *Neuropediatrics* 45, 261–264. doi: 10.1055/s-0034-1372302
- Hagen, N. A., Cantin, L., Constant, J., Haller, T., Blaise, G., Ong-Lam, M., du Souich, P., et al. (2017). Tetrodotoxin for moderate to severe cancer-related pain: a multicentre, randomized, double-blind, placebo-controlled, parallel-design trial. *Pain Res. Manag.* 2017:7212713. doi: 10.1155/2017/7212713
- Hains, B. C., Klein, J. P., Saab, C. Y., Craner, M. J., Black, J. A., and Waxman, S. G. (2003). Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. *J. Neurosci.* 23, 8881–8892. doi: 10.1523/JNEUROSCI.23-26-08881.2003

- Hains, B. C., Saab, C. Y., and Waxman, S. G. (2005). Changes in electrophysiological properties and sodium channel Nav1.3 expression in thalamic neurons after spinal cord injury. *Brain* 128, 2359–2371. doi: 10.1093/brain/awh623
- Hains, B. C., Saab, C. Y., and Waxman, S. G. (2006). Alterations in burst firing of thalamic VPL neurons and reversal by Na(v)1.3 antisense after spinal cord injury. *J. Neurophysiol.* 95, 3343–3352. doi: 10.1152/jn.01009.2005
- Han, C., Huang, J., and Waxman, S. G. (2016). Sodium channel Nav1.8: emerging links to human disease. *Neurology* 86, 473–483. doi: 10.1212/WNL.0000000000002333
- Han, C., Yang, Y., De Greef, B. T., Hoeijmakers, J. G., Gerrits, M. M., Verhamme, C., et al. (2015). The domain II S4-S5 linker in Nav1.9: a missense mutation enhances activation, impairs fast inactivation, and produces human painful neuropathy. *Neuromolecular Med.* 17, 158–169. doi: 10.1007/s12017-015-8347-9
- Han, C., Yang, Y., Te Morsche, R. H., Drenth, J. P., Politei, J. M., Waxman, S. G., et al. (2017). Familial gain-of-function Nav1.9 mutation in a painful channelopathy. *J. Neurol. Neurosurg. Psychiatry* 88, 233–240. doi: 10.1136/jnnp-2016-313804
- Henriques, S. T., Deplazes, E., Lawrence, N., Cheneval, O., Chaouis, S., Inerra, M., et al. (2016). Interaction of tarantula venom peptide proTx-II with lipid membranes is a prerequisite for its inhibition of human voltage-gated sodium channel Nav1.7. *J. Biol. Chem.* 291, 17049–17065. doi: 10.1074/jbc.M116.729095
- Hiyama, T. Y., Matsuda, S., Fujikawa, A., Matsumoto, M., Watanabe, E., Kajiwara, H., et al. (2010). Autoimmunity to the sodium-level sensor in the brain causes essential hyponatremia. *Neuron* 66, 508–522. doi: 10.1016/j.neuron.2010.04.017
- Hiyama, T. Y., Watanabe, E., Ono, K., Inenaga, K., Tamkun, M. M., Yoshida, S., et al. (2002). Na(x) channel involved in CNS sodium-level sensing. *Nat. Neurosci.* 5, 511–512. doi: 10.1038/nn0602-856
- Ho, C., and O'Leary, M. E. (2011). Single-cell analysis of sodium channel expression in dorsal root ganglion neurons. *Mol. Cell. Neurosci.* 46, 159–166. doi: 10.1016/j.mcn.2010.08.017
- Ho, W. S., Davis, A. J., Chadha, P. S., and Greenwood, I. A. (2013). Effective contractile response to voltage-gated Na⁺ channels revealed by a channel activator. *Am. J. Physiol. Cell Physiol.* 304, C739–C747. doi: 10.1152/ajpcell.00164.2012
- Hockley, J. R., Winchester, W. J., and Bulmer, D. C. (2016). The voltage-gated sodium channel NaV 1.9 in visceral pain. *Neurogastroenterol. Motil.* 28, 316–326. doi: 10.1111/nmo.12698
- Holmes, D. (2016). The pain drain. *Nature* 535, S2–S3. doi: 10.1038/53552a
- Huang, J., Han, C., Estacion, M., Vasylyev, D., Hoeijmakers, J. G., Gerrits, M. M., et al. (2014). Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. *Brain* 137, 1627–1642. doi: 10.1093/brain/awu079
- Huang, J., Vanoye, C. G., Cutts, A., Goldberg, Y. P., Dib-Hajj, S. D., Cohen, C. J., et al. (2017). Sodium channel Nav1.9 mutations associated with insensitivity to pain dampen neuronal excitability. *J. Clin. Invest.* 127, 2805–2814. doi: 10.1172/JCI92373
- Huang, Q., Chen, Y., Gong, N., and Wang, Y. X. (2016). Methylglyoxal mediates streptozotocin-induced diabetic neuropathic pain via activation of the peripheral TRPA1 and Nav1.8 channels. *Metabolism* 65, 463–474. doi: 10.1016/j.metabol.2015.12.002
- Iio, C., Ogimoto, A., Nagai, T., Suzuki, J., Inoue, K., Nishimura, K., et al. (2015). Association between genetic variation in the SCN10A gene and cardiac conduction abnormalities in patients with hypertrophic cardiomyopathy. *Int. Heart* 56, 421–427. doi: 10.1536/ihj.14-411
- Inerra, M. C., Israel, M. R., Caldwell, A., Castro, J., Deuis, J. R., Harrington, A. M., et al. (2017). Multiple sodium channel isoforms mediate the pathological effects of Pacific ciguatoxin-1. *Sci. Rep.* 7:42810. doi: 10.1038/srep42810
- Israel, M. R., Tay, B., Deuis, J. R., and Vetter, I. (2017). Sodium channels and venom peptide pharmacology. *Adv. Pharmacol.* 79, 67–116. doi: 10.1016/bs.apha.2017.01.004
- Jami, S., Erickson, A., Brierley, S. M., and Vetter, I. (2017). Pain-causing venom peptides: insights into sensory neuron pharmacology. *Toxins* 10:E15 doi: 10.3390/toxins10010015
- Jarecki, B. W., Sheets, P. L., Xiao, Y., Jackson, J. O. II, and Cummins, T. R. (2009). Alternative splicing of Na(V)1.7 exon 5 increases the impact of the painful PEPD mutant channel I1461T. *Channels* 3, 259–267. doi: 10.4161/chan.3.4.9341
- Jimenez-Andrade, J. M., Herrera, M. B., Ghilardi, J. R., Vardanyan, M., Melemedjian, O. K., and Mantyh, P. W. (2008). Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. *Mol. Pain* 4:10. doi: 10.1186/1744-8069-4-10
- Jo, T., Nagata, T., Iida, H., Imuta, H., Iwasawa, K., Ma, J., et al. (2004). Voltage-gated sodium channel expressed in cultured human smooth muscle cells: involvement of SCN9A. *FEBS Lett.* 567, 339–343. doi: 10.1016/j.febslet.2004.04.092
- Jung, H. J., Lee, J. Y., Kim, S. H., Eu, Y. J., Shin, S. Y., Milescu, M., et al. (2005). Solution structure and lipid membrane partitioning of VSTx1, an inhibitor of the KvAP potassium channel. *Biochemistry* 44, 6015–6023. doi: 10.1021/bi0477034
- Ke, C. B., He, W. S., Li, C. J., Shi, D., Gao, F., and Tian, Y. K. (2012). Enhanced SCN7A/Nav expression contributes to bone cancer pain by increasing excitability of neurons in dorsal root ganglion. *Neuroscience* 227, 80–89. doi: 10.1016/j.neuroscience.2012.09.046
- Kim, C. H., Oh, Y., Chung, J. M., and Chung, K. (2001). The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. *Brain Res. Mol. Brain Res.* 95, 153–161. doi: 10.1016/S0169-328X(01)00226-1
- King, M. K., Leipold, E., Goehring, J. M., Kurth, I., and Challman, T. D. (2017). Pain insensitivity: distal S6-segment mutations in Nav1.9 emerge as critical hotspot. *Neurogenetics* 18, 179–181. doi: 10.1007/s10048-017-0513-9
- Kinsman, B. J., Nation, H. N., and Stocker, S. D. (2017). Hypothalamic signaling in body fluid homeostasis and hypertension. *Curr. Hypertens. Rep.* 19:50. doi: 10.1007/s11906-017-0749-7
- Kist, A. M., Sagafos, D., Rush, A. M., Neacsu, C., Eberhardt, E., Schmidt, R., et al. (2016). SCN10A mutation in a patient with erythromelalgia enhances c-fiber activity dependent slowing. *PLoS One* 11:e0161789. doi: 10.1371/journal.pone.0161789
- Kleggetveit, I. P., Schmidt, R., Namer, B., Salter, H., Helas, T., Schmelz, M., et al. (2016). Pathological nociceptors in two patients with erythromelalgia-like symptoms and rare genetic Nav 1.9 variants. *Brain Behav.* 6:e00528. doi: 10.1002/brb3.528
- Klint, J. K., Chin, Y. K., and Mobli, M. (2015a). Rational engineering defines a molecular switch that is essential for activity of spider-venom peptides against the analgesic target Nav1.7. *Mol. Pharmacol.* 88, 1002–1010. doi: 10.1124/mol.115.100784
- Klint, J. K., Smith, J. J., Vetter, I., Rupasinghe, D. B., Er, S. Y., Senff, S., et al. (2015b). Seven novel modulators of the analgesic target Nav 1.7 uncovered using a high-throughput venom-based discovery approach. *Br. J. Pharmacol.* 172, 2445–2458. doi: 10.1111/bph.13081
- Klint, J. K., Senff, S., Rupasinghe, D. B., Er, S. Y., Herzog, V., Nicholson, G. M., et al. (2012). Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads. *Toxicol.* 60, 478–491. doi: 10.1016/j.toxicol.2012.04.337
- Koenig, J., Werdehausen, R., Linley, J. E., Habib, A. M., Vernon, J., Lolignier, S., et al. (2015). Regulation of Nav1.7: a conserved SCN9A natural antisense transcript expressed in dorsal root ganglia. *PLoS One* 10:e0128830. doi: 10.1371/journal.pone.0128830
- Laedermann, C. J., Abriel, H., and Decosterd, I. (2015). Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes. *Front. Pharmacol.* 6:263. doi: 10.3389/fphar.2015.00263
- Lai, J., Hunter, J. C., and Porreca, F. (2003). The role of voltage-gated sodium channels in neuropathic pain. *Curr. Opin. Neurobiol.* 13, 291–297. doi: 10.1016/S0959-4388(03)00074-6
- Lamar, T., Vanoye, C. G., Calhoun, J., Wong, J. C., Dutton, S. B. B., Jorge, B. S., et al. (2017). SCN3A deficiency associated with increased seizure susceptibility. *Neurobiol. Dis.* 102, 38–48. doi: 10.1016/j.nbd.2017.02.006
- Lee, J. H., Park, C. K., Chen, G., Han, Q., Xie, R. G., Liu, T., et al. (2014). A monoclonal antibody that targets a Nav1.7 channel voltage sensor for pain and itch relief. *Cell* 157, 1393–1404. doi: 10.1016/j.cell.2014.03.064

- Leipold, E., Hanson-Kahn, A., Frick, M., Gong, P., Bernstein, J. A., Voigt, M., et al. (2015). Cold-aggravated pain in humans caused by a hyperactive Nav1.9 channel mutant. *Nat. Commun.* 6:10049. doi: 10.1038/ncomms10049
- Leipold, E., Liebmann, L., Korenke, G. C., Heinrich, T., Giesselmann, S., Baets, J., et al. (2013). A de novo gain-of-function mutation in SCN11A causes loss of pain perception. *Nat. Genet.* 45, 1399–1404. doi: 10.1038/ng.2767
- Leng, X. R., Qi, X. H., Zhou, Y. T., and Wang, Y. P. (2017). Gain-of-function mutation p.Arg225Cys in SCN11A causes familial episodic pain and contributes to essential tremor. *J. Hum. Genet.* 62, 641–646. doi: 10.1038/jhg.2017.21
- Lewis, A. H., and Raman, I. M. (2014). Resurgent current of voltage-gated Na(+) channels. *J. Physiol.* 592, 4825–4838. doi: 10.1113/jphysiol.2014.277582
- Li, C., Wang, S., Chen, Y., and Zhang, X. (2018). Somatosensory neuron typing with high-coverage single-Cell RNA sequencing and functional analysis. *Neurosci. Bull.* 34, 200–207. doi: 10.1007/s12264-017-0147-9
- Liao, Y., Anttonen, A. K., Liukkonen, E., Gaily, E., Maljevic, S., Schubert, S., et al. (2010). SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. *Neurology* 75, 1454–1458. doi: 10.1212/WNL.0b013e3181f8812e
- Liem, L., Van Dongen, E., Huygen, F. J., Staats, P., and Kramer, J. (2016). The dorsal root ganglion as a therapeutic target for chronic pain. *Reg. Anesth. Pain Med.* 41, 511–519. doi: 10.1097/AAP.0000000000000408
- Lin, W. H., and Baines, R. A. (2015). Regulation of membrane excitability: a convergence on voltage-gated sodium conductance. *Mol. Neurobiol.* 51, 57–67. doi: 10.1007/s12035-014-8674-0
- Liu, D., Tseng, M., Epstein, L. F., Green, L., Chan, B., Soriano, B., Lim, D., et al. (2016). Evaluation of recombinant monoclonal antibody SVMab1 binding to Na V1.7 target sequences and block of human Na V1.7 currents. *F1000Res.* 5:2764.
- Liu, H., Chen, Y., Huang, L., Sun, X., Fu, T., Wu, S., et al. (2018). Drug distribution into peripheral nerve. *J. Pharmacol. Exp. Ther.* 365, 336–345. doi: 10.1124/jpet.117.245613
- Liu, X. D., Yang, J. J., Fang, D., Cai, J., Wan, Y., and Xing, G. G. (2014). Functional upregulation of nav1.8 sodium channels on the membrane of dorsal root ganglia neurons contributes to the development of cancer-induced bone pain. *PLoS One* 9:e114623. doi: 10.1371/journal.pone.0114623
- Liu, Y., Tang, J., Zhang, Y., Xun, X., Tang, D., Peng, D., et al. (2014a). Synthesis and analgesic effects of mu-TRTX-Hhn1b on models of inflammatory and neuropathic pain. *Toxins* 6, 2363–2378. doi: 10.3390/toxins6082363
- Liu, Y., Wu, Z., Tang, D., Xun, X., Liu, L., Li, X., et al. (2014b). Analgesic effects of Huwentoxin-IV on animal models of inflammatory and neuropathic pain. *Protein Pept. Lett.* 21, 153–158. doi: 10.2174/09298665113206660119
- Liu, Z., Cai, T., Zhu, Q., Deng, M., Li, J., Zhou, X., et al. (2013). Structure and function of hainantoxin-III, a selective antagonist of neuronal tetrodotoxin-sensitive voltage-gated sodium channels isolated from the Chinese bird spider *Ornithoctonus hainana*. *J. Biol. Chem.* 288, 20392–20403. doi: 10.1074/jbc.M112.426627
- Liu, Z., Tao, J., Ye, P., and Ji, Y. (2012). Mining the virgin land of neurotoxicology: a novel paradigm of neurotoxic peptides action on glycosylated voltage-gated sodium channels. *J. Toxicol.* 2012:843787. doi: 10.1155/2012/843787
- Liu, Z. H., Chen, P., and Liang, S. P. (2002). Synthesis and oxidative refolding of hainantoxin-IV. *Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao* 34, 516–519.
- Lolignier, S., Amsalem, M., Maingret, F., Padilla, F., Gabriac, M., Chapuy, E., et al. (2011). Nav1.9 channel contributes to mechanical and heat pain hypersensitivity induced by subacute and chronic inflammation. *PLoS One* 6:e23083. doi: 10.1371/journal.pone.0023083
- Lolignier, S., Eijkelkamp, N., and Wood, J. N. (2015). Mechanical allodynia. *Pflugers Arch.* 467, 133–139. doi: 10.1007/s00424-014-1532-0
- Lolignier, S., Gkika, D., Andersson, D., Leipold, E., Vetter, I., Viana, F., et al. (2016). New insight in cold pain: role of ion channels, modulation, and clinical perspectives. *J. Neurosci.* 36, 11435–11439. doi: 10.1523/JNEUROSCI.2327-16.2016
- Luo, W., Wickramasinghe, S. R., Savitt, J. M., Griffin, J. W., Dawson, T. M., and Ginty, D. D. (2007). A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. *Neuron* 54, 739–754. doi: 10.1016/j.neuron.2007.04.027
- Makinson, C. D., Tanaka, B. S., Lamar, T., Goldin, A. L., and Escayg, A. (2014). Role of the hippocampus in Nav1.6 (Scn8a) mediated seizure resistance. *Neurobiol. Dis.* 68, 16–25. doi: 10.1016/j.nbd.2014.03.014
- Minasian, N. A., Gibbs, A., Shih, A. Y., Liu, Y., Neff, R. A., Sutton, S. W., et al. (2013). Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (mu-TRTX-Hh2a). *J. Biol. Chem.* 288, 22707–22720. doi: 10.1074/jbc.M113.461392
- Mogil, J. S. (2009). Animal models of pain: progress and challenges. *Nat. Rev. Neurosci.* 10, 283–294. doi: 10.1038/nrn2606
- Moraes, E. R., Kushmerick, C., and Naves, L. A. (2014). Characteristics of dorsal root ganglia neurons sensitive to Substance P. *Mol. Pain* 10:73. doi: 10.1186/1744-8069-10-73
- Moyer, B. D., Murray, J. K., Ligutti, J., Andrews, K., Favreau, P., Jordan, J. B., et al. (2018). Pharmacological characterization of potent and selective Nav1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V. *PLoS One* 13:e0196791. doi: 10.1371/journal.pone.0196791
- Mulley, J. C., Hodgson, B., McMahon, J. M., Iona, X., Bellows, S., Mullen, S. A., et al. (2013). Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome. *Epilepsia* 54, e122–e126. doi: 10.1111/epi.12323
- Muroi, Y., and Undem, B. J. (2014). Targeting voltage gated sodium channels Nav1.7, Na V1.8, and Na V1.9 for treatment of pathological cough. *Lung* 192, 15–20. doi: 10.1007/s00408-013-9533-x
- Murray, J. K., Long, J., Zou, A., Ligutti, J., Andrews, K. L., Poppe, L., et al. (2016). Single residue substitutions that confer voltage-gated sodium ion channel subtype selectivity in the Nav1.7 inhibitory peptide GpTx-1. *J. Med. Chem.* 59, 2704–2717. doi: 10.1021/acs.jmedchem.5b01947
- Namadurai, S., Yereddi, N. R., Cusdin, F. S., Huang, C. L., Chirgadze, D. Y., and Jackson, A. P. (2015). A new look at sodium channel beta subunits. *Open Biol.* 5:140192. doi: 10.1098/rsob.140192
- Negus, S. S. (2018). Addressing the opioid crisis: the importance of choosing translational endpoints in analgesic drug discovery. *Trends Pharmacol. Sci.* 39, 327–330. doi: 10.1016/j.tips.2018.02.002
- Nehme, B., Henry, M., Mougnot, D., and Drolet, G. (2012). The expression pattern of the Na(+) Sensor, Na(X) in the hydromineral homeostatic network: a comparative study between the rat and mouse. *Front. Neuroanat.* 6:26. doi: 10.3389/fnana.2012.00026
- Nishiyama, Y., Yokokawa, S., Fukuda, A., Yamagata, T., Inayoshi, A., Obinata, M., et al. (2011). The generation of rat dorsal root ganglion cell lines to identify the target of KW-7158, a novel treatment for overactive bladder. *Neurosci. Res.* 71, 278–288. doi: 10.1016/j.neures.2011.07.1823
- O'Brien, J. E., and Meisler, M. H. (2013). Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability. *Front. Genet.* 4:213. doi: 10.3389/fgene.2013.00213
- O'Donnell, A. M., Coyle, D., and Puri, P. (2016). Decreased Nav1.9 channel expression in Hirschsprung's disease. *J. Pediatr. Surg.* 51, 1458–1461. doi: 10.1016/j.jpedsurg.2016.05.007
- Okuda, H., Noguchi, A., Kobayashi, H., Kondo, D., Harada, K. H., Youssefian, S., et al. (2016). Infantile pain episodes associated with novel Nav1.9 mutations in familial episodic pain syndrome in Japanese families. *PLoS One* 11:e0154827. doi: 10.1371/journal.pone.0154827
- Ono, S., Kimura, T., and Kubo, T. (2011). Characterization of voltage-dependent calcium channel blocking peptides from the venom of the tarantula *Grammostola rosea*. *Toxicon* 58, 265–276. doi: 10.1016/j.toxicon.2011.06.006
- Osmakov, D. I., Andreev, Y. A., and Kozlov, S. A. (2014). Acid-sensing ion channels and their modulators. *Biochemistry* 79, 1528–1545. doi: 10.1134/S0006297914130069
- Osteen, J. D., Herzog, V., Gilchrist, J., Emrick, J. J., Zhang, C., Wang, X., et al. (2016). Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. *Nature* 534, 494–499. doi: 10.1038/nature17976
- Osteen, J. D., Sampson, K., Iyer, V., Julius, D., and Bosmans, F. (2017). Pharmacology of the Nav1.1 domain IV voltage sensor reveals coupling between inactivation gating processes. *Proc. Natl. Acad. Sci. U.S.A.* 114, 6836–6841. doi: 10.1073/pnas.1621263114
- Pan, H. L., Wu, Z. Z., Zhou, H. Y., Chen, S. R., Zhang, H. M., and Li, D. P. (2008). Modulation of pain transmission by G-protein-coupled receptors. *Pharmacol. Ther.* 117, 141–161. doi: 10.1016/j.pharmthera.2007.09.003
- Parke, W. W., and Whalen, J. L. (2002). The vascular pattern of the human dorsal root ganglion and its probable bearing on a compartment syndrome. *Spine* 27, 347–352. doi: 10.1097/00007632-200202150-00004

- Patrick Harty, T., and Waxman, S. G. (2007). Inactivation properties of sodium channel Nav1.8 maintain action potential amplitude in small DRG neurons in the context of depolarization. *Mol. Pain* 3:12.
- Payandeh, J., Scheuer, T., Zheng, N., and Catterall, W. A. (2011). The crystal structure of a voltage-gated sodium channel. *Nature* 475, 353–358. doi: 10.1038/nature10238
- Peng, K., Shu, Q., Liu, Z., and Liang, S. (2002). Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider *Selenocosmia huwena*. *J. Biol. Chem.* 277, 47564–47571. doi: 10.1074/jbc.M204063200
- Pettersson, C. A., and Olsson, Y. (1989). Blood supply of spinal nerve roots. An experimental study in the rat. *Acta Neuropathol.* 78, 455–461. doi: 10.1007/BF00687706
- Phatarakijirund, V., Mumm, S., Mcalister, W. H., Novack, D. V., Wenkert, D., Clements, K. L., et al. (2016). Congenital insensitivity to pain: fracturing without apparent skeletal pathobiology caused by an autosomal dominant, second mutation in SCN11A encoding voltage-gated sodium channel 1.9. *Bone* 84, 289–298. doi: 10.1016/j.bone.2015.11.022
- Pineda, S. S., Chaumeil, P. A., Kunert, A., Kaas, Q., Thang, M. W. C., Le, L., et al. (2018). ArachnoServer 3.0: an online resource for automated discovery, analysis and annotation of spider toxins. *Bioinformatics* 34, 1074–1076. doi: 10.1093/bioinformatics/btx661
- Porreca, F., and Navratilova, E. (2017). Reward, motivation, and emotion of pain and its relief. *Pain* 158(Suppl. 1), S43–S49. doi: 10.1097/j.pain.0000000000000798
- Qiu, F., Jiang, Y., Zhang, H., Liu, Y., and Mi, W. (2012). Increased expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 within dorsal root ganglia in a rat model of bone cancer pain. *Neurosci. Lett.* 512, 61–66. doi: 10.1016/j.neulet.2012.01.069
- Rahnama, S., Deuis, J. R., Cardoso, F. C., Ramanujam, V., Lewis, R. J., Rash, L. D., et al. (2017). The structure, dynamics and selectivity profile of a Nav1.7 potency-optimised huwentoxin-IV variant. *PLoS One* 12:e0173551. doi: 10.1371/journal.pone.0173551
- Raymon, H. K., Thode, S., Zhou, J., Friedman, G. C., Pardinas, J. R., Barrere, C., et al. (1999). Immortalized human dorsal root ganglion cells differentiate into neurons with nociceptive properties. *J. Neurosci.* 19, 5420–5428. doi: 10.1523/JNEUROSCI.19-13-05420.1999
- Raymond, C. K., Castle, J., Garrett-Engle, P., Armour, C. D., Kan, Z., Tsinoemas, N., et al. (2004). Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia. *J. Biol. Chem.* 279, 46234–46241. doi: 10.1074/jbc.M406387200
- Ren, Y. S., Qian, N. S., Tang, Y., Liao, Y. H., Yang, Y. L., Dou, K. F., et al. (2012). Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes. *Brain Res. Bull.* 87, 244–249. doi: 10.1016/j.brainresbull.2011.10.015
- Renganathan, M., Cummins, T. R., and Waxman, S. G. (2001). Contribution of Nav1.8 sodium channels to action potential electrogenesis in DRG neurons. *J. Neurophysiol.* 86, 629–640. doi: 10.1152/jn.2001.86.2.629
- Ritter, A. M., Martin, W. J., and Thorneloe, K. S. (2009). The voltage-gated sodium channel Nav1.9 is required for inflammation-based urinary bladder dysfunction. *Neurosci. Lett.* 452, 28–32. doi: 10.1016/j.neulet.2008.12.051
- Rubinstein, M., Patowary, A., Stanaway, I. B., Mccord, E., Nesbitt, R. R., Archer, M., et al. (2018). Association of rare missense variants in the second intracellular loop of Nav1.7 sodium channels with familial autism. *Mol. Psychiatry* 23, 231–239. doi: 10.1038/mp.2016.222
- Saez, N. J., Senff, S., Jensen, J. E., Er, S. Y., Herzig, V., Rash, L. D., et al. (2010). Spider-venom peptides as therapeutics. *Toxins* 2, 2851–2871. doi: 10.3390/toxins2122851
- Sah, D. W., Ray, J., and Gage, F. H. (1997). Bipotent progenitor cell lines from the human CNS. *Nat. Biotechnol.* 15, 574–580. doi: 10.1038/nbt0697-574
- Salvatierra, J., Castro, J., Erickson, A., Li, Q., Braz, J., Gilchrist, J., et al. (2018). Nav1.1 inhibition can reduce visceral hypersensitivity. *JCI Insight* 3:121000. doi: 10.1172/jci.insight.121000
- Savage, S. R., Kirsh, K. L., and Passik, S. D. (2008). Challenges in using opioids to treat pain in persons with substance use disorders. *Addict. Sci. Clin. Pract.* 4, 4–25. doi: 10.1151/ascp08424
- Schirmeyer, J., Szafranski, K., Leipold, E., Mawrin, C., Platzer, M., and Heinemann, S. H. (2014). Exon 11 skipping of SCN10A coding for voltage-gated sodium channels in dorsal root ganglia. *Channels* 8, 210–215. doi: 10.4161/chan.28146
- Schmalhofer, W. A., Calhoun, J., Burrows, R., Bailey, T., Kohler, M. G., Weinglass, A. B., et al. (2008). ProTx-II, a selective inhibitor of Nav1.7 sodium channels, blocks action potential propagation in nociceptors. *Mol. Pharmacol.* 74, 1476–1484. doi: 10.1124/mol.108.047670
- Scholz, A., Gruss, M., and Vogel, W. (1998). Properties and functions of calcium-activated K⁺ channels in small neurones of rat dorsal root ganglion studied in a thin slice preparation. *J. Physiol.* 513(Pt 1), 55–69. doi: 10.1111/j.1469-7793.1998.055by.x
- Scholz, A., and Vogel, W. (2000). Tetrodotoxin-resistant action potentials in dorsal root ganglion neurons are blocked by local anesthetics. *Pain* 89, 47–52. doi: 10.1016/S0304-3959(00)00345-6
- Smith, J. J., Cummins, T. R., Alphy, S., and Blumenthal, K. M. (2007). Molecular interactions of the gating modifier toxin ProTx-II with Nav 1.5: implied existence of a novel toxin binding site coupled to activation. *J. Biol. Chem.* 282, 12687–12697. doi: 10.1074/jbc.M610462200
- Sommer, C. (2016). Exploring pain pathophysiology in patients. *Science* 354, 588–592. doi: 10.1126/science.aaf8935
- Song, W., Liu, Z., Tan, J., Nomura, Y., and Dong, K. (2004). RNA editing generates tissue-specific sodium channels with distinct gating properties. *J. Biol. Chem.* 279, 32554–32561. doi: 10.1074/jbc.M402392200
- Sousa, S. R., Wingerd, J. S., Brust, A., Bladen, C., Ragnarsson, L., Herzig, V., et al. (2017). Discovery and mode of action of a novel analgesic β -toxin from the African spider *Ceratogyrus darlingi*. *PLoS One* 12:e0182848. doi: 10.1371/journal.pone.0182848
- Spray, D. C., and Hanani, M. (2017). Gap junctions, pannexins and pain. *Neurosci. Lett.* doi: 10.1016/j.neulet.2017.06.035 [Epub ahead of print].
- Sun, H., Kollarik, M., and Udem, B. J. (2017). Blocking voltage-gated sodium channels as a strategy to suppress pathological cough. *Pulm. Pharmacol. Ther.* 47, 38–41. doi: 10.1016/j.pupt.2017.05.010
- Taddese, A., Nah, S. Y., and McCleskey, E. W. (1995). Selective opioid inhibition of small nociceptive neurons. *Science* 270, 1366–1369. doi: 10.1126/science.270.5240.1366
- Tan, A. M., Samad, O. A., Dib-Hajj, S. D., and Waxman, S. G. (2015). Virus-mediated knockdown of Nav1.3 in dorsal root ganglia of STZ-induced diabetic rats alleviates tactile allodynia. *Mol. Med.* 21, 544–552. doi: 10.2119/molmed.2015.00063
- Tan, J., Liu, Z., Nomura, Y., Goldin, A. L., and Dong, K. (2002). Alternative splicing of an insect sodium channel gene generates pharmacologically distinct sodium channels. *J. Neurosci.* 22, 5300–5309. doi: 10.1523/JNEUROSCI.22-13-05300.2002
- Tanaka, B. S., Zhao, P., Dib-Hajj, F. B., Morisset, V., Tate, S., Waxman, S. G., and Dib-Hajj, S. D. (2016). A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgia. *Mol. Med.* 22, 338–348. doi: 10.2119/molmed.2016.00131
- Tanaka, K., Sekino, S., Ikegami, M., Ikeda, H., and Kamei, J. (2015). Antihyperalgesic effects of ProTx-II, a Nav1.7 antagonist, and A803467, a Nav1.8 antagonist, in diabetic mice. *J. Exp. Pharmacol.* 7, 11–16. doi: 10.2147/JEP.S79973
- Thakor, D. K., Lin, A., Matsuka, Y., Meyer, E. M., Ruangsri, S., Nishimura, I., and Spigelman, I. (2009). Increased peripheral nerve excitability and local Nav1.8 mRNA up-regulation in painful neuropathy. *Mol. Pain* 5:14. doi: 10.1186/1744-8069-5-14
- Thompson, C. H., Kahlig, K. M., and George, A. L. Jr. (2011). SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. *Epilepsia* 52, 1000–1009. doi: 10.1111/j.1528-1167.2011.03040.x
- Tonello, R., Fusi, C., Materazzi, S., Marone, I. M., De Logu, F., Benemei, S., et al. (2017). The peptide phalpa1beta, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice. *Br. J. Pharmacol.* 174, 57–69. doi: 10.1111/bph.13652
- Torres-Perez, J. V., Adamek, P., Palecek, J., Vizcaychipi, M., Nagy, I., and Varga, A. (2018). The Nav1.7 blocker protoxin II reduces burn injury-induced spinal nociceptive processing. *J. Mol. Med.* 96, 75–84. doi: 10.1007/s00109-017-1599-0
- Trimmer, J. S., and Rhodes, K. J. (2004). Localization of voltage-gated ion channels in mammalian brain. *Annu. Rev. Physiol.* 66, 477–519. doi: 10.1146/annurev.physiol.66.032102.113328

- Vetter, I., Deuis, J. R., Mueller, A., Israel, M. R., Starobova, H., Zhang, A., et al. (2017). Nav1.7 as a pain target - from gene to pharmacology. *Pharmacol. Ther.* 172, 73–100. doi: 10.1016/j.pharmthera.2016.11.015
- Vijayaragavan, K., Powell, A. J., Kinghorn, I. J., and Chahine, M. (2004). Role of auxiliary beta1-, beta2-, and beta3-subunits and their interaction with Na(v)1.8 voltage-gated sodium channel. *Biochem. Biophys. Res. Commun.* 319, 531–540. doi: 10.1016/j.bbrc.2004.05.026
- Watanabe, E., Hiyama, T. Y., Shimizu, H., Kodama, R., Hayashi, N., Miyata, S., et al. (2006). Sodium-level-sensitive sodium channel Na(x) is expressed in glial laminate processes in the sensory circumventricular organs. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 290, R568–R576. doi: 10.1152/ajpregu.00618.2005
- Waxman, S. G., Kocsis, J. D., and Black, J. A. (1994). Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. *J. Neurophysiol.* 72, 466–470. doi: 10.1152/jn.1994.72.1.466
- Wiesenfeld-Hallin, Z., and Xu, X. J. (2001). Neuropeptides in neuropathic and inflammatory pain with special emphasis on cholecystokinin and galanin. *Eur. J. Pharmacol.* 429, 49–59. doi: 10.1016/S0014-2999(01)01305-X
- Wolff, M., Johannesen, K. M., Hedrich, U. B. S., Masnada, S., Rubboli, G., Gardella, E., et al. (2017). Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. *Brain* 140, 1316–1336. doi: 10.1093/brain/awx054
- Woods, C. G., Babiker, M. O., Horrocks, I., Tolmie, J., and Kurth, I. (2015). The phenotype of congenital insensitivity to pain due to the Nav1.9 variant p.L811P. *Eur. J. Hum. Genet.* 23, 561–563. doi: 10.1038/ejhg.2014.166
- Xiao, Y., Luo, X., Kuang, F., Deng, M., Wang, M., Zeng, X., and Liang, S. (2008). Synthesis and characterization of huwentoxin-IV, a neurotoxin inhibiting central neuronal sodium channels. *Toxicon* 51, 230–239. doi: 10.1016/j.toxicon.2007.09.008
- Xie, W., Strong, J. A., Ye, L., Mao, J. X., and Zhang, J. M. (2013). Knockdown of sodium channel Nav1.6 blocks mechanical pain and abnormal bursting activity of afferent neurons in inflamed sensory ganglia. *Pain* 154, 1170–1180. doi: 10.1016/j.pain.2013.02.027
- Xie, W., Tan, Z. Y., Barbosa, C., Strong, J. A., Cummins, T. R., and Zhang, J. M. (2016). Upregulation of the sodium channel Navbeta4 subunit and its contributions to mechanical hypersensitivity and neuronal hyperexcitability in a rat model of radicular pain induced by local dorsal root ganglion inflammation. *Pain* 157, 879–891. doi: 10.1097/j.pain.0000000000000453
- Xing, D., Wu, Y., Li, G., Song, S., Liu, Y., Liu, H., et al. (2015). Role of cerebrospinal fluid-contacting nucleus in sodium sensing and sodium appetite. *Physiol. Behav.* 147, 291–299. doi: 10.1016/j.physbeh.2015.04.034
- Xiong, Z., Yi, L., Cao, D., He, W., Chen, J., Gao, S., and Sun, X. (2016). Dravet syndrome with autism inherited from a paternal mosaic heterozygous mutation on SCN1A. *J. Neurol. Sci.* 369, 53–56. doi: 10.1016/j.jns.2016.07.038
- Yang, C., Hua, Y., Zhang, W., Xu, J., Xu, L., Gao, F., and Jiang, P. (2018). Variable epilepsy phenotypes associated with heterozygous mutation in the SCN9A gene: report of two cases. *Neurol. Sci.* 39, 1113–1115. doi: 10.1007/s10072-018-3300-y
- Yang, Y., Mis, M. A., Estacion, M., Dib-Hajj, S. D., and Waxman, S. G. (2018). Nav1.7 as a pharmacogenomic target for pain: moving toward precision medicine. *Trends Pharmacol. Sci.* 39, 258–275. doi: 10.1016/j.tips.2017.11.010
- Yang, L., Li, Q., Liu, X., and Liu, S. (2016). Roles of voltage-gated tetrodotoxin-sensitive sodium channels Nav1.3 and Nav1.7 in diabetes and painful diabetic neuropathy. *Int. J. Mol. Sci.* 17:E1479 doi: 10.3390/ijms17091479
- Yekkirala, A. S., Roberson, D. P., Bean, B. P., and Woolf, C. J. (2017). Breaking barriers to novel analgesic drug development. *Nat. Rev. Drug Discov.* 16, 545–564. doi: 10.1038/nrd.2017.87
- Yu, F. H., and Catterall, W. A. (2003). Overview of the voltage-gated sodium channel family. *Genome Biol.* 4:207.
- Yu, F. H., and Catterall, W. A. (2004). The VGL-chanome: a protein superfamily specialized for electrical signaling and ionic homeostasis. *Sci. STKE* 2004:re15. doi: 10.1126/stke.2532004re15
- Zeng, X., Li, P., Chen, B., Huang, J., Lai, R., Liu, J., and Rong, M. (2018). Selective closed-State Nav1.7 blocker JZTX-34 exhibits analgesic effects against pain. *Toxins* 10:E64. doi: 10.3390/toxins10020064
- Zhang, A. H., Sharma, G., Undheim, E. A. B., Jia, X., and Mobli, M. (2018). A complicated complex: ion channels, voltage sensing, cell membranes and peptide inhibitors. *Neurosci. Lett.* 679, 35–47. doi: 10.1016/j.neulet.2018.04.030
- Zhang, X., Priest, B. T., Belfer, I., and Gold, M. S. (2017). Voltage-gated Na(+) currents in human dorsal root ganglion neurons. *eLife* 6:e23235 doi: 10.7554/eLife.23235
- Zhang, X. Y., Wen, J., Yang, W., Wang, C., Gao, L., Zheng, L. H., et al. (2013). Gain-of-function mutations in SCN11A cause familial episodic pain. *Am. J. Hum. Genet.* 93, 957–966. doi: 10.1016/j.ajhg.2013.09.016
- Zimmer, T., Haufe, V., and Blechschmidt, S. (2014). Voltage-gated sodium channels in the mammalian heart. *Glob. Cardiol. Sci. Pract.* 2014, 449–463. doi: 10.5339/gcsp.2014.58

Conflict of Interest Statement: TG and MP are current or former employees of Sanofi.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Gonçalves, Benoit, Partiseti and Servent. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

1.4. Objectifs de la thèse

Ces dernières décennies, un immense effort a été fourni par les chercheurs académiques et industriels afin de trouver des alternatives pharmacologiques par voie orale au fléau que constituent les opioïdes, traitement antalgique de palier III établi par l'Organisation mondiale de la Santé (OMS). En effet, leurs effets secondaires sont une véritable catastrophe sanitaire entraînant tolérance et dépendance sans oublier de mentionner la détresse respiratoire associée aux fortes doses qui augmente de façon catastrophique le nombre de décès par overdose aux opiacés, aux Etats Unis en particulier (Jones et al., 2013). Certaines équipes ont misé sur la découverte de petites molécules chimiques telles que les dérivés des sulfonamides qui inhibent les canaux Na_v impliqués dans la transmission du message douloureux. D'autres équipes ont misé sur la découverte d'opioïdes analgésiants avec des effets secondaires réduits tels que le PZM21 qui n'active que la voie intracellulaire de messagers secondaires liée au message douloureux. Finalement, certaines équipes ont misé sur une approche plus originale basée sur la découverte de peptides dérivés de venins d'animaux (McCormack et al., 2013; Sun et al., 2014; Ahuja et al., 2015; Manglik et al., 2016; Hamad et al., 2018).

Tous les récepteurs localisés au niveau des neurones sensoriels primaires et secondaires en périphérie, ou à l'entrée du système nerveux central, peuvent devenir la cible de ces peptides potentiellement antinociceptifs (Pan et al., 2008; Bennett & Woods, 2014; Waxman & Zamponi, 2014; Yekkirala et al., 2017). Cependant, le sous-type $Na_v1.7$ de canaux sodium dépendant du potentiel, hautement exprimé au niveau des DRG composés des corps cellulaires des neurones sensoriels primaires, joue un rôle primordial dans le processus de signalisation de la douleur (Vetter et al., 2017).

L'objectif de ma thèse était d'identifier, dans les venins d'animaux, des inhibiteurs efficaces pour bloquer avec une haute puissance et sélectivement le sous-type $Na_v1.7$ et de caractériser leur profil pharmacologique par des approches fonctionnelles multi-échelles. Pour ce faire, un criblage à haut débit de deux banques de venins a été réalisé sur ce sous-type de canal sodium et des peptides possédant des propriétés fonctionnelles originales ont été identifiés.

Partie 2

RESULTATS et DISCUSSION

Avant-propos

Les résultats sont présentés sous forme d'articles publiés ou en révision dans des journaux à comité de lecture, d'articles en préparation et de résultats non publiés. Cette partie est structurée en cinq sous-parties:

1. La première sous-partie présente l'identification et la caractérisation de la cyriotoxine-1a, isolée à partir du venin de l'araignée *Cyriopagopus schioedtei*, dont les propriétés fonctionnelles sont proches de celles des peptides appartenant à la famille 1 des toxines d'araignées inhibant les canaux Na_v (NaSpTx-1).
2. La deuxième sous-partie est consacrée à des études de "structure-activité" concernant la phlotoxine-1, une toxine découverte il y a une décennie dans le venin d'une araignée *Phlogiellus* au cours d'un criblage guidé par la toxicité produite chez les souris.
3. La troisième sous-partie décrit la mise en évidence de l'interaction entre l'huwentoxine-IV, toxine d'araignée déjà connue pour ses propriétés antinociceptives, et le sous-type $\text{Na}_v1.6$ de canaux sodium, principal responsable des effets moteurs indésirables observés lors de l'injection du peptide *in vivo*.
4. La quatrième sous-partie montre l'intérêt d'effectuer un profil de sélectivité sur un large éventail de sous-types de canaux ioniques qui peut révéler la véritable spécificité d'une toxine pour un sous-type différent de celui qui a permis de l'identifier initialement. C'est le cas de la poécitoxine-1a, mise en évidence par un criblage sur le sous-type $\text{Na}_v1.7$ *versus* $\text{Na}_v1.5$ de canaux sodium, mais qui présente en fait une puissance accrue pour le sous-type $\text{Ca}_v1.2$ de canaux calcium.
5. La cinquième sous-partie est dédiée à la présentation des résultats du second criblage à haut débit, actuellement en cours, d'une banque de venins appartenant à SANOFI dont les sous-fractions les plus intéressantes proviennent de venins d'araignées et de scorpions non étudiés jusqu'à présent.

Les publications étant en anglais, nous présenterons en français, préalablement à chacune d'entre elles, le contexte dans lequel s'est faite l'étude puis, après la publication, un résumé des principaux résultats obtenus et éventuellement de ceux non publiés d'expériences complémentaires, suivi d'une brève conclusion.

2.1. De l'identification à la caractérisation fonctionnelle de la cyriotoxine-1a, une toxine issue du venin de l'araignée *Cyriopagopus schioedtei* ayant des propriétés antinociceptives

2.1.1. Contexte de l'étude

Un criblage à haut débit d'une banque de 117 venins appartenant à Smartox Biotechnology (Saint-Egrève, France) a été réalisé en utilisant des plateformes électrophysiologiques ("patch-clamp") automatisées. Dans un premier temps, la plateforme IonWorks Quattro® (Molecular Devices, Sunnyvale, CA, USA) a été employée pour un criblage rapide des fractions et sous-fractions de venins sur des lignées cellulaires recombinantes humaines (HEK-293 pour "human embryonic kidney") exprimant les sous-types $hNa_v1.7$ et 1.5 , déposées dans des plaques de 384 puits et enregistrées en configuration "cellule entière" et en mode "cellule multiple" (le courant correspondant à la moyenne des courants obtenus à partir de 10 cellules). Dans un deuxième temps, la plateforme QPatch HTX (Sophion BioScience, Danemark) a été utilisée pour étudier les effets des peptides sélectionnés sur des lignées cellulaires recombinantes exprimant les sous-types de canaux ioniques étudiés, déposées dans des plaques de 48 puits et enregistrées (1) en configuration "cellule entière" et en mode "cellule multiple" (le courant enregistré correspondant à la sommation des courants obtenus à partir de 10 cellules), pour la caractérisation des propriétés pharmacologiques des sous-types de canaux ioniques étudiés et, en particulier, pour obtenir les courbes "concentration-réponse" en appliquant des concentrations cumulées de peptides, et (2) en configuration "cellule entière" et en mode "cellule unique" (le courant enregistré correspondant à celui obtenu à partir d'une seule cellule) pour la caractérisation des propriétés électrophysiologiques des sous-types de canaux ioniques étudiés et, en particulier, pour une détermination plus fine des effets des peptides sur certains de ces sous-types (Bertrand et al., 2016; Chambers et al., 2016).

Le criblage de la banque de 117 venins d'animaux (incluant les serpents, les araignées, les scorpions, les guêpes, les abeilles, les lézards et les poissons) a été mené sur des lignées cellulaires HEK-293 exprimant les sous-types $hNa_v1.7$ et 1.5 avec, pour objectif, de sélectionner des peptides ("hits") ayant une forte puissance vis-à-vis de $hNa_v1.7$ et n'étant pas ou que peu actifs sur $hNa_v1.5$. Ce criblage a permis de mettre en évidence de nombreux "hits" dont 80% sont des toxines issues de venins d'araignée. C'est dans ce contexte que la cyriotoxine-1a (CyrTx-1a) a été sélectionnée.

2.1.2. Publication n°2

British Journal of Pharmacology (publication en révision)

“Cyriotoxin-1a, the first toxin from *Cyriopagopus schioedtei* spider with antinociceptive properties: from identification to functional characterization”

Tânia C. Gonçalves, Evelyne Benoit, Michael Kurz, Laetitia Lucarain, Sophie Fouconnier, Stéphanie Combemale, Lucie Jaquillard, Brigitte Schombert, Jean-Marie Chambard, Rachid Boukaiba, Gerhard Hessler, Andrees Bohme, Laurent Bialy, Stéphane Hourcade, Rémy Bérout, Michel De Waard, Denis Servent & Michel Partiseti

1 **RESEARCH PAPER**

2
3 **Title:** Cyriotoxin-1a, the first toxin from *Cyriopagopus schioedtei* spider
4 with antinociceptive properties: from identification to functional
5 characterization

6
7 **Full names of the authors:** Tânia C. Gonçalves^{†,#}, Evelyne Benoit^{#,‡}, Michael Kurz[!], Laetitia
8 Lucarain[†], Sophie Fouconnier[†], Stéphanie Combemale[‡], Lucie Jaquillard[‡], Brigitte Schombert[†],
9 Jean-Marie Chambard[†], Rachid Boukaiba[†], Gerhard Hessler[!], Andrees Bohme[†], Laurent Bialy[!],
10 Stéphane Hourcade[!], Rémy Béroud[‡], Michel De Waard^{‡,§}, Denis Servent^{#,*}, Michel Partiseti^{†,*}

11 **Authors' institutional affiliations:** [†] Sanofi R & D, Integrated Drug Discovery – High Content Biology, F-
12 94440 Vitry-sur-Seine, France. [#] Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA,
13 Université Paris-Saclay, F-91191 Gif sur Yvette, France. [‡] Institut des Neurosciences Paris-Saclay (Neuro-
14 PSI), UMR CNRS/Université Paris-Sud 9197, Université Paris-Saclay, F-91198 Gif sur Yvette, France/ [!]
15 Sanofi R & D, Integrated Drug Discovery – Synthetic Molecular Design, G-65929 Frankfurt, Germany. [‡]
16 Smartox Biotechnology, 6 rue des Platanes, F-38120 Saint-Egrève, France. [!] Sanofi R & D, Neuroscience
17 Therapeutic Area, Neurodegeneration Research, F-91385 Chilly-Mazarin, France. [§] Institut du Thorax,
18 Inserm UMR 1087 / CNRS UMR 6291, LabEx “Ion Channels, Science & Therapeutics”, F-44007 Nantes,
19 France.

20 ***Corresponding authors:** Denis Servent, PhD. Service d'Ingénierie Moléculaire des Protéines (SIMOPRO),
21 CEA, Université Paris-Saclay, F-91191 Gif sur Yvette, France. Tel : 33 1 69 08 52 02. denis.servent@cea.fr
22 ORCID 0000-0002-0774-1691. Michel Partiseti, PhD. Sanofi R & D, Integrated Drug Discovery – High
23 Content Biology, F-94440 Vitry-sur-Seine, France. Tel: 33 1 58 93 29 96. Michel.Partiseti@sanofi.com

24
25 **Word count** (excluding abstract, methods, references and figure legends): **Intro: 609 + Results: 2519+**
26 **Discussion: 1510 : 4638**

27
28 **Acknowledgements:** This research was funded by a collaborative grant (#153114) between Sanofi
29 Research & Development (Chilly-Mazarin, France) and the French Alternative Energies and
30 Atomic Energy Commission (CEA, Gif sur Yvette, France). M.D.W. acknowledges financial
31 support from the French Agence Nationale de la Recherche (grant ANR-11-LABX-0015). T.C.G.
32 was supported by a doctoral CIFRE fellowship from Sanofi. The authors wish to thank Dr Muriel
33 AMAR (CEA de Saclay, Gif sur Yvette, France) for her help in the calculation of kinetic
34 parameters of sodium current activation and inactivation, and Dr Isabel LEFEVRE (Sanofi R & D,
35 Chilly-Mazarin, France) for her critical reading of the manuscript.

36 **Conflict of interest statement:** The authors L. Bialy, A. Bohme, R. Boukaiba, J.M. Chambard, S.
37 Fouconnier, T.C. Gonçalves, G. Hessler, S. Hourcade M. Kurz, L. Lucarain, B. Schombert, and M.
38 Partiseti declare the following competing interest: current or former employees of Sanofi.

39 **Author contributions:** L.L. performed experiments and J.-M.C. analyzed the data for the venom
40 fraction screenings. L.L. performed experiments and J.-M.C. analyzed the data for the venom
41 fraction screenings. S.C. and L.J. performed experiments and M.D.W. and R.Bé. analyzed the data
42 for the peptide purification, sequencing and synthesis experiments. T.C.G., S.F., R.Bo., B.S., A.B.
43 and M.P. performed and analyzed experiments done on recombinant ion channel cell lines. T.C.G.
44 and E.B. performed and analyzed experiments done on DRG neurons and mice. M.K. and G.H.
45 determined 3D-structure. L.B. and S.H. aided in the preparation of the manuscript. T.C.G, E.B,
46 M.P, M.D.W. and D.S wrote the manuscript and supervised the study. All authors approved the
47 manuscript.

48

49 **ABSTRACT**

50 **BACKGROUND AND PURPOSE :** $Na_V1.7$ channel subtype is highly expressed in dorsal root
51 ganglia of the sensory nervous system and plays a central role in the pain signalling process. We
52 investigated venoms to identify selective inhibitors of this target.

53 **EXPERIMENTAL APPROACH :** We used high-throughput screening of a large venom
54 collection using automated patch-clamp experiments on human voltage-gated sodium channel
55 subtypes, and then *in vitro* and *in vivo* electrophysiological experiments to characterize the active
56 peptides that have been purified, sequenced and chemically synthesized. Analgesic effects were
57 evaluated *in vivo* in mice models.

58 **KEY RESULTS :** We identified the first peptide, cyriotoxin-1a (CyrTx-1a), isolated from the
59 *Cyriopagopus schioedtei* spider venom. This 33 amino acids toxin belongs to the inhibitor cysteine
60 knot structural family and inhibits $hNa_V1.1-1.3$ and $1.6-1.7$ in the low nanomolar range, compared
61 to the micromolar range for $hNa_V1.4-1.5$ and 1.8 . CyrTx-1a was 635 times more efficient at
62 inhibiting tetrodotoxin (TTX)-sensitive than TTX-resistant sodium currents recorded from adult
63 mouse dorsal root ganglia neurons and *in vivo* electrophysiological experiments showed that
64 CyrTx-1a was approximately 170 times less efficient than huwentoxin-IV at altering mouse skeletal
65 neuromuscular excitability properties. CyrTx-1a exhibited an analgesic effect in mice by increasing
66 reaction time in the hot plate assay and decreasing tactile sensitivity in automated plantar von Frey
67 experiments.

68 **CONCLUSIONS AND IMPLICATIONS :** The pharmacological profile of CyrTx-1a paves the
69 way for further engineering studies aimed to optimize the potential antinociceptive properties of this
70 peptide.

71

72 **Key Words:** *Cyriopagopus schioedtei* spider, cyriotoxin-1a, voltage-gated sodium channel
73 subtypes, cell lines overexpressing ion channel subtypes, mouse dorsal root ganglia neurons, mouse
74 tactile and cold pain sensitivity, mouse skeletal neuromuscular excitability *in vivo*.

75 **Abbreviations:** aPC, automated patch-clamp; Ca_V channel, voltage-gated calcium channel; CHO,
76 Chinese hamster ovary; CMAP, compound muscle action potential; CyrTx-1a, cyriotoxin-1a;

77 DMEM, Dulbecco's modified Eagle's medium; DRG, dorsal root ganglia; ERG, *ether-a-go-go*-
78 related gene; HEK, human embryonic kidney; HEPES, N-2-hydroxyethylpiperazine-N'-2-
79 ethanesulfonic acid; HwTx-IV, huwentoxin-IV; i.m., intramuscular; IC₅₀, toxin concentration
80 necessary to inhibit 50% of the response; ICK, inhibitor cystine knot; K_v channel, voltage-gated
81 potassium channel; mPC, manual patch-clamp; NaSpTx, Na_v channel spider toxin; Na_v channel,
82 voltage-gated sodium channel; PBS, phosphate buffered saline; PPC, population patch-clamp;
83 TCEP, Tris (2-carboxyethyl) phosphine hydrochloride; TTX, tetrodotoxin; TTX-R, resistant to
84 tetrodotoxin; TTX-S, sensitive to tetrodotoxin.

85

86 **Introduction**

87 Sensory neurons express many transmembrane proteins that are therapeutic target candidates for the
88 treatment of pain. In particular, inhibitors of ion channels (such as voltage-gated sodium (Na_v) and
89 calcium (Ca_v) channels, transient receptor potential channels, acid-sensing ion channels, piezo
90 proteins, ionotropic P2X receptors), as well as potassium channel (K_v) enhancers, are being
91 investigated as potential analgesics (Bennett *et al.*, 2014; Waxman *et al.*, 2014). Na_v channels
92 include nine subtypes (Na_v1.1-1.9), each of them having non-redundant functions due to specific
93 expression patterns and/or singular biophysical properties. During this last decade, attention has
94 been given to several Na_v channel subtypes (Na_v1.1, 1.3 and 1.6-1.9) as potential analgesic targets
95 (Cardoso *et al.*, 2017a).

96 Among these Na_v channel subtypes, the Na_v1.7 subtype seems to be the most interesting target
97 to treat chronic debilitating pain. Indeed, this subtype is highly expressed in the sensory nervous
98 system, principally in small and large dorsal root ganglia (DRG) neurons, the anatomic support of
99 pain signalling from the skin and organs to the spinal cord (Dib-Hajj *et al.*, 2013). Furthermore, a
100 multitude of genetic mutations of Na_v1.7 are linked to painless or painful phenotypes (de Lera Ruiz
101 *et al.*, 2015; Vetter *et al.*, 2017). Moreover, it is well established that small molecules that target
102 Na_v channels, like tetrodotoxin (TTX), attenuate chronic and debilitating pain in humans. However,
103 pronounced side-effects have been described, such as nausea, dizziness, oral numbness and tingling,
104 due to a lack of selectivity (Hagen *et al.*, 2017). The current challenge is thus to identify a new
105 therapeutic class of analgesic molecules antagonizing the Na_v1.7 channel subtype with high
106 selectivity compared to other Na_v subtypes, particularly the Na_v1.5 subtype and the Na_v1.6 and 1.4
107 subtypes due to cardiac and neuromuscular safety issues, respectively.

108 Several peptide toxins from animal venoms (spiders, scorpions, cone snails, sea anemones,
109 centipedes ...) have been reported to block or modulate Na_v channel function (Israel *et al.*, 2017).
110 Some of them, mainly isolated from spider venoms, showed promising selectivity for Na_v1.7
111 (Vetter *et al.*, 2017). Their sequence is mostly composed of 30-35 amino-acids, including three
112 disulfide bridges with an inhibitor cystine knot (ICK) motif. These positively-charged toxins are
113 gating-modifier peptides that bind to the receptor-sites 3 (on Domain IV) and/or 4 (on Domain II)
114 of Na_v channels, inducing variable pharmacological effects in *in vitro* tests and *in vivo* pain models
115 (Saez *et al.*, 2010). For instance, HwTx-IV and GpTx-1, two well-characterized Na_v1.7-blocking

116 spider toxins with high selectivity over Na_v1.4 and Na_v1.5 channel subtypes, have analgesic
117 properties in animal models. However, they also produce strong side-effects such as inactivity,
118 paralysis and death in standard pain tests in rodents, due to the lack of selectivity over the Na_v1.6
119 channel subtype (Deuis *et al.*, 2016; Goncalves *et al.*, 2018). Other spider toxins, such as protoxin-
120 II, exhibit a 100-fold higher potency on Nav1.7 compared to all Na_v subtypes, except Na_v1.6.
121 Interestingly, the *in vivo* safety margin of this toxin is increased for the mutant JNJ 63955918 due to
122 an improved selectivity against Na_v1.1, 1.2 and 1.6 (Flinspach *et al.*, 2017). Very recently, the
123 jingzhaotoxin-V analog AM-8145 was reported to display a more than 100-fold higher potency on
124 Na_v1.7 compared to all Na_v subtypes (Moyer *et al.*, 2018).

125 The present work reports the identification, structural characterization and pharmacological
126 profile of the first toxin isolated from the venom of *Cyriopagopus schioedtei* spider, using a high
127 throughput electrophysiological screening assay on Na_v channel subtypes. This ICK toxin is shown
128 to possess nanomolar range affinity for Na_v1.1-1.3, 1.6 and 1.7 subtypes, micromolar affinity for
129 other channel subtypes and to exhibit analgesic effects in rodent pain models. It represents an
130 interesting lead for future analogues designed to possess a better therapeutic window.

131

132 **Methods**

133 *Isolation and purification of CyrTx-1a*

134 A library was prepared from 117 different animal venoms by crude venom fractionation using an
135 analytical RP-HPLC C18 column (XBridge™ BEH 130, 3.5 μm and 4.6 mm ID x 250 mm L
136 column) attached to an Agilent 1260 HPLC (Agilent Technologies). Primary fractions were first
137 evaluated in a functional screening assay on an engineered human embryonic kidney (HEK)-293
138 cell line overexpressing human (h) Na_v1.7 and hNa_v1.5 channel subtypes using the IonWorks
139 Quattro platform (Molecular Devices, USA). For instance, the *Cyriopagopus schioedtei* spider
140 venom, one of the venoms of interest, was separated into fractions that contained between 5 and 15
141 peptides each at an estimated concentration of 0.5 μg.μL⁻¹. Active fractions were finally
142 subfractionated using cation exchange chromatography with a TOSOH Bioscience column (TSK
143 gel SP-STAT, 7 μm, 4.6 mm ID x 10 cm L, TOSOH Bioscience, Germany) onto an Agilent 1260
144 HPLC (Agilent technologies) to individualize the compounds. The purified compounds were
145 screened on HEK-293 cells overexpressing hNa_v1.7, hNa_v1.2, hNa_v1.5 and hNa_v1.6 channel
146 subtypes, using the QPatch HTX automated electrophysiology platform (Sophion BioScience,
147 Denmark), leading to the identification of CyrTx-1a as one of the peptides of interest.

148 *Amino acid sequencing of CyrTx-1a*

149 The peptide amino acid sequence was determined by *de novo* MS/MS sequencing and Edman
150 degradation. The purified venom peptide obtained after successive RP-HPLC and cation exchange
151 chromatography, from a starting material of 2 mg, was resuspended in 100 mM ammonium
152 bicarbonate (pH 8), reduced with 17 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP)
153 (incubated at 55°C for 1 hr) and alkylated with 24 mM iodoacetamide (incubated at room

154 temperature in the dark for 1 hr) prior to enzyme digestion. The reduced/alkylated venom peptide
155 was digested by using trypsin or V8 proteases. The enzyme was added at a 1:10 ratio
156 (enzyme/peptide, w/w) and incubated overnight at 37°C before LC-MS(/MS) analyses.

157 A Waters Q-TOF Xevo G2S mass spectrometer equipped with an Acquity UHPLC system and
158 Lockspray source was used for the acquisition of the LC-ESI-MS and LC-ESI-MS/MS data and the
159 amino acid sequence determination based on Edman degradation was performed using an Applied
160 Biosystems gas-phase sequencer model 492 (s/n: 9510287J). These protocols are detailed in the
161 Supporting Information.

162 *Chemical synthesis and folding of CyrTx-1a*

163 CyrTx-1a was assembled stepwise using 2-chlorotrityl chloride resin (substitution rate of 1.6
164 mmol.g⁻¹) by solid-phase fmoc chemistry on a Symphony Synthesizer (Protein technologies Inc.).
165 Amino acid coupling reaction was 15 min (repeated three times to increase the coupling yield).
166 After resin cleavage and deprotection with 92.5% (vol) TFA, 2.5% H₂O and scavengers (1,3-
167 dimethoxybenzene (2.5%) and triisopropylsilane (2.5%)), the peptide was purified to homogeneity
168 by C18 RP-HPLC on a Jupiter Proteo column (Phenomenex, 4 μm, 21.2 mm ID x 250 mm L) using
169 an Agilent Technologies preparative HPLC (1260 Infinity). Finally, CyrTx-1a was folded/oxidized
170 in 50 mM Tris-HCl, pH 8.3 during 72 hrs. The resulting oxidized CyrTx-1a with its three disulfide
171 bridges was purified to homogeneity (>99% purity according to the integration of the purified
172 chromatogram peak at 214 nm) using RP-HPLC with the Jupiter Proteo column. The molecular
173 mass of CyrTx-1a was determined by LC-ESI-QTOF MS. The absence of contaminant masses
174 attested of the purity of synthetic CyrTx-1a.

175 *3D-structure of CyrTx-1a*

176 The structure of CyrTx-1a was determined by high-resolution NMR spectroscopy in an aqueous
177 solution (10% D₂O) of 6 mg.mL⁻¹ peptide in a 50 mM phosphate buffer at pH 5.0 and a temperature
178 of 305°K. Data were obtained on a Bruker Avance 700 MHz using standard 2D spectra. Resonances
179 were assigned with 2D-spectra including DQF-COSY, TOCSY, NOESY, 1H- 13C-HSQC, and 1H-
180 15N-HSQC. For conformational analysis, NOE based distance restraints were obtained from a
181 NOESY spectrum with 200 ms mixing time. 431 distance restraints were used in a simulated
182 annealing protocol starting from a linear, extended structure including 71 intra residual distances,
183 126 sequential distances, 69 medium distances (2-4 amino acids apart) and 165 long range distances
184 (> 4 amino acids apart). Calculations were performed with the software package SYBYL version
185 2.1.1. All energy calculations were based on AMBER7 F99 force field. Distance restraints for non-
186 separated methylene protons and methyl groups were used with pseudoatom correction: 0.9 Å were
187 added to the upper bound for methylene groups, 1.0 Å was added for methyl groups. 20 structures
188 were obtained which converged well. The rmsd over all backbone atoms was 0.465 ± 0.285 Å.

189 *Toxins used for functional assays*

190 Lyophilized synthetic CyrTx-1a (molecular mass of 3578.68, purity rate > 97%) was dissolved in
191 phosphate buffered saline (PBS, 1X) solution to give a 6.8 mM stock solution. Lyophilized
192 synthetic huwentoxin-IV (HwTx-IV; molecular mass of 4106.811, purity rate > 97%) was obtained

193 from Smartox Biotechnology (Saint-Egrève, France). This toxin was dissolved in PBS solution to
194 give a 6.1 mM stock solution. TTX citrate (molecular mass of 319.27, purity rate > 98%) was
195 purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). This toxin was dissolved in PBS
196 solution to give a 2.85 mM stock solution. Just prior to experiments, successive dilutions were
197 performed in the appropriate standard physiological medium to give the toxin final concentrations
198 indicated in the text.

199 *Cell lines, animals and primary culture of DRG neurons used for functional assays*

200 Generation of inducible cell lines was achieved using the Flp-In® T-Rex® expression system
201 (Invitrogen, USA). For this purpose, cDNAs encoding for hNav1.5 (NM_000335) and hNav1.2
202 (NM_021007.2) were cloned into the Flp-In® T-Rex® expression vector (Invitrogen) and
203 subsequently transfected into HEK-293 cell lines. Recombinant HEK-293 cell lines stably
204 expressing hNav1.7, hNav1.1 and hNav1.8 were purchased from Eurofins (St Charles, MO, USA),
205 those for stably expressing hNav1.6 from ChanTest (Charles River, Cleveland, OH), and those
206 stably expressing hNav1.3 and hNav1.4 from SB Drug Discovery (UK). Protocols for cell culture
207 are detailed in the Supporting Information.

208 *In vivo* experiments (neuromuscular system, as well as heat and tactile pain sensitivity) and
209 dissociation of DRG neurons were performed by using adult female Swiss mice (10-12 weeks of
210 age and 28-32 g body weight) purchased from Janvier Elevage (Le Genest-Saint-Isle, France) and
211 housed at the CEA animal facility. All animal experiments performed in this study were conducted
212 in compliance with the guidelines established by the French Council on animal care “Guide for the
213 Care and Use of Laboratory Animals” (EEC86/609 Council Directive – Decree 2001-131), and the
214 experimental protocols were approved on November 27 2015 by the French General Directorate for
215 Research and Innovation (project APAFIS#2671-2015110915123958v3 authorized to E.B.).

216 Mouse DRG were removed from the spinal cord and enzymatically dissociated, and neurons
217 were maintained in culture, as detailed previously (Goncalves *et al.*, 2018). Experiments were
218 carried out within 2 to 6 days after plating.

219 *Electrophysiological recordings*

220 Automated and manual patch-clamp recordings were performed on cell lines and DRG neurons as
221 described in the Supporting Information. *In vivo* recordings from the neuromuscular system of
222 anaesthetized mouse were obtained by means of a minimally-invasive electrophysiological method,
223 using the Qtrac© software (Prof. H. Bostock, Institute of Neurology, London, United Kingdom), as
224 previously detailed (Goncalves *et al.*, 2018). Briefly, the anaesthetized mice were placed on a
225 heating pad to maintain body temperature throughout the experiments ($35.99 \pm 0.03^\circ\text{C}$, as
226 determined in 29 mice using a rectal probe). Electrical stimulations were delivered to the caudal
227 motor nerve (at the base of the tail) by surface electrodes, and the compound muscle action
228 potential (CMAP) was recorded using needle-electrodes inserted into the tail muscle. To study the
229 local action of CyrTx-1a and TTX, intramuscular (i.m.) injections (4- μL maximal volume) of PBS
230 solution containing various concentrations of a given toxin were delivered with a 10- μL micro-
231 syringe at the base of the tail, between stimulation and ground electrodes. Similar injections (4 μL)

232 were also done with PBS solution to test for any effect of the vehicle. On-line recordings were
233 initiated approximately 5 min before a given injection to assess the toxin and/or vehicle effects on
234 selected excitability parameters, such as the excitability threshold and CMAP amplitude
235 continuously recorded over time. To better identify the underlying mechanism(s) of action and the
236 duration of CyrTx-1a and TTX effects, five different excitability tests (stimulus-response, strength-
237 duration and current-threshold relationships, as well as threshold electrotonus and recovery cycle
238 (detailed in (Cerles *et al.*, 2017)) were performed together before and at various times (from 30 min
239 to 12 hrs) after a given injection. As a whole, more than thirty parameters were determined from
240 these five excitability tests and analyzed. Most of them provide specific and complementary
241 information on the density and functional status of ion channels, receptors and pumps, as well as on
242 the passive membrane properties of the neuromuscular system (Kiernan *et al.*, 2000; Krishnan *et*
243 *al.*, 2008).

244 *Heat and tactile pain sensitivity of mice in vivo*

245 Prior to hot-plate testing, each mouse underwent a 30-min acclimation to the experimental
246 laboratory environment (in its home cage). Then, mice were either not injected or received an
247 intraplantar injection of 5-10 µL of PBS or toxin solution in each hind paw under low anaesthesia
248 achieved by means of isoflurane (AErrane®, Baxter S.A., Lessines, Belgique) inhalation. After 60
249 min rest in its home cage, the mouse was put on the hot-plate set at the temperature of $55.0 \pm 0.2^{\circ}\text{C}$.
250 The measured parameter as the first pain-related manifestation was the latency (in sec) for the
251 animal either to shake one of its two hind limbs or to jump. This latency, considered as a painful
252 response to heat, was recorded simultaneously by two observers (one being blind to treatment
253 group) with a timer integrated into the set-up. A maximal cut-off time of 30 sec was used to prevent
254 tissue damage.

255 Tactile sensitivity was assessed using an automated plantar von Frey apparatus (Dynamic
256 Plantar Aesthesiometer 37450, Ugo Basile, Comerio, Italy). Prior to testing, each mouse was placed
257 on a mesh grid, surrounded by a clear Plexiglas barrier with a top cover, and left to calm down for
258 30 min without probing. After the settling phase, the mouse was motionless allowing for either of
259 its hind limbs to be touched by a flexible plastic fibre of a fixed diameter. The fibre was pressed
260 through the mesh grid against the plantar surface at a right angle, and the force of application
261 increased slowly (at the determined rate of $1.67 \text{ g}\cdot\text{sec}^{-1}$). The force intensity (in g) at which the
262 animal removed its hind limb was recorded with a timer integrated into the set-up as the mean of at
263 least four tests. A cut-off automatically occurred if the animal did not remove its hind limb when
264 the point at which the greatest pre-set force was met, to prevent tissue damage. The force intensity
265 was determined every 5 min during 30-45 min before and 15 min after intraplantar injection of 5 µL
266 of PBS or toxin solution in each hind limb under low anaesthesia by means of isoflurane.

267 *Data and statistical analyses*

268 Concentration-response relationships were established by plotting the response, recorded in the
269 presence of a given toxin (Rt) and expressed as percentage of the value obtained in absence of toxin
270 (Rc), against the toxin concentration ([toxin]). The theoretical concentration-response curves were

271 calculated from typical sigmoid nonlinear regressions through data points (correlation coefficient =
272 r^2) according to the Hill equation (GraphPad Prism 5 or QPatch assay software): $R_t / R_c = 1 / [1 +$
273 $([toxin] / IC_{50})^{n_H}]$, where IC_{50} is the toxin concentration necessary to inhibit 50% of the response,
274 and n_H is the Hill number. Conductance (g) was calculated according to the following equation: $g =$
275 $I / (V_T - V_{Na})$, where I is the peak current amplitude, V_T is the test-pulse voltage, and V_{Na} is the
276 equilibrium potential of Na ions. Conductance-voltage relationships were established by plotting
277 the conductance, expressed as percentage of the maximal conductance (g_{max}) calculated at strongly
278 positive test-pulses, as a function of test-pulse voltage. The theoretical curves correspond to data
279 point fits according to the Boltzmann equation (GraphPad Prism 5 software): $g / g_{max} = 1 - [1 / (1$
280 $+ \exp ((V_T - V_{T50\%}) / k_g))]$, where $V_{T50\%}$ is the test-pulse voltage corresponding to 50% maximal
281 conductance, and k_g is the slope of the curve. Steady-state inactivation-voltage relationships were
282 established by plotting the peak current amplitude, expressed as percentage of the maximal
283 amplitude (I_{max}) recorded in response to strongly negative pre-pulses, as a function of pre-pulse
284 voltage (V_P). The theoretical curves correspond to data point fits, according to the Boltzmann
285 equation (GraphPad Prism 5 software): $I / I_{max} = 1 / [1 + \exp ((V_P - V_{P50\%}) / k_h)]$, where $V_{P50\%}$ is
286 the pre-pulse voltage corresponding to 50% maximal peak amplitude of current, and k_h is the slope
287 of the curve. Current kinetics were evaluated by calculating: (1) the time to peak (t_p), defined as the
288 time between test-pulse triggering and the peak current, and (2) the time constant (τ_h) of the current
289 decay, for current inactivation that occurs as a mono-exponential decay as a function of time, *i.e.*,
290 $I_{(t)} = I_{(0)} e^{(-t/\tau_h)}$.

291 Data are expressed as means \pm standard deviations (S.D.) of n different experiments. The
292 statistical comparison of values was carried out using the parametric two-tailed Student's t -test
293 (either paired samples for comparison within a single population or unpaired samples for
294 comparison between two populations). Differences between values were considered to be
295 statistically significant at $P \leq 0.05$.

296

297 **Results**

298 *Isolation, purification and de novo amino acid sequencing of CyrTx-1a*

299 A primary high-throughput screening of the Smartox venom collection was performed on
300 automated patch-clamp (aPC) Ionworks Quattro platform using HEK-293 cells overexpressing
301 hNa_v1.7 channel subtypes (Figure 1a). Following successful priming and sealing steps, a 10-pulse
302 train protocol from -120 to -10 mV at 10 Hz was elicited, bringing hNa_v1.7 channel subtypes from
303 closed to open configuration (Figure 1b). The so-called pre-scan performed in presence of
304 extracellular buffer was used as a control signal. An average peak current from pulse 1 of 880 ± 280
305 pA ($n = 29$ plates) was elicited. A similar average amplitude was measured from pulse 10 on the
306 same recording (no current rundown was observed under our conditions). In control experiments
307 using the same protocol, no inhibitory effect of 0.1% bovine serum albumin was found. Conversely,
308 addition of 1 μ M TTX produced a full block of the elicited currents ($n = 928$ wells from 29 plates).
309 This expected pharmacology was used as internal positive control (data not shown).




Figure 1: Screening flowchart from crude venom fraction to isolated peptide identification. (a) Collection of 117 venoms was prepared into 7548 fractions individually added to 384-well plates (columns 1 and 2 are 1 μ M TTX full block and columns 3 and 4 are maximal current obtained in extracellular buffer) for testing *versus* $hNa_V1.7$ on the Ionworks Quattro (IWQ, Molecular Devices). The train protocol described as an insert was applied before and after 10-min incubation of cells with the fraction containing the toxin of interest. Traces of pre- and post-scan are shown in full (b). Also, tonic block obtained on $hNa_V1.7$ has been enlarged (c). Source of the screened crude venom is shown in (d). Percentage of inhibition for all tested fractions was plotted. As shown in (e), a threshold was set at 50% block (red line). From the venom library tested, only 8% hits *versus* $hNa_V1.7$ came from scorpion venom, 6% from snake while the larger majority (86%) was spider fractions (f). (g) Hits were sub-fractioned and tested again *versus* $hNa_V1.7$ and $hNa_V1.5$ to identify most promising hits to be further characterized using whole-cell patch-clamp aPC (QPatch).

310 As mentioned in Figure 1, a total of 7548 fractions coming from 117 crude venoms were tested
 311 from a large variety of species including snake, spider, scorpion, wasp, bee, amphibians, lizard and
 312 fish (see Figure 1d). The 384-well screening plates were prepared in such a way that individual
 313 fractions were tested at an average concentration of 0.5 μ g. μ L⁻¹ (500 ng of dry mass suspended in
 314 water). An overview of the percentage of inhibition obtained for each fraction before and after
 315 application is given in Figure 1e. Note that 97 fractions were discarded because of a negative
 316 impact on the sealing process or because they disrupted seals over time. Also, 26 samples which
 317 elicited large sodium current increases were removed from the analysis. From the primary
 318 screening, 117 fractions were flagged based on their potency vs. recombinant $Na_V1.7$, then selected
 319 for sub-fractionation and compound isolation using cation exchange chromatography (Figure 1f).
 320 Following this process, 227 sub-fractions from 3 species (snake, spider and scorpion; Figure 1g)
 321 were prepared and used at a final estimated amount of 100 ng per well. These sub-fractions were
 322 tested in our functional automated patch-clamp $hNa_V1.7$ but also $hNa_V1.5$ assays (in conventional

323 closed to open configuration protocols), as a first line selectivity assay. From the 42 hits highlighted
 324 at this stage, 14 were discarded because of strong effects on hNa_V1.5.

325 Figure 2a,b illustrates the screening process for the spider venom *Cyriopagopus schioedtei*
 326 from primary fraction selection to individual purified compound selection by secondary screening.
 327 Following selection through the multi-step chromatographic approach, a new peptide was identified
 328 using combined orthogonal reversed-phase and ion exchange techniques (Figure 2c,d).




Figure 2: Flowchart for hNa_V1.7 hit peptide identification. **(a)** Percentage of inhibition of peak hNa_V1.7 elicited current by application of 0.05 μg of each of the 64 fractions obtained from *Cyriopagopus schioedtei* spider venom. **(b)** Each fraction of interest was then separated again to isolate one peptide per well. Sub-fractions were tested again in our automated patch-clamp Quattro assay. At this stage, hNa_V1.7 (red squares) and hNa_V1.5 (black circles) inhibition was investigated. **(c)** Fractionation of the crude venom from *Cyriopagopus schioedtei* by reversed-phase chromatography and detection by UV at 214 nm. The fraction containing the peptide of interest is highlighted in green. **(d)** Cation exchange sub-fractionation of the primary fraction highlighted in **(c)**. The inset illustrates the MS of m/z 1193.8947 [M+3H]³⁺.

329 Using the IonWorks Quattro automated patch-clamp system, the peptide (2.8 μM) displayed a
 330 potent blocking effect on hNa_v1.7 (98.9 ± 1.2% block, n = 3; Figure 2b) while fully sparing
 331 hNa_v1.5 (4.1 ± 1.2% inhibition, n = 3). The molecular mass value of 3578.68 Da for this peptide, as
 332 determined by LC-ESI QTOF MS, indicates that the peptide should be amenable to chemical
 333 synthesis (Inset in Figure 2d).

334 As this peptide belongs to a species that has not been genotyped, its sequence was determined
 335 by *de novo* sequencing using mass spectrometry analyses. Hence, the purified peptide was reduced
 336 using TCEP and alkylated with iodoacetamide. The alterations in molecular mass from 3578.7 to
 337 3926.7 Da indicate that the peptide should contain six cysteine residues and hence three disulfide
 338 bridges if one takes into account the loss of 1 Da upon reduction of disulfide bridges and the
 339 addition of 57.02 Da upon alkylation on each cysteine residue. Samples of the reduced/alkylated
 340 toxin were then digested overnight with either trypsin or V8 proteases. The digests were next
 341 analysed by LC-ESI-MS(/MS) for *de novo* sequencing. Table S1 (Supporting Information) provides
 342 the list of fragments detected and sequenced after trypsin and Glu-C digestion. While full sequence
 343 coverage of the toxin was obtained by mass spectrometry, a complementary characterization was
 344 performed using Edman degradation, especially for the precise determination of the isobaric leucine
 345 and isoleucine residues. The final sequence is reported in Figure 3a with a single post-translational
 346 modification identified as C-terminal amidation of the peptide.




Figure 3: Primary structure, disulfide bridge alignment and sequence homologies of CyrTx-1a. (a) Primary structure of CyrTx-1a. Asterik denotes amidation. Disulfide bridging, as defined by homology, occurs according to the C1-C4, C2-C5 and C3-C6 pattern. (b) Consensus sequence of the NaSpTx family 1, adapted from Klint et al. (2012). (c) Comparison of amino acid sequences between CyrTx-1a and the 9 most similar analgesic toxins from NaSpTx family 1. Sequence alignment performed with Clustal Omega (version 1.2.4 from Emboss programs, EBlosum62 matrix for two pair alignment). The green gradient was used to highlight the percentage of identity (Jalview program according to EBlosum62 matrix).

347 The peptide, composed of 33 amino acids (3578.68 Da), was identified as μ -theraphotoxin-
348 Cs1a or cyriotoxin-1a (CyrTx-1a). It is the first toxin described so far from the crude venom of
349 *Cyriopagopus schioedtei* spider, known as the Malaysian earth tiger tarantula, classified in the
350 Ornithoctoninae subfamily. CyrTx-1a contains the ICK architectural motif previously reported in
351 toxins from the same theraphosid spider family, the Na_v channel spider toxin (NaSpTx) family 1
352 (Figure 3b). Furthermore, comparison of amino acid sequences between CyrTx-1a and the 9 most
353 similar toxins (of 33-35 amino acids) with analgesic properties from the NaSpTx family 1 revealed
354 that the peptide shares 82% of identity with hainantoxin-I and μ -theraphotoxin-Hhn2b, and 73% of
355 identity with hainantoxin-III and μ -theraphotoxin-Hhn2a (Figure 3c). In contrast, the well-known
356 potent analgesic peptides ω -theraphotoxin-Gr2a (GpTx-1) and μ -theraphotoxin-Hh2a (HwTx-IV)
357 share only 45% and 42% of identity, respectively, with CyrTx-1a.

358 *Chemical synthesis and in vitro folding of CyrTx-1a*

359 CyrTx-1a was chemically synthesized using solid-phase Fmoc chemistry. Figure S1a,b (Supporting
360 Information) illustrates the HPLC profiles of the crude and purified synthesized peptide,
361 respectively. Mass spectrometry data established that the purified reduced peptide had the expected
362 mass with m/z value of 1195.9097 [M+3H]³⁺. Finally, the reduced CyrTx-1a peptide was oxidized
363 to produce oxidized/folded CyrTx-1a along with its three-disulfide bridges (Supporting Information
364 Figure S1c). The yield of oxidation was 13%, indicating good formation of the secondary structures
365 and easy disulfide bridge connectivity during oxidation. To confirm that the synthetic CyrTx-1a
366 was indeed identical to its native counterpart, both peptides were mixed at equal concentrations and
367 run simultaneously onto analytical RP-HPLC. As a single major peak was detected, we conclude
368 that the two peptides co-elute, hence demonstrating identical retention times on the C18 column
369 (Supporting Information Figure S1d). The experimental molecular mass of the synthetic peptide
370 (Inset in Figure S1c, 1193.8956 [M+3H]³⁺) was in close agreement with the theoretical mass
371 (1193.8918).

372 *3D-structure of CyrTx-1a*

373 The three-dimensional solution structure of CyrTx-1a was determined by 2D homonuclear ¹H-NMR
374 spectroscopy. Spectra were recorded at 305°K where the amid resonances show a good dispersion.
375 One signal set of sharp and well-dispersed resonances is indicative of a single structure in solution
376 (Figure 4b). NMR-derived interproton distances were used for structure calculations with a
377 molecular dynamic-based protocol. An ensemble of 20 conformations was obtained, containing a
378 well determined backbone conformation of an ICK motif (Figure 4a) (PDB: 6GFT). The ¹H-
379 chemical shifts of CyrTx-1a in H₂O/D₂O highlight the high precision and stereochemical quality of
380 the ensemble of CyrTx-1a structures (Supporting Information Table S2). The entire structure has an
381 electrical dipole moment with a larger positive pole, likely important for CyrTx-1a binding to Na_v
382 channels (Figure 4c). Such a motif has also been found for other Na_v1.7 inhibitory peptides such as
383 HnTx-IV, ProTx-III and HwTx-IV (Figure 4d).





Figure 4: Representation of CyrTx-1a identified by PyMOL. **(a)** Superposition of 20 structures derived from a 6-ns restrained MD simulation (all heavy atoms are shown). All backbone atoms of residues 2-31 were used for fitting. Structures were sampled in 300 ps intervals and energy minimized. The rmsd over all backbone atoms (including residues 1-33) is 0.465 Å with a standard deviation of 0.157 Å. Considering all heavy atoms, the rmsd is 1.072 Å with a standard deviation of 0.285 Å (PDB: 6GFT). **(b)** Cartoon representation of the backbone peptide folding of CyrTx-1a determined by 1H 2D NMR method. The structure topology is composed of double stranded antiparallel β -sheet (arrows). The three disulfide bonds are C2–C17, C9–C22 and C16–C29 (in yellow). Hydrophobic residues are colored in green, and basic and acidic residues are colored in blue and red, respectively. The other polar residues are colored in white. **(c)** Electrostatic charged surface representation of CyrTx-1a. The molecule is rendered as a surface colored according to the electrostatic potential. As indicated in the colored legend, an excess of negative and positive charges near the surface are represented in red (-1000) and blue (1000), respectively, while fairly neutral potentials are represented in white. The entire structure has a clear dipole potential with E1 and E15 forming a negative zone while K3, K7, K13, K25, H26, K27 and K30 form a positive zone. **(d)** Superposition of backbone peptide folding of CyrTx-1a and three other toxins of the NaSpTx family 1 previously described to possess analgesic effects (PDB entries of HnTx-IV: 1NIY, ProTx-III: 2MXM and HwTx-IV: 1MB6).

384 *Effects of CyrTx-1a on $hNa_V1.1$ -1.8-overexpressing HEK-293 cells and on CHO cells*
 385 *overexpressing $hCa_V1.2$ and $hK_V11.1$ channel subtypes*

386 Whole-cell automated patch-clamp (QPatch HTX) experiments performed on HEK-293 cells
 387 overexpressing $hNa_V1.1$ -1.8 subtypes revealed that 1 μ M of synthetic CyrTx-1a was effective to
 388 block $hNa_V1.1$ -1.2-1.3-1.6-1.7 currents while $hNa_V1.4$ -1.5-1.8 currents were unaffected (Figure 5a).
 389 The following increasing order for IC_{50} values was obtained from the concentration-response curves

390 of CyrTx-1a effects on currents flowing through the different subtypes (Figure 5b): hNav_v1.2 (75.5 ±
 391 4.3 nM, n = 8) ≈ hNav_v1.1 (97.0 ± 6.4 nM, n = 3) ≈ hNav_v1.6 (115.0 ± 7.5 nM, n = 5) ≈ hNav_v1.7
 392 (129.5 ± 2.1 nM, n = 7) > hNav_v1.3 (306.6 ± 15.2 nM, n = 8) >> hNav_v1.4 (7.7 ± 0.2 μM, n = 7) for
 393 TTX-sensitive (TTX-S) subtypes, and hNav_v1.5 = hNav_v1.8 (> 10 μM, n = 5-8) for TTX-resistant
 394 (TTX-R) subtypes. Additionally, the peptide had very low affinity for cardiac hCa_v1.2 and hK_v11.1
 395 subtypes overexpressed in Chinese hamster ovary (CHO) cells, since 10 μM of toxin had no effect
 396 on currents flowing through these two channel subtypes (n = 2-5) (data not shown).



397
 398 **Figure 5:** Effects of CyrTx-1a on HEK-293 cells overexpressing hNav_v1.1-1.8 channel subtypes, (a)
 399 Representative traces of sodium currents flowing through hNav_v1.1-1.8 channel subtypes, recorded before
 400 (in black) and after (in blue) exposure to 1 μM CyrTx-1a. (b) Histograms of IC₅₀ values obtained from the
 401 concentration-response curves of CyrTx-1a effects on HEK-293 cells overexpressing hNav_v1.1-1.8 channel
 402 subtypes. Each value represents the mean ± S.D. of data obtained from 3-8 cells. Mean value ± S.D. of n_H
 403 was 1.1 ± 0.2.

404
 405 Further investigation, using whole-cell manual patch-clamp, provided IC₅₀ values of 59.6 nM
 406 from the concentration-response curves of CyrTx-1a effects on currents flowing through hNav_v1.7

407 channels overexpressed in HEK-293 cells (Figure 6b, left panel). This CyrTx-1a-induced blocking
 408 action occurred without any change in steady-state inactivation- and conductance-voltage
 409 relationships of $hNa_V1.7$ channel subtype (Figure 6c (left panel) and Supporting Information Table
 410 S3).




Figure 6: Effects of CyrTx-1a on HEK-293 cells overexpressing $hNa_V1.7$ channel subtype (left panels) and on TTX-S and TTX-R sodium currents of adult mouse DRG neurons (right panels). (a) Representative traces of sodium currents flowing through $hNa_V1.7$ channels and of TTX-S sodium currents of DRG neurons, recorded before (in black) and after (in blue) exposure to 100 and 250 nM CyrTx-1a, respectively. (b) Concentration-response curves of CyrTx-1a effects on $hNa_V1.7$ channel current and on TTX-S and TTX-R sodium currents of DRG neurons. Each value, expressed as percentage of that obtained before toxin application, represents the mean \pm S.D. of data obtained from 2-5 HEK-293 cells and 2-4 DRG neurons. IC_{50} and n_H values were, respectively, 59.6 nM and 1.1 for $hNa_V1.7$ current ($r^2 = 0.976$), 0.17 μ M and 1.4 for TTX-S current ($r^2 = 0.965$), and 108 μ M and 0.8 for TTX-R current ($r^2 = 1.000$). (c) Steady-state inactivation- (circles) and conductance- (squares) voltage relationships for HEK-293 cells overexpressing $hNa_V1.7$ channels and for neurons having TTX-S current, before (black symbols) and after (blue symbols) exposure to 50 nM and 0.25-0.5 μ M CyrTx-1a, respectively. Each value represents the mean \pm S.D. of data obtained from 3-4 HEK-293 cells and 4 DRG neurons, and is expressed as percentage of either maximal peak amplitude of current at strongly negative pre-pulse voltages or maximal conductance calculated at strongly positive test-pulse voltages. The theoretical curves correspond to data point fits with the mean $V_{P50\%}$, k_h , $V_{T50\%}$ and k_g values indicated in Table S3.

411 *Effects of CyrTx-1a and TTX on adult mouse DRG neurons*

412 Before evaluating the effects of CyrTx-1a on the sodium currents of DRG neurons, the sensitivity
413 of these currents to 100 nM TTX was first determined. Under this condition, two types of neurons
414 were recorded. The first type (82%, *i.e.*, 9/11 neurons) had only TTX-S current, which was blocked
415 by the toxin to $3 \pm 2\%$ of initial peak amplitude values within 1 min. The effects of CyrTx-1a (from
416 0.02 to 1 μM) on these neurons were evaluated by expressing the current peak amplitude recorded
417 in the presence of the peptide relatively to its initial value determined after washing-out TTX with a
418 toxin-free solution for 8-10 min. The second type of neurons (18%, *i.e.*, 2/11 neurons) had a mixed
419 TTX-S and TTX-R current, which was decreased by the toxin to around 60% of initial peak
420 amplitude values. The effects of CyrTx-1a (from 5 to 20 μM) on these neurons were evaluated by
421 expressing the current peak amplitude recorded in the presence of the peptide relatively to its initial
422 value determined in the presence of 100 nM TTX.

423 Exposing neurons to standard physiological solutions containing various CyrTx-1a
424 concentrations, using a fast solution application system, produced a decrease of sodium current
425 amplitude which was dependent on peptide concentration and duration of exposure and on the
426 current sensitivity to TTX. In particular, the concentration-response curves of CyrTx-1a effects on
427 the peak amplitude of TTX-S and TTX-R currents revealed IC₅₀ values of 0.17 and 108 μM ,
428 respectively (Figure 6b, right panel). The peptide was thus approximately 635 times more efficient
429 to inhibit TTX-S than TTX-R sodium currents of adult mouse DRG neurons. The blocking effects
430 of CyrTx-1a on the peak amplitude of TTX-S current were stationary 5 and 1.5 min after the
431 application of 0.02 and 1 μM of peptide, respectively. Those on the peak amplitude of the TTX-R
432 current were stationary 4 min after the application of 20 μM of peptide. The CyrTx-1a effects on the
433 TTX-R current, not very noticeable, were not further studied, in contrast to those on the TTX-S
434 current.

435 The peak amplitude of TTX-S current, which was $6 \pm 2\%$ of initial values after exposure to 1
436 μM CyrTx-1a returned to $29 \pm 7\%$ of initial values ($n = 4$) by exposing neurons to a peptide-free
437 solution for 12-14 min, indicating that the effect of CyrTx-1a was at least partially reversible. The
438 analyses of activation and inactivation kinetics of TTX-S sodium current in the absence and in the
439 presence of 0.25 and 0.5 μM CyrTx-1a revealed that the peptide did not affect these kinetics since
440 the time to peak (t_p) and the time constant of the current decay (τ_h) were not significantly modified
441 (Supporting Information Table S4). Similarly, CyrTx-1a (0.25-0.5 μM) did not produce any
442 alteration of steady-state inactivation- and conductance-voltage relationships for neurons exhibiting
443 TTX-S current (Figure 6c, right panel, and Supporting Information Table S3).

444 *Effects of CyrTx-1a on heat and tactile sensitivity of mice in vivo - Comparison with HwTx-IV*

445 Hot-plate testing in mice was performed by intraplantar injection of 102 nmol.kg^{-1} of CyrTx-1a or
446 49 nmol.kg^{-1} of HwTx-IV. Under these conditions, a marked increase in the treated-mouse reaction
447 time to heat, *i.e.*, the latency either to shake one of the two hind limbs or to jump, was observed
448 compared to animals injected with PBS (Figure 7a). In particular, the reaction time was increased
449 by 1.83 times for mice injected with CyrTx-1a (17.2 ± 1.7 s, $n = 13$) and by 1.64 times for animals

450 injected with HwTx-IV (15.4 ± 1.9 s, $n = 13$), versus animals injected with PBS (9.4 ± 0.6 s, $n =$
 451 12), the difference between the two peptide effects being not significant. Similarly, tactile
 452 sensitivity testing showed an increase in the force intensity at which the mice, injected with 102
 453 nmol.kg^{-1} of CyrTx-1a or 49 nmol.kg^{-1} of HwTx-IV, removed their hind limb submitted to an
 454 increasing fiber pressure, *i.e.*, 8.6 ± 1.1 g ($n = 8$) and 8.5 ± 1.4 g ($n = 8$), respectively, compared to
 455 animals injected with PBS, *i.e.*, 7.0 ± 1.7 g ($n = 19$) (Figure 7b). The injection itself was innocuous
 456 since no difference in the reaction time or force intensity occurred between mice injected with PBS
 457 and non-injected animals (Figure 7).




Figure 7: Effects of CyrTx-1a on heat and tactile sensitivity of mice *in vivo*. **(a)** The heat sensitivity of mice was assessed using a hot-plate set at $55.0 \pm 0.2^\circ\text{C}$, by determining the latency for the animals either to shake one of their two hind limbs or to jump. Three groups of mice were tested after intraplantar injection in each hind limb of $5 \mu\text{L}$ of PBS, CyrTx-1a (*i.e.*, 102 nmol.kg^{-1}) or HwTx-IV (*i.e.*, 49 nmol.kg^{-1}), while another group of animals was tested without any injection. **(b)** The tactile sensitivity of mice was assessed using an automated plantar von Frey apparatus, by determining the force intensity at which the animals removed their hind limb submitted to an increasing fiber pressure. The same mice were tested before (no injection) and 15 min after intraplantar injection in each hind limb of $5 \mu\text{L}$ of PBS, CyrTx-1a (*i.e.*, 102 nmol.kg^{-1}) or HwTx-IV (*i.e.*, 49 nmol.kg^{-1}). **(a)** and **(b)** Means \pm S.D. of data obtained from 7-19 mice under each condition, *i.e.*, before and/or 60 min after injection. *: $0.0113 \leq P \leq 0.0425$ and ***: $P = 0.0005$ versus PBS. NS: non-significant between CyrTx-1a and HwTx-IV.

458 *Effects of CyrTx-1a, compared to HwTx-IV, on the mouse neuromuscular system in vivo*

459 Online recordings revealed that the major effect of i.m. injections of PBS solutions containing
 460 various concentrations of either CyrTx-1a (from 0.3 to $448.7 \text{ nmol.kg}^{-1}$ mouse) or HwTx-IV (from
 461 4.1 pmol.kg^{-1} to $41.4 \text{ nmol.kg}^{-1}$ mouse) to anaesthetized mice was a marked decrease of CMAP
 462 amplitude. This is exemplified in Figure 8a for CMAP recordings performed before and between 10
 463 and 15 min after injections of 29.4 nmol CyrTx-1a and 41.4 nmol HwTx-IV per kg of mouse. The
 464 maximal CMAP amplitude measured 30 min after injections of PBS solution alone, and compared
 465 to values before injections, was not significantly affected, *i.e.*, $97.8 \pm 2.3\%$ ($n = 8$ mice), indicating
 466 that injections of the toxin vehicle had no effect on the maximal CMAP amplitude and that no
 467 marked run-down of the response occurred.




Figure 8: Effects of CyrTx-1a and HwTx-IV on the CMAP recorded *in vivo* from mouse tail muscle in response to caudal motor nerve stimulation. (a) Superimposed traces of CMAP following increasing intensities of stimulation (scheme), before (control) and after CyrTx-1a (29.4 nmol.kg⁻¹ mouse, full blue arrow in (b)) or HwTx-IV (41.4 nmol.kg⁻¹ mouse, full black arrow in (b)) injection. (b) Concentration-response curves of the effects of CyrTx-1a (blue circles) and HwTx-IV (black circles) on the maximal CMAP amplitude. Each value, expressed as percentage of that obtained before injection, represents the mean \pm S.D. of data obtained from 4-5 mice. IC₅₀ and n_H values were, respectively, 152.3 nmol.kg⁻¹ mouse and 0.6 for CyrTx-1a ($r^2 = 0.992$) and 0.9 nmol.kg⁻¹ mouse and 0.5 for HwTx-IV ($r^2 = 0.998$). The dashed arrows indicate the toxin concentrations used for hot-plate and von Frey assays.

468 The toxin blocking effect was quantified by establishing the concentration-response curves and
 469 determining the IC₅₀ values. As shown in Figure 8b, the concentration-response curves for CyrTx-
 470 1a and HwTx-IV revealed IC₅₀ values of 152.3 and 0.9 nmol.kg⁻¹ mouse, respectively. The five
 471 different excitability tests (stimulus-response, strength-duration and current-threshold relationships,
 472 as well as threshold electrotonus and recovery cycle) were performed together before and 30 min
 473 after i.m. injections of PBS solution containing CyrTx-1a (448.7 nmol.kg⁻¹ mouse) and the derived
 474 neuromuscular excitability parameters were determined (Supporting Information Figure S2 and
 475 Table S5). With the exception of decreased maximal CMAP amplitude and increased stimulus
 476 intensity required to generate a 50% maximal amplitude CMAP (stimulus-response relationship),
 477 analysis of strength-duration relationship, threshold electrotonus, current-threshold relationship, and
 478 recovery cycle did not reveal other CyrTx-1a effects. The CyrTx-1a-induced effects were
 479 completely reversed within 12 hrs after peptide injections.

480 *In vivo toxicity of CyrTx-1a, compared to HwTx-IV, in mice*

481 No death of animals occurred following intraplantar injection of 102 nmol CyrTx-1a and 49 nmol

482 HwTx-IV per kg of mouse. In contrast, i.m. injection of 144.4 nmol CyrTx-1a per kg of mouse (a
483 concentration which produced an inhibition of ~50% of maximal CMAP amplitude), at the tail base,
484 caused death of 50% (2/4) of animals within one hour. By comparison, a similar *in vivo* toxicity was
485 observed following injection of an approximately 3.5 times lower HwTx-IV concentration, *i.e.*,
486 41.4 nmol.kg⁻¹. These results strongly suggest a lower *in vivo* toxicity of CyrTx-1a, compared to
487 HwTx-IV, following i.m. injections of toxins at the base of mouse tail, suggesting that CyrTx-1a
488 may possess an interesting therapeutic potential for pain treatment at non-toxic doses.

489

490 **Discussion and Conclusion**

491 This study was undertaken to identify a peptide with antinociceptive properties, among the Smartox
492 venom collection. The strategy consisted of (1) a high throughput screening of 117 different
493 venoms using automated patch-clamp platforms on cells overexpressing the antinociceptive target
494 hNa_v1.7 and the cardiac hNa_v1.5 subtypes, (2) the isolation and identification of a new peptide,
495 CyrTx-1a, from the *Cyriopagopus schioedtei* venom, (3) its structure characterization and chemical
496 synthesis, and (4) the evaluation of the synthetic peptide functional properties using multiscale
497 (from individual cell to *in vivo*) approaches.

498 With the identification of a large number of hits from our primary screening campaigns, a
499 triage was performed based on potency, in both tonic and use-dependent current inhibition
500 protocols. The use of venoms from different species (snakes, spiders, scorpions, wasps, bees,
501 amphibians, lizards and fishes) provided interesting information with regard to the target on which
502 these libraries were screened on. The most striking observation was that spider venoms contain by
503 far the greatest number of compounds active on hNa_v1.7 with a hit rate (for the primary screening)
504 that was 7-times higher than scorpion venoms and up to 40-fold higher than snake venoms. These
505 data point to the impressive specialization of spider venoms for targeting Na_v channels. Based on
506 this screening procedure, we focused our attention on CyrTx-1a which was identified in the
507 screening and highlighted for progression in our flowchart for deeper *in vitro* and *in vivo*
508 investigation.

509 The isolation of CyrTx-1a followed a two-step purification procedure using a double *in vitro*-
510 guided assay (block of hNa_v1.7 and inactivity on the cardiac safety-compromising hNa_v1.5). Once
511 the activity of the purified compound was confirmed by patch-clamp, the toxin entered the phase of
512 sequence deconvolution. Any doubts on Leu or Ile residues were solved by Edman sequencing. The
513 peptide was then synthesized and properly folded according to mass determination and coelution
514 properties, a *sine qua non* condition for *in vitro* characterization and *in vivo* evaluation.

515 Despite a high sequence identity with HnTx-I (82%), CyrTx-1a shares more pharmacological
516 properties with less similar toxins, such as HwTx-IV (42% identity) and GpTx-1 (45% identity).
517 This is likely mainly due to the presence of Asn²³ instead of Ser²³ in the HnTx-I sequence that
518 excludes any Na_v1.7 activity (Klint *et al.*, 2015), while a high potency for Na_v1.7 associated with a
519 good selectivity against Na_v1.5 and Na_v1.4 is due to the conservation of highly functional residues
520 (Xiao *et al.*, 2008; Murray *et al.*, 2015). Indeed, CyrTx-1a possesses several highly conserved and

521 crucial amino-acids, known to govern the Nav activity, such as the Phe⁵, Pro¹¹, Leu²⁰, Ser²³, His²⁶,
522 and more importantly the Trp²⁸ and Lys³⁰ residues (Minassian *et al.*, 2013; Murray *et al.*, 2016;
523 Shcherbatko *et al.*, 2016). In addition, its sequence includes a hydrophobic patch (Gly⁴, Gly⁶, Val³¹)
524 that has been described to reinforce the inhibitory potency of ICK toxins at Nav1.7 channels (Agwa
525 *et al.*, 2017). Due to these similarities, CyrTx-1a may share the same binding site on TTX-sensitive
526 Nav channels as the one determined by mutational analysis and *in silico* docking for HnTx-IV,
527 HwTx-IV and GpTx-1a (Cai *et al.*, 2015; Minassian *et al.*, 2013; Murray *et al.*, 2016). Indeed,
528 positively-charged amino acids Lys²⁵, His²⁶, Lys²⁷, Lys³⁰, surrounded by hydrophobic Phe⁵ and
529 Trp²⁸ clustered on one toxin face may be involved in interactions with negatively charged Glu⁷⁵³,
530 Glu⁸¹¹, Asp⁸¹⁶ and Glu⁸¹⁸ or aliphatic residues (Met⁷⁵⁰) located in S1-S2 and S3-S4 loops of DII
531 domain of TTX-sensitive Nav channels (Klint *et al.*, 2014; Li *et al.*, 2004; Liu *et al.*, 2012; Xiao *et al.*
532 *et al.*, 2008; Xiao *et al.*, 2010).

533 The first step to evaluate CyrTx-1a functional properties was to study the effects of the
534 synthetic peptide on cells overexpressing hNav1.1-1.8 subtypes, using patch-clamp techniques. This
535 study allowed (1) to test whether the potent blocking effect of the synthetic peptide, compared to
536 the native molecule, was conserved on hNav1.7, (2) to reinforce the evaluation of its selectivity
537 profile on the various Nav channel subtypes.

538 Synthetic (1 μ M) and native (0.57 μ M) CyrTx-1a produced $89.1 \pm 4.1\%$ (n = 7) and $98.8 \pm$
539 0.7% (n = 3) inhibition of hNav1.7, respectively, indicating that the two peptides were similarly and
540 highly potent to interact with this subtype. The mean IC₅₀ values of CyrTx-1a interaction with
541 hNav1.7, obtained from automated and manual patch-clamp experiments, were 129.5 and 59.6 nM,
542 respectively. From this point of view and compared to toxins belonging to the NaSpTx family 1
543 such as HnTx-I, HnTx-III, Hd1a, HnTx-IV, ProTx-III, Cm1a, GpTx-1 and HwTx-IV previously
544 reported to interact with this subtype, CyrTx-1a is thus among the most efficient peptides (Cardoso
545 *et al.*, 2015; Klint *et al.*, 2014; Klint *et al.*, 2015; Liu *et al.*, 2012; Liu *et al.*, 2013; Murray *et al.*,
546 2015; Murray *et al.*, 2016; Shcherbatko *et al.*, 2016; Xiao *et al.*, 2008). In addition to hNav1.7,
547 CyrTx-1a was also shown to be highly potent to block the TTX-S hNav1.1, 1.2, 1.3 and 1.6
548 subtypes with the following increasing order for mean IC₅₀ values (between approximately 75 and
549 300 nM): hNav1.2 \approx hNav1.1 \approx hNav1.6 \approx hNav1.7 > hNav1.3. The recent discovery that Nav1.1
550 and 1.3 subtypes are involved in pain pathways (Cardoso *et al.*, 2017b; Chen *et al.*, 2014; Osteen *et al.*
551 *et al.*, 2016) and that the Nav1.2 subtype is only located in the central nervous system (de Lera Ruiz *et al.*,
552 2015) does not impair further development of CyrTx-1a as a potential antinociceptive agent to
553 access only peripheral Nav channel subtypes. Moreover, the native and synthetic peptides have at
554 best micromolar affinities for hNav1.5, hCa_v1.2 and hK_v11.1 subtypes, well-known targets in
555 cardiac safety (Crumb *et al.*, 2016). However, although fully sparing the skeletal muscle hNav1.4
556 subtype, the fact that CyrTx-1a also targets the peripheral nerve hNav1.6 subtype may represent a
557 limitation for its *in vivo* efficacy and will require the development of analogues with improved
558 selectivity.

559 The second step to evaluate CyrTx-1a's functional properties was to study the peptide effects
560 on TTX-S and TTX-R sodium currents of adult mouse DRG neurons, including mainly the TTX-S

561 $Na_V1.1$, 1.6 and 1.7 subtypes and the TTX-R $Na_V1.8$ and 1.9 subtypes (Rush *et al.*, 2007). This
562 study was motivated by the well-known physiological importance of DRG neurons in pain
563 signalling. As expected, the preferential blocking effect of TTX-S Na_V channel subtypes by CyrTx-
564 1a was confirmed on mouse DRG neurons since the peptide was 635 times more efficient to inhibit
565 the peak amplitude of TTX-S than TTX-R sodium currents recorded from these neurons. These
566 results are consistent with previous observations on adult rodent DRG neurons showing that other
567 potential antinociceptive toxins, such as HnTx-IV, GpTx-1 and HwTx-IV, inhibit TTX-S current
568 without markedly affecting TTX-R current (Liu *et al.*, 2003; Murray *et al.*, 2015; Peng *et al.*, 2002).
569 Most of these peptides, including CyrTx-1a, inhibit h Na_V17 and/or TTX-S currents without any
570 significant modification of activation and inactivation kinetics and/or voltage-dependence.

571 The third step to evaluate CyrTx-1a functional properties, and to go deeper in the
572 antinociceptive appraisal of the peptide, was to study its effects on heat and tactile sensitivity of
573 mice *in vivo*. Following intraplantar injections, the peptide (102 nmol.kg^{-1}) was as efficient as
574 HwTx-IV (49 nmol.kg^{-1}) to increase both the time to first pain manifestation of animals to
575 nociceptive heat and the force intensity at which the animals removed their hind limb. The fact that
576 CyrTx-1a also targets the $Na_V1.6$ subtype with high affinity, a subtype located in motor axons
577 innervating skeletal muscles (Caldwell *et al.*, 2000), could limit the safe use of this peptide as an
578 antinociceptive agent. Experiments were thus also conducted to test CyrTx-1a effects on the mouse
579 neuromuscular system *in vivo*. These effects mainly consisted in a CMAP inhibition, as shown in
580 the present work and previously reported for HwTx-IV (Goncalves *et al.*, 2018). These results
581 strongly suggest that the two peptides produce a marked decrease of the density of functional
582 "transient" Na_V channels. Besides these effects, CyrTx-1a, as HwTx-IV (Goncalves *et al.*, 2018),
583 did not modify other excitability parameters, indicating that the peptide does not affect the density
584 of other functional ion channels, receptors and pumps, nor the passive membrane properties of the
585 neuromuscular system (Kiernan *et al.*, 2000; Krishnan *et al.*, 2008). CyrTx-1a was approximately
586 170 times less efficient than HwTx-IV to inhibit CMAP. Assuming that both toxins have also
587 similar affinity on the mouse $Na_V1.6$ subtype, we infer that the accessibility to this subtype, located
588 mainly at the nodes of Ranvier of motor myelinated axons (Caldwell *et al.*, 2000), is somehow more
589 limited for CyrTx-1a than for HwTx-IV. The pharmacokinetic properties of CyrTx-1a should
590 therefore be favorable for its further development as an antinociceptive compound.

591

592 In conclusion, the present results highlight that CyrTx-1a, the first toxin purified from
593 *Cyriopagopus schioedtei* spider venom, is an attractive compound for the development of an
594 antinociceptive agent. Further pharmacokinetics and Structure-Activity Relationships (SAR) studies
595 will be necessary to improve the Na_V profile selectivity of CyrTx-1a. In particular, it is likely that
596 synthetic modified homologues, associated with Molecular Dynamics simulation using CyrTx-1a
597 and Na_V channels, will reinforce the potential use of the peptide as a lead molecule for the
598 development of novel pain therapeutics.

599 **ASSOCIATED CONTENT**

600 **Supporting information:** Tables and additional figures illustrating the fragments sequenced by
601 LC-MS/MS analyses of CyrTx-1a digests, chemical synthesis, refolding and ¹H-chemical shifts of
602 CyrTx-1a, detailed *in vitro* and *in vivo* electrophysiological parameters, and a supplementary
603 Experimental Section. This material is available free of charge via the Internet at
604 <http://pubs.acs.org>.

605 **Accession Codes:** PDB code for CyrTx-1a is 6GFT. Authors will release the atomic coordinates
606 and experimental data upon article publication.

607

608 **References**

- 609 Agwa AJ, Huang YH, Craik DJ, Henriques ST, Schroeder CI (2017). Lengths of the C-Terminus and
610 Interconnecting Loops Impact Stability of Spider-Derived Gating Modifier Toxins. *Toxins* 9: 248-263.
- 611 Bennett DL, Woods CG (2014). Painful and painless channelopathies. *Lancet Neurol.* 13: 587-599.
- 612 Cai T, Luo J, Meng E, Ding J, Liang S, Wang S, *et al.* (2015). Mapping the interaction site for the tarantula toxin
613 hainantoxin-IV (beta-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium
614 channels. *Peptides* 68: 148-156.
- 615 Caldwell JH, Schaller KL, Lasher RS, Peles E, Levinson SR (2000). Sodium channel Na(v)1.6 is localized at
616 nodes of ranvier, dendrites, and synapses. *Proc. Natl. Acad. Sci. U S A* 97: 5616-5620.
- 617 Cardoso FC, Dekan Z, Rosengren KJ, Erickson A, Vetter I, Deuis JR, *et al.* (2015). Identification and
618 Characterization of ProTx-III [μ -TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from
619 Venom of the Tarantula *Thrixopelma pruriens*. *Mol. Pharmacol.* 88: 291-303.
- 620 Cardoso FC, Dekan Z, Smith JJ, Deuis JR, Vetter I, Herzig V, *et al.* (2017a). Modulatory features of the novel
621 spider toxin μ -TRTX-Df1a isolated from the venom of the spider *Davus fasciatus*. *Br. J. Pharmacol.* 174:
622 2528-2544.
- 623 Cardoso FC, Lewis RJ (2017b). Sodium channels and pain: from toxins to therapies. *Br. J. Pharmacol.*
- 624 Cerles O, Benoit E, Chereau C, Chouzenoux S, Morin F, Guillaumot MA, *et al.* (2017). Niclosamide Inhibits
625 Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response. *Mol. Cancer Ther.* 16:
626 300-311.
- 627 Chen HP, Zhou W, Kang LM, Yan H, Zhang L, Xu BH, *et al.* (2014). Intrathecal miR-96 inhibits Nav1.3
628 expression and alleviates neuropathic pain in rat following chronic construction injury. *Neurochem. Res.* 39:
629 76-83.
- 630 Crumb WJ, Jr., Vicente J, Johannesen L, Strauss DG (2016). An evaluation of 30 clinical drugs against the
631 comprehensive *in vitro* proarrhythmia assay (CiPA) proposed ion channel panel. *J. Pharmacol. Toxicol.*
632 *Methods* 81: 251-262.
- 633 de Lera Ruiz M, Kraus RL (2015). Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and
634 Clinical Indications. *J. Med. Chem.* 58: 7093-7118.
- 635 Deuis JR, Wingerd JS, Winter Z, Durek T, Dekan Z, Sousa SR, *et al.* (2016). Analgesic Effects of GpTx-1, PF-
636 04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. *Toxins* 8: 78-87.
- 637 Dib-Hajj SD, Yang Y, Black JA, Waxman SG (2013). The Na(V)1.7 sodium channel: from molecule to man. *Nat.*
638 *Rev. Neurosci.* 14: 49-62.
- 639 Flinspach M, Xu Q, Piekarczyk AD, Fellows R, Hagan R, Gibbs A, *et al.* (2017). Insensitivity to pain induced by a
640 potent selective closed-state Nav1.7 inhibitor. *Sci. Rep.* 7: 39662.
- 641 Goncalves TC, Boukaiba R, Molgo J, Amar M, Partiseti M, Servent D, *et al.* (2018). Direct evidence for high
642 affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional
643 approaches. *Neuropharmacology* 133: 404-414.
- 644 Hagen NA, Cantin L, Constant J, Haller T, Blaise G, Ong-Lam M, *et al.* (2017). Tetrodotoxin for Moderate to
645 Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design
646 Trial. *Pain Res. Manag.* 2017: 7212713.
- 647 Israel MR, Tay B, Deuis JR, Vetter I (2017). Sodium Channels and Venom Peptide Pharmacology. *Adv.*

- 648 Pharmacol. 79: 67-116.
- 649 Kiernan MC, Bostock H (2000). Effects of membrane polarization and ischaemia on the excitability properties of
650 human motor axons. *Brain* 123: 2542-2551.
- 651 Klint JK, Berecki G, Durek T, Mobli M, Knapp O, King GF, *et al.* (2014). Isolation, synthesis and
652 characterization of omega-TRTX-Cc1a, a novel tarantula venom peptide that selectively targets L-type Cav
653 channels. *Biochem. Pharmacol.* 89: 276-286.
- 654 Klint JK, Chin YKY, Mobli M (2015). Rational Engineering Defines a Molecular Switch That Is Essential for
655 Activity of Spider-Venom Peptides against the Analgesics Target Na(V)1.7. *Mol. Pharmacol.* 88: 1002-1010.
- 656 Krishnan AV, Lin CSY, Park SB, Kiernan MC (2008). Assessment of nerve excitability in toxic and metabolic
657 neuropathies. *J. Periph. Nerv. Syst.* 13: 7-26.
- 658 Li D, Xiao Y, Xu X, Xiong X, Lu S, Liu Z, *et al.* (2004). Structure--activity relationships of hainantoxin-IV and
659 structure determination of active and inactive sodium channel blockers. *J. Biol. Chem.* 279: 37734-37740.
- 660 Liu Y, Li D, Wu Z, Li J, Nie D, Xiang Y, *et al.* (2012). A positively charged surface patch is important for
661 hainantoxin-IV binding to voltage-gated sodium channels. *Journal of peptide science : an official publication
662 of the European Peptide Society* 18: 643-649.
- 663 Liu Z, Cai T, Zhu Q, Deng M, Li J, Zhou X, *et al.* (2013). Structure and function of hainantoxin-III, a selective
664 antagonist of neuronal tetrodotoxin-sensitive voltage-gated sodium channels isolated from the Chinese bird
665 spider *Ornithoctonus hainana*. *J. Biol. Chem.* 288: 20392-20403.
- 666 Liu Z, Dai J, Chen Z, Hu W, Xiao Y, Liang S (2003). Isolation and characterization of hainantoxin-IV, a novel
667 antagonist of tetrodotoxin-sensitive sodium channels from the Chinese bird spider *Selenocosmia hainana*. *Cell
668 Mol. Life Sci.* 60: 972-978.
- 669 Minassian NA, Gibbs A, Shih AY, Liu Y, Neff RA, Sutton SW, *et al.* (2013). Analysis of the structural and
670 molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (mu-TRTX-
671 Hh2a). *J. Biol. Chem.* 288: 22707-22720.
- 672 Moyer BD, Murray JK, Ligutti J, Andrews K, Favreau P, Jordan JB, *et al.* (2018). Pharmacological
673 characterization of potent and selective NaV1.7 inhibitors engineered from *Chilobrachys jingzhao* tarantula
674 venom peptide JzTx-V. *PLoS one* 13: e0196791.
- 675 Murray JK, Ligutti J, Liu D, Zou A, Poppe L, Li H, *et al.* (2015). Engineering potent and selective analogues of
676 GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. *J. Med. Chem.* 58: 2299-2314.
- 677 Murray JK, Long J, Zou A, Ligutti J, Andrews KL, Poppe L, *et al.* (2016). Single Residue Substitutions That
678 Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1. *J.
679 Med. Chem.* 59: 2704-2717.
- 680 Osteen JD, Herzig V, Gilchrist J, Emrick JJ, Zhang C, Wang X, *et al.* (2016). Selective spider toxins reveal a role
681 for the Nav1.1 channel in mechanical pain. *Nature* 534: 494-499.
- 682 Peng K, Shu Q, Liu Z, Liang S (2002). Function and solution structure of huwentoxin-IV, a potent neuronal
683 tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider *Selenocosmia huwena*. *J.
684 Biol. Chem.* 277: 47564-47571.
- 685 Rush AM, Cummins TR, Waxman SG (2007). Multiple sodium channels and their roles in electrogenesis within
686 dorsal root ganglion neurons. *J. Physiol.* 579: 1-14.
- 687 Saez NJ, Senff S, Jensen JE, Er SY, Herzig V, Rash LD, *et al.* (2010). Spider-venom peptides as therapeutics.
688 *Toxins* 2: 2851-2871.
- 689 Shcherbatko A, Rossi A, Foletti D, Zhu G, Bogin O, Galindo Casas M, *et al.* (2016). Engineering Highly Potent
690 and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain. *J. Biol. Chem.* 291:
691 13974-13986.
- 692 Vetter I, Deuis JR, Mueller A, Israel MR, Starobova H, Zhang A, *et al.* (2017). NaV1.7 as a pain target - From
693 gene to pharmacology. *Pharmacol. Ther.* 172: 73-100.
- 694 Waxman SG, Zamponi GW (2014). Regulating excitability of peripheral afferents: emerging ion channel targets.
695 *Nat. Neurosci.* 17: 153-163.
- 696 Xiao Y, Bingham JP, Zhu W, Moczydlowski E, Liang S, Cummins TR (2008). Tarantula huwentoxin-IV inhibits
697 neuronal sodium channels by binding to receptor site 4 and trapping the domain ii voltage sensor in the closed
698 configuration. *J. Biol. Chem.* 283: 27300-27313.
- 699 Xiao Y, Blumenthal K, Jackson JO, 2nd, Liang S, Cummins TR (2010). The tarantula toxins ProTx-II and
700 huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and
701 inactivation. *Mol. Pharmacol.* 78: 1124-1134.

Supporting information for:

Cyriotoxin-1a, the first toxin from *Cyriopagopus schioedtei* spider with antinociceptive properties: from identification to functional characterization

Tânia C. Gonçalves^{†,‡}, Evelyne Benoit^{#,‡}, Michael Kurz¹, Laetitia Lucarain[†], Sophie Fontaine[†], Stéphanie Combemale[‡], Lucie Jaquillard[‡], Brigitte Schombert[†], Jean-Marie Chambard[†], Rachid Boukaiba[†], Gerhard Hessler¹, Andrees Bohme[†], Laurent Bialy¹, Stéphane Hourcade¹, Rémy Bérout[‡], Michel De Waard^{†,§}, Denis Servent^{#,*}, Michel Partiseti^{†,*}

[†] Sanofi R & D, Integrated Drug Discovery – High Content Biology, F-94440 Vitry-sur-Seine, France.

[#] Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, F-91191 Gif sur Yvette, France.

[‡] Institut des Neurosciences Paris-Saclay (Neuro-PSI), UMR CNRS/Université Paris-Sud 9197, Université Paris-Saclay, F-91198 Gif sur Yvette, France.

¹ Sanofi R & D, Integrated Drug Discovery – Synthetic Molecular Design, Frankfurt, Germany.

[‡] Smartox Biotechnology, 6 rue des Platanes, 38120 Saint-Egrève, France.

¹ Sanofi R & D, Neuroscience Therapeutic Area, Neurodegeneration Research, F-91385 Chilly-Mazarin, France.

[§] Institut du Thorax, Inserm UMR 1087 / CNRS UMR 6291, LabEx “Ion Channels, Science & Therapeutics”, F-44007 Nantes, France.

Table S1. Fragments sequenced by LC-MS/MS analyses of the CyrTx-1a digests. Symbol * indicates C-terminal amidation, and all cysteine residues were detected as carbamidomethyl derivatives with the addition of 57 Da.

	Sequence	Mass	m/z	Relative error
Trypsin digestion	SCVPGK	646.3109	324.1636	2.9 ppm
	HKWCK	757.3694	379.6914	-1.6 ppm
	ECKGFGK	824.3851	413.1994	-1.0 ppm
	SGLTCSNK	865.3964	433.7061	1.5 ppm
	CSGLTCSNK	1025.4270	513.7209	0.3 ppm
	SCVPGKNEC	1049.4270	525.7209	0.3 ppm
	SCVPGKNECC	1209.4576	605.7358	-0.4 ppm
	NECCSGLTCSNK	1428.5432	715.2799	1.4 ppm
	PGK NECCSGLTCSNK	1710.7124	856.3679	5.1 ppm
	SCVPGKNECCSGLTCSNK	2056.8435	1029.4368	7.5 ppm
	SCVPGKNECCSGLTCSNKHK	2321.9973	775.0079	2.0 ppm
Glu-C	ECKGFGKSCVPGKNE	1695.7709	566.2644	0.3 ppm
	CCSGLTCSNKHKWCKVLL*	2249.0691	1125.5420	0.2 ppm




Figure S1. Chemical synthesis and refolding of CyrTx-1a. **(a)** Crude CyrTx-1a synthesis as revealed by a C18 reversed-phase chromatography. **(b)** Crude folded/oxidized CyrTx-1a. **(c)** Purified folded/oxidized CyrTx-1a illustrating the purity of the synthetic compound. Inset: illustrates the MS of synthetic CyrTx-1a of m/z 1193.8556 $[M+3H]^{3+}$. **(d)** C18 coelution profile of natural CyrTx-1a (4 μ g) mixed with synthetic CyrTx-1a (4 μ g). The presence of a single uniform peak demonstrates the identity of both compounds. The two contaminating peaks preceding the major peak represent contaminants from the natural peptide.

Table S2. ¹H-chemical shifts of CyrTx-1a in H₂O/D₂O, 50 mM phosphate buffer, pH 5.0 at 305°K (concentration: 6 mg/mL)*.

No.	Residue	NH	H α	H β	Others
1	Glu	-	4.17	2.17	γ : 2.53
2	Cys	8.74	4.89	3.26/2.95	
3	Lys	8.86	4.39	1.82/1.71	γ : 1.60/1.41, δ : 1.78/ 1.50, ϵ : 2.99
4	Gly	8.05	4.08/3.68		
5	Phe	8.45	3.79	3.07/2.82	δ : 7.10, ϵ : 7.44, ζ : 7.34
6	Gly	8.78	3.55/2.73		
7	Lys	7.66	4.44	2.05/1.83	γ : 1.48/1.19, δ : 1.62, ϵ : 3.02/2.96
8	Ser	8.48	4.93	4.01/3.96	
9	Cys	8.17	4.97	3.17/2.95	
10	Val	8.42	4.38	1.79	γ : 0.96, γ' : 0.90
11	Pro	-	4.01	2.30/1.93	γ : 2.16/1.74, δ : 4.07/3.77
12	Gly	9.19	4.33/3.78		
13	Lys	7.54	4.50	2.03/1.80	γ : 1.42/1.28, δ : 1.60, ϵ : 2.98/2.94
14	Asn	8.81	4.72	3.08/2.72	NH ₂ : 7.60/6.89
15	Glu	9.03	4.28	2.11/2.02	γ : 2.27
16	Cys	8.55	5.18	3.06/2.87	
17	Cys	9.14	4.54	3.46/2.59	
18	Ser	8.26	4.255	3.89/3.86	
19	Gly	8.95	4.40/3.72		
20	Leu	8.19	5.38	2.30/1.31	γ : 1.47, δ : 0.91, δ' : 0.87
21	Thr	9.29	4.62	3.98	γ : 1.02
22	Cys	8.83	4.68	3.19/2.98	
23	Ser	8.35	4.49	4.05/3.75	
24	Asn	9.09	4.27	2.79/2.70	NH ₂ : 7.62/6.98
25	Lys	7.89	4.01	1.51/1.21	γ : 1.07/0.84, δ : 1.51, ϵ : 2.86
26	His	7.68	4.26	1.52/1.41	δ : 7.16, ϵ : 8.60
27	Lys	8.19	3.99	2.34/2.02	γ : 1.22, δ : 1.70/1.60, ϵ : 2.97
28	Trp	6.93	5.59	3.10/2.53	H1: 10.26, H2: 6.89, H4: 7.35, H5: 7.02, H6: 7.01, H7: 7.01
29	Cys	8.58	5.00	3.28/2.69	
30	Lys	9.67	5.02	2.14/1.83	γ : 1.55/1.31, δ : 1.78/1.71, ϵ : 2.92
31	Val	8.45	4.10	2.09	γ : 1.05, γ' : 1.00
32	Leu	8.17	4.32	1.60/1.21	γ : 1.43, δ : 0.91, δ' : 0.88
33	Leu	8.28	4.39	1.68/1.58	γ : 1.64, δ : 0.95, δ' : 0.89, NH ₂ : 7.56/7.03

*: Proton chemical shifts are referenced to sodium-3-(Trimethylsilyl)propionate-2,2,3,3-d₄.

Table S3. Parameters of steady-state inactivation- ($V_{P50\%}$ and k_h) and conductance- ($V_{T50\%}$ and k_g) voltage relationships for HEK-293 cells overexpressing the hNav1.7 channel subtype (means \pm S.D. of 3-4 cells) and mouse DRG neurons displaying endogenous TTX-S sodium current (means \pm S.D. of 4 neurons).

	$V_{P50\%}$ (mV)	k_h (mV^{-1})	$V_{T50\%}$ (mV)	k_g (mV^{-1})
hNav1.7 current before CyrTx-1a	-70 ± 1	5.2 ± 0.4	-23 ± 2	4.5 ± 0.7
hNav1.7 current after CyrTx-1a	-71 ± 1	5.4 ± 0.1	-26 ± 2	4.0 ± 0.6
TTX-S current before CyrTx-1a	-82 ± 7	8.5 ± 0.3	-34 ± 6	3.2 ± 1.0
TTX-S current after CyrTx-1a perfusion ³	-89 ± 9	10.5 ± 1.3	-24 ± 9	4.6 ± 1.9

¹ 50 nM, ² 300 nM, and ³ 0.25-0.5 μ M.

Table S4. Kinetic parameters of activation (tp) and inactivation (τ_h) of endogenous TTX-S sodium current recorded from DRG neurons under the indicated conditions (means \pm S.D. of 4 cells).

	tp (ms)	τ_h (ms)
TTX-S current after TTX ¹ wash-out	1.27 ± 0.21	0.81 ± 0.26
TTX-S current after CyrTx-1a	1.78 ± 0.12^3	1.49 ± 0.18^4

¹ 100 nM, ² 0.25-0.5 μ M. ³ $P = 0.056$ and ⁴ $P = 0.055$ (versus current after TTX wash-out).




Figure S2. Superimposed excitability curves obtained *in vivo* by stimulating the mouse caudal motor nerve and recording the CMAP from tail muscle before (black circles, $n = 29$ mice) and ~ 30 min after injections of CyrTx-1a (448.7 nmol/kg mouse, blue circles, $n = 4$ mice). Data are represented as means \pm S.D. (a) stimulus-response relationships [absolute (a1) and relative (a2) CMAP amplitudes], (b) strength-duration relationship, (c) threshold electrotonus, (d) current-threshold relationship, and (e) recovery cycle. In a1, arrows indicate stimulus currents for 50% maximal response.

Table S5. Comparison of neuromuscular excitability parameters (means \pm S.D.) from mouse tail muscle recordings before toxin injections (control, $n = 29$ mice) and ~ 30 min after injections of CyrTx-1a (448.7 nmol/kg mouse, $n = 4$ mice).

Excitability parameter ²		Before toxin Injection	After CyrTx-1a injection
a ¹	Peak response (mV)	5.31 \pm 0.57	1.60 \pm 0.47**
a	Latency (ms)	3.89 \pm 0.06	4.05 \pm 0.15
a	Stimulus (mA) for 50% max response	0.35 \pm 0.05	0.42 \pm 0.03*
a	Stimulus-response slope	3.11 \pm 0.18	3.42 \pm 0.15
b ¹	Strength-duration time constant (ms)	0.69 \pm 0.12	0.88 \pm 0.12
b	Rheobase (mA)	0.21 \pm 0.04	0.18 \pm 0.09
c ¹	TEd (10-20 ms, 40%)	59.53 \pm 1.27	54.93 \pm 2.57
c	TEd (peak, 40%)	59.00 \pm 1.17	54.95 \pm 2.33
c	TEd (peak, 20%)	35.81 \pm 0.75	32.99 \pm 1.61
c	TEd (40-60 ms, 40%)	47.92 \pm 1.14	45.25 \pm 2.01
c	TEd (90-100 ms, 40%)	39.52 \pm 1.27	37.49 \pm 1.55
c	Accommodation half-time (ms, 40%)	46.02 \pm 0.93	45.66 \pm 2.28
c	TEd (undershoot, 40%)	-15.34 \pm 1.01	-13.64 \pm 1.57
c	TEh (10-20 ms, -40%)	-93.31 \pm 1.12	-88.95 \pm 4.09
c	TEh (20-40 ms, -40%)	-120.1 \pm 1.9	-113.3 \pm 5.7
c	TEh (90-100 ms, -40%)	-152.7 \pm 5.2	-149.3 \pm 9.2
c	TEh (slope 101-140 ms, -40%)	2.62 \pm 0.17	2.75 \pm 0.25
c	TEh (peak, -70%)	-312.4 \pm 6.7	-291.3 \pm 16.2
c	TEh (overshoot, -40%)	17.33 \pm 1.05	15.89 \pm 1.77
d ¹	Resting slope	0.89 \pm 0.09	0.88 \pm 0.12
d	Minimum slope	0.23 \pm 0.01	0.23 \pm 0.02
d	Hyperpolarization slope	0.49 \pm 0.03	0.44 \pm 0.06
e ¹	Refractoriness at 2 ms (%)	45.82 \pm 5.60	44.08 \pm 8.16
e	Refractoriness at 2.5 ms (%)	34.48 \pm 4.78	28.58 \pm 9.97
e	Relative refractory period (ms)	4.38 \pm 1.09	4.09 \pm 1.17
e	Superexcitability (%)	-19.00 \pm 3.91	-13.93 \pm 4.05
e	Superexcitability at 5 ms (%)	-0.49 \pm 3.26	-2.75 \pm 8.92
e	Superexcitability at 7 ms (%)	-5.94 \pm 2.06	-10.46 \pm 2.16
e	Subexcitability (%)	5.60 \pm 1.09	6.43 \pm 1.15

¹ a: stimulus-response relationship, b: strength-duration relationship, c: threshold electrotonus, d: current-threshold relationship, and e: recovery cycle. ² TEd: threshold electrotonus from depolarizing currents and TEh: threshold electrotonus from hyperpolarizing currents. Differences (*versus* control), considered to be significant at $P \leq 0.05$ (*: $P = 0.038$, **: $P = 4.3 \times 10^{-5}$), are highlighted in blue.

725 **SUPPLEMENTARY EXPERIMENTAL SECTION**

726

727 **Protocols for amino acid sequencing of CyrTx-1a.** A Waters Q-TOF Xevo G2S mass
728 spectrometer equipped with an Acquity UHPLC system and Lockspray source was used for the
729 acquisition of the LC-ESI-MS and LC-ESI-MS/MS data. Five μ L of each digested peptide sample
730 was injected into an Acquity UPLC BEH300 C18 column (1.7 μ m, 2.1 mm ID \times 150 mm L,
731 Waters). Peptide elutions were performed at a flow rate of 0.4 mL/min with a 10-70% gradient of
732 buffers B/A over 10 min (solvent A composition: H₂O/formic acid, 99.9/0.1 (v/v) and solvent B
733 composition: ACN/formic acid, 99.9/0.1 (v/v)). The eluted solution was directly injected into the
734 coupled MS system. Acquisition and analysis of the peptide samples were carried out in the positive
735 mode, within a mass range of m/z 100-2,000 using the Agilent MassLynx software version 4.1
736 (Waters). The mass spectrometer settings for the MS analyses were: capillary voltage, 0.5 kV; cone
737 voltage, 40 V; source temperature, 150°C; desolvation temperature, 600°C; gas flow, 80 L/hr; and
738 gas desolvation, 1000 L/hr. MS data were acquired using a data-dependent acquisition method
739 (DDA) for which MS/MS data were acquired using CID activation mode based on mass and charge
740 state of the candidate ions. For calibration, an external lock mass was used with a separate reference
741 spray (LockSpray) using a solution of leucine enkephalin eluted at a flow rate of 5 μ L/min. The
742 calibration was based on the MS detection of m/z 278.1141 and 556.2771 ions at collision energy of
743 23 eV. The resulting MS/MS spectra data were analysed by *De Novo* sequencing using PEAKS®
744 studio version 5.2 software (Bioinformatics Solutions Inc.) with the following settings: trypsin or
745 V8 protease; carbamidomethyl (C) as a fixed modification and amidation as variable modification;
746 mass accuracy for MS/MS data at 0.05 Da; and mass accuracy for the precursor mass at 20 ppm.
747 Amino acid sequence scores between 50 and 100 were recorded.

748 Amino acid sequence determination based on Edman degradation was performed using an
749 Applied Biosystems gas-phase sequencer model 492 (s/n: 9510287J). Phenylthiohydantoin amino
750 acid derivatives generated at each sequence cycle were identified and quantitated on-line with an
751 Applied Biosystems Model 140C HPLC system using the data analysis system for protein
752 sequencing from Applied Biosystems (software Procise PC v2.1). The PTH-amino acid standard kit
753 (Perkin-Elmer P/N 4340968) was used and reconstituted according to the manufacturer's
754 instructions. The procedures and reagents used were those recommended by the manufacturer.
755 Chromatography was used to identify and quantify the derivatized amino acid removed at each
756 sequence cycle. Retention times and integration values of peaks were compared to the
757 chromatographic profile obtained for a standard mixture of derivatized amino acids.

758

759 **Protocols for cell line culture.** HEK-293 cells heterologously overexpressing the hNa_v1.7 channel
760 subtype were cultured in suspension in FreestyleTM293 (Gibco). Those overexpressing hNa_v1.6
761 and hNa_v1.8 subtypes were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12
762 Glutamax (Gibco), while those overexpressing hNa_v1.3 and hNa_v1.4 subtypes were cultured in
763 MEM (Sigma, M5650). The complete media contain 10% FBS (Gibco) and selected antibiotics and

764 additives as recommended by the manufacturer. In-house HEK-Flip-In-T-REx cells were kept in
765 culture under standard conditions (37°C, air supplemented with 5% CO₂) in DMEM (Invitrogen)
766 supplemented with 10% fetal calf serum (Invitrogen), 50 µg/mL hygromycin (Invitrogen), and 15
767 µg/mL blasticidin (Invivogen). Cells were sub-cultured every 3 to 4 days using accutase® (Sigma)
768 or TrypLE Select (Gibco) as enzymatic dissociation to detach the cells. At least 12 to 24 h prior to
769 assays, doxycycline (BD Biosciences) was added to induce target expression when needed.

770 CHO cells heterologously overexpressing hCa_v1.2/β2/α2δ1 channel subtype (ChanTest,
771 Cleveland, OH, USA) were cultured in Ham’s F12 nutrient mix with GlutaMAXTM medium
772 (Gibco). Those overexpressing the hK_v11.1 channel subtype (B’SYS GmbH, Switzerland), encoded
773 by the human *ether-a-go-go*-related gene (hERG), were cultured in DMEM/F12 nutrient mixture
774 Ham’s medium (Sigma). All culture media contained fetal bovine serum (10% v/v) and selected
775 antibiotics and additives, as recommended by the manufacturer. Cells were grown in flasks, in a
776 humidified 5% CO₂ incubator at 37°C, and subcultured/passaged every 3-4 days using TrypLE
777 Select enzyme (Gibco).

778

779 **Automated patch-clamp recordings.** For primary screening, planar assay electrophysiology
780 recordings were made on an IonWorks Quattro® system (Molecular Devices, Sunnyvale, CA,
781 USA) enabling population patch-clamp (PPC) measurement. HEK-293 cell suspensions were
782 prepared as described in a previous article using similar technology. {Chambard, 2014 #240} For
783 electrophysiological recordings, cells were resuspended in 5 mL pre-filtered external buffer
784 containing (in mM): 137 NaCl, 4 KCl, 1 MgCl₂, 1.8 CaCl₂, 10 HEPES, 5 glucose (osmolarity set at
785 306 mOsm/L and pH 7.3 adjusted with NaOH). All recordings were made using an internal solution
786 containing (in mM): 100 K-gluconate, 40 KCl, 1 MgCl₂, 1 EGTA, 5 glucose and 10 HEPES
787 (osmolarity set at 300 mOsm/L and pH 7.4 adjusted with KOH). Sealing process and access of the
788 perforated patch-clamp configuration were obtained as already described in the literature. {Trivedi,
789 2008 #237} Cells/wells were clamped using the electronics (E-) head held at -120 mV (with
790 reference to a common “intracellular” ground electrode). Pre-compound currents were recorded,
791 followed by addition of test peptide venoms prepared in external solution complemented with 0.2%
792 bovine serum albumin (BSA; Sigma). Fractions were incubated for 10 min before the post-
793 compound response was recorded. The pre- and post-compound responses were evoked by a
794 voltage train as follows: after a 10-sec period holding at -120 mV, ten pulses, each consisting of a
795 50 ms step to the voltage of the peak current of the current-voltage relationship for each channel
796 followed by a 300 ms step back to -120 mV, were applied at 10 Hz. The current signal was sampled
797 at 10 kHz. Currents were leak-subtracted based on the estimate of current evoked during the -10
798 mV step at the start of the voltage pulse protocol. Pre- and post-compound sodium current
799 amplitudes were measured automatically from the leak-subtracted traces by the IonWorks software
800 through averaging a 10 ms current during the initial holding period at -90 mV (baseline current) and
801 subtracting this from the peak of the current response for each of the eight voltage steps. Data
802 shown are calculated for pulse 1 (tonic block) or pulse 10 (use-dependent block). Filters were set to
803 a pre-scan seal resistance of 40 MΩ, pre-scan hNa_v1.7 current amplitude of 200 pA, and post-scan

804 seal resistance of 40 MΩ. Cells that did not meet these criteria were discarded from the
805 measurements. Dividing the post-scan current amplitude by the respective pre-scan current
806 amplitude for each well assessed the degree of inhibition of the hNa_v1.7 current.

807 Secondary screening for hit confirmation, as well as rapid selectivity check, were also
808 performed on an automated patch-clamp system, the QPatch HTX (Sophion Bioscience, Denmark)
809 recording currents in whole-cell configuration, allowing both signal acquisition and data analyses.³
810 The day of their use, HEK-293 and CHO cells were transferred into Eppendorf tubes containing a
811 FreeStyle 293 expression medium (Gibco) which were then placed in the automated
812 electrophysiology platform. The extracellular medium composition for hNa_v-overexpressing HEK-
813 293 cells was (in mM): NaCl 154, KCl 4, CaCl₂ 2, MgCl₂ 1, and HEPES 10 (pH 7.4, adjusted with
814 NaOH), and that of intracellular (*i.e.*, patch-clamp pipette) medium: CsF 150, EGTA/CsOH 1/50,
815 HEPES 10, NaCl 10, MgCl₂ 1, and CaCl₂ 1 (pH 7.4, adjusted with CsOH). The extracellular
816 medium composition for hCa_v1.2-overexpressing CHO cells was (in mM): NaCl 145, KCl 4, CaCl₂
817 10, and HEPES 10 (pH 7.4, adjusted with NaOH), and that of intracellular medium: CsF 27, CsCl
818 112, EGTA 8.2, HEPES 10, NaCl 2, and MgATP 4 (pH 7.4, adjusted with CsOH). The extracellular
819 medium composition for hK_v11.1-overexpressing CHO cells was (in mM): NaCl 145, KCl 4, CaCl₂
820 2, MgCl₂ 1, HEPES 10, and D-glucose 10 (pH 7.4, adjusted with NaOH), and that of intracellular
821 medium: KCl 120, CaCl₂ 5.4, EGTA 10, HEPES 10, Mg-ATP 4, and MgCl₂ 1.75 (pH 7.4, adjusted
822 with KOH). Venom fractions and sub-fractions, as well as CyrTx-1a, were diluted in the
823 extracellular medium supplemented with bovine serum albumin (0.1%), to give the final
824 concentrations indicated in the text. The times of incubation varied between ~2 and ~7 min to
825 achieve steady-state effects. The experiments were carried out at room temperature (20-22°C). The
826 hNa_v-overexpressing HEK-293 cells were maintained at a holding potential of either -90 mV
827 (hNa_v1.5) or -100 mV (other hNa_v channel subtypes). Currents were elicited at a frequency of 0.2
828 Hz by 20-ms test-pulses to -20 mV (hNa_v1.1, 1.2, 1.4, and 1.7), -10 mV (hNa_v1.3), -40 mV
829 (hNa_v1.5), -15 mV (hNa_v1.6) or +10 mV (hNa_v1.8), preceded by 200-ms (hNa_v1.5) or 40-ms
830 (hNa_v1.7) pulses to -120 mV, or not (hNa_v1.1, 1.2, 1.3, 1.4 and 1.6). The hCa_v1.2-overexpressing
831 CHO cells were maintained at a holding potential of -50 mV, and currents were elicited at a
832 frequency of 0.05 Hz by 200-ms test-pulses to +0 mV. The hK_v11.1-overexpressing CHO cells
833 were maintained at a holding potential of -80 mV, and tail currents were elicited at a frequency of
834 0.07 Hz by 5-sec test-pulses to -50 mV, preceded by 4.8-sec pulses to +20 mV following 20-ms
835 pulses to -50 mV. The leakage current was not compensated for. The concentration-response
836 relationships were established by expressing the peak amplitude of the sum of ten cell currents
837 recorded after 2-7 min in the presence of a given toxin concentration relatively to that of the sum of
838 these currents recorded before toxin incubation.

839
840 **Manual patch-clamp recordings.** A few days before experiments, HEK-293 cells were transferred
841 to 12-mm glass coverslips placed in 35-mm Petri dishes. The day of their use, the culture medium
842 was changed to a standard physiological medium of the following composition (in mM): NaCl 134,
843 KCl 3, CaCl₂ 1, MgCl₂ 1, D-glucose 10, tetraethylammonium chloride 10, CdCl₂ 0.1, and N-2-

844 hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) 10 (pH 7.35, adjusted with NaOH), for a
845 minimum of 15 min at 37°C prior to recordings. The day of their use, the DRG neurons plated on
846 coverslips were transferred, for a minimum of 30 min at 37°C prior to recordings, in 35-mm Petri
847 dishes filled with a standard physiological medium similar to that used for HEK-293 cells. The
848 HEK-293 cells or DRG neurons, plated on coverslips, were then transferred in the recording bath
849 filled with the standard physiological medium.

850 Whole-cell manual patch-clamp experiments were performed by using a MultiClamp 700B
851 integrating patch-clamp amplifier and the pClamp10.6 software (Molecular Devices), as previously
852 described.⁴ The patch-clamp pipettes were filled with a medium composed of (in mM): CsCl 90,
853 CsMeSO₃ 40, NaCl 10, MgCl₂ 2, EGTA 2, Na₂ATP 4, and HEPES 10 (pH 7.32, adjusted with
854 CsOH), and had ~3-MΩ resistance in the standard physiological medium. A fast solution
855 application system allowed changing the solution (standard physiological medium supplemented or
856 not with a given toxin concentration) around the recorded cell or neuron within a few seconds. The
857 experiments were carried out at constant room temperature (22°C).

858 The cells and neurons were maintained at a holding potential of -60 mV, and currents were
859 elicited at a frequency of 0.5 Hz by 50-ms test-pulses to -20 mV preceded by 1-sec pulses to -120
860 mV. The concentration-response relationships were established by expressing the peak current
861 amplitude measured in the presence of a given toxin concentration relatively to that before toxin
862 application. Current-voltage relationships were obtained by varying test-pulses from -80 to +10 mV
863 in 5-mV increments, and steady-state inactivation-voltage relationships by changing pre-pulses
864 from -120 to -20 mV in 5-mV increments.

865

866 **References**

867 ¹ Chambard JM, Tagat E, Boudeau P, Partiseti M (2014). Transforming TRP channel drug
868 discovery using medium-throughput electrophysiological assays. *J. Biomol. Screen* 19: 468-477.

869 ² Trivedi S, Dekermendjian K, Julien R, Huang J, Lund PE, Krupp J, Kronqvist R, Larsson O,
870 Bostwick R (2008). Cellular HTS assays for pharmacological characterization of Na(V)1.7
871 modulators. *Assay Drug Dev. Technol.* 6: 167-179.

872 ³ Bell DC, Dallas ML (2017). Using automated patch clamp electrophysiology platforms in pain-
873 related ion channel research: insights from industry and academia. *Br. J. Pharmacol.* doi:
874 10.1111/bph.13916.

875 ⁴ Goncalves TC, Boukaiba R, Molgo J, Amar M, Partiseti M, Servent D, *et al.* (2018). Direct
876 evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide,
877 using multiscale functional approaches. *Neuropharmacology* 133: 404-414.

878

2.1.3. Résumé des résultats obtenus

La CyrTx-1a, aussi nommée μ -théraphotoxine-Cs1a, est la première toxine isolée et purifiée à partir du venin de l'araignée *Cyriopagopus schioedtei*, une mygale connue sous le nom de "tigre terrestre malaisienne" qui appartient à la sous-famille des Ornithoctoninae. Ce peptide de 3578,68 Da fait partie de la famille NaSpTx-1, possède 33 acides aminés et se structure autour du motif architectural ICK (pour "inhibitor cystine knot"), très conservé parmi les peptides de cette famille.

D'un point de vue fonctionnel, la CyrTx-1a inhibe les sous-types hNav1.1-1.3 et 1.6-1.7 à une concentration de l'ordre de la centaine de nanomolaires et les sous-types hNav1.4 et 1.8 ainsi que les principales cibles moléculaires cardiaques hNav1.5, hCa_v1.2 et hK_v11.1 à une concentration supérieure à 10 μ M. Il est à souligner qu'à une concentration de 3,3 μ M, cette toxine n'affecte pas notablement certains autres sous-types de canaux ioniques également impliqués plus particulièrement dans le potentiel d'action cardiaque (hCa_v2.2, 3.1 et 3.2, hK_v7.1 et hKir2.1). La CyrTx-1a présente une puissance pour les canaux sodium des neurones de DRG sensibles à la tétrodotoxine (TTX-S) de souris adultes qui est 635 fois plus élevée que celle pour les canaux sodium des neurones de DRG résistants à la tétrodotoxine (TTX-R). Bien que la CyrTx-1a ne possède qu'un faible pourcentage d'identité de séquence (42%) avec la μ -théraphotoxine-Hh2a ou huwentoxine-IV (HwTx-IV), autre toxine de la famille NaSpTx-1, les deux peptides possèdent des profils similaires de sélectivité. Nous avons donc utilisé l'HwTx-IV comme contrôle positif lors des expériences *in vivo*. À des doses équivalentes aux concentrations de peptides inhibant de 50% le courant hNav1.7 (IC₅₀), les injections locales intramusculaires (i.m.) de CyrTx-1a sont 170 fois moins efficaces que celles d'HwTx-IV pour altérer, *in vivo*, les propriétés d'excitabilité du système neuromusculaire de souris anesthésiées. Les injections de peptides, à des doses relativement élevées, produisent occasionnellement le décès d'animaux et là encore, la CyrTx-1a est environ 3,5 fois moins efficace que l'HwTx-IV. Finalement, les sensibilités à la température et à une stimulation mécanique chez des souris ayant subi des injections intraplantaires de CyrTx-1a (102 nmol par kg de souris) et d'HwTx-IV (49 nmol par kg de souris) ont été évaluées en utilisant, respectivement, les tests de plaque chauffante (55°C) et de von Frey automatisé. Les résultats obtenus montrent que les deux peptides, de façon similaire, diminuent les sensibilités à la température et mécanique des animaux.

Des expériences complémentaires, dont les résultats ne sont pas inclus dans la publication, ont été réalisées récemment afin d'étoffer le profil de sélectivité de la CyrTx-1a en étudiant les effets de 10 μ M de ce peptide sur des lignées cellulaires recombinantes exprimant certains sous-types de canaux calcium et potassium: hCa_v, hK_v et hKir. A cette concentration, la CyrTx-1a n'affecte pas certains sous-types de canaux ioniques impliqués plus particulièrement dans le potentiel d'action

cardiaque (hCa_v 3.1 et 3.2 et hKir2.1), à l'exception du sous-type hK_v4.3 qui est inhibé de 95,5 ± 0,7% [IC₅₀ = 707 ± 136 nM; coefficient de Hill (n_H) = 1,2 ± 0,2; moyenne ± ES de 4 expériences) et des sous-types hCa_v2.2 et hK_v7.1 dont les courants sont notablement augmentés en présence du peptide (Figure 2-1).




Figure 2-1. Effets de la CyrTx-1a sur les courants hCa_v, hK_v et hKir. Pourcentage de courant restant en présence de 10 μM de peptide (moyenne ± ES, n = 4-13) en fonction du sous-type de canal indiqué. **: 0.002 < p < 0.006, ****: 0.00001 < p < 0.00003 et *****: p < 0.000001, versus contrôle.

L'effet de la CyrTx-1a sur le sous-type hCa_v2.2 exprimé dans les cellules CHO (pour "Chinese hamster ovary") est original puisqu'une augmentation progressive de 19,3 ± 6,2% à 57,1 ± 20,0% du courant se produit en présence de 0,12 μM et 10 μM de peptide, respectivement (moyenne ± ES de 5 à 6 expériences; Figure 2-2A, B et C). Il est à souligner que hCa_v2.2 est un sous-type neuronal de Ca_v impliqué dans la douleur et qui est la cible principale du Prial[®] (ω-conotoxine-MVIIA provenant du venin du cône *Conus magus*) qui a obtenu l'autorisation de mise sur le marché (AMM) en 2004 pour traiter les douleurs chroniques récalcitrantes par voie intrathécale (Molinski et al., 2009). L'augmentation du courant hCa_v2.2 produite par 10 μM de CyrTx-1a est réversible en environ 10 min (Figure 2-2B et C) et est spécifique puisqu'en présence de 10 μM de peptide et de 100 μM de chlorure de cadmium, le courant ne représente plus que 12,4 ± 8,2% du courant contrôle (moyenne ± ES de 5 expériences). En présence de 10 μM de CyrTx-1a, aucune modification notable des cinétiques et des dépendances vis-à-vis du potentiel de membrane de l'activation et de l'inactivation du courant hCa_v2.2 n'a été observée (Figure 2-2C et D). Il est donc fortement probable que l'augmentation du courant hCa_v2.2 produite par le peptide résulte d'un accroissement du nombre de sous-types exprimés à la membrane et/ou de leur conductance unitaire.




Figure 2-2. Effets de la CyrTx-1a sur le courant hCa_v2.2. (A) Pourcentage de courant restant (moyenne \pm ES, $n = 5-6$) en fonction de la concentration de peptide. **: $0.001 < p < 0.004$ et ***: $0.0006 < p < 0.0007$, *versus* contrôle. (B) Cinétiques de l'effet de $10 \mu\text{M}$ de CyrTx-1a et du lavage du peptide sur le pic de courant. (C) Traces représentatives du courant avant (en noir) et après soit $10 \mu\text{M}$ de CyrTx-1a (en bleu) soit le lavage du peptide (en gris). La trace bleue en pointillés représente le courant enregistré en présence du peptide et normalisé par rapport au pic de courant contrôle. (D) Courbes d'inactivation stationnaire (cercles) et de conductance (carrés) en fonction du potentiel de membrane, avant (symboles noirs) et après (symboles bleus) exposition des cellules CHO à $10 \mu\text{M}$ de CyrTx-1a. Chaque valeur représente la moyenne \pm ES des données de 3 cellules, exprimée en pourcentage de l'amplitude maximale du courant à des valeurs fortement négatives de pré-potentiel ou de la conductance maximale calculée à des valeurs fortement positives de potentiel-test. Les courbes théoriques correspondent aux ajustements des points de données avec les valeurs moyennes $V_{p50\%} = -49,4 \pm 0,7 \text{ mV}$, $k_h = -7,6 \pm 0,6 \text{ mV}^{-1}$, $V_{T50\%} = 8,8 \pm 2,0 \text{ mV}$ et $k_g = 4,7 \pm 0,3 \text{ mV}^{-1}$ (contrôle) et $V_{p50\%} = -47,1 \pm 0,2 \text{ mV}$, $k_h = -7,4 \pm 0,5 \text{ mV}^{-1}$, $V_{T50\%} = 7,6 \pm 0,4 \text{ mV}$ et $k_g = 4,0 \pm 0,3 \text{ mV}^{-1}$ (CyrTx-1a).

L'effet de la CyrTx-1a sur le sous-type hK_v7.1 exprimé dans les cellules U2OS (pour "human bone osteosarcoma epithelium") consiste également en une augmentation progressive de 6,4 ± 7,8% à 37,4 ± 18,8% du courant en présence de 0,12 µM et 10 µM de peptide, respectivement (moyenne ± ES de 3 à 13 expériences; Figure 2-3A, B et C).




Figure 2-3. Effets de la CyrTx-1a sur le courant hK_v7.1. (A) Pourcentage de courant restant (moyenne ± ES, n = 3-13) en fonction de la concentration de peptide. ****: p = 0.00001 *versus* contrôle. (B) Cinétiques de l'effet de 10 µM de CyrTx-1a et du lavage du peptide sur le courant. (C) Traces représentatives du courant avant (en noir) et après soit 10 µM de CyrTx-1a (en bleu) soit le lavage du peptide (en gris). (D) Courbes "courant-potentiel" avant (cercles noirs) et après (cercles bleus) exposition des cellules U2OS à 10 µM de CyrTx-1a. Chaque valeur représente la moyenne ± ES des données obtenues à partir de 6 cellules. Les courbes ont été tracées manuellement.

L'augmentation du courant $hK_v7.1$ produite par $10 \mu\text{M}$ de CyrTx-1a est réversible en environ 3 min (Figure 2-3B et C) et est spécifique puisqu'en présence de $10 \mu\text{M}$ de peptide et de $10 \mu\text{M}$ d'HMR 1556, le courant ne représente plus que $11,3 \pm 7,5\%$ du courant contrôle (moyenne \pm ES de 4 expériences). En présence de $10 \mu\text{M}$ de CyrTx-1a, aucune modification notable de la cinétique et de la dépendance vis-à-vis du potentiel de membrane de l'activation du courant $hK_v7.1$ n'a été observée (Figure 2-3C et D). Il est donc fortement probable que, là encore, l'augmentation du courant $hK_v7.1$ produite par le peptide résulte d'un accroissement du nombre de sous-types exprimés à la membrane et/ou de leur conductance unitaire.

Des expériences de "patch-clamp" en configuration "cellule attachée", qui permettent d'enregistrer le courant unitaire ne traversant que quelques sous-types de canaux, seraient nécessaires pour pouvoir conclure définitivement sur l'origine de l'augmentation des courants $hCa_v2.2$ et $hK_v7.1$ produite par la CyrTx-1a.

2.1.4. Conclusion

Les résultats présentés dans cette sous-partie mettent en évidence la purification, la synthèse, la détermination de la structure et la caractérisation fonctionnelle de la première toxine qui, à notre connaissance, ait été extraite du venin de l'araignée *Cyriopagopus schioedtei*. Cette toxine possède des propriétés antinociceptives indéniables et représente une molécule intéressante pour servir de base au développement d'analogues peptidiques synthétiques ayant une puissance accrue pour le sous-type $hNa_v1.7$ et ainsi une fenêtre thérapeutique plus importante. En particulier, le profil de sélectivité de la CyrTx-1a vis-à-vis des sous-types Na_v TTX-S, $Ca_v2.2$ et $K_v4.3$ pourrait être amélioré par des études de mutagenèse du peptide.

2.2. Relations "structure-activité" d'une toxine d'araignée *Phlogiellus* ciblant le sous-type Na_v1.7 de canaux sodium

2.2.1. Contexte de l'étude

La phlotoxine-1 (PhlTx-1), aussi nommée μ -théraphotoxine-Pspp1, est une toxine isolée et purifiée à partir du venin d'une araignée du genre *Phlogiellus* vivant en Papouasie-Nouvelle-Guinée. Comme la CyrTx-1a, ce peptide de 4055,77 Da et constitué de 34 acides aminés fait partie de la famille NaSpTx-1 et se structure autour du motif architectural ICK (Bosmans et al., 2005; Escoubas et al., 2006; www.uniprot.org/uniprot/PODM14). Il présente un fort pourcentage d'identité de séquence (76% d'après la recherche Blast sur le compte NCBI des protéines) avec le peptide insecticide actif par voie orale OAIP-2 (pour "orally active insecticidal peptide") issue de la mygale *Selenotypus Plumipes* (Hardy et al., 2013; Wong et al., 2013).

L'étude de cette toxine a été entreprise en 2000 par Escoubas et collaborateurs à l'Institut Suntory pour la Recherche Bioorganique, au Japon. Les résultats obtenus ont été présentés pour la première fois en 2005, lors des Rencontres en Toxinologie organisées par la SFET (Société Française pour l'Etude des Toxines) à Paris, puis en 2006 lors du congrès international de l'IST (pour "International Society on Toxinology") à Glasgow en Ecosse (voir page suivante). En particulier, les effets de la PhlTx-1 avaient été étudiés sur différents sous-types de canaux Na_v exprimés avec la sous-unité β 1 dans les ovocytes de xénope. A une concentration de 1 μ M, la toxine inhibe de plus de 90% le courant Na_v1.7 (IC₅₀ = 260 nM), de 35-39% les courants Na_v1.4 et 1.6 et de moins de 10% les courants Na_v1.1, 1.2, 1.3, 1.5 et Na_v1.8, ainsi que le courant Para/TipE de la drosophile. Les premiers essais évaluant la douleur neuropathique et les deux phases (aigüe et inflammatoire) de la douleur mettent en évidence des effets anti-allodynies et analgésiques de la PhlTx-1 qui sont toutefois moins importants que ceux de la morphine. Ces résultats ont été confirmés par la suite par l'équipe de John Wood (Collège de Londres, Angleterre) qui, de plus, a montré l'action synergique entre le peptide et des opioïdes pour obtenir une analgésie pendant la phase inflammatoire dite "II" de la douleur (Brevet WO 2015036734 A1, 2015; Emery et al., 2016; Deuis et al., 2017).

Dans le but de compléter l'étude de PhlTx-1, nous avons entrepris des expériences de "structure-activité" visant à évaluer les profils de sélectivité de la toxine et de certains de ses analogues peptidiques synthétiques sur un large éventail de sous-types de canaux ioniques.



Isolation and characterization of Phlotoxin 1 (PhITx1), a novel peptide active on voltage-gated sodium channels

F. BOSMANS¹, P. ESCOUBAS², S. DIOCHOT², D. MEBS³, D. CRAIK⁵, J. HILL⁵, T. NAKAJIMA⁴, M. LAZDUNSKI², J. TYTGAT¹

(1) Laboratory of Toxicology, University of Leuven, E. Van Evenstraat 4, 3000 Leuven, Belgium; (2) Institut de Pharmacologie Moléculaire et Cellulaire, 660 Route des Lucioles, Valbonne, France; (3) Zentrum der Rechtsmedizin, University of Frankfurt, Kennedyallee 104, Frankfurt, Germany; (4) Suntory Institute for Bioorganic Research, Mishima-Gun, Shimamoto-Cho, , Osaka, Japan; (5) University of Queensland, Centre for Drug Research and Development, Brisbane, Australia

Phlotoxin 1 (PhITx1), a novel toxin from tarantula venom (*Phlogiellus* sp., Theraphosidae Selenocosmiinae endemic to Papua New Guinea) was isolated as the major toxic component of this venom. Its sequence was determined and confirmed by chemical synthesis:

ACLGQWDSCDPKASKCCPNYACEWKYPWCYKLF

MALDI-TOF analysis of PhITx1 revealed a molecular mass of 4058.83 and indicated that the C-terminus of this peptide has a carboxylic form. PhITx1 is homologous to the other tarantula venom toxins TITx1 (73 %, a Kv4.2 inhibitor) and HnTxIII (65%, a voltage-gated sodium channel inhibitor). Mouse intracerebroventricular injections of the crude venom showed unusual toxicity symptoms: the mice died rapidly, from gradual cardiac and respiratory failure, without the symptoms of neurotoxicity (excitotoxicity, convulsion, paralysis) usually associated with spider venoms. In order to determine its molecular target, PhITx1 was tested on an array of ion channels expressed in either *X. laevis* oocytes or COS cells. The principal effects were seen on voltage-gated sodium channels (Nav1.1/β1 – Nav1.8/β1, para/tipE). The activation of both Nav1.2/β1 and Nav1.3/β1 was shifted towards more hyperpolarized voltages and Nav1.7/β1 was almost completely blocked (90%) at a concentration of 1.2 μM (IC₅₀ = 260 ± 46 nM).



15th World Congress
on Animal, Plant and
Microbial Toxins



Poster 45: Phlotoxin 1, a toxin from tarantula venom, is a potent modulator of Nav1.7 sodium channels and a potential analgesic

Escoubas P.^{1*}, Bosmans F.², Cuyppers E.², Diochot S.¹, Mebs D.³, Craik D.⁴, Hill J.⁴, Maertens C.², Nakajima T.⁵, Lazdunski M.¹, Tytgat J.²

¹ Institut de Pharmacologie Moléculaire et Cellulaire – CNRS, Valbonne, France, *escoubas@ipmc.cnrs.fr; ² Laboratory of Toxicology, University of Leuven, Leuven, Belgium; ³ Zentrum der Rechtsmedizin, University of Frankfurt, Frankfurt, Germany; ⁴ Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia; ⁵ Suntory Institute for Bioorganic Research, Mishima-Gun, Shimamoto-Cho, Osaka, Japan

Voltage-gated sodium (Nav) channels play an essential role in the biophysical properties of nociceptive neurons. Several Nav subtypes are key components of nociceptive neurotransmission and are potential targets for the development of novel analgesic strategies. Importantly, the Nav1.7 channel is found in peripheral primary sensory, and sympathetic, neurons and is involved in acute and inflammatory pain. We report here the discovery, structural characterization and pharmacological properties of phlotoxin 1 (PhITx1), a novel 34-residue peptide toxin from the venom of a tarantula of the genus *Phlogiellus*, which selectively inhibits Nav1.7. PhITx1 was isolated as the major component of the venom and its sequence was determined and confirmed by solid-phase peptide synthesis. Homology modelling revealed that it belongs to the inhibitory cystine knot (ICK) family of spider toxins and mass spectrometry indicates three disulfide bridges. PhITx1 shows limited homology with other Nav toxins from Chinese tarantulas (Hainantoxins, Huwentoxins). PhITx1 almost completely blocked (~90%) Nav1.7 channel currents at a concentration of 1.2 μM and the dose-response relationship on heterologously expressed channels revealed an IC₅₀ value of 260 nM. The voltage-dependence of steady-state Nav1.7 channel activation and inactivation were not affected, suggesting that PhITx1 does not act as a gating-modifier toxin but rather blocks or impedes ion flux through the channel pore. PhITx1 was almost exclusively selective for the Nav1.7 channel subtype, failing to modulate other Nav channels at concentrations up to 2 μM. In a model of inflammatory pain (mouse paw injection of formalin), intrathecal injection of PhITx1 resulted in a significantly reduced response to the pain stimulus in both the acute and inflammatory phases, strongly suggesting that PhITx1 produces an analgesic effect through inhibition of the Nav1.7 channel in dorsal root ganglion neurones. Phlotoxin 1 may therefore represent a lead for the development of novel analgesic agents.

2.2.2. Publication n°3

Publication en préparation

“Structure-activity relationships of phlotoxin-1, a Nav1.7-targetting toxin from a *Phlogiellus* spider”

Tania C. Gonçalves, Pierre Lesport, Sarah Kuylle, Justyna Ciolek, Gilles Mourier, Denis Servent, Emmanuel Bourinet, Evelyne Benoit & Nicolas Gilles

199 **Structure-activity relationships of phlotoxin-1, a Na_v1.7-targetting toxin from a**
200 ***Phlogiellus* genus spider with antinociceptive properties**

201

202 Tânia C. Gonçalves^{1,2}, Pierre Lesport³, Sarah Kuyllé¹, Justyna Ciolek¹, Gilles Mourier¹, Denis
203 Servent¹, Emmanuel Bourinet³, Evelyne Benoit^{1,4,*}, Nicolas Gilles¹

204 ¹Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, F-91191
205 Gif sur Yvette, France; ²Sanofi R&D, Integrated Drug Discovery – High Content Biology, F-94440
206 Vitry-sur-Seine, France; ³Institut de Génomique Fonctionnelle (IGF), CNRS-UMR 5203, Inserm-
207 U661, Université de Montpellier UM1-UM2, F-34094 Montpellier, France; ⁴Institut des
208 Neurosciences Paris-Saclay (Neuro-PSI), UMR CNRS/Université Paris-Sud 9197, Université Paris-
209 Saclay, F-91198 Gif sur Yvette, France

210 *Corresponding author: evelyne.benoit@cea.fr

211

212 **ABBREVIATIONS** – Ala, alanine; Arg, arginine; Asn, asparagine; Asp, aspartic acid; BLAST, basic
213 local alignment search tool; BSA, bovine serum albumin; Ca_v channel, voltage-gated calcium
214 channel; CD, circular dichroism; CHO, Chinese hamster ovary; Cm, ceratotoxin; Cys, cysteine;
215 Delta-C-ter mutant, C-terminal-deleted mutant; DMEM, Dulbecco's modified Eagle's medium;
216 DMSO, dimethylsulfoxide; ERG, *ether-a-go-go*-related gene; Gln, glutamine; Glu, glutamic acid;
217 GPCR, G-protein-coupled receptor; GSH, reduced glutathione; GSSG, oxidized glutathione; h,
218 human; HEK, human embryonic kidney; HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
219 acid; His, histidine; HnTx, hainantoxin; HOAT, 1-hydroxy-7-azabenzotriazole; HwTx, huwentoxin;
220 IC₅₀, molecule concentration necessary to inhibit 50% of the response; ICK, inhibitor cystine knot;
221 K_v channel, voltage-gated potassium channel; MEM, minimum essential medium; MS, mass
222 spectrometry; NaSpTx, Na_v channel spider toxin; Na_v channel, voltage-gated sodium channel; n_H,
223 Hill number; OD1, toxin 1 from the *Odonthobuthus doriae* scorpion; PBS, phosphate buffered
224 saline; PDB, protein data bank; PhITx-1, phlotoxin-1; RP-HPLC, analytical reversed-phase high
225 pressure liquid chromatography; SAR, structure-activity relationship; Ser, serine; Thr, threonine;
226 Trp, tryptophan; TTX-R, resistant to tetrodotoxin; TTX-S, sensitive to tetrodotoxin; Tyr, tyrosine.

227

228 **ABSTRACT**

229 Over the two last decades, venom toxins have been explored as alternatives to opioids widely
230 overconsumed in developed countries to treat chronic debilitating pain. Actually, approximately
231 20 potential analgesic toxins, mainly from spider venoms, are known to inhibit with high affinity
232 the Na_v1.7 subtype of voltage-gated sodium (Na_v) channels, the most promising genetically
233 validated antinociceptive target identified so far. The present study aimed to consolidate the
234 clinical development of phlotoxin-1 (PhITx-1), a 34-amino acid and 3-disulfide bridge peptide of a
235 *Phlogiellus* genus spider, as an antinociceptive agent by improving its affinity and selectivity for
236 the Na_v1.7 subtype. As a first step, PhITx-1 was synthesized, as well as some of its mutants using

237 an alanine scanning mutagenesis approach. The synthetic peptide and each of its 8 successfully
238 synthesized mutants equilibrated between two active forms whose relative amounts were
239 dependent on the temperature. As a second step, the effects of PhlTx-1 wild-type and mutant
240 forms were studied on cell lines stably overexpressing human (h) Na_v subtypes, as well as two
241 cardiac targets, the hCa_v1.2 and hK_v11.1 subtypes of voltage-gated calcium (Ca_v) and potassium
242 (K_v) channels, respectively, using automated whole-cell patch-clamp electrophysiology. PhlTx-1
243 and D7A-PhlTx-1 were shown to inhibit hNa_v1.1-1.3 and 1.5-1.7 at hundred nanomolar
244 concentrations, while their affinities for hNa_v1.4 and 1.8, hCa_v1.2 and hK_v11.1 were over
245 micromolar concentrations. Despite similar selectivity profiles, the affinity of the peptide mutant
246 form was at least 4 times higher than that of the wild-type form for the Na_v1.7 subtype. Finally,
247 the wild-type form of PhlTx-1 exhibited potent analgesic effects in a mouse model of inflammatory
248 pain, those of D7A-PhlTx-1 being still under investigation. In conclusion, the present SAR study of
249 PhlTx-1 results in an improved affinity of the molecule for the Na_v1.7 subtype but without any
250 marked change in the molecule selectivity against the other studied ion channel subtypes. Further
251 experiments are therefore necessary before considering the clinical development of PhlTx-1.

252 **Keywords** – *Phlogiellus* spider, phlotoxin-1, human voltage-gated ion channel subtypes, Na_v1.7
253 channel subtype, cell lines overexpressing ion channel subtypes, human induced pluripotent stem
254 cell-derived cardiomyocytes, mouse model of Na_v1.7-mediated pain.

255

256 1. INTRODUCTION

257 More than 10% of the worldwide population is complaining about pain (Goldberg and McGee,
258 2011). The first anatomic supports of pain transmission from the periphery to the central nervous
259 system are the dorsal root ganglia (DRG) neurons. These neurons express a multitude of
260 transmembrane proteins, such as G-protein-coupled receptors (GPCRs) and ion channels, which
261 can be considered as targets for therapeutic treatment of pain. Hence, some molecules interacting
262 with GPCRs or ion channels have been reported to be involved in pain relief (Pan et al., 2008;
263 Bennett and Woods, 2014; Waxman and Zamponi, 2014; Spray et al., 2017; Yekkirala et al., 2017).
264 However, in developed countries, and mainly in the United States, an overconsumption of opioids
265 is observed due to unjustified medical prescriptions, as well as the tolerance acquisition and non-
266 evitable dependence of patients to these GPCR-targeting painkillers. Finding pharmacological,
267 surgical and/or behavioral alternatives has thus become an emergency (Savage et al., 2008;
268 Negus et al., 2018).

269 In this context, venom toxins have been explored over the two last decades as an original
270 source of innovative antinociceptive drugs targetting different ion channel subtypes. Only one of
271 these toxins, the ω -conotoxin-MVIIA isolated from a cone snail and which inhibits the N-type,
272 Ca_v2.2 subtype of voltage-gated calcium (Ca_v) channels, was commercialized as Prialt® after the
273 FDA approval in 2004. However, the narrow spectrum of use of this molecule and its intrathecal
274 route of administration, associated to side-effects, represent major drawbacks for the treatment
275 of chronic debilitating pain (Molinski et al., 2009). Among voltage-gated sodium (Na_v) channels,

276 the Na_v1.7 subtype was widely reported to be the most incriminated in channelopathies related to
277 pain, although mutations in the genes encoding some of the eight other Na_v subtypes, identified
278 so far, result in painful or painless diseases with strong phenotypes (de Lera Ruiz and Kraus, 2015;
279 Vetter et al., 2017; Gonçalves et al., 2018b). Hence, numerous high-throughput screenings of
280 venom banks from various animals (spiders, scorpions, snakes, lizards, cone snails ...) have been
281 performed on the Na_v1.7 subtype, leading to the discovery of potential analgesic candidates
282 mainly from spider venoms. Actually, approximately 20 spider toxins, comprising between 26
283 and 35 amino acids and sharing the same inhibitor cystine knot (ICK) architectural motif, are
284 known to inhibit with high affinity the Na_v1.7 subtype (reviewed by Gonçalves et al., 2018b).
285 However, the lack of target selectivity of most of these peptides greatly impairs the
286 neuromuscular and/or cardiac safety issues and thus compromises their clinical development as
287 potential antinociceptive agents (Liu et al., 2014; Deuis et al., 2016; Flinspach et al., 2017;
288 Rahnama et al., 2017; Gonçalves et al., 2018c).

289 More than 10 years ago, a toxin, identified as μ -theraphotoxin-Pspp1 and also named
290 phlotoxin-1 (PhITx-1), was purified from the venom of a *Phlogiellus* genus spider endemic to Papua
291 New Guinea. PhITx-1 (4058.83 Da), characterized by a 34 amino acid sequence with three disulfide
292 bridges and structured around the ICK architectural motif, was shown to belong to the Na_v
293 channel spider toxin (NaSpTx) family 1. This peptide was reported to inhibit the Na_v1.7 subtype
294 expressed in *Xenopus* oocytes with high affinity and selectivity against the other studied Na_v
295 subtypes and to produce, although with lower efficiency than morphine, analgesic effects in a
296 mouse model of inflammatory pain (www.uniprot.org/uniprot/P0DM14; Bosmans et al., 2005,
297 Escoubas et al., 2006). More recently, a synergistic action between PhITx-1 and opioids (at low,
298 non-therapeutic doses) was revealed to induce analgesia during the phase II of inflammatory pain
299 (Patent # WO 2015036734 A1, 2015; Emery et al., 2016; Deuis et al., 2017).

300 The aim of the present study was to consolidate the clinical development of PhITx-1 as an
301 antinociceptive agent by studying the peptide interactions with a large panel of ion channels, to
302 ensure its neuromuscular and cardiac safety properties, and by evaluating the structure-activity
303 relationships (SARs) of the molecule to improve its affinity and selectivity for the target of interest
304 (*i.e.* the Na_v1.7 subtype). The effects of synthetic PhITx-1 and some of its mutants, obtained by the
305 alanine (Ala) scanning mutagenesis approach, were thus investigated on cell lines stably
306 overexpressing human (h) Na_v subtypes, as well as two cardiac targets, hCa_v1.2 and the hK_v11.1
307 subtype of voltage-gated potassium (K_v) channels encoded by the human *ether-a-go-go*-related
308 gene (hERG), using automated whole-cell patch-clamp electrophysiology. Some preliminary
309 experiments were also carried-out to evaluate the analgesic properties of the peptide and of its
310 most promising mutant.

311

312 2. EXPERIMENTAL SECTION

313 2.1. Chemical synthesis and *in vitro* folding of PhITx-1 and its mutants

314 The assembly of different peptides was carried out using the stepwise solid-phase method

315 with dicyclohexylcarbodiimide/1-hydroxy-7-azabenzotriazole (HOAT) as coupling reagents and N-
316 methylpyrrolidone as solvent. Fmoc-protected amino acids were used with the following side
317 chain protections: tert-butyl ester (Glu, Asp), tert-butyl ether (Ser, Thr, Tyr), trityl group (Cys, His,
318 Asn, Gln), 2,2,5,7,8-pentamethyl-chromane-6-sulfonyl group (Arg), and tert-butyloxycarbonyl
319 group (Trp). The peptides were assembled on a Fmoc-Phe(OtBu)-Wang resin (0.5 mmol/g loading),
320 with the exception of the C-terminal-deleted (Delta-C-ter) mutant which was assembled on a
321 Fmoc-Cys(Boc)-Wang resin (0.55 mmol/g loading). Automated chain assembly was performed on a
322 standard Applied Biosystems 433 peptide synthesizer (Applied Biosystems, Foster City, CA, USA).
323 The different syntheses were run on a modified version of the Applied Biosystems standard 0.1-
324 mmol small-scale program using 0.05 mmol of each resin. The linear peptide forms were purified
325 from the crude synthetic products by analytical reversed-phase high pressure liquid
326 chromatography (RP-HPLC). The maturation of peptides was performed in 100 mM tris-HCl buffer
327 (pH 8) added with 2 mM of reduced (GSH) and oxidized glutathione (GSSG), during 48 hr at 4°C.
328 Mass spectrometry (MS) analysis was performed on a 4800 MALDI TOF/TOF™ Analyzer (Applied
329 Biosystems). Temperature dependent circular dichroism (CD) spectra were obtained using a Jasco
330 J-815 spectropolarimeter equipped with a Peltier cell holder Jasco CDF-426S.

331 Protected amino acid derivatives, resins and dicyclohexylcarbodiimide were from
332 Novabiochem (Meudon, France), HOAT from Applied Biosystems (Courtaboeuf, France), N-
333 methylpyrrolidone from Carlo Erba Reactifs - Sds (Peypin, France), and GSH, GSSG and L-cysteine
334 from Sigma-Aldrich (Saint-Quentin-Fallavier, France).

335 **2.2. Predicted 3D-structure of PhlTx-1**

336 Computational modelling was performed, using the PyMOL software, to deduce the 3D-
337 structure of PhlTx-1 from those of closely-related toxins archived in the protein data bank (PDB):
338 ceratotoxin-1 (Cm1a, PDB: 6BRO), ceratotoxin-2 (Cm1b, PDB: 6BTv), F8A mutant of Pre-1a (PDB:
339 5I1X), peptide Hs1a (PDB: 2MT7), hainantoxin-III (HnTx-III, PDB: 2JTB) and huwentoxin-I (HwTx-I,
340 PDB: 1QK6).

341 **2.3. Toxins, chemicals and cell lines used for functional assays**

342 Lyophilized synthetic PhlTx-1 wild-type and mutant forms (purity rate > 97%) were dissolved
343 in appropriate solutions to give adequate stock solutions. All compounds used as reference
344 molecules to pharmacologically validate the current flowing through each channel subtype, as
345 indicated in Table 1, were purchased from Sigma-Aldrich and Smartox Biotechnology (Saint-
346 Egrève, France). The toxins were dissolved in distilled water to give a 100-µM stock solution, and
347 the chemicals were dissolved in 100% dimethylsulfoxide (DMSO, Sigma-Aldrich) to give a 10-mM
348 stock solution. Just prior to experiments, successive dilutions were performed in the appropriate
349 standard physiological medium [supplemented with 0.1% bovine serum albumin (BSA, Sigma-
350 Aldrich) for toxins to avoid plastic adherence, and with 0.3% DMSO for chemicals to maintain
351 solubility], to give the compound final concentrations indicated in the text.

352 Generation of inducible cell lines was achieved by cloning cDNAs encoding for hNav1.2
353 (NM_021007.2) and hNav1.5 (NM_000335) subtypes into the Flp-In® T-Rex® expression vector

354 (Invitrogen, USA) and subsequently transfected them into human embryonic kidney (HEK)-293 cell
 355 lines. These cell lines were cultured under standard conditions (37°C, 5% CO₂) in Dulbecco's
 356 modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum
 357 (Invitrogen), 50 µg/mL hygromycin (Invitrogen) and 15 µg/mL blasticidin (Invivogen). They were
 358 sub-cultured every 3-4 days using accutase® (Sigma-Aldrich) or TrypLE Select (Gibco, Thermo
 359 Fisher Scientific, France) enzyme. Doxycycline (BD Biosciences, France) was added to induce target
 360 expression, at least between 12 and 24 hr prior to experiments.

Table 1. Compounds used as reference molecules to pharmacologically validate the current flowing through each hNa_v, hCa_v and hK_v channel subtype.

Channel subtype	Drug reference			Provider	IC ₉₀₋₉₅ ²
	Name	MM	Purity rate		
hNa _v 1.1-1.8	Tetrodotoxin (citrate)	319.27	> 98%	Sigma-Aldrich	1 µM
	Nifedipine	346.33	> 98%		
hCa _v 1.2	Cadmium (Cl) ¹	183.32	> 99.99%	Sigma-Aldrich	200 µM
	BeKm-1	4091.70	> 97%		
hK _v 11.1	BeKm-1	4091.70	> 97%	Smartox Biotechnology	1 µM

¹Cl: chloride, ²IC₉₀₋₉₅, compound concentration necessary to inhibit 90-95% of current.

361 Recombinant HEK-293 cell lines, stably overexpressing the other hNa_v subtypes, were
 362 purchased from SB Drug Discovery (UK; hNa_v1.3 and 1.4), ChanTest (Cleveland, OH, USA; hNa_v1.6)
 363 and Eurofins (St Charles, MO, USA; hNa_v1.1, 1.7 and 1.8/β1). These cell lines were cultured in
 364 Eagle's minimum essential medium (MEM, Sigma-Aldrich; hNa_v1.3 and 1.4), in DMEM/F-12
 365 nutrient mixture with GlutaMAXTM (Gibco; hNa_v1.1, 1.6 and 1.8/β1) or in suspension in
 366 FreestyleTM293 (Gibco, hNa_v1.7). The Chinese hamster ovary (CHO) cells heterologously
 367 overexpressing hCa_v1.2/β2/α2δ1 (purchased from ChanTest) were cultured in Ham's F12 nutrient
 368 mix with GlutaMAXTM medium (Gibco), and those overexpressing hK_v11.1 (purchased from B'SYS
 369 GmbH, Switzerland) in DMEM/F-12 nutrient mixture Ham's medium (Sigma-Aldrich). All culture
 370 media contained 10% fetal bovine serum (Gibco) and selected antibiotics and additives, as
 371 recommended by the manufacturers. The cells were grown in flasks (37°C, 5% CO₂), and sub-
 372 cultured every 3-4 days using TrypLE Select enzyme.

373 **2.4. Automated whole-cell patch-clamp electrophysiology**

374 The effects of synthetic PhITx-1 and some of its mutants were investigated on the cell lines
 375 overexpressing hNa_v1.1-1.8, hCa_v1.2 and hK_v11.1 subtypes, using an automated patch-clamp
 376 system, the QPatch HTX (Sophion Bioscience, Denmark), allowing current recordings in whole-cell
 377 configuration and both signal acquisition and data analyses, as previously reported (Gonçalves et
 378 al., 2018a). The day of their use, HEK-293 and CHO cells were transferred into Eppendorf tubes
 379 containing a FreeStyle 293 expression medium (Gibco) which were then placed in the automated
 380 electrophysiology platform. The extracellular medium composition for hNa_v-overexpressing HEK-
 381 293 cells was (in mM): NaCl 154, KCl 4, CaCl₂ 2, MgCl₂ 1, and HEPES 10 (pH 7.4 adjusted with
 382 NaOH), and that of intracellular (*i.e.* patch-clamp pipette) medium: CsF 150, EGTA/CsOH 1/50,
 383 HEPES 10, NaCl 10, MgCl₂ 1, and CaCl₂ 1 (pH 7.4 adjusted with CsOH). The extracellular medium

384 composition for hCa_v1.2-overexpressing CHO cells was (in mM): NaCl 145, KCl 4, CaCl₂ 10, and
385 HEPES 10 (pH 7.4 adjusted with NaOH), and that of intracellular medium: CsF 27, CsCl 112, EGTA
386 8.2, HEPES 10, NaCl 2, and Mg-ATP 4 (pH 7.4 adjusted with CsOH). The extracellular medium
387 composition for hK_v11.1-overexpressing CHO cells was (in mM): NaCl 145, KCl 4, CaCl₂ 2, MgCl₂ 1,
388 HEPES 10, and D-glucose 10 (pH 7.4 adjusted with NaOH), and that of intracellular medium: KCl
389 120, CaCl₂ 5.4, EGTA 10, HEPES 10, Mg-ATP 4, and MgCl₂ 1.75 (pH 7.4 adjusted with KOH). The
390 time of cell incubation with PhITx-1 wild-type and mutant forms, as well as reference molecules,
391 was adjusted to achieve steady-state effects, *i.e.* between approximately 2 and 7 minutes. The
392 experiments were carried out at room temperature (20-22°C).

393 In addition to the classical "closed-open" protocol, a "fully-inactivated" protocol was also used
394 to test an eventual inactivated-state-dependent effect of peptides on hNa_v subtypes. During the
395 "**closed-open**" protocol, the hNa_v-overexpressing HEK-293 cells were maintained at a holding
396 potential of either -90 mV (hNa_v1.5) or -100 mV (other hNa_v subtypes), and currents were elicited
397 at a frequency of 0.2 Hz by 20-ms test-pulses to -20 mV (hNa_v1.2 and 1.7), -40 mV (hNa_v1.5) or 10
398 mV (hNa_v1.8), preceded by 40-ms (hNa_v1.7) or 200-ms (hNa_v1.5) pulses to -120 mV, or not
399 (hNa_v1.2 and 1.8). The hCa_v1.2-overexpressing CHO cells were maintained at a holding potential of
400 -50 mV, and currents were elicited at a frequency of 0.05 Hz by 200-ms test-pulses to 0 mV. The
401 hK_v11.1-overexpressing CHO cells were maintained at a holding potential of -80 mV, and tail
402 currents were elicited at a frequency of 0.07 Hz by 5-sec test-pulses to -50 mV, preceded by 4.8-
403 sec pulses to 20 mV following 20-ms pulses to -50 mV. During the "**fully-inactivated**" protocol, the
404 hNa_v-overexpressing HEK-293 cells were maintained at a holding potential of either -40 mV
405 (hNa_v1.1, 1.2 and 1.6) or -50 mV (other hNa_v subtypes), and currents were elicited at a frequency
406 of 0.2 Hz by 20-ms test-pulses to -40 mV (hNa_v1.5) or -20 mV (other hNa_v subtypes), preceded by
407 40-ms (hNa_v1.3 and 1.4) or 20-ms (other hNa_v subtypes) pulses to -120 mV.

408 The concentration-response relationships were established by plotting the peak amplitude of
409 the sum of ten cell currents recorded in the presence of a given molecule (P_m), expressed
410 relatively to that of the sum of these currents recorded before molecule application (P_c), against
411 the molecule concentration ([m]). The theoretical concentration-response curves were calculated
412 from typical sigmoid nonlinear regressions through data points according to the Hill equation
413 (QPatch assay software): $P_m / P_c = 1 / [1 + ([m] / IC_{50})^{n_H}]$, where IC₅₀ is the molecule
414 concentration necessary to inhibit 50% of the response, and n_H is the Hill number.

415 **2.5. Mouse model of inflammatory pain**

416 The experiments were performed on 8-week adult male and female C57BL/6 mice purchased
417 from Janvier Elevage (Le Genest-Saint-Isle, France) and housed at the IGF animal facility 3-4 per
418 cage, under 12 hr light/dark cycles, with standard rodent chow and free access to food and water
419 *ad-libitum*. They were conducted in compliance with the guidelines established by the French
420 Council on animal care "Guide for the Care and Use of Laboratory Animals" (EEC86/609 Council
421 Directive – Decree 2001-131), and the experimental protocols were approved on November 27
422 2015 by the French General Directorate for Research and Innovation (project APAFIS#2671-
423 2015110915123958v4 authorized to E.B.).

424 The peptide analgesic effects were studied at room temperature on mouse model of Na_v1.7-
425 mediated pain, based on intraplantar injection of toxin 1 from the *Odonthobuthus doriae* scorpion
426 (OD1, Smartox Biotechnology) that potently enhances the activity of Na_v1.7 by inhibiting channel
427 fast inactivation and increasing peak current, as previously described (Deuis et al., 2016). The pain
428 behavior of mice was quantified by the number of spontaneous licking, flinching, shaking and
429 biting of the paw, injected with 40- μ L phosphate buffered saline (PBS) solution containing either
430 300 nM OD1 alone or OD1 and 3, 30 or 300 nM PhITx-1, during 5-min periods following the
431 injection. The experiments were video recorded and blind analysis of mouse pain behavior was
432 done, off-line, by an observer unaware of which treatment each animal has received.

433 2.6. Statistical analyses

434 Data are expressed as means \pm standard deviations (S.D.) or \pm standard error of the mean
435 (S.E.M.) of n different experiments. The statistical comparison of values was carried out (i) using
436 the parametric two-tailed Student's *t*-test (either paired samples for comparison within a single
437 population or unpaired samples for comparison between two independent populations) for *in*
438 *vitro* data, or (ii) using the one-way analysis of variance (ANOVA, for comparison between three or
439 more independent populations) for *in vivo* data. Differences between values were considered to
440 be statistically significant at $P \leq 0.05$.

441

442 3. RESULTS

443 3.1. Chemical synthesis and *in vitro* folding of PhITx-1

444 PhITx-1, a 34-amino acid toxin containing 6 cysteines (Figure 1A), was synthesized using the
445 Fmoc strategy (Figure 1Ba). The linear peptide was purified and different folding protocols were
446 tested according to the nature and pH of the buffer and to the redox couple used which are crucial
447 parameters. The Tris-HCl buffer at pH 8.5 was associated with the reduced and oxidized
448 glutathione (GSH/GSSG, 1/1) while the HEPES buffer at pH 7.5 was associated with L-cysteine/L-
449 cystine (Cys/C-C, 1/0.1). For solubilization purposes, the chosen additives were 20% acetonitrile
450 and glycerol. The reaction was left for 48 hr at 4°C to slow down the oxidation kinetics, which
451 resulted in a more stable toxin. The best folding condition was found to be the Tris-HCl buffer and
452 redox glutathione couple (Figure 1Bb). Folding of the linear peptide generated a complicated
453 profile with two main peaks, A and B, B being surrounded by two side-peaks, C and D. Mass
454 analysis of these four peaks revealed a similar mass corresponding to the full oxidation of the
455 three disulfide bridges. The pharmacological activity of 1 μ M of these four peaks was tested on
456 HEK-293 cell lines stably overexpressing the hNa_v1.7 subtype. Only the peak A was observed to
457 strongly inhibit the hNa_v1.7 current, the peak B and peaks C and D showing moderate and no
458 activity, respectively (data not shown). Therefore, the peak A was further analyzed in detail by
459 analytical RP-HPLC chromatography. The results revealed the existence of two peaks, A' and A'', of
460 similar areas and separated by retention times of almost 4 minutes (Figure 1Bc). The peaks A' and
461 A'', injected separately, generated again two peaks (data not shown). This demonstrates that the
462 product equilibrated between two structural organizations having different interaction properties

463 with the column phase.




Figure 1. Primary structure, chemical synthesis and *in vitro* folding of PhITx-1. **(A)** Primary structure of PhITx-1, a 34-amino acid and amidated (*) peptide including 3 disulfide bridges, as defined by homology with toxins from the NaSpTx family 1, *i.e.* occurring according to the C1-C4, C2-C5 and C3-C6 pattern. **(B)** Chemical synthesis of PhITx-1. Analytical RP-HPLC profiles, detected at 214 nm, of crude peptide synthesis (a), crude peptide folding using the Tris-HCl buffer, the redox glutathione couple and acetonitrile (b), and peak A (c) detected in (b). Note that the presence of two peaks in (c) limits a non-well defined peak. **(d)** Effect of temperature on the equilibrium between the two peaks A' and A'', revealed by analytical RP-HPLC analysis of peak A at the indicated temperatures.

464 The influence of temperature (between 0 and 60°C) was studied on the equilibrium between
 465 the two forms, A' and A'', of peak A (Figure 1Bd). Decreasing the temperature from 23 to 0°C
 466 produced a decrease of the area of peak A'', which finally disappeared at 0°C, while that of peak A'
 467 increased. On the opposite, increasing the temperature from 23 to 60°C was favorable to peak A''.
 468 It is worth noting that the elution times of the different forms of PhITx-1 were inversely

469 proportional to the temperature.

470 All these characterizations demonstrated that the folding of PhITx-1 generated many forms
 471 visible onto analytical RP-HPLC analysis. The pharmacological activity of these forms clearly
 472 indicated that peak A was associated to the purest and the most active peptide, whatever the
 473 analytical RP-HPLC conditions were, with a CD spectrum coherent with its ICK architectural motif
 474 (data not shown).

475 3.2. Comparison of amino acid sequences and 3D-structures of PhITx-1 with closely-related 476 toxins

477 The 3D-structure of PhITx-1, containing the ICK motif in its backbone conformation expected
 478 by the amino acid sequence, was modelled by structural homology with the closest toxins from
 479 NCBI basic local alignment search tool (BLAST) (Figure 2A and Table 2). Six of the 14 toxins
 480 extracted from NCBI BLAST had their 3D-structure defined by 2D-homonuclear ¹H-NMR
 481 spectroscopy, which helped the computational determination of PhITx-1 3D-structure (Figure
 482 2B). All the 3D-structures were similar except those of F8A-Pre-1a and Hs1a, which displayed the
 483 3D-structure of peptide precursors with a long N-terminal (Figure 2B), and those of CcoTx2 and
 484 HwTx-I pointing out three β leaflets instead of two for the other peptides.




Figure 2. 3D-Structure modelling of PhITx-1. (A) Ribbon representation indicating elements of secondary structure. The structure topology is composed of double stranded antiparallel β -sheet (arrows). The three disulfide bonds are C2-C17, C9-C22 and C16-C29 (in yellow). Hydrophobic residues are colored in green, and basic and acidic residues in blue and red, respectively. The other polar residues are colored in white. (B) Backbone peptide folding of PhITx-1 and toxins with PDB entries and showing the highest percentage of amino acid sequence identity with PhITx-1 (PDB entries of Cm1a: 6BRO, Cm1b: 6BTX, F8A-Pre-1a: 5I1X, Hs1a: 2MT7, HnTx-III: 2JTB, and HwTx-I: 1QK6).

485 All the toxins with percentage of sequence identity close to PhITx-1 (between 45 and 76%)
 486 were Na_v, K_v and/or Ca_v channel ligands (Table 2). These toxins have homologous amino acid
 487 sequences including three amino acids highly conserved (G4, P11 and W28), in addition to the four
 488 charged patches necessary for toxin-ion channel binding (Table 2; Minassian et al., 2013; Murray

489 et al., 2016; Shcherbatko et al., 2016). Some of these toxins, such as Cd1a, CcoTx1 and HnTx-III,
 490 were described to target the Na_v1.7 subtype with nanomolar affinities (IC₅₀ between 2 and 232
 491 nM, Table 2) and, thus, with potential implications in the pain therapeutic field (Liu et al., 2013;
 492 Shcherbatko et al., 2016; Sousa et al., 2017).

Table 2. Comparison of amino acid sequences between PhlTx-1 and the 14 most similar and/or well-documented toxins described in the literature. The sequence alignment was performed with ClustalW (version 12.1 from Emboss programs, EBlosum62 matrix for two pair alignment). The cysteine scaffold and conserved residues are indicated in red, and important residues for toxin interaction with ion channels are surrounded in blue. The percentage of sequence identity with PhlTx-1, the known targets and the activity (IC₅₀ in nM reported for hNa_v1.7 subtype) are described in the right columns, according to data sourced from Pubmed and ArachnoServer (Herzig et al., 2011).

Name*	Amino acid sequence	Identity	Target	Activity
PhlTx-1 (μ-TRTX-Pspp-1)	--A-- CLGQWDS CDP KASK CC PNY ACE WRY FW CRYKLF-	100%	Na _v	254
OAIP2	--D-- CLGQWAS CEP KNSK CC PNY ACT WKY FW CRYRAGK	76%	?	-
TlTx1 (κ-TRTX-Tb1a)	-AA-- CLGMFES CDP NNDK CC PNRE CN RR HK W CK YKLV--	59%	K _v	-
Osp1b (μ-TRTX-Osp1b)	--E-- CLGWMKG CEP KNNK CC SSY VCT YKY FW CRYDL--	58%	Na _v	- ¹
TlTx2 (κ-TRTX-Tb1b)	-DD-- CLGMFSS CDP KNDK CC PNRV CR SR DQ W CK YKLV--	56%	K _v	-
Cd1a (β-TRTX-Cd1a)	--D-- CLGWFKS CDP KNDK CC KNY CS RR DR W CK YDL--	55%	Na _v	16 ²
CcoTx1 (β-TRTX-Cm1a)	--D-- CLGWFKS CDP KNDK CC KNY CS RR DR W CK YDL--	55%	Na _v	2-130 ^{3,4}
CcoTx2 (β-TRTX-Cm1b)	--D-- CLGWFKS CDP KNDK CC KNY CS RR DR W CK YYL--	55%	Na _v	95 ⁴
TlTx3 (κ-TRTX-Tb1c)	-DD-- CLGMFSS CDP NNDK CC PNRV CR VR DQ W CK YKLV--	53%	K _v	-
Prela (β/δ-TRTX-Prela)	-ED-- CLGWFSR CS PKNDK CC PNY KCS SK DL W CK YKIW-	53%	Na _v	114 ⁵
Hs1a	GND-- CLGFWSA CNP KNDK CC ANLV CSS SK HK W CK GKL-	52%	Na _v	- ⁶
HnTxIII (μ-TRTX-Hhn2a)	---- GCKGF GD SCT PGKNE CC PNY ACS SR HK W CK VYLGK	50%	Na _v	232 ⁷
Ccylb (μ-TRTX-Ccylb)	-DD-- CLGFFKS CNP DNDK CC ENY KCN RR DK W CK YVL--	48%	Na _v	- ¹
Pmrla (μ-TRTX-Pmrla)	-DD-- CLGMFSS CDP DNDK CC EGR KCN RR DK W CK YVL--	48%	Na _v	- ⁸
HwTxI (μ/ω-TRTX-Hs1a)	---- ACKGV FDA CT PGKNE CC PNRV CS DR HK W CK WKL--	45%	Na _v /Ca _v	<200 ⁹

*The Greek letter(s) before the toxin name is associated to its type of action: μ for Na_v channel inhibition, β for shift in the voltage-dependence of Na_v channel activation, δ for delay inactivation of Na_v channels, ω for Ca_v channel inhibition, and κ for K_v channel inhibition. TRTX, theraphotoxin. ¹Klint et al. (2015b), ²Sousa et al. (2017), ³Shcherbatko et al. (2016), ⁴Agwa et al. (2018), ⁵Wingerd et al. (2017), ⁶Klint et al. (2015a, unpublished data), ⁷Liu et al. (2013), ⁸Meir et al. (2012, unpublished data), ⁹Wang et al. (2012).

493 3.3. Effects of PhlTx-1 on hNa_v1.1-1.8, hCa_v1.2 and K_v11.1 channel subtypes

494 Whole-cell automated patch-clamp (QPatch HTX) experiments performed on HEK-293 cells
 495 overexpressing hNa_v1.1-1.8 channel subtypes revealed, whatever the electrophysiological
 496 protocol was, that 1 μM PhlTx-1 was effective to inhibit hNa_v1.1-1.7 currents, without any marked
 497 subtype selectivity, while the hNa_v1.8 current was unaffected (Figure 3A and B). Hence, the
 498 following increasing order for IC₅₀ values was obtained from the concentration-response curves of
 499 PhlTx-1 effects on currents flowing through the different channel subtypes: hNa_v1.2 (73.7 ± 46.3
 500 nM, n = 12) ≈ hNa_v1.3 (201.5 ± 109.8 nM, n = 6) ≈ hNa_v1.7 (254.3 ± 147.6 nM, n = 5) ≈ hNa_v1.1
 501 (280.3 ± 117.7 nM, n = 11) > hNa_v1.6 (491.2 ± 109.0 nM, n = 6) >> hNa_v1.4 (> 2.1 ± 1.3 μM, n = 9)
 502 for tetrodotoxin-sensitive (TTX-S) channel subtypes, and hNa_v1.5 (710.6 ± 32.7 nM, n = 10) <
 503 hNa_v1.8 (> 10 μM, n = 4) for tetrodotoxin-resistant (TTX-R) channel subtypes. Thus, all the TTX-S
 504 hNa_v channel subtypes studied, with the exception of hNa_v1.4, were sensitive to PhlTx-1, as well
 505 as the TTX-R cardiac sodium channel subtype hNa_v1.5 (although at hundred nanomolar
 506 concentrations), while the TTX-R hNa_v1.8 subtype was resistant to the peptide (at ten micromolar
 507 concentrations). Additionally, PhlTx-1 had very low affinity for cardiac hCa_v1.2 and hK_v11.1
 508 channel subtypes overexpressed in CHO cells, since 10 μM of peptide had no effect on the hK_v11.1

509 current (n = 4) and had only low effect on the hCa_v1.2 current (IC₅₀ = 5.9 ± 2.1 μM, n = 6; Figure
510 3B).




Figure 3. Effects of PhITx-1 on HEK-293 cells overexpressing hNav_v subtypes and on CHO cells overexpressing hCa_v1.2 and hK_v11.1 subtypes. **(A)** Histogram of IC₅₀ values (in nM) obtained from the concentration-response curves of PhITx-1 effects on hNav_v1.1-1.8 currents recorded during a “fully inactivated” (FI) protocol. Each value represents the mean ± S.D. of data obtained from 4-12 cells. Mean value ± S.D. of n_H was 1.15 ± 0.42. **(B)** Histogram of IC₅₀ values (in nM) obtained from the concentration-response curves of PhITx-1 effects on hNav_v1.2, 1.5 and 1.7-1.8, hCa_v1.2 and hK_v11.1 currents recorded during a “closed-open” (CO) protocol. Each value represents the mean ± S.D. of data obtained from 2-3 cells. Mean value ± S.D. of n_H was 1.05 ± 0.15. The recording protocols are detailed in the Experimental section.

511 3.4. Structure-activity relationships of PhITx-1 using an alanine scanning mutagenesis approach

512 The SAR study was carried out on PhITx-1 by replacing each amino acid of its sequence with an
513 alanine residue which possesses a non-bulky and chemically inert methyl group, with two
514 exceptions: the first amino acid which was a pyroglutamic acid-modified alanine, and the five C-
515 terminal amino acids that were removed. This alanine scanning mutagenesis approach has thus
516 the advantage to highlight the importance of amino acids in the peptide secondary structure.

517 Linear forms of all peptide mutants were synthesized and purified, and between 5.5 and 12.3
518 mg were obtained for each peptide (Table 3). The experimental conditions of their folding were
519 similar to those used to perform the folding of PhITx-1 (see section 3.1). However, only 8 over 21
520 mutants were obtained with the adequate biophysical characteristics. As observed for PhITx-1, all
521 of them equilibrated between two forms, depending on the temperature (only one peak was
522 detected at the extreme temperatures of 0 and 60°C), and had CD spectra close to that of PhITx-1
523 (data not shown). The 13 other mutants resulted in misfolded toxins (Table 3). This may be due to
524 the fact that the substitution of amino acids produced changes in the peptide sequences that were
525 in contact with the solvent or that the substituted amino acids were buried inside the peptide
526 structure, which may affect dramatically the peptide folding properties.

Table 3. Production and biochemical and pharmacological characterizations of wild-type (WT) PhITx1 and its mutants obtained by an alanine scanning mutagenesis approach.

PhITx1	Production			Biochemical characterization			Pharmacological characterization	
	Linear (mg)	Oxidized (mg)	Folding yield	CD	Theo. mass	Exp. mass	hNav _v 1.7 IC ₅₀ (nM)	Ratio (vs WT)
WT	150	17.3	12	OK	4055.72	4055.73	254	1.00
A1Z*	9.8	1.1	11	OK	4095.71	4095.71	171	0.67
L3A	5.3	0	0					
Q5A	12.5	0	0					
W6A	11.3	0	0					
D7A	12.1	2.5	21	OK	4011.73	4011.72	47	0.18
S8A	9.9	0.55	6	OK	4039.72	4039.70	180	0.71
D10A	8.5	0	0					
P11A	7.3	0	0					
K12A	9.5	0.75	8	OK	3998.66	3998.67	253	1.00
S14A	9.4	0	0					
K15A	8.6	1.1	13	OK	3998.66	3998.66	706	2.78
P18A	11	0	0					
N19A	12.3	0	0					
Y20A	14.2	0	0					
E23A	7.8	0	0					
W24A	9	1.1	12	OK	3940.68	3940.68	> 10000	> 39.37
K25A	9.2	2	22	OK	3998.66	3998.67	> 10000	> 39.37
Y26A	11.1	2.5	23	OK	3963.69	3963.68	> 10000	> 39.37
P27A	11.5	0	0					
W28A	5.5	0	0					
Delta-C-ter**	9.7	0	0					

*Z pyroglutamic acid; **PhITx-1 without its five last C-terminal residues; Theo. Mass: theoretical mass; Exp. Mass: experimental mass.




Figure 4. Structure-activity relationships of PhITx-1 using an alanine scanning mutagenesis approach. **(A)** Effects of PhITx-1 wild-type (WT) and mutants on HEK-293 cells overexpressing the hNav_v1.7 subtype. Histogram of IC₅₀ values (in nM) obtained from the concentration-response curves of peptide effects on the current recorded during a “fully inactivated” (FI) protocol. Each value represents the mean ± S.D. of data obtained from 3-5 cells. Mean value ± S.D. of n_H was 0.99 ± 0.42. **(B)** Effects of D7A-PhITx-1 on HEK-293 cells overexpressing hNav_v1.2, 1.5 and 1.7-1.8 subtypes and on CHO cells overexpressing hCav_v1.2 and hKv_v11.1 subtypes. Histogram of IC₅₀ values (in nM) obtained from the concentration-response curves of peptide effects on the currents recorded during a “closed-open” (CO) protocol. Each value represents the mean ± S.D. of data obtained from 3 cells. Mean value ± S.D. of n_H was 1.06 ± 0.13.

527 The substitution of amino acids close to the peptide C-terminus with alanine produced a loss
 528 of affinity for the hNav_{1.7} subtype, whereas the mutations more close to the peptide N-terminus
 529 had either little effect on this affinity or even induced a gain of affinity, as observed for D7A-PhlTx-
 530 1 which had a ratio of 0.18 *versus* PhlTx-1 (Figure 4A and Table 3). Indeed, this mutant, compared
 531 to PhlTx-1, had a 4.2-fold higher affinity for the hNav_{1.7} and 1.5 subtypes [73.0 ± 23.7 nM *versus*
 532 308.9 ± 17.0 nM ($n = 3$), and 93.3 ± 32.9 nM *versus* 395.6 ± 121.6 nM ($n = 2-3$), respectively], a 5.9-
 533 fold higher affinity for the hNav_{1.2} subtype [47.3 ± 5.2 nM *versus* 279.4 ± 6.1 ($n = 3$)], and at least
 534 2.5- and 7.4-fold higher affinities for the hNav_{1.8} and hCa_v1.2 subtypes, respectively [4.0 ± 0.5 μ M
 535 *versus* > 10 μ M ($n = 3-4$), and 799.6 ± 253.3 nM *versus* 5.9 ± 2.2 μ M ($n = 3-6$), respectively], while
 536 an absence of affinity still remained for the K_v11.1 subtype (Figures 3B and 4B).

537 3.5. Effects of PhlTx-1 on OD1-induced painful behavior of mice

538 The *in vivo* analgesic effects of PhlTx-1 were studied on mouse model of Nav_{1.7}-mediated
 539 pain, based on intraplantar injection of OD1. When PBS containing only OD1 (300 nM) was
 540 injected to mice, the animal pain behavior, quantified the number of spontaneous licking,
 541 flinching, shaking and biting of the paw, reached a maximal value between 5 and 10 minutes
 542 following the injection and then disappeared progressively over 40 minutes. Under these
 543 conditions, the pain behavior occurring during the first 10 minutes following PBS and OD1
 544 injection was 117.2 ± 15.8 ($n = 6$). This pain behavior was not significantly modified by the co-
 545 injection of PBS, OD1 (300 nM) and 3 or 30 nM PhlTx-1, *i.e.* 124.5 ± 17.0 ($n = 6$) and 117.5 ± 18.3
 546 ($n = 6$), respectively (Figure 5). In contrast, the co-injection with 300 nM PhlTx-1 produced a 2-fold
 547 decrease of mouse pain behavior (*i.e.* 56.7 ± 17.2 , $n = 6$), indicating that this peptide concentration
 548 reversed, to some extent, the OD1-induced pain (Figure 5).




Figure 5. Effects of PhlTx-1 on OD1-induced painful behavior of mice. Pain behavior was quantified by the number of spontaneous licking, flinching, shaking and biting of the paw occurring during the first 10 minutes following intraplantar injection of PBS + 300 nM OD1, added or not with 3, 30 or 300 nM PhlTx-1. Mean \pm S.E.M. of 6 mice under each condition. * $P = 0.014$ *versus* PBS.

549 4. DISCUSSION

550 The present study was undertaken to better characterize PhlTx-1, previously described as a
 551 potential antinociceptive agent, in order to consolidate the clinical development of this peptide.
 552 The research strategy consisted of (1) a home-made chemical synthesis and a computational

553 modelling of 3D-structure to better understand the peptide effects already studied for closely-
554 related toxins, (2) a deep pharmacological evaluation (from individual cells to *in vivo*) of synthetic
555 PhITx-1, and (3) a SAR study carried out on PhITx-1, using an alanine scanning mutagenesis
556 approach, to improve the peptide affinity and selectivity.

557 The effects of synthetic PhITx-1 were studied on HEK-293 cells overexpressing hNav_v1.1-1.8
558 subtypes and on CHO cells overexpressing hCa_v1.2 and hK_v11.1 subtypes, using whole-cell
559 automated patch-clamp technique. This studied was undertaken (i) to reinforce, on human Nav
560 subtypes, the previous evaluation of the peptide selectivity profile performed on undetailed
561 species of Nav subtypes, and (ii) to ensure its cardiac safety properties. More than ten years ago,
562 the effects of PhITx-1 were studied on different Nav subtypes expressed with the β1 subunit in
563 *Xenopus* oocytes (Bosmans et al., 2005, Escoubas et al., 2006). At a concentration of 1 μM, the
564 peptide produced a more than 90% inhibition of Nav_v1.7 current, a 35-39% inhibition of Nav_v1.4 and
565 1.6 currents, and a less than 10% inhibition of Nav_v1.1-1.3, 1.5 and 1.8 currents, as well as of
566 *Drosophila* Para/TipE current. The comparison of these results obtained from undetailed or
567 *Drosophila* species of Nav subtypes expressed in *Xenopus* oocytes with those we got from human
568 Nav subtypes stably overexpressed in mammalian cell lines is not accurate, although similar mean
569 IC₅₀ values were determined for PhITx-1 interaction with the Nav_v1.7 subtype (*i.e.* 260 and 254-309
570 nM, respectively). Therefore, this study allows confirming both the peptide efficacy on the human
571 Nav_v1.7 subtype and some of its cardiac safety properties since the two cardiac hCa_v1.2 and
572 hK_v11.1 targets were relatively saved (*i.e.* IC₅₀ ≥ 5.9 μM).

573 Compared to toxins belonging to the NaSpTx family 1, such as HnTx-I, HnTx-III, Hd1a, HnTx-IV,
574 ProTx-III, Cm1a, GpTx-1 and HwTx-IV, previously reported in the literature to interact with the
575 hNav_v1.7 subtype, PhITx-1 is among the lowest potent peptides (Xiao et al., 2008; Liu et al., 2012;
576 Liu et al., 2013; Cardoso et al., 2015; Klint et al., 2015a; Klint et al., 2015b; Murray et al., 2015;
577 Murray et al., 2016; Shcherbatko et al., 2016). In addition, the peptide displayed a less than 10-
578 fold selectivity towards the TTX-R (with the exception of hNav_v1.8) and other TTX-S (with the
579 exception of hNav_v1.4) hNav subtypes (mean IC₅₀ values between 74 and 711 nM). It is worth
580 noting that relatively similar IC₅₀ values were obtained from the "fully-inactivated" and classical
581 "closed-open" protocols, suggesting that no inactivated-state-dependent effect of PhITx-1
582 occurred on the studied hNav subtypes. The poor peptide selectivity towards the hNav_v1.1 and 1.3
583 subtypes may be an advantage since these two subtypes have been reported to be also involved in
584 in pain pathways (see Gonçalves et al., 2018b). That towards the hNav_v1.2 subtype, located at the
585 level of the central nervous system, will have no important consequence taking into account the
586 peripheral administration of PhITx-1. Therefore, the only problem of the peptide is its poor
587 selectivity towards the hNav_v1.5 and 1.6 subtypes since its potential use as an analgesic molecule
588 may be associated with *in vivo* cardiac and neuromuscular side-effects, respectively.

589 The antinociceptive properties as well as the cardiac and neuromuscular side-effects of PhITx-
590 1 were evaluated *in vivo* on OD1-induced painful behavior of mice. The results revealed that the
591 intraplantar co-injection of OD1 and PhITx-1 (300 nM) was efficient to produce a 2-fold decrease
592 of animal pain behavior induced by the injection of only OD1. These results indicate that PhITx-1

593 exhibited antinociceptive properties since this peptide concentration reversed, to some extent,
594 the OD1-induced pain. Further experiments are needed to test whether higher PhlTx-1
595 concentrations will be able to completely reverse the OD1-induced pain. Interestingly, no sign of
596 cardiac and neuromuscular side-effects was detected during these experiments. This strongly
597 suggests that, under our experimental conditions, the poor peptide selectivity towards the
598 hNa_v1.5 and 1.6 subtypes has no consequence *in vivo*. PhlTx-1 was previously reported to
599 produce, although with lower efficiency than morphine, anti-allodynies and analgesic effects in
600 rodent models of acute and inflammatory neuropathic pain (Escoubas et al., 2006). The effects of
601 9 toxins, showing higher affinity than PhlTx-1 for the hNa_v1.7 subtype [with the following
602 increasing order for mean IC₅₀ values (between 0.9 and 130 nM): Pn3a, Df1a-NH₂, m3-HwTx-IV,
603 GpTx-1, ProTx-III, Cd1a, Df1a-OH, CcoTx2 and CcoTx1], were also tested *in vivo* on OD1-induced
604 painful behavior of mice (Cardoso et al., 2015; Murray et al., 2015; Shcherbatko et al., 2016;
605 Cardoso et al., 2017; Deuis et al., 2016, 2017; Rahmana et al., 2017; Sousa et al., 2017; Agwa et al.,
606 2018). Although Pn3a has the highest affinity for the hNa_v1.7 subtype, close doses of
607 intraperitoneal injection of this toxin and intraplantar injection of PhlTx-1 have similar effects on
608 OD1-induced painful behavior of mice. This questions the existence of a correlation between a
609 peptide hNa_v1.7 affinity and its *in vivo* effects on OD1-induced pain rodent models. The evaluation
610 of m3-HwTx-IV, GpTx-1 and ProTx-III, performed under similar experimental conditions as that of
611 PhlTx-1, revealed that these toxins produced a 10-, 5- and 2-fold decrease of animal pain behavior
612 induced by OD1, respectively. However, marked neuromuscular side-effects were reported for
613 m3-HwTx-IV and GpTx-1. The other 5 toxins were also efficient to diminish or completely reverse
614 the OD1-induced manifestations of pain but at relatively high concentrations (1 μM for Cd1a,
615 CcoTx1 and CcoTx2 and 10 μM for Df1a-NH₂ and Df1a-OH). Recently, a synergistic action between
616 PhlTx-1 or Pn3a and low, non-therapeutic doses of opioids (such as oxycodone or buprenorphine)
617 or enkephalinase inhibitors (such as thiorphan) was revealed to induce analgesia during the phase
618 II of inflammatory pain. From this point of view, PhlTx-1 was reported to be more efficient than
619 Pn3a (Patent # WO 2015036734 A1, 2015; Emery et al., 2016; Deuis et al., 2017).

620 The relatively low affinity of PhlTx-1 for the hNa_v1.7 subtype motivated a SAR study using an
621 alanine scanning mutagenesis approach. Among the 8 peptide mutant forms tested on HEK-293
622 cells overexpressing the hNa_v1.7 subtype, D7A-PhlTx-1 was the only one showing an
623 approximately 5-fold improved affinity for this subtype (mean IC₅₀ values of 47-73 nM for D7A-
624 PhlTx-1 *versus* 254-309 nM for PhlTx-1). However, a gain of affinity (between 2.5- and 7.4-fold)
625 was also observed not only for the hNa_v1.2 and 1.8 subtypes, but also for the hNa_v1.5 and hCa_v1.2
626 subtypes.

627

628 5. CONCLUSION

629 The results obtained from the exhaustive characterization of physicochemical and functional
630 properties of PhlTx-1 and some of its mutants, on a wide range of ion channel subtypes, highlight a
631 relatively interesting molecule, D7A-PhlTx-1, with improved affinity for the hNa_v1.7 subtype.
632 Further experiments are needed to improve the mutant selectivity and to study its effects on the

633 OD1-induced painful behavior of mice and/or its synergistic action with non-therapeutic doses of
634 opioids or enkephalinase inhibitors.

635

636 **ACKNOWLEDGMENTS** –T.C.G. was supported by a doctoral CIFRE fellowship from Sanofi. The
637 authors wish to thank Enrico A. Stura (SIMOPRO, CEA of Saclay, France) for PhlTx-1 3D-structure
638 modelling, and Andrees Bohme and Brigitte Schombert (Sanofi R&D, Vitry-sur-Seine, France) for
639 their help in experiments regarding cardiosafety issue.

640

641 **CONFLICT OF INTEREST** – The author, T.C. Gonçalves, declares the following competing interest:
642 current or former employees of Sanofi.

643

644 REFERENCES

645 Agwa, A.J., Peigneur, S., Chow, C.Y., Lawrence, N., Craik, D.J., Tytgat, J., King, G.F., Henriques, S.T., and
646 Schroeder, C.I. (2018). Gating modifier toxins isolated from spider venom: Modulation of voltage-gated
647 sodium channels and the role of lipid membranes. *J Biol Chem* 293, 9041-9052.

648 Bell, D.C., and Dallas, M.L. (2017). Using automated patch clamp electrophysiology platforms in pain-
649 related ion channel research: insights from industry and academia. *Br J Pharmacol*.

650 Bennett, D.L., and Woods, C.G. (2014). Painful and painless channelopathies. *Lancet Neurol* 13, 587-599.

651 Bosmans, F., Escoubas, P., Diochot, S., Mebs, D., Craik, D., Hill, J., Nakajima, T., Lazdunski M., and Tytgat, J.
652 (2005). Isolation and characterization of Phlotoxin 1 (PhlTx1), a novel peptide active on voltage-gated
653 sodium channels. Dans: 13èmes Rencontres en Toxinologie "Toxines et douleur" organisées par la
654 Société Française pour l'Etude des Toxines, Paris, 1 et 2 décembre 2005. Recueil des abstracts, p. 12.

655 Cardoso, F.C., Dekan, Z., Rosengren, K.J., Erickson, A., Vetter, I., Deuis, J.R., Herzig, V., Alewood, P.F., King,
656 G.F., and Lewis, R.J. (2015). Identification and Characterization of ProTx-III [μ -TRTX-Tp1a], a New
657 Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula *Thrixopelma pruriens*. *Mol*
658 *Pharmacol* 88, 291-303.

659 Cardoso, F.C., Dekan, Z., Smith, J.J., Deuis, J.R., Vetter, I., Herzig, V., Alewood, P.F., King, G.F., and Lewis, R.J.
660 (2017). Modulatory features of the novel spider toxin μ -TRTX-Df1a isolated from the venom of the
661 spider *Davus fasciatus*. *Br J Pharmacol* 174, 2528-2544.

662 De Lera Ruiz, M., and Kraus, R.L. (2015). Voltage-Gated Sodium Channels: Structure, Function,
663 Pharmacology, and Clinical Indications. *J Med Chem* 58, 7093-7118.

664 Deuis, J.R., Dekan, Z., Wingerd, J.S., Smith, J.J., Munasinghe, N.R., Bhola, R.F., Imlach, W.L., Herzig, V.,
665 Armstrong, D.A., Rosengren, K.J., Bosmans, F., Waxman, S.G., Dib-Hajj, S.D., Escoubas, P., Minett, M.S.,
666 Christie, M.J., King, G.F., Alewood, P.F., Lewis, R.J., Wood, J.N., and Vetter, I. (2017). Pharmacological
667 characterisation of the highly NaV1.7 selective spider venom peptide Pn3a. *Sci Rep* 7, 40883.

668 Deuis, J.R., Wingerd, J.S., Winter, Z., Durek, T., Dekan, Z., Sousa, S.R., Zimmermann, K., Hoffmann, T.,
669 Weidner, C., Nassar, M.A., Alewood, P.F., Lewis, R.J., and Vetter, I. (2016). Analgesic Effects of GpTx-1,
670 PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. *Toxins (Basel)* 8.

671 Emery, E.C., Luiz, A.P., and Wood, J.N. (2016). Nav1.7 and other voltage-gated sodium channels as drug
672 targets for pain relief. *Expert Opin Ther Targets* 20, 975-983.

673 Escoubas, P., Bosmans, F., Cuypers, E., Diochot, S., Mebs, D., Craik, D., Hill, J., Nakajima, T., Lazdunski M.,
674 and Tytgat, J. (2006). Phlotoxin-1, a toxin from tarantula venom, is a potent modulator of Na_v1.7 sodium
675 channels and a potential analgesic. In: 15th World congress on Animal, plant & microbial toxins
676 organized by the International Society on Toxinology, Glasgow, Scotland, 23-28 July 2006. *Abstract book*,
677 p. 220.

- 678 Flinspach, M., Xu, Q., Piekarz, A.D., Fellows, R., Hagan, R., Gibbs, A., Liu, Y., Neff, R.A., Freedman, J., Eckert,
679 W.A., Zhou, M., Bonesteel, R., Pennington, M.W., Eddinger, K.A., Yaksh, T.L., Hunter, M., Swanson, R.V.,
680 and Wickenden, A.D. (2017). Insensitivity to pain induced by a potent selective closed-state Nav1.7
681 inhibitor. *Sci Rep* 7, 39662.
- 682 Goldberg, D.S., and Mcgee, S.J. (2011). Pain as a global public health priority. *BMC Public Health* 11, 770.
- 683 Gonçalves, T.C., Benoit, E., Kurz, M., Lucarain, L., Fouconnier, S., Combemale, S., Jaquillard, L., Schombert,
684 B., Chambard, J.-M., Boukaiba, R., Hessler, G., Bohme, A., Bialy, L., Hourcade, S., Bérout, R., De Waard,
685 M., Servent, S., and Partiseti, M. (2018a). Cyriotoxin-1a, the first toxin from *Cyriopagopus schioedtei*
686 spider with antinociceptive properties: from identification to functional characterization. *Br J Pharmacol*
687 (in revision).
- 688 Gonçalves, T.C., Benoit, E., Partiseti, M., and Servent, D. (2018b). The NaV1.7 Channel Subtype as an
689 Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons. *Front Pharmacol* 9, 1000.
- 690 Gonçalves, T.C., Boukaiba, R., Molgo, J., Amar, M., Partiseti, M., Servent, D., and Benoit, E. (2018c). Direct
691 evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using
692 multiscale functional approaches. *Neuropharmacology* 133, 404-414.
- 693 Herzig, V., Wood, D.L., Newell, F., Chaumeil, P.A., Kaas, Q., Binford, G.J., Nicholson, G.M., Gorse, D., and
694 King, G.F. (2011). ArachnoServer 2.0, an updated online resource for spider toxin sequences and
695 structures. *Nucleic Acids Res* 39, D653-657.
- 696 Klint, J.K., Castro, J., Vetter, I., Er, S.Y., Cardoso, F., Liu, Y., Hagan, R., Neff, R., Minassian, N., Huang, J.X.,
697 Cooper, M.A., Wickenden, A., Mobli, M., Jin, L., Nicolazzo, J.A., Lewis, R.J., Bosmans, F., Brierley, S.M.,
698 and King, G.F. (2015a). Nav1.7 inhibitors normalise mechanical responses in chronic visceral
699 hypersensitivity. Submitted to Protein Data Bank.
- 700 Klint, J.K., Smith, J.J., Vetter, I., Rupasinghe, D.B., Er, S.Y., Senff, S., Herzig, V., Mobli, M., Lewis, R.J.,
701 Bosmans, F., and King, G.F. (2015b). Seven novel modulators of the analgesic target NaV 1.7 uncovered
702 using a high-throughput venom-based discovery approach. *Br J Pharmacol* 172, 2445-2458.
- 703 Liu, Y., Li, D., Wu, Z., Li, J., Nie, D., Xiang, Y., and Liu, Z. (2012). A positively charged surface patch is
704 important for hainantoxin-IV binding to voltage-gated sodium channels. *J Pept Sci* 18, 643-649.
- 705 Liu, Y., Tang, J., Zhang, Y., Xun, X., Tang, D., Peng, D., Yi, J., Liu, Z., and Shi, X. (2014). Synthesis and analgesic
706 effects of mu-TRTX-Hhn1b on models of inflammatory and neuropathic pain. *Toxins (Basel)* 6, 2363-
707 2378.
- 708 Liu, Z., Cai, T., Zhu, Q., Deng, M., Li, J., Zhou, X., Zhang, F., Li, D., Li, J., Liu, Y., Hu, W., and Liang, S. (2013).
709 Structure and function of hainantoxin-III, a selective antagonist of neuronal tetrodotoxin-sensitive
710 voltage-gated sodium channels isolated from the Chinese bird spider *Ornithoctonus hainana*. *J Biol*
711 *Chem* 288, 20392-20403.
- 712 Meir, A., Cherki, R.S., Kolb, E., Langut, Y., and Bajayo, N. (2012). Novel peptides isolated from spider
713 venom, and uses thereof. Submitted to UniProtKB.
- 714 Minassian, N.A., Gibbs, A., Shih, A.Y., Liu, Y., Neff, R.A., Sutton, S.W., Mirzadegan, T., Connor, J., Fellows, R.,
715 Husovsky, M., Nelson, S., Hunter, M.J., Flinspach, M., and Wickenden, A.D. (2013). Analysis of the
716 structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin
717 huwentoxin-IV (mu-TRTX-Hh2a). *J Biol Chem* 288, 22707-22720.
- 718 Molinski, T.F., Dalisay, D.S., Lievens, S.L., and Saludes, J.P. (2009). Drug development from marine natural
719 products. *Nat Rev Drug Discov* 8, 69-85.
- 720 Murray, J.K., Ligutti, J., Liu, D., Zou, A., Poppe, L., Li, H., Andrews, K.L., Moyer, B.D., Mcdonough, S.I.,
721 Favreau, P., Stocklin, R., and Miranda, L.P. (2015). Engineering potent and selective analogues of GpTx-1,
722 a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. *J Med Chem* 58, 2299-2314.
- 723 Murray, J.K., Long, J., Zou, A., Ligutti, J., Andrews, K.L., Poppe, L., Biswas, K., Moyer, B.D., Mcdonough, S.I.,
724 and Miranda, L.P. (2016). Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel
725 Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1. *J Med Chem* 59, 2704-2717.
- 726 Negus, S.S. (2018). Addressing the Opioid Crisis: The Importance of Choosing Translational Endpoints in
727 Analgesic Drug Discovery. *Trends Pharmacol Sci* 39, 327-330.

- 728 Pan, H.L., Wu, Z.Z., Zhou, H.Y., Chen, S.R., Zhang, H.M., and Li, D.P. (2008). Modulation of pain transmission
729 by G-protein-coupled receptors. *Pharmacol Ther* 117, 141-161.
- 730 Rahnema, S., Deuis, J.R., Cardoso, F.C., Ramanujam, V., Lewis, R.J., Rash, L.D., King, G.F., Vetter, I., and
731 Mobli, M. (2017). The structure, dynamics and selectivity profile of a Nav1.7 potency-optimised
732 huwentoxin-IV variant. *PLoS One* 12, e0173551.
- 733 Savage, S.R., Kirsh, K.L., and Passik, S.D. (2008). Challenges in using opioids to treat pain in persons with
734 substance use disorders. *Addict Sci Clin Pract* 4, 4-25.
- 735 Shcherbatko, A., Rossi, A., Foletti, D., Zhu, G., Bogin, O., Galindo Casas, M., Rickert, M., Hasa-Moreno, A.,
736 Bartsevich, V., Cramer, A., Steiner, A.R., Henningsen, R., Gill, A., Pons, J., Shelton, D.L., Rajpal, A., and
737 Strop, P. (2016). Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel
738 for Treatment of Pain. *J Biol Chem* 291, 13974-13986.
- 739 Sousa, S.R., Wingerd, J.S., Brust, A., Bladen, C., Ragnarsson, L., Herzig, V., Deuis, J.R., Dutertre, S., Vetter, I.,
740 Zamponi, G.W., King, G.F., Alewood, P.F., and Lewis, R.J. (2017). Discovery and mode of action of a novel
741 analgesic beta-toxin from the African spider *Ceratogyrus darlingi*. *PLoS One* 12, e0182848.
- 742 Spray, D.C., and Hanani, M. (2017). Gap junctions, pannexins and pain. *Neurosci Lett*.
- 743 Vetter, I., Deuis, J.R., Mueller, A., Israel, M.R., Starobova, H., Zhang, A., Rash, L.D., and Mobli, M. (2017).
744 Nav1.7 as a pain target - From gene to pharmacology. *Pharmacol Ther* 172, 73-100.
- 745 Wang, M., Rong, M., Xiao, Y., and Liang, S. (2012). The effects of huwentoxin-I on the voltage-gated sodium
746 channels of rat hippocampal and cockroach dorsal unpaired median neurons. *Peptides* 34, 19-25.
- 747 Waxman, S.G., and Zamponi, G.W. (2014). Regulating excitability of peripheral afferents: emerging ion
748 channel targets. *Nat Neurosci* 17, 153-163.
- 749 Wingerd, J.S., Mozar, C.A., Ussing, C.A., Murali, S.S., Chin, Y.K., Cristofori-Armstrong, B., Durek, T., Gilchrist,
750 J., Vaughan, C.W., Bosmans, F., Adams, D.J., Lewis, R.J., Alewood, P.F., Mobli, M., Christie, M.J., and
751 Rash, L.D. (2017). The tarantula toxin beta/delta-TRTX-Pre1a highlights the importance of the S1-S2
752 voltage-sensor region for sodium channel subtype selectivity. *Sci Rep* 7, 974.
- 753 Xiao, Y., Bingham, J.P., Zhu, W., Moczydlowski, E., Liang, S., and Cummins, T.R. (2008). Tarantula
754 huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain
755 ii voltage sensor in the closed configuration. *J Biol Chem* 283, 27300-27313.
- 756 Yekkirala, A.S., Roberson, D.P., Bean, B.P., and Woolf, C.J. (2017). Breaking barriers to novel analgesic drug
757 development. *Nat Rev Drug Discov* 16, 545-564.
-

2.2.3. Résumé des résultats obtenus

D'un point de vue physico-chimique, la PhITx-1 s'équilibre entre deux formes actives sur les canaux Na_v dont l'une des deux peut être favorisée par des variations de température. D'un point de vue fonctionnel, la PhITx-1 inhibe les sous-types $hNa_v1.1-1.3$ et $1.5-1.7$ à une concentration de l'ordre de la centaine de nanomolaires, les sous-types $hNa_v1.4$ et 1.8 à une concentration supérieure à $2,1$ et $10 \mu M$ respectivement, et deux des trois principales cibles moléculaires cardiaques, $hCa_v1.2$ et $hK_v11.1$, à une concentration supérieure à $5,9$ et $10 \mu M$ respectivement, quel que soit le protocole d'enregistrement utilisé, *i.e.* que le potentiel de maintien produise préalablement ou ne produise pas l'inactivation des canaux.

Une étude de "structure-activité" a été réalisée sur la PhITx-1 en remplaçant chacun de ses acides aminés par une alanine qui possède une chaîne latérale méthyle non encombrante et chimiquement non chargée à pH neutre mais apolaire, ce qui a permis de mettre en évidence l'importance des autres acides aminés dans la fonction du peptide et définir ainsi son pharmacophore. Cette approche "alanine scanning" a été faite à deux exceptions près: le premier acide aminé, qui était une alanine modifiée par un acide pyroglutamique, et 5 acides aminés en C-terminal qui ont été enlevés. Des 21 analogues peptidiques synthétiques ainsi créés, seuls 8 ont pu être oxydés et repliés. Le remplacement des acides aminés en C-terminal par une alanine a produit une perte de puissance de la toxine pour le sous-type $hNa_v1.7$ alors que les mutations en N-terminal ont eu peu d'effet sur cette puissance, à l'exception de l'analogue D7A. En effet, pour cet analogue, nous avons observé un gain de puissance d'un facteur 4,2 pour les sous-types $hNa_v1.7$ et 1.5 , d'un facteur 5,9 pour le sous-type $hNa_v1.2$ et d'un facteur 2,5 pour le sous-type $hNa_v1.8$, ainsi qu'une valeur d' IC_{50} proche de $1 \mu M$ pour le sous-type cardiaque $hCa_v1.2$.

Finalement, chez un modèle murin de douleur produite par l'OD1, une toxine du scorpion *Odonthobuthus doriae* qui inhibe plus spécifiquement l'inactivation du sous-type $hNa_v1.7$ (Deuis et al., 2016b), nous avons observé une diminution d'un facteur 2 des comportements douloureux des souris produits par cette toxine (nombre de léchages, de tremblements, de morsures...), pendant les 10 premières minutes suivant la co-injection d'OD1 (300 nM) et de PhITx-1 (300 nM).

2.2.4. Conclusion

Les résultats obtenus de la caractérisation exhaustive des propriétés physico-chimiques et fonctionnelles de la PhITx-1 et de certains de ses analogues peptidiques synthétiques, sur un large éventail de sous-types de canaux ioniques, mettent en évidence une molécule intéressante, l'analogue D7A, dont les effets sur les comportements douloureux des souris, produits par l'OD1, restent à être étudiés.

2.3. Mise en évidence d'un blocage de haute puissance du sous-type $\text{Na}_v1.6$ de canaux sodium par le peptide d'araignée huwentoxine-IV, en utilisant des approches fonctionnelles multi-échelles

2.3.1. Contexte de l'étude

Actuellement, une vingtaine de toxines sont décrites dans la littérature pour exercer un pouvoir antinociceptif en agissant de façon puissante et sélective sur le sous-type $\text{Na}_v1.7$ de canaux sodium (Vetter et al., 2017; Cardoso et al., 2018; Gonçalves et al., 2018a). Cependant, le manque de sélectivité des molécules vis-à-vis des autres sous-types de canaux sodium TTX-S est un problème pour leur développement thérapeutique. La sélectivité de ces molécules vis-à-vis du sous-type foetal $\text{Na}_v1.3$ n'est pas requise car ce sous-type n'est exprimé chez l'adulte que lors de lésions nerveuses de type mécanique, inflammatoire ou neuropathique (Waxman et al., 1994; Black et al., 1999; Dib-Hajj et al., 1999; Boucher et al., 2000; Kim et al., 2001; Tan et al., 2015; Yang et al., 2016). La faible sélectivité des toxines vis-à-vis des sous-types TTX-S est à l'origine de troubles indésirables au niveau du système nerveux central (*via* l'inhibition de $\text{Na}_v1.1$, 1.2 et/ou 1.6) et du système neuromusculaire (*via* l'inhibition de $\text{Na}_v1.4$ et/ou 1.6). Les troubles indésirables au niveau du système neuromusculaire sont les plus souvent mentionnés dans la littérature car ils peuvent entraîner le décès des animaux par arrêt respiratoire lors des expérimentations. En effet, la voie d'administration des peptides se faisant majoritairement par voie i.m., intrapéritonéale (i.p.) ou intrapleurale (i.pl.), les sous-types de canaux ioniques exprimés dans le système nerveux central sont épargnés (Liu et al., 2014b; Liu et al., 2014c; Deuis et al., 2016b; Flinspach et al., 2017; Rahnama et al., 2017).

Parmi ces toxines, l'HwTx-IV est une des premières à avoir été bien caractérisée comme molécule potentiellement analgésique sur des modèles animaux (rongeurs) de douleur inflammatoire et neuropathique (Liu et al., 2014c). L'HwTx-IV est issue du venin de l'araignée-oiseau chinoise *Cyriopagopus schmidti*, plus connue sous le nom de *Haplopelma schmidti* (Schmidt, 2010), qui appartient à la sous-famille des Ornithoctoninae. Cette toxine peptidique 4113,9 Da est composée de 35 acides aminés, est structurée autour du motif architectural ICK et appartient à la famille NaSpTx-1 (Klint et al., 2012). L'HwTx-IV a été initialement identifiée comme étant un puissant inhibiteur du sous-type $\text{Na}_v1.7$ avec une forte sélectivité vis-à-vis du sous-type cardiaque $\text{Na}_v1.5$ et du sous-type du muscle squelettique $\text{Na}_v1.4$ de canaux sodium qui sont relativement insensibles au peptide (Xiao et al., 2008). Sa forte puissance est conservée pour les sous-types de canaux sodium TTX-S des

neurones de DRG de rat ($IC_{50} = 30 \text{ nM}$; Peng et al., 2002). L'HwTx-IV, validée comme molécule analgésique par des tests sur des modèles rongeurs de douleur inflammatoire et neuropathique (Liu et al., 2014c), semblait donc prometteuse comme agent thérapeutique. Cependant, peu d'informations existaient dans la littérature concernant l'interaction du peptide avec le sous-type neuronal $Na_v1.6$ de canaux sodium présent, plus particulièrement, au niveau des neurones de DRG et des nœuds de Ranvier des motoneurones α , et concernant donc les effets secondaires indésirables résultant de cette interaction *in vivo* (Rahnama et al., 2017).

Lors de notre étude des effets fonctionnels de la CyrTx-1a (voir sous-partie 2.1), notre attention a été attirée par les altérations relativement importantes provoquées par l'HwTx-IV au niveau des propriétés d'excitabilité du système neuromusculaire de souris *in vivo*. Nous avons donc entrepris une étude afin de déterminer la puissance de cette toxine vis-à-vis du sous-type $Na_v1.6$ de canaux sodium, en utilisant des approches fonctionnelles multi-échelles (de l'organisme *in vivo* à la cellule unique).

2.3.2. Publication n°4

Neuropharmacology (2018) 133 : 404-414

“Direct evidence for high affinity blockade of $Na_v1.6$ channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches”

Tânia C. Gonçalves, Rachid Boukaiba, Jordi Molgó, Muriel Amar, Michel Partiseti, Denis Servent & Evelyne Benoit



Direct evidence for high affinity blockade of Nav1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches

Tânia C. Gonçalves^{a, b}, Rachid Boukaiba^a, Jordi Molgó^{b, c}, Muriel Amar^b, Michel Partiseti^a, Denis Servent^b, Evelyne Benoit^{b, c, *}

^a Sanofi R & D, Integrated Drug Discovery, In Vitro Biology & Pharmacology, F-94440, Vitry-sur-Seine, France

^b Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, F-91191, Gif sur Yvette, France

^c Institut des Neurosciences Paris-Saclay (Neuro-PSI), UMR CNRS/Université Paris-Sud 9197, Université Paris-Saclay, F-91198, Gif sur Yvette, France

ARTICLE INFO

Article history:

Received 27 October 2017

Received in revised form

16 January 2018

Accepted 19 February 2018

Available online 21 February 2018

Keywords:

Huwentoxin-IV

Voltage-gated sodium channels

Nav channel subtypes

Electrophysiology

Mouse neuromuscular excitability

Mouse dorsal root ganglia neurons

Cell lines overexpressing Nav channel subtypes

ABSTRACT

The Chinese bird spider huwentoxin-IV (HwTx-IV) is well-known to be a highly potent blocker of Nav1.7 subtype of voltage-gated sodium (Nav) channels, a genetically validated analgesic target, and thus promising as a potential lead molecule for the development of novel pain therapeutics. In the present study, the interaction between HwTx-IV and Nav1.6 channel subtype was investigated using multiscale (from *in vivo* to individual cell) functional approaches. HwTx-IV was approximately 2 times more efficient than tetrodotoxin (TTX) to inhibit the compound muscle action potential recorded from the mouse skeletal neuromuscular system *in vivo*, and 30 times more effective to inhibit nerve-evoked than directly-elicited muscle contractile force of isolated mouse hemidiaphragms. These results strongly suggest that the inhibition of nerve-evoked skeletal muscle functioning, produced by HwTx-IV, resulted from a toxin-induced preferential blockade of Nav1.6, compared to Nav1.4, channel subtype. This was confirmed by whole-cell automated patch-clamp experiments performed on human embryonic kidney (HEK)-293 cells overexpressing hNav1.1–1.8 channel subtypes. HwTx-IV was also approximately 850 times more efficient to inhibit TTX-sensitive than TTX-resistant sodium currents recorded from mouse dorsal root ganglia neurons. Finally, based on our data, we predict that blockade of the Nav1.6 channel subtype was involved in the *in vivo* toxicity of HwTx-IV, although this toxicity was more than 2 times lower than that of TTX. In conclusion, our results provide detailed information regarding the effects of HwTx-IV and allow a better understanding of the side-effect mechanisms involved *in vivo* and of channel subtype interactions resulting from the toxin activity.

© 2018 Elsevier Ltd. All rights reserved.

1. Introduction

Pain treatment diversification remains a big health and economic concern, and animal venom peptides seem to be an original source of new antinociceptive drugs targeting ion channels implicated in pain signalling pathways. Their modest size, compact structure due to disulfide bridges, physicochemical resistance to enzyme degradation and tissue clearance make them good candidates (Saez et al., 2010). A FDA-approved painkiller is already

* Corresponding author. Current address: CEA de Saclay, SIMOPRO, Bât. 152, 91191, Gif-sur-Yvette, France.

E-mail address: evelyne.benoit@cea.fr (E. Benoit).

commercialized as Prialt[®] since a decade. This peptide derived from a conus venom toxin, blocks the Cav2.2 subtype (N-type) of voltage-gated calcium (Cav) channels to relieve chronic pain of spinal cord injury non treatable by opioid therapy (Molinski et al., 2009). Unfortunately, the peptide administered *via* intrathecal injection induces severe side-effects which restrain its wider application (Wang et al., 2016). Even if Prialt[®] is still the only venom-derived drug approved for pain treatment, many other toxins entered in pre-clinical or clinical development due to their capacity to interact with major molecular targets of pain pathways, such as sodium, calcium, and acid-sensing ion channels, as well as nicotinic receptors (Netirojjanakul and Miranda, 2017).

Due to their major role in initiating and propagating action potentials, voltage-gated sodium (Nav) channels are implicated in

Abbreviations

Ca _v	voltage-gated calcium channel
CHO	Chinese hamster ovary
CMAP	compound muscle action potential
DMEM	Dulbecco's modified Eagle's medium
DRG	dorsal root ganglia
ERG	<i>ether-a-go-go</i> -related gene
h	human
HEK	human embryonic kidney
HEPES	N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
HwTx-IV	huwentoxin-IV

i.m.	intramuscular
IC ₅₀	toxin concentration necessary to inhibit 50% of the response
ICK	inhibitory cystine knot
K _v	voltage-gated potassium channel
NaSpTx	voltage-gated sodium channel spider toxin
Na _v	voltage-gated sodium channel
PBS	phosphate buffered saline
ProTx-II	protoxin-II
r	rat
TTX	tetrodotoxin
TTX-R	resistant to tetrodotoxin
TTX-S	sensitive to tetrodotoxin

numerous pain diseases. Some of these diseases can be directly linked to mutations of genes encoding the Na_v1.7 channel subtype, leading to either exacerbation of pain, such as inherited erythromelalgia, paroxysmal extreme pain disorder and small fiber neuropathy, or no pain sensation at all, such as congenital insensitivity to pain or type-1ID hereditary sensory and autonomic neuropathy (de Lera Ruiz and Kraus, 2015; Vetter et al., 2016). Na_v channels are transmembrane proteins composed of a pore-forming α subunit constituted by four domains, each containing 6 transmembrane segments, the S1-S4 forming the voltage-sensing domain and the S5 connected to the S6 with an extracellular re-entrant P-loop constituting the ion-conducting pore (Goldin et al., 2000; Catterall, 2000; de Lera Ruiz and Kraus, 2015). The gating properties and turnover of Na_v channels may be modified by some members of the cell adhesion molecule superfamily, the β subunits, linked to the α subunit (Namadurai et al., 2015).

More than ten toxins have been reported so far to act selectively and potently on Na_v1.7 channel subtype (Vetter et al., 2016). Among these toxins, protoxin-II (β/ω -theraphotoxin-Tp2a or ProTx-II) and huwentoxin-IV (μ -theraphotoxin-Hs2a or HwTx-IV) have been well characterized (Xiao et al., 2014). HwTx-IV, extracted from the venom of the Chinese bird spider *Cyriopagopus schmidtii*, formerly known as *Haplopelma schmidtii* (Schmidt, 2010), is a 35 amino acid peptide, with an inhibitory cystine knot (ICK) architectural motif, belonging to Na_v channel spider toxin (NaSpTx) family 1 (Klint et al., 2012). HwTx-IV was first identified as a highly potent blocker of the genetically validated analgesic target Na_v1.7 channel subtype, showing in addition a marked selectivity for this channel subtype compared, in particular, to the heart channel subtype Na_v1.5 and the skeletal muscle channel subtype Na_v1.4 which were relatively resistant to the peptide (Xiao et al., 2008). Great efforts were then provided to link the promising toxin to an antinociceptive effect via Na_v channels. The first report introduced the toxin as having a high efficacy on tetrodotoxin (TTX)-sensitive Na_v channels located in rat dorsal root ganglia (DRG) neurons [toxin concentration necessary to inhibit 50% of the response (IC₅₀) of 30 nM] which are involved in pain pathway (Peng et al., 2002). More recently, HwTx-IV was reported to have analgesic effects in rodent inflammatory and neuropathic pain models (Liu et al., 2014a). The peptide was thus promising as a potential lead molecule for the development of novel pain therapeutics. However, until now, very few information was reported about the efficiency of HwTx-IV to interact with the Na_v1.6 channel subtype, a TTX-sensitive (TTX-S) Na_v channel subtype present in the brain, in DRG neurons and in Ranvier nodes of α -motoneurons, as well as the resulting *in vivo* side-effects resulting from this interaction (Rahnama et al., 2017). This point is very important since such interaction would, in particular, impair the neuromuscular system

functioning, leading to the death of experimental animals, as previously suggested (Liu et al., 2014b; Flinspach et al., 2017; Rahnama et al., 2017; Deuis et al., 2016).

The present study was therefore undertaken to determine the interaction between HwTx-IV and Na_v1.6 channel subtype, using multiscale (from *in vivo* to individual cell) functional approaches. Our results provide detailed information regarding the effects of the peptide on the mouse neuromuscular system *in vivo*, on isolated mouse neuromuscular preparations, on mouse DRG neurons and on human embryonic kidney (HEK)-293 cells heterologously overexpressing the human (h) Na_v1.6 channel subtype, therefore providing a clue to understand the mechanisms of *in vivo* motor side-effects resulting from HwTx-IV and Na_v1.6 channel subtype interaction.

2. Material and methods

2.1. Toxins

Lyophilized synthetic HwTx-IV (molecular weight of 4106.811, purity rate > 97%) was obtained from Smartox Biotechnology (Saint Martin d'Hères, France). This toxin was dissolved in phosphate buffered saline (PBS 1 \times) solution to give a 2.5×10^{-2} g/mL (*i.e.* 6.1 mM) stock solution. TTX citrate (molecular weight of 319.27, purity rate > 98%) was purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). This toxin was dissolved in PBS 1 \times solution to give a 9×10^{-4} g/mL (*i.e.* 2.85 mM) stock solution. Just prior to experiments, successive dilutions were performed in the adequate standard physiological medium to give the HwTx-IV and TTX final concentrations indicated in the text.

2.2. Experimental animals

Adult female Swiss mice (10–12 weeks of age and 28–32 g body weight) were purchased from Janvier Elevage (Le Genest-Saint-Isle, France) and housed at the CEA animal facility. The experiments were performed in accordance with the guidelines established by the French Council on animal care "Guide for the Care and Use of Laboratory Animals" (EEC86/609 Council Directive – Decree, 2001–131), on mice under anaesthesia by means of isoflurane (AErrane[®], Baxter S.A., Lessines, Belgique) inhalation. The experimental protocols were approved on November 27, 2015 by the French General Directorate for Research and Innovation (project APAFIS#2671-2015110915123958v3 authorized to E.B.).

2.3. Isolated mouse neuromuscular preparations

Mouse hemidiaphragms with their respective associated

phrenic nerve were rapidly and carefully dissected after anaesthesia (by isoflurane inhalation) and euthanasia (by cervical vertebrae dislocation) of mice. After removal, the isolated neuromuscular preparation was mounted on a silicone-lined organ bath (4 mL volume) filled with a standard physiological medium of the following composition (in mM): NaCl 145, KCl 5, CaCl₂ 2, MgCl₂ 1, D-glucose 11, and N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) 5 (pH 7.4, adjusted with NaOH), continuously gassed with pure O₂ throughout the experiment.

2.4. Primary cultures of mouse DRG neurons

Mouse DRG were removed from the animal spinal cord, placed in iced-Ham's F-12 medium (Sigma-Aldrich) and enzymatically dissociated with collagenase type IA (2 mg/mL; Sigma-Aldrich) and dispase (5 mg/mL; Gibco, Thermo Fisher Scientific, Villebon-sur-Yvette, France). Neurons were then plated on 12-mm glass coverslips placed in a 24-wells plate coated with 10 µg/mL of poly-D-lysine and 100 µg/mL of murin laminin (Sigma-Aldrich). The cells were maintained in culture at 37 °C (in 95% air and 5% CO₂) in Neurobasal A medium (Gibco) containing horse serum (5%; Gibco), penicillin/streptomycin (47.64 U/mL; Gibco), nerve growth factor (83.33 ng/mL; Sigma-Aldrich), N2 supplement (3.18×; Gibco), Dulbecco's phosphate-buffered saline (1×) w/o CaCl₂ and MgCl₂ (1.68%; Gibco), bovine serum albumin (16.83 µg/mL; Sigma-Aldrich), corticosteron (214.85 nM; Sigma-Aldrich), T3 hormone (56.06 nM; Sigma-Aldrich) and L-glutamine (1.90 mM; Sigma-Aldrich). Cytosine β-D-arabinofuranoside (2 µM; Sigma-Aldrich) was added to the culture medium, 24 h later, to stop astrocyte proliferation.

Experiments were carried out within 2–6 days after cell plating. The day of their use, the neurons plated on coverslips were transferred, for a minimum of 30 min at 37 °C prior to manual patch-clamp recordings, in 35-mm Petri dishes filled with a standard physiological medium of the following composition (in mM): NaCl 134, KCl 3, CaCl₂ 1, MgCl₂ 1, D-glucose 10, tetraethylammonium chloride (TEA) 10, CdCl₂ 0.1, and HEPES 10 (pH 7.35, adjusted with NaOH), and then in the recording bath filled with the standard physiological medium.

2.5. HEK-293 and Chinese hamster ovary (CHO) cell line cultures

HEK-293 cells heterologously overexpressing hNav_v1.7 (Eurofins, Discovery Services, St Charles, MO, USA) were cultured in suspension in FreestyleTM293 (Gibco; #12338–018). Those overexpressing hNav_v1.1 (Eurofins), hNav_v1.6 (ChanTest, Cleveland, OH, USA) or hNav_v1.8 (Eurofins) were cultured in Dulbecco's modified Eagle's medium (DMEM)/F-12 nutrient mixture with GlutaMAX™ supplement (Gibco; #31331), those overexpressing hNav_v1.2 (SB Drug Discovery, Glasgow, United Kingdom) and hNav_v1.5 (Sanofi, Frankfurt, Germany) in DMEM with GlutaMAX™ supplement (Gibco; #31966), and those overexpressing hNav_v1.3 and 1.4 (SB Drug Discovery) in minimum essential medium (Sigma-Aldrich; #M5650). CHO cells heterologously overexpressing hCa_v1.2/β2/α2δ1 (ChanTest, Cleveland, OH, USA) were cultured in Ham's F12 nutrient mix with GlutaMAX™ medium (Gibco; #31765). Those overexpressing the voltage-gated potassium (K_v) channel subtype hK_v11.1 (B'SYS GmbH, Switzerland), encoded by the human *ether-a-go-go*-related gene (hERG), were cultured in DMEM/F-12 nutrient mixture Ham's medium (Sigma; #D6434). All culture media contained fetal bovine serum (10% v/v) and selected antibiotics and additives, as recommended by the manufacturer. Cells were grown in flasks, in a humidified 5% CO₂ incubator at 37 °C, and sub-cultured/passaged every 3–4 days using TrypLE Select enzyme (Gibco).

For manual patch-clamp recordings, a few days before experiments, the cells were transferred on 12-mm glass coverslips placed in 35-mm Petri dishes. The day of their use, the culture medium was changed to a standard physiological medium, similar to that used for DRG neurons (see paragraph 2.4), for a minimum of 15 min at 37 °C prior to experiments. The cells plated on coverslips were then transferred in the recording bath filled with the standard physiological medium. For automated patch-clamp recordings, the day of their use, the cells were transferred in Eppendorf tubes containing a FreeStyle 293 expression medium (Gibco; #12338) which were then placed in the automated electrophysiology platform.

2.6. Electrophysiological recordings from the mouse neuromuscular system in vivo

Recordings from the neuromuscular system of anaesthetized mouse were obtained by means of a minimally-invasive electrophysiological method, using the Qtrac[®] software (Prof. H. Bostock, Institute of Neurology, London, United Kingdom), as previously detailed (Marrouchi et al., 2013). Briefly, the anaesthetized mice were placed on a heating pad to maintain body temperature throughout the experiments (between 35.94 ± 0.05 and 35.99 ± 0.03 °C, as determined in 29 mice using a rectal probe). Electrical stimulations were delivered to the caudal motor nerve (at the base of the tail) by surface electrodes, and the compound muscle action potential (CMAP) was recorded using needle-electrodes inserted into the tail muscle. To study the local action of HwTx-IV and TTX, intramuscular (i.m.) injections (4-µL maximal volume) of PBS 1× solution containing various concentrations of a given toxin were delivered with a 10-µL micro-syringe at the base of mouse tail, between stimulation and ground electrodes. Similar injections (4 µL) were also done with PBS 1× solution to test an eventual effect of the vehicle.

On-line recordings were initiated approximately 5 min before a given injection to determine the toxin and/or vehicle effects on selected excitability parameters, such as the excitability threshold and CMAP amplitude continuously registered as a function of time. To better identify the underlying mechanism(s) of action and the duration of HwTx-IV and TTX effects, five different excitability tests (stimulus-response, strength-duration and current-threshold relationships, as well as threshold electrotonus and recovery cycle; detailed in Cerles et al., 2017) were performed together before and at various times (from ~30 min to ~12 h) after a given injection. As a whole, more than thirty parameters were determined from these five excitability tests, and analyzed. Most of them provide specific and complementary information on the density and functional status of ion channels, receptors and pumps, as well as on the passive membrane properties of the neuromuscular system (Kiernan and Bostock, 2000; Krishnan et al., 2008).

2.7. Mechanical recordings from isolated mouse neuromuscular preparations

Measurements of isometric contractile force (i.e. single twitch), elicited by stimulating the muscle either indirectly via the phrenic nerve or directly, were performed as previously described (Schlumberger et al., 2010). Briefly, the central tendon of the hemidiaphragm was attached to an isometric force displacement transducer (FT03 model; Grass Instruments, West Warwick, RI, USA) via an adjustable stainless-steel hook, and the other tendon (at the rib side) was securely anchored onto the silicone-coated bath. A mobile micrometer stage allowed adjusting the muscle length to obtain maximal contractile responses. The resting tension was monitored and kept constant throughout the experiment.

Electrical square pulses of 200 μ s duration and supramaximal voltage (15–20 V for nerve stimulation and 80–100 V for direct stimulation) were delivered by a stimulator (S-48 model; Grass Instruments) at a frequency of 0.1 Hz. Signals from the force transducer were amplified, collected, and digitized with the aid of a computer equipped with an analog-to-digital converter (Digidata-1322A model; Molecular Devices, Sunnyvale, CA, USA) managed by the Axoscope 9.2 software (Molecular Devices). The collected signals were analyzed off-line using the Clampfit 9.2 program (Molecular Devices). The experiments were carried out at constant room temperature (22 °C).

2.8. Automated patch-clamp recordings from HEK-293 and CHO cells

Whole-cell automated patch-clamp experiments were performed on a QPatch HTX automated electrophysiology platform (Sophion Bioscience, Ballerup, Denmark), allowing both signal acquisition and data analyses (Bell and Dallas, 2017). The extracellular medium composition of hNav_v-overexpressing HEK293 cells was (in mM): NaCl 154, KCl 4, CaCl₂ 2, MgCl₂ 1, and HEPES 10 (pH 7.4, adjusted with NaOH), and that of intracellular (*i.e.* patch-clamp pipette) medium: CsF 150, EGTA/CsOH 1/50, HEPES 10, NaCl 10, MgCl₂ 1, and CaCl₂ 1 (pH 7.4, adjusted with CsOH). The extracellular medium composition of hCa_v1.2-overexpressing CHO cells was (in mM): NaCl 145, KCl 4, CaCl₂ 10, and HEPES 10 (pH 7.4, adjusted with NaOH), and that of intracellular medium: CsF 27, CsCl 112, EGTA 8.2, HEPES 10, NaCl 2, and Mg-ATP 4 (pH 7.4, adjusted with CsOH). The extracellular medium composition of hK_v11.1-overexpressing CHO cells was (in mM): NaCl 145, KCl 4, CaCl₂ 2, MgCl₂ 1, HEPES 10, and D-glucose 10 (pH 7.4, adjusted with NaOH), and that of intracellular medium: KCl 120, CaCl₂ 5.4, EGTA 10, HEPES 10, Mg-ATP 4, and MgCl₂ 1.75 (pH 7.4, adjusted with KOH). HwTx-IV was diluted in the extracellular medium added with bovine serum albumin (0.1%), to give the final concentrations indicated in the text. The times of incubation varied between -2 and -7 min to achieve steady-state effects. The experiments were carried out at room temperature (20–22 °C).

The hNav_v-overexpressing HEK-293 cells were maintained at a holding potential of either -90 mV (hNav_v1.5) or -100 mV (other hNav_v channel subtypes). Currents were elicited at a frequency of 0.2 Hz by 20-ms test-pulses to -20 mV (hNav_v1.1, 1.2, 1.4, and 1.7), -10 mV (hNav_v1.3), -40 mV (hNav_v1.5), -15 mV (hNav_v1.6) or +10 mV (hNav_v1.8), preceded by 200-ms (hNav_v1.5) or 40-ms (hNav_v1.7) pulses to -120 mV, or not (hNav_v1.1, 1.2, 1.3, 1.4 and 1.6). The hCa_v1.2-overexpressing CHO cells were maintained at a holding potential of -50 mV, and currents were elicited at a frequency of 0.05 Hz by 200-ms test-pulses to +0 mV. The hK_v11.1-overexpressing CHO cells were maintained at a holding potential of -80 mV, and tail currents were elicited at a frequency of 0.07 Hz by 5-s test-pulses to -50 mV, preceded by 4.8-s pulses to +20 mV following 20-ms pulses to -50 mV. The concentration-response relationships were established by expressing the peak amplitude of the sum of ten cell currents recorded in the presence of a given HwTx-IV concentration relatively to that of the sum of these currents recorded before toxin incubation.

2.9. Manual patch-clamp recordings from HEK-293 cells and mouse DRG neurons

Whole-cell manual patch-clamp experiments were performed by using a MultiClamp 700B integrating patch-clamp amplifier and the pClamp10.6 software (Molecular Devices, Sunnyvale, CA, USA), as previously described (Schlumberger et al., 2014). The signals, acquired at a 4-kHz sample rate, were filtered at 2 kHz with a low-

pass Bessel filter and digitized with the aid of a computer equipped with an analog-to-digital converter (Digidata-1440A model; Molecular Devices). The patch-clamp pipettes were filled with a medium composed of (in mM): CsCl 90, CsMeSO₃ 40, NaCl 10, MgCl₂ 2, EGTA 2, ATP-Na₂ 4, and HEPES 10 (pH 7.32, adjusted with CsOH), and had ~3-M Ω resistance in the standard physiological medium. A fast perfusion system allowed changing the solution (standard physiological medium added or not with a given toxin concentration) around the recorded cell within a few seconds. The experiments were carried out at constant room temperature (22 °C).

The cells were maintained at a holding potential of -60 mV, and currents were elicited at a frequency of 0.5 Hz by 50-ms test-pulses to -20 mV (+10 mV for hNav_v1.6-overexpressing HEK-293 cells) preceded by 1-s pulses to -120 mV. The concentration-response relationships were established by expressing the peak current amplitude measured in the presence of a given toxin concentration relatively to that before toxin application. Current-voltage relationships were obtained by varying test-pulses from -80 to +10 mV in 5-mV increments, and steady-state inactivation-voltage relationships by changing pre-pulses from -120 to -20 mV in 5-mV increments.

2.10. Data and statistical analyses

Concentration-response relationships were established by plotting the response, recorded in the presence of a given toxin (R_t) and expressed as percentage of the value obtained in absence of toxin (R_c), against the toxin concentration ([toxin]). The theoretical concentration-response curves were calculated from typical sigmoidal nonlinear regressions through data points (correlation coefficient = r^2) according to the Hill equation (GraphPad Prism 5 or QPatch assay software): $R_t/R_c = 1/[1 + ([toxin]/IC_{50})^{n_H}]$, where n_H is the Hill number.

Conductance (g) was calculated according to the following equation: $g = I/(V_T - V_{Na})$, where I is the peak current amplitude, V_T is the test-pulse voltage, and V_{Na} is the equilibrium potential of Na ions. Conductance-voltage relationships were established by plotting the conductance, expressed as percentage of the maximal conductance (g_{max}) calculated at large positive test-pulses, as a function of test-pulse voltage. The theoretical curves correspond to data point fits, according to the Boltzmann equation (GraphPad Prism 5 software): $g/g_{max} = 1 - [1/(1 + \exp((V_T - V_{T50\%})/k_g))]$, where $V_{T50\%}$ is the test-pulse voltage corresponding to 50% maximal conductance, and k_g is the slope of the curve.

Steady-state inactivation-voltage relationships were established by plotting the peak current amplitude, expressed as percentage of the maximal amplitude (I_{max}) recorded in response to large negative pre-pulses, as a function of pre-pulse voltage (V_p). The theoretical curves correspond to data point fits, according to the Boltzmann equation (GraphPad Prism 5 software): $I/I_{max} = 1/[1 + \exp((V_p - V_{P50\%})/k_h)]$, where $V_{P50\%}$ is the pre-pulse voltage corresponding to 50% maximal peak amplitude of current, and k_h is the slope of the curve.

Current kinetics were evaluated by calculating the two following activation and inactivation parameters: (1) the time to peak (t_p), defined as the time between test-pulse triggering and the peak current, and (2) the time constant (τ_h) of the current decay, assuming that the current inactivation is a mono-exponential decay as a function of time, *i.e.* $I(t) = I_{(0)} e^{(-t/\tau_h)}$.

Data are expressed as means \pm standard deviations (S.D.) of n different experiments. The statistical comparison of values was carried out using the parametric two-tailed Student's t -test (either paired samples for comparison within a single population or unpaired samples for comparison between two populations), the 2-factor ANOVA test or the nonparametric Mann-Whitney U test,

according to the equality of sample variances estimated with the Lilliefors test. Differences between values were considered to be statistically significant at $P \leq 0.05$.

3. Results

3.1. Effects of HwTx-IV and TTX on the mouse neuromuscular system *in vivo*

On-line recordings revealed that the major effect of i.m. injections of PBS 1× solutions containing various concentrations of either HwTx-IV (from 4.1 pmol/kg to 41.4 nmol/kg mouse) or TTX (from 3.4 pmol/kg to 166.5 nmol/kg mouse) to anaesthetized mice was a marked concentration-dependent decrease of CMAP amplitude. This is exemplified in Fig. 1A (insets) for CMAP recordings performed before and ~10 min after injections of 41.4 nmol HwTx-IV and 166.5 nmol TTX per kg of mouse. This effect occurred within various times, depending on the concentration of toxin injected,




Fig. 1. Effects of HwTx-IV and TTX on the maximal CMAP amplitude recorded *in vivo* from mouse tail muscle in response to caudal motor nerve stimulation. **A:** Representative time-course of the effects of HwTx-IV (from 4.1 pmol/kg to 41.4 nmol/kg mouse, in black) and TTX (from 3.4 pmol/kg to 166.5 nmol/kg mouse, in grey) on the maximal CMAP amplitude recorded continuously as a function of time. Values are expressed as percentage of those before injections (indicated by the arrow). **Insets:** Superimposed traces of maximal CMAP, before (a) and ~10 min after HwTx-IV (41.4 nmol/kg mouse, b) or TTX (166.5 nmol/kg mouse, c) injection. **B:** Concentration-response curves of the effects of HwTx-IV (black circles) and TTX (grey circles) on the maximal CMAP amplitude. Each value, expressed as percentage of that obtained before injection, represents the mean \pm S.D. of data obtained from 4 to 8 mice. IC_{50} and n_H values were, respectively, 0.9 nmol/kg mouse and 0.5 for HwTx-IV ($r^2 = 0.998$) and 1.9 nmol/kg mouse and 0.8 for TTX ($r^2 = 0.997$).

ranging from ~10 to ~20 min (Fig. 1A). It is worth noting that the maximal CMAP amplitude remained stable before toxin injections and during ~25 min after injection of 3.4 pmol/kg mouse of TTX. Moreover, the maximal CMAP amplitude measured ~30 min after injections of PBS 1× solution alone, and compared to values before injections, was not significantly affected, *i.e.* $97.8 \pm 2.3\%$ ($n = 8$ mice), indicating (i) that injections of the toxin vehicle had no effect on the maximal CMAP amplitude and (ii) that no marked run-down of the response occurred.

The toxin blocking effect was quantified by establishing the concentration-response curves, *i.e.* the maximal CMAP amplitude as a function of the concentration of toxin injected, and determining the IC_{50} values (see for more details the Material and methods section). As shown in Fig. 1B, the concentration-response curves for HwTx-IV and TTX revealed IC_{50} values of 0.9 and 1.9 nmol/kg mouse, respectively. It thus appears that HwTx-IV was approximately 2 times more efficient than TTX, on equimolar basis, to inhibit the CMAP.

The five different excitability tests (stimulus-response, strength-duration and current-threshold relationships, as well as threshold electrotonus and recovery cycle) were performed together before and ~30 min after i.m. injections of PBS 1× solution containing HwTx-IV (4.1–41.4 nmol/kg mouse) or TTX (5.3–17.8 nmol/kg mouse), and the derived neuromuscular excitability parameters were determined (Supplementary data, Fig. S1, Fig. S2 and Table S1). With the exception of decreased maximal CMAP amplitude and increased stimulus intensity required to generate a 50% maximal amplitude CMAP (stimulus-response relationship; Fig. S1Aa, Fig. S2Aa and Table S1), analysis of strength-duration relationship, threshold electrotonus, current-threshold relationship, and recovery cycle did not reveal other HwTx-IV and TTX effects since no significant modification of excitability waveforms and derived parameters was detected (Fig. S1B–E, Fig. S2B–E and Table S1). The toxin-induced effects were completely reversed within ~12 h after HwTx-IV (4.1–41.4 nmol/kg mouse) or TTX (5.3–17.8 nmol/kg mouse) injections (Fig. S3 and Table S1).

It should be emphasized that injections of 41.4 and 394.3 nmol HwTx-IV per kg of mouse (concentrations corresponding to 46 and 438 times the IC_{50} value, respectively) caused death of 40% (2/5) and 80% (4/5) of the mice, respectively, within 1 h. Similarly, injections of 17.8 and 166.5 nmol TTX per kg of mouse (*i.e.* 9 and 88 times the IC_{50} value, respectively) produced death of 43% (3/7) and 75% (6/8) of the animals, respectively, within 1 h. These results indicate a more than 2-time lower *in vivo* toxicity of HwTx-IV compared to TTX.

3.2. Effects of HwTx-IV on isolated mouse neuromuscular preparations

The evaluation of HwTx-IV effects on isolated mouse phrenic nerve-hemidiaphragm preparations revealed that various toxin concentrations (from 152 nM to 14 μ M) produced an inhibition of both nerve-evoked and directly-elicited muscle contractile force of single twitches. This is illustrated in Fig. 2A (insets) for twitch recordings performed in the absence and in the presence of 14 μ M HwTx-IV. The toxin-induced blockade of nerve-evoked muscle twitch was concentration- and time-dependent (Fig. 2). In particular, a complete inhibition of nerve-evoked contractile response occurred within ~8 min after addition of 14 μ M HwTx-IV to the standard physiological medium, as exemplified by the representative time-course of toxin effect shown in Fig. 2A.

Similarly, the toxin (14 μ M) produced a marked decrease of directly-elicited muscle twitch within ~8 min (Fig. 2A). However, the maximal amplitude of directly-elicited muscle twitch was much less affected by HwTx-IV concentrations from 152 nM to




Fig. 2. Effects of HwTx-IV on nerve-evoked and directly-elicited muscle contractile force (single twitch) of isolated mouse phrenic nerve-hemidiaphragm preparation. **A:** Representative time-course of HwTx-IV (14 μ M) effects on the maximal twitch amplitude recorded continuously as a function of time, and expressed as percentage of that before toxin addition to the standard physiological medium (indicated by the arrow), in response to stimulation applied either indirectly *via* the motor nerve (light grey) or directly to muscle (dark grey). **Insets:** Superimposed traces of maximal twitch recorded before (a) and \sim 10 min after HwTx-IV (14 μ M) addition to the standard physiological medium (b and c), and elicited *via* nerve stimulation (b) or by direct muscle stimulation (c). **B:** Histogram representing nerve-evoked (light grey) and directly-elicited muscle (dark grey) maximal twitch amplitude determined in the presence of indicated HwTx-IV concentrations. Each value, expressed as percentage of that obtained before toxin addition to the standard physiological medium, represents the mean \pm S.D. of data obtained from 4 to 10 muscles.

14 μ M than the nerve-evoked twitch. In particular, when muscle twitch evoked by nerve stimulation was completely blocked by 14 μ M HwTx-IV (*i.e.* maximal amplitude reduced to $1.2 \pm 0.9\%$ of initial values measured in the absence of toxin, $n = 5$ muscles), a contractile response, although of low maximal amplitude (*i.e.* $16.9 \pm 1.3\%$ of initial values measured in the absence of toxin, $n = 5$ muscles), could be still obtained by direct stimulation of hemidiaphragms. For comparison, an only slightly higher maximal amplitude (*i.e.* $24.2 \pm 2.6\%$ of initial values measured in the absence of toxin, $n = 10$ muscles) was obtained when muscle twitch was evoked by nerve stimulation in the presence of 152 nM HwTx-IV (Fig. 2B). It is worth noting that no decrease of twitch amplitude occurred when neuromuscular preparations were only bathed with standard physiological medium for 20 min (data not shown). This indicates, in particular, that there was no important run-down of twitch amplitude under these experimental conditions.

Assuming that n_H was equal to 1, IC_{50} values of 30 and 900 nM were calculated according to the Hill equation (see Material and methods section for more details), for the toxin-induced decrease of maximal amplitude of nerve-evoked and directly-elicited muscle twitches, respectively. HwTx-IV was therefore 30 times more efficient to inhibit nerve-evoked than directly-elicited muscle contractile force of isolated mouse hemidiaphragms.

3.3. Effects of HwTx-IV and TTX on hNav_v1.1–1.8-overexpressing HEK-293 cells and on CHO cells overexpressing hCav1.2 and hKv11.1 channel subtypes

Whole-cell automated patch-clamp experiments performed on HEK-293 cells overexpressing hNav_v1.1–1.8 channel subtypes revealed the following increasing order for IC_{50} values obtained from the concentration-response curves of HwTx-IV effects on




Fig. 3. Effects of HwTx-IV and TTX on HEK-293 cells overexpressing hNav_v1.1–1.8 channel subtypes. Histogram of IC_{50} values obtained from the concentration-response curves of HwTx-IV (dark grey) and TTX (light grey) effects on hNav_v1.1–1.8 currents. Each value represents the mean \pm S.D. of data obtained from 2 to 10 cells. Mean values \pm S.D. of n_H were 1.3 ± 0.2 and 1.0 ± 0.1 for HwTx-IV and TTX effects, respectively.

currents flowing through the different channel subtypes (Fig. 3): hNav_v1.1 (41 ± 1 nM, $n = 4$) > hNav_v1.2 (44 ± 2 nM, $n = 10$) > hNav_v1.6 (52 ± 9 nM, $n = 3$) > hNav_v1.7 (100 ± 6 nM, $n = 4$) > hNav_v1.3 (190 ± 24 nM, $n = 7$) > hNav_v1.4 (>10 μ M, $n = 8$) for TTX-S (IC_{50} values between 3 ± 2 and 78 ± 2 nM, $n = 2$ –5) channel subtypes, and hNav_v1.5 = hNav_v1.8 (>10 μ M, $n = 7$ –9) for TTX-resistant (TTX-R; IC_{50} values of 3 ± 1 and >10 μ M, respectively, $n = 5$) channel subtypes. Therefore, all the TTX-R channel subtypes studied were also relatively resistant to HwTx-IV while all the TTX-S channel




Fig. 4. Effects of HwTx-IV on HEK-293 cells overexpressing hNav1.6 and hNav1.7 channel subtypes. **A:** Concentration-response curves of HwTx-IV effects on hNav1.6 (black circles) and hNav1.7 (grey circles) currents. Each value, expressed as percentage of that obtained before toxin perfusion, represents the mean \pm S.D. of data obtained from 4 to 9 cells. IC_{50} and n_H values were, respectively, 83.3 nM and 1.2 for hNav1.6 current ($r^2 = 0.983$), and 32.6 nM and 0.8 for hNav1.7 current ($r^2 = 0.901$). **B** and **C:** Steady-state inactivation- (circles) and conductance- (squares) voltage relationships for HEK-293 cells overexpressing hNav1.6 (**B**) and hNav1.7 (**C**) channel subtypes, before (open symbols) and after (close symbols) perfusion of 70–100 nM (**B**) or 20 nM (**C**) HwTx-IV. Each value represents the mean \pm S.D. of data obtained from 4 to 5 cells, and is expressed as percentage of either maximal peak amplitude of current at large negative pre-pulse voltages or maximal conductance calculated at large positive test-pulse voltages. The theoretical curves correspond to data point fits with the mean $V_{P50\%}$, k_h , $V_{T50\%}$ and k_g values indicated in Table 1.

subtypes studied, with the exception of hNav1.4 channel subtype, were also relatively sensitive to HwTx-IV. Additionally, HwTx-IV was ~ 2 times more potent to block hNav1.6 than hNav1.7 channel subtypes. It is worth noting that the toxin had very low affinity for hCav1.2 and hKv11.1 channel subtypes overexpressed in CHO cells since the IC_{50} values obtained from the concentration-response curves of HwTx-IV effects on currents flowing through these two ion channels were higher than 10 μ M ($n = 2-4$, data not shown).

Detailed experiments, using whole-cell manual patch-clamp,

displayed IC_{50} values of 83.3 and 32.6 nM from the concentration-response curves of HwTx-IV effects on currents flowing through hNav1.6 and hNav1.7 channel subtypes overexpressed in HEK-293 cells, respectively (Fig. 4A). Under these conditions, the toxin was thus approximately 2.5 times less efficient to block hNav1.6 than hNav1.7 channel subtypes. This HwTx-IV-induced blocking action occurred without any change in steady-state inactivation- and conductance-voltage relationships of hNav1.6 and hNav1.7 channel subtypes, as shown in Fig. 4B–C and Table 1 for toxin concentrations of 70–100 and 20 nM, respectively, i.e. close to the IC_{50} values.

3.4. Effects of HwTx-IV and TTX on mouse DRG neurons

Before evaluating the effects of HwTx-IV on the sodium currents of DRG neurons, the TTX sensitivity of these currents was first determined by perfusion of cells with a standard physiological medium containing 100 nM TTX. Under this condition, two types of neurons were recorded (Fig. 5A): those (67%, i.e. 12/18 cells) having TTX-S current, i.e. which was blocked by the toxin to $5 \pm 5\%$ of initial peak amplitude values within 1 min, and those (33%, i.e. 6/18 cells) having TTX-R current, i.e. which was blocked by the toxin, perfused for ~ 6 min, to $83 \pm 6\%$ of initial peak amplitude values but was completely inhibited by 100 μ M TTX. It should be noted that the activation and inactivation kinetics of TTX-R current were significantly slower than those of TTX-S current (Fig. 5A and Table 2).

After washing-out TTX by perfusion of neurons with a toxin-free solution for 8–10 min, the cell perfusion with standard physiological solutions containing various HwTx-IV concentrations (from 5 nM to 20 μ M) produced then a decrease of sodium current amplitude which was dependent on the time following the perfusion, the toxin concentration and the current sensitivity to TTX. In particular, the concentration-response curves of HwTx-IV effects on the peak amplitude of TTX-S and TTX-R currents revealed IC_{50} values of 0.13 and 110 μ M, respectively (Fig. 5B). It thus appears that the toxin was approximately 850 times more efficient to inhibit TTX-S than TTX-R sodium currents of mouse DRG neurons. The blocking effects of HwTx-IV on the peak amplitude of TTX-S current were stationary approximately 7 and 2 min after perfusion of 0.005 and 1 μ M of toxin, respectively. Those on the peak amplitude of TTX-R current were stationary approximately 6 min after perfusion of 10–20 μ M of toxin. The HwTx-IV effects on TTX-R current, not very noticeable, were not further studied, in contrast to those on TTX-S current.

The peak amplitude of TTX-S current, which was 9 and 3% of initial values after perfusion of 1 and 10 μ M HwTx-IV, respectively, returned to $43 \pm 17\%$ of initial values ($n = 9$) by perfusion of neurons with a toxin-free solution for 15–20 min. The analyses of activation and inactivation kinetics of TTX-S sodium current in the absence and in the presence of HwTx-IV concentrations close to the IC_{50} value (i.e. 0.1 μ M) revealed that the toxin did not affect these kinetics since t_p and τ_h were not significantly modified (Table 2). Similarly, HwTx-IV (0.1 μ M) did not produce any alteration of steady-state inactivation- and conductance-voltage relationships for neurons exhibiting TTX-S current (Fig. 5C and Table 1).

4. Discussion

The present study was undertaken to determine the interaction between HwTx-IV and Nav1.6 channel subtype, using multiscale (from *in vivo* to individual cell) functional approaches. The results obtained can be summarized as follow: (i) HwTx-IV was approximately 2 times more efficient than TTX to inhibit the CMAP recorded from the mouse skeletal neuromuscular system *in vivo*, (ii) HwTx-IV was approximately 30 times more effective to inhibit

Table 1

Parameters of steady-state inactivation- ($V_{P50\%}$ and k_h) and conductance- ($V_{T50\%}$ and k_g) voltage relationships for HEK-293 cells overexpressing hNav_v1.6 and hNav_v1.7 channel subtypes (means \pm S.D. of 4–5 cells) and mouse DRG neurons having TTX-S sodium current (means \pm S.D. of 4 neurons).

	$V_{P50\%}$ (mV)	k_h (mV^{-1})	$V_{T50\%}$ (mV)	k_g (mV^{-1})
hNav _v 1.6 current before HwTx-IV perfusion	-61 ± 3	5.7 ± 0.3	-20 ± 2	5.4 ± 0.4
hNav _v 1.6 current after HwTx-IV perfusion ^a	-65 ± 2	5.9 ± 0.4	-22 ± 3	4.8 ± 0.4
hNav _v 1.7 current before HwTx-IV perfusion	-76 ± 3	6.9 ± 0.3	-21 ± 2	5.6 ± 0.5
hNav _v 1.7 current after HwTx-IV perfusion ^b	-79 ± 3	7.4 ± 0.6	-22 ± 2	6.6 ± 0.5
TTX-S current before HwTx-IV perfusion	-80 ± 2	7.0 ± 0.6	-38 ± 4	3.7 ± 1.4
TTX-S current after HwTx-IV perfusion ^c	-86 ± 7	6.3 ± 0.5	-38 ± 3	4.4 ± 1.7

^a 70–100 nM.

^b 20 nM, and.

^c 0.1 μ M.




Fig. 5. Effects of HwTx-IV on TTX-S and TTX-R sodium currents of mouse DRG neurons. **A:** Representative traces of sodium currents recorded from two different neurons having either TTX-S (left) or TTX-R (right) current. In each case, the current was recorded before (black or dark grey) and 1–5 min after (light grey) perfusion of 100 nM TTX. **B:** Concentration-response curves of HwTx-IV effects on the peak amplitude of TTX-S (black circles) and TTX-R (grey circles) sodium currents. Each value, expressed as percentage of that obtained before toxin perfusion, represents the mean \pm S.D. of data obtained from 2 to 9 neurons. IC_{50} and n_H values were, respectively, 0.13 μ M and 0.9 for TTX-S current ($r^2 = 0.967$), and 110 μ M and 0.4 for TTX-R current ($r^2 = 0.612$). **C:** Steady-state inactivation- (circles) and conductance- (squares) voltage relationships for neurons having TTX-S current, before (open symbols) and after (close symbols) perfusion of 0.1 μ M HwTx-IV. Each value represents the mean \pm S.D. of data obtained from 4 neurons, and is expressed as percentage of either maximal peak amplitude of current at large negative pre-pulse voltages or maximal conductance calculated at large positive test-pulse voltages. The theoretical curves correspond to data point fits with the mean $V_{P50\%}$, k_h , $V_{T50\%}$ and k_g values indicated in Table 1.

Table 2

Kinetics parameters of current activation (τ_p) and inactivation (τ_h) calculated from TTX-S and TTX-R sodium currents recorded from DRG neurons under the indicated conditions (means \pm S.D. of 4–12 cells).

	τ_p (ms)	τ_h (ms)
TTX-S current before TTX perfusion ¹	1.22 ± 0.29	0.78 ± 0.40
TTX-S current after TTX wash-out	0.81 ± 0.04	0.63 ± 0.18
TTX-S current after HwTx-IV perfusion ²	0.75 ± 0.06	0.60 ± 0.12
TTX-R current before TTX perfusion	$2.31 \pm 0.62^*$	$1.11 \pm 0.24^*$

¹ 100 nM, ² 0.1 μ M *; $P < 0.032$ (versus TTX-S current before TTX perfusion).

nerve-evoked than directly-elicited muscle contractile force in isolated mouse hemidiaphragms, (iii) HwTx-IV was more potent to block TTX-S (hNav_v1.1, 1.2, 1.3, 1.6 and 1.7, with the exception of hNav_v1.4) than TTX-R (hNav_v1.5 and 1.8) Na_v channel subtypes overexpressed in HEK-293 cells, (iv) HwTx-IV was approximately 850 times more efficient to inhibit TTX-S than TTX-R sodium currents of mouse DRG neurons, and (v) the *in vivo* toxicity of HwTx-IV was more than 2 times lower than that of TTX.

The effects of *i.m.* injections of HwTx-IV and TTX on the mouse neuromuscular system *in vivo* consisted in an inhibition of CMAP and an increase in the stimulus intensity required to generate a 50% maximal amplitude CMAP. The duration of the observed effects was less than 12 h. These results strongly suggest that HwTx-IV and TTX produce a marked and reversible decrease of sodium currents, *i.e.* of the density and/or functional status of “transient” Na_v channels, as might be expected with toxins known to block these types of channels (Cestèle and Catterall, 2000). Besides these effects, HwTx-IV and TTX did not modify other excitability parameters, indicating that the two toxins do not affect the density and functional status of other types and subtypes of ion channels, receptors and pumps, nor the passive membrane properties of the neuromuscular system (Kiernan and Bostock, 2000; Krishnan et al., 2008).

The HwTx-IV-induced inhibition of CMAP could be explained by an *in vivo* action of this toxin on the Na_v channel subtypes identified so far in adult nerves and skeletal muscles, *i.e.* the Na_v1.6 and Na_v1.4 channel subtypes, respectively (Caldwell et al., 2000; de Lera Ruiz and Kraus, 2015). HwTx-IV would be approximately 2 times more efficient than TTX to interact with and to block Na_v1.6 and/or Na_v1.4 channel subtypes. Available *in vitro* evidence indicated however that the Na_v1.4 channel subtype is not preferentially sensitive to HwTx-IV since the toxin affinity for this channel subtype ($IC_{50} > 10 \mu$ M; Xiao et al., 2008) was more than 1000 times less than that of TTX ($IC_{50} \approx 8$ nM; Tsukamoto et al., 2017), without giving information on the interaction between HwTx-IV and Na_v1.6 channel subtype. It was therefore probable that the relative high efficiency of HwTx-IV to inhibit *in vivo* the CMAP, compared to TTX, results from toxin-induced preferential blockade of the Na_v1.6 and not Na_v1.4 channel subtype. This hypothesis was tested directly by studying the HwTx-IV effects on isolated mouse neuromuscular

preparations and recording the isometric contractile force elicited by stimulating either directly the muscle or indirectly *via* its associated motor nerve.

The study of HwTx-IV effects on isolated mouse phrenic nerve-hemidiaphragm preparations reveals that the toxin produced an inhibition of the nerve-evoked contractile force with a calculated IC_{50} value of 30 nM. These results confirm those obtained *in vivo* on the CMAP recorded from tail muscle in response to caudal motor nerve stimulation, *i.e.* the relative high affinity of HwTx-IV for $Na_V1.6$ and/or $Na_V1.4$ channel subtypes. It is worth noting that HwTx-IV was previously reported to completely block the conduction of isolated mouse phrenic nerve-hemidiaphragm preparations, by acting on multiple ion channel proteins, especially the Ca_V channels (Yu et al., 2014). However, this is not supported by the present results showing a very low affinity of the peptide for hCaV1.2 channel subtype overexpressed in CHO cells.

Additionally, HwTx-IV also inhibited the directly-elicited muscle twitch of isolated mouse hemidiaphragms with a calculated IC_{50} value of 300 nM. The conditions of direct muscle stimulation are very interesting because it makes possible to decrease the implication of $Na_V1.6$ channel subtype (located in nerves and not in muscles; Caldwell et al., 2000) in the contractile response, and thus to get direct information on the affinity of interaction between HwTx-IV and $Na_V1.4$ channel subtype (located in skeletal muscles and not in nerves; de Lera Ruiz and Kraus, 2015). The results obtained under these conditions therefore strongly suggest that the toxin was 30 times less potent to block the $Na_V1.4$ than the $Na_V1.6$ channel subtype. These results confirm the hypothesis that the HwTx-IV-induced inhibition of nerve-evoked hemidiaphragm twitch and of the CMAP recorded *in vivo* from tail muscle in response to caudal motor nerve stimulation resulted from a preferential blockade of $Na_V1.6$ channel subtype by the toxin.

The following step was thus to undertake the study of HwTx-IV effects on HEK-293 cells overexpressing h $Na_V1.1$ –1.8 channel subtypes to get complementary information on the relative selectivity of interaction between the toxin and $Na_V1.6$ channel subtype, as well as on the relative IC_{50} value of HwTx-IV on this channel subtype, since poor evidence was available in the literature (Rahnama et al., 2017).

The results obtained from whole-cell automated patch-clamp experiments performed on HEK-293 cells overexpressing h $Na_V1.1$ –1.8 channel subtypes highlighted two groups of channel subtypes: (i) a relatively HwTx-IV-sensitive group ($IC_{50} = 41$ –190 nM) including, by increasing order of IC_{50} values, h $Na_V1.1 > hNa_V1.2 > hNa_V1.6 > hNa_V1.7 > hNa_V1.3$, and (ii) a relatively HwTx-IV-resistant group ($IC_{50} > 10 \mu M$) composed of h $Na_V1.4 \approx hNa_V1.5 \approx hNa_V1.8$. These results are similar to the following sequence of peptide affinities reported so far in the literature, with respect to the Na_V channel subtype overexpressed in HEK-293 cells: h $Na_V1.7$ ($IC_{50} = 26$ nM) $> rNa_V1.2$ ($IC_{50} = 150$ nM) $> rNa_V1.3$ ($IC_{50} = 338$ nM) $>> rNa_V1.4 \approx hNa_V1.5$ ($IC_{50} > 10 \mu M$) (Xiao et al., 2008). The slight IC_{50} differences between the two studies may reflect those between the species, human or rat (r), of the Na_V channel subtypes studied. It seems therefore that the selectivity of HwTx-IV towards h $Na_V1.7$ is not as important as previously reported since the toxin is also highly potent to block h $Na_V1.1$, h(r) $Na_V1.2$, h(r) $Na_V1.3$ and h $Na_V1.6$ channel subtypes. However, the discovery that $Na_V1.1$ and 1.3 channel subtypes are involved in pain pathways (Chen et al., 2014; Osteen et al., 2016; Cardoso and Lewis, 2017) and that $Na_V1.2$ channel subtype is only located in the central nervous system (see de Lera Ruiz and Kraus, 2015) does not impair further development of HwTx-IV as a potential antinociceptive agent to access only peripheral Na_V channel subtypes. In contrast, the fact that this toxin also targets $Na_V1.6$ channel subtype is more problematic because of

the resulting side-effects which limit its *in vivo* efficacy in pre-clinical pain models.

The poor selectivity of HwTx-IV for h $Na_V1.7$ over h $Na_V1.6$ channel subtypes is further supported by the recent characterization of the effects of a triple-mutant of HwTx-IV (E1G, E4G and Y33W; m3-HwTx-IV) on either HEK-293 cells overexpressing h $Na_V1.1$ –1.5 channel subtypes, and the $\beta 1$ auxiliary subunit, or CHO cells overexpressing h $Na_V1.6$ –1.7 and h $Na_V1.8/\beta 3$ channel subtypes (Rahnama et al., 2017). Despite the fact that mutations may influence the peptide selectivity over Na_V channel subtypes, this study revealed quite similar Na_V channel subtype selectivity, but higher blockade potency of the recombinant peptide, compared to HwTx-IV (present results):

h $Na_V1.7 > hNa_V1.6 > hNa_V1.3 > hNa_V1.1 > hNa_V1.2$
($IC_{50} = 3.3$ –11.9 nM) $>> hNa_V1.4$ ($IC_{50} = 369$ nM) $>>$
h $Na_V1.5 \approx hNa_V1.8$ ($IC_{50} > 1 \mu M$). Taken altogether, these data indicate that all the TTX-R channel subtypes studied (TTX $IC_{50} = 3$ –10 μM) were also resistant to HwTx-IV and m3-HwTx-IV blockade, while all the TTX-S channel subtypes studied (TTX $IC_{50} = 3$ –78 nM), with the exception of h $Na_V1.4$ channel subtype, were also sensitive to HwTx-IV and m3-HwTx-IV inhibition.

The effects of HwTx-IV were further investigated on TTX-S and TTX-R Na_V channel subtypes of adult mouse DRG neurons, *i.e.* mainly the TTX-S $Na_V1.1$, 1.6 and 1.7 channel subtypes and the TTX-R $Na_V1.8$ and 1.9 channel subtypes (Rush et al., 2007). This study was motivated, on one hand, by the well-known important role of DRG neurons as the primary sensitive pathway of chronic pain and, on the other hand, by the absence of report of such study in mouse, until now. The effects consisted in a marked and reversible decrease of the peak amplitude of TTX-S sodium current ($IC_{50} = 0.13 \mu M$), without any significant modification of activation and inactivation kinetics and voltage-dependencies. As expected from the results obtained from whole-cell automated patch-clamp experiments, the peptide was approximately 850 times less efficient in inhibiting the peak amplitude of TTX-R sodium current ($IC_{50} = 110 \mu M$). From this point of view, HwTx-IV is very interesting compared to TTX which was only approximately 90 times more potent to block TTX-S than TTX-R Na_V channel subtypes (IC_{50} values of 5.5 and 500 nM, respectively).

These results are consistent with previous observations on adult rat DRG neurons showing that 0.1 μM HwTx-IV inhibited TTX-S sodium current, without any alteration of activation and inactivation kinetics, but had no effect on TTX-R currents (Peng et al., 2002). Interestingly, the activation and inactivation kinetics of TTX-R sodium current were slower than those of TTX-S sodium current. This is due to the prevalence of TTX-R $Na_V1.8$ and to a less extent of $Na_V1.9$ channel subtypes which are exceptionally characterized by slow ($Na_V1.8$) and even very slow ($Na_V1.9$) activation and inactivation kinetics (Rush et al., 2007).

During experiments aimed to study the effects of *i.m.* injections of HwTx-IV and TTX on the mouse neuromuscular system *in vivo*, 17.8 and 166.5 nmol TTX per kg of mouse (corresponding to 9 and 88 times the *in vivo* IC_{50} value, respectively) produced death of 43% and 75% of the animals, respectively, within 1 h. These values are close to those reported in the literature, *i.e.* *i.m.* injections of 5.3 μg (16.6 nmol) TTX per kg rodent caused the death of 50% of the animals (Xu et al., 2003). By comparison, *i.m.* injections of HwTx-IV concentrations corresponding to 46 and 438 times the *in vivo* IC_{50} value produced death of 40% and 80% of the mice, respectively, within 1 h. Although these results indicate a more than 2-time lower *in vivo* toxicity of HwTx-IV compared to TTX, the resulting side-effects of the peptide may limit its use as a potential lead molecule for the development of novel pain therapeutics. In particular, the therapeutic window of HwTx-IV as an analgesic

appears to be markedly reduced taking into account that the peptide was previously reported to have analgesic activity at 100 µg/kg mouse (*i.e.* 24 nmol/kg mouse) when *i.m.* injected to animals (Liu et al., 2014a).

Since HwTx-IV had very low affinity for hNav_v1.5 channel subtype, as well as for hCa_v1.2 and hK_v11.1 channel (IC₅₀ > 10 µM), it is unlikely that the death of mice resulted from heart dysfunctioning. In contrast, given the poor selectivity of the peptide over Nav_v1.6 channel subtype, it is likely that impaired motor functioning is involved since peptides interacting with this subtype of Nav channels are well-known to typically lead to such severe side-effects.

5. Conclusion

To the best of our knowledge, this is the first report showing directly that high affinity interaction occurs between HwTx-IV and Nav_v1.6 channel subtype. Indeed, the toxin has been reported so far in the literature as being highly specific for the Nav_v1.7 channel subtype, without effects on the Nav_v1.6 channel subtype being evidenced. The present study showing quite similar affinities of HwTx-IV for Nav_v1.6 and Nav_v1.7 channel subtypes allows better understanding the mechanisms of motor *in vivo* side-effects produced by this peptide, and makes this molecule significantly less attractive for an eventual therapeutic use as antinociceptive agent.

Conflicts of interest

The authors declare that they have no actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning this work.

Acknowledgments

This research was funded by a collaborative grant (#153114) between Sanofi Research & Development (Chilly-Mazarin, France) and the French Alternative Energies and Atomic Energy Commission (CEA, Gif-sur-Yvette, France). T.C.G. was supported by a doctoral CIFRE fellowship from Sanofi. The authors are grateful to thank Dr Andrees Bohme and Brigitte Schombert for their help in the establishment of hCa_v1.2 and hK_v11.1 electrophysiological protocols, and Sophie Fontaine for her technical assistance for the Nav_v cell lines management.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.neuropharm.2018.02.016>.

References

Bell, D.C., Dallas, M.L., 2017. Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia. *Br. J. Pharmacol.* <https://doi.org/10.1111/bph.13916> (in press).

Caldwell, J.H., Schaller, K.L., Lasher, R.S., Peles, E., Levinson, S.R., 2000. Sodium channel Nav_v1.6 is localized at nodes of Ranvier, dendrites, and synapses. *Proc. Natl. Acad. Sci. U.S.A.* 97, 5616–5620.

Cardoso, F.C., Lewis, R.J., 2017. Sodium channels and pain: from toxins to therapies. *Br. J. Pharmacol.* <https://doi.org/10.1111/bph.13962> (in press).

Catterall, W.A., 2000. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. *Neuron* 26, 13–25.

Cerles, O., Benoit, E., Chéreau, C., Chouzenoux, S., Morin, F., Guillaumot, M.A., Coriat, R., Kavian, N., Loussier, T., Santulli, P., Marcellin, L., Saidu, N.E., Weill, B., Batteux, F., Nicco, C., 2017. Niclosamide inhibits oxaliplatin neurotoxicity while improving colorectal cancer therapeutic response. *Mol. Canc. Therapeut.* 16, 300–311.

Cestèle, S., Catterall, W.A., 2000. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. *Biochimie* 82, 883–892.

Chen, H.P., Zhou, W., Kang, L.M., Yan, H., Zhang, L., Xu, B.H., Cai, W.H., 2014. Intrathecal miR-96 inhibits Nav_v1.3 expression and alleviates neuropathic pain in rat following chronic constriction injury. *Neurochem. Res.* 39, 76–83.

de Lera Ruiz, M., Kraus, R.L., 2015. Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. *J. Med. Chem.* 58, 7093–7118.

Deuis, J.R., Wingerd, J.S., Winter, Z., Durek, T., Dekan, Z., Sousa, S.R., Zimmermann, K., Hoffmann, T., Weidner, C., Nassar, M.A., Alewood, P.F., Lewis, R.J., Vetter, I., 2016. Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of Nav_v1.7-mediated Pain, vol. 8. *Toxins*, Basel pii: E78.

Flinspach, M., Xu, Q., Piekarz, A.D., Fellows, R., Hagan, R., Gibbs, A., Liu, Y., Neff, R.A., Freedman, J., Eckert, W.A., Zhou, M., Bonesteel, R., Pennington, M.W., Eddinger, K.A., Yaksh, T.L., Hunter, M., Swanson, R.V., Wickenden, A.D., 2017. Insensitivity to pain induced by a potent selective closed-state Nav_v1.7 inhibitor. *Sci. Rep.* 7, 39662.

Goldin, A.L., Barchi, R.L., Caldwell, J.H., Hofmann, F., Howe, J.R., Hunter, J.C., Kallen, R.G., Mandel, G., Meisler, M.H., Netter, Y.B., Noda, M., Tamkun, M.M., Waxman, S.G., Wood, J.N., Catterall, W.A., 2000. Nomenclature of voltage-gated sodium channels. *Neuron* 28, 365–368.

Kiernan, M.C., Bostock, H., 2000. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. *Brain* 123, 2542–2551.

Klint, J.K., Senff, S., Rupasinghe, D.B., Er, S.Y., Herzig, V., Nicholson, G.M., King, G.F., 2012. Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads. *Toxicon* 60, 478–491.

Krishnan, A., Park, S., Lin, C.S., Kiernan, M.C., 2008. Assessment of nerve excitability in toxic and metabolic neuropathies. *J. Peripher. Nerv. Syst.* 13, 7–26.

Liu, Y., Wu, Z., Tang, D., Xun, X., Liu, L., Li, X., Nie, D., Xiang, Y., Yi, J., Yi, J., 2014a. Analgesic effects of huwentoxin-IV on animal models of inflammatory and neuropathic pain. *Protein Pept. Lett.* 21, 153–158.

Liu, Y., Tang, J., Zhang, Y., Xun, X., Tang, D., Peng, D., Yi, J., Liu, Z., Shi, X., 2014b. Synthesis and analgesic effects of µ-TRTX-Hhn1b on models of inflammatory and neuropathic pain. *Toxins* 6, 2363–2378.

Marrouchi, R., Rome, G., Kharrat, R., Molgó, J., Benoit, E., 2013. Analysis of the action of gymnodimine-A and 13-desmethyl spirilolide C on the mouse neuromuscular system *in vivo*. *Toxicon* 75, 27–34.

Molinski, T.F., Dalisay, D.S., Lievens, S.L., Saludes, J.P., 2009. Drug development from marine natural products. *Nat. Rev. Drug Discov.* 8, 69–86.

Namadurai, S., Yereddi, N.R., Cusdin, F.S., Huang, C.L., Chirgadze, D.Y., Jackson, A.P., 2015. A new look at sodium channel β subunits. *Open Biol.* 5, 140192.

Netirojjanakul, C., Miranda, L.P., 2017. Progress and challenges in the optimization of toxin peptides for development as pain therapeutics. *Curr. Opin. Chem. Biol.* 38, 70–79.

Osteen, J.D., Herzig, V., Gilchrist, J., Emrick, J.J., Zhang, C., Wang, X., Castro, J., Garcia-Caraballo, S., Grundy, L., Rychkov, G.Y., Weyer, A.D., Dekan, Z., Undheim, E.A., Alewood, P., Stucky, C.L., Brierley, S.M., Basbaum, A.I., Bosmans, F., King, G.F., Julius, D., 2016. Selective spider toxins reveal a role for the Nav_v1.1 channel in mechanical pain. *Nature* 534, 494–499.

Peng, K., Shu, Q., Liu, Z., Liang, S., 2002. Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider *Selenocosmia huwena*. *J. Biol. Chem.* 277, 47564–47571.

Rahnama, S., Deuis, J.R., Cardoso, F.C., Ramanujam, V., Lewis, R.J., Rash, L.D., King, G.F., Vetter, I., Mobli, M., 2017. The structure, dynamics and selectivity profile of a Nav_v1.7 potency-optimised huwentoxin-IV variant. *PLoS One* 12, e0173551.

Rush, A.M., Cummins, T.R., Waxman, S.G., 2007. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. *J. Physiol. Lond* 579, 1–14.

Saez, N.J., Senff, S., Jensen, J.E., Er, S.Y., Herzig, V., Rash, L.D., King, G.F., 2010. Spider-venom peptides as therapeutics. *Toxins* 2, 2851–2871.

Schlumberger, S., Kristan, K.C., Ota, K., Frangež, R., Molgó, J., Sepčić, K., Benoit, E., Maček, P., 2014. Permeability characteristics of cell-membrane pores induced by ostreolysin A/pleurotolysin B, binary pore-forming proteins from the oyster mushroom. *FEBS Lett.* 588, 35–40.

Schlumberger, S., Ouanounou, G., Girard, E., Sasaki, M., Fuwa, H., Louzao, M.C., Botana, L.M., Benoit, E., Molgó, J., 2010. The marine polyether gambierol enhances muscle contraction and blocks a transient K(+) current in skeletal muscle cells. *Toxicon* 56, 785–791.

Schmidt, G., 2010. Wie lautet der korrekte Name von *Selenocosmia huwena* Wang, Peng & Xie, 1993? *Tarantulas World* 142, 23–27.

Tsukamoto, T., Chiba, Y., Wakamori, M., Yamada, T., Tsunogae, S., Cho, Y., Sakakibara, R., Imazu, T., Tokoro, S., Satake, Y., Adachi, M., Nishikawa, T., Yotsu-Yamashita, M., Konoki, K., 2017. Differential binding of tetrodotoxin and its derivatives to voltage-sensitive sodium channel subtypes (Nav_v1 to Nav_v1.7). *Br. J. Pharmacol.* <https://doi.org/10.1111/bph.13985> (in press).

Vetter, I., Deuis, J.R., Mueller, A., Israel, M.R., Starobova, H., Zhang, A., Rash, L., Mobli, M., 2016. Nav_v 1.7 as a pain target – from gene to pharmacology. *Pharmacol. Ther.* 172, 73–100.

Wang, F., Yan, Z., Liu, Z., Wang, S., Wu, Q., Yu, S., Ding, J., Dai, Q., 2016. Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA. *Neuropharmacology* 101, 137–145.

Xiao, Y., Bingham, J.P., Zhu, W., Moczydlowski, E., Liang, S., Cummins, T.R., 2008. Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain II voltage sensor in the closed configuration. *J. Biol. Chem.* 283, 27300–27313.

Xiao, Y., Blumenthal, K., Cummins, T.R., 2014. Gating-pore currents demonstrate selective and specific modulation of individual sodium channel voltage-sensors by biological toxins. *Mol. Pharmacol.* 86, 159–167.

Xu, Q., Huang, K., Gao, L., Zhang, H., Rong, K., 2003. Toxicity of tetrodotoxin towards

mice and rabbits. *Wei Sheng Yan Jiu (Chinese)* 32, 371–374.

Yu, H., Liu, H., Yan, Y., Duan, Z., Wang, X., 2014. Detection and identification of huwentoxin-IV interacting proteins by biotin-avidin chemistry combined with mass spectrometry. *J. Venom. Anim. Toxins Incl. Trop. Dis.* 20, 18.

Direct evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches

T.C. Gonçalves, R. Boukaiba, J. Molgó, M. Amar, M. Partiseti, D. Servent, and E. Benoit

SUPPLEMENTARY FIGURE 1




Figure S1. Superimposed excitability curves obtained *in vivo* by stimulating the mouse caudal motor nerve and recording the CMAP from tail muscle before (black circles, $n = 29$ mice) and ~ 30 min after injections of HwTx-IV (4.1-41.4 nmol/kg mouse, grey circles, $n = 6$ mice). Data are represented as means \pm S.D. **A:** stimulus-response relationships [absolute (**a**) and relative (**b**) CMAP amplitudes], **B:** strength-duration relationship, **C:** threshold electrotonus, **D:** current-threshold relationship, and **E:** recovery cycle. In Aa, arrows indicate stimulus currents for 50% maximal response.

Direct evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches

T.C. Gonçalves, R. Boukaiba, J. Molgó, M. Amar, M. Partiseti, D. Servent, and E. Benoit

SUPPLEMENTARY FIGURE 2




Figure S2. Superimposed excitability curves obtained *in vivo* by stimulating the mouse caudal motor nerve and recording the CMAP from tail muscle before (black circles, $n = 29$ mice) and ~ 30 min after injections of TTX (5.3-17.8 nmol/kg mouse, grey circles, $n = 9$ mice). Data are represented as means \pm S.D. **A:** stimulus-response relationships [absolute (a) and relative (b) CMAP amplitudes], **B:** strength-duration relationship, **C:** threshold electrotonus, **D:** current-threshold relationship, and **E:** recovery cycle. In Aa, arrows indicate stimulus currents for 50% maximal response.

Direct evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches

T.C. Gonçalves, R. Boukaiba, J. Molgó, M. Amar, M. Partiseti, D. Servent, and E. Benoit

SUPPLEMENTARY FIGURE 3




Figure S3. Superimposed excitability curves obtained *in vivo* by stimulating the mouse caudal motor nerve and recording the CMAP from tail muscle before (black circles, $n = 29$ mice) and ~ 12 h after injections (white circles, $n = 12$ mice) of HwTx-IV (4.1-41.4 nmol/kg mouse) or TTX (5.3-17.8 nmol/kg mouse). Data are represented as means \pm S.D. **A**: stimulus-response relationships [absolute (**a**) and relative (**b**) CMAP amplitudes], **B**: strength-duration relationship, **C**: threshold electrotonus, **D**: current-threshold relationship, and **E**: recovery cycle. In **Aa**, arrows indicate stimulus currents for 50% maximal response.

Direct evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches

T.C. Gonçalves, R. Boukaiba, J. Molgó, M. Amar, M. Partiseti, D. Servent, and E. Benoit

SUPPLEMENTARY TABLE 1

Table S1. Comparison of neuromuscular excitability parameters (means \pm S.D.) from mouse tail muscle recordings before toxin injections (control, n = 29 mice), ~30 min after injections of HwTx-IV (4.1-41.4 nmol/kg mouse, n = 6 mice) or TTX (5.3-17.8 nmol/kg mouse, n = 9 mice), and ~12 h after toxin injections (n = 12 mice).

Excitability parameter ²	Before toxin injection	~30 min after injection HwTx-IV	TTX	~12 h after toxin injection
A ¹ Peak response (mV)	5.31 \pm 0.57	0.92 \pm 0.31**	1.36 \pm 0.25**	5.04 \pm 0.56
A Latency (ms)	3.89 \pm 0.06	4.09 \pm 0.26	4.09 \pm 0.12	3.91 \pm 0.04
A Stimulus (mA) for 50% max response	0.35 \pm 0.05	0.46 \pm 0.05*	0.44 \pm 0.08*	0.36 \pm 0.06
A Stimulus-response slope	3.11 \pm 0.18	3.42 \pm 0.17	2.96 \pm 0.17	3.21 \pm 0.16
B ¹ Strength-duration time constant (ms)	0.69 \pm 0.12	0.86 \pm 0.14	0.87 \pm 0.11	0.66 \pm 0.03
B Rheobase (mA)	0.21 \pm 0.04	0.19 \pm 1.16	0.19 \pm 0.03	0.22 \pm 0.08
C ¹ TEd (10-20 ms, 40%)	59.53 \pm 1.27	54.84 \pm 1.58	59.19 \pm 1.84	56.07 \pm 2.07
C TEd (peak, 40%)	59.00 \pm 1.17	63.62 \pm 1.43	60.52 \pm 1.96	56.28 \pm 1.92
C TEd (peak, 20%)	35.81 \pm 0.75	38.65 \pm 1.69	36.14 \pm 1.03	33.57 \pm 1.53
C TEd (40-60 ms, 40%)	47.92 \pm 1.14	51.90 \pm 1.09	50.17 \pm 2.03	43.29 \pm 2.29
C TEd (90-100 ms, 40%)	39.52 \pm 1.27	41.49 \pm 1.25	42.20 \pm 1.67	36.56 \pm 2.41
C Accommodation half-time (ms, 40%)	46.02 \pm 0.93	44.09 \pm 1.15	46.05 \pm 1.70	45.16 \pm 2.69
C S2 accommodation	19.48 \pm 0.77	19.13 \pm 1.32	18.32 \pm 0.89	18.72 \pm 1.45
C TEd (undershoot, 40%)	-15.34 \pm 1.01	-12.26 \pm 1.27	-17.67 \pm 1.35	-13.43 \pm 1.29
C TEh (10-20 ms, -40%)	-93.31 \pm 1.12	-94.49 \pm 1.56	-91.87 \pm 2.14	-90.88 \pm 4.93
C TEh (20-40 ms, -40%)	-120.1 \pm 1.9	-124.0 \pm 3.0	-119.8 \pm 3.4	-116.2 \pm 7.5
C TEh (90-100 ms, -40%)	-152.7 \pm 5.2	-167.9 \pm 4.9	-156.7 \pm 5.6	-149.4 \pm 12.1
C TEh (slope 101-140 ms, -40%)	2.62 \pm 0.17	2.74 \pm 0.11	2.93 \pm 0.20	2.60 \pm 0.30
C TEh (peak, -70%)	-312.4 \pm 6.7	-321.8 \pm 11.0	-300.3 \pm 10.1	-297.8 \pm 22.8
C S3 (-70%)	80.28 \pm 6.98	102.1 \pm 11.4	80.48 \pm 7.91	78.85 \pm 11.20
C TEh (overshoot, -40%)	17.33 \pm 1.05	20.23 \pm 1.41	17.70 \pm 1.20	15.62 \pm 1.71
D ¹ Resting slope	0.89 \pm 0.09	0.86 \pm 0.12	0.89 \pm 0.11	0.96 \pm 0.26
D Minimum slope	0.23 \pm 0.01	0.23 \pm 0.02	0.23 \pm 0.02	0.24 \pm 0.02
D Hyperpolarization slope	0.49 \pm 0.03	0.39 \pm 0.05	0.40 \pm 0.06	0.48 \pm 0.05
E ¹ Refractoriness at 2 ms (%)	45.82 \pm 5.60	46.20 \pm 11.00	47.91 \pm 4.41	48.05 \pm 10.20
E Refractoriness at 2.5 ms (%)	34.48 \pm 4.78	43.90 \pm 6.62	31.13 \pm 5.72	32.36 \pm 7.01
E Relative refractory period (ms)	4.38 \pm 1.09	5.05 \pm 1.22	4.36 \pm 1.11	4.70 \pm 1.07
E Superexcitability (%)	-19.00 \pm 3.91	-23.53 \pm 8.01	-17.94 \pm 3.74	-9.00 \pm 3.17
E Superexcitability at 5 ms (%)	-0.49 \pm 3.26	3.98 \pm 2.84	-1.63 \pm 4.46	-2.40 \pm 1.75
E Superexcitability at 7 ms (%)	-5.94 \pm 2.06	-1.78 \pm 1.69	-7.06 \pm 2.83	-7.01 \pm 1.76
E Subexcitability (%)	5.60 \pm 1.09	3.29 \pm 0.85	6.61 \pm 1.46	2.93 \pm 0.64

¹ A: stimulus-response relationship, B: strength-duration relationship, C: threshold electrotonus, D: current-threshold relationship, and E: recovery cycle. ² TEd: threshold electrotonus from depolarizing currents and TEh: threshold electrotonus from hyperpolarizing currents. Differences (*versus* control), considered to be significant at $P \leq 0.05$ (*: $P \leq 0.032$, **: $P \leq 9.4 \times 10^{-8}$), are highlighted in grey.

2.3.3. Résumé des résultats obtenus

Les résultats obtenus fournissent des informations détaillées concernant les effets du peptide (i) sur les sous-types $\text{Na}_v1.6$ et 1.4 de canaux sodium impliqués dans les propriétés d'excitabilité du système neuromusculaire de souris *in vivo*, (ii) sur ces mêmes sous-types impliqués dans la contraction musculaire enregistrée au niveau de préparations neuromusculaires isolées de souris, (iii) sur les sous-types Na_v TTX-S et TTX-R des neurones de DRG de souris adultes et (iv) sur le sous-type $\text{hNa}_v1.6$ exprimé dans des cellules recombinantes HEK-293. En particulier, les injections locales i.m. d'HwTx-IV sont aussi efficaces que celles de la TTX pour altérer, *in vivo*, les propriétés d'excitabilité du système neuromusculaire de souris anesthésiées. Au niveau de préparations neuromusculaires isolées de souris, le peptide est 30 fois plus efficace pour inhiber la contraction musculaire obtenue suite à la stimulation du nerf que celle obtenue suite à la stimulation directe du muscle. De même, l'HwTx-IV présente une puissance pour les sous-types Na_v TTX-S des neurones de DRG de souris qui est 850 fois plus élevée que celle pour les sous-types TTX-R. Finalement, des puissances similaires du peptide ont été déterminées pour les sous-types $\text{hNa}_v1.6$ et 1.7 (IC_{50} de 83.3 et 32.6 nM, respectivement) exprimés dans des cellules HEK-293. L'ensemble de ces résultats montre une interaction directe et de haute puissance entre l'HwTx-IV et le sous-type $\text{Na}_v1.6$ de canaux sodium. Comme l'HwTx-IV a une très faible puissance pour les sous-types cardiaques $\text{hNa}_v1.5$, $\text{hCa}_v1.2$ et $\text{hK}_v11.1$ ($\text{IC}_{50} > 10 \mu\text{M}$), il est peu probable que le décès des animaux injectés avec ce peptide soit dû à un arrêt cardiaque lors des expérimentations. En revanche, il est fort probable qu'il résulte d'un arrêt respiratoire, *i.e.* un des troubles indésirables produits par l'HwTx-IV au niveau du système neuromusculaire, suite à l'interaction de haute puissance entre le peptide et le sous-type $\text{Na}_v1.6$ puisque le sous-type $\text{Na}_v1.4$ est peu sensible à ce peptide. Cette interaction entre l'HwTx-IV et le sous-type $\text{Na}_v1.6$ permet également de mieux comprendre les mécanismes des effets secondaires indésirables produits par ce peptide au niveau du système neuromusculaire.

Des expériences complémentaires, dont les résultats ne sont pas inclus dans la publication, ont été réalisées récemment afin d'étoffer le profil de sélectivité de l'HwTx-IV en étudiant ses effets sur des lignées cellulaires recombinantes exprimant certains sous-types hCa_v , hK_v et hKir non étudiés jusqu'à ce jour. A une concentration de $10 \mu\text{M}$, l'HwTx-IV n'affecte pas notablement certains sous-types de canaux ioniques impliqués plus particulièrement dans le potentiel d'action cardiaque ($\text{hCa}_v1.2$, 2.2, 3.1 et 3.2, $\text{hK}_v7.1$ et 11.1, hKir2.1). En revanche, comme observé précédemment avec la CyrTx-1a (voir sous-partie 2.1), le sous-type $\text{hK}_v4.3$ est inhibé de $82,8 \pm 1,7\%$ en présence de $10 \mu\text{M}$ d'HwTx-IV ($\text{IC}_{50} = 2,3 \pm 0,3 \mu\text{M}$; $n_H = 1,2 \pm 0,1$; moyenne \pm ES de 6 expériences; [Figure 2-4](#)).




Figure 2-4. Effets de l'HwTx-IV sur les courants hCa_v, hK_v et hK_{ir}. Histogramme exprimant les pourcentages de courant restant (en gris foncé) et inhibé (en gris clair) en fonction du sous-type de canal indiqué, en présence de 10 μM de peptide (moyenne ± ES, n = 2-17).

2.3.4. Conclusion

Cette étude est la première montrant une interaction directe et de haute puissance entre l'HwTx-IV et le sous-type Na_v1.6 de canaux sodium. En effet, cette toxine avait été décrite dans la littérature pour être hautement spécifique du sous-type Na_v1.7 sans aucune mention de ses effets éventuels sur le sous-type Na_v1.6. Or, nos résultats mettent en évidence des puissances similaires de l'HwTx-IV pour ces deux sous-types de canaux sodium, permettant de mieux comprendre les mécanismes des effets secondaires indésirables produits par ce peptide au niveau du système neuromusculaire. De plus, les résultats obtenus des expériences complémentaires montre que l'HwTx-IV, à de plus fortes concentrations, exerce également un effet inhibiteur sur le sous-type K_v4.3 de canaux potassium responsable de la première phase de repolarisation (rapide) du potentiel d'action cardiaque (Huo et al., 2014), ce qui peut éventuellement entraîner des arythmies. En conséquence, cette molécule, potentiellement antinociceptive, est nettement moins attractive pour son développement en tant qu'agent thérapeutique.

2.4. Profil de sélectivité original de la poécitoxine-1a de l'araignée *Poecilotheria subfusca* pour les sous-types humains de canaux ioniques dépendants du potentiel

2.4.1. Contexte de l'étude

Parmi les sous-types de canaux Na_v , le sous-type $Na_v1.7$ semble être la cible la plus intéressante pour traiter notamment la douleur chronique débilante (de Lera Ruiz & Kraus, 2015; Vetter et al., 2017; Gonçalves et al., 2018a). Cependant, la découverte de nouveaux peptides qui ciblent ce sous-type de canaux Na_v reste un défi dans le traitement pharmacologique de la douleur car ces peptides analgésiques potentiels peuvent également produire des effets secondaires non négligeables en raison de leur manque de sélectivité vis-à-vis des autres types et sous-types de canaux ioniques (Gonçalves et al., 2018b). Pour répondre correctement à la question de la sélectivité, il est donc nécessaire d'étudier les effets d'un peptide d'intérêt non seulement sur d'autres sous-types de canaux Na_v , tels que $Na_v1.4$, 1.5 et 1.6 , mais aussi sur certains sous-types de canaux K_v , Kir et Ca_v pour s'assurer d'une action limitée du peptide sur les systèmes cardiaque et neuromusculaire.

Trois grandes familles de canaux Ca_v ont été identifiées à ce jour (Catterall, 2011): les canaux à haut seuil d'activation $Ca_v1.x$ de type L, les canaux $Ca_v2.x$ neuronaux de types N, P/Q et R, et les canaux à bas seuil d'activation $Ca_v3.x$ de type T (voir partie 1). Aux Etats-Unis, le sous-type $Ca_v1.2$, comme les sous-types de canaux $Na_v1.5$, $K_v4.3$, $K_v7.1$, $K_v11.1$ et $Kir2.1$, est inclus dans la liste des canaux ioniques cardiaques mentionnés par la FDA (pour "Food and Drug Administration") dans son initiative CiPA (pour "Comprehensive *in vitro* Proarrhythmia Assay"). Il a été signalé que le blocage de ce sous-type, responsable notamment du "plateau" des potentiels d'action cardiaques, contrebalançait le syndrome du QT long, qu'il soit congénital (*i.e.* d'origine génétique) ou produit par certains médicaments inhibiteurs du sous-type $K_v11.1$, et la tachycardie ventriculaire associée dite "torsade de pointes" (Crumb et al. 2016).

Le criblage de la banque de 117 venins, menée sur des lignées cellulaires HEK-293 exprimant les sous-types $hNa_v1.7$ et 1.5 de canaux sodium et réalisée pour mettre en évidence la CyrTx-1a (voir sous-partie 2.1), nous a également permis d'identifier une autre toxine, la poécitoxine-1a (PecTx-1a) dans le venin de l'araignée *Poecilotheria subfusca*. Cette toxine a été purifiée, séquencée, synthétisée chimiquement, et son profil pharmacologique a été établi sur une large gamme de sous-types de canaux hNa_v , hK_v , $hKir$ et hCa_v exprimés dans différentes lignées cellulaires recombinantes.

2.4.2. Publication n°5

Publication en préparation

“Original selectivity profile of *Poecilotheria subfusca* spider poecitoxin-1a for human voltage-gated ion channel subtypes”

Tânia C. Gonçalves, Evelyne Benoit, Michel De Waard, Michael Kurz, Camille Sanson, Brigitte Schombert, Andrees Bohme, Jean-Marie Chambard, Rémy Bérout, Jean-Michel Itier, Denis Servent & Michel Partiseti

1 Original selectivity profile of *Poecilotheria subfusca* spider poecitoxin-1a for 2 human voltage-gated ion channel subtypes

3
4 Tânia C. Gonçalves^{1,2}, Evelyne Benoit^{2,3}, Michel De Waard^{4,5}, Michael Kurz⁶, Camille Sanson¹,
5 Brigitte Schombert¹, Andrees Bohme¹, Jean-Marie Chambard¹, Rémy Béroud⁴, Jean-Michel Itier⁷,
6 Denis Servent², Michel Partiseti^{1,*}

7 ¹Sanofi R&D, Integrated Drug Discovery – High Content Biology, F-94440 Vitry-sur-Seine, France;

8 ²Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, F-91191

9 Gif sur Yvette, France; ³Institut des Neurosciences Paris-Saclay (Neuro-PSI), UMR CNRS/Université

10 Paris-Sud 9197, Université Paris-Saclay, F-91198 Gif sur Yvette, France; ⁴Smartox Biotechnology, 6

11 rue des Platanes, F-38120 Saint-Egrève, France; ⁵Institut du Thorax, Inserm UMR 1087 / CNRS UMR

12 6291, LabEx "Ion Channels, Science & Therapeutics", F-44007 Nantes, France; ⁶Sanofi R&D,

13 Integrated Drug Discovery – Synthetic Molecular Design, G-65929 Frankfurt, Germany; ⁷Sanofi

14 R&D, Translational sciences – Cell-omics, F-94440 Vitry-sur-Seine, France

15 *Corresponding author: Michel.Partiseti@sanofi.com

16
17 **ABBREVIATIONS** – BMP, bone morphogenetic protein; BSA, bovine serum albumin; Ca_v channel,
18 voltage-gated calcium channel; CHO, Chinese hamster ovary; DMEM, Dulbecco's modified Eagle's
19 medium; DMSO, dimethylsulfoxide; ECG, electrocardiogram; ERG, *ether-a-go-go*-related gene;
20 FBS, fetal bovine serum; GPCR, G-protein-coupled receptor; h, human; HEK, human embryonic
21 kidney; HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; hiPSC-CM, human induced
22 pluripotent stem cell-derived cardiomyocyte; IC₅₀, toxin concentration necessary to inhibit 50% of
23 the response; IC₉₀₋₉₅, compound concentration necessary to inhibit 90-95% of current; ICK,
24 inhibitor cystine knot; IWR-1, inhibitor type 1 of Wnt response; JzTx, jingzhaotoxin; Kir channel,
25 inward-rectifier potassium channel; K_v channel, voltage-gated potassium channel; NaSpTx, Na_v
26 channel spider toxin; Na_v channel, voltage-gated sodium channel; PBS, phosphate buffered saline;
27 PecTx-1a, poecitoxin-1a; PTM, post-translational modification; RPMI, Roswell Park Memorial
28 Institute; TEA, tetraethylammonium; TTX, tetrodotoxin; TTX-R, resistant to tetrodotoxin; TTX-S,
29 sensitive to tetrodotoxin; U2OS cell, human bone osteosarcoma epithelial cell.

30 31 **ABSTRACT**

32 Over the last two decades, animal venom toxins have been explored as an original source of
33 new antinociceptive drugs targeting different ion channel subtypes. Although the gold standard
34 remains the time-consuming manual patch-clamp, automated patch-clamp platforms were
35 developed to increase the number of positive hits. The experimental approach of the present
36 study was to perform high-throughput screening of a large collection of venom toxins through
37 automated whole-cell patch-clamp experiments on human embryonic kidney (HEK)-293 cells
38 overexpressing the genetically validated antinociceptive target Na_v1.7 and the cardiac Na_v1.5

39 human (h) subtypes of voltage-gated sodium (Na_v) channels. This first step aimed to identify
40 bioactive peptides that were then purified, sequenced and chemically synthesized. The second
41 step consisted in characterizing the synthetic peptide of interest on hNa_v , voltage-gated potassium
42 (hK_v) and calcium (hCa_v), as well as on inward-rectifier potassium (hKir), channel subtypes
43 overexpressed in cells and on calcium currents of human induced pluripotent stem cell-derived
44 cardiomyocytes. The key results are the identification of a new bioactive peptide, poecitoxin-1a
45 (PecTx-1a), the first one isolated from the *Poecilotheria subfusca* spider venom, as a 35 amino acid
46 toxin belonging to the inhibitor cystine knot (ICK) structural family. This peptide inhibited the
47 $\text{hCa}_v1.2$ channel subtype with very high affinity (5 nM producing 50% current inhibition) and
48 selectivity against the studied hNa_v , hK_v , hKir and other hCa_v subtypes, including those implicated
49 in cardiac action potential. In conclusion, PecTx-1a is the first ICK spider toxin specifically targeting
50 the L-type, $\text{hCa}_v1.2$ channel subtype with an original selectivity profile. This peptide represents
51 thus, at least, a valuable tool to study the $\text{Ca}_v1.2$ subtype function and location and, at best, a
52 valuable drug to treat some cardiomyopathies such as the long QT syndrome.

53 **Keywords** – *Poecilotheria subfusca* spider, poecitoxin-1a, human voltage-gated ion channel
54 subtypes, $\text{Ca}_v1.2$ channel subtype, cell lines overexpressing ion channel subtypes, human induced
55 pluripotent stem cell-derived cardiomyocytes.

56

57 1. INTRODUCTION

58 Pain transmission is conveyed by neurons from the periphery (*i.e.* skin and tendons) to the
59 brain. These neurons express many proteins at the plasmatic membrane surface that may be
60 considered as targets for therapeutic treatment of pain, as well as some enzymes such as
61 cyclooxygenase already attained by nonsteroidal anti-inflammatory drugs. The transmembrane
62 proteins, often human (h) genetically validated, are part of big families including ion channels and
63 G-protein-coupled receptors (GPCRs). The agonists of GPCRs (such as opioid, cannabinoid,
64 angiotensin type II, $\alpha 2$ -adrenergic, muscarinic acetylcholine, γ -aminobutyric acid B, groups II and
65 III metabotropic glutamate, chemokine and somatostatin receptors) have been reported to exhibit
66 antinociceptive effects (Pan et al., 2008; Yekkirala et al., 2017). In addition, the blockers of ion
67 channels [such as voltage-gated sodium (Na_v) and calcium (Ca_v) channels, transient receptor
68 potential channels, acid sensing ion channels, piezo proteins, ionotropic P2X receptors], as well as
69 potassium channel enhancers, have been shown to be involved in pain relief (Bennett and Woods,
70 2014; Waxman and Zamponi, 2014).

71 In many cases, peptides derived from animal venoms are the most potent modulators of the
72 above channels and receptors. In particular, animal venom toxins have been explored over the last
73 two decades as an original source of new antinociceptive drugs targeting different types of ion [Na_v ,
74 Ca_v and voltage-gated potassium (K_v)] channels, giving more recently an attention to Na_v channel
75 subtypes (Cardoso and Lewis, 2017). Nine Na_v channel subtypes ($\text{Na}_v1.1$ -1.9), composed of a
76 voltage-sensing pore forming α -subunit surrounded by small regulatory β subunits, are known to be
77 distributed in the mammal organism where they are responsible for action potential generation and

78 propagation (Catterall, 2000; Goldin et al., 2000; de Lera Ruiz and Kraus, 2015; Namadurai et al.,
79 2015). These subtypes have specific expression pattern and/or biophysical properties: Na_v1.1-1.3
80 and 1.6 are expressed in the central nervous system, Na_v1.5 is mainly present in the heart, Na_v1.4 is
81 located in the skeletal muscle innervated by motoneurons α where Na_v1.6 is expressed, and Na_v1.7-
82 1.9 convey mainly pain message through dorsal root ganglia neurons from the periphery to the
83 central nervous system (Cardoso and Lewis, 2017; Israel et al., 2017).

84 Among Na_v channel subtypes, the Na_v1.7 subtype seems to be the most interesting target to
85 treat chronic debilitating pain (de Lera Ruiz and Kraus, 2015; Vetter et al., 2017; Gonçalves et al.,
86 2018a). However, finding out new peptides that target the Na_v1.7 subtype remains a challenge in
87 the pharmacological treatment of pain because these potential analgesic peptides may also
88 produce strong side-effects due to their lack of target selectivity (Gonçalves et al., 2018b). To
89 properly address the question of selectivity, additional experiments are therefore necessary to
90 study the effects of the peptide of interest not only on other Na_v subtypes, such as Na_v1.4, 1.5 and
91 1.6, but also on some Ca_v, K_v and Kir channel subtypes to ensure neuromuscular and cardiac safety
92 issues. In particular, three superfamilies of Ca_v channels have been identified nowadays (Catterall,
93 2011): Ca_v1 (high voltage-activated, L-type channels), Ca_v2 (intermediate voltage-activated, P/Q-,
94 N- and R-type channels) and Ca_v3 (low voltage-activated, T-type channels). The Ca_v1.2 subtype is
95 expressed in neurons, adrenal chromaffin cells, pancreatic islets cells, the heart (sinoatrial and
96 atrioventricular nodes, cardiomyocytes), the vascular system and intestinal/bladder smooth
97 muscles. This subtype is required for normal brain and endocrine functioning, and exerts different
98 roles in the heart (Zamponi et al., 2015). The Ca_v1.2 channel subtype, like the Na_v1.5, K_v4.3, K_v7.1,
99 K_v11.1 and Kir2.1 channel subtypes, belongs to the panel of cardiac ion channels mentioned in the
100 FDA's Comprehensive *in-vitro* Proarrhythmia Assay initiative. It is notably responsible for the
101 "plateau" of cardiac action potentials. Blocking this subtype has been reported to counteract drug-
102 induced (by K_v11.1 blockers, for example) or mutation-induced long QT syndromes and eventual
103 associated "torsade de pointes" ventricular arrhythmia (Crumb et al., 2016).

104 In the present study, we identified a new bioactive peptide, poecitoxin-1a (PecTx-1a), from
105 the *Poecilotheria subfusca* spider venom, following high-throughput screening of a large venom
106 collection using automated patch-clamp electrophysiology on cells overexpressing the hNa_v1.7
107 channel subtype. This peptide was purified, sequenced, chemically synthesized, and its
108 pharmacological profile was established on various subtypes of hNa_v, hK_v, hKir and hCa_v channels
109 overexpressed in cell lines. PecTx-1a, a 35 amino acid toxin belonging to the inhibitor cystine knot
110 (ICK) structural family, was shown to inhibit the hCa_v1.2 channel subtype at nanomolar
111 concentrations, *i.e.* with high affinity *versus* hNav1.7 and high selectivity against the other studied
112 channel subtypes, including those involved in the cardiac action potential.

113

114 **2. EXPERIMENTAL SECTION**

115 **2.1. Isolation, purification and amino acid sequencing of PecTx-1a**

116 The *Poecilotheria subfusca* spider venom was fractionated using an analytical RP-HPLC C18

117 column (XBridge™ BEH 130, 3.5 µm and 4.6 mm ID x 250 mm L column) attached to an Agilent
118 1260 HPLC (Agilent Technologies). Fractions that contained between 5 and 15 peptides each, at an
119 estimated average concentration of 0.5 µg/µL (500 ng of dry mass suspended in water), were first
120 evaluated in a functional screening assay on engineered human embryonic kidney (HEK)-293 cell
121 lines overexpressing the human (h)Na_v1.7 channel subtype, using the IonWorks Quattro platform
122 (Molecular Devices, USA), as previously reported (Gonçalves et al., 2018c). To individualize the
123 compounds, active fractions were finally sub-fractionated using cation exchange chromatography
124 with a TOSOH Bioscience column (TSK gel SP-STAT, 7 µm, 4.6 mm ID x 10 cm L, TOSOH Bioscience,
125 Germany) onto an Agilent 1260 HPLC. The purified compounds were screened on HEK-293 cells
126 overexpressing hNa_v1.7 and hNa_v1.5 channel subtypes, using the QPatch HTX automated
127 electrophysiology platform (Sophion BioScience, Denmark), leading to the identification of PecTx-
128 1a as one of the peptides of interest.

129 The peptide amino acid sequence was determined by *de novo* MS/MS sequencing and EDMAN
130 degradation. The purified venom peptide obtained after successive RP-HPLC and cation exchange
131 chromatography was resuspended in 100 mM ammonium bicarbonate (pH 8), reduced with 17
132 mM TCEP (incubated at 55°C for 1 hr) and alkylated with 24 mM iodoacetamide (incubated at
133 room temperature in the dark for 1 hr) prior to enzyme digestion. The reduced/alkylated venom
134 peptide was digested by using trypsin or V8 proteases. The enzyme was added at a 1:10 ratio
135 (enzyme/peptide, w/w) and incubated overnight at 37°C before LC-MS(/MS) analyses. A Waters Q-
136 TOF Xevo G2S mass spectrometer equipped with an Acquity UHPLC system and Lockspray source
137 was used for the acquisition of the LC-ESI-MS and LC-ESI-MS/MS data, and the amino acid
138 sequence determination, based on Edman degradation, was performed using an Applied
139 Biosystems gas-phase sequencer model 492 (s/n: 9510287J), as previously detailed (Gonçalves et
140 al., 2018c).

141 2.2. Chemical synthesis, folding and 3D-structure of PecTx-1a

142 PecTx-1a was assembled stepwise using a 2-chlorotrityl chloride resin (substitution rate of 1.6
143 mmol/g) by solid-phase fmoc chemistry on a Symphony Synthesizer (Protein technologies Inc.).
144 The coupling reaction of each amino acid took 15 min and the reaction was repeated 3 times to
145 increase the amino acid coupling yield. After resin cleavage and deprotection with 92.5% (vol)
146 trifluoroacetic acid (TFA), 2.5% H₂O and scavengers [1,3-dimethoxybenzene (2.5%) and
147 triisopropylsilane (2.5%)], the peptide was purified to homogeneity by C18 RP-HPLC on a Jupiter
148 Proteo column (Phenomenex, 4 µm, 21.2 mm ID x 250 mm L), using an Agilent Technologies
149 preparative HPLC (1260 Infinity). Finally, PecTx-1a was folded/oxidized in 50 mM Tris-HCl (pH 8.3)
150 for 72 hr. The resulting oxidized PecTx-1a with its three disulfide bridges was purified to
151 homogeneity (> 99% purity according to the integration of the purified chromatogram peak at 214
152 nm) using RP-HPLC, again with the Jupiter Proteo column. The molecular mass of PecTx-1a was
153 determined by LC-ESI-QTOF MS. The absence of contaminant masses attested of the purity of
154 synthetic PecTx-1a.

155 The 3D-structure of PecTx-1a was determined by high-resolution NMR spectroscopy in an
156 aqueous solution (10% D₂O) of 3 mg peptide in 600 µL of 100 mM acetate buffer (pH 5), at 307°K.

157 Data were obtained on a Bruker Avance 700 MHz using standard 2D spectra. Resonances were
158 assigned with 2D-spectra including DQF-COSY, TOCSY, NOESY, ^1H - ^{13}C -HSQC and ^1H - ^{15}N -HSQC. For
159 conformational analysis, NOE based distance restraints were obtained from a NOESY spectrum
160 with 100 ms mixing time. 648 distance restraints were used in a simulated annealing protocol
161 starting from a linear, extended structure including 97 intra residual distances, 174 sequential
162 distances, 132 medium distances (2-4 amino acids apart) and 245 long range distances (> 4 amino
163 acids apart). Calculations were performed with the software package SYBYL (version 2.1.1). All
164 energy calculations were based on AMBER7 F99 force field. Distance restraints for non-separated
165 methylene protons and methyl groups were used with pseudoatom correction: 0.9 Å were added
166 to the upper bound for methylene groups, and 1.0 Å was added for methyl groups. Ten well-
167 converged structures were obtained. The rmsd over all backbone atoms was 0.353 ± 0.141 Å, and
168 that over all heavy atoms was 0.659 ± 0.271 Å.

169 **2.3. Toxins, chemicals and cell lines used for functional assays**

170 Lyophilized synthetic PecTx-1a (molecular mass of 3996.6, purity rate > 99%) was dissolved in
171 appropriate solutions to give adequate stock solutions. A reduced (S-carboxymethylated) inactive
172 form of the peptide (molecular mass of 4347.1, purity rate > 95%) was used in some experiments.
173 This reduced form was obtained by shaking 1 mg of oxidized peptide in 1 mL of solution containing
174 100 mM Tris-HCl and 10 mM dithiotreitol (pH 8), for 90 min at 37°C. Then, the molecule was S-
175 carboxymethylated by adding 20 µL of a solution containing 1.25 M iodoacetic acid and 6 M
176 gadolinium, and by shaking for 2 hr in the dark before being acidified (20% TFA, pH 1) and purified
177 using an analytical RP-HPLC C18 column. All compounds used as reference molecules to
178 pharmacologically validate the current flowing through each channel subtype, as indicated in
179 Table 1, were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France) or obtained from
180 Smartox Biotechnology (Saint-Egrève, France) and Sanofi-Aventis (Vitry-sur-Seine, France). The
181 toxins were dissolved in distilled water to give a 100-µM stock solution, and the chemicals were
182 dissolved in 100% dimethylsulfoxide (DMSO, Sigma-Aldrich) to give a 10-mM stock solution. Just
183 prior to experiments, successive dilutions were performed in the appropriate standard
184 physiological medium [supplemented with 0.1% bovine serum albumin (BSA, Sigma-Aldrich) for
185 toxins to avoid plastic adherence, and with 0.3% DMSO for chemicals to maintain solubility], to
186 give the compound final concentrations indicated in the text.

187 Generation of inducible cell lines was achieved by cloning cDNAs encoding for hNa_v1.2
188 (NM_021007.2), hNa_v1.5 (NM_000335), hCa_v3.2 (NM_021098.2), hCa_v3.1 (NM_018896.4) and
189 hK_v1.5 (NM_002234.3) channel subtypes into the Flp-In[®] T-Rex[®] expression vector (Invitrogen,
190 USA) and subsequently transfected them into HEK-293 or Chinese hamster ovary (CHO) cell lines.
191 The cDNA encoding for the hK_v7.1 subtype (NM_000218.2) was cloned into the Jump-In[®] T-Rex[®]
192 expression vector (Invitrogen) and subsequently transfected into human bone osteosarcoma
193 epithelial (U2OS) cell line. Recombinant HEK-293 cell lines, stably overexpressing the other hNa_v
194 subtypes, were purchased from SB Drug Discovery (UK; hNa_v1.4), ChanTest (Cleveland, OH, USA;
195 hNa_v1.6) and Eurofins (St Charles, MO, USA; hNa_v1.7 and hNa_v1.8/β1). CHO cells, heterologously
196 overexpressing hKir2.1 and the other hCa_v and hK_v subtypes, were purchased from ChanTest


197 (hCa_v1.2/β2/α2δ1, hCa_v2.2/β3/α2δ1, hKir2.1 and hK_v4.3/KCHIP2.2) and B'SYS GmbH [Switzerland;
198 hK_v11.1 encoded by the human *ether-a-go-go*-related gene (hERG)].

Table 1. Compounds used as reference molecules to pharmacologically validate the current flowing through each hNa_v, hCa_v and hK_v channel subtype.

Channel subtype	Drug reference			Provider	IC ₉₀₋₉₅ ³
	Name	MM	Purity rate		
hNa _v 1.1-1.8	Tetrodotoxin (citrate)	319.27	> 98%	Sigma-Aldrich	1 μM
hCa _v 1.2	Nifedipine	346.33	> 98%	Sigma-Aldrich	10 μM
	Cadmium (Cl) ¹	183.32	> 99.99%	Sigma-Aldrich	200 μM
hCa _v 2.2	ω-Conotoxin GVIA ^A	3036.05	> 95%	Smartox Biotechnology	1 μM
hCa _v 3.1-3.2	Mibefradil (H ₂ Cl) ²	568.55	> 98%	Sigma-Aldrich	30 μM
	Nickel (Cl) ¹	237.69	> 99.99%	Sigma-Aldrich	2 mM
hK _v 1.5	Quinidine	324.42	> 98%	Sigma-Aldrich	100 μM
hK _v 4.3	SNX-482	4495.00	> 98%	Sigma-Aldrich	1 μM
hK _v 7.1	HMR 1556	411.44	> 99.99%	Sanofi-Aventis	1 μM
hK _v 11.1	BeKm-1	4091.70	> 97%	Smartox Biotechnology	1 μM
hKir2.1	Barium (Cl) ¹	208.23	> 99.99%	Sigma-Aldrich	30 μM

¹Cl: chloride, ²H₂Cl, dihydrochloride, ³IC₉₀₋₉₅, compound concentration necessary to inhibit 90-95% of current.

A. Concentration-response curve of ω-conotoxin GVIA effects on hCa_v2.2 peak current (not documented in the literature). Each value, expressed as percentage of that obtained before toxin application, represents the mean ± S.D. of data obtained from 3-4 cells. The theoretical curve corresponds to data point fit with IC₅₀ and n_H values of 229.4 nM and 2.2, respectively (r² = 0.993).



199 Transfected or stably overexpressing hNa_v1.1-8, hCa_v1.2 and hK_v11.1 cells were cultured as
200 previously reported (Gonçalves et al., 2018c). CHO cells heterologously overexpressing hCa_v2.2
201 and hK_v4.3 channel subtypes were cultured in Ham's F-12 Nutrient Mix with GlutaMAXTM medium
202 (Gibco, Thermo Fisher Scientific, France). Those overexpressing hKir2.1 subtype were cultured in
203 Dulbecco's modified Eagle's medium (DMEM)/F-12 Glutamax (Gibco). The complete media contain
204 10% fetal bovine serum (FBS, Gibco) and selected antibiotics and additives as recommended by
205 the manufacturer. In-house CHO-Flip-In-T-REx cells were kept in culture under standard conditions
206 (37°C, 5% CO₂) in Ham's F-12 Nutrient Mix with GlutaMAXTM medium supplemented with 10%
207 fetal calf serum (Invitrogen), 300 μg/mL hygromycin (Invitrogen) and 30 μg/mL blasticidin
208 (Invivogen). In-house U2OS-Jump-In-T-REx cells were kept in culture under standard conditions
209 (37°C, 5% CO₂) in McCoy's 5A (modified) with GlutaMAXTM medium (Gibco) supplement with 10%

210 fetal calf serum (Invitrogen), 0.1 mM of non-essential amino acids (Gibco), 25 mM N-2-
211 hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 1 µg/mL puromycin (Invitrogen) and 5
212 µg/mL blasticidin (Invivogen). Cells were sub-cultured/passaged every 3-4 days using accutase®
213 (Sigma-Aldrich) or TrypLE Select (Gibco) enzyme. Doxycycline (BD Biosciences, France) was added
214 to induce target expression when needed, at least between 12 and 24 hr prior to experiments.

215 The human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) UB47 cell line
216 was purchased from Univercell Biosolutions (Toulouse, France). The cells, derived from skin
217 fibroblasts were cultured in m-TeSR™1 medium (StemCell Technologies, Vancouver, Canada) on
218 matrigel-coated (BD Biosciences) dishes. They were sub-cultured/passaged once per week using
219 accutase® at a cell density of 5×10^3 cells/cm. Four days before induction of cardiac differentiation,
220 2×10^6 cells were plated on 60-mm diameter Petri dishes. The basal medium used for cardiac
221 induction was the Roswell Park Memorial Institute (RPMI) medium 1640 (Gibco) supplemented
222 with 500 µg/mL of human serum albumin (Sigma-Aldrich) and 213 µg/mL of ascorbic acid
223 (StemCell Technologies). The first day of induction, the basal medium was supplemented with 4
224 µM CHIR99021 (Miltenyi Biotech, Bergisch Gladbach, Allemagne) and 10 ng/mL bone
225 morphogenetic protein (BMP) 4 (Miltenyi Biotech). On Day 2, the medium was replaced with the
226 basal medium supplemented with 2 µM Wnt-C59 antagonist (Selleckchem, Texas, USA) and then,
227 on Day 3, with the basal medium supplemented with 2.5 µM inhibitor type 1 of Wnt response
228 (IWR-1, Sigma-Aldrich). On Day 4 and later, the cells were maintained in DMEM/F-12 medium
229 added with 5% FBS, 1% of non-essential amino acids, 1% of GlutaMax™, 1% of Penicillin-
230 Steptomycin (Gibco) and 0.2% of β-mercaptoethanol (Gibco). From Day 25 to Day 27, Multi Tissue
231 Dissociation Kits and the human PSC-Derived Cardiomyocyte Isolation Kit (Miltenyi Biotech) were
232 used to dissociate the beating cell layer and purify the cardiomyocytes which were then plated on
233 glass coverslips coated with 10 µg/mL of human fibronectin (Corning, New York, USA) for
234 subsequent experiments.

235 **2.4. Electrophysiological recordings**

236 Automated patch-clamp recordings. For screening of venom fractions, planar assay current
237 recordings from HEK-293 cells, in perforated patch-clamp configuration, were made on an
238 IonWorks Quattro® system (Molecular Devices, Sunnyvale, CA, USA) enabling population patch-
239 clamp measurement, as previously detailed (Trivedi et al., 2008; Chambard et al., 2014; Gonçalves
240 et al., 2018c). Cells were resuspended in 5 mL pre-filtered external buffer containing: 137 mM
241 NaCl, 4 mM KCl, 1 mM MgCl₂, 1.8 mM CaCl₂, 10 mM HEPES, and 5 mM D-glucose (osmolarity set at
242 306 mOsm/L and pH 7.3 adjusted with NaOH). The internal solution had the following
243 composition: 100 mM K-gluconate, 40 mM KCl, 1 mM MgCl₂, 1 mM EGTA, 10 mM HEPES, and 5
244 mM D-glucose (osmolarity set at 300 mOsm/L and pH 7.4 adjusted with KOH). The experiments
245 were carried out at room temperature (20-22°C). After a 10-sec period holding at -100 mV,
246 currents were evoked by ten pulses, each consisting of a 50-ms step to the voltage of the peak
247 current of the current-voltage relationship for each channel subtype, followed by a 300-ms step
248 back to -120 mV, applied at 10 Hz. Currents were recorded before and 10 min after incubation of
249 cells in external solution added with venom fractions and supplemented with 0.1% BSA. The

250 degree of current inhibition was assessed by expressing the ratio of peak currents, calculated for
251 pulse 1 (tonic block) or pulse 10 (use-dependent block), recorded after and before fraction
252 application.

253 Screening of venom sub-fractions, as well as for hit confirmation and channel subtype
254 selectivity of PecTx-1a, was also performed on an automated patch-clamp system, the QPatch HTX
255 (Sophion Bioscience, Denmark), recording currents in whole-cell configuration and allowing both
256 signal acquisition and data analyses, as previously reported (Bell and Dallas, 2017; Gonçalves et al.,
257 2018c). The day of their use, HEK-293, CHO and U2OS cells were transferred into Eppendorf tubes
258 containing a FreeStyle 293 expression medium (Gibco) which were then placed in the automated
259 electrophysiology platform. The extracellular medium composition for hNav_v-overexpressing HEK-
260 293 cells was: 154 mM NaCl, 4 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, and 10 mM HEPES (pH 7.4
261 adjusted with NaOH), and that of intracellular (*i.e.* patch-clamp pipette) medium: 150 mM CsF, 1/50
262 mM EGTA/CsOH, 10 mM HEPES, 10 mM NaCl, 1 mM MgCl₂, and 1 mM CaCl₂ (pH 7.4 adjusted with
263 CsOH). The extracellular medium composition for hCa_v-overexpressing CHO cells was: 145 mM
264 NaCl, 4 mM KCl, 10 mM CaCl₂, and 10 mM HEPES (pH 7.4 adjusted with NaOH), and that of
265 intracellular medium: 27 mM CsF, 112 mM CsCl, 8.2 mM EGTA, 10 mM HEPES, 2 mM NaCl, and 4
266 mM Mg-ATP (pH 7.4 adjusted with CsOH). The extracellular medium composition for hK_v-
267 overexpressing CHO and U2OS cells was: 145 mM NaCl, 4 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 10
268 mM HEPES, and 10 mM D-glucose (pH 7.4 adjusted with NaOH). That of intracellular medium was :
269 120 mM KCl, 5.4 mM CaCl₂, 10 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP, and 1.75 mM MgCl₂ (pH
270 7.4 adjusted with KOH) for hK_v11.1-overexpressing CHO cells; 130 mM potassium aspartate, 5 mM
271 EGTA, 10 mM HEPES, and 5 mM MgCl₂ (pH 7.4 adjusted with KOH) for hK_v1.5- and hK_v4.3-
272 overexpressing CHO cells; 120 mM potassium fluoride, 20 mM KCl, 10/31.25 mM EGTA/KOH, 10
273 mM EDTA, and 10 mM HEPES (pH 7.2 adjusted with KOH) for hK_v7.1-overexpressing U2OS cells;
274 and 120 mM KCl, 10 mM EGTA, 5mM CaCl₂, 10 mM HEPES, and 1.75 mM MgCl₂ (pH 7.4 adjusted
275 with KOH) for hKir2.1-overexpressing CHO cells. Venom sub-fractions and PecTx-1a were diluted in
276 the extracellular medium supplemented with BSA (0.1%), to give the final concentrations indicated
277 in the text. The times of incubation were adjusted to achieve steady-state effects. The
278 concentration-response relationships were established by expressing the maximal amplitude of
279 the sum of ten cell currents recorded in the presence of a given sub-fraction or toxin
280 concentration relatively to that of the sum of these currents recorded before sub-fraction or toxin
281 application.

282 The experiments were carried out at room temperature (20-22°C). The hNav_v-overexpressing
283 HEK-293 cells were maintained at a holding potential of either -90 mV (hNav_v1.5) or -100 mV (other
284 hNav_v channel subtypes). Currents were elicited at a frequency of 0.2 Hz by 20-ms test-pulses to -
285 20 mV (hNav_v1.2, 1.4, and 1.7), -40 mV (hNav_v1.5), -15 mV (hNav_v1.6) or 10 mV (hNav_v1.8), preceded
286 by 40-ms (hNav_v1.7) or 200-ms (hNav_v1.5) pulses to -120 mV, or not (hNav_v1.2, 1.4, 1.6, and 1.8). The
287 hCa_v-overexpressing CHO cells were maintained at a holding potential of -50 mV (hCa_v1.2), -90 mV
288 (hCa_v2.2) or -100 mV (hCa_v3.1 and 3.2), and currents were elicited at a frequency of 0.05 Hz by
289 200-ms test-pulses to 0 mV (hCa_v1.2), by 500-ms test-pulses to 20 mV (hCa_v2.2) or by 500-ms test-

290 pulses to -20 mV (hCa_v3.1 and 3.2). The hK_v11.1-overexpressing CHO cells were maintained at a
291 holding potential of -80 mV, and tail currents were elicited at a frequency of 0.07 Hz by 5-sec test-
292 pulses to -50 mV, preceded by 4.8-sec pulses to 20 mV following 20-ms pulses to -50 mV. The
293 hKir2.1-overexpressing CHO cells were maintained at a holding potential of -20 mV, and currents
294 were elicited at a frequency of 0.03 Hz by 500-ms test-pulses to -120 mV followed by 1-sec
295 potential ramps from -120 to 0 mV. The hK_v1.5-overexpressing CHO cells were maintained at a
296 holding potential of -90 mV, and currents were elicited at a frequency of 0.05 Hz by 500-ms test-
297 pulses to 20 mV. The hK_v4.3-overexpressing CHO cells were maintained at a holding potential of -
298 90 mV, and currents were elicited at a frequency of 0.1 Hz by 300-ms test-pulses to 20 mV. The
299 hK_v7.1-overexpressing U2OS cells were maintained at a holding potential of -60 mV, and currents
300 were elicited at a frequency of 0.07 Hz by 1-sec test-pulses to 40 mV preceded by 200-ms pulses to
301 -80 mV.

302 Manual patch-clamp recordings. Whole-cell manual patch-clamp experiments were
303 performed on hiPSC-CMs by using an Axopatch 200B integrating patch-clamp amplifier and the
304 pClamp10.2 software (Molecular Devices, Sunnyvale, CA, USA). The signals, acquired at a 4-kHz
305 sample rate, were filtered at 2 kHz with a low-pass Bessel filter and digitized with the aid of a
306 computer equipped with an analog-to-digital converter (Digidata-1440A model; Molecular
307 Devices). The patch-clamp pipettes were filled with a medium composed of: 110 mM CsCl, 20 mM
308 tetraethylammonium (TEA) chloride, 10 mM EGTA, 5 mM Mg-ATP, 2 mM MgCl₂, and 10 mM
309 HEPES (pH 7.2, adjusted with CsOH), and had about 2-MΩ resistance in the standard physiological
310 medium. A fast perfusion system allowed changing the extracellular medium (added or not with a
311 given toxin concentration) around the recorded hiPSC-CM within a few seconds. The composition
312 of the extracellular physiological medium was: 120 mM N-methyl-d-glucamine chloride, 20 mM
313 TEA chloride, 10 mM CaCl₂, 2 mM MgCl₂, 10 mM HEPES, and 10 mM D-glucose (pH 7.4 adjusted
314 with TEA hydroxide). The experiments were carried out at constant room temperature (22°C). The
315 cells were maintained at a holding potential of -80 mV, and currents were elicited at a frequency
316 of 1 Hz by 300-ms test-pulses varying from -70 to 50 mV in 5-mV increments.

317 **2.5. Data and statistical analyses**

318 Concentration-response relationships were established by plotting the response, recorded in
319 the presence of a given toxin (R_t) and expressed as percentage of the value obtained in absence of
320 toxin (R_c), against the toxin concentration ([toxin]). The theoretical concentration-response curves
321 were calculated from typical sigmoid nonlinear regressions through data points (correlation
322 coefficient = r²) according to the Hill equation (GraphPad Prism 5 or QPatch assay software):
323 $R_t / R_c = 1 / [1 + ([toxin] / IC_{50})^{n_H}]$, where IC₅₀ is the toxin concentration necessary to inhibit 50%
324 of the response, and n_H is the Hill number. Conductance (g) was calculated according to the
325 following equation: $g = I / (V_T - V_X)$, where I is the peak current amplitude, V_T is the test-pulse
326 voltage, and V_X is the equilibrium potential of ions. Conductance-voltage relationships were
327 established by plotting the conductance, expressed as percentage of the maximal conductance
328 (g_{max}) calculated at strongly positive test-pulses, as a function of test-pulse voltage. The
329 theoretical curves correspond to data point fits, according to the Boltzmann equation (GraphPad

330 Prism 5 software): $g / g_{max} = 1 - [1 / (1 + \exp ((V_T - V_{T50\%}) / k_g))]$, where $V_{T50\%}$ is the test-pulse
331 voltage corresponding to 50% maximal conductance, and k_g is the slope of the curve. Steady-state
332 inactivation-voltage relationships were established by plotting the peak current amplitude,
333 expressed as percentage of the maximal amplitude (I_{max}) recorded in response to strongly
334 negative pre-pulses, as a function of pre-pulse voltage (V_p). The theoretical curves correspond to
335 data point fits, according to the Boltzmann equation (GraphPad Prism 5 software):
336 $I / I_{max} = 1 / [1 + \exp ((V_p - V_{p50\%}) / k_h)]$, where $V_{p50\%}$ is the pre-pulse voltage corresponding to 50%
337 maximal peak amplitude of current, and k_h is the slope of the curve. Current kinetics were
338 evaluated by calculating: (1) the time to peak (t_p), defined as the time between test-pulse
339 triggering and the peak current, and (2) the time constant (τ_h) of the current decay, for current
340 inactivation that occurs as a mono-exponential decay as a function of time, *i.e.*
341 $I_{(t)} = I_{(0)} e^{(-t/\tau_h)}$ (Equation 1) where $I_{(0)}$ is the current at time zero of depolarization.

342 Data are expressed as means \pm standard deviations (S.D.) of n different experiments. The
343 statistical comparison of values was carried out using the parametric two-tailed Student's t -test
344 (either paired samples for comparison within a single population or unpaired samples for
345 comparison between two populations). Differences between values were considered to be
346 statistically significant at $P \leq 0.05$.

347

348 3. RESULTS

349 3.1. Isolation, purification and *de novo* amino acid sequencing of PecTx-1a

350 The screening process for the spider venom *Poecilotheria subfusca*, from primary fraction
351 selection to individual purified compound selection by secondary screening, is presented in Figure
352 1A-B. The primary screening of venom fractions was performed on automated patch-clamp
353 Ionworks Quattro platform using HEK-293 cells overexpressing the hNav_v1.7 channel subtype. It is
354 worth noting that, under our experimental conditions, no control current rundown was observed,
355 since the average peak current from pulse 1 was similar to that from pulse 10. In addition, no
356 inhibitory effect of 0.1% BSA was detected on the elicited current while it was fully blocked by 1
357 μ M TTX (used as internal positive control during the screening process). The percentage of
358 inhibition of peak hNav_v1.7 current obtained for each of the 64 fractions (tested at an average
359 concentration of 0.5 μ g/ μ L for a 10-min incubation period) is shown in Figure 1A (left panel).
360 Based on their relatively high potency for the hNav_v1.7 channel subtype, one fraction was selected
361 from this primary screening for sub-fractionation and compound isolation using cation exchange
362 chromatography. Hence, 5 sub-fractions were prepared and tested, at a final estimated amount of
363 100 ng per well, on HEK-293 cells overexpressing hNav_v1.7 and hNav_v1.5 channel subtypes, using the
364 QPatch HTX automated electrophysiology platform (Figure 1A, right panel). Two of them, SF03 and
365 SF05, were shown to display a potent blocking effect on hNav_v1.7 (94.7-96.9% block) while being
366 less efficient on hNav_v1.5 (35.0-75.4% block) channel subtypes. However, the SF05 sub-fraction also
367 produced a marked slow-down of hNav_v1.7 inactivation and was thus discarded.




Figure 1. Isolation, purification and *de novo* amino acid sequencing of PecTx-1a. **(A)** Percentage of inhibition of peak hNav_v1.7 current by 0.5 µg/µL of each of the 64 fractions obtained from *Poecilotheria subfusca* spider venom (left panel) and 100 ng per well of each of the 5 sub-fractions (SF) obtained from the fraction of interest (right panel), tested on HEK-293 cells overexpressing hNav_v1.7 (green circles) and hNav_v1.5 (black circles) channel subtypes. **(Ba and b)** Fractionation of the *Poecilotheria subfusca* crude venom by reversed-phase chromatography (RP-HPLC) and detection by UV at 214 nm. The fraction containing the peptide of interest is highlighted in green. **(Bc)** MALDI-TOF mass spectrometry of the primary fraction highlighted in (Bb), showing two predominant peaks corresponding to PecTx-1a (**1**, 3996.6 Da) and a non-characterized toxin (**2**, 3835.5 Da). **(Bd)** ESI-MS spectrum of PecTx-1a [M+3H]³⁺ detected at *m/z* 1333.2201. **(C)** Primary structure and disulfide bridge alignment of PecTx-1a. Disulfide bridging of the amidated (*) peptide of 35 amino acid residues including 6 cysteines, as defined by homology with toxins from the NaSpTx family 2, occurs according to the C1-C4, C2-C5 and C3-C6 pattern.

368 Finally, through the multi-step chromatographic approach, two new peptides, 1 and 2, were
 369 identified from SF03 sub-fraction using combined orthogonal reversed-phase and ion exchange
 370 techniques (Figure 1Ba-c). The molecular mass values of 3996.6 and 3835.5 Da for peptides 1 and

371 2, respectively, determined by LC-ESI QTOF MS (as exemplified for peptide 1 in Figure 1Bd),
372 indicated that these peptides should be amenable to chemical synthesis. However, natural peptide
373 2 was observed to be 66 times less potent than natural peptide 1 on HEK-293 cells overexpressing
374 hNav1.7 channel subtype and was thus discarded.

375 As peptide 1 belongs to a species that has not been genotyped, its primary sequence was
376 determined by *de novo* sequencing using a combination of analytical techniques including top-
377 down and bottom-up approaches with high resolution mass spectrometry. Hence, the purified
378 peptide was reduced using Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) and alkylated
379 with iodoacetamide. The alterations in molecular mass from 3996.6 to 4344.6 Da indicate that the
380 peptide should contain six cysteine residues and hence three disulfide bridges if one takes into
381 account the loss of 1 Da upon reduction of disulfide bridges and the addition of 57.02 Da upon
382 alkylation on each cysteine residue. Samples of the reduced/alkylated toxin were then digested
383 overnight with either trypsin or V8 proteases. The digests were next analysed by LC-ESI-MS(/MS)
384 for *de novo* sequencing. While full sequence coverage of the toxin was obtained by mass
385 spectrometry, a complementary characterization was performed using Edman degradation,
386 especially for the precise determination of the isobaric residues leucine and isoleucine. The final
387 sequence, with cysteine bonds assigned by blast homology with structurally related toxins, is
388 reported in Figure 1C. A C-terminal amidation of the peptide was identified as a post-translational
389 modification (PTM).

390 Peptide 1, composed of 35 amino acids (3996.6 Da), was identified as μ/ω -theraphotoxin-
391 Ps1a, also named poecitoxin-1a or PecTx-1a. It is the first toxin described so far from the venom of
392 *Poecilotheria subfusca* spider, known as the ivory-billed ornamental or montane tiger spider, an
393 arboreal tarantula endemic to Sri Lanka and classified in the Selenocosmiinae-Poecilotheriini
394 subfamily. PecTx-1a contains the ICK architectural motif previously reported in toxins from the
395 same Theraphosidae spider family. Moreover, the primary sequence of the peptide was submitted
396 to the SwissProt database using the protein Blast of NCBI. Although appearing as undescribed and
397 innovative compound, PecTx-1a shows high sequence identity (66-74%) and similarity (74-80%)
398 with peptides issued from the Chinese tarantula *Chilobrachys jingzhao* (previously named
399 *Chilobrachys guangxiensis*) for most of them, characterized by a 33-35 amino acid sequence with
400 three disulfide bridges, and belonging to the Nav channel spider toxin (NaSpTx) family 2.

401 **3.2. Chemical synthesis, *in vitro* folding and 3D-structure of PecTx-1a**

402 PecTx-1a was chemically synthesized using solid-phase Fmoc chemistry, and the reduced
403 PecTx-1a peptide was oxidized to produce oxidized/folded PecTx-1a along with its three-disulfide
404 bridges. The yield of oxidation indicated good formation of the secondary structures and easy
405 disulfide bridge connectivity during oxidation. To confirm that the synthetic PecTx-1a was identical
406 to its natural counterpart, the retention time of the natural peptide extracted from the crude
407 venom of *Poecilotheria subfusca* spider was compared to that of the synthetic folded analog by
408 analytical RP-HPLC-UV. Single uniform peak signals were detected for natural and synthetic PecTx-
409 1a (Figure 2Aa-b). In addition, both peptides were mixed at equal concentrations and run
410 simultaneously onto analytical RP-HPLC. As a single major peak was detected (Figure 2Ac), we

411 conclude that the two peptides co-elute, hence demonstrating identical retention times on the
412 C18 column.




Figure 2. Chemical synthesis, *in vitro* folding and 3D-structure of PecTx-1a. **(A)** RP-HPLC-UV profiles observed at 214 nm for natural **(a)** and synthetic folded **(b)** PecTx-1a, as well as for both **(c)**. The presence of single uniform peaks demonstrates the suchness of the two compounds. **(B)** 3D-Structure of PecTx-1a. **(a)** Superposition of 10 structures derived from a 2-ns restrained MD simulation “in water” (all heavy atoms are shown). All backbone atoms of residues 2-32 were used for fitting. Structures were sampled in 50 ps intervals and energy minimized. The rmsd over all backbone atoms is 0.353 ± 0.141 Å. Considering all heavy atoms, the rmsd is 0.659 ± 0.271 Å (PDB: XXXX). **(b)** Ribbon representation indicating elements of secondary structure. The structure topology is composed of double stranded antiparallel β -sheet (arrows). The three disulfide bonds are C2-C17, C9-C22 and C16-C29 (in yellow). Hydrophobic residues are colored in green, and basic and acidic residues in blue and red, respectively. The other polar residues are colored in white.

413 The experimental molecular mass of the non-reduced form (with its disulfide bridges) of the
414 synthetic peptide (Figure 1Bd, m/z 1333.2201 for $[M+3H]^{3+}$) was in close agreement with the
415 theoretical mass of the postulated sequence (m/z 1333.2260 for $[M+3H]^+$). Moreover, synthetic
416 and natural peptides had similar potencies to interact with the hNav1.7 channel subtype
417 overexpressed in HEK-293 cells.

418 The 3D-structure of PecTx-1a was determined by 2D homonuclear ^1H -NMR spectroscopy
419 (Figure 2B). Spectra were recorded at 307°K where the amid resonances show a good dispersion.
420 One signal set of sharp and well-dispersed resonances is indicative of a single structure in solution.

421 NMR-derived interproton distances were used for structure calculations with a molecular
 422 dynamic-based protocol. An ensemble of 10 conformations was obtained, containing a well
 423 determined backbone conformation of an ICK motif (PDB: XXXX). The ¹H-chemical shifts of PecTx-
 424 1a in H₂O/D₂O highlight the high precision and stereochemical quality of the ensemble of PecTx-1a
 425 structures (Table 2).

Table 2. ¹H-chemical shifts of PecTx-1a in H₂O/D₂O, 100 mM acetate buffer, pH 5 at 307°K (3 mg in 600 μL)*.

No.	Residue	NH	H α	H β	Others
1	Glu	-	4.16	2.19/2.15	γ : 2.46
2	Cys	8.765	4.73	3.17/2.86	
3	Arg	9.14	4.51	2.08	γ : 1.96/1.79, δ : 3.34/3.26, ϵ : 7.27
4	Gln	8.23	4.05	2.32/1.87	γ : 2.57/2.46, ϵ : 7.63/6.83
5	Met	8.19	3.656	1.74/1.59	γ : 1.935/1.27, ϵ : 1.86
6	Phe	8.925	3.565	3.42/3.00	δ : 6.60, ϵ : 7.245, ζ : 7.245
7	Gly	9.01	4.23/3.515		
8	Gly	8.71	4.38/3.85		
9	Cys	7.77	5.09	3.22/3.18	
10	Thr	9.81	4.46	4.21	γ : 1.20
11	Lys	7.82	4.71	2.01/1.78	γ : 1.37, δ : 1.61, ϵ : 2.90
12	Asp	8.89	4.15	2.89/2.69	
13	Ser	8.18	4.245	4.06/3.885	
14	Glu	7.44	4.26	2.37/2.15	γ : 2.37/2.21
15	Cys	8.03	5.16	3.17/2.88	
16	Cys	8.97	4.60	3.48/2.50	
17	Ala	7.85	3.98	1.14	
18	His	8.48	4.10	3.63/3.39	δ : 7.17, ϵ : 8.52
19	Leu	7.74	5.05	2.17/1.10	γ : 1.49, δ : 0.74, δ' : 0.63
20	Gly	8.96	4.35/3.67		
21	Cys	9.59	4.71	2.70/2.55	
22	Arg	8.07	4.11	2.14/1.79	γ : 1.71, δ : 2.94/2.22, ϵ : 7.05
23	Thr	8.03	4.285	4.54	γ : 1.245
24	Lys	7.22	4.61	1.76/1.57	γ : 1.43, δ : 1.71, ϵ : 3.03
25	Trp	8.30	3.09	2.99	H1: 10.21, H2: 7.18, H4: 7.22, H5: 7.13, H6: 7.25, H7: 7.51
26	Pro	-	2.75	1.31/0.82	γ : 1.43/0.99, δ : 3.18/3.00
27	Tyr	7.53	4.305	3.305/3.11	δ : 7.19, ϵ : 6.85
28	Tyr	6.785	5.555	2.76/2.675	δ : 6.86, ϵ : 6.68
29	Cys	8.89	5.02	3.00/2.66	
30	Ala	9.72	4.88	1.51	
31	Trp	8.585	4.84	3.35/3.18	H1: 10.46, H2: 7.61, H4: 7.61, H5: 7.13, H6: 7.13, H7: 7.24
32	Asp	8.216	4.45	2.75/2.32	
33	Gly	~6.46	3.65/~2.61		
34	Thr	8.075	4.44	4.30	γ : 1.135
35	Val	8.13	4.09	2.00	γ : 0.90, γ' : 0.90, NH ₂ : 7.49/6.99

*Proton chemical shifts are referenced to sodium-3-(Trimethylsilyl)propionate-2,2,3,3-d₄.

426 3.3. Effects of PecTx-1a on hNav_v channel subtypes

427 Automated patch-clamp experiments performed on HEK-293 cells overexpressing hNav_v1.2
 428 and 1.4-1.8 channel subtypes revealed that 1 μM of synthetic PecTx-1a was effective to block
 429 hNav_v1.5 and 1.7 currents while fully sparing hNav_v1.2, 1.4, 1.6 and 1.8 currents (Figure 3A). The
 430 following increasing order for IC₅₀ values was obtained from the concentration-response curves of
 431 PecTx-1a effects on currents flowing through the different hNav_v channel subtypes (Figure 3B):
 432 hNav_v1.7 (118.4 ± 23.7 nM, n ≥ 3) > hNav_v1.5 (260.9 ± 8.9 nM, n = 3) > hNav_v1.6 (> 3200 nM, n = 9) ≥
 433 hNav_v1.2 (> 4200 nM, n = 3) ≥ hNav_v1.4 (> 10000 nM, n = 4) ≥ hNav_v1.8 (> 10000 nM, n = 3). This
 434 indicates that the main hNav_v channel subtypes affected by low concentrations of peptide (below 1
 435 μM) were restricted to hNav_v1.7 and 1.5 (Table 3A). It is worth noting that some preliminary
 436 experiments revealed that PecTx-1a seems to be at least between 15 and 26 times more potent to
 437 interact with hNav_v1.7 than hNav_v1.3 (IC₅₀ > 1800 nM, n = 3) and hNav_v1.1 (IC₅₀ > 3100 nM, n = 3)
 438 channel subtypes.




Figure 3. Effects of PecTx-1a on HEK-293 cells overexpressing hNav_v channel subtypes. **(A)** Representative traces of sodium currents flowing through hNav_v1.2, and 1.4-1.8 channel subtypes, recorded before (in black) and after (in green) exposure to 1 μM PecTx-1a. The recording protocols are detailed in the Experimental section. **(B)** Histograms of IC₅₀ values (in nM) obtained from the concentration-response curves of PecTx-1a effects on HEK-293 cells overexpressing hNav_v1.2, and 1.4-1.8 channel subtypes. Each value represents the mean ± S.D. of data obtained from 3-10 cells. Mean value ± S.D. of n_H was 0.7 ± 0.1. The dark grey bars indicate the minimum values determined under our experimental conditions.

Table 3. Changes in current amplitude (I) and activation (tp) and inactivation (th) kinetic parameters induced by 1 and 10 μM concentrations of PecTx-1a ([PecTx-1a]) on HEK-293 cells overexpressing hNav channel subtypes (A), changes in current amplitude, activation and inactivation kinetic parameters and voltage curves (shift) induced by 0.1-10 μM of peptide on CHO and U2OS cells overexpressing hKir and hKv channel subtypes (B), and on CHO cells overexpressing hCa_v channel subtypes (C).

A	[PecTx-1a]	I change	th change	tp change	Conclusion
hNav1.2	1 μM	22% \searrow	1.5x \nearrow	0.9x \searrow	No marked effect at low [PecTx-1a]
	10 μM	nd	nd	nd	
hNav1.4	1-10 μM	\rightarrow	\rightarrow	\rightarrow	No effect, even at high [PecTx-1a]
hNav1.5	1 μM	75% \searrow	1.8x \nearrow	1.4x \nearrow	At low [PecTx-1a], decreased peak current and moderated effects on activation and inactivation kinetics
	10 μM	97% \searrow	nd	nd	
hNav1.6	1 μM	\rightarrow	\rightarrow	\rightarrow	No effect at low [PecTx-1a]
	10 μM	nd	nd	nd	
hNav1.7	1 μM	57% \searrow	4.8x \nearrow	1.7x \nearrow	At low [PecTx-1a], decreased peak current and marked slow-down of activation and inactivation
	10 μM	86% \searrow	5.7x \nearrow	2.0x \nearrow	
hNav1.8	1 μM	\rightarrow	1.6x \nearrow	\rightarrow	At high [PecTx-1a], increased peak current due to marked slow-down of inactivation
	10 μM	37% \nearrow	6.6x \nearrow	1.1x \nearrow	
B	[PecTx-1a]	I change	Kinetic change	Voltage shift	Conclusion
hKir2.1	0.1 μM	\rightarrow	\rightarrow	nd	No effect, even at high [PecTx-1a]
	10 μM	\rightarrow	\rightarrow	nd	
hKv1.5	0.1 μM	9% \nearrow	nd	nd	At high [PecTx-1a], increased current not associated with current-voltage shift
	10 μM	70-90% \nearrow	nd	\rightarrow	
hKv4.3	0.1 μM	43% \searrow	1.3-1.7x \nearrow	Positive shift	At low [PecTx-1a], decreased peak current due to marked current-voltage positive shift
	10 μM	46% \searrow	1.4-1.8x \nearrow	Positive shift	
hKv7.1	0.1 μM	nd	nd	nd	No marked effect, even at high [PecTx-1a]
	10 μM	19% \nearrow	nd	\rightarrow	
hKv11.1	0.1 μM	16% \searrow	nd	nd	At high [PecTx-1a], decreased current
	10 μM	75% \searrow	nd	nd	
C	[PecTx-1a]	I change	Kinetic change	Voltage shift	Conclusion
hCa _v 1.2	0.1 μM	94% \searrow	nd	nd	At low [PecTx-1a], decreased current
hCa _v 2.2	0.1-10 μM	\rightarrow	\rightarrow	nd	No effect, even at high [PecTx-1a]
hCa _v 3.1	0.1 μM	\rightarrow	\rightarrow	nd	No marked effect, even at high [PecTx-1a]
	10 μM	19% \searrow	\rightarrow	nd	
hCa _v 3.2	0.1-10 μM	\rightarrow	\rightarrow	nd	No effect, even at high [PecTx-1a]

nd: not determined, \searrow : decreased, \nearrow : increased, \rightarrow : unchanged.

439 Further investigation was performed to detail the effects of PecTx-1a on the biophysical
 440 properties of hNav1.7 and 1.5 channel subtypes (Figure 4). In addition to a decreased peak
 441 current, the peptide also produced a marked and significant slow-down of the activation and

442 inactivation of hNa_v1.7 channel subtype, while the effects on those of hNa_v1.5 channel subtype
 443 were moderated and non-significant (Figure 4A, Tables 3A and 4). To overcome the potential
 444 increase that might arise from the effects of PecTx-1a on activation and inactivation kinetics, the
 445 current was calculated at time zero of depolarization (time-0 current or I₍₀₎), according to Equation
 446 1 (see Experimental section). Under these conditions, IC₅₀ values of 61.7 and 260.9 nM were
 447 determined from the concentration-response curves of PecTx-1a effects on hNa_v1.7 and 1.5 time-
 448 0 currents, respectively (Figure 4B). It is worth noting that similar IC₅₀ values were obtained for
 449 hNa_v1.5 time-0 and peak currents (Figure 4B, right panel). On the contrary, the IC₅₀ value for the
 450 hNa_v1.7 peak current was higher than that of the hNa_v1.7 time-0 current (Figure 4B, left panel). In
 451 particular, for peptide concentrations between 1 and 10 μM, the hNa_v1.7 peak current re-
 452 increased as the variations of activation and inactivation kinetic parameters (t_p and τ_h,
 453 respectively) became higher (Figure 4B, left panel, dashed grey rectangle). In addition, PecTx-1a
 454 induced marked negative and positive shifts of steady-state inactivation- and conductance-voltage
 455 relationships of hNa_v1.7 channel subtype, respectively, while the peptide-induced blocking action
 456 occurred without any significant change in these relationships for hNa_v1.5 channel subtype (Figure
 457 4C and Table 4). The hNa_v1.5 peak current, which was decreased to 4.1 ± 1.6% (n = 3) by 10 μM
 458 PecTx-1a, recovered to 30.8 ± 6.3% (n = 2) after peptide wash-out for periods up to 3 min,
 459 compared to control values determined before cell exposure to PecTx-1a. In addition, the hNa_v1.5
 460 peak current decrease measured in the presence of 250 nM of folded and reduced inactive forms
 461 of PecTx-1a was of 48.2 ± 2.1% (n=7) and 2.5 ± 1.0% (n = 8), respectively, compared to control
 462 values determined before cell exposure to any peptide form, further supporting the specificity of
 463 PecTx-1a action.

Table 4. Kinetic parameters of activation (t_p) and inactivation (τ_h), and parameters of steady-state inactivation- (V_{P50%} and k_h) and conductance- (V_{T50%} and k_g) voltage relationships for HEK-293 cells overexpressing hNa_v1.7 and hNa_v1.5 channel subtypes, and CHO cells overexpressing hCa_v1.2 and hK_v4.3 channel subtypes (means ± S.D. of 3-10 cells).

		t _p (ms)	τ _h (ms)	V _{P50%} (mV)	k _h (mV ⁻¹)	V _{T50%} (mV)	k _g (mV ⁻¹)
hNa _v 1.7	Control	0.71 ± 0.03	0.49 ± 0.03	-65 ± 1	4.4 ± 0.2	-26 ± 2	3.4 ± 0.5
	PecTx-1a ¹	1.00 ± 0.06 ⁵	1.02 ± 0.09 ⁵	-75 ± 2 ⁵	7.5 ± 0.5 ⁵	-16 ± 2 ⁵	7.0 ± 1.0 ⁵
hNa _v 1.5	Control	0.83 ± 0.05	0.63 ± 0.08	-71 ± 2	4.8 ± 0.2	-51 ± 2	4.6 ± 0.7
	PecTx-1a ²	0.97 ± 0.05	0.84 ± 0.11	-74 ± 2	4.9 ± 0.1	-43 ± 4	8.3 ± 3.5
hK _v 4.3	Control	8.79 ± 0.31	69.21 ± 3.32	-33 ± 2	5.0 ± 0.7	<i>nd</i>	<i>nd</i>
	PecTx-1a ³	15.04 ± 0.58 ⁵	89.32 ± 1.98 ⁵	-23 ± 3 ⁵	6.8 ± 0.4 ⁵	<i>nd</i>	<i>nd</i>
hCa _v 1.2	Control	3.82 ± 0.14	16.47 ± 3.13	-28 ± 2	3.2 ± 0.7	-10 ± 3	4.6 ± 0.6
	PecTx-1a ⁴	4.05 ± 0.31	17.82 ± 3.88	-33 ± 3 ⁵	3.9 ± 0.7	-9 ± 3	5.6 ± 1.6

¹351.5 nM, ²250 nM, ³37 nM, and ⁴3.3 nM. ⁵P < 0.05 (versus control). *nd*: not determined.

464 The effects of high concentrations (*i.e.* > 1 μM) of PecTx-1a were also studied on some other
 465 hNa_v channel subtypes (see Table 3A). While no significant alteration of hNa_v1.4 current was
 466 detected, the hNa_v1.8 peak current was markedly increased and its inactivation markedly slowed
 467 down by the peptide (Figure 4bisA and B). The increase in peak current was dependent on PecTx-

468 1a concentration and was completely reversed by peptide wash-out for periods up to 4 min
 469 (Figure 4bisA). Hence, the current, which was enhanced to $137 \pm 4\%$ ($n = 3$) by $10 \mu\text{M}$ PecTx-1a,
 470 recovered to $101 \pm 6\%$ ($n = 3$) after wash-out, compared to values determined before cell
 471 exposure to the peptide. Interestingly, similar IC_{50} values were obtained from the concentration-
 472 response curves of PecTx-1a effects on $\text{hNa}_v1.8$ peak current and τ_{h} variations, *i.e.* 2.5 and 2.8
 473 μM , respectively (Figure 4bisC).




Figure 4. Effects of PecTx-1a on HEK-293 cells overexpressing $\text{hNa}_v1.7$ (left panels) and 1.5 (right panels) channel subtypes. **(A)** Representative traces of currents flowing through $\text{hNa}_v1.7$ and 1.5 subtypes, recorded before (in black) and after (in green) exposure to 351.5 and 250 nM PecTx-1a, respectively. In light green, current recorded in the presence of PecTx-1a and expressed relatively to the peak control current. **(B)** Concentration-response curves of PecTx-1a effects on peak (black closed circles) and time-0 (black open circles) currents, and on the variations of activation (τ_{p} , green open circles) and inactivation (τ_{h} , green closed circles) kinetic parameters. Each value, expressed as percentage of that obtained before toxin application, represents the mean \pm S.D. of data obtained from 3-9 cells. The theoretical curves correspond to data point fits with IC_{50} and n_{H} values of, respectively, 61.7 nM and 0.6 ($r^2 = 0.976$, black curve in left panel), 378.0 nM and 1.1 ($r^2 = 0.956$, green curve in left panel), and 260.9 nM and 0.8 ($r^2 = 0.986$, black curve in right panel). **(C)** Steady-state inactivation- (circles) and conductance- (squares) voltage relationships for HEK-293 cells overexpressing $\text{hNa}_v1.7$ and 1.5 subtypes, before (black symbols) and after (green symbols) exposure to 351.5 and 250 nM PecTx-1a, respectively. Each value represents the mean \pm S.D. of data obtained from 3-6 cells, and is expressed as percentage of either maximal peak amplitude of current at strongly negative pre-pulse voltages or maximal conductance calculated at strongly positive test-pulse voltages. The theoretical curves correspond to data point fits with the mean $V_{\text{P}50\%}$, k_{h} , $V_{\text{T}50\%}$ and k_{g} values indicated in Table 4.




Figure 4bis. Effects of PecTx-1a on HEK-293 cells overexpressing the hNav_v1.8 channel subtype. (A) Representative time course of the effects of successive applications of various PecTx-1a concentrations (from 41 nM to 10 µM), and peptide wash-out, on the amplitude of peak current flowing through hNav_v1.8 subtype. (B) Representative traces of current flowing through hNav_v1.8 subtype, recorded before (in black) and after (in green) exposure to 10 µM PecTx-1a. In light green, current recorded in the presence of PecTx-1a and expressed relatively to the peak control current. (C) Concentration-response curves of PecTx-1a effects on the peak current (black circles) and inactivation kinetic parameter (τ_h , green circles) variations. Each value, expressed as percentage of that obtained before toxin application, represents the mean \pm S.D. of data obtained from 3 cells. The theoretical curves correspond to data point fits with IC_{50} and n_H values of, respectively, 2.5 µM and 1.5 ($r^2 = 0.982$, black curve), and 2.8 µM and 2.0 ($r^2 = 0.985$, green curve).

474 3.4. Effects of PecTx-1a on hKir and hK_v channel subtypes

475 Automated patch-clamp experiments performed on CHO and U2OS cells overexpressing
 476 hKir2.1 and hK_v1.5, 4.3, 7.1 and 11.1 channel subtypes revealed that 100 nM PecTx-1a was
 477 efficient to block the hK_v4.3 current without any marked alteration of hKir2.1 and hK_v1.5, 7.1 and
 478 11.1 currents (Figure 5A). The following increasing order for IC_{50} values was obtained from the
 479 concentration-response curves of PecTx-1a effects on currents flowing through the different hKir
 480 and hK_v channel subtypes (Figure 5B): hK_v4.3 (7.2-37 nM, $n \geq 4$) > hK_v11.1 (2931 \pm 1587 nM, $n = 4$)
 481 > hK_v1.5 (> 10000 nM, $n = 10$) \geq hK_v7.1 (> 10000 nM, $n = 4$) \geq hKir2.1 (> 10000, $n = 8$). This
 482 indicates that, among the studied hK_v channel subtypes, hK_v4.3 was the only one affected by low
 483 concentrations of peptide (below 100 nM, Table 3B).

484 Further investigation was performed to detail the effects of PecTx-1a on the biophysical
 485 properties of hK_v4.3 channel subtype (Figure 6). In addition to a decreased peak current, the
 486 peptide also produced moderated but significant slow-down of hK_v4.3 activation and inactivation




Figure 5. Effects of PecTx-1a on CHO and U2OS cells overexpressing hKir and hKv channel subtypes. **(A)** Representative traces of potassium currents flowing through hKir2.1, and hKv1.5, 4.3, 7.1 and 11.1 channel subtypes, recorded before (in black) and after (in green) exposure to 0.1-10 μ M PecTx-1a. The recording protocols are detailed in the Experimental section. **(B)** Histograms of IC₅₀ values (in nM) obtained from the concentration-response curves of PecTx-1a effects on CHO and U2OS cells overexpressing hKir2.1, and hKv1.5, 4.3, 7.1 and 11.1 channel subtypes. Each value represents the mean \pm S.D. of data obtained from 4-8 cells. Mean value \pm S.D. of n_H was 0.9 ± 0.1 . The dark grey and green bars indicate the minimum values determined under our experimental conditions.

487 kinetics (Figure 6A, Tables 3 and 4). The concentration-response curve of PecTx-1a effect on
 488 hKv4.3 current revealed that the peak current was not completely inhibited by the peptide (Figure
 489 6B). Hence, in the presence of PecTx-1a concentrations varying from 37 nM to 10 μ M, the peak
 490 amplitude was $56.87 \pm 2.13\%$ ($n = 6-26$) of its control value. Taking into account only the blocked
 491 peak current, an IC₅₀ value of 7.2 nM was determined from the concentration-response curve.
 492 PecTx-1a also induced a marked positive shift of the hKv4.3 peak current-voltage relationship
 493 without modifying the maximal conductance, *i.e.* the slope of curves (Figure 6C). The shift
 494 magnitude was dependent on the peptide concentration: it increased between 3.3 and 37 nM and
 495 then remained at a constant value of about 35 mV between 37 nM and 10 μ M. Interestingly, the
 496 decrease of hKv4.3 peak current only due to positive shifts of current-voltage relationship
 497 perfectly fits with the concentration-response curve established for the blocked peak current
 498 (Figure 6B). Finally, PecTx-1a produced a moderated but significant positive shift of the hKv4.3

499 steady-state inactivation-voltage relationship (Figure 6D and Table 4). The effects of PecTx-1a on
 500 hK_V4.3 current were not easily reversed upon wash-out of cells with peptide-free standard
 501 physiological solution for periods up to 3 min. Hence, the peak current, which was decreased to 54
 502 ± 6% (n = 11) by 10 μM PecTx-1a, recovered to only 58 ± 6% (n = 6) after wash-out, compared to
 503 values determined before cell exposure to the peptide (data not shown).




Figure 6. Effects of PecTx-1a on CHO cells overexpressing the hK_V4.3 channel subtype. **(A)** Representative traces of current flowing through the hK_V4.3 subtype, recorded before (in black) and after (in green) exposure to 37 nM PecTx-1a. In light green, the current recorded in the presence of PecTx-1a and expressed relatively to the peak control current. **(B)** Concentration-response curves of PecTx-1a effect on hK_V4.3 peak current (black circles), recorded during a 20-mV test-pulse voltage, and that on the decrease of hK_V4.3 peak current only due to positive shifts of the current-voltage relationship (green circles). Each value, expressed as percentage of that obtained before toxin application, represents the mean ± S.D. of data obtained from 4-26 cells. The theoretical curve corresponds to data point fit with IC₅₀ and n_H values of, respectively, 7.2 nM and 1.4 (r² = 0.992). **(C)** Current-voltage relationships for hK_V4.3 peak current, before (black circles) and after exposure to 37 nM (light green circles) and 10 μM (dark green circles) PecTx-1a. Each value represents the mean ± S.D. of data obtained from 5-6 cells. The curves were drawn by eye. **(D)** Steady-state inactivation-voltage relationships for hK_V4.3 peak current, before (black circles) and after (green circles) exposure to 37 nM PecTx-1a. Each value represents the mean ± S.D. of data obtained from 6-7 cells, and is expressed as percentage of maximal peak amplitude of current at strongly negative pre-pulse voltages. The theoretical curves correspond to data point fits with the mean V_{p50%} and k_n indicated in Table 4.

504

505 The effects of high concentrations (*i.e.* 10 μM) of PecTx-1a were also studied on hKir2.1 and
 506 some other hK_V channel subtypes (see Table 3B). While no significant alteration of hKir2.1 and
 507 hK_V7.1 currents was detected, the hK_V11.1 current was decreased to 25% of its control value, as
 508 expected from the corresponding IC₅₀ value close to 3 μM (see Figure 5). In contrast, the hK_V1.5

509 current was between 70 and 90 times increased by 10 μ M PecTx-1a (Figure 6bisA and B). This
 510 effect was associated with an increased maximal conductance, *i.e.* the slope of the current-voltage
 511 curve, without any significant shift of the current-voltage relationship (Figure 6bisC). The increase
 512 in hK_V1.5 current was completely reversed by peptide wash-out for periods up to 5 min (Figure
 513 6bisA and B). Hence, the current, which was enhanced to $168 \pm 25\%$ ($n = 3$) by 10 μ M PecTx-1a,
 514 recovered to $107 \pm 4\%$ ($n = 3$) after wash-out, compared to values determined before cell
 515 exposure to the peptide.




Figure 6bis. Effects of PecTx-1a (10 μ M) on CHO cells overexpressing the hK_V1.5 channel subtype. (A) Representative time course of the effect of PecTx-1a application and peptide wash-out on the amplitude of current flowing through hK_V1.5 subtype. (B) Representative traces of current flowing through hK_V1.5 subtype, recorded before (in black) and after (in green) exposure to PecTx-1a, and after peptide wash-out (in grey). (C) Current-voltage relationships for hK_V1.5 current, before (black circles) and after (green circles) exposure to PecTx-1a. Each value represents the mean \pm S.D. of data obtained from 4 cells. Curves drawn by eye.

516 3.5. Effects of PecTx-1a on hCa_v channel subtypes

517 Automated patch-clamp experiments performed on CHO cells overexpressing hCa_v1.2, 2.2, 3.1
 518 and 3.2 channel subtypes revealed that less than 100 nM PecTx-1a was efficient to almost
 519 completely block the hCa_v1.2 current without any marked alteration of hCa_v2.2, 3.1 and 3.2
 520 currents (Figure 7A). From the concentration-response curves of PecTx-1a effects on currents
 521 flowing through the different hCa_v channel subtypes, an IC₅₀ value of 4.96 ± 0.09 nM ($n = 4-6$) was

522 obtained for the hCa_v1.2 channel subtype, while those for hCa_v2.2, 3.1 and 3.2 channel subtypes
 523 were over 10 μM (n = 4-6) (Figure 7B). This indicates that, among the studied hCa_v channel
 524 subtypes, hCa_v1.2 was the only one affected by PecTx-1a, even at high concentrations of peptide
 525 (*i.e.* 10 μM, Table 3C).




Figure 7. Effects of PecTx-1a on CHO cells overexpressing hCa_v channel subtypes. **(A)** Representative traces of calcium currents flowing through hCa_v1.2, 2.2, 3.1 and 3.2 channel subtypes, recorded before (in black) and after (in green) exposure to 0.09-10 μM PecTx-1a. The recording protocols are detailed in the Experimental section. **(B)** Histograms of IC₅₀ values (in nM) obtained from the concentration-response curves of PecTx-1a effects on CHO cells overexpressing hCa_v channel subtypes. Each value represents the mean ± S.D. of data obtained from 4-6 cells. Mean value ± S.D. of n_H was 0.8 ± 0.1. The dark grey bars indicate the minimum values determined under our experimental conditions.

526 Further investigation was performed to detail the effects of PecTx-1a on the biophysical
 527 properties of hCa_v1.2 channel subtype (Figure 8). The decrease of hCa_v1.2 peak current was
 528 dependent on PecTx-1a concentration and was partly reversed by peptide wash-out for periods up
 529 to 4 min (Figure 8A). Hence, the current, which was decreased to 6.3 ± 3.9% (n = 4) by 90 nM
 530 PecTx-1a, recovered to 51 ± 2% (n = 2) after wash-out, compared to values determined before cell
 531 exposure to the peptide. The blocking effect of PecTx-1a on the hCa_v1.2 channel subtype was not
 532 associated with alteration of current activation and inactivation kinetics (Figure 8B, Table 4).




Figure 8. Effects of PecTx-1a on CHO cells overexpressing the hCa_v1.2 channel subtype. **(A)** Representative time course of the effects of successive applications of various PecTx-1a concentrations (from 0.37 to 90 nM), and peptide wash-out, on the amplitude of peak current flowing through hCa_v1.2 subtype. **(B)** Representative traces of current flowing through hCa_v1.2 subtype, recorded before (in black) and after (in green) exposure to 3.3 nM PecTx-1a. In light green, current recorded in the presence of PecTx-1a and expressed relatively to the peak control current. **(C)** Concentration-response curves of folded (black closed circles) and reduced (black open circles) PecTx-1a effects on hCa_v1.2 peak current. Each value, expressed as percentage of that obtained before toxin application, represents the mean \pm S.D. of data obtained from 3-7 cells. The theoretical curve for the folded toxin corresponds to data point fit with IC₅₀ and n_H values of 4.96 nM and 0.8, respectively ($r^2 = 0.997$). That for the reduced toxin corresponds to a straight line through the mean of data points, *i.e.* 99.91% ($r^2 = 0.947$). **(D)** Steady-state inactivation- (circles) and conductance- (squares) voltage relationships for CHO cells overexpressing the hCa_v1.2 subtype, before (black symbols) and after (green symbols) exposure to 3.3 nM PecTx-1a. Each value represents the mean \pm S.D. of data obtained from 6-7 cells, and is expressed as percentage of either maximal peak amplitude of current at strongly negative pre-pulse voltages or maximal conductance calculated at strongly positive test-pulse voltages. The theoretical curves correspond to data point fits with the mean $V_{p50\%}$, k_{hv} , $V_{T50\%}$ and k_g values indicated in Table 4.

533 To further support the specificity of peptide action, the concentration-response curves of the
534 effects of both the folded and reduced inactive forms of PecTx-1a on hCa_v1.2 peak current were
535 established (Figure 8C). Under these conditions, an IC₅₀ value of 4.96 nM was calculated for the
536 folded toxin while the reduced one was without any significant effect at concentrations up to 10
537 μM, *i.e.* the current decrease measured in the presence of 10 μM of reduced form was of 4 ± 8%
538 (n = 3) compared to control value determined before cell exposure to this peptide form. Finally,
539 PecTx-1a produced a moderated but significant negative shift of the hCa_v1.2 steady-state
540 inactivation-voltage relationship without any significant change in the conductance-voltage
541 relationship (Figure 8D and Table 4).

542 Manual patch-clamp experiments were performed on hCa_v channels of hiPSC-CMs. These
543 channels included hCa_v1.1, 1.2 and 1.3 subtypes, responsible for the L-type calcium current having
544 maximal peak amplitude at 0-mV test-pulse, and hCa_v3.1 and 3.2 subtypes, responsible for the T-
545 type calcium current having maximal peak amplitude at -40-mV test-pulse (Ivashchenko et al.,
546 2013). Among the 22 studied hiPSC-CMs, 27% (*i.e.* 6 cells over 22) had a 118 ± 41 pF membrane
547 capacity and exhibited only L-type current, 5% (*i.e.* 1 cell over 22) had a 15 pF membrane capacity
548 and exhibited only T-type current, and 68% (*i.e.* 15 cells over 22) had a 51 ± 8 pF membrane
549 capacity and exhibited both L-and T-type currents. The effects of PecTx-1a were studied at 100
550 nM, a peptide concentration that fully inhibited the L-type, hCa_v1.2 channel subtype while sparing
551 the T-type, hCa_v3.1 and 3.2 subtypes. The cell perfusion with standard physiological solution
552 containing 100 nM PecTx-1a had no significant effect on the T-type calcium current but produced
553 a marked decrease of the L-type current (Figure 9A). The ratio of L-type to T-type peak calcium
554 currents, recorded during test-pulses to 0 and -40 mV, respectively, was calculated before and
555 after cell exposure to 100 nM PecTx-1a. As shown in Figure 9B, this ratio was decreased by 58% by
556 the peptide, *i.e.* from 5.70 ± 1.25 (n = 13) to 2.41 ± 0.67 (n = 13), and further reduced to 1.26 ±
557 0.43 (n = 4) by 10 μM nifedipine. Taking into account that this nifedipine concentration fully
558 inhibited the L-type calcium current (Ivashchenko et al., 2013), these results indicate that the
559 percentages of L- and T-type calcium currents in hiPSC-CMs were 78% and 22%, respectively.

560

561 4. DISCUSSION

562 The present study was undertaken to identify a new peptide with antinociceptive properties,
563 among the Smartox venom collection by a high-throughput screening of 117 different animal
564 venoms using automated patch-clamp platforms on HEK-293 cells overexpressing the genetically
565 validated antinociceptive target hNa_v1.7 and the cardiac hNa_v1.5 channel subtypes. This approach
566 led to the purification and identification of PecTx-1a from the *Poecilotheria subfusca* spider venom
567 and, then, to the peptide chemical synthesis and 3D-structure characterization.

568 PecTx-1a, identified as a 35 amino acid peptide including three disulfide bridges and the ICK
569 architectural motif, belongs to the NaSpTx family 2. Among the toxins belonging to this family, the
570 peptide shows more particularly relative high sequence identity (66-74%) and similarity (74-80%)
571 with three jingzhaotoxins (JzTx) issued from the Chinese tarantula *Chilobrachys jingzhao* (also
572 known as Chinese fawn tarantula), one of the most venomous spiders inhabiting the hilly areas of

573 Hainan province in China (Table 5).




Figure 9. Effects of PecTx-1a (100 nM) on L- and T-type Ca_v channels of hiPSC-CMs. **(A)** Representative traces of T-type calcium current, recorded during test-pulses to -40 mV from a holding potential of -80 mV (left panel) and L-type calcium current, recorded during test-pulses to 0 mV from a holding potential of -80 mV (right panel), before (in black) and after (in green) cell exposure to PecTx-1a. **(B)** Ratio of L-type to T-type peak calcium currents, recorded during test-pulses to 0 and -40 mV, respectively, calculated before (in grey) and after cell exposure to PecTx-1a (in green) and then to 10 μ M nifedipine (in blue). Each bar represents the mean \pm S.D. of data obtained from 4-13 cells. *: $P < 0.01$ (versus control).

574 4.1. 3D-structure of PecTx-1a

575 The ensemble of the 10 structures derived from the calculations "in water" showed a well-
 576 determined backbone conformation which is typical of an ICK motif. The pattern of hydrogen
 577 bonds is very similar to that observed for the antinociceptive cyriotoxin-1a, the first toxin found
 578 out previously from *Cyriopagopus schioedtei* spider venom using a similar approach (Gonçalves et
 579 al., 2018c). Interestingly, the amide bond between Trp25 and Pro26 obtained a cis conformation.
 580 This is indicated by a very intensive NOE between Trp25-H α and Pro26-H α (corresponding to a
 581 distance of 2.53 Å), as well as by the large difference of ^{13}C -chemical shifts between Pro26-C β and
 582 Pro-C γ ($\Delta^{13}C_{\beta,\gamma} = 8.7$ ppm, whereas the difference is in the order of 4-5 ppm in case of a trans
 583 conformation). The cis conformation seemed to be stabilized by hydrogen bonds between the
 584 polar protons of the Arg22 side chain (H ϵ and H η) and the carbonyl groups of Trp25 and Pro26.

585 The well-defined orientation of the Arg22 side chain was confirmed by numerous NOEs and the
586 large differences of chemical shifts obtained for the Arg22 δ -protons (2.94 and 2.22 ppm,
587 respectively). The conformation of the three N-terminal amino acids (Gly33, Thr34 and Val35)
588 seemed to be less well-defined (not reflected by the ensemble of the 10 conformers shown in
589 Figure 2Ba). This is indicated by several constraint violations in this region and NOEs, which cannot
590 be explained by a single conformation (some of these NOEs have not been used for the final
591 calculations). Another indication of flexibility might be the extreme line broadening observed for
592 the signals of Gly33.

593 **4.2. Evaluation of synthetic PecTx-1a functional properties**

594 The evaluation of PecTx-1a functional properties on HEK-293 cells overexpressing hNav1.1-1.8
595 channel subtypes reveals that the potent blocking effect of the synthetic peptide, compared to the
596 native molecule, was conserved on hNav1.7 channel subtype. Hence, the mean IC₅₀ value of PecTx-
597 1a effect on the hNav1.7 peak current was 118.4 nM, a value in the range of those previously
598 reported for the interaction between this channel subtype and potential analgesic peptide toxins
599 belonging to the NaSpTx family 2, such as Pn3a, Df1a, ProTx-I, Phlo1b, Phlo1a and JzTx-34 (IC₅₀
600 between 0.9 and 610 nM, respectively) showing relatively low percentages (between 44 and 66%)
601 of amino acid sequence identity with PecTx-1a (Table 5; Gonçalves et al., 2018a). Some of these
602 toxins, in addition to a decreased peak current and as observed for PecTx-1a, were shown to
603 markedly slow-down the inactivation of certain tetrodotoxin-sensitive (TTX-S) Na_v channel
604 subtypes, including the hNav1.7 subtype, leading to an overestimation of IC₅₀ values
605 corresponding to peak current blockage. Hence, the mean IC₅₀ value of PecTx-1a effect on the
606 hNav1.7 current calculated at time zero of depolarization (time-0 current), to overcome the peak
607 current increase arising from the peptide effects on currents kinetics, was only 61.7 nM, *i.e.* about
608 2-times lower than that for the peak current. These results strongly suggest that the peptide acts
609 not only as a pore-blocker molecule but also as a channel functioning modulator by binding to the
610 well-known toxin receptor-sites 3 (*i.e.* S3-S4 segments of DIV domain) and 4 of Na_v channels
611 (Deuis et al., 2017). Interestingly, and although at high peptide concentrations (*i.e.* > 1 μ M), the
612 effects of PecTx-1a on the TTX-S hNav1.8 channel subtype consisted in slowing-down the current
613 inactivation, leading to a marked peak current increase, while no inhibitory action of the peptide
614 was detected on this type of channel subtype (*i.e.* IC₅₀ > 10 μ M). Furthermore, PecTx-1a induced
615 10-mV positive and negative shifts of conductance- and steady-state inactivation-voltage
616 relationships of hNav1.7 channel subtype, respectively, in agreement with the alterations in the
617 voltage-dependence of both activation (10-37-mV positive shifts) and steady-state inactivation
618 (2.7-17.5-mV negative shifts) produced by some toxins belonging to the NaSpTx family 2
619 (Gonçalves et al., 2018a).

620 PecTx-1a was at least 15 times more potent to interact with hNav1.7 than hNav1.1-1.4, 1.6
621 and 1.8 channel subtypes. The fact that the peptide had over micromolar range affinities for the
622 hNav1.4 and 1.6 channel subtypes is of great interest in the optic to further develop the molecule
623 as a potential antinociceptive agent since the neuromuscular safety issue is likely to be ensured,
624 which will not limit the peptide *in vivo* efficacy (Gonçalves et al., 2018b). However, PecTx-1a was

625 also shown to be highly potent to decrease the hNav1.5 peak current within nanomolar range
 626 affinities (*i.e.* IC₅₀ = 260.9 nM). As expected for this TTX-resistant (TTX-R) cardiac subtype, the
 627 peptide-induced blocking effect occurred without any significant change in the current activation
 628 and inactivation kinetics (similar IC₅₀ values were obtained for hNav1.5 time-0 and peak currents)
 629 and in conductance- and steady-state inactivation-voltage relationships. The main hNav channel
 630 subtypes affected by low concentrations of PecTx-1a (below 1 μM) were therefore restricted to
 631 hNav1.7 and 1.5, the interaction between the latter channel subtype and the peptide greatly
 632 impairing its cardiac safety properties and thus its development as potential antinociceptive agent.

Table 5. Comparison of amino acid sequences between PecTx-1a and the 8 most similar and well documented toxins in literature from NaSpTx family 2. Sequence alignment performed with Clustal Omega (version 1.2.4 from Emboss programs, EBlosum62 matrix for two pair alignment). Cysteine scaffold is indicated in red, and important residues for toxin interaction with the hKv2.1 subtype are surrounded in green. The percentage of sequence identity with PecTx-1a is shown in parentheses, and the activity (IC₅₀) reported for each peptide toxin is described in the far right columns according to data sourced from Pubmed and ArachnoServer database (Herzig et al., 2011). All these toxins are amidated at their C-terminal amino acid sequence ending.

		hNav1.7	hNav1.5	hKv2.1
PecTx-1a	E C R Q M F G G C TKDSE C C AH L G C RT K W P Y Y C A W D G T V	118 nM	261 nM	<i>nd</i>
JzTx-IX (74%)	E C T K L L G G C TKDSE C C PH L G C R K K W P Y H C G W D G T F -	<i>nd</i>	450 nM	3.3 μM
JzTx-XI (69%)	E C R K M F G G C SVDS D C C AH L G C K P T L K - Y C A W D G T F -	<i>nd</i>	437 nM	96 nM
JzTx-34 (66%)	A C R E W L G G C SKDAD C C AH L E C R K K W P Y H C V W D W T V -	610 nM	> 10 μM	> 10 μM
Phlo1a (66%)	A C R E L L G G C SKDSD C C AH L E C R K K W P Y H C V W D W T I -	459 nM	> 1 μM	<i>nd</i>
Phlo1b (66%)	A C R E L L G G C SKDSD C C AH L E C R K K W P Y H C V W D W T F -	360 nM	> 1 μM	<i>nd</i>
Pn3a (62%)	D C R Y M F G D C E K D E D C C K H L G C R K K M K Y - C A W D F T F T	0.9 nM	800 nM	> 300 nM
ProTx-I (47%)	E C R Y W L G G C SAGQT C C K H L V C S R R H G W - C V W D G T F S	51 nM	<i>nd</i>	411 nM
Df1a (44%)	E C R W F L G G C SGGQT C C E H L V C H R K H Q W - C V W D W S F -	1.9 nM	45 nM	> 1 μM

nd: not determined.

633 The hNav1.5 channel subtype was previously reported to be blocked with IC₅₀ values of 437-
 634 450 nM, *i.e.* in the range of that determined for PecTx-1a, by two toxins from the NaSpTx family 2,
 635 JzTx-IX and JzTx-XI, showing relatively high percentages (between 66 and 74%) of amino acid
 636 sequence identity with our peptide of interest (Table 5; Gonçalves et al., 2018a). In contrast, JzTx-
 637 34, which shows also 66% of amino acid sequence identity with PecTx-1a, was not efficient to
 638 affect this channel subtype (IC₅₀ > 10 μM), probably due to the presence of negatively-charged

639 amino acid residues between Cys2 and Cys21 which impede the peptide binding to hNav1.5, as
640 previously described for JzTx-XIII (Yuan et al., 2012). The amino acid residues K23, Y27 and H28,
641 located between Cys21 and Cys29 in the JzTx-IX sequence, could be involved in modifying the Nav
642 channel gating properties, as proposed for some ceratotoxins isolated from the tarantula
643 *Ceratogyrus cornuatus* venom (Bosmans et al., 2006). However, this is unlikely because these
644 three residues are among the seven that are not identical or not conservatively substituted
645 between JzTx-IX, JzTx-XI and PecTx-1a, some of them being even highly conserved in other toxins
646 from the NaSpTx family 2 that cannot target the hNav1.5 channel subtype (Deng et al., 2009).
647 Further experiments are thus necessary to study the PecTx-1a structure-activity relationship
648 before definitively establishing the key amino acid residues that are involved in the peptide
649 binding to hNav1.7 and 1.5 channel subtypes.

650 The evaluation of PecTx-1a functional properties on CHO and U2OS cells overexpressing hKir
651 and hKv channel subtypes reveals that the peptide was at least 80 and 280 times more potent to
652 decrease the hKv4.3 current than the hKv11.1 and hKir2.1, hKv1.5 or hKv7.1 current, respectively.
653 Among the studied hKir and hKv channel subtypes, the hKv4.3 subtype was thus the only one
654 affected by low concentrations of PecTx-1a (below 100 nM). The peptide effects on the hKv4.3
655 channel subtype consisted in a marked concentration-dependent ($IC_{50} = 7.2$ nM) positive shift of
656 the peak current-voltage relationship without any modification of the maximal conductance and
657 with only moderated, but significant, positive shift of the steady-state inactivation-voltage
658 relationship and slow-down of activation and inactivation kinetics. As a consequence of this
659 channel functioning modulator and not pore-blocker action produced by PecTx-1a, a 43% maximal
660 decrease of hKv4.3 peak current was observed in the presence of 36 nM to 10 μ M of peptide.
661 Similarly, no PecTx-1a inhibitory action was detected on the hKv1.5 channel subtype since the
662 peptide, although at a high concentration (*i.e.* 10 μ M), produced an increased current due to an
663 increased maximal conductance. Therefore, PecTx-1a was highly potent to act on the hNav1.7
664 channel subtype as a pore-blocker and on the hKv4.3 channel subtype as a channel functioning
665 modulator.

666 Among the toxins from the NaSpTx family 2 showing at least 44% of amino acid sequence
667 identity with PecTx-1a, and to the best of our knowledge, JzTx-XI is the only one reported to
668 interact with hKv channel subtypes at concentrations below 100 nM. In particular, the key amino
669 acid residues that are involved in the peptide binding to hKv2.1 have been identified (Table 5).
670 Hence, the 34 times lower affinity of JzTx-IX for this channel subtype has been attributed to the
671 presence of a threonine (T3) instead an arginine (R3) in the peptide sequence (Chi et al., 2011).
672 Similarly, the loss of affinity of JzTx-34 for hKv2.1 channel subtype was explained by the presence
673 of a glutamic acid (E20), a negatively-charged amino acid, instead of a glycine (G20) in the peptide
674 sequence (Chen et al., 2009). The hydrophobic patch surrounded by positively-charged amino
675 acids was thus proposed to be necessary for peptide binding to the hKv2.1 channel subtype, in
676 particular the one located at position 24 in the peptide sequence which interacts with the
677 negatively-charged amino acid located at position 277 in the channel subtype (Wang et al., 2004;
678 Deng et al., 2009). Taking into account the relatively conserved key amino acids for the peptide

679 binding to hK_v2.1 between PecTx-1a and JzTx-XI, it would be interesting to study the effects of the
680 former on this channel subtype.

681 The evaluation of PecTx-1a functional properties on CHO cells overexpressing hCa_v1.2, 2.2, 3.1
682 and 3.2 channel subtypes reveals that the peptide produced a hCa_v1.2 current decrease with very
683 high affinity (IC₅₀ = 4.96 nM) and selectivity against the other studied hCa_v currents (IC₅₀ > 10 μM).
684 This decrease occurred without any significant alteration of current activation and inactivation
685 kinetics, as well as conductance-voltage relationship, and with only moderated, but significant,
686 negative shift (5 mV) of the steady-state inactivation-voltage relationship, indicating that the
687 peptide acted mainly as a pore-blocker on this L-type, channel subtype. In agreement, PecTx-1a
688 (100 nM) produced an about 60% decrease of L-type (hCa_v1.1, 1.2 and 1.3) current while sparing
689 the T-type (hCa_v3.1 and 3.2) current in hiPSC-CMs. Taking into account that 100 nM of peptide
690 fully inhibited the L-type, hCa_v1.2 channel subtype overexpressed in CHO cells, these results
691 strongly suggest that PecTx-1a was less potent to interact with the L-type, hCa_v1.1 and/or 1.3
692 channel subtype(s). Further experiments on cells overexpressing these two channel subtypes are
693 necessary to definitively conclude.

694 To the best of our knowledge, PecTx-1a is the first molecule showing such high affinity for the
695 L-type, Ca_v1.2 channel subtype and selectivity against the various studied Na_v, K_v, Kir and other
696 Ca_v channel subtypes. Hence, drugs exhibiting hundred nanomolar affinities for the Ca_v1.2 channel
697 subtype, such as verapamil, diltiazem and dihydropyridines, have been widely described in the
698 literature (Crumb et al., 2016). However, three snake toxins of roughly 60 amino acids and 3-4
699 disulfide bridges, the *Dendroaspis polylepis* calciseptine, as well as a natural variant (FS2 with 3
700 different amino acids), and the *Dendroaspis angusticeps* calcicludine, were reported to have
701 higher affinities than the above drugs for L-type channels without any mention of their selectivity
702 between the four L-type, channel subtypes (Yasuda et al., 1994; Pringos et al., 2011). One snake
703 venom metalloproteinase was also described to inhibit the vascular L-type Ca_v channel with high
704 affinity (Zhang et al., 2009). The neuronal L-type Ca_v channel was preferentially targeted by two
705 scorpion toxins (Dutra et al., 2008; Liu et al., 2014), as well as by three spider toxins of 55-70
706 amino acids, with some relative selectivity among the Ca_v channel types (Sutton et al., 1998;
707 Kubista et al., 2007; Villegas et al., 2008). Although the spider κ-theraphotoxin-Gr2c (GsAFII) is
708 well-known to produce analgesic effects *via* the stretch-activated ion channels, the peptide was
709 also reported to exhibit relatively high affinity for the rat Ca_v1.2 channel subtype overexpressed in
710 *Xenopus* oocytes (IC₅₀ close to 17 nM; (Ono et al., 2011). The ω-theraphotoxin-Cc1a, the only
711 spider toxin more documented nowadays to interact with the rabbit Ca_v1.2 channel subtype,
712 shows relatively low affinity (IC₅₀ = 825 nM) and selectivity between rabbit/rat Ca_v2.x, hNa_v1.5 and
713 hNa_v1.7 channel subtypes (Klint et al., 2014). Finally, the two spider toxins ProTx-I and ProTx-II
714 were described to potently inhibit the Ca_v1.2 channel subtype but, once again, with relatively low
715 selectivity against Na_v, K_v and other Ca_v channel subtypes (Middleton et al., 2002; Priest et al.,
716 2007).

717 5. CONCLUSION

718 To the best of our knowledge, PecTx-1a is the first ICK spider toxin specifically targeting the L-

719 type, Ca_v1.2 channel subtype with high affinity and selectivity against the studied Na_v, K_v, Kir and
720 other Ca_v channel subtypes. This peptide represents thus a valuable tool to study the Ca_v1.2
721 subtype function and location at the cell level by *ex vivo* adding a tag to track the target of
722 interest. In addition, as responsible for the "plateau" of cardiac action potential, it may be a
723 valuable drug to treat some cardiomyopathies such as the long QT syndrome.

724

725 **ACKNOWLEDGMENTS** – This research was funded by a collaborative grant (#153114) between
726 Sanofi Research & Development (Chilly-Mazarin, France) and the French Alternative Energies and
727 Atomic Energy Commission (CEA, Gif sur Yvette, France). M.D.W. acknowledges financial support
728 from the French Agence Nationale de la Recherche (grant ANR-11-LABX-0015). T.C.G. was
729 supported by a doctoral CIFRE fellowship from Sanofi. The authors wish to thank Sandra VIALE
730 (Sanofi R&D, Vitry-sur-Seine, France) for providing hiPSC-CMs cells, Dr Gilles MOURIER and Margot
731 VANDEN DRIESSCHE (CEA de Saclay, Gif sur Yvette, France) for their help in peptide linearization,
732 Laetitia LUCARAIN (Sanofi R&D, Vitry-sur-Seine, France) for her help in screening experiments and
733 Lucille JAQUILLARD (Smartox Biotechnology, Saint-Egrève, France) for her help in peptide
734 purification, sequencing and synthesis experiments.

735

736 **CONFLICT OF INTEREST** – The authors, T.C. Gonçalves, M. Kurz, C. Sanson, B. Schombert, A.
737 Bohme, J.-M. Chambard, J.-M. Itier and M. Partiseti declare the following competing interest:
738 current or former employees of Sanofi.

739

740 **Accession Codes** – PDB code for PecTx-1a is XXXX. Authors will release the atomic coordinates and
741 experimental data upon article publication.

742

743 REFERENCES

- 744 Bell, D.C., and Dallas, M.L. (2017). Using automated patch clamp electrophysiology platforms in pain-
745 related ion channel research: insights from industry and academia. *Br J Pharmacol*.
- 746 Bennett, D.L., and Woods, C.G. (2014). Painful and painless channelopathies. *Lancet Neurol*. 13, 587-599.
- 747 Bosmans, F., Rash, L., Zhu, S., Diochot, S., Lazdunski, M., Escoubas, P., and Tytgat, J. (2006). Four novel
748 tarantula toxins as selective modulators of voltage-gated sodium channel subtypes. *Mol Pharmacol* 69,
749 419-429.
- 750 Cardoso, F.C., and Lewis, R.J. (2017). Sodium channels and pain: from toxins to therapies. *Br. J. Pharmacol*.
- 751 Catterall, W.A. (2000). From ionic currents to molecular mechanisms: the structure and function of voltage-
752 gated sodium channels. *Neuron* 26, 13-25.
- 753 Catterall, W.A. (2011). Voltage-gated calcium channels. *Cold Spring Harb Perspect Biol* 3, a003947.
- 754 Chambard, J.M., Tagat, E., Boudeau, P., and Partiseti, M. (2014). Transforming TRP channel drug discovery
755 using medium-throughput electrophysiological assays. *J. Biomol. Screen* 19, 468-477.
- 756 Chen, J., Zhang, Y., Rong, M., Zhao, L., Jiang, L., Zhang, D., Wang, M., Xiao, Y., and Liang, S. (2009).
757 Expression and characterization of jingzhaotoxin-34, a novel neurotoxin from the venom of the tarantula
758 Chilobrachys jingzhao. *Peptides* 30, 1042-1048.

- 759 Chi, Y., Deng, M., Wu, Y., Luo, J., Rong, M., Zhang, Y., Zhang, D., Zeng, X., and Liang, S. (2011). [Synthesis,
760 refolding and identification of pharmacological activities of neurotoxin JZTX-XI and R3A-JZTX-XI]. *Sheng*
761 *Wu Gong Cheng Xue Bao* 27, 900-908.
- 762 Crumb, W.J., Jr., Vicente, J., Johannesen, L., and Strauss, D.G. (2016). An evaluation of 30 clinical drugs
763 against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. *J Pharmacol*
764 *Toxicol Methods* 81, 251-262.
- 765 De Lera Ruiz, M., and Kraus, R.L. (2015). Voltage-Gated Sodium Channels: Structure, Function,
766 Pharmacology, and Clinical Indications. *J. Med. Chem.* 58, 7093-7118.
- 767 Deng, M., Kuang, F., Sun, Z., Tao, H., Cai, T., Zhong, L., Chen, Z., Xiao, Y., and Liang, S. (2009). Jingzhaotoxin-
768 IX, a novel gating modifier of both sodium and potassium channels from Chinese tarantula *Chilobrachys*
769 *jingzhao*. *Neuropharmacology* 57, 77-87.
- 770 Deuis, J.R., Dekan, Z., Wingerd, J.S., Smith, J.J., Munasinghe, N.R., Bhola, R.F., Imlach, W.L., Herzig, V.,
771 Armstrong, D.A., Rosengren, K.J., Bosmans, F., Waxman, S.G., Dib-Hajj, S.D., Escoubas, P., Minett, M.S.,
772 Christie, M.J., King, G.F., Alewood, P.F., Lewis, R.J., Wood, J.N., and Vetter, I. (2017). Pharmacological
773 characterisation of the highly NaV1.7 selective spider venom peptide Pn3a. *Sci Rep* 7, 40883.
- 774 Dutra, A.A., Sousa, L.O., Resende, R.R., Brandao, R.L., Kalapothakis, E., and Castro, I.M. (2008). Expression
775 and characterization of LTx2, a neurotoxin from *Lasiodora* sp. effecting on calcium channels. *Peptides*
776 29, 1505-1513.
- 777 Goldin, A.L., Barchi, R.L., Caldwell, J.H., Hofmann, F., Howe, J.R., Hunter, J.C., Kallen, R.G., Mandel, G.,
778 Meisler, M.H., Netter, Y.B., Noda, M., Tamkun, M.M., Waxman, S.G., Wood, J.N., and Catterall, W.A.
779 (2000). Nomenclature of voltage-gated sodium channels. *Neuron* 28, 365-368.
- 780 Gonçalves, T.C., Benoit, E., Partiseti, M., and Servent, D. (2018a). The Na_v1.7 channel subtype as an
781 antinociceptive target for spider toxins in adult dorsal root ganglia neurons. *Front Pharmacol* 9:1000.
782 doi: 10.3389/fphar.2018.01000.
- 783 Gonçalves, T.C., Boukaiba, R., Molgo, J., Amar, M., Partiseti, M., Servent, D., and Benoit, E. (2018b). Direct
784 evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using
785 multiscale functional approaches. *Neuropharmacology* 133, 404-414.
- 786 Gonçalves, T.C., Benoit, E., Kurz, M., Lucarain, L., Fouconnier, S., Combemale, S., Jaquillard, L., Schombert,
787 B., Chambard, J.-M., Boukaiba, R., Hessler, G., Bohme, A., Bialy, L., Hourcade, S., Bérout, R., De Waard,
788 M., Servent, S., and Partiseti, M. (2018c). Cyriotoxin-1a, the first toxin from *Cyriopagopus schioedtei*
789 spider with antinociceptive properties: from identification to functional characterization. *Br J Pharmacol*
790 (in revision).
- 791 Herzig, V., Wood, D.L., Newell, F., Chaumeil, P.A., Kaas, Q., Binford, G.J., Nicholson, G.M., Gorse, D., and
792 King, G.F. (2011). ArachnoServer 2.0, an updated online resource for spider toxin sequences and
793 structures. *Nucleic Acids Res* 39, D653-657.
- 794 Israel, M.R., Tay, B., Deuis, J.R., and Vetter, I. (2017). Sodium Channels and Venom Peptide Pharmacology.
795 *Adv. Pharmacol.* 79, 67-116.
- 796 Ivashchenko, C.Y., Pipes, G.C., Lozinskaya, I.M., Lin, Z., Xiaoping, X., Needle, S., Grygielko, E.T., Hu, E.,
797 Toomey, J.R., Lepore, J.J., and Willette, R.N. (2013). Human-induced pluripotent stem cell-derived
798 cardiomyocytes exhibit temporal changes in phenotype. *Am J Physiol Heart Circ Physiol* 305, H913-922.
- 799 Klint, J.K., Berecki, G., Durek, T., Mobli, M., Knapp, O., King, G.F., Adams, D.J., Alewood, P.F., and Rash, L.D.
800 (2014). Isolation, synthesis and characterization of omega-TRTX-Cc1a, a novel tarantula venom peptide
801 that selectively targets L-type Cav channels. *Biochem. Pharmacol.* 89, 276-286.
- 802 Kubista, H., Mafra, R.A., Chong, Y., Nicholson, G.M., Beirao, P.S., Cruz, J.S., Boehm, S., Nentwig, W., and
803 Kuhn-Nentwig, L. (2007). CSTX-1, a toxin from the venom of the hunting spider *Cupiennius salei*, is a
804 selective blocker of L-type calcium channels in mammalian neurons. *Neuropharmacology* 52, 1650-1662.
- 805 Liu, X., Li, C., Chen, J., Du, J., Zhang, J., Li, G., Jin, X., and Wu, C. (2014). AGAP, a new recombinant
806 neurotoxic polypeptide, targets the voltage-gated calcium channels in rat small diameter DRG neurons.
807 *Biochem Biophys Res Commun* 452, 60-65.

- 808 Middleton, R.E., Warren, V.A., Kraus, R.L., Hwang, J.C., Liu, C.J., Dai, G., Brochu, R.M., Kohler, M.G., Gao,
809 Y.D., Garsky, V.M., Bogusky, M.J., Mehl, J.T., Cohen, C.J., and Smith, M.M. (2002). Two tarantula
810 peptides inhibit activation of multiple sodium channels. *Biochemistry* 41, 14734-14747.
- 811 Namadurai, S., Yereddi, N.R., Cusdin, F.S., Huang, C.L., Chirgadze, D.Y., and Jackson, A.P. (2015). A new look
812 at sodium channel beta subunits. *Open Biol.* 5, 140192.
- 813 Ono, S., Kimura, T., and Kubo, T. (2011). Characterization of voltage-dependent calcium channel blocking
814 peptides from the venom of the tarantula *Grammostola rosea*. *Toxicon* 58, 265-276.
- 815 Pan, H.L., Wu, Z.Z., Zhou, H.Y., Chen, S.R., Zhang, H.M., and Li, D.P. (2008). Modulation of pain transmission
816 by G-protein-coupled receptors. *Pharmacol. Ther.* 117, 141-161.
- 817 Priest, B.T., Blumenthal, K.M., Smith, J.J., Warren, V.A., and Smith, M.M. (2007). ProTx-I and ProTx-II: gating
818 modifiers of voltage-gated sodium channels. *Toxicon* 49, 194-201.
- 819 Pringos, E., Vignes, M., Martinez, J., and Rolland, V. (2011). Peptide neurotoxins that affect voltage-gated
820 calcium channels: a close-up on omega-agatoxins. *Toxins (Basel)* 3, 17-42.
- 821 Sutton, K.G., Siok, C., Stea, A., Zamponi, G.W., Heck, S.D., Volkmann, R.A., Ahlijanian, M.K., and Snutch, T.P.
822 (1998). Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3. *Mol Pharmacol*
823 54, 407-418.
- 824 Trivedi, S., Dekermendjian, K., Julien, R., Huang, J., Lund, P.E., Krupp, J., Kronqvist, R., Larsson, O., and
825 Bostwick, R. (2008). Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators.
826 *Assay Drug Dev. Technol.* 6, 167-179.
- 827 Vetter, I., Deuis, J.R., Mueller, A., Israel, M.R., Starobova, H., Zhang, A., Rash, L.D., and Mobli, M. (2017).
828 NaV1.7 as a pain target - From gene to pharmacology. *Pharmacol Ther* 172, 73-100.
- 829 Villegas, E., Adachi-Akahane, S., Bosmans, F., Tytgat, J., Nakajima, T., and Corzo, G. (2008). Biochemical
830 characterization of cysteine-rich peptides from *Oxyopes* sp. venom that block calcium ion channels.
831 *Toxicon* 52, 228-236.
- 832 Wang, J.M., Roh, S.H., Kim, S., Lee, C.W., Kim, J.I., and Swartz, K.J. (2004). Molecular surface of tarantula
833 toxins interacting with voltage sensors in K(v) channels. *J Gen Physiol* 123, 455-467.
- 834 Waxman, S.G., and Zamponi, G.W. (2014). Regulating excitability of peripheral afferents: emerging ion
835 channel targets. *Nat Neurosci* 17, 153-163.
- 836 Yasuda, O., Morimoto, S., Jiang, B., Kuroda, H., Kimura, T., Sakakibara, S., Fukuo, K., Chen, S., Tamatani, M.,
837 and Ogihara, T. (1994). FS2, a mamba venom toxin, is a specific blocker of the L-type calcium channels.
838 *Artery* 21, 287-302.
- 839 Yekkirala, A.S., Roberson, D.P., Bean, B.P., and Woolf, C.J. (2017). Breaking barriers to novel analgesic drug
840 development. *Nat. Rev. Drug Discov.* 16, 545-564.
- 841 Yuan, C., Liu, Z., Hu, W., Gao, T., and Liang, S. (2012). JZTX-XIII, a Kv channel gating modifier toxin from
842 Chinese tarantula *Chilobrachys jingzhao*. *Toxicon* 59, 265-271.
- 843 Zamponi, G.W., Striessnig, J., Koschak, A., and Dolphin, A.C. (2015). The Physiology, Pathology, and
844 Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. *Pharmacol*
845 *Rev* 67, 821-870.
- 846 Zhang, P., Shi, J., Shen, B., Li, X., Gao, Y., Zhu, Z., Zhu, Z., Ji, Y., Teng, M., and Niu, L. (2009). Stejnihagin, a
847 novel snake metalloproteinase from *Trimeresurus stejnegeri* venom, inhibited L-type Ca²⁺ channels.
848 *Toxicon* 53, 309-315.
-

2.4.3. Résumé des résultats obtenus

La PecTx-1a, aussi nommée μ/ω -théraphotoxine-Ps1a, a été extraite du venin de l'araignée *Poecilotheria subfusca*, une mygale arboricole endémique au Sri Lanka aussi connue sous le nom "d'araignée de tigre ornementale" ou de "montane à bec d'ivoire". Ce peptide de 3999,66 Da fait partie de la famille 2 des toxines d'araignées inhibant les canaux Na_v (NaSpTx-2), possède 35 acides aminés et se structure autour du motif architectural ICK. Son profil de sélectivité a été établi sur différentes lignées cellulaires recombinantes exprimant les sous-types hNa_v , hK_v , hKir et hCa_v de canaux ioniques.

L'évaluation des propriétés fonctionnelles de la PecTx-1a sur des cellules HEK-293 exprimant les sous-types $\text{hNa}_v1.1-1.8$ révèle que le peptide est au moins 15 fois plus puissant pour interagir avec le sous-type $\text{hNa}_v1.7$ ($\text{IC}_{50} = 118,4 \text{ nM}$) qu'avec les sous-types $\text{hNa}_v1.1-1.4$, 1.6 et 1.8 ($\text{IC}_{50} > 1800 \text{ nM}$). Le fait que le peptide agisse à des concentrations de l'ordre du micromolaire sur les sous-types $\text{hNa}_v1.4$ et 1.6 est intéressant car son action sur le système neuromusculaire sera limitée. Cependant, la PecTx-1a s'est avérée également être très puissante pour interagir avec le sous-type cardiaque $\text{hNa}_v1.5$ ($\text{IC}_{50} = 260,9 \text{ nM}$), ce qui compromet fortement le développement de la molécule en tant qu'agent antinociceptif potentiel. Outre une diminution du pic de courant, le peptide produit une modification des cinétiques d'activation et d'inactivation, et leur dépendance vis-à-vis du potentiel, non seulement du sous-type $\text{hNa}_v1.7$ mais aussi d'autres sous-types de canaux Na_v TTX-S. En particulier, et bien qu'à des concentrations élevées (*i.e.* $> 1 \mu\text{M}$), l'inactivation du sous-type $\text{hNa}_v1.8$ est fortement ralentie, ce qui conduit à une augmentation du pic de courant. L'évaluation des propriétés fonctionnelles de la PecTx-1a sur des cellules CHO et U2OS exprimant les sous-types hK_v et hKir révèle que le peptide est au moins 80 fois plus puissant pour interagir avec le sous-type $\text{hK}_v4.3$ ($\text{IC}_{50} = 37 \text{ nM}$) qu'avec les sous-types $\text{hK}_v1.5$, 7.1 ou 11.1 et $\text{hKir}2.1$ ($\text{IC}_{50} > 2900 \text{ nM}$). Les effets de la PecTx-1a sur le sous-type $\text{hK}_v4.3$ consistent en une diminution maximale de 43% du pic de courant, indépendante de la concentration de peptide entre 36 nM et 10 μM et principalement due à un déplacement positif de la courbe "conductance-potentiel" [concentration effective produisant 50% de l'effet (EC_{50}) de 7,2 nM], sans modification notable de la conductance maximale. Finalement, l'évaluation des propriétés fonctionnelles de la PecTx-1a sur des cellules CHO exprimant les sous-types $\text{hCa}_v1.2$, 2.2, 3.1 et 3.2 révèle que le peptide est au moins 2000 fois plus puissant pour interagir avec le sous-type $\text{hCa}_v1.2$ ($\text{IC}_{50} = 4,96 \text{ nM}$) qu'avec les autres sous-types de canaux Ca_v étudiés ($\text{IC}_{50} > 10 \mu\text{M}$). Les effets de la PecTx-1a sur le sous-type $\text{hCa}_v1.2$ consistent en une diminution du pic de courant sans modification notable des cinétiques d'activation et d'inactivation, et leur dépendance vis-à-vis du potentiel. La PecTx-1a (100 nM) produit également une diminution d'environ 60% du

courant de type L (hCa_v1.1, 1.2 et 1.3) sans modifier le courant de type T (hCa_v3.1 et 3.2) de cardiomyocytes dérivés de cellules souches pluripotentes humaines (hiPSC-CM pour "human induced pluripotent stem cell derived cardiomyocytes"). Compte tenu du fait que 100 nM de peptide bloque complètement le sous-type hCa_v1.2 exprimé dans les cellules CHO, ces résultats suggèrent fortement que la Pectx-1a est moins efficace pour interagir avec les sous-types hCa_v1.1 et/ou 1.3, l'expression du sous-type hCa_v1.1 au niveau des hiPSC-CM restant à démontrer.

Des expériences similaires, dont les résultats ne sont pas inclus dans la publication, ont été réalisées récemment en utilisant la protoxine-II (ProTx-II) décrite également pour inhiber le sous-type Ca_v1.2 avec une forte puissance. Ce peptide de 3823 Da, extrait du venin de la mygale péruvienne de velours vert connue sous le nom de *Thrixopelma pruriens*, fait partie de la famille 3 des toxines d'araignées inhibant les canaux Na_v (NaSpTx-3), possède 30 acides aminés et se structure autour du motif architectural ICK. La ProTx-II a été décrite pour la première fois au début des années 2000 comme étant une toxine inhibitrice de tous les sous-types Na_v (IC₅₀ < 150 nM) mais aussi de certains sous-types Ca_v1.x, Ca_v3.x et K_v (Middleton et al., 2002). Cependant, peu de résultats quantitatifs de la puissance du peptide pour ces cibles sont rapportés dans la littérature (Kraus et al., 2000; Kraus et al., 2002; Priest et al., 2007; Bladen et al., 2014). Afin de quantifier le profil de sélectivité de la ProTx-II, nous avons étudié ses effets sur des lignées cellulaires recombinantes exprimant certains sous-types hNa_v, hCa_v, hK_v et hKir de canaux ioniques (Figure 2-5).




Figure 2-5. Effets de la ProTx-II sur les courants hNa_v, hCa_v, hK_v et hKir. Histogramme exprimant les pourcentages de courant restant (en foncé) et inhibé (en clair) en fonction du sous-type de canal indiqué, en présence de 10 μM (en violet) et de 37-41 nM (en bordeaux) de peptide (moyenne ± ES, n = 3-15).

La puissance de la ProTx-II pour les différents sous-types de canaux ioniques est estimée par l'action inhibitrice de 10 μ M et de 37-41 nM de peptide sur les courants transitant par ces sous-types (moyenne \pm ES de 3-15 expériences). Ainsi, à une concentration de 10 μ M, la ProTx-II affecte de façon croissante les courants hK_V7.1 (inhibition de 3,2 \pm 0,1%) < hKir2.1 (inhibition de 17,0 \pm 4,6%) < hCa_V2.2 (inhibition de 19,1 \pm 2,3%) < hCa_V3.2 (inhibition de 28,8 \pm 0,1%) < hCa_V3.1 (inhibition de 56,0 \pm 0,1%) (Figure 2-5, colonnes violettes), les courants hNa_V1.7, hCa_V1.2, hK_V4.3 et hK_V11.1 étant bloqué entre 90 et 100%. Le peptide a donc une puissance relativement forte pour les sous-types hNa_V1.7, hCa_V1.2, hK_V4.3 et hK_V11.1 de canaux ioniques. Ainsi, à une concentration de 37-41 nM, la ProTx-II affecte de façon croissante les courants hK_V11.1 (inhibition de 21,5 \pm 5,4 %) < hK_V4.3 (inhibition de 42,3 \pm 1.4 %) < hCa_V1.2 (inhibition de 51,5 \pm 4,5%) < hNa_V1.7 (inhibition de 85,0 \pm 0,1%) (Figure 2-5, colonnes bordeaux). Bien que la très haute puissance de la ProTx-II pour le sous-type Na_V1.7 soit maintenue, une forte puissance est également détectable pour les sous-types hCa_V1.2, hK_V4.3 et hK_V11.1 impliqués dans le potentiel d'action cardiaque.

2.4.4. Conclusion

Bien que mise en évidence par sa puissance relativement haute vis-à-vis du sous-type hNa_V1.7 de canaux sodium, la Pectx-1a se révèle être 24 fois plus efficace pour bloquer le sous-type hCa_V1.2 de canaux calcium. De plus, ce peptide présente une grande sélectivité vis-à-vis des autres sous-types de canaux ioniques, en particulier ceux impliqués dans le potentiel d'action cardiaque, contrairement à la ProTx-II qui possède une puissance similaire pour les sous-types Ca_V1.2, Na_V1.7, K_V4.3 et, de façon moindre, pour le sous-type K_V11.1. Outre la ProTx-II, de nombreuses toxines de venins de serpents, de scorpions et d'araignées sont décrites dans la littérature comme ciblant les canaux Ca_V de type L, incluant le sous-type Ca_V1.2. Cependant, certains critères les concernant en font de mauvais candidats pour un développement thérapeutique comme (1) leur grande taille (55-70 acides aminés, 4 ponts disulfures) rendant difficile leur synthèse chimique et leur repliement structural, (2) leur manque de sélectivité vis-à-vis des autres sous-types de canaux Ca_V de type L (*i.e.* Ca_V1.1, 1.3 et 1.4), ou de types T, P/Q, N et R, de canaux Na_V et de canaux K_V, (3) les fonctions multiples que peuvent avoir certaines d'entre elles, comme par exemple les métalloprotéinases, (4) leur puissance validée sur le sous-type Ca_V1.2 d'une espèce non humaine (rongeurs ou lagomorphe), et (5) leur faible puissance (d'une dizaine à plusieurs centaines de nanomolaires) pour le sous-type Ca_V1.2 (Yasuda et al., 1994; Sutton et al., 1998; Kubista et al., 2007; Dutra et al., 2008; Villegas et al., 2008; Ono et al., 2011; Pringos et al., 2011; Klint et al., 2014; Liu et al., 2014a).

La PecTx-1a représente donc un outil précieux pour étudier l'expression, la localisation et la fonction du sous-type $Ca_v1.2$ au niveau cellulaire. De plus, en tant que responsable du "plateau" du potentiel d'action cardiaque, elle peut être envisagée comme agent thérapeutique potentiel pour traiter le syndrome du QT long afin d'avoir une alternative aux molécules non peptidiques (telles que le vérapamil, le diltiazem et les dihydropyridines) déjà présentes sur le marché et n'étant pas ou que peu très peu sélectives d'un sous-type donné de canaux Ca_v de type L (Crumb et al., 2016).

2.5. Criblage à haut débit d'une banque de venins appartenant à SANOFI

2.5.1. Contexte de l'étude

Parallèlement à l'étude des propriétés pharmacologiques et fonctionnelles des 4 toxines présentée précédemment (voir sous-parties 2.1 à 2.4), nous avons effectué le criblage à haut débit de 9 venins d'une banque rachetée par SANOFI à l'entreprise de biotechnologie "VenomeTech" (Valbonne) et contenant 450 venins de diverses espèces animales (araignées, cônes, scorpions, serpents et insectes). Le but de ce second criblage est de révéler des toxines originales par leur provenance et/ou leur spécificité vis-à-vis non seulement du sous-type hNa_v1.7 mais également des sous-types hNa_v1.2 et 1.6 de canaux sodium, tout en épargnant le sous-type cardiaque hNa_v1.5.

Le choix de ces 3 sous-types de canaux a été guidé par l'optique de mettre en évidence (1) des toxines analgésiques, *i.e.* ayant une forte spécificité pour le sous-type hNa_v1.7, (2) des toxines inhibant spécifiquement le sous-type neuronal hNa_v1.2, pour une meilleure connaissance de l'expression, de la localisation et du rôle de ce sous-type dans les différentes régions du cerveau, et (3) des toxines inhibant spécifiquement le sous-type hNa_v1.6, afin de concevoir des agents thérapeutiques pour traiter l'épilepsie et certains cancers impliquant ce sous-type de canal (Catterall, 2012; Hernandez-Plata et al., 2012). Dans cette dernière optique, nous cherchons plus particulièrement des toxines ayant un effet anti-invasif au niveau de cellules cancéreuses exprimant le sous-type hNa_v1.6 ou pouvant être utilisées comme outils moléculaires de marquage afin de caractériser le stade de développement du cancer.

2.5.2. Résultats obtenus

2.5.2.1. Criblage primaire de la banque de venins

Un premier criblage des fractions de venins avait été préalablement mené en utilisant une plateforme automatisée de "patch-clamp", le système à haut débit IonWorks Quattro® (voir sous-partie 2.1). Ce criblage avait été réalisé sur des lignées cellulaires recombinantes humaines HEK-293 exprimant les sous-types hNa_v1.7 et 1.5 et enregistrées en configuration "membrane perforée" et en mode "cellule multiple" (Figure 2-6).

Dans un premier temps, toutes les fractions de venins produisant une perte de scellement (*i.e.*

collage hermétique entre la pipette de "patch" et la membrane cellulaire) ont été éliminées de notre étude. En effet, une perte de scellement avait été rapportée antérieurement lors de l'étude de venins cytotoxiques contenant de la phospholipase A2 et/ou des peptides formant des pores membranaires (Jami et al., 2017), comme cela était le cas pour les fractions des deux venins de cobras (*Naja* sp.) appartenant à la sous-famille Elapidae stricto sensu que nous avons étudiées (A3-x pour *Naja naja Philippinensis* et B3-x pour *Naja oxiana*). Outre les fractions de venins produisant une perte de scellement, et par précaution, l'ensemble des fractions de ces deux venins ont été éliminées de notre étude, incluant même celles pour lesquelles le scellement était préservé. Dans un deuxième temps, toutes les fractions de venins considérées comme ayant une faible activité sur le sous-type hNa_v1.7 (*i.e.* celles produisant une inhibition inférieure à 40% à une concentration de 0,5 µg/µL) ont été également éliminées de notre étude, à savoir les fractions des venins des deux espèces de cônes (C3-x pour *Conus radiatus* et D3-x pour *Conus geographus*) et d'insecte (A4-x pour *Pachycondila strigulosa*).




Figure 2-6. Criblage primaire de la banque de venins appartenant à SANOFI. Pourcentage d'inhibition des pics de courants hNa_v1.7 (carrés rouges) et hNa_v1.5 (ronds noirs) suite à l'application de 0,5 µg/µL de chacune des 49 fractions obtenues à partir des venins d'araignées (A5-x pour *Selenotypus plumipes* et B5-x pour *Phoneyusa celerieri*), de scorpions (G4-x pour *Hottentota gentili* et H4-x pour *Hottentota jayakari*), de serpents (A3-x pour *Naja naja Philippinensis* et B3-x pour *Naja oxiana*), de cônes (C3-x pour *Conus radiatus* et D3-x pour *Conus geographus*) et d'insecte (A4-x pour *Pachycondila strigulosa*). Le cercle rouge à hauteur de 40% d'inhibition marque la limite au-delà de laquelle les fractions ont été analysées en détail.

Suite à ce criblage primaire, les fractions les plus intéressantes qui ont été analysées en détail proviennent des venins de deux espèces d'araignées (A5-x pour *Selenotypus plumipes* et B5-x pour *Phoneyusa celerieri*) et de deux espèces de scorpions (G4-x pour *Hottentota gentili* et H4-x pour *Hottentota jayakari*), venins qui n'avaient jamais, voire que très peu, été étudiés jusqu'à présent.

2.5.2.2. Etude du venin de l'araignée *Selenotypus plumipes* (A5-x)

Bien que *Selenotypus plumipes* soit une araignée endémique du Queensland, en Australie, son venin n'a été étudié que par l'équipe de Glenn F. King (Brisbane, Australie) pour son activité létale sur les termites, les coléoptères ainsi que les larves de lépidoptères (Hardy et al., 2013; Wong et al., 2013). Deux toxines, actives par voie orale, ont été ainsi décrites suite à un criblage bioguidé pour leur activité insecticide: l'OAIP-1 constituée de 34 acides aminés et l'OAIP-4 constituée de 29 acides aminés réticulés par 3 ponts disulfures (Tableau 2-1).

Tableau 2-1. Caractéristiques des deux toxines (OAIP-1 et OAIP-4) extraites du venin de *Selenotypus plumipes* et déjà décrites dans la littérature.

Nom scientifique	Nom d'usage	Masse (Da)	Séquence en acides aminés
U ₁ -théraphotoxine-Spl1a	OAIP-1	3813,72	DCGHLHDPCPNDRPGHRTCCIGLQCRYGKCLVRV*
U ₄ -théraphotoxine-Spl1a	OAIP-4	3651,53	YCQKWMWTCDAERKCCEDMACELWCCKRL*

U: cible moléculaire inconnue. *: amidation en C-terminal. La masse correspond à la masse mono-isotopique de la toxine oxydée. En rouge, les 6 résidus cystéine qui structurent la toxine.

En utilisant la plateforme automatisée QPatch HTX de "patch-clamp" (voir sous-partie 2.1), nous avons réalisé un criblage plus sensible de 42 sous-fractions du venin de *Selenotypus plumipes* sur des lignées cellulaires recombinantes humaines HEK-293 exprimant les sous-types hNa_v1.7, 1.2, 1.6 et 1.5 et enregistrées en configuration "cellule entière" et en mode "cellule multiple" (Figure 2-7).

Sur ces 42 sous-fractions de venin, 6 produisaient une forte inhibition du sous-type hNa_v1.7 sans affecter le sous-type hNa_v1.5. Malheureusement, elles ont dû être éliminées de notre étude à cause de leur manque de sélectivité vis-à-vis des sous-types hNa_v1.2 et 1.6 (sous-fractions A5-18-7, A5-19-4-4, A5-19-6, A5-21-1, A5-21-4 et A5-23-4 soulignées en rouge dans la Figure 2-7).

En revanche, 7 sous-fractions de venin produisaient une forte inhibition des sous-types hNa_v1.2 et/ou 1.6 et présentaient une forte sélectivité vis-à-vis des sous-types hNa_v1.5 et 1.7. Leur analyse a donc été poursuivie (sous-fractions A5-19-2, A5-19-3, A5-19-4-5, A5-20-3, A5-20-4, A5-20-6 et A5-22-5 soulignées en vert dans la Figure 2-7).




Figure 2-7. Criblage des sous-fractions du venin de *Selenotypus plumipes*. Pourcentage d'inhibition du pic de courant hNav_v1.7 (carrés rouges), suite à l'application de 5 ng/μL de chacune des 42 sous-fractions secondaires et tertiaires, et des pics de courants hNav_v1.5 (ronds noirs), hNav_v1.2 (losanges verts) et hNav_v1.6 (triangles bleus), suite à l'application de 23 ng/μL de ces mêmes sous-fractions. Les sous-fractions manquant de sélectivité sont soulignées en rouge et ont été éliminées de notre étude. Celles présentant une sélectivité originale (hNav_v1.2 et/ou 1.6 *versus* hNav_v1.7) sont soulignées en vert et leur analyse a été poursuivie. Les cercles rouges indiquent le pourcentage d'inhibition non négligeable du courant hNav_v1.7 produit par deux d'entre elles.

Ces 7 sous-fractions, en quantité limitée, ne contenaient chacune qu'une à deux toxines qui ont été identifiées par leur masse. Le regroupement de certaines sous-fractions contenant des masses similaires a permis d'avoir la quantité nécessaire pour réaliser directement le séquençage des toxines correspondantes. En particulier, deux toxines étaient présentes dans différentes sous-fractions: la toxine de 3791,5-3791,9 Da présente dans 5 sous-fractions et celle de 4362,1-4362,6 Da présente dans 3 sous-fractions, la faible variation de masse (de 0,4-0,5 Da) étant probablement due à une imprécision dans la mesure (Tableau 2-2). En tenant compte de ces similitudes de masse, nous avons donc identifié 6 toxines dans les 7 sous-fractions d'intérêt.

Avant d'effectuer le séquençage de ces 6 toxines, nous avons recherché les toxines déjà décrites dans la littérature et ayant des masses proches, voire identiques, à celles de nos toxines d'intérêt,

dans la base de données "ArachnoServer" (Pineda et al., 2018) qui est une source d'informations sur les toxines de venins d'araignées (Tableau 2-3). Il est à souligner qu'une étude précédente de prédiction informatique des séquences en acides aminés des toxines matures, à partir du transcriptome du venin de *Selenotypus plumipes*, révèle que de nombreuses séquences sont retrouvées dans le venin d'autres araignées de type mygalomorphe telles que *Chilobrachys guangxiensis* avec laquelle *Selenotypus plumipes* a un peu plus de 90% des séquences en commun (Figure 2-8; Wong et al., 2013).

Tableau 2-2. Masse mono-isotopique des toxines oxydées identifiées dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes*.

Sous-fraction	Masse (Da)
A5-19-2	3791,9 et 4324,9
A5-19-3	3791,9 et 4362,1
A5-19-4-5	3791,5 et 4362,1
A5-20-3	3791,9 et 4362,6
A5-20-4	3791,9 et 4376,2
A5-20-6	3923,1
A5-22-5	4124,1

Tableau 2-3. Toxines trouvées dans ArachnoServer (AS) dont les masses avoisinent celles des 6 toxines présentes dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes* (Sp).

Masse Sp (Da)	Masse AS (Da)	Nom scientifique	Nom d'usage	Araignée
3791,5	3792,73	U ₂ -Agatoxine-Ao1d	Agel_03	<i>Agelena orientalis</i>
3791,9	3793,14	M-Ctenitoxine-Cs1d	Cupiennine 1d	<i>Cupiennius salei</i>
	3793,51	ω-Hexatoxine-Ar1b	ω-Atracotoxine-Ar1b	<i>Atrax robustus</i>
3923,1	3923,43	δ-Amaurobitoxine-Pl1c	δ-Palutoxine IT3	<i>Pireneitega luctuosa</i>
4124,1	4124,37	M-Oxotoxine-Ot2a	Oxyopinine-2a	<i>Oxyopes takobius</i>
4324,9	4325,00	U ₃ -Théraphotoxine-Cg1a	Jingzhaotoxine-8.2	<i>Chilobrachys guangxiensis</i>
4362,1	4362,03	ω-Hexatoxine-Hv2i	-	<i>Hadronyche versuta</i>
4362,6	4362,23	ω-Théraphotoxine-Bs1b	Brachypelma smithi toxine 5	<i>Brachypelma smithi</i>
4376,2	4375,83	U ₂₁ -Théraphotoxine-Hs1a	Huwentoxine-XIXa1	<i>Haplopelma schmidtii</i>
	4376,24	ω-Théraphotoxine-Ba1c	Peptide Ba3 de venin	<i>Brachypelma albiceps</i>

U: cible moléculaire inconnue. M: toxines inhibitrices des canaux mécano-sensoriels. ω: toxines inhibitrices des canaux Ca_v. δ: toxines ralentissant l'inactivation des canaux Na_v. La masse correspond à la masse mono-isotopique de la toxine oxydée.

Les séquences primaires (en acides aminés) de 5 sur 6 de nos peptides naturels d'intérêt ont été déterminées par séquençage *de novo* en utilisant la spectrométrie de masse en tandem (MS/MS) et la dégradation d'Edman, soit une combinaison de techniques analytiques incluant une approche ascendante ("bottom-up") et une spectrométrie de masse à haute résolution (Tableau 2-4).




Figure 2-8. Nombres de séquences de *Selenotypus plumipes* qui ont une homologie avec celles des toxines de différentes espèces d'araignées d'après la base de données "ArachnoServer". Ne sont mentionnées que les paires issues de chaque Blast avec un fort pourcentage d'identité. Les nombres sont ceux des séquences de *Selenotypus plumipes* qui correspondent aux toxines connues des espèces suivantes: *Chilobrachys jing zhao* (tarentule-tigre chinoise), *Coremiocnemis valida* (tarentule brune de Singapour), *Haplopelma huwenum* (araignée-oiseau chinoise), *Grammostola rosea* (mygale rose du Chili) et *Lycosa singoriensis* (araignée-loup). À l'exception de *Lycosa singoriensis*, toutes ces araignées sont des mygalomorphes primitives apparentées à *Selenotypus plumipes*. D'après Wong et al., 2013.

Tableau 2-4. Séquences en acides aminés des toxines contenues dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes*.

Peptide	Sous-fraction d'origine	Masse (Da)	Séquence en acides aminés
A5-19-2-1	A5-19-3/A5-19-4-5/A5-20-3	4325,0	LFEC S FS C DIKKN G K P C K GS G E K K C SG G W R C K M N F C V K V
A5-20-3-2	A5-19-2	4362,1	FE C V L K C DIQ Y NG K N C K G K G E N K C SG G W R C R F K L C L K I
A5-20-4-1	A5-19-2/A5-19-3/A5-20-3/ A5-20-4	3791,5	D C L G Q W S G C D P K N S K C C P S Y A C T S K Y P W C R Y H I*
A5-20-5-1	A5-20-4	4376,2	FE C V L K C DIQ Y NG K N C K G K G E K K C SG G W R C R F K L C L K I
A5-20-6-1	A5-20-6	3921,3	Non déterminée
A5-22-5-2	A5-22-5	4123,7	E C L G Q W S G C D P N D N K C C P N Y A C T W K Y P W C R K Y L W

*: amidation en C-terminal. La masse correspond à la masse mono-isotopique de la toxine oxydée. En rouge, les 6 résidus cystéine qui structurent la toxine. En vert, le seul acide aminé (en position 22) qui diffère l'A5-20-5-1 de l'A5-20-3-2.

Deux des séquences primaires déterminées, celles de l'A5-19-2-1 et de l'A5-20-3-2, sont repliées par 3 ponts disulfures caractérisés par un appariement spécial des cystéines (C_I-C_{III}, C_{II}-C_V, C_{IV}-C_{VI}) et

sont déjà connues. La séquence primaire de l'A5-19-2-1, de 39 résidus d'acides aminés, correspond à 100% à celle de la jinghaotoxine (JzTx)-8.2, aussi nommée U₃-théraphotoxine-Cg1a, dont la cible était inconnue jusque-là (Chen et al., 2008). La séquence primaire de l'A5-20-3-2, de 38 résidus d'acides aminés, correspond à 100% à celle de l'OAIP-5 dont la cible était, là encore, inconnue jusque-là (Wong et al., 2013). La séquence primaire de l'**A5-20-5-1** montre que cette toxine est un variant qui ne diffère que par un seul acide aminé de l'A5-20-3-2 [une lysine (K) à la place d'une asparagine (N) en position 22, ce qui explique la différence de 14,1 Da entre les deux masses; Tableau 2-4]. Ces trois séquences ont la particularité d'être très riches en acides aminés basiques: 8 à 9 lysines (K) et 1 à 2 arginines (R). Les séquences primaires de l'**A5-20-4-1**, de 33 résidus d'acides aminés, et celle de l'**A5-22-5-2**, de 34 résidus d'acides aminés, partagent 79% et 53% d'identité, respectivement, avec celle de l'OAIP-2 qui, comme les OAIP-1 et 4, se structure autour du motif architectural ICK et est caractérisée par un appariement des cystéines (C_I-C_{IV}, C_{II}-C_V, C_{III}-C_{VI}) fréquemment retrouvé dans les toxines décrites comme antinociceptives (voir partie 1). Il est à souligner que la séquence primaire de l'A5-22-5-2 partage 73% d'identité avec celle de la β-théraphotoxine-Pmr1a connue pour son action inhibitrice de certains sous-types de canaux Na_v, *i.e.* Na_v1.3 et 1.8 (Meir et al., 2012).

Les synthèses des 3 toxines JzTx-8.2/A5-19-2-1, OAIP-5/A5-20-3-2 et son variant K22N-OAIP-5/A5-20-5-1, incluant une structure en épingle à cheveux β, ont été très difficiles à réaliser de par une étape d'oxydation compliquée. Les synthèses des 2 toxines originales se structurant autour du motif ICK ont conduit à une qualité correcte des séquences brutes, malgré un repliement difficile pour l'A5-20-4-1. Après l'utilisation de méthodes de chromatographie en phase liquide à haute performance (HPLC pour "high performance liquid chromatography"), sur phase inverse, et de chromatographie échangeuse de cations, la purification des produits de synthèse s'est traduite par l'obtention de larges pics, chacun contenant des peptides de même masse, mais ayant probablement des appariements de ponts disulfure variables, ce qui nous a souvent amené à étudier 2 à 3 produits de synthèse pour un peptide naturel donné (Tableau 2-5).

Les effets de chaque produit de synthèse ont été évalués sur les lignées cellulaires recombinantes humaines HEK-293 exprimant les sous-types hNa_v1.2, 1.6 et 1.7, en utilisant la même plateforme automatisée de "patch-clamp" que celle utilisée pour le criblage primaire de la banque de venins, à savoir le système à haut débit IonWorks Quattro[®]. Les résultats obtenus montrent que seuls les produits de synthèse 1690 F1X1F1 (une fraction de l'A5-20-4-1) et 1853 F1, 1853 F5 et 1853 F6 (les trois fractions de l'A5-22-5-2) produisaient une inhibition des courants hNa_v1.2, 1.6 et 1.7 avec une valeur moyenne d'IC₅₀ proche de 1 μM, les valeurs moyennes d'IC₅₀ pour les autres produits de synthèse étant supérieures à 10 μM (Tableau 2-5).

Tableau 2-5. Produits de synthèse obtenus après le séquençage des peptides naturels contenus dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes*.

Peptide naturel	Produit de synthèse	Pureté	IC ₅₀ moyen (hNa _v 1.2, 1.6 et 1.7)
A5-19-2-1 (JzTx-8.2)	1687 F2	Plusieurs motifs de repliement	> 10 µM
A5-20-3-2 (OAIP-5)	1688 F1	Plusieurs motifs de repliement	> 10 µM
	1688 F2		
	1688 F3		
A5-20-4-1	1690 F1	94%	> 10 µM
	1690 F1X1F1	83%	≈ 1 µM
A5-20-5-1 (K22N-OAIP-5)	1781 F1	Plusieurs motifs de repliement	> 10 µM
	1781 F2		
	1781 F3		
A5-22-5-2	1853 F1	99%	≈ 1 µM
	1853 F5	82%	
	1853 F6	91%	

Suite à ces résultats, il nous a semblé intéressant de mieux caractériser la puissance des produits de synthèse contenus dans les trois fractions de l'A5-22-5-2 pour les cibles d'intérêt, à savoir les sous-types hNa_v1.2, 1.5, 1.6 et 1.7 de canaux Na_v, en utilisant la plateforme automatisée QPatch HTX de "patch-clamp". Les produits de synthèse agissaient préférentiellement sur les sous-types TTX-S (hNa_v1.2, 1.6 et 1.7), avec une sélectivité moyenne vis-à-vis du sous-type TTX-R cardiaque hNa_v1.5 (facteur de sélectivité supérieur à 11, [Tableau 2-6](#)). Leurs effets consistent en une diminution des pics de courant sans modification notable des cinétiques d'activation et d'inactivation, et de leur dépendance vis-à-vis du potentiel. Ces propriétés suggèrent fortement un mode d'action du type "bloqueurs de pore". Le produit 1853 F1 possède une forte puissance (IC₅₀ de plusieurs dizaines de nanomolaires) pour les 3 sous-types TTX-S. La puissance des produits 1853 F5 et 1853 F6 est moins importante pour ces 3 sous-types (IC₅₀ de plusieurs centaines de nanomolaires) mais le produit 1853 F5 semble être plus efficace pour interagir avec le sous-type hNa_v1.2 ([Tableau 2-6](#)). Cependant, avec un facteur de sélectivité inférieur à 6 vis-à-vis des sous-types hNa_v1.6 et 1.7, ce produit est peu intéressant comme outil potentiel visant le sous-type hNa_v1.2.

Tableau 2-6. Puissance des produits de synthèse des trois fractions de l'A5-22-5-2 (IC₅₀ moyen ± ES en nM, n = 2-6) pour les sous-types hNa_v1.2, 1.5, 1.6 et 1.7.

Produit de synthèse	hNa _v 1.7	hNa _v 1.2	hNa _v 1.5	hNa _v 1.6
1853 F1	79 ± 20	126 ± 18	1605 ± 279	50 ± 15
1853 F5	3761 ± 1064	659 ± 226	> 10000	1197 ± 103
1853 F6	2602 ± 607	903 ± 294	> 10000	1187 ± 34

2.5.2.3. Etude du venin de l'araignée *Phoneyusa celerieri* (B5-x)

Phoneyusa celerieri (aussi nommée *Hysteroocrates celerieri*) est une araignée babouin endémique de l'Afrique subsaharienne et du Moyen-Orient. En utilisant la plateforme automatisée QPatch HTX de "patch-clamp", nous avons réalisé un criblage secondaire de 11 sous-fractions du venin de cette araignée sur des lignées cellulaires recombinantes humaines HEK-293 exprimant les sous-types hNav_v1.7, 1.2, 1.6 et 1.5 et enregistrées en configuration "cellule entière" et en mode "cellule multiple" (Figure 2-9).




Figure 2-9. Criblage des sous-fractions du venin de *Phoneyusa celerieri*. Pourcentage d'inhibition du pic de courant hNav_v1.7 (carrés rouges), suite à l'application de 5 ng/μL de chacune des 11 sous-fractions secondaires, et des pics de courants hNav_v1.5 (ronds noirs), hNav_v1.2 (losanges verts) et hNav_v1.6 (triangles bleus), suite à l'application de 23 ng/μL de ces mêmes sous-fractions. Les sous-fractions manquant de sélectivité sont soulignées en rouge. Celle présentant une sélectivité originale (hNav_v1.6 et 1.2 *versus* hNav_v1.7) est soulignée en vert.

Sur ces 11 sous-fractions, 2 produisaient une inhibition de plus de 90% du sous-type hNav_v1.7 sans affecter le sous-type hNav_v1.5, mais manquaient de sélectivité vis-à-vis des sous-types hNav_v1.2 et

1.6 (sous-fractions B5-19-10 et B5-19-11 soulignées en rouge dans la [Figure 2-9](#)). En revanche, comparée à ces deux sous-fractions, une troisième sous-fraction de venin produisait une inhibition relativement moins forte des sous-types hNa_v1.6 et 1.2 mais présentait une sélectivité relativement plus forte vis-à-vis du sous-type hNa_v1.7 (sous-fraction B5-19-9 soulignée en vert dans la [Figure 2-9](#)). L'analyse de 2 de ces 3 sous-fractions, B5-19-9 et B5-19-11, a été poursuivie.

Ces 2 sous-fractions ne contenaient chacune qu'une à deux toxines identifiées par leur masse ([Tableau 2-7](#)). En tenant compte de la similitude de masse, nous avons identifié 2 toxines dans les 2 sous-fractions d'intérêt: une de 3792,7-3793,7 Da et l'autre de 5299,6 Da. Cette dernière a été éliminée de notre étude compte-tenu de sa masse relativement élevée et du fait que la sous-fraction d'origine manquait de sélectivité vis-à-vis des sous-types hNa_v1.2, 1.6 et 1.7 (voir [Figure 2-9](#)). Nous avons recherché les toxines déjà décrites dans la littérature et ayant des masses proches, voire identiques, à notre toxine d'intérêt dans la base de données "ArachnoServer" ([Tableau 2-8](#)). Il est à souligner que la masse de cette toxine d'intérêt du venin de *Phoneyusa celerieri* (3792,7-3793,7) est proche de celle d'une des toxines identifiées dans certaines sous-fractions du venin de *Selenotypus plumipes* (3791,5-3791,9). En conséquence, il n'est pas étonnant que les toxines ayant une masse apparentée et trouvées dans ArachnoServer soient les mêmes (voir [Tableaux 2.3 et 2.8](#)).

Tableau 2-7. Masse mono-isotopique des toxines oxydées identifiées dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri*.

Sous-fraction	Masse (Da)
B5-19-9	3793,7 et 5299,6
B5-19-11	3792,7

Tableau 2-8. Toxines trouvées dans ArachnoServer (AS) dont les masses avoisinent celles de la toxine présente dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri* (Pc).

Masse Pc (Da)	Masse AS (Da)	Nom scientifique	Nom d'usage	Araignée
3792,7	3792,73	U ₂ -Agatoxine-Ao1d	Agel_03	<i>Agelena orientalis</i>
3793,7	3793,14	M-Ctenitoxine-Cs1d	Cupiennine 1d	<i>Cupiennius salei</i>
	3793,51	ω-Hexatoxine-Ar1b	ω-Atracotoxine-Ar1b	<i>Atrax robustus</i>

U: cible moléculaire inconnue. M: toxines inhibitrices des canaux mécano-sensoriels. ω: toxines inhibitrices des canaux Ca_v. La masse correspond à la masse mono-isotopique de la toxine oxydée.

La séquence primaire de notre peptide naturel d'intérêt a été déterminée par séquençage *de novo* en utilisant la spectrométrie de MS/MS et la dégradation d'Edman, malgré un doute sur l'originalité de séquence entre la toxine de 3792,7-3793,7 Da du venin de *Phoneyusa celerieri* et celle de 3791,5-3791,9 Da du venin de *Selenotypus plumipes*. La séquence primaire déterminée (toxine B5-

19-10-1 de 3793,7 Da) inclut 34 résidus d'acides aminés dont 6 cystéines qui structurent la toxine autour du motif architectural ICK (Tableau 2-9). Elle ne partage que 53% d'identité avec celle de l'A5-20-4-1 de *Selenotypus plumipes*, bien que les deux peptides aient des masses similaires. En revanche, avec un résidu glycine (G) en plus en N-terminal et un résidu asparagine (N) au lieu d'un résidu aspartate (D) pour l'acide aminé suivant, la séquence de la B5-19-10-1 correspond à 100% à celle du peptide Hs1a d'une araignée du genre *Hysteroocrates* qui comprend 35 résidus d'acides aminés et dont la structure (2MT7) a été déposée dans la base de données des protéines (PDB pour "protein data bank") par Klint et collaborateurs en août 2014 (DOI: 10.2210/pdb2MT7/pdb). Comme rapporté par ces auteurs, le peptide Hs1a produit une diminution de l'hypersensibilité chronique viscérale en interagissant avec le sous-type Na_v1.7.

Tableau 2-9. Séquence en acides aminés de la toxine contenue dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri*.

Peptide	Sous-fraction d'origine	Masse (Da)	Séquence en acides aminés
B5-19-10-1	B5-19-11	3793,7	DDCLGFW ^C SACNPKNDK ^C CANLV ^C SSKHKW ^C KGKL*

*: amidation en C-terminal. La masse correspond à la masse mono-isotopique de la toxine oxydée. En rouge, les 6 résidus cystéine qui structurent la toxine autour du motif architectural ICK.

La synthèse de la toxine B5-19-10-1 (probablement associée à un motif structural de type ICK) a été de nouveau suivie d'une étape de repliement complexe conduisant en fin de purification à l'obtention de larges pics isomassiques. Nous avons évalué les effets de 6 fractions de ces pics, soit 6 produits de synthèse pour ce peptide naturel, sur les lignées cellulaires HEK-293 exprimant les sous-types hNa_v1.2, 1.6 et 1.7, en utilisant le système à haut débit IonWorks Quattro® (Tableau 2-10). Les résultats obtenus montrent que seuls les produits de synthèse 1722 F1, 1722 F5 et 1722 F6 produisaient une inhibition des courants hNa_v1.2, 1.6 et 1.7 avec une valeur moyenne d'IC₅₀ proche de 1 μM, les valeurs moyennes d'IC₅₀ pour les 3 autres produits de synthèse étant supérieures à 10 μM.

Tableau 2-10. Produits de synthèse obtenus après le séquençage du peptide naturel contenu dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri*.

Peptide naturel	Produit de synthèse	Pureté	IC ₅₀ moyen (hNa _v 1.2, 1.6 et 1.7)
B5-19-10-1	1722 F1	97%	≈ 1 μM
	1722 F5	72%	
	1722 F6	83%	
	1722 F7	62% et 37% (2 pics)	> 10 μM
	1722 F8	70% et 28% (2 pics)	
	1722 F11	90%	

La caractérisation de la puissance des produits de synthèse 1722 F1, 1722 F5 et 1722 F6 pour les sous-types hNa_v1.2, 1.5, 1.6 et 1.7 de canaux Na_v a été poursuivie en utilisant la plateforme automatisée QPatch HTX de "patch-clamp". Comme nous l'avons déjà observé pour les produits de synthèse décrits lors de l'étude du venin de l'araignée *Selenotypus plumipes*, les produits 1722 F1, 1722 F5 et 1722 F6 agissaient préférentiellement sur les sous-types TTX-S (hNa_v1.2, 1.6 et 1.7), avec une sélectivité vis-à-vis du sous-type TTX-R cardiaque hNa_v1.5 qui était très forte pour le produit 1722 F1 (facteur de sélectivité supérieur à 150) mais plus faible pour les produits 1722 F5 et 1722 F6 (facteur de sélectivité supérieur à 7) (Tableau 2-11). Leurs effets consistent en une diminution des pics de courant sans modification notable des cinétiques d'activation et d'inactivation, et de leur dépendance vis-à-vis du potentiel. Le produit 1722 F1 possède une forte puissance (IC₅₀ de quelques dizaines de nanomolaires) pour les 3 sous-types TTX-S alors que celle de 1722 F5 et 1722 F6 est moins importante (IC₅₀ de plusieurs centaines de nanomolaires). Cependant, aucun de ces peptides n'est sélectif de l'un des 3 sous-types étudiés, excluant leur utilisation comme outil pharmacologique visant les sous-types Na_v1.2, 1.6 ou 1.7.

Tableau 2-11. Puissance de 3 produits de synthèse du peptide naturel B5-19-10-1 (IC₅₀ moyen ± ES en nM, n = 2-6) pour les sous-types hNa_v1.2, 1.5, 1.6 et 1.7.

Produit de synthèse	hNa _v 1.7	hNa _v 1.2	hNa _v 1.5	hNa _v 1.6
1722 F1	43 ± 5	65 ± 12	> 10000	23 ± 6
1722 F5	736 ± 79	344 ± 75	> 10000	392 ± 58
1722 F6	1475 ± 532	706 ± 249	> 10000	625 ± 112

2.5.2.4. Etude du venin du scorpion *Hottentotta gentili* (G4-x)

Hottentotta gentili est un scorpion endémique du Maroc et de l'Algérie. En utilisant la plateforme automatisée QPatch HTX de "patch-clamp", nous avons réalisé un criblage secondaire de 7 sous-fractions du venin de ce scorpion sur des lignées cellulaires HEK-293 exprimant les sous-types hNa_v1.7, 1.2, 1.6 et 1.5 et enregistrées en configuration "cellule entière" et en mode "cellule multiple" (Figure 2-10).

Sur ces 7 sous-fractions, une seule produisait une inhibition de plus de 70% du sous-type hNa_v1.7 mais manquait de sélectivité vis-à-vis des sous-types hNa_v1.2, 1.6 et même 1.5 puisqu'elle bloquait également les sous-types hNa_v1.2 et 1.6 d'environ 60% et le sous-type hNa_v1.5 d'environ 30%, (sous-fraction G4-24-3 soulignée en rouge dans la Figure 2-10). Des résultats similaires, bien que les inhibitions soient moins marquées, ont été obtenus avec la sous-fraction G4-24-4. Finalement, une troisième sous-fraction de venin produisait une inhibition de 50 à 60% des sous-types hNa_v1.2 et 1.6 et présentait une certaine sélectivité vis-à-vis du sous-type hNa_v1.7 mais pas vis-à-vis du sous-type

hNav_v1.5 qui étaient bloqués d'environ 10 et 35%, respectivement (sous-fraction G4-24-5 soulignée en vert dans la [Figure 2-10](#)). L'analyse de ces 3 sous-fractions a été malgré tout poursuivie.




Figure 2-10. Criblage des sous-fractions du venin de *Hottentotta gentili*. Pourcentage d'inhibition du pic de courant hNav_v1.7 (carrés rouges), suite à l'application de 5 ng/μL de chacune des 7 sous-fractions secondaires, et des pics de courants hNav_v1.5 (ronds noirs), hNav_v1.2 (losanges verts) et hNav_v1.6 (triangles bleus), suite à l'application de 23 ng/μL de ces mêmes sous-fractions. La sous-fraction manquant de sélectivité est soulignée en rouge. Celle présentant une sélectivité originale (hNav_v1.6 et 1.2 *versus* hNav_v1.7) est soulignée en vert.

Ces 3 sous-fractions contenaient chacune (sous-fraction G4-24-3) à cinq (sous-fraction G4-24-4) toxines identifiées par leur masse ([Tableau 2-12](#)). En tenant compte de la similitude de masse, nous n'avons identifié qu'une seule toxine présente dans 2 sous-fractions d'intérêt: celle de 7046,1 Da présente dans les sous-fractions G4-24-4 et G4-24-5 et dont la masse est identique à celle de la toxine LqhIII, une toxine de type α issue du scorpion *Leiurus quinquestriatus hebraeus* (Benoit & Gordon, 2001). La variabilité des masses était particulièrement marquée dans ces sous-fractions. Ainsi, nous avons pu mettre en évidence une protéine de 14741 Da, identifiée comme étant probablement une phospholipase A2, dans la sous-fraction G4-24-5.

Tableau 2-12. Masse mono-isotopique des toxines oxydées identifiées dans 3 sous-fractions d'intérêt du venin de *Hottentotta gentili*.

Sous-fraction	Masse (Da)
G4-24-3	6938,99
G4-24-4	3788,7/6938,9/7046,1/7229,8/8138,7
G4-24-5	7046,1/7815,4/14741

La détermination des séquences primaires des toxines identifiées dans les 3 sous-fractions et leur synthèse, incluant leur repliement, n'ont pas été envisagées dans le cadre de ma thèse de par le manque de temps et les difficultés prévisibles au vu de leur grande taille et de leur nombre de ponts disulfures probablement supérieur à 3. La seule tentative de séquençage que nous ayons effectuée est celle de la toxine de 7815,4 Da, originale par sa masse, de la sous-fraction G4-24-5. Malheureusement, elle s'est soldée par un échec car la toxine était en quantité insuffisante et a été perdue au cours de la procédure. La caractérisation des toxines a donc été poursuivie en étudiant les effets des 3 sous-fractions sur les lignées cellulaires HEK-293 exprimant les sous-types $hNa_v1.7$, 1.2, et 1.6 et enregistrées en configuration "cellule entière" et en mode "cellule multiple" en utilisant la plateforme automatisée QPatch HTX de "patch-clamp".

Avant de rentrer dans le détail de l'analyse des résultats obtenus, il est à rappeler que les **toxines α de scorpion**, en général de faible masse et qui se fixent sur le site 3 des canaux Na_v , altèrent leur inactivation ce qui implique, au niveau du courant, (1) une inhibition d'une partie de son inactivation et un ralentissement de sa cinétique d'inactivation, sans modification notable de l'amplitude du pic de courant, et (2) une altération de la dépendance vis-à-vis du potentiel de l'inactivation sans que celle de l'activation ne soit notablement modifiée. Ces effets se traduisent par une forte augmentation de la durée des potentiels d'action, comme cela est le cas, par exemple, de ceux de la toxine LqhIII sur le sous-type $Na_v1.6$ (Benoit & Gordon, 2001). Les **toxines β de scorpion**, en général de masse plus élevée et qui se fixent sur le site 4 des canaux Na_v , bloquent ces canaux et altèrent leur activation ce qui implique, au niveau du courant, (1) une diminution de l'amplitude du pic de courant, sans modification de ses cinétiques d'activation et d'inactivation, et (2) une altération de la dépendance vis-à-vis du potentiel de l'activation sans que celle de l'inactivation ne soit notablement modifiée. Ces effets se traduisent par l'apparition, à une fréquence plus élevée, de potentiels d'action de plus faible amplitude (Cestele et al., 1998).

Les résultats obtenus des effets des sous-fractions G4-24-3, G4-24-4 et G4-24-5 sur les sous-types $Na_v1.7$, 1.2 et 1.6 sont présentés dans les Figures 2-11 et 2-12 et dans le Tableau 2-13.




Figure 2-11. Effets des sous-fractions secondaires du venin de *Hottentotta gentili* sur les courants hNa_v1.7 (en rouge), hNa_v1.2 (en vert) et hNa_v1.6 (en bleu). Traces représentatives des courants avant (en noir) et après soit 5 ng/μL (en rouge) soit 23 ng/μL (en vert et en bleu) de chacune des 3 sous-fractions (G4-24-3, G4-24-4 et G4-24-5). Les traces de couleur claire représentent le courant enregistré en présence d'une sous-fraction donnée et normalisé par rapport au pic de courant contrôle.

Les effets de la sous-fraction **G4-24-3**, qui ne contient qu'une seule masse à priori, sur le sous-type hNa_v1.7 consistent en une forte diminution du pic de courant, principalement due à un déplacement positif de la courbe "conductance-potentiel", sans que les cinétiques d'activation et d'inactivation du courant ne soient altérées, le ralentissement apparent de l'inactivation résultant de l'imprécision des mesures due à la forte diminution du courant. Cette sous-fraction est un peu moins efficace pour inhiber les sous-types hNa_v1.2 et 1.6 dont la diminution du pic de courant peut être due, en partie, au léger déplacement négatif de leur courbe "inactivation stationnaire-potentiel", sans que la dépendance de leur activation vis-à-vis du potentiel ne soit notablement modifiée. Aucun de ces effets ne peut être relié à la présence d'une toxine α ou β de scorpion dans la sous-fraction G4-24-3.




Figure 2-12. Effets des sous-fractions secondaires du venin de *Hottentotta gentili* sur la dépendance vis-à-vis du potentiel de membrane de l'inactivation stationnaire et de la conductance des sous-types hNav_v1.7 (en rouge), hNav_v1.2 (en vert) et hNav_v1.6 (en bleu). Courbes d'inactivation stationnaire (cercles) et de conductance (carrés) en fonction du potentiel de membrane, avant (symboles noirs) et après (symboles rouges, verts et bleus) exposition des cellules HEK à soit 5 ng/μL (en rouge) soit 23 ng/μL (en vert et en bleu) de chacune des 3 sous-fractions (G4-24-3, G4-24-4 et G4-24-5). Chaque valeur représente la moyenne ± ESM des données de 4 à 6 cellules, exprimée en pourcentage de l'amplitude maximale du courant à des valeurs fortement négatives de pré-potentiel ou de la conductance maximale calculée à des valeurs fortement positives de potentiel-test. Les courbes théoriques correspondent aux ajustements des points de données avec les valeurs moyennes indiquées dans le Tableau 2-13.

Tableau 2-13. Effets des sous-fractions secondaires du venin de *Hottentotta gentili* sur les paramètres (moyenne ± ESM de 4-6 cellules) associés à la dépendance vis-à-vis du potentiel de l'inactivation stationnaire ($V_{P50\%}^1$ et k_h^2) et de la conductance ($V_{T50\%}^1$ et k_g^2) des sous-types hNav_v1.7, 1.2 et 1.6.

	$V_{P50\%}$ (mV)	k_h (mV ⁻¹)	$V_{T50\%}$ (mV)	k_g (mV ⁻¹)	$V_{P50\%}$ (mV)	k_h (mV ⁻¹)	$V_{T50\%}$ (mV)	k_g (mV ⁻¹)
	Contrôle				G4-24-3			
hNav _v 1.7 ³	-67.1 ± 0.3	5.9 ± 0.2	-33.3 ± 0.3	3.6 ± 0.3	-64.0 ± 0.2	5.0 ± 0.2	-17.5 ± 0.3	6.6 ± 0.3
hNav _v 1.2 ⁴	-51.1 ± 0.2	4.5 ± 0.1	-22.4 ± 0.3	4.3 ± 0.2	-60.2 ± 1.2	6.7 ± 1.1	-24.3 ± 0.2	6.7 ± 0.1
hNav _v 1.6 ⁴	-65.4 ± 0.2	6.4 ± 0.2	-32.4 ± 0.3	2.5 ± 0.3	-70.1 ± 0.4	7.8 ± 0.4	-41.1 ± 0.4	3.5 ± 0.3
	Contrôle				G4-24-4			
hNav _v 1.7 ³	-64.9 ± 0.3	4.8 ± 0.2	-32.1 ± 0.4	3.9 ± 0.3	-66.0 ± 0.3	5.8 ± 0.3	-36.2 ± 0.7	5.0 ± 0.6
hNav _v 1.2 ⁴	-51.0 ± 0.2	4.8 ± 0.2	-20.9 ± 0.3	4.7 ± 0.2	-61.6 ± 1.6	7.2 ± 1.2	-35.3 ± 0.2	5.1 ± 0.2
hNav _v 1.6 ⁴	-50.9 ± 0.2	4.3 ± 0.1	-20.4 ± 0.5	6.5 ± 0.4	-85.6 ± 0.7	9.8 ± 0.6	-54.2 ± 0.3	6.9 ± 0.3
	Contrôle				G4-24-5			
hNav _v 1.7 ³	-57.0 ± 0.2	5.2 ± 0.1	-28.1 ± 0.3	5.1 ± 0.2	-61.4 ± 0.2	5.7 ± 0.2	-25.6 ± 0.5	8.5 ± 0.5
hNav _v 1.2 ⁴	-58.0 ± 0.2	5.6 ± 0.1	-29.9 ± 0.2	5.4 ± 0.2	-68.8 ± 0.4	6.7 ± 0.3	-40.6 ± 0.2	5.0 ± 0.2
hNav _v 1.6 ⁴	-56.0 ± 0.2	5.8 ± 0.2	-31.9 ± 0.4	5.5 ± 0.3	-75.0 ± 1.1	9.8 ± 1.1	-56.2 ± 0.5	7.7 ± 0.4

¹ $V_{P50\%}$ et $V_{T50\%}$: potentiel de membrane correspondant à une diminution de 50% de l'inactivation stationnaire et de la conductance, respectivement. ² k_h et k_g : pentes des courbes de l'inactivation stationnaire et de la conductance en fonction du potentiel de membrane, respectivement. ³5 ng/μL. ⁴23 ng/μL.

La sous-fraction **G4-24-4** ne montre aucun effet détectable sur le sous-type hNav_v1.7 ce qui, à priori, la rend peu attractive pour poursuivre l'étude des 5 toxines qu'elle contient dans le cadre de la thématique de ma thèse. En revanche, les effets de cette sous-fraction, similaires sur les sous-types hNav_v1.2 et 1.6, consistent en une faible diminution des pics de courant associée à des déplacements négatifs des courbes "inactivation stationnaire-potentiel" et "conductance-potentiel", sans que les cinétiques d'activation et d'inactivation des courants ne soient altérées. Là encore, aucun de ces effets ne peut être relié à la présence d'une toxine α (en particulier la toxine LqhIII) ou β de scorpion dans la sous-fraction G4-24-3. Une possibilité est que les effets observés résultent d'une modification des charges de surface au niveau de l'environnement membranaire des sous-types de canaux, ce qui impliquerait que ces charges soient différentes entre, d'une part, le sous-type hNav_v1.7 et, d'autre part, les sous-types hNav_v1.2 et 1.6.

Les effets de la sous-fraction **G4-24-5** sur les sous-types hNav_v1.7, 1.2 et 1.6 sont qualitativement similaires à ceux de la sous-fraction G4-24-4 mais, quantitativement, environ 4 fois plus importants. Il est peu probable que ces effets soient ceux de la seule toxine présente dans ces deux sous-fractions et dont la masse est identique à celle de la toxine LqhIII (voir Benoit & Gordon, 2001).

2.5.2.5. Etude du venin du scorpion *Hottentotta jayakari* (H4-x)

Hottentotta jayakari est un scorpion endémique de la péninsule Arabique. En utilisant la plateforme automatisée QPatch HTX de "patch-clamp", nous avons réalisé un criblage secondaire de 3 sous-fractions du venin de ce scorpion sur des lignées cellulaires HEK-293 exprimant les sous-types hNav_v1.7, 1.2, 1.6 et 1.5 et enregistrées en configuration "cellule entière" et en mode "cellule multiple".

Bien que nous ayons observé une inhibition du sous-type hNav_v1.7 d'environ 45% par la fraction primaire H4-25 lors du criblage des fractions des 9 venins (voir [Figure 2-6](#)), les 3 sous-fractions dérivant de cette fraction ne montrent aucun effet notable sur les sous-types hNav_v1.2, 1.5, 1.6 et 1.7 étudiés ([Figure 2-13](#)). Le fait que l'activité d'origine n'ait pas été retrouvée lors du criblage secondaire est probablement dû à une quantité insuffisante de produit(s) bioactif(s) dans les sous-fractions, ce qui implique soit une perte de ce(s) produit(s) lors du sous-fractionnement, soit une dispersion entre plusieurs sous-fractions. L'identification des toxines présentes dans les 3 sous-fractions, par leur masse, pourrait confirmer ou infirmer cette hypothèse.

2.5.3. Conclusion

Le criblage primaire à haut débit de la banque de 9 venins originaux appartenant à SANOFI a

permis de mettre en évidence des fractions intéressantes provenant des venins de deux espèces d'araignées (*Selenotypus plumipes* et *Phoneyusa celerieri*) et de deux espèces de scorpions (*Hottentota gentili* et *Hottentota jayakari*), venins qui n'avaient jamais, ou très peu, été étudiés jusqu'à présent. Le criblage secondaire des sous-fractions de ces venins a conduit à l'identification d'un certain nombre de toxines d'intérêt dans des sous-fractions de *Selenotypus plumipes*, *Phoneyusa celerieri* et *Hottentota gentili* mais, malheureusement, pas dans celles d'*Hottentota jayakari*.




Figure 2-13. Criblage des sous-fractions du venin de *Hottentota jayakari*. Pourcentage d'inhibition du pic de courant hNav_v1.7 (carrés rouges), suite à l'application de 5 ng/μL de chacune des 3 sous-fractions secondaires, et des pics de courants hNav_v1.5 (ronds noirs), hNav_v1.2 (losanges verts) et hNav_v1.6 (triangles bleus), suite à l'application de 23 ng/μL de ces mêmes sous-fractions.

Sur les 5 toxines séquencées de l'araignée *Selenotypus plumipes*, 3 étaient déjà décrites dans la littérature [A5-19-2-1 = JzTx-8.2 (Chen et al., 2008), A5-20-3-2 = OAIP-5 (Wong et al., 2013) et A5-20-5-1 = K22N-OAIP-5]. Bien que leurs cibles moléculaires ne soient toujours pas identifiées à ce jour, nos résultats montrent qu'il est peu probable que les sous-types de canaux Na_v étudiés soient impliqués. Les 2 autres toxines séquencées, l'A5-20-4-1 et l'A5-22-5-2, non rapportées dans la littérature, présentent cependant 79% d'identité de séquence avec l'OAIP-2 (Hardy et al., 2013; Wong et al., 2013) et 73% d'identité de séquence avec la β-théràphotoxine-Pmr1a décrite pour bloquer les sous-types Na_v1.3 et 1.8 à des concentrations micromolaires (Meir et al., 2012),

respectivement. Les résultats obtenus avec l'A5-20-4-1 sont difficilement interprétables de par la grande différence de puissance entre les deux produits de synthèse, obtenus à partir de ce peptide naturel, pour les sous-types de canaux Na_v TTX-S étudiés. En revanche, ceux des effets de l'A5-22-5-2 suggèrent fortement que les 3 produits de synthèse issus de ce peptide naturel interagissent préférentiellement avec les sous-types de canaux Na_v TTX-S étudiés, à des concentrations de plusieurs dizaines/centaines de nanomolaires mais avec des sélectivités assez limitées.

La seule toxine séquencée de l'araignée *Phoneyusa celerieri* (la **B5-19-10-1**) correspond, avec un résidu glycine (G) en plus en N-terminal et un résidu asparagine (N) au lieu d'un résidu aspartate (D) pour l'acide aminé suivant, au peptide Hs1a d'une araignée du genre *Hysteroocrates* déposé dans la PDB comme inhibiteur du sous-type Na_v1.7 (DOI: 10.2210/pdb2MT7/pdb). Nos résultats non seulement confirment cette interaction mais suggèrent également et fortement l'implication des sous-types Na_v1.2 et 1.6 TTX-S mais pas celle du sous-type Na_v1.5 TTX-R.

L'interprétation des résultats des effets des sous-fractions secondaires du venin de *Hottentotta gentili* est être d'autant plus complexe et les conclusions d'autant moins fiables qu'aucune des toxines n'apparaissait comme étant majoritaire dans ces sous-fractions, à l'exception de la sous-fraction **G4-24-3** qui ne contenait qu'une seule toxine de 6938,99 Da. Il ne semble cependant pas très intéressant de poursuivre l'étude de cette toxine, tout comme celle des 5 toxines présentes dans la sous-fraction **G4-24-4**, au vu des effets non originaux et peu sélectifs de ces sous-fractions sur les 3 sous-types de canaux Na_v étudiés. En revanche, les déplacements négatifs importants (d'environ 30 mV) des courbes "inactivation stationnaire-potentiel" et "conductance-potentiel" produits par la sous-fraction **G4-24-5** sur les sous-types hNa_v1.2 et 1.6 sont des effets peu courants qui justifieraient de poursuivre l'étude des 3 toxines contenues dans cette sous-fraction. Ils pourraient résulter de l'action combinée d'une ou plusieurs toxines α et β ou montrant des caractéristiques fonctionnelles mixtes α/β , comme cela l'a déjà été rapporté pour certaines toxines de scorpion telles que la toxine CsslI du scorpion *Centruroides suffusus suffusus* (Saucedo et al., 2012).

En conclusion, il apparait que notre objectif initial de mettre en évidence des toxines interagissant spécifiquement avec le sous-type hNa_v1.7, 1.2 ou 1.6, en criblant la banque de 9 venins originaux appartenant à SANOFI, n'ait pas été atteint. Cependant, nous avons obtenu des informations intéressantes sur les cibles de certaines des toxines étudiées (en particulier celles des venins des deux araignées) et/ou sur leur mécanisme d'action (en particulier celui des toxines du venin de *Hottentotta gentili*) qui mériteraient d'être consolidées par des études approfondies.

Partie 3

CONCLUSION et PERSPECTIVES

Les objectifs de cette thèse étaient, au début, (i) de mettre en évidence et de caractériser, par une approche pharmacologique multi-échelle (de la cellule individuelle à l'organisme *in vivo*) de nouvelles toxines à potentiel analgésique agissant principalement sur le sous-type $Na_v1.7$ de canal sodium, et aussi (ii) d'étudier les limites éventuelles d'utilisation de celles-ci dues à l'apparition d'effets secondaires principalement au niveau du système neuromusculaire. Parallèlement à ces études, la puissance et le profil de sélectivité d'une toxine déjà connue pour son action intéressante en synergie avec de faibles doses d'opioïdes ont été caractérisés. D'autre part, de façon inattendue, nous avons mis en évidence une toxine ayant un profil de sélectivité différent de celui des toxines analgésiques et qui pourrait être utilisée comme outil moléculaire pour étudier les canaux Ca_v de type L au niveau cardiovasculaire. Finalement, un criblage de la banque de venins appartenant à SANOFI a été initié dans l'espoir de trouver des toxines ayant un profil de sélectivité original.

3.1. Profils de sélectivité et applications potentielles des 4 toxines étudiées

Les effets des 4 toxines synthétiques étudiées vis-à-vis des lignées cellulaires exprimant la sous-unité α humaine de $Na_v1.7$ ont été déterminés par des méthodes électrophysiologiques de "patch-clamp" automatique et manuel. Les résultats obtenus mettent en évidence les puissances suivantes (par ordre décroissant): HwTx-IV > CyrTx-1a > PecTx-1a > PhITx-1a. L'évaluation des effets de ces 4 toxines sur des lignées cellulaires exprimant des sous-types de canaux Na_v , autres que $hNa_v1.7$, révèlent que l'HwTx-IV et la CyrTx-1a inhibent également la sous-unité α humaine de $Na_v1.6$ (qui a 69% d'identité de séquence avec celle de $hNa_v1.7$) avec une puissance environ 5 à 10 fois moindre mais qui est cependant suffisante pour être à l'origine d'effets secondaires indésirables en cas de développement thérapeutique de ces 2 toxines (paralysie musculaire pouvant provoquer la mort par détresse respiratoire). L'évaluation des effets des toxines synthétiques au niveau de systèmes natifs a porté (i) sur des cultures primaires de neurones de DRG de souris adultes, premier relais du message douloureux (étude préalable à l'évaluation du niveau de douleur chez la souris par des tests comportementaux), et (ii) sur le système neuromusculaire de souris adultes, *ex vivo* et *in vivo*, ce qui a permis, en particulier, d'étudier leurs effets indésirables éventuels sur les sous-types $Nav1.6$ et 1.4 de canaux sodium.

Les résultats obtenus avec l'HwTx-IV et la CyrTx-1a montrent que ces 2 toxines inhibent, avec une forte puissance, le courant sodium TTX-S des neurones de DRG ($Na_v1.1$, 1.2 , 1.3 , 1.6 et 1.7) et, avec une moindre puissance, celui TTX-R ($Na_v1.8$ et 1.9). Ces deux toxines inhibent aussi, avec une

forte puissance, la contraction et le potentiel d'action composés enregistrés, respectivement *ex vivo* et *in vivo*, au niveau du muscle suite à la stimulation du nerf (le sous-type $Na_v1.6$ étant principalement exprimé au niveau du nerf), la CyrTx-1a offrant une plus grande marge de sécurité. Par conséquent, les potentialités d'exploitation en tant qu'antalgique/analgésique de l'HwTx-IV et de la CyrTx-1a ne semblent pas optimales mais, en revanche, ces toxines peuvent être envisagées comme outils pour disséquer pharmacologiquement les sous-types $Na_v1.4$ et $Na_v1.6$ *versus* $Na_v1.7$ de canaux sodium. Des études de "structure-activité", utilisant des techniques d'ingénierie, seraient nécessaires pour obtenir des analogues synthétiques de ces toxines ayant un meilleur profil de sélectivité vis-à-vis des différents sous-types de canaux Na_v .

Il est à noter que de grandes campagnes de mutagenèse des toxines les plus intéressantes ont été menées par quelques sociétés pharmaceutiques dans le monde. Par exemple, la société Astra Zeneca, suite à des stratégies "alanine scanning" et de mutations ponctuelles, a obtenu une toxine triplement mutée, la m3-HwTx-IV, qui présente la même sélectivité sur les Na_v que l'HwTx-IV mais avec une puissance accrue pour le sous-type $Na_v1.7$ (Revell et al., 2013; Rahnama et al., 2017). La société Amgen, quant à elle, a créé une centaine d'analogues peptidiques synthétiques à partir de la GpTx-1, en utilisant l'analogie par balayage positionnel multi-attributs (MAPS pour "Multi Attribute Positional Scan analoging") qui ont été analysés sur 3 sous-types de canaux sodium (Murray et al., 2015b, Murray et al., 2016). Cette approche consiste à remplacer chaque acide aminé non-cystéine par un des acides aminés suivants: A, W, 1-Nal (l'encombrement et l'hydrophobicité étant croissants), E (acide aminé acide), R et K (acides aminés basiques). Elle permet de cibler rapidement les acides aminés importants pour la liaison de la molécule au canal sodium ou encore d'identifier les analogues qui présentent une puissance augmentée. La combinaison de plusieurs d'entre eux a permis l'obtention d'un quadruple mutant agissant à une concentration de l'ordre du nanomolaire et avec une sélectivité *versus* les sous-types cardiaque et du muscle squelettique supérieure d'un facteur 1000. De plus, ces toxines mutées possèdent des propriétés antinociceptives non associées à des effets secondaires sur la locomotion mais qui sont dépendantes de l'activation des voies de signalisation des opioïdes (Murray et al., 2016; Chen et al. 2018).

La société Janssen a remplacé chacun des 24 acides aminés de la ProTx-II par tous les acides aminés excepté la cystéine et la méthionine, leur combinaison ayant finalement conduit à la JNJ-63955918 ayant une puissance et une sélectivité améliorées par rapport à la toxine naturelle. Bien que les analogues améliorés de l'HwTx-IV et de la GpTx-1 présentent une faible sélectivité envers les sous-types Na_v TTX-S, celle de la JNJ-63955918 est importante même comparée à la ProTx-II naturelle, ce qui laisse présager une plus large fenêtre thérapeutique évitant les effets locomoteurs.

Parallèlement à l'optimisation par la création d'analogues peptidiques synthétiques, des dimères de GpTx-1, des conjugués peptide-anticorps ainsi que des anticorps monoclonaux, dont le Svmab1, ont été créés mais leur apport au développement de la thématique reste mitigé, voire controversé (Lee et al., 2014; Murray et al., 2015a; Liu et al., 2016; Biswas et al., 2017).

Les profils de sélectivité de la PecTx-1a et de la PhITx-1 sont différents des deux premières toxines puisqu'ils ne mettent pas en évidence de sélectivité particulière vis-à-vis d'un sous-type donné de canal Na_v . La PhITx-1, montrant une faible sélectivité et une puissance moyenne (active à une concentration de l'ordre de la centaine de nanomolaires) pour les canaux Na_v à l'exception du sous-type $Na_v1.8$, est une toxine déjà connue pour ses effets analgésiques indéniables. En particulier, elle agit en synergie avec les opioïdes avec des quantités de toxine et d'opioïdes diminuées par rapport à celles nécessaires lors de l'utilisation de l'une de ces molécules seule. Nous avons observé *in vivo*, chez un modèle murin de douleur, que la PhITx-1 (300 nM) diminue d'un facteur 2 les comportements douloureux des souris produits par l'OD1. Il serait intéressant d'étudier de plus fortes doses de PhITx-1 afin de vérifier si ces effets antalgiques dépendent de la dose injectée et s'ils sont éventuellement associés à des effets secondaires non désirés. L'analogue D7A de cette même toxine, obtenu par une approche "alanine scanning", possède une puissance améliorée d'un facteur 4 pour la cible d'intérêt. Il reste à déterminer s'il faudrait une quantité moindre de cet analogue pour produire les mêmes effets analgésiques que la molécule d'origine. Cependant, et bien que les souris ne présentaient pas de signes évoquant l'apparition d'effets secondaires neuromusculaires sur les images vidéo enregistrées lors de cette étude, il serait nécessaire d'évaluer en détail certains paramètres, tels que la force musculaire et ceux liés à la locomotion des souris injectées avec la PhITx-1 ou son analogue D7A, en mettant en place un test rotarod pour les quantifier.

Quant à la PecTx-1a, elle a un profil de sélectivité particulier et intéressant qui nécessiterait une exploration approfondie des effets de cette toxine sur la fonction cardiaque par des expériences *in vitro* et *in vivo*. En effet, la PecTx-1a a pour cible principale le sous-type $Ca_v1.2$ de canal calcium avec lequel elle interagit avec une grande puissance et une sélectivité importante vis-à-vis des sous-types Na_v , K_v , Kir et des autres sous-types de canaux Ca_v . Nous avons aussi évalué les effets de cette toxine (100 nM) sur des cardiomyocytes dérivés de cellules souches pluripotentes humaines et avons observé qu'elle inhibait 40% du courant calcium de type L ($hCa_v1.1$, 1.2 et 1.3), contrairement à la nifédipine (10 μ M) qui inhibait 100% de ce type de courant. Compte tenu du fait que 100 nM de PecTx-1a bloque complètement le sous-type $hCa_v1.2$ exprimé dans les cellules CHO, ces résultats suggèrent fortement que la PecTx-1a est moins efficace pour interagir avec les sous-types $hCa_v1.1$ et/ou 1.3. Afin de confirmer ce dernier point, des expériences seraient nécessaires pour étudier les

effets du peptide (i) sur des tissus musculaires squelettiques qui n'expriment que le sous-type $Ca_v1.1$, pour une première approche de la sélectivité $Ca_v1.2$ versus $Ca_v1.1$, et (ii) sur des lignées recombinantes surexprimant les sous-types $Ca_v1.1$, 1.3 ou 1.4 (ces lignées n'étant pas accessibles commercialement, leur fabrication devra être envisagée). La PecTx-1a constitue par conséquent un outil précieux qui, modifié par un tag, permettrait le suivi du sous-type $Ca_v1.2$ et ainsi l'étude de sa fonction et de sa localisation au niveau cellulaire. De plus, le sous-type $Ca_v1.2$ étant responsable du "plateau" du potentiel d'action cardiaque, la PecTx-1a pourrait être également utilisée comme traitement de certaines cardiomyopathies comme le syndrome du QT long. Cependant, et au préalable, des expériences seraient nécessaires au niveau de systèmes natifs tels que (i) les fibres de Purkinje cardiaques de lapin, dont le potentiel d'action est particulièrement sensible pour déceler des effets transposables à l'homme, (ii) les cœurs isolés de lapin afin d'évaluer les effets du peptide sur un organe dont les fonctions mécaniques sont préservées, et (iii) des cardiomyocytes humains prélevés sur des cadavres.

3.2. Limites et avantages d'un criblage à haut débit d'une banque contenant une quantité importante de venins

Les deux collections de venins de chez Smartox et de SANOFI ont permis de mettre en évidence un nombre de hits très importants versus $hNa_v1.7$ et d'espèces variées (scorpions, araignée, serpents...). Ceci étant, les principaux hits étaient extraits de venins d'araignées. Ceci est loin d'être surprenant puisque les 20 toxines décrites dans la littérature pour cibler $hNa_v1.7$ avec un potentiel thérapeutique antalgique sont des petites toxines d'une trentaine d'acides aminés structurés autour d'un motif ICK de 3 ponts disulfures, très compactes et ayant une résistance physico-chimique élevée. Cependant, les profils de sélectivité de nombreuses toxines synthétiques obtenus après le criblage des banques de venins appartenant à Smartox et à SANOFI, comme par exemple l'A5-22-5-2 et la B5-19-10-1, ne sont pas assez discriminants pour envisager de continuer la caractérisation pharmacologique de ces toxines.

Il serait peut-être plus judicieux de réaliser le criblage primaire des banques sur une autre cible antinociceptive telle que $Na_v1.8$ ou $Na_v1.9$ dont les sites de liaison potentiels sont très différents de ceux des sous-types Na_v TTX-S. En effet, ces deux sous-types, comme le sous-type $Na_v1.7$, sont préférentiellement exprimés au niveau des petits neurones sensoriels de DRG non myélinisés de rat et jouent un rôle majeur dans la genèse et/ou la propagation du potentiel d'action, ainsi que dans sa rythmicité (Rush et al., 2007; Ho & O'Leary, 2011; Deuis et al., 2016a; Dick et al., 2016).

L'optimisation des "hits" par ingénierie protéique ainsi que leur caractérisation pharmacologique sur un plus large éventail de sous-types de canaux ioniques (Na_v , K_v et Ca_v) pourraient être beaucoup plus prometteur que la réduction de l'étude à une seule famille de canaux ioniques. L'idée, derrière ces quelques lignes, est qu'il faudrait d'abord étudier les toxines par une approche pharmacologique, pour mieux les appréhender, puis, si un profil pharmacologique original en ressort, leur trouver par la suite une application thérapeutique voire même, dans le meilleur des cas, théranostique.

La sélection de "hits" parmi une banque importante de venins, guidée par des tests biologiques, peut être un frein à la découverte de toxines ayant des propriétés et des profils de sélectivité qui nous intéressent. En effet, leur quantité dans le venin criblé est souvent insuffisante pour générer une inhibition importante de la fonction de la cible d'intérêt lors du criblage primaire réalisé, dans la plupart des cas, à une dose unique. Pour les venins n'ayant pas conduit à l'identification de fractions actives, une analyse des données pharmacologiques brutes autres que le simple pourcentage d'inhibition devrait être systématique, comme, par exemple, celui du scorpion *Hottentota jakayari*. En effet, dans ce cas-là, on peut supposer que les quantités de peptides bioactifs soient faibles, ce qui conduit à une inhibition limitée de la cible. Ainsi, le pourcentage d'inhibition en présence de 0,5 $\mu\text{g}/\mu\text{L}$ de fractions et/ou sous-fractions ne devrait pas toujours être conservé comme seul critère pour la sélection des venins dans le cadre d'une recherche plus approfondie, on devrait aussi s'intéresser aux altérations biophysiques sur les cibles étudiées que peuvent provoquer certaines de ces fractions et/ou sous-fractions sans induire un pourcentage d'inhibition très élevé.

La biodiversité des venins d'animaux étant importante, l'exploration exhaustive de celle-ci est donc un élément majeur pour la découverte de différentes familles pouvant moduler la cible d'intérêt avec une activité similaire (soit, dans notre cas, l'inhibition du sous-type $hNa_v1.7$). Les toxines trouvées peuvent donc être originales par leur provenance (venins de scorpions, d'araignées, de cônes, de centipèdes...), leur séquence (diversité parmi les toxines d'araignée) et leur activité (inhibiteurs de pore et/ou modulateurs des propriétés fonctionnelles du pore).

Par conséquent, une fois qu'un "hit" a été identifié, il est souvent utile d'explorer davantage les espèces animales de la même lignée phylogénétique. En effet, des peptides ayant des séquences similaires peuvent avoir des profils pharmacologiques différents et donc des puissances différentes pour une cible d'intérêt. En tirant parti de la sélection naturelle, il est bien établi que la diversification génétique a conduit à une grande diversité de toxines de venins, à partir de quelques échafaudages moléculaires judicieusement choisis. En effet, des isoformes d'une toxine donnée sont présentes non seulement dans le même venin, mais également dans les venins d'espèces apparentées. Il faut se rappeler que l'évolution a choisi ces peptides pour leur activité biologique et que la mutagenèse qui

s'est naturellement produite a donné lieu à la conservation d'un ensemble limité de formes peptidiques actives (Fry et al., 2009).

L'analyse des propriétés pharmacologiques des isoformes de toxines, combinée à la création d'une banque de variants grâce une approche de type "MAPS" par synthèse chimique ou par "phage display", peut aider à orienter l'ingénierie future des peptides. Par ailleurs, une alternative au criblage bioguidé peut être envisagée en faisant appel à des études transcriptomiques et protéomiques des venins, permettant ainsi de constituer une banque de séquences de toxines qu'il faudra alors produire par voie chimique ou recombinante (Figure 3-1). Cette stratégie a été mise en œuvre dans le cadre du projet européen "Venomics" et a conduit à l'obtention d'une banque synthétique de plusieurs milliers de toxines (Gilles & Servent, 2014).




Figure 3-1. Représentation schématisée du projet "Venomics" dans la découverte de pistes thérapeutiques à base de venin. Adapté de Wilson et Daly (2018).

La synthèse par voie chimique ou recombinante de ces "hits" présente aussi un frein au choix d'un criblage bioguidé de ces venins. En effet, les toxines synthétiques ont parfois une perte de puissance si on les compare aux toxines naturelles ou encore certaines ne sont pas synthétisables (Yang et al., 2013; Wang et al., 2017a). Cela peut éventuellement s'expliquer par un repliement différent de la structure 3D des molécules ou par des modifications post-traductionnelles non présentes sur les toxines synthétiques (Wright et al., 2017).

Finalement, au vue du nombre important de "hits" obtenus, le criblage bioguidé permet l'identification de nombreuses toxines ayant un profil de sélectivité pharmacologique intéressant, telles que la CyrTx-1a et la PecTx-1a.

Liste des illustrations

Partie 1 – Introduction

Figure 1-1. Nombre de chaque classe de cibles moléculaires humaines et la part de chacune d'entre elle dans le panel thérapeutique actuel. Adapté de Harding et al. (2018) et de Hopkins & Groom (2002).

Figure 1-2. Représentation des relations entre les séquences d'acides aminés du pore formant le canal de la superfamille des canaux ioniques dépendants du potentiel de membrane (Yu & Catterall, 2004).

Figure 1-3. Bases chimiques de la signalisation électrique et propriétés d'ouverture et de fermeture des canaux cationiques dépendants du potentiel.

Figure 1-4. Structure architecturale des canaux Na_v (d'après Catterall & Swanson, 2015; Ahern et al., 2016; Tibbs et al., 2016; Pan et al., 2018).

Tableau 2-1. Matrice d'identité en pourcentage des sous-unités α des sous-types de Na_v humain.

Figure 1-5. Propriétés biophysiques et implication dans la genèse du potentiel d'action neuronal ou cardiaque des différents sous-types de canaux sodium.

Figure 1-6. Influence des sous-unités β hautement exprimés au niveau des petits ou grands neurones de DRG sur le courant $Na_v1.7$.

Figure 1-7. Les sous-unités des canaux potassium dépendants du potentiel (Catterall et al., 2007).

Tableau 1-2. Site d'expression, nom et localisation chromosomique du gène des 40 sous-unités α des canaux potassium dépendants du potentiel.

Figure 1-8. Rôle des canaux potassium dépendants du potentiel.

Figure 1-9. Structure globale du sous-type $Ca_v1.1$ de canal calcium de lapin associé à ses 4 sous-unités auxiliaires à une résolution de 3.6 Å (Cryo-ME).

Tableau 1-3. Matrice d'identité en pourcentage des sous-unités α des sous-types de Ca_v humain.

Figure 1-10. Exemple de certaines fonctions des trois superfamilles de canaux calcium Ca_v .

Tableau 1-4. Caractéristiques physiologiques et pharmacologiques des canaux Ca_v .

Tableau 1-5. Canalopathies associées aux sous-types Na_v .

Tableau 1-6. Maladies orphelines associées aux sous-types Na_v .

Tableau 1-7. Canalopathies associées aux sous-types K_v .

Tableau 1-8. Maladies orphelines associées aux sous-types K_v .

Tableau 1-9. Canalopathies associées aux sous-types Ca_v .

Tableau 1-10. Maladies orphelines associées aux sous-types Ca_v .

Tableau 3-11. Exemples de toxines peptidiques ciblant les canaux Ca_v selon le type de famille (Gandini et al., 2015).

Figure 3-11. Convergence observée de l'action des neurotoxines extraites de différentes espèces animales (Fry et al., 2009).

Tableau 1-14. Pharmacologie des composés dérivés de venins d'animaux sélectionnés.

Figure 1-12. Sites de fixation des différents types de toxines sur les canaux Na_V (Ahern et al., 2016).

Figure 1-13. Représentations schématiques des effets des toxines sur le courant sodium.

Tableau 1-13. Exemples des principales toxines produisant la douleur *via* l'activation de certains sous-types de canaux Na_V (Jami et al., 2017).

Figure 1-14. Toxines d'araignées à trois ponts disulfures réarrangés en structure ICK (Saez et al., 2010).

Figure 1-15. Les différentes étapes de la douleur chronique (Crofford et al., 2015).

Figure 1-16. Zoom sur deux manifestations cliniques de la douleur (Bridges et al., 2001; Rostaing-Rigattieri & Guerin, 2014).

Tableau 1-14. Famille d'antalgiques (Palier I à III) à prescrire selon l'intensité de la douleur (de faible à sévère).

Figure 1-17. Effets théoriques des inhibiteurs/activateurs des canaux Na_V , Ca_V et K_V en cas d'activité neuronale altérée (adapté de Wulff et al., 2009).

Figure 1-18. Régulation synergique de la signalisation pro- et antinociceptive chez des souris déficientes en $NaV1.7$ (Isensee et al., 2017).

Partie 2 – Résultats et Discussion

Figure 2-1. Effets de la CyrTx-1a sur les courants hCa_V , hK_V et $hKir$.

Figure 2-2. Effets de la CyrTx-1a sur le courant $hCa_V2.2$.

Figure 2-3. Effets de la CyrTx-1a sur le courant $hK_V7.1$.

Figure 2-4. Effets de l'HwTx-IV sur les courants hCa_V , hK_V et $hKir$.

Figure 2-5. Effets de la ProTx-II sur les courants hNa_V , hCa_V , hK_V et $hKir$.

Figure 2-6. Criblage primaire de la banque de venins appartenant à SANOFI.

Tableau 2-1. Caractéristiques des deux toxines (OAIP-1 et OAIP-4) extraites du venin de *Selenotypus plumipes* et déjà décrites dans la littérature.

Figure 2-7. Criblage des sous-fractions du venin de *Selenotypus plumipes*.

Tableau 2-2. Masse mono-isotopique des toxines oxydées identifiées dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes*.

Tableau 2-3. Toxines trouvées dans ArachnoServer (AS) dont les masses avoisinent celles des 6 toxines présentes dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes* (Sp).

Figure 2-8. Nombres de séquences de *Selenotypus plumipes* qui ont une homologie avec celles des toxines de différentes espèces d'araignées d'après la base de données "ArachnoServer".

Tableau 2-4. Séquences en acides aminés des toxines contenues dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes*.

Tableau 2-5. Produits de synthèse obtenus après le séquençage des peptides naturels contenus dans les 7 sous-fractions d'intérêt du venin de *Selenotypus plumipes*.

Tableau 2-6. Puissance des produits de synthèse des trois fractions de l'A5-22-5-2 (IC_{50} moyen \pm ES en nM, $n = 2-6$) pour les sous-types $hNa_V1.2$, 1.5, 1.6 et 1.7.

Figure 2-9. Criblage des sous-fractions du venin de *Phoneyusa celerieri*.

Tableau 2-7. Masse mono-isotopique des toxines oxydées identifiées dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri*.

Tableau 2-8. Toxines trouvées dans ArachnoServer (AS) dont les masses avoisinent celles de la toxine présente dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri* (Pc).

Tableau 2-9. Séquence en acides aminés de la toxine contenue dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri*.

Tableau 2-10. Produits de synthèse obtenus après le séquençage du peptide naturel contenu dans 2 sous-fractions d'intérêt du venin de *Phoneyusa celerieri*.

Tableau 2-11. Puissance de 3 produits de synthèse du peptide naturel B5-19-10-1 (IC_{50} moyen \pm ES en nM, $n = 2-6$) pour les sous-types $hNa_v1.2$, 1.5, 1.6 et 1.7.

Figure 2-10. Criblage des sous-fractions du venin de *Hottentotta gentili*.

Tableau 2-12. Masse mono-isotopique des toxines oxydées identifiées dans 3 sous-fractions d'intérêt du venin de *Hottentotta gentili*.

Figure 2-11. Effets des sous-fractions secondaires du venin de *Hottentotta gentili* sur les courants $hNa_v1.7$ (en rouge), $hNa_v1.2$ (en vert) et $hNa_v1.6$ (en bleu).

Figure 2-12. Effets des sous-fractions secondaires du venin de *Hottentotta gentili* sur la dépendance vis-à-vis du potentiel de membrane de l'inactivation stationnaire et de la conductance des sous-types $hNa_v1.7$ (en rouge), $hNa_v1.2$ (en vert) et $hNa_v1.6$ (en bleu).

Tableau 2-13. Effets des sous-fractions secondaires du venin de *Hottentotta gentili* sur les paramètres (moyenne \pm ESM de 4-6 cellules) associés à la dépendance vis-à-vis du potentiel de membrane de l'inactivation stationnaire ($V_{P50\%}^1$ et k_h^2) et de la conductance ($V_{T50\%}^1$ et k_g^2) des sous-types $hNa_v1.7$, 1.2 et 1.6.

Figure 2-13. Criblage des sous-fractions du venin de *Hottentotta jayakari*.

Partie 3 – Conclusion et Perspectives

Figure 3-1. Représentation schématique du projet "Venomics" dans la découverte de pistes thérapeutiques à base de venin.

Références bibliographiques

- Ahern, C.A., Payandeh, J., Bosmans, F., & Chanda, B. (2016). The hitchhiker's guide to the voltage-gated sodium channel galaxy. *J Gen Physiol* 147, 1-24.
- Ahuja, S., Mukund, S., Deng, L., Khakh, K., Chang, E., Ho, H., Shriver, S., Young, C., Lin, S., Johnson, J.P., Jr., Wu, P., Li, J., Coons, M., Tam, C., Brillantes, B., Sampang, H., Mortara, K., Bowman, K.K., Clark, K.R., Estevez, A., Xie, Z., Verschoof, H., Grimwood, M., Dehnhardt, C., Andrez, J.C., Focken, T., Sutherlin, D.P., Safina, B.S., Starovasnik, M.A., Ortwine, D.F., Franke, Y., Cohen, C.J., Hackos, D.H., Koth, C.M., & Payandeh, J. (2015). Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. *Science* 350, aac5464.
- Alexander, S.P., Striessnig, J., Kelly, E., Marrion, N.V., Peters, J.A., Faccenda, E., Harding, S.D., Pawson, A.J., Sharman, J.L., Southan, C., Davies, J.A., & Collaborators, C. (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Voltage-gated ion channels. *Br J Pharmacol* 174 Suppl 1, S160-S194.
- Bahring, R., Dannenberg, J., Peters, H.C., Leicher, T., Pongs, O., & Isbrandt, D. (2001). Conserved Kv4 N-terminal domain critical for effects of Kv channel-interacting protein 2.2 on channel expression & gating. *J Biol Chem* 276, 23888-23894.
- Barbosa, C., Tan, Z.Y., Wang, R., Xie, W., Strong, J.A., Patel, R.R., Vasko, M.R., Zhang, J.M., & Cummins, T.R. (2015). Navbeta4 regulates fast resurgent sodium currents and excitability in sensory neurons. *Mol Pain* 11, 60.
- Bennett, D.L., & Woods, C.G. (2014). Painful and painless channelopathies. *Lancet Neurol* 13, 587-599.
- Benoit, E., & Gordon, D. (2001). The scorpion alpha-like toxin Lqh III specifically alters sodium channel inactivation in frog myelinated axons. *Neuroscience* 104, 551-559.
- Bertrand, D., Biton, B., Licher, T., Chambard, J.M., Lanneau, C., Partiseti, M., & Lefevre, I.A. (2016). Functional Studies of Sodium Channels: From Target to Compound Identification. *Curr Protoc Pharmacol* 75, 9 21 21-29 21 35.
- Biswas, K., Nixey, T.E., Murray, J.K., Falsey, J.R., Yin, L., Liu, H., Gingras, J., Hall, B.E., Herberich, B., Holder, J.R., Li, H., Ligutti, J., Lin, M.J., Liu, D., Soriano, B.D., Soto, M., Tran, L., Tegley, C.M., Zou, A., Gunasekaran, K., Moyer, B.D., Doherty, L., & Miranda, L.P. (2017). Engineering Antibody Reactivity for Efficient Derivatization to Generate Nav1.7 Inhibitory GpTx-1 Peptide-Antibody Conjugates. *ACS Chem Biol* 12, 2427-2435.
- Black, J.A., Cummins, T.R., Plumpton, C., Chen, Y.H., Hormuzdiar, W., Clare, J.J., & Waxman, S.G. (1999). Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. *J Neurophysiol* 82, 2776-2785.
- Black, J.A., & Waxman, S.G. (2013). Noncanonical roles of voltage-gated sodium channels. *Neuron* 80, 280-291.
- Bladen, C., Hamid, J., Souza, I.A., & Zamponi, G.W. (2014). Block of T-type calcium channels by protoxins I and II. *Mol Brain* 7, 36.
- Bosmans, F., Escoubas, P., Diochot, S., Mebs, D., Craik, D., Hill, J., Nakajima, T., Lazdunski M., & Tytgat, J. (2005). Isolation and characterization of Phlotoxin 1 (PhlTx1), a novel peptide active on voltage-gated sodium channels. Dans: 13^{èmes} Rencontres en Toxinologie "Toxines et douleur" organisées par la Société Française pour l'Etude des Toxines, Paris, 1 et 2 décembre 2005. *Recueil des abstracts*, p. 12.

- Boucher, T.J., Okuse, K., Bennett, D.L., Munson, J.B., Wood, J.N., & McMahon, S.B. (2000). Potent analgesic effects of GDNF in neuropathic pain states. *Science* 290, 124-127.
- Bouhassira, D., Lanteri-Minet, M., Attal, N., Laurent, B., & Touboul, C. (2008). Prevalence of chronic pain with neuropathic characteristics in the general population. *Pain* 136, 380-387.
- Bourdin, B., Shakeri, B., Tetreault, M.P., Sauve, R., Lesage, S., & Parent, L. (2015). Functional characterization of CaV α 2delta mutations associated with sudden cardiac death. *J Biol Chem* 290, 2854-2869.
- Bourdain, F., & Fontaine, B. (2005). [Voltage-gating ionic channels and neuromuscular disorders]. *EMC-Neurologie* 2, 403-429.
- Brackenbury, W.J. & Isom L.L. (2011). Na Channel β Subunits: Overachievers of the Ion Channel Family. *Front Pharmacol.* 28;2:53.
- Brackenbury, W.J. (2012). Voltage-gated sodium channels and metastatic disease. *Channels (Austin)* 6, 352-361.
- Bressan, E., Touska, F., Vetter, I., Kistner, K., Kichko, T.I., Teixeira, N.B., Picolo, G., Cury, Y., Lewis, R.J., Fischer, M.J., Zimmermann, K., & Reeh, P.W. (2016). Crotaline desensitizes TRPA1 ion channels to alleviate inflammatory hyperalgesia. *Pain* 157, 2504-2516.
- Bridges, D., Thompson, S.W., & Rice, A.S. (2001). Mechanisms of neuropathic pain. *Br J Anaesth* 87, 12-26.
- Callaghan, B., Haythornthwaite, A., Berecki, G., Clark, R.J., Craik, D.J., & Adams, D.J. (2008). Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. *J Neurosci* 28, 10943-10951.
- Cardoso, F.C., Dekan, Z., Smith, J.J., Deus, J.R., Vetter, I., Herzig, V., Alewood, P.F., King, G.F., & Lewis, R.J. (2017). Modulatory features of the novel spider toxin mu-TRTX-Df1a isolated from the venom of the spider *Davus fasciatus*. *Br. J. Pharmacol.* 174, 2528-2544.
- Cardoso, F.C., & Lewis, R.J. (2018). Sodium channels and pain: from toxins to therapies. *Br J Pharmacol* 175, 2138-2157.
- Catterall, W.A. (2011). Voltage-gated calcium channels. *Cold Spring Harb Perspect Biol* 3, a003947.
- Catterall, W.A. (2012). "Sodium Channel Mutations and Epilepsy," in *Jasper's Basic Mechanisms of the Epilepsies*, eds. Th, J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen & A.V. Delgado-Escueta. (Bethesda (MD)).
- Catterall, W.A., Cestele, S., Yarov-Yarovoy, V., Yu, F.H., Konoki, K., & Scheuer, T. (2007). Voltage-gated ion channels and gating modifier toxins. *Toxicon* 49, 124-141.
- Catterall, W.A., Goldin, A.L., & Waxman, S.G. (2005a). International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. *Pharmacol Rev* 57, 397-409.
- Catterall, W.A., Perez-Reyes, E., Snutch, T.P., & Striessnig, J. (2005b). International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. *Pharmacol Rev* 57, 411-425.
- Catterall, W.A., & Swanson, T.M. (2015). Structural Basis for Pharmacology of Voltage-Gated Sodium and Calcium Channels. *Mol Pharmacol* 88, 141-150.
- Catterall, W.A., Wisedchaisri, G., & Zheng, N. (2017). The chemical basis for electrical signaling. *Nat Chem Biol* 13, 455-463.

- Cerles, O., Benoit, E., Chéreau, C., Chouzenoux, S., Morin, F., Guillaumot, M.A., Coriat, R., Kavian, N., Loussier, T., Santulli, P., Marcellin, L., Saidu, N.E., Weill, B., Batteux, F., & Nicco, C. (2017) Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response. *Mol Cancer Ther* 16, 300-311.
- Cestele, S., Qu, Y., Rogers, J.C., Rochat, H., Scheuer, T., & Catterall, W.A. (1998). Voltage sensor-trapping: enhanced activation of sodium channels by beta-scorpion toxin bound to the S3-S4 loop in domain II. *Neuron* 21, 919-931.
- Chai, Z., Wang, C., Huang, R., Wang, Y., Zhang, X., Wu, Q., Wang, Y., Wu, X., Zheng, L., Zhang, C., Guo, W., Xiong, W., Ding, J., Zhu, F., & Zhou, Z. (2017). CaV2.2 Gates Calcium-Independent but Voltage-Dependent Secretion in Mammalian Sensory Neurons. *Neuron* 96, 1317-1326 e1314.
- Chambers, C., Witton, I., Adams, C., Marrington, L., & Kammonen, J. (2016). High-Throughput Screening of Na(V)1.7 Modulators Using a Giga-Seal Automated Patch Clamp Instrument. *Assay Drug Dev Technol* 14, 93-108.
- Chen, C., Xu, B., Shi, X., Zhang, M., Zhang, Q., Zhang, T., Zhao, W., Zhang, R., Wang, Z., Li, N., & Fang, Q. (2018). GpTx-1 and [Ala(5) , Phe(6) , Leu(26) , Arg(28)]GpTx-1, two peptide NaV 1.7 inhibitors: analgesic and tolerance properties at the spinal level. *Br J Pharmacol* 175, 3911-3927.
- Chen, J., Deng, M., He, Q., Meng, E., Jiang, L., Liao, Z., Rong, M., & Liang, S. (2008). Molecular diversity and evolution of cystine knot toxins of the tarantula *Chilobrachys jingzhao*. *Cell Mol Life Sci* 65, 2431-2444.
- Coriat, R., Alexandre, J., Nicco, C., Quinquis, L., Benoit, E., Chéreau, C., Lemaréchal, H., Mir, O., Borderie, D., Tréluyer, J.M., Weill, B., Coste, J., Goldwasser, F., & Batteux, F. (2014) Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. *J Clin Invest* 124, 262-272.
- Crofford, L.J. (2015). Chronic Pain: Where the Body Meets the Brain. *Trans Am Clin Climatol Assoc* 126, 167-183.
- Crumb, W.J., Jr., Vicente, J., Johannesen, L., & Strauss, D.G. (2016). An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. *J Pharmacol Toxicol Methods* 81, 251-262.
- De Lera Ruiz, M., & Kraus, R.L. (2015). Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. *J Med Chem* 58, 7093-7118.
- Deuis, J.R., Dekan, Z., Inserra, M.C., Lee, T.H., Aguilar, M.I., Craik, D.J., Lewis, R.J., Alewood, P.F., Mobli, M., Schroeder, C.I., Henriques, S.T., & Vetter, I. (2016a). Development of a muO-Conotoxin Analogue with Improved Lipid Membrane Interactions and Potency for the Analgesic Sodium Channel NaV1.8. *J Biol Chem* 291, 11829-11842.
- Deuis, J.R., Dekan, Z., Wingerd, J.S., Smith, J.J., Munasinghe, N.R., Bholá, R.F., Imlach, W.L., Herzig, V., Armstrong, D.A., Rosengren, K.J., Bosmans, F., Waxman, S.G., Dib-Hajj, S.D., Escoubas, P., Minett, M.S., Christie, M.J., King, G.F., Alewood, P.F., Lewis, R.J., Wood, J.N., & Vetter, I. (2017). Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a. *Sci Rep* 7, 40883.
- Deuis, J.R., Wingerd, J.S., Winter, Z., Durek, T., Dekan, Z., Sousa, S.R., Zimmermann, K., Hoffmann, T., Weidner, C., Nassar, M.A., Alewood, P.F., Lewis, R.J., & Vetter, I. (2016b). Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. *Toxins (Basel)* 8.
- Dib-Hajj, S.D., Black, J.A., & Waxman, S.G. (2015). NaV1.9: a sodium channel linked to human pain. *Nat Rev Neurosci* 16, 511-519.

- Dib-Hajj, S.D., Fjell, J., Cummins, T.R., Zheng, Z., Fried, K., Lamotte, R., Black, J.A., & Waxman, S.G. (1999). Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. *Pain* 83, 591-600.
- Dick, O.E., Krylov, B.V., & Nozdrachev, A.D. (2017). Possible mechanism of bursting suppression in nociceptive neurons. *Dokl Biochem Biophys* 473, 137-140.
- Diochot, S., Baron, A., Salinas, M., Douguet, D., Scarzello, S., Dabert-Gay, A.S., Debayle, D., Friend, V., Alloui, A., Lazdunski, M., & Lingueglia, E. (2012). Black mamba venom peptides target acid-sensing ion channels to abolish pain. *Nature* 490, 552-555.
- Dupoiron D, Bore F, Lefebvre-Kuntz D, Brenet O, Debourmont S, Dixmierias F, Buisset N, Lebrech N, & Monnin D. (2012) Pain Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. *Physician* 15, 395-403.
- Dutertre S., Jin A.H., Vetter I., Hamilton B., Sunagar K., Lavergne V., Dutertre V., Fry B.G., Antunes A., Venter D.J., Alewood P.F., & Lewis R.J. (2014) Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails. *Nature Communications* 5:3521.
- Dutra, A.A., Sousa, L.O., Resende, R.R., Brandao, R.L., Kalapothakis, E., & Castro, I.M. (2008). Expression and characterization of LTx2, a neurotoxin from *Lasiadora* sp. effecting on calcium channels. *Peptides* 29, 1505-1513.
- Emery, E.C., Luiz, A.P., & Wood, J.N. (2016). Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. *Expert Opin Ther Targets* 20, 975-983.
- Escoubas, P., Bosmans, F., Cuypers, E., Diochot, S., Mebs, D., Craik, D., Hill, J., Nakajima, T., Lazdunski M., & Tytgat, J. (2006). Phlotoxin-1, a toxin from tarantula venom, is a potent modulator of Nav_v1.7 sodium channels and a potential analgesic. In: 15th World congress on Animal, plant & microbial toxins organized by the International Society on Toxinology, Glasgow, Scotland, 23-28 July 2006. *Abstract book*, p. 220.
- Field, M.J., Cox, P.J., Stott, E., Melrose, H., Offord, J., Su, T.Z., Bramwell, S., Corradini, L., England, S., Winks, J., Kinloch, R.A., Hendrich, J., Dolphin, A.C., Webb, T., & Williams, D. (2006). Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. *Proc Natl Acad Sci U S A* 103, 17537-17542.
- Flinspach, M., Xu, Q., Piekarz, A.D., Fellows, R., Hagan, R., Gibbs, A., Liu, Y., Neff, R.A., Freedman, J., Eckert, W.A., Zhou, M., Bonesteel, R., Pennington, M.W., Eddinger, K.A., Yaksh, T.L., Hunter, M., Swanson, R.V., & Wickenden, A.D. (2017). Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor. *Sci Rep* 7, 39662.
- Francois, A., Laffray, S., Pizzoccaro, A., Eschalier, A., & Bourinet, E. (2014). T-type calcium channels in chronic pain: mouse models and specific blockers. *Pflugers Arch* 466, 707-717.
- Fry, B.G., Roelants, K., Champagne, D.E., Scheib, H., Tyndall, J.D., King, G.F., Nevalainen, T.J., Norman, J.A., Lewis, R.J., Norton, R.S., Renjifo, C., & De La Vega, R.C. (2009). The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms. *Annu Rev Genomics Hum Genet* 10, 483-511.
- Gajewiak, J., Azam, L., Imperial, J., Walewska, A., Green, B.R., Bandyopadhyay, P.K., Raghuraman, S., Ueberheide, B., Bern, M., Zhou, H.M., Minassian, N.A., Hagan, R.H., Flinspach, M., Liu, Y., Bulaj, G., Wickenden, A.D., Olivera, B.M., Yoshikami, D., & Zhang, M.M. (2014). A disulfide tether stabilizes the block of sodium channels by the conotoxin muO section sign-GVIII. *Proc Natl Acad Sci U S A* 111, 2758-2763.
- Gandini, M.A., Sandoval, A., & Felix, R. (2015). Toxins targeting voltage-activated Ca²⁺ channels and their potential biomedical applications. *Curr Top Med Chem* 15, 604-616.

- Gilchrist, J., Olivera, B.M., & Bosmans, F. (2014). Animal toxins influence voltage-gated sodium channel function. *Handb Exp Pharmacol* 221, 203-229.
- Gilles, N., & Servent, D. (2014). The European FP7 Venomics Project. *Future Med Chem* 6, 1611-1612.
- Goldberg, D.S., & Mcgee, S.J. (2011). Pain as a global public health priority. *BMC Public Health* 11, 770.
- Goldin, A.L. (2001). Resurgence of sodium channel research. *Annu Rev Physiol* 63, 871-894.
- Gonçalves, T.C., Benoit, E., Partiseti, M., & Servent, D. (2018a). The NaV1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons. *Front Pharmacol* 9, 1000.
- Gonçalves, T.C., Boukaiba, R., Molgo, J., Amar, M., Partiseti, M., Servent, D., & Benoit, E. (2018b). Direct evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches. *Neuropharmacology* 133, 404-414.
- Hagen, N.A., Cantin, L., Constant, J., Haller, T., Blaise, G., Ong-Lam, M., Du Souich, P., Korz, W., & Lapointe, B. (2017). Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial. *Pain Res Manag* 2017, 7212713.
- Hamad, M.K., He, K., Abdulrazeq, H.F., Mustafa, A.M., Luceri, R., Kamal, N., Ali, M., Nakhla, J., Herzallah, M.M., & Mammis, A. (2018). Potential Uses of Isolated Toxin Peptides in Neuropathic Pain Relief: A Literature Review. *World Neurosurg* 113, 333-347 e335.
- Harding, S.D., Sharman, J.L., Faccenda, E., Southan, C., Pawson, A.J., Ireland, S., Gray, A.J.G., Bruce, L., Alexander, S.P.H., Anderton, S., Bryant, C., Davenport, A.P., Doerig, C., Fabbro, D., Levi-Schaffer, F., Spedding, M., Davies, J.A., & Nc, I. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucleic Acids Res* 46, D1091-D1106.
- Hardy, M.C., Daly, N.L., Mobli, M., Morales, R.A., & King, G.F. (2013). Isolation of an orally active insecticidal toxin from the venom of an Australian tarantula. *PLoS One* 8, e73136.
- Hernandez-Plata, E., Ortiz, C.S., Marquina-Castillo, B., Medina-Martinez, I., Alfaro, A., Berumen, J., Rivera, M., & Gomora, J.C. (2012). Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer. *Int J Cancer* 130, 2013-2023.
- Hiyama, T.Y., Watanabe, E., Ono, K., Inenaga, K., Tamkun, M.M., Yoshida, S., & Noda, M. (2002). Na(x) channel involved in CNS sodium-level sensing. *Nat Neurosci* 5, 511-512.
- Ho, C., & O'leary, M.E. (2011). Single-cell analysis of sodium channel expression in dorsal root ganglion neurons. *Mol Cell Neurosci* 46, 159-166.
- Ho, C., Zhao, J., Malinowski, S., Chahine, M., & O'leary, M.E. (2012). Differential expression of sodium channel beta subunits in dorsal root ganglion sensory neurons. *J Biol Chem* 287, 15044-15053.
- Hopkins, A.L., & Groom, C.R. (2002). The druggable genome. *Nat Rev Drug Discov* 1, 727-730.
- Huo, R., Sheng, Y., Guo, W.T., & Dong, D.L. (2014). The potential role of Kv4.3 K⁺ channel in heart hypertrophy. *Channels (Austin)* 8, 203-209.
- Imbrici, P., Nicolotti, O., Leonetti, F., Conte, D., & Liantonio, A. (2018). Ion Channels in Drug Discovery and Safety Pharmacology. *Methods Mol Biol* 1800, 313-326.
- Inserra, M.C., Israel, M.R., Caldwell, A., Castro, J., Deuis, J.R., Harrington, A.M., Keramidas, A., Garcia-Caraballo, S., Maddern, J., Erickson, A., Grundy, L., Rychkov, G.Y., Zimmermann, K., Lewis, R.J.,

- Brierley, S.M., & Vetter, I. (2017). Multiple sodium channel isoforms mediate the pathological effects of Pacific ciguatoxin-1. *Sci Rep* 7, 42810.
- Isensee, J., Krahé, L., Moeller, K., Pereira, V., Sexton, J.E., Sun, X., Emery, E., Wood, J.N., & Hucho, T. (2017) Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice. *Sci Signal* 10(461).
- Isom, L.L. (2001). Sodium channel beta subunits: anything but auxiliary. *Neuroscientist* 7, 42-54.
- Israel, M.R., Tay, B., Deuis, J.R., & Vetter, I. (2017). Sodium Channels and Venom Peptide Pharmacology. *Adv Pharmacol* 79, 67-116.
- Jami, S., Erickson, A., Brierley, S.M., & Vetter, I. (2017). Pain-Causing Venom Peptides: Insights into Sensory Neuron Pharmacology. *Toxins (Basel)* 10.
- Jones, C.M., Mack, K.A., & Paulozzi, L.J. (2013). Pharmaceutical overdose deaths, United States, 2010. *JAMA* 309, 657-659.
- Kalia, J., Milescu, M., Salvatierra, J., Wagner, J., Klint, J.K., King, G.F., Olivera, B.M., & Bosmans, F. (2015). From foe to friend: using animal toxins to investigate ion channel function. *J Mol Biol* 427, 158-175.
- Kim, C.H., Oh, Y., Chung, J.M., & Chung, K. (2001). The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. *Brain Res Mol Brain Res* 95, 153-161.
- King, G.F. (2011). Venoms as a platform for human drugs: translating toxins into therapeutics. *Expert Opin Biol Ther* 11, 1469-1484.
- King, G.F., Gentz, M.C., Escoubas, P., & Nicholson, G.M. (2008). A rational nomenclature for naming peptide toxins from spiders and other venomous animals. *Toxicon* 52, 264-276.
- Klint J.K., Smith J.J., Vetter I., Rupasinghe D.B., Er S.Y., Senff S., Herzig V., Mobli M., Lewis R.J., Bosmans F., & King G.F.(2015) Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach. *Br J Pharmacol*. 172, 2445–2458.
- Klint, J.K., Berecki, G., Durek, T., Mobli, M., Knapp, O., King, G.F., Adams, D.J., Alewood, P.F., & Rash, L.D. (2014). Isolation, synthesis and characterization of omega-TRTX-Cc1a, a novel tarantula venom peptide that selectively targets L-type Cav channels. *Biochem Pharmacol* 89, 276-286.
- Klint, J.K., Senff, S., Rupasinghe, D.B., Er, S.Y., Herzig, V., Nicholson, G.M., & King, G.F. (2012). Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads. *Toxicon* 60, 478-491.
- Koh, W.U., Choi, S.S., Lee, J.H., Lee, S.H., Lee, S.K., Lee, Y.K., Leem, J.G., Song, J.G., & Shin, J.W. (2014). Perineural pretreatment of bee venom attenuated the development of allodynia in the spinal nerve ligation injured neuropathic pain model; an experimental study. *BMC Complement Altern Med* 14, 431.
- Kraus, R.L., Warren, V.A., Smith, M.M., Middleton, R.E., & Cohen, C.J. (2000). Modulation of R1G and R1C calcium channels by the spider toxin ProTx-II. *Soc. Neurosci. Abstr.* 26, 623.
- Kraus, R.L., Warren, V.A., Smith, M.M., Middleton, R.E., Blumenthal, K.M., & Cohen, C.J. (2002) A spider toxin that inhibits activation of voltage-gated sodium channels. *Biophys. J.* 82, 85a.
- Kubista, H., Mafra, R.A., Chong, Y., Nicholson, G.M., Beirao, P.S., Cruz, J.S., Boehm, S., Nentwig, W., & Kuhn-Nentwig, L. (2007). CSTX-1, a toxin from the venom of the hunting spider *Cupiennius salei*, is a selective blocker of L-type calcium channels in mammalian neurons. *Neuropharmacology* 52, 1650-1662.

- Lee, J.H., Park, C.K., Chen, G., Han, Q., Xie, R.G., Liu, T., Ji, R.R., & Lee, S.Y. (2014). A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. *Cell* 157, 1393-1404.
- Liu, D., Tseng, M., Epstein, L.F., Green, L., Chan, B., Soriano, B., Lim, D., Pan, O., Murawsky, C.M., King, C.T., & Moyer, B.D. (2016). Evaluation of recombinant monoclonal antibody SVMab1 binding to Na V1.7 target sequences and block of human Na V1.7 currents. *F1000Res* 5, 2764.
- Liu, X., Li, C., Chen, J., Du, J., Zhang, J., Li, G., Jin, X., & Wu, C. (2014a). AGAP, a new recombinant neurotoxic polypeptide, targets the voltage-gated calcium channels in rat small diameter DRG neurons. *Biochem Biophys Res Commun* 452, 60-65.
- Liu, Y., Tang, J., Zhang, Y., Xun, X., Tang, D., Peng, D., Yi, J., Liu, Z., & Shi, X. (2014b). Synthesis and analgesic effects of mu-TRTX-Hhn1b on models of inflammatory and neuropathic pain. *Toxins (Basel)* 6, 2363-2378.
- Liu, Y., Wu, Z., Tang, D., Xun, X., Liu, L., Li, X., Nie, D., Xiang, Y., Yi, J., & Yi, J. (2014c). Analgesic effects of Huwentoxin-IV on animal models of inflammatory and neuropathic pain. *Protein Pept Lett* 21, 153-158.
- Lopez-Santiago, L.F., Pertin, M., Morisod, X., Chen, C., Hong, S., Wiley, J., Decosterd, I., & Isom, L.L. (2006). Sodium channel beta2 subunits regulate tetrodotoxin-sensitive sodium channels in small dorsal root ganglion neurons and modulate the response to pain. *J Neurosci* 26, 7984-7994.
- Lory, P., Bidaud, I., Mezghrani, A., & Monteil, A. (2006). [Calcium channelopathies: the current challenges]. *Med Sci (Paris)* 22, 1028-1031.
- Lotarski, S., Hain, H., Peterson, J., Galvin, S., Strenkowski, B., Donevan, S., & Offord, J. (2014). Anticonvulsant activity of pregabalin in the maximal electroshock-induced seizure assay in alpha2delta1 (R217A) and alpha2delta2 (R279A) mouse mutants. *Epilepsy Res* 108, 833-842.
- Lotarski, S.M., Donevan, S., El-Kattan, A., Osgood, S., Poe, J., Taylor, C.P., & Offord, J. (2011). Anxiolytic-like activity of pregabalin in the Vogel conflict test in alpha2delta-1 (R217A) and alpha2delta-2 (R279A) mouse mutants. *J Pharmacol Exp Ther* 338, 615-621.
- Luo, Z.D., Calcutt, N.A., Higuera, E.S., Valder, C.R., Song, Y.H., Svensson, C.I., & Myers, R.R. (2002). Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. *J Pharmacol Exp Ther* 303, 1199-1205.
- Luo, Z.D., Chaplan, S.R., Higuera, E.S., Sorkin, L.S., Stauderman, K.A., Williams, M.E., & Yaksh, T.L. (2001). Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. *J Neurosci* 21, 1868-1875.
- Manglik, A., Lin, H., Aryal, D.K., Mccorvy, J.D., Dengler, D., Corder, G., Levit, A., Kling, R.C., Bernat, V., Hubner, H., Huang, X.P., Sassano, M.F., Giguere, P.M., Lober, S., Da, D., Scherrer, G., Kobilka, B.K., Gmeiner, P., Roth, B.L., & Shoichet, B.K. (2016). Structure-based discovery of opioid analgesics with reduced side effects. *Nature* 537, 185-190.
- Marionneau, C., Carrasquillo, Y., Norris, A.J., Townsend, R.R., Isom, L.L., Link, A.J., & Nerbonne, J.M. (2012) The sodium channel accessory subunit Navβ1 regulates neuronal excitability through modulation of repolarizing voltage-gated K⁺ channels. *J Neurosci* 32, 5716-5527.
- Martin-Eauclaire M.F., Abbas N., Sauze N., Mercier L., Berge-Lefranc J.L., Condo J., Bougis P.E., & Guieu R. (2010) Involvement of endogenous opioid system in scorpion toxin-induced antinociception in mice. *Neurosci Lett*. 482, 45-50.
- Mattei, C. (2018). Tetrodotoxin, a Candidate Drug for Nav1.1-Induced Mechanical Pain? *Mar Drugs* 16.

- Matthies, D., Bae, C., Toombes, G.E., Fox, T., Bartesaghi, A., Subramaniam, S., & Swartz, K.J. (2018). Single-particle cryo-EM structure of a voltage-activated potassium channel in lipid nanodiscs. *Elife* 7.
- Mccormack, K., Santos, S., Chapman, M.L., Krafte, D.S., Marron, B.E., West, C.W., Krambis, M.J., Antonio, B.M., Zellmer, S.G., Printzenhoff, D., Padilla, K.M., Lin, Z., Wagoner, P.K., Swain, N.A., Stuppel, P.A., De Groot, M., Butt, R.P., & Castle, N.A. (2013). Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. *Proc Natl Acad Sci U S A* 110, E2724-2732.
- Meir, A., Cherki, R.S., Kolb, E., Langut, Y., & Bajayo, N. (2012). Novel peptides isolated from spider venom, and uses thereof. *Submitted to UniProtKB*.
- Meng, X., Xu, Y., Zhao, M., Wang, F., Ma, Y., Jin, Y., Liu, Y., Song, Y., & Zhang, J. (2015). The Functional Property Changes of Muscular Na(v)1.4 and Cardiac Na(v)1.5 Induced by Scorpion Toxin BmK AGP-SYPU1 Mutants Y42F and Y5F. *Biochemistry* 54, 2988-2996.
- Middleton, R.E., Warren, V.A., Kraus, R.L., Hwang, J.C., Liu, C.J., Dai, G., Brochu, R.M., Kohler, M.G., Gao, Y.D., Garsky, V.M., Bogusky, M.J., Mehl, J.T., Cohen, C.J., & Smith, M.M. (2002). Two tarantula peptides inhibit activation of multiple sodium channels. *Biochemistry* 41, 14734-14747.
- Molinski, T.F., Dalisay, D.S., Lievens, S.L., & Saludes, J.P. (2009). Drug development from marine natural products. *Nat Rev Drug Discov* 8, 69-85.
- Murray, J.K., Biswas, K., Holder, J.R., Zou, A., Ligutti, J., Liu, D., Poppe, L., Andrews, K.L., Lin, F.F., Meng, S.Y., Moyer, B.D., Mcdonough, S.I., & Miranda, L.P. (2015a). Sustained inhibition of the NaV1.7 sodium channel by engineered dimers of the domain II binding peptide GpTx-1. *Bioorg Med Chem Lett* 25, 4866-4871.
- Murray, J.K., Ligutti, J., Liu, D., Zou, A., Poppe, L., Li, H., Andrews, K.L., Moyer, B.D., Mcdonough, S.I., Favreau, P., Stocklin, R., & Miranda, L.P. (2015b). Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. *J Med Chem* 58, 2299-2314.
- Murray, J.K., Long, J., Zou, A., Ligutti, J., Andrews, K.L., Poppe, L., Biswas, K., Moyer, B.D., Mcdonough, S.I., & Miranda, L.P. (2016). Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1. *J Med Chem* 59, 2704-2717.
- Namadurai, S., Yereddi, N.R., Cusdin, F.S., Huang, C.L., Chirgadze, D.Y., & Jackson, A.P. (2015). A new look at sodium channel beta subunits. *Open Biol* 5, 140192.
- Nguyen H.M., Miyazaki H., Hoshi N., Smith B.J., Nukina N., Goldin A.L., & Chandy K.G. (2012). Modulation of voltage-gated K⁺ channels by the sodium channel beta1 subunit. *Proc. Natl. Acad. Sci. U. S. A.* 109, 18577-18582.
- Nerbonne, J.M., & Kass, R.S. (2005). Molecular physiology of cardiac repolarization. *Physiol Rev* 85, 1205-1253.
- Norton, R.S., & Chandy, K.G. (2017). Venom-derived peptide inhibitors of voltage-gated potassium channels. *Neuropharmacology* 127, 124-138.
- Ono, S., Kimura, T., & Kubo, T. (2011). Characterization of voltage-dependent calcium channel blocking peptides from the venom of the tarantula *Grammostola rosea*. *Toxicon* 58, 265-276.
- Osteen, J.D., Herzig, V., Gilchrist, J., Emrick, J.J., Zhang, C., Wang, X., Castro, J., Garcia-Caraballo, S., Grundy, L., Rychkov, G.Y., Weyer, A.D., Dekan, Z., Undheim, E.A., Alewood, P., Stucky, C.L., Brierley, S.M., Basbaum, A.I., Bosmans, F., King, G.F., & Julius, D. (2016). Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. *Nature* 534, 494-499.

- Pan, H.L., Wu, Z.Z., Zhou, H.Y., Chen, S.R., Zhang, H.M., & Li, D.P. (2008). Modulation of pain transmission by G-protein-coupled receptors. *Pharmacol Ther* 117, 141-161.
- Pan, X., Li, Z., Zhou, Q., Shen, H., Wu, K., Huang, X., Chen, J., Zhang, J., Zhu, X., Lei, J., Xiong, W., Gong, H., Xiao, B., & Yan, N. (2018). Structure of the human voltage-gated sodium channel Nav1.4 in complex with beta1. *Science* 362.
- Payandeh, J., & Minor, D.L., Jr. (2015). Bacterial voltage-gated sodium channels (BacNa(V)s) from the soil, sea, and salt lakes enlighten molecular mechanisms of electrical signaling and pharmacology in the brain and heart. *J Mol Biol* 427, 3-30.
- Payandeh, J., Scheuer, T., Zheng, N., & Catterall, W.A. (2011). The crystal structure of a voltage-gated sodium channel. *Nature* 475, 353-358.
- Peng, K., Shu, Q., Liu, Z., & Liang, S. (2002). Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider *Selenocosmia huwena*. *J Biol Chem* 277, 47564-47571.
- Pennington, M.W., Czerwinski, A., & Norton, R.S. (2018). Peptide therapeutics from venom: Current status and potential. *Bioorg Med Chem* 26, 2738-2758.
- Penzotti, J.L., Fozzard, H.A., Lipkind, G.M., & Dudley, S.C., Jr. (1998). Differences in saxitoxin and tetrodotoxin binding revealed by mutagenesis of the Na⁺ channel outer vestibule. *Biophys J* 75, 2647-2657.
- Pineda, S.S., Chaumeil, P.A., Kunert, A., Kaas, Q., Thang, M.W.C., Le, L., Nuhn, M., Herzig, V., Saez, N.J., Cristofori-Armstrong, B., Anangi, R., Senff, S., Gorse, D., & King, G.F. (2018). ArachnoServer 3.0: an online resource for automated discovery, analysis and annotation of spider toxins. *Bioinformatics* 34, 1074-1076.
- Priest, B.T., Blumenthal, K.M., Smith, J.J., Warren, V.A., & Smith, M.M. (2007). ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels. *Toxicon* 49, 194-201.
- Pringos, E., Vignes, M., Martinez, J., & Rolland, V. (2011). Peptide neurotoxins that affect voltage-gated calcium channels: a close-up on omega-agatoxins. *Toxins (Basel)* 3, 17-42.
- Raffaelli W., Sarti D., Demartini L., Sotgiu A., & Bonezzi C.(2011) Italian registry on long-term intrathecal ziconotide treatment. *Pain Physician* 14, 15-24.
- Rahnama, S., Deus, J.R., Cardoso, F.C., Ramanujam, V., Lewis, R.J., Rash, L.D., King, G.F., Vetter, I., & Mobli, M. (2017). The structure, dynamics and selectivity profile of a Nav1.7 potency-optimised huwentoxin-IV variant. *PLoS One* 12, e0173551.
- Revell, J.D., Lund, P.E., Linley, J.E., Metcalfe, J., Burmeister, N., Sridharan, S., Jones, C., Jermutus, L., & Bednarek, M.A. (2013). Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider *Selenocosmia huwena*. *Peptides* 44, 40-46.
- Rigo, F.K., Trevisan, G., De Pra, S.D., Cordeiro, M.N., Borges, M.H., Silva, J.F., Santa Cecilia, F.V., De Souza, A.H., De Oliveira Adamante, G., Milioli, A.M., De Castro Junior, C.J., Ferreira, J., & Gomez, M.V. (2017). The spider toxin Phalpha1beta recombinant possesses strong analgesic activity. *Toxicon* 133, 145-152.
- Rostaing-Rigattieri, S., & Guerin, J. (2014). [Cancer pain management: good clinical practices, use of strong opioids]. *Presse Med* 43, 252-262.
- Rush, A.M., Cummins, T.R., & Waxman, S.G. (2007). Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. *J. Physiol.* 579, 1-14.

- Saegusa, H., Kurihara, T., Zong, S., Kazuno, A., Matsuda, Y., Nonaka, T., Han, W., Toriyama, H., & Tanabe, T. (2001). Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca²⁺ channel. *EMBO J* 20, 2349-2356.
- Saez, N.J., Senff, S., Jensen, J.E., Er, S.Y., Herzig, V., Rash, L.D., & King, G.F. (2010). Spider-venom peptides as therapeutics. *Toxins (Basel)* 2, 2851-2871.
- Safavi-Hemami, H., Brogan, S.E., & Olivera, B.M. (2018). Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways. *J Proteomics*.
- Santana R.C., Perez D., Dobson J., Panagides N., Raven R.J., Nouwens A., Jones A., King G.F., & Fry B.G. (2017) Venom Profiling of a Population of the Theraphosid Spider *Phlogius crassipes* Reveals Continuous Ontogenetic Changes from Juveniles through Adulthood. *Toxins (Basel)* 9.
- Saucedo, A.L., Del Rio-Portilla, F., Picco, C., Estrada, G., Prestipino, G., Possani, L.D., Delepierre, M., & Corzo, G. (2012). Solution structure of native and recombinant expressed toxin CsslI from the venom of the scorpion *Centruroides suffusus suffusus*, and their effects on Nav1.5 sodium channels. *Biochim Biophys Acta* 1824, 478-487.
- Schmidt, G. (2010). Wie lautet der korrekte Name von *Selenocosmia huwena* Wang, Peng & Xie, 1993?. *Tarantulas World* 142, 23e27.
- Sekiguchi, F., Tsubota, M., & Kawabata, A. (2018). Involvement of Voltage-Gated Calcium Channels in Inflammation and Inflammatory Pain. *Biol Pharm Bull* 41, 1127-1134.
- Sevenet, T. (2006). [Toxines toxiques, toxines utiles chez les plantes]. *Biofutur*, 272, 30-34.
- Shen, H., Zhou, Q., Pan, X., Li, Z., Wu, J., & Yan, N. (2017). Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution. *Science* 355.
- Snutch, T.P., &Monteil, A. (2007) The sodium "leak" has finally been plugged. *Neuron* 54, 505-507.
- Sousa, S.R., Vetter, I., & Lewis, R.J. (2013). Venom peptides as a rich source of cav2.2 channel blockers. *Toxins (Basel)* 5, 286-314.
- Sousa, S.R., Wingerd, J.S., Brust, A., Bladen, C., Ragnarsson, L., Herzig, V., Deuis, J.R., Dutertre, S., Vetter, I., Zamponi, G.W., King, G.F., Alewood, P.F., & Lewis, R.J. (2017). Discovery and mode of action of a novel analgesic beta-toxin from the African spider *Ceratogyrus darlingi*. *PLoS One* 12, e0182848.
- Staats P.S., Yearwood T., Charapata S.G., Presley R.W., Wallace M.S., Byas-Smith M., Fisher R., Bryce D.A., Mangieri E.A., Luther R.R., Mayo M., McGuire D., & Ellis D. (2004) Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. *JAMA* 291, 63-70.
- Sun, S., Jia, Q., Zenova, A.Y., Chafeev, M., Zhang, Z., Lin, S., Kwan, R., Grimwood, M.E., Chowdhury, S., Young, C., Cohen, C.J., & Oballa, R.M. (2014). The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7. *Bioorg Med Chem Lett* 24, 4397-4401.
- Sutton, K.G., Siok, C., Stea, A., Zamponi, G.W., Heck, S.D., Volkmann, R.A., Ahlijanian, M.K., & Snutch, T.P. (1998). Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3. *Mol Pharmacol* 54, 407-418.
- Tan, A.M., Samad, O.A., Dib-Hajj, S.D., & Waxman, S.G. (2015). Virus-Mediated Knockdown of Nav1.3 in Dorsal Root Ganglia of STZ-Induced Diabetic Rats Alleviates Tactile Allodynia. *Mol Med* 21, 544-552.
- Templin, C., Ghadri, J.R., Rougier, J.S., Baumer, A., Kaplan, V., Albasa, M., Sticht, H., Rauch, A., Puleo, C., Hu, D., Barajas-Martinez, H., Antzelevitch, C., Luscher, T.F., Abriel, H., & Duru, F. (2011).

- Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). *Eur Heart J* 32, 1077-1088.
- Tibbs, G.R., Posson, D.J., & Goldstein, P.A. (2016). Voltage-Gated Ion Channels in the PNS: Novel Therapies for Neuropathic Pain? *Trends Pharmacol Sci* 37, 522-542.
- Tobassum S., Tahir H.M., Zahid M.T., Gardner Q.A., & Ahsan M.M. (2018). Effect of Milking Method, Diet, and Temperature on Venom Production in Scorpions. *J Insect Sci* 18.
- Trimmer, J.S., & Rhodes, K.J. (2004). Localization of voltage-gated ion channels in mammalian brain. *Annu Rev Physiol* 66, 477-519.
- Veeresham, C. (2012). Natural products derived from plants as a source of drugs. *J Adv Pharm Technol Res* 3, 200-201.
- Vetter, I., Deuis, J.R., Mueller, A., Israel, M.R., Starobova, H., Zhang, A., Rash, L.D., & Mobli, M. (2017). Nav1.7 as a pain target - From gene to pharmacology. *Pharmacol Ther* 172, 73-100.
- Villanueva, M.T. (2017). Analgesia: Designing out opioid side effects. *Nat Rev Drug Discov* 16, 311.
- Villegas, E., Adachi-Akahane, S., Bosmans, F., Tytgat, J., Nakajima, T., & Corzo, G. (2008). Biochemical characterization of cysteine-rich peptides from *Oxyopes* sp. venom that block calcium ion channels. *Toxicon* 52, 228-236.
- Wang, C., Shan, B., Wang, Q., Xu, Q., Zhang, H., & Lei, H. (2017a). Fusion of Ssm6a with a protein scaffold retains selectivity on Nav 1.7 and improves its therapeutic potential against chronic pain. *Chem Biol Drug Des* 89, 825-833.
- Wang, F., Yan, Z., Liu, Z., Wang, S., Wu, Q., Yu, S., Ding, J., & Dai, Q. (2016). Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA. *Neuropharmacology* 101, 137-145.
- Wang, Y., Li, X., Yang, M., Wu, C., Zou, Z., Tang, J., & Yang, X. (2017b). Centipede venom peptide SsmTX-I with two intramolecular disulfide bonds shows analgesic activities in animal models. *J Pept Sci* 23, 384-391.
- Waxman, S.G., Kocsis, J.D., & Black, J.A. (1994). Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. *J Neurophysiol* 72, 466-470.
- Waxman, S.G., & Zamponi, G.W. (2014). Regulating excitability of peripheral afferents: emerging ion channel targets. *Nat Neurosci* 17, 153-163.
- Wilson, D., & Daly, N.L. (2018). Venomics: A Mini-Review. *High Throughput* 7.
- Winters, S., Martin, C., Murphy, D., & Shokar, N.K. (2017). Breast Cancer Epidemiology, Prevention, and Screening. *Prog Mol Biol Transl Sci* 151, 1-32.
- Wong, E.S., Hardy, M.C., Wood, D., Bailey, T., & King, G.F. (2013). SVM-based prediction of propeptide cleavage sites in spider toxins identifies toxin innovation in an Australian tarantula. *PLoS One* 8, e66279.
- Wright, Z.V.F., Mccarthy, S., Dickman, R., Reyes, F.E., Sanchez-Martinez, S., Cryar, A., Kilford, I., Hall, A., Takle, A.K., Topf, M., Gonen, T., Thalassinis, K., & Tabor, A.B. (2017). The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Nav1.7. *J Am Chem Soc* 139, 13063-13075.
- Wu, J., Yan, Z., Li, Z., Qian, X., Lu, S., Dong, M., Zhou, Q., & Yan, N. (2016). Structure of the voltage-gated calcium channel Ca(v)1.1 at 3.6 Å resolution. *Nature* 537, 191-196.
- Wulff, H., Castle, N.A., & Pardo, L.A. (2009). Voltage-gated potassium channels as therapeutic targets. *Nat Rev Drug Discov* 8, 982-1001.

- Xiao, Y., Luo, X., Kuang, F., Deng, M., Wang, M., Zeng, X., & Liang, S. (2008). Synthesis and characterization of huwentoxin-IV, a neurotoxin inhibiting central neuronal sodium channels. *Toxicon* 51, 230-239.
- Xie, W., Tan, Z.Y., Barbosa, C., Strong, J.A., Cummins, T.R., & Zhang, J.M. (2016). Upregulation of the sodium channel Navbeta4 subunit and its contributions to mechanical hypersensitivity and neuronal hyperexcitability in a rat model of radicular pain induced by local dorsal root ganglion inflammation. *Pain* 157, 879-891.
- Yang, L., Li, Q., Liu, X., & Liu, S. (2016). Roles of Voltage-Gated Tetrodotoxin-Sensitive Sodium Channels Nav1.3 and Nav1.7 in Diabetes and Painful Diabetic Neuropathy. *Int J Mol Sci* 17.
- Yan Z., Zhou Q., Wang L., Wu J., Zhao Y., Huang G., Peng W., Shen H., Lei J., & Yan N. (2017) Structure of the Nav1.4-b1 Complex from Electric Eel. *Cell* 170, 470–482.
- Yang, S., Xiao, Y., Kang, D., Liu, J., Li, Y., Undheim, E.A., Klint, J.K., Rong, M., Lai, R., & King, G.F. (2013). Discovery of a selective Nav1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models. *Proc Natl Acad Sci U S A* 110, 17534-17539.
- Yasuda, O., Morimoto, S., Jiang, B., Kuroda, H., Kimura, T., Sakakibara, S., Fukuo, K., Chen, S., Tamatani, M., & Ogihara, T. (1994). FS2, a mamba venom toxin, is a specific blocker of the L-type calcium channels. *Artery* 21, 287-302.
- Yekkirala, A.S., Roberson, D.P., Bean, B.P., & Woolf, C.J. (2017). Breaking barriers to novel analgesic drug development. *Nat Rev Drug Discov* 16, 810.
- Young, K., Lin, S., Sun, L., Lee, E., Modi, M., Hellings, S., Husbands, M., Ozenberger, B., & Franco, R. (1998). Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen. *Nat Biotechnol* 16, 946-950.
- Yu, F. H., & Catterall, W. A. (2004). The VGL-chanome: a protein superfamily specialized for electrical signaling and ionic homeostasis. *Sci STKE*, 2004: re15.
- Zambelli, V.O., Pasqualoto, K.F., Picolo, G., Chudzinski-Tavassi, A.M., & Cury, Y. (2016). Harnessing the knowledge of animal toxins to generate drugs. *Pharmacol Res* 112, 30-36.
- Zamponi, G.W., Striessnig, J., Koschak, A., & Dolphin, A.C. (2015). The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. *Pharmacol Rev* 67, 821-870.
- Zemel, B.M., Ritter, D.M., Covarrubias, M., & Muzem, T. (2018). A-Type KV Channels in Dorsal Root Ganglion Neurons: Diversity, Function, and Dysfunction. *Front Mol Neurosci* 11, 253.

ANNEXES

A1. Liste des publications, des participations à des congrès et des formations

A1.1. Publications

Articles

1. **GONÇALVES T.C.**, BOUKAIBA R., MOLGO J., AMAR M., PARTISETI M., SERVENT D. & BENOIT E. (2018) Direct evidence for high affinity blockade of Na_v1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches. *Neuropharmacology*, 133: 404-414.
2. **GONÇALVES T.C.**, BENOIT E., PARTISETI M. & SERVENT D. (2018) The Na_v1.7 channel subtype as an antinociceptive target for spider toxins in adult dorsal root ganglia neurons. *Frontiers in Pharmacology*, 9:1000. doi: 10.3389/fphar.2018.01000.
3. **GONÇALVES T.C.**, BENOIT E., KURZ M., LUCARAIN L., FOUCONNIER S., COMBEMALE S., JAQUILLARD L., SCHOMBERT B., CHAMBARD J.-M., BOUKAIBA R., HESSLER G., BOHME A., BIALY L., HOURCADE S., BÉROUD R., DE WAARD M., SERVENT D. & PARTISETI M. (2018) Cyriotoxin-1a, the first toxin from *Cyriopagopus schioedtei* spider with antinociceptive properties: from identification to functional characterization. *British Journal of Pharmacology* (en révision).
4. CERLES O., **GONÇALVES T.C.**, CHOUZENOUX S., BENOIT E., SCHMITT A., BENETT SAIDU N.E., KAVIAN N., CHÉREAU C., GOBEAUX C., WEILL B., CORIAT R., NICCO C. & BATTEUX F. (2018) Blocking muscarinic receptors by benztropine prevents platinum-induced peripheral neuropathies and tumor growth. *Acta Neuropathologica Communications* (en révision).

Abstracts

1. **GONÇALVES T.C.**, AMAR A., BOUKAIBA R., PARTISETI M., SERVENT D. & BENOIT E. (2018) D peptide, a promising toxin as potential antinociceptive agent targeting the Na_v1.7 subtype of voltage-gated sodium channels. *Toxicon*, 149: 89.
2. **GONÇALVES T.C.**, PARTISETI M., SERVENT D. & BENOIT E. (2018) A non-invasive method to appraise time-dependent effects of venom toxins on the mouse neuromuscular excitability *in vivo*. *Toxicon*, 149: 104.
3. **GONÇALVES T.C.**, BOUKAIBA R., MOLGO J., AMAR A., PARTISETI M., SERVENT D. & BENOIT E. (2018) A multiscale functional approach to assess pharmacological interactions between huwentoxin-IV spider peptide and sodium channel subtypes. *Toxicon*, 149: 105-106.

A1.2. Participations à des congrès

Conférence invitée

1. **GONÇALVES T.C.**, BENOIT E., SERVENT D. & PARTISETI M. (septembre 2018) Antinociceptive evaluation of cyriotoxin-1a and huwentoxin-IV, two spider toxins that block with high affinity the Na_v1.7 subtype of voltage-gated sodium channels. 29th Ion Channel Meeting, Sète.

Communications orales

1. **GONÇALVES T.C.**, AMAR M., BOUKAIBA R., PARTISETI M., SERVENT D. & BENOIT E. (décembre 2016) D peptide, a promising toxin as potential antinociceptive agent targeting the Na_v1.7 subtype of voltage-gated sodium channels. 23^{èmes} Rencontres en Toxinologie "Toxins: Immunity, Inflammation and Pain" organisées par la Société Française pour l'Etude des Toxines (SFET), Institut Pasteur, Paris.
2. **GONÇALVES T.C.** (juillet 2017) Evaluation multi-échelle de toxines de venins comme agents thérapeutiques potentiels ou marqueurs diagnostiques (180 secondes). Journées des doctorants de l'Institut des Sciences de la Vie Frédéric Joliot, CEA de Saclay, Gif-sur-Yvette.
3. **GONÇALVES T.C.**, AMAR M., BOUKAIBA R., PARTISETI M., SERVENT D. & BENOIT E. (août 2017) Comparison of D peptide and Huwentoxin-IV as potential antinociceptive agents targeting the Na_v1.7 subtype of voltage-gated sodium channels. 4th International Symposium "Venoms 2017: Evolutionary diversity of natural toxins: implications for antivenom development and drug discovery", Oxford, Angleterre.

Posters (le présentateur est souligné)

1. **GONÇALVES T.C.**, AMAR M., MOLGO J., PARTISETI M., SERVENT D. & BENOIT E. (mai 2016) Multiscale evaluation of venom toxins as potential antinociceptive agents. Journées des doctorants de l'Institut de Biologie et de Technologies de Saclay (IBITEC-S), CEA de Saclay, Gif-sur-Yvette.
2. **GONÇALVES T.C.**, AMAR M., MOLGO J., PARTISETI M., SERVENT D. & BENOIT E. (juin 2016) Multi-scale evaluation of venom toxins as potential antinociceptive agents. Journées de l'Ecole Doctorale "Innovation Thérapeutique: du fondamental à l'appliqué", Châtenay-Malabry.
3. **GONÇALVES T.C.**, AMAR M., BOUKAIBA R., PARTISETI M., SERVENT D. & BENOIT E. (juin 2017) Cyriotoxin-1a, a promising toxin as potential antinociceptive agent targeting the Na_v1.7 subtype of voltage-gated sodium channels. 15^{ème} Symposium ICSN "Substances Naturelles ICSN-UPSay", Gif-sur-Yvette.
4. **GONÇALVES T.C.**, BOUKAIBA R., MOLGO J., AMAR M., PARTISETI M., SERVENT D. & BENOIT E. (décembre 2017) A multiscale functional approach to assess the pharmacological interactions between Huwentoxin-IV spider peptide and sodium channel subtypes. 24^{èmes} Rencontres en Toxinologie "Toxins: Biodiversity, Environment and Evolution" organisées par la SFET, Institut Pasteur, Paris.
5. **GONÇALVES T.C.**, PARTISETI M., SERVENT D. & BENOIT E. (décembre 2017) A non-invasive method to appraise time-dependent effects of venom toxins on the mouse neuromuscular excitability *in vivo*. 24^{èmes} Rencontres en Toxinologie "Toxins: Biodiversity, Environment and Evolution" organisées par la SFET, Institut Pasteur, Paris.
6. **GONÇALVES T.C.**, BOUKAIBA R., MOLGO J., AMAR M., PARTISETI M., SERVENT D. & BENOIT E. (décembre 2017) A multiscale functional approach to evidence high affinity blockade of Na_v1.6 channel subtype by huwentoxin-IV spider peptide. 7^{ème} colloque annuel du LabEx LERMIT, LAL, Orsay.
7. **GONÇALVES T.C.**, PARTISETI M., SERVENT D. & BENOIT E. (janvier 2018) A non-invasive method to appraise time-dependent effects of venom toxins on the mouse neuromuscular excitability *in vivo*. Journées Scientifiques organisées dans le cadre du programme national de la lutte contre le terrorisme (projet NRBC-E), CEA de Saclay, Gif-sur-Yvette.
8. **GONÇALVES T.C.**, BENOIT E., BOUKAIBA R., HESSLER G., SERVENT D. & PARTISETI M. (avril 2018) *In vivo* evaluation of antinociceptive effects of cyriotoxin-1a, the first toxin purified from *Cyriopagopus schioedtei* spider venom. 1st international symposium of Paris-Saclay University "Drug Discovery and New Therapeutics", Orsay.

9. GILLES N., MOURIER M., KESSLER P., DROCTOVE L., **GONÇALVES T.C.**, BENOIT E. & SERVENT D. (avril 2018) Therapeutic potential of venom peptides interacting with GPCRs and ion channels. 1st international symposium of Paris-Saclay University "Drug Discovery and New Therapeutics", Orsay.
10. **GONÇALVES T.C.**, PARTISETI M., SERVENT D. & BENOIT E. (avril 2018) A non-invasive method to appraise time-dependent effects of venom toxin-based therapeutics on the mouse neuromuscular excitability *in vivo*. 1st international symposium of Paris-Saclay University "Drug Discovery and New Therapeutics", Orsay.
11. **GONÇALVES T.C.**, PARTISETI M., SERVENT D. & BENOIT E. (mai 2018) A multiscale functional approach to appraise the pharmacological interactions between spider venom peptides and Na_v1.7, a genetically validated analgesic target. 9th Young Researchers in Life Science (YRLS), Campus ENS Jourdan, Paris.
12. **GONÇALVES T.C.**, BENOIT E., KURZ M., LUCARAIN L., FOUCONNIER S., COMBEMALE S., JAQUILLARD L., SCHOMBERT B., CHAMBARD J.-M., BOUKAIBA R., HESSLER G., BOHME A., BIALY L., HOURCADE S., BÉROUD R., DE WAARD M., SERVENT D. & PARTISETI M. (août 2018) Cyriotoxin-1a, the first toxin with antinociceptive properties purified from *Cyriopagopus schioedtei* spider venom: from identification to structural and functional characterization. Gordon Research Conference "Venom Evolution, Function and Biomedical Applications", Mount Snow, West Dover, Vermont, USA.
13. **GONÇALVES T.C.**, BOUKAIBA R., MOLGO J., AMAR M., PARTISETI M., SERVENT D. & BENOIT E. (septembre 2018) Multiscale functional approaches to evidence high affinity blockade of Na_v1.6 channel subtype by huwentoxin-IV spider peptide. 29th Ion Channel Meeting, Sète.
14. **GONÇALVES T.C.**, BENOIT E., PARTISETI M. & SERVENT D. (novembre 2018) Antinociceptive targets for spider toxins in adult dorsal root ganglia neurons. 25^{èmes} Rencontres en Toxinologie "Toxins and Health: From molecules to organisms" organisées par la SFET, Institut Pasteur, Paris.

A1.3. Formations

1. Technique de dissociation et de mise en culture primaire de neurones des ganglions de la racine dorsale (DRG) de souris adultes. SANOFI Aventis, Chilly-Mazarin (novembre 2015).
2. UE de Master II: Protéines solubles et membranaires: expression, purification et caractérisation. INSTN, CEA de Saclay, Gif-sur-Yvette (décembre 2015).
3. Formation spécifique destinée aux personnes concevant ou réalisant des procédures expérimentales sur modèle rongeur (ancien niveau 1). Ecole vétérinaire, Maisons-Alfort (mai 2016).
4. Formation en Neurosciences sur l'imagerie optique et l'électrophysiologie. École des Neurosciences de Paris (ENP) – Université Paris Descartes – École Normale Supérieure (ENS), Paris (juin 2017).
5. Formation sur la chaîne du médicament: point de vue des industriels par le LabEx LERMIT. Montigny-le-Bretonneux (juillet 2017).
6. Cours d'anglais général et de communication scientifique en anglais (niveau intermédiaire) par l'Université Paris-Sud. Campus d'Orsay (octobre 2017).
7. "How to improve your scientific presentations" par la Fondation Estève, en collaboration avec le GDR 3545, le CNRS et le Collège de France. Paris (novembre 2017).
8. Séminaire DRF Animal et Société par le Comité d'Éthique pour l'Expérimentation Animale du CEA. CEA de Fontenay aux Roses (novembre 2017).

9. "Les impacts de la diversité et de la mixité sur les métiers de la recherche et de l'innovation" par l'ANRT (Association Nationale Recherche Technologie). Paris (mars 2018).
10. E-learning SANOFI "Lutte contre la corruption" (mai 2018).
11. E-learning SANOFI "Code éthique" (juin 2018).
12. E-learning SANOFI "Essentiels sur la protection des données personnelles" (juillet 2018).
13. E-learning SANOFI "L'essentiel de la confidentialité" (septembre 2018).

A2. Publication n°6

Contexte de l'étude

L'oxaliplatine est l'une des principales molécules utilisées en oncologie digestive ayant prouvé sa capacité à traiter certaines tumeurs solides dont le cancer colorectal en situation métastatique et le cancer gastrique. Cependant, la neuropathie périphérique induite par cet agent anticancéreux conduit fréquemment à l'arrêt de son administration. Depuis 2014, notre équipe, en collaboration avec celle du Pr. Frédéric Batteux (Hôpital Cochin, Paris), explore les mécanismes de cette neuropathie en utilisant un modèle murin de neurotoxicité induite chimiquement par l'oxaliplatine. En particulier, les effets thérapeutiques du mangafodipir et du niclosamide, molécules dotées de propriétés anti-oxydantes, ont été évalués chez ce modèle murin et certains des résultats obtenus ont été confirmés chez l'homme (Coriat et al., 2014; Cerles et al., 2017).

La neurotoxicité induite chimiquement peut être due, entre autres, aux interactions de l'agent anticancéreux avec l'ADN, à des perturbations mitochondriales, à des dérégulations des canaux ioniques ou encore à des dysfonctionnements de la neurotransmission glutaminergique. Des lésions peuvent survenir au niveau des neurones sensoriels, incluant les neurones de DRG, associées à des défauts de transport axonal ou à la dégénérescence de l'axone. Les cellules de Schwann sont connues pour être les principaux effecteurs de la régénération axonale dans une variété de 94 affections neuropathiques périphériques (notamment héréditaires, inflammatoires et toxiques) et dans le cas de lésions traumatiques des fibres nerveuses périphériques.

La benztropine est un inhibiteur des récepteurs muscariniques M1-M3 de l'acétylcholine. Ce médicament est connu pour favoriser la différenciation de cellules précurseurs d'oligodendrocytes tout en permettant une remyélinisation axonale avec une puissance supérieure à celle des molécules actuellement prescrites aux patients atteints de sclérose en plaques. Par ailleurs, lors de traitements à l'oxaliplatine, des croissances tumorales induites par l'acétylcholine, et impliquant principalement

une surexpression du récepteur muscarinique M3 de l'acétylcholine, ont été détectées dans plusieurs organes. De plus, plusieurs études ont mis en évidence une prévention de la croissance tumorale et des métastases par le blocage des récepteurs muscariniques.

C'est dans ce contexte que nous avons évalué les effets de la benztropine non seulement sur les neuropathies périphériques induites par l'oxaliplatine mais également sur celles apparaissant dans les cas de diabète, *in vivo* chez des modèles expérimentaux de souris, *ex vivo* sur les nerfs sciatiques isolés de souris et *in vitro* sur des cultures primaires de neurones de DRG de souris.

Acta Neuropathologica Communications (publication en révision)

"Blocking muscarinic receptors by benztropine prevents platinum-induced peripheral neuropathies and tumor growth"

Olivier Cerles, **Tânia C. Gonçalves**, Sandrine Chouzenoux, Evelyne Benoit, Alain Schmitt, Nathaniel Edward Bennett Saidu, Niloufar Kaviani, Christiane Chéreau, Camille Gobeaux, Bernard Weill, Romain Coriat, Carole Nicco & Frédéric Batteux

Blocking muscarinic receptors by benztropine prevents platinum-induced peripheral neuropathies and tumor growth

Olivier Cerles¹, Tânia Cristina Gonçalves^{2,3}, Sandrine Chouzenoux¹, Evelyne Benoit², Alain Schmitt⁴, Nathaniel Edward Bennett Saidu¹, Niloufar Kaviani^{1,5}, Christiane Chéreau¹, Camille Gobeaux⁶, Bernard Weill^{1,5}, Romain Coriat^{1,7}, Carole Nicco^{§1}, Frédéric Batteux^{§1,5*}

Author Affiliations: ¹Department "Development, Reproduction and Cancer", Institut Cochin, Paris Descartes University, Sorbonne Paris City, INSERM U1016, Paris, France; ²Molecular engineering of proteins unit (SIMOPRO), CEA of Saclay, and Paris-Saclay Institute of Neuroscience (Neuro-PSI), UMR CNRS 9197, Paris-Saclay University, Gif-sur-Yvette, France; ³Sanofi R & D, Integrated Drug Discovery – High Content Biology, Vitry-sur-Seine, France; ⁴Plateforme imagerie : microscopie électronique, Institut Cochin, INSERM U1016, Paris, France; ⁵Department of Immunology, Cochin Teaching Hospital, AP-HP, Paris, France; ⁶Service de diagnostic biologique automatisé, Cochin Teaching Hospital, Paris, France; ⁷Department of Gastroenterology, Cochin Teaching Hospital, Paris Descartes University, Paris, France.

§ Frédéric Batteux and Carole Nicco contributed equally to this article.

***Corresponding Author:** Frédéric Batteux, Cochin Teaching Hospital, 27 rue du faubourg Saint-Jacques, Paris F75014, France; Phone: +33 (1) 5841 2141; Fax: +33 (1) 4441 2546
Email: frederic.batteux@cch.aphp.fr

Conflicts of Interest: The authors declare no competing financial interests.

Keywords: Benztropine, Oxaliplatin, Peripheral neuropathies, Muscarinic receptors, Myelin.

Abstract

The endogenous cholinergic system plays a key role in neuronal cells, by suppressing neurite outgrowth and myelination and, in some cancer cells, favoring tumor growth. Platinum compounds are widely used as part of first line conventional cancer chemotherapy but their efficacy is however limited by peripheral neuropathy as a major side-effect. We have evaluated whether blocking muscarinic receptors M1 and M3 with benztropine can increase anti-tumoral efficacy of oxaliplatin, while preventing its neurotoxicity.

Benzotropine ameliorates acute and chronic clinical symptoms of oxaliplatin-induced peripheral neuropathies in mice. Sensory alterations detected by electrophysiology in oxaliplatin-treated mice were consistent with a decreased nerve conduction velocity and membrane hyperexcitability due to alterations in the density and/or functioning of both sodium and potassium channels, confirmed by action potential analysis from *ex-vivo* cultures of mouse dorsal root ganglion sensory neurons using whole-cell patch-clamp. These alterations were all prevented by benztropine. In oxaliplatin-treated mice, MBP expression, confocal and electronic microscopy of the sciatic nerves revealed a demyelination and confirmed the alteration of the myelinated axons morphology when compared to animals injected with oxaliplatin plus benztropine. Benztropine also prevented the decrease in neuronal density in the paws of mice injected with oxaliplatin. The neuroprotection conferred by benztropine against chemotherapeutic drugs was associated with a lower expression of inflammatory cytokines and extended to diabetic-induced peripheral neuropathy in mice.

Mice receiving benztropine alone presented a lower tumor growth when compared to untreated

43 animals and synergized the anti-tumoral effect of oxaliplatin, a phenomenon explained at least in
44 part by benztropine-induced ROS imbalance in tumor cells.

45 This report shows that blocking muscarinic receptors with benztropine prevents peripheral
46 neuropathies and increases the therapeutic index of oxaliplatin. These results can be rapidly
47 transposable to patients as benztropine is currently indicated in Parkinson's disease in the United
48 States.

49

50 **Introduction**

51 Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and long lasting side effect caused
52 by diverse anticancer agents that damage sensory and/or motor nerves. CIPN occurs in 30–70% of
53 patients treated with specific categories of anticancer agents ¹. Symptoms of CIPN include
54 numbness, pain, burning, tingling, heat/cold hyperalgesia, and mechanical allodynia, as well as
55 reduced motor function. CIPN commonly presents a “stocking-glove” distribution with the most
56 distal portions of the limb exhibiting the greatest deficits ². These symptoms usually begin after
57 multiple doses of the chemotherapeutic agents, and progress as treatment continues. After the
58 treatments end, they can resolve in a short time period, or persist as an after-effect of cancer
59 therapy.

60 Oxaliplatin-associated CIPN is the most frequent cause of interruption of an otherwise successful
61 therapy ³. About 12% to 18% of patients experience the highest grade 3 CIPN evaluated on the
62 National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE)
63 scale ^{4,5}, when persistent neuropathy graded more than 2 usually results in complete discontinuation
64 of the chemotherapy.

65 Oxaliplatin is a platinum compound indicated in solid tumor cancers ^{6,7}, which induces peripheral
66 neuropathies of two forms: an acute but reversible form ⁸ which manifests within hours following
67 the first infusion and a chronic form that occurs following cumulative high doses of the drug and is
68 non-reversible ⁹. Several clinical manifestations characterize this condition, but hallmark symptoms
69 include persistent distal chronic paresthesia, allodynia and thermoalgesia. Indeed, the severity of the
70 pain endured by some patients may require treatment arrest, rendering this neuropathy a limiting-
71 factor for this chemotherapy.

72 The mechanisms behind the neurotoxicity of chemotherapy are complex and are not fully
73 understood ^{10,11}. Neurotoxicity may be due to chemotherapy interactions with DNA, mitochondrial
74 perturbations, ion channel dysregulations, reactive oxygen balance modifications, kinases and / or
75 glutamatergic neurotransmission dysfunction. The lesions can occur at the level of the dorsal root
76 ganglia (DRG), at the level of the sensory neurons, associated with defects of axonal transport
77 related to the microtubules or to degeneration of the axon. They may also affect Schwann cells by
78 inducing dedifferentiation and mitochondrial ¹² and satellite cell ¹³ dysfunction. The complexity of
79 the involved mechanisms partly explains the lack of effective treatments to prevent CIPN.

80 Diabetic neuropathies (DN) are similar in their anatomo-pathological features to oxaliplatin-induced
81 peripheral neuropathies, as they involve demyelination, axonal swelling and reduced cutaneous
82 nerve fiber density ^{14,15}. A progressive development with sensory loss, pain and autonomic
83 dysfunction are common symptoms ¹⁶. Pathologically, DN is characterized by interrelated
84 metabolic abnormalities with insulin deficiency and hyperglycemia as the initiating culprits ¹⁶. The
85 neuropathy accompanying type 2 DM (insulin resistance) and type 1 DM (insulin deficiency)

86 appears to differ, the former showing a milder axonal involvement and segmental myelin
87 breakdown, whereas the latter shows a more severe axonal atrophy and axonal loss. The disorder
88 does not only involve somatic peripheral nerves but also autonomic and central nerve tracts. Today
89 no successful therapy exists for DN.

90 In both CIPN¹³ and DN¹⁶, myelin-forming Schwann cells of the peripheral nervous system are
91 crucial for the proper function and maintenance of peripheral nerves. Schwann cells wrap around
92 axons and thereby provide insulation, acceleration of electric signal propagation, and axonal
93 protection and maintenance. Schwann cells are the main effectors for regeneration in a variety of
94 peripheral neuropathic conditions¹⁷⁻¹⁹, including inherited, inflammatory, toxic (e.g. CIPN), and
95 DN, as well as traumatic injuries to peripheral nerve fibers.

96 Over the last two decades, fundamental progress have been made in understanding the molecular
97 basis of Schwann cells biology with potential clinical applications in peripheral nerve disorders.
98 Benztropine, an inhibitor of acetylcholine (ACh) muscarinic M1 and M3 receptors (mAChR), has
99 been shown to promote oligodendrocyte precursor cells differentiation while allowing greater
100 axonal remyelination than molecules currently prescribed to multiple sclerosis patients²⁰.
101 Interestingly, M3 and M1 mAChR are also expressed on peripheral myelin forming Schwann cells
102 but their roles in the myelination process remain unclear.

103 Muscarinic acetylcholine receptors are widely expressed both in the central and peripheral nervous
104 system, and are involved in relevant physiological processes like myelination and modulation of
105 nociceptive stimuli^{21,22}. Indeed, M1 and M3 muscarinic receptors agonist can block M channels
106 thus increasing neuronal excitability, by contrast muscarinic M1 and M3 receptor antagonists can
107 activate M channels and attenuate the discharge of sensory A δ or C-fibers induced by heat
108 stimulation. Interestingly, flupirtine, an M channel enhancer has been shown to reduce oxaliplatin-
109 induced peripheral nerve hyperexcitability²³. Moreover the expression of muscarinic receptors in
110 leucocytes has been known since early 1970s, their activation can modulate the inflammatory
111 responses^{24,25}.

112 Targeting a particular pathway to prevent CIPN must be considered with caution, since additional
113 treatments may directly or indirectly favor tumor growth or dissemination. Interestingly, in the case
114 of muscarinic receptor blockade, several studies have highlighted the potential of targeting M3
115 muscarinic receptors to prevent tumor growth and metastases^{26,27}. Furthermore, ACh-induced
116 tumorigenesis has been reported in several organs that are commonly treated with oxaliplatin^{26,28}.
117 In addition, the differential distribution between mAChR subtypes could allow the specific targeting
118 of tumor cells.

119 These observations of potential for both preventing neurotoxicity by promoting axonal protection as
120 well as increasing the efficacy profile of neurotoxic chemotherapies, prompted us to investigate the
121 effects of the mAChRs inhibitor, benztropine, associated with oxaliplatin, in vitro and in vivo on
122 CIPN, DN and tumor growth.

123

124 **Results**

125 ***In vivo* effects of oxaliplatin and benztropine on mouse cold hyperalgesia**

126 To determine whether benztropine could abrogate oxaliplatin-induced peripheral neuropathy, cold
127 hyperalgesia was evaluated in oxaliplatin-exposed mice treated or not with benztropine. After
128 oxaliplatin cycle 1, the mean number of brisk lifts was over twice as high in oxaliplatin-treated mice

129 than in animals injected with vehicle alone (26.57 ± 2.45 with oxaliplatin *versus* 11.43 ± 1.13 with
 130 vehicle, $p = 0.0001$). The same changes were observed after the second injection of oxaliplatin
 131 (17.43 ± 1.70 with oxaliplatin *versus* 11.29 ± 0.84 with vehicle, $p = 0.0071$). Association with
 132 benztropine rescued this hyperalgesia from the first injection of oxaliplatin (17.71 ± 2.76 with
 133 oxaliplatin plus benztropine *versus* 11.43 ± 1.13 with vehicle, $p = 0.0566$) (Fig. 1).




Figure 1. *In vivo* effects of oxaliplatin and benztropine on mouse cold hyperalgesia. Evaluation of hyperalgesia required two 5-day cycles of daily oxaliplatin (3 mg/kg). Control mice received either oxaliplatin or vehicle alone. Cold hyperalgesia was evaluated using a cold plate set at +2°C. Data are expressed as means \pm SEM of 7 different mice under each condition. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ *versus* vehicle.

134 ***In vivo* effects of oxaliplatin and benztropine on mouse cold and tactile hypoesthesia**

135 In addition to acute cold hyperalgesia, patients treated with oxaliplatin also suffer from permanent
 136 pathological thermal and tactile perception at their extremities. Mice injected with 10 mg/kg
 137 oxaliplatin developed diminished tactile perception from week 3 of treatment (0.2419 ± 0.0687 with
 138 oxaliplatin *versus* 0.0625 ± 0.0107 with vehicle, $p = 0.0151$) with a peak tactile hypoesthesia
 139 observed at the end of the testing period (at week 6, 0.7225 ± 0.0973 with oxaliplatin *versus* 0.1188
 140 ± 0.0348 with vehicle, $p < 0.0001$). Mice treated with benztropine associated with the
 141 chemotherapy did not display these symptoms of altered tactile hypoesthesia at week 3 ($0.1515 \pm$
 142 0.0704 with oxaliplatin plus benztropine *versus* 0.0625 ± 0.0107 with vehicle, $p = 0.2212$) nor at
 143 any time point during the experiment (at week 6, 0.1575 ± 0.0458 with oxaliplatin plus benztropine
 144 *versus* 0.1188 ± 0.0348 with vehicle, $p = 0.5054$) (Fig. 2a). Mice injected with 10 mg/kg oxaliplatin
 145 developed reduced cold hypoesthesia from week 3 of treatment (13.13 ± 1.11 with oxaliplatin
 146 *versus* 17.25 ± 0.87 with vehicle, $p = 0.0066$). The most severe cold hypoesthesia in oxaliplatin-
 147 treated mice was observed at the end of the testing period (at week 6, 5.44 ± 0.36 with oxaliplatin
 148 *versus* 16.19 ± 0.81 with vehicle, $p < 0.0001$). Mice treated with benztropine associated with the
 149 chemotherapy did not display these symptoms of altered cold hypoesthesia at week 3 (15.56 ± 1.00
 150 with oxaliplatin plus benztropine *versus* 17.25 ± 0.87 with vehicle, $p = 0.2145$) nor at any time
 151 point during the experiment (at week 6, 13.75 ± 0.99 with oxaliplatin plus benztropine *versus* 16.19
 152 ± 0.81 with vehicle, $p = 0.0659$) (Fig. 2b).




Figure 2. *In vivo* effects of oxaliplatin and benztropine on oxaliplatin peripheral neuropathies. (a) von Frey test and (b) cold-plate test. Experimental mice received oxaliplatin (10 mg/kg) weekly and benztropine (10 mg/kg) daily for 6 weeks. Control mice received either oxaliplatin or vehicle alone. Both the von Frey and the cold-plate tests were performed on a weekly basis. Data are expressed as means \pm SEM of 8 different mice under each condition. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus vehicle.

153 ***In vivo* effects of benztropine on diabetic mouse tactile hypoesthesia and hot hyperesthesia**

154 Since peripheral neuropathies can result from causes other than oxaliplatin infusions, we sought to
 155 investigate whether benztropine could alleviate painful symptoms brought about by other etiologies.
 156 Mice models of streptozotocin (STZ)-induced diabetes are robust and well-documented²⁹. These
 157 mice develop peripheral neuropathies similar to those witnessed in diabetic patients. Diabetic mice
 158 developed diminished tactile perception from week 1 (0.1780 ± 0.0398 in diabetic mice *versus*
 159 0.0636 ± 0.0173 in non-diabetic mice, $p = 0.0168$). Peak tactile hypoesthesia in diabetic mice was
 160 observed at the end of the testing period (week 6, 1.0800 ± 0.0800 in diabetic mice *versus* $0.1950 \pm$
 161 0.0481 in non-diabetic mice, $p < 0.0001$). Diabetic mice treated with benztropine did not display
 162 these symptoms of altered tactile hypoesthesia at week 1 (0.0768 ± 0.0191 in benztropine-treated
 163 diabetic mice *versus* 0.0636 ± 0.0173 in non-diabetic mice, $p = 0.6153$) nor at any time point during
 164 the experiment (at week 6, 0.1200 ± 0.0355 in benztropine-treated diabetic mice *versus* $0.1950 \pm$
 165 0.0481 in non-diabetic mice, $p = 0.2253$) (Fig. 3a). Diabetic mice developed transient heat
 166 hyperalgesia from week 1 (7.70 ± 0.68 in diabetic mice *versus* 11.00 ± 0.75 in non-diabetic mice, p
 167 $= 0.0043$). Diabetic mice treated with benztropine did not display these symptoms of exacerbated

168 pain to the hot plate at week 1 (10.00 ± 0.97 in benztropine-treated diabetic mice *versus* $11.00 \pm$
 169 0.75 in non-diabetic mice, $p = 0.4232$) or symptoms of hot hypoalgesia at week 6 (9.90 ± 0.85 in
 170 benztropine-treated diabetic mice *versus* 9.20 ± 0.93 in non-diabetic mice, $p = 0.5849$), at which it
 171 peaked in diabetic mice (17.20 ± 1.36 in diabetic mice *versus* 9.20 ± 0.93 in non-diabetic mice, $p =$
 172 0.0001) (Fig. 3b). Benztropine corrected both thermal perception abnormalities, namely transient
 173 hot hyperalgesia and persistent hot hypoalgesia, as well as tactile hypoesthesia in diabetic mice.




Figure 3. *In vivo* effects of oxaliplatin and benztropine on diabetes-induced peripheral neuropathies. (a) von Frey test and (b) hot-plate test. Experimental diabetic mice received benztropine (10 mg/kg) daily for 6 weeks. Control mice received either benztropine or vehicle alone. Both, the von Frey as well as the hot-plate tests were performed on a weekly basis. Data are expressed as means \pm SEM of 8 different mice under each condition. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ *versus* vehicle.

174 ***In vivo* effects of benztropine on sensory and neuromuscular excitability of oxaliplatin-treated**
 175 **and diabetic mice**

176 Oxaliplatin-treated mice presented significant alterations, consistent with membrane
 177 hyperexcitability, in sensory excitability variables, compared with control animals (*i.e.*, mice
 178 injected with vehicle). In particular, the maximal CNAP amplitude was significantly reduced in
 179 oxaliplatin-treated mice compared to week 1 control mice (0.026 ± 0.012 with oxaliplatin *versus* $0.041 \pm$
 180 0.012 with vehicle, $p = 0.0137$). Associating benztropine to the chemotherapy abrogated this
 181 reduction (0.037 ± 0.009 with oxaliplatin plus benztropine *versus* 0.041 ± 0.012 with vehicle, $p =$

182 0.4060), while benztropine alone did not alter maximal CNAP (0.040 ± 0.009 with benztropine
 183 *versus* 0.041 ± 0.012 with vehicle, $p = 0.8096$) (Fig. 4a). The stimulus intensity required to give
 184 50% of maximal CNAP amplitude was also altered in mice treated with oxaliplatin (0.179 ± 0.059
 185 with oxaliplatin *versus* 0.259 ± 0.038 with vehicle, $p = 0.0041$). Associating benztropine to the
 186 chemotherapy abrogated this reduction (0.256 ± 0.024 with oxaliplatin plus benztropine *versus*
 187 0.259 ± 0.038 with vehicle, $p = 0.8090$), while benztropine alone did not alter this variable ($0.290 \pm$
 188 0.033 with benztropine *versus* 0.259 ± 0.038 with vehicle, $p = 0.0909$) (Fig. 4b). Finally, an
 189 increased latency was observed in oxaliplatin-treated mice (3.552 ± 0.202 with oxaliplatin *versus*
 190 3.163 ± 0.218 with vehicle, $p = 0.0014$). This increase was not observed when mice treated with the
 191 chemotherapy also received benztropine (3.187 ± 0.220 with oxaliplatin plus benztropine *versus*
 192 3.163 ± 0.218 with vehicle, $p = 0.8284$) or when mice received benztropine alone (3.137 ± 0.261
 193 with benztropine *versus* 3.163 ± 0.218 with vehicle, $p = 0.8230$) (Fig. 4c). It is worth noting that the




Figure 4. *In vivo* effects of oxaliplatin and benztropine on mouse sensory excitability variables. Histograms of mean values \pm SD of maximal CNAP peak amplitude (a), stimulus intensity necessary to evoke 50% of maximal CNAP amplitude (b), and latency (c) determined from recordings at the tail base in response to caudal nerve stimulation in mice treated for 6 weeks with vehicle ($n = 9$), oxaliplatin ($n = 10$), oxaliplatin plus benztropine ($n = 10$) or benztropine alone ($n = 10$). * $p < 0.05$, ** $p < 0.01$ *versus* vehicle.

194 sensory alterations detected in oxaliplatin-treated mice were consistent with a decreased nerve
 195 conduction velocity, suggesting an apparent reduction in the number of fast-conducting fibers or
 196 decrease of density and/or functioning of transient sodium channels, and a modification in the
 197 voltage dependence of these channels.

198 Oxaliplatin-treated and diabetic mice also presented significant alterations, consistent with
 199 membrane hyperexcitability, in neuromuscular (motor) excitability waveforms and derived
 200 variables, compared with animals injected with vehicle (Supplementary Fig. 1 and 2;
 201 Supplementary Table 1). These alterations mainly consisted of (i) an enhanced CMAP amplitude
 202 and a reduced stimulus intensity to evoke 50% of maximal CMAP amplitude, suggesting an
 203 apparent decreased density and/or functioning of fast potassium channels and modification in the
 204 voltage dependence of transient sodium channels, respectively, with no change in the latency, *i.e.*,
 205 no modification in the neurotransmission velocity; (ii) reduced minimum and hyperpolarizing
 206 slopes of the current–threshold relationship, indicating decreased density and/or functioning of
 207 cyclic nucleotide-gated channels; (iii) increased threshold changes in response to depolarizing
 208 and/or hyperpolarizing currents (threshold electrotonus), likely caused by reduced density and/or
 209 functioning of potassium channels; and (iv) lower superexcitability (recovery cycle), reflecting
 210 again fast potassium channel dysfunction. These alterations were not detected, or were greatly
 211 reduced, in oxaliplatin-treated and diabetic mice injected with benztropine, or in animals
 212 administered with benztropine alone.

213 ***In vitro* effects of oxaliplatin and benztropine on excitability of mouse DRG sensory neurons**

214 The *in vitro* effects of oxaliplatin, associated or not with benztropine, were assessed on the resting
 215 membrane and action potentials recorded from primary cultures of mouse DRG sensory neurons,
 216 using whole-cell patch-clamp technique (Fig. 5).

217




Figure 5. *In vitro* effects of oxaliplatin, associated or not with benztropine, on excitability of mouse DRG sensory neurons, using whole-cell patch-clamp technique. Resting membrane potential (a), and action potential peak amplitude (b), rise time (c) and decay time (d) measured from recordings performed on DRG neurons before (control) and 10-20 min after addition of first 25-50 μM oxaliplatin (O) and then 25-50 μM oxaliplatin plus 10 μM benztropine (B) to the standard physiological medium. Mean ± SD of 5-18 neurons. **p* = 0.010-0.014, ***p* = 0.002-0.005 and ****p* < 0.001 versus control.

Recordings were performed on relatively small neurons since their mean \pm SD cell diameter (determined from their membrane capacity) was $21.6 \pm 4.5 \mu\text{m}$ ($n = 18$). Under control conditions, two types of responses were recorded from neurons stimulated by 100-ms current test-pulses: a single action potential (tonic response) from 39% (7/18) of cells, and more than one action potential (phasic response) from 61% (11/18) of cells. The mean \pm SD ratio of the number of action potentials on the current intensity necessary to evoke action potentials was $0.007 \pm 0.001 \text{ pA}^{-1}$ ($n = 18$). This ratio was significantly increased ($p = 0.024$) to $0.011 \pm 0.002 \text{ pA}^{-1}$ ($n = 11$) in the presence of $50 \mu\text{M}$ oxaliplatin, due to both an increased number of action potentials in response to 100-ms current test-pulses and a decreased current intensity necessary to evoke action potentials, indicating membrane hyperexcitability of these neurons. When oxaliplatin ($50 \mu\text{M}$) was added together with benztropine ($10 \mu\text{M}$) to the standard external medium, the ratio returned to $0.005 \pm 0.002 \text{ pA}^{-1}$ ($n = 9$), *i.e.*, mean \pm SD values were not statistically different ($p = 0.148$) from those determined under control conditions. The addition of oxaliplatin (25 or $50 \mu\text{M}$) to the external medium bathing the neurons produced (i) about 20-mV membrane depolarization identified by a reduced resting membrane potential, (ii) a significant decreased peak amplitude, and (iii) significant increased rise and decay times of action potentials, compared to control conditions. These modifications, indicating alterations in the density and/or functioning of both sodium and potassium channels, were greatly reduced, if not completely reversed, when oxaliplatin was added together with benztropine ($10 \mu\text{M}$) to the external standard medium.

237 **Ex vivo effects of oxaliplatin and benztropine on mouse sciatic nerve fiber morphology and** 238 **myelin content**

The morphology of myelinated axons of mouse sciatic nerves was assessed using confocal microscopy. Quantification of morphometric parameters of single myelinated axons revealed a significant increase in the nodal diameter, length and volume, as functions of the internodal diameter, in mice injected for 6 weeks with oxaliplatin, compared to vehicle-treated animals (Fig. 6, left panels; Supplementary Table 2). These results are likely the consequence of oxaliplatin-induced




Figure 6. *Ex vivo* effects of oxaliplatin and benztropine on the morphology of myelinated axons isolated from mouse sciatic nerves, using confocal microscopy. Representations of nodal length, diameter and volume, as functions of internodal diameter, of myelinated axons isolated from mice ($n = 4$ in each group) injected with vehicle (black closed circles, $n = 137$), oxaliplatin (red closed circles, $n = 206$), oxaliplatin plus benztropine (green closed circles, $n = 150$) or benztropine alone (blue closed circles, $n = 160$) for 6 weeks. The curves represent the linear (upper and middle panels) or non-linear (lower panels) fits of data points with R^2 (correlation coefficients) between 0.441 and 0.877. In left panels, the arrows underline the effects of oxaliplatin.

244 membrane hyperexcitability. In these animals, a reduction of the internodal diameter was also
 245 observed, which may reflect either a preferential loss of large myelinated nerve fibers or an
 246 alteration in myelin sheath layers surrounding the axons. These alterations of morphometric
 247 parameters were greatly reduced, if not absent, in mice injected for 6 weeks with oxaliplatin plus
 248 benztropine (Fig. 6, middle panels; Supplementary Table 2) or benztropine alone (Fig. 6, right
 249 panels; Supplementary Table 2).

250 The myelin sheaths of sciatic nerves from experimental and control groups of mice were also
 251 assessed using electronic microscopy. Analyses revealed a demyelination in oxaliplatin-treated
 252 mice compared to animals injected with vehicle, oxaliplatin plus benztropine or benztropine alone
 253 (Fig. 7).




Figure 7. Effect of benztropine on demyelination and axonal atrophy in oxaliplatin-treated mice. (a) Representative images of EM micrographs of ultrathin cross-sections of sciatic nerves from vehicle, oxaliplatin, benztropine and oxaliplatin plus benztropine animals at 6 weeks. (b) Quantification of myelin state through g-ratio analysis reported to axonal caliber. At least 200 axons per animal (n = 2-3) were analyzed. The curves are linear regression fits of data points. * $p < 0.05$, ** $p < 0.01$.

254 Semi-automated computerized measurement of myelin thickness allowed the quantification of the
255 profound demyelination in sciatic nerves from oxaliplatin mice (0.0344 ± 0.0037 with oxaliplatin
256 *versus* 0.0233 ± 0.0023 with vehicle, $p = 0.007$). Associating benztropine to the chemotherapy
257 abrogated the reduction in myelin sheath thickness observed in oxaliplatin mice (0.0261 ± 0.0019
258 with oxaliplatin plus benztropine *versus* 0.0233 ± 0.0023 with vehicle, $p = 0.346$). Benztropine did
259 not impair myelin formation nor did it lead to excessive myelination (0.0224 ± 0.0038 with
260 benztropine *versus* 0.0233 ± 0.0023 with vehicle, $p = 0.842$).

261 **Ex vivo study of myelin protein content in sciatic nerves**

262 The myelin basic protein (MBP) expression was reduced in oxaliplatin-treated mice ($0.5825 \pm$
263 0.1014 with oxaliplatin *versus* 0.7125 ± 0.1409 with vehicle, $p = 0.4823$), while co-administration
264 of benztropine with the chemotherapy rescued this reduced expression of this key myelin protein
265 (0.6767 ± 0.1172 with oxaliplatin plus benztropine *versus* 0.7125 ± 0.1409 with vehicle, $p =$
266 0.8603). It is worth nothing that MBP expression was identical in mice receiving benztropine alone
267 and control animals (0.7075 ± 0.2781 with benztropine *versus* 0.7125 ± 0.1409 with vehicle, $p =$
268 0.8603) (Fig. 8).




Figure 8. Effect of benztropine on MBP expression in the sciatic nerves of oxaliplatin-treated mice. Western blot analyses of total protein lysates from brain sciatic nerves of control, and treated mice. (a) panel shows detection of MBP and (b) panel shows anti- β -actin for loading control. NS: non-significant.

269 **Ex vivo effects of oxaliplatin and benztropine on mouse cutaneous nerve fiber density**

270 The density of cutaneous nerve fibers was examined in the paws of mice injected with vehicle,
271 oxaliplatin, oxaliplatin plus benztropine or benztropine alone for 6-8 weeks (Fig. 9). Staining of the
272 nerve fibers with PGP9.5 antibody revealed a reduced cutaneous nerve fiber density in paw skin of

273 oxaliplatin-treated mice (7.67 ± 0.99 with oxaliplatin *versus* 16.33 ± 1.87 with vehicle, $p = 0.0022$).
 274 Benztropine abrogated this alteration in oxaliplatin-treated mice since the density of PGP9.5-stained
 275 nerves was maintained in these animals (13.50 ± 1.56 with oxaliplatin plus benztropine *versus*
 276 16.33 ± 1.87 with vehicle, $p = 0.2728$). Benztropine alone did not alter cutaneous nerve fiber’s
 277 integrity (15.00 ± 2.85 with benztropine *versus* 16.33 ± 1.87 with vehicle, $p = 0.7042$).




Figure 9. Effect of benztropine cutaneous nerve fiber density reduction induced by oxaliplatin. (a) Representative images of staining with PGP9.5 of cutaneous nerve fibers. (b) Analysis of cutaneous nerve fiber density from paw skin samples (6 μ m) of mice treated for 6 weeks with vehicle, oxaliplatin, oxaliplatin plus benztropine or benztropine alone. Mean \pm SEM of 8 mice. * $p < 0.05$, ** $p < 0.01$. NS: non-significant. Scale bar = 50 μ m.

278 **Ex vivo effects of oxaliplatin and benztropine on systemic inflammatory markers**

279 In order to evaluate the systemic effects of benztropine on pro-inflammatory cytokine levels, serum
 280 samples were analyzed (Fig. 10). Sera IL-6 levels were significantly increased in the oxaliplatin-

281 treated group (21.14 ± 1.07 ng/mL with oxaliplatin *versus* 15.87 ± 1.27 ng/mL with vehicle, $p =$
 282 0.0034). Associating benztropine to the chemotherapy prevented this systemic inflammation (16.97
 283 ± 0.81 ng/mL with oxaliplatin plus benztropine *versus* 15.87 ± 1.27 ng/mL with vehicle, $p =$
 284 0.4674 , and *versus* 21.14 ± 1.07 ng/mL with oxaliplatin, $p = 0.0042$). Benztropine alone did not
 285 induce any changes in IL-6 levels (15.12 ± 1.28 ng/mL with benztropine *versus* 15.87 ± 1.27 ng/mL
 286 with vehicle, $p = 0.6829$) (Fig. 10a). Sera TNF- α levels were also significantly increased in the
 287 oxaliplatin-treated group compared to the control group (84.18 ± 6.86 pg/mL with oxaliplatin
 288 *versus* 58.36 ± 7.27 pg/mL with vehicle, $p = 0.0150$). Similar to its effects on IL-6 levels,
 289 benztropine also prevented the significant increase in TNF- α levels observed in oxaliplatin-treated-
 290 animals (54.36 ± 5.17 pg/mL with oxaliplatin plus benztropine *versus* 58.36 ± 7.27 pg/mL with
 291 vehicle, $p = 0.6570$, and *versus* 84.18 ± 6.86 pg/mL with oxaliplatin, $p = 0.0016$). Benztropine on
 292 its own induced a slight, but non-significant, decrease in TNF- α levels (47.30 ± 5.17 pg/mL with
 293 benztropine *versus* 58.36 ± 7.27 pg/mL with vehicle, $p = 0.2246$) (Fig. 10b).




Figure 10. Sera inflammatory markers. (a) ELISA-quantified levels of IL-6 in sera from mice treated for 6 weeks with vehicle, oxaliplatin, oxaliplatin plus benztropine or benztropine alone. (b) ELISA-quantified levels of TNF- α in sera from mice treated for 6 weeks with vehicle, oxaliplatin, oxaliplatin plus /benztropine or benztropine alone. Data are mean \pm SEM of 8 mice. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ *versus* vehicle. NS: non-significant.

294 ***In vivo* effects of benztropine on oxaliplatin-induced tumor growth in mice**

295 Results obtained from neurological tests provided a rationale to use benztropine as a
 296 neuroprotective drug. However, further data regarding its effect on oxaliplatin efficacy had to be
 297 gathered to guarantee its safety in addressing the primary aspect of the condition which is tumor
 298 growth (Fig. 11). From day 6 of treatment, benztropine displayed antitumor efficacy upon

299 association with oxaliplatin (tumor size of $333.5 \pm 42.3 \text{ mm}^3$ with oxaliplatin plus benztropine
 300 *versus* $832.1 \pm 105.8 \text{ mm}^3$ with vehicle, $p = 0.0009$). Moreover, from day 6 treatment, benztropine
 301 potentiated the chemotherapy response (tumor size of $333.5 \pm 42.3 \text{ mm}^3$ with oxaliplatin plus
 302 benztropine *versus* $624.8 \pm 69.8 \text{ mm}^3$ with oxaliplatin, $p = 0.0039$), while oxaliplatin alone had not
 303 yet demonstrated antitumor efficacy (tumor size of $624.8 \pm 69.8 \text{ mm}^3$ with oxaliplatin *versus* 832.1
 304 $\pm 105.8 \text{ mm}^3$ with vehicle, $p = 0.1279$). At the end of the experiment, when the largest tumors had
 305 reached ethical guidelines' endpoint, mice which received benztropine associated with oxaliplatin
 306 presented the lowest tumor burden ($687.5 \pm 103.3 \text{ mm}^3$ with oxaliplatin plus benztropine *versus*
 307 $4721.0 \pm 560.0 \text{ mm}^3$ with vehicle, $p < 0.0001$). In addition, mice which received benztropine alone
 308 displayed smaller, although non-significant, tumors compared to control mice ($4132.0 \pm 522.8 \text{ mm}^3$
 309 with benztropine *versus* $4721.0 \pm 560.0 \text{ mm}^3$ with vehicle, $p = 0.4571$).




Figure 11. Benztropine prevents tumor growth and displays a synergistic antitumoral effect when associated with oxaliplatin in an ectopic model of colorectal cancer. Tumor size in mice injected subcutaneously into the back with 106 CT26 cells and treated with vehicle, oxaliplatin, oxaliplatin associated with benztropine or benztropine alone. Data are mean \pm SEM of 8 tumor volume under each condition. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ *versus* vehicle.

310 ***In vitro* effects of oxaliplatin associated or not with benztropine on cultured cell viability**

311 The *in vitro* neuroprotective potential of benztropine on oxaliplatin-induced peripheral neuropathies
 312 was assessed on N2a neuron-like cells. The effects of benztropine on oxaliplatin-induced anti-tumor
 313 effect were also evaluated *in vitro* on CT26 colon carcinoma cell lines. Our results indicate that
 314 oxaliplatin has a cytotoxic effect on both N2a and CT26 cells. Benztropine modulates cell viability
 315 in a cell-type-dependent manner. Benztropine potentiated oxaliplatin cytotoxicity on CT26 cells
 316 (Fig. 12a). Inversely, in benztropine-treated neuron-like N2a cells, the cytotoxicity of oxaliplatin
 317 was reduced with a viability increased from 56% without benztropine to 70% with benztropine (Fig.
 318 12b). Moreover, in cells treated with $6.25 \mu\text{M}$ oxaliplatin, co-incubation with $15 \mu\text{M}$ of benztropine
 319 induced a significant decrease of GSH in CT26 cells (2141 ± 120 *versus* 2931 ± 142 in untreated cells,
 320 $p < 0.05$, Fig. 12c) but a significant increase of GSH in N2a (18344 ± 634 *versus* 11355 ± 934 in
 321 untreated cells, $p < 0.001$, Fig. 12d). ROS production evidenced by H2DCFDA staining was
 322 stimulated in both cell types treated with oxaliplatin. However, benztropine at a concentration of 7.5
 323 and $15 \mu\text{M}$ decreased oxaliplatin-induced ROS production in N2a cells ($p < 0.05$) (Fig. 12f) and, in

324 contrast, 15 μ M of benztropine increased oxaliplatin-induced ROS production in CT26 cells
 325 ($p < 0.05$ to $p < 0.01$) (Fig. 12e).




Figure 12. *In vitro* effects of oxaliplatin associated or not with benztropine on cell viability, GSH and ROS production. Viability was expressed as percent \pm SEM *versus* cells in culture medium alone (100% viability) in CT26 cells (a) and N2a cells (b). GSH was measured using the monochlorobimane dye in CT26 cells (c) and N2a cells (d). ROS generation was measured using H2DCFDA fluorescent emission when converted to the highly fluorescent DCF in CT26 cells (e) and N2a cells (f). Data from at least 4 independent experiments have been pooled and were expressed as means \pm SEM of triplicates. * $p < 0.05$, ** $p < 0.01$ *versus* oxaliplatin.

326 Discussion

327 Peripheral neuropathy is one of the most prevalent neurologic conditions encountered by physicians
 328 of all specialties³⁰ and is frequently associated with viral, toxic or metabolic etiologies³¹. Despite
 329 its high prevalence, no efficient curative treatment is available to decrease peripheral neuropathic
 330 pain and disability³². In this report, we demonstrate that benztropine, an inhibitor of acetylcholine
 331 (ACh) muscarinic M1, M2 and M3 receptors (mAChR)²⁰, improves both acute and chronic clinical
 332 symptoms of experimental peripheral neuropathies in mice induced either by treatment with the
 333 chemotherapeutic drug oxaliplatin {Citation} or with streptozotocin (STZ) in a model of diabetes-
 334 induced peripheral neuropathy^{29,33}.

335 In order to better understand the mechanisms of this protection at neuronal levels, we performed
336 electrophysiological tests to evaluate sensory and neuromuscular excitability. Oxaliplatin-treated
337 mice presented significant reductions of the maximal CNAP amplitude and of the stimulus intensity
338 required to give 50% of maximal CNAP as well as an increase in latency, both these signs being
339 associated with membrane hyperexcitability. The sensory alterations detected in oxaliplatin-treated
340 mice were consistent with a decreased nerve conduction velocity, suggesting an apparent reduction
341 in the number of fast-conducting fibers or a decrease of density and/or functioning of transient
342 sodium channels, and a modification in the voltage dependence of these channels. These alterations
343 were all prevented by treatment with benztropine. The *in vitro* effects of oxaliplatin on the resting
344 membrane and action potentials recorded from primary cultures of mouse DRG sensory neurons
345 using whole-cell patch-clamp showed modifications characteristic of alterations in the density
346 and/or functioning of both sodium and potassium channels. These alterations were greatly reduced,
347 if not completely reversed, when the anticancer agent was added together with benztropine (10 μ M)
348 to the external standard medium.

349 Oxaliplatin is known to exhibit a tetrodotoxin-like inhibitory effect on neuronal voltage-gated
350 sodium (Na⁺) channels^{34–36}. It remarkably slows their inactivation and reduces the peak Na⁺
351 current, leading to an increase in the duration of the relative refractory period of sensory neurons
352 that become hyperexcitable. Oxaliplatin may also affect the Na⁺ channels indirectly *via* the
353 chelation of extracellular calcium ions by its metabolite oxalate (diaminocyclohexane-platinum-
354 C2O4)³⁴. Peripheral nerve axonal excitability studies performed after oxaliplatin administration *in*
355 *vivo* have revealed acute abnormalities in sensory nerve function related to Na⁺ channel
356 dysfunction, including decreased refractoriness and increased superexcitability³⁷. The effects of
357 oxaliplatin on the Nav1.6 voltage-gated Na⁺ channel isoforms have been associated with the
358 development of unique neuropathy symptoms such as cold-aggravated peripheral pain^{38,39}. In rat
359 hippocampal neurons, muscarinic receptor agonists modulate Na⁺ channel activity through
360 activation of PKC⁴⁰. In the periphery, the implication of PKC activation in nociceptive neurons has
361 been largely studied and linked to hyperexcitability and hyperalgesia through upregulation of both
362 Nav1.8 and Nav1.9^{41,42}. Blocking PKC by muscarinic antagonists could be relevant to prevent
363 peripheral neuropathies, as PKC inhibition has been shown to prevent hyperalgesia in an *in vivo*
364 model of diabetic neuropathy⁴³.

365 Kagiava et al⁴⁴ suggested that altered voltage-gated potassium channel activity may also be
366 involved in oxaliplatin-induced neurotoxicity. Oxaliplatin was found to cause broadening of action
367 potentials and repetitive firing, suggesting its antagonistic effect on fast and slow neuronal
368 potassium channels. Many sensory neurons in rat dorsal root ganglia express Kv7.2, Kv7.3 and
369 Kv7.5. These channels are known as M channels and are closed by receptors coupled to Gq such as
370 M1 and M3 muscarinic receptors. This blockade increases neuronal excitability and underlies some
371 forms of cholinergic excitation. By contrast, their activation attenuates sensory A δ and C-fiber
372 discharges induced by heat stimulation when applied to the *peripheral* endings of sensory fibers in
373 the isolated rat skin nerve preparation⁴⁵, and increases the threshold for C-fiber stimulation in
374 human sural nerves⁴⁶. These experiments clearly demonstrate the presence of Kv7/M-channels at
375 various sites along the sensory neuraxis and also indicate the therapeutic potential of enhancing
376 their activity⁴⁷. Interestingly, Sittl et al²³ showed that enhancement of axonal potassium
377 conductance by flupirtine, a Kv7/M-channel enhancer could reduce oxaliplatin-induced peripheral
378 nerve hyperexcitability, supporting our findings that blockade of muscarinic receptor M1 and M3
379 by benztropine can produce the same effects.

380 Oxaliplatin-treated and diabetic mice also presented significant alterations, consistent with

381 membrane hyperexcitability, in neuromuscular (motor) excitability waveforms and derived
382 variables, compared with animals injected with vehicle, suggesting an apparent decreased density
383 and/or functioning of fast potassium channels and modification in the voltage dependence of
384 transient sodium channels, respectively; decreased density and/or functioning of cyclic nucleotide-
385 gated channels; reduced density and/or functioning of potassium channels. These alterations were
386 not detected, or were greatly reduced, in oxaliplatin-treated and diabetic mice injected with
387 benztropine, or in animals administered with benztropine alone. At the neuromuscular levels,
388 oxaliplatin has been shown to increase both evoked and spontaneous neurotransmitter release in the
389 motor nerve terminal of a phrenic nerve hemidiaphragm preparation ³⁵. The hyperexcitability
390 effects of oxaliplatin on the mammalian neuromuscular junction appear related to a mechanism
391 which delays entry of Na⁺ channels into an inactivated state and, to a lesser extent, to a reduced K⁺-
392 channel activity, both of which can be prevented by benztropine.

393 Electronic microscopy of the myelin sheaths of the sciatic nerves revealed a demyelination in
394 oxaliplatin-treated mice compared to animals injected with vehicle alone, oxaliplatin plus
395 benztropine or benztropine alone. Confocal microscopy of mouse sciatic nerves confirms the
396 alteration of the morphology of myelinated axons with a significant increase in the nodal diameter,
397 length and volume, as functions of the internodal diameter, in oxaliplatin-treated mice compared to
398 vehicle-treated animals. These results are likely the consequence of oxaliplatin-induced membrane
399 hyperexcitability as previously described ³⁶. In these animals, a reduction of the internodal diameter
400 was also observed, which may reflect either a preferential loss of large myelinated nerve fibers or
401 an alteration in myelin sheath layers surrounding the axons. The drop in MBP expression in
402 oxaliplatin-treated animals confirmed the severe reduction of neuron myelination in DRG and
403 sciatic nerves. These alterations of morphometric parameters were greatly reduced, if not absent, in
404 mice co-injected with oxaliplatin and benztropine. In a recent study, Imai and coworkers ¹² showed
405 that treatment with oxaliplatin induced cytotoxicity of myelin-forming Schwann cells accompanied
406 by mitochondrial dysfunction at concentrations lower than those impairing DRG neurons. These
407 direct effects of oxaliplatin on Schwann cells might be an underlying cause of CIPN in addition to
408 its direct toxicity in peripheral neurons. Schwann cells express muscarinic receptors M1, M2, M3,
409 and M4 ^{48,49} and localize to the axon-Schwann cell boundary ⁵⁰. Activation of AChR on Schwann
410 cells modified the myelin sheet by altering the viscosity of the myelin membrane ⁵¹ that can be
411 prevented by muscarinic receptor antagonists.

412 A severe reduction in the number of cutaneous nerve fibers is frequently observed in humans and
413 mice treated with oxaliplatin as a result of neuronal toxicity of the platinum compound.
414 Interestingly, benztropine also prevented the drop in neuronal density in the paws of mice injected
415 with oxaliplatin. It has recently been demonstrated that neurite outgrowth is controlled by
416 muscarinic receptors through regulation of mitochondrial function. M1R-deficient mice rendered
417 diabetic with STZ are protected from physiological and structural indices of sensory neuropathy and
418 pharmacological blockade of M1R using antimuscarinic drugs prevented or reversed indices of
419 diabetic or chemotherapy-induced peripheral neuropathy ⁵².

420 Proinflammatory cytokines like TNF α or IL-6 contribute to axonal damage, alteration of the myelin
421 structure and voltage dependent channel integrity but also modulate spontaneous nociceptor
422 sensitivity and activity by increasing Na⁺ and Ca²⁺ currents at the nociceptor peripheral terminals,
423 which results in an increased membrane excitability, and a reduction in pain threshold and
424 peripheral sensitization ^{53,54,55}. The pain sensation in distal extremities has been attributed to
425 dysfunction of small myelinated A δ or unmyelinated C-fibers ^{56,57}. Sensitizing uninjured adjacent

426 nerve fibers (nociceptors) or sensory neurons by proinflammatory cytokines plays a critical role in
427 the development of the chemotherapy- and diabetic-induced painful peripheral neuropathy as
428 evidenced by numerous clinical and experimental studies^{55,58}. Indeed, following intravenous
429 administration of chemotherapy drugs, an important activation of Schwann cells along with a
430 massive infiltration of activated macrophages in the DRG and in peripheral nerves leads to a
431 subsequent production and secretion of inflammatory cytokines like TNF α , IL-1 β and IL-6;
432 promoting neuroinflammation with allodynia and hyperalgesia⁵⁹. Injection of an anti-IL-6
433 neutralizing antibody alleviated pain-related behaviors^{60,61} and a recent clinical study reported that
434 IL-6 levels were significantly higher after the conclusion of chemotherapy in breast cancer patients
435 with CIPN than in those without CIPN, providing the first clinical evidence of the involvement of
436 IL-6 in CIPN⁶². In diabetes, an enhanced expression of the NF- κ B-derived cytokine TNF α in the
437 sciatic nerve of diabetic rats and mice was associated with decreased expression of myelin basic
438 protein and with both large and small nerve fiber dysfunction, as documented by reductions in the
439 motor and sensory nerve conduction velocities and in the intraepidermal nerve fiber density in the
440 diabetic animals⁶³. These neuronal dysfunctions were all reverted by blocking TNF with a
441 recombinant human TNF receptor–antibody fusion protein⁶⁴. Interestingly, neurons and immune
442 cells, especially macrophages, express all five muscarinic²⁵ receptors and their stimulation promotes
443 a pro-inflammatory reaction while blocking the M1, M2 and M3 receptors has been shown to
444 reduce the synthesis of the pro-inflammatory cytokines IL-6 and TNF α ²⁴.

445 In addressing the primary aspect of the condition, which is tumor growth, we found that mice
446 receiving benztropine alone had a reduced size of tumors compared to untreated animals and when
447 associated with oxaliplatin presented the lowest tumor burden compared to mice treated with
448 oxaliplatin alone. These data are in line with the role of muscarinic receptors on tumor growth and
449 especially on colon cancer progression. Indeed, the levels of expression and activation of M3
450 muscarinic receptors in colon cancer cells are very high and associated with increased tumor cell
451 proliferation by activation of the MAPKinase pathways and invasiveness by increasing MMP1
452 release. All of these effects are reduced by M3R antagonists⁶⁵.

453 Benztropine exerts an original effect on neuronal cells by increasing the level of reduced
454 glutathione thus reducing ROS levels induced by oxaliplatin and cell death. Blocking muscarinic
455 receptors has already been associated with a reduction in ROS release, prevention of glutathione
456 depletion and enhanced viability in various normal non tumoral cell types⁶⁶. By contrast,
457 benztropine potentiates the cytotoxic effect of oxaliplatin on tumor cells via a drop in GSH level
458 and an increase in H₂O₂ production, in line with the capacity of benztropine to reduce neuronal
459 toxicity while maintaining the anti-tumor efficacy of oxaliplatin. Activation of the M1 muscarinic
460 receptor by various agonists decreases SOD activities and induces superoxide anion production in
461 neuronal cells⁶⁷. Interestingly, superoxide anions have been shown to be particularly cytotoxic for
462 neurons upon exposure to oxaliplatin, as superoxide dismutase mimics prevent oxaliplatin-induced
463 neuropathies while increasing the anti-tumoral effect of the chemotherapy on colon cancer cells⁶⁸.
464 SOD increase by M1 blockade leads to superoxide anions dismutation into H₂O₂, whose
465 cytotoxicity towards tumor cells adds up to that of oxaliplatin. The differences observed between
466 normal and tumor cells fate upon oxaliplatin and benztropin exposure can be related to their
467 different basal levels of GSH and responses towards a H₂O₂-mediated stress^{69–72}. Tumor cells are
468 more sensitive to ROS-induced cell death than normal cells due to increased metabolism of tumor
469 cells and antioxidant defense exhaustion. Indeed, in normal cells, similar levels of H₂O₂ that kill
470 tumor cells favor cellular viability and proliferation through adaptation and mobilization of
471 antioxidant defenses, usually through NRF2 induction⁷³. Furthermore, GSH homeostasis is of prime

472 importance for neurons as their depletion in this antioxidant molecule ultimately leads to their
473 senescence mediated by oxidative stress⁷⁴. Several studies concur with the observation that GSH-
474 mediated detoxification of H₂O₂ is paramount to address neurologic disorders, may they be central
475 or peripheral^{75,76}. In clinical settings, GSH infusions significantly reduce the severity of the
476 neurodegenerative side effects of oxaliplatin⁷⁷.

477 A limitation of this study is that results have been gained in animals only. However, the literature
478 indicates that murine models of peripheral neuropathies are robust models for modeling human
479 neuropathy^{38,78}. Indeed, the components of this murine neurodegeneration are also observed in
480 humans and the neuroprotection conferred by molecules on these models is also observed in
481 humans^{68,79}. This observation leads us to believe that the neuroprotection conferred by benzotropine,
482 which is currently indicated in Parkinson's disease in the United States, could be transposable to
483 patients suffering from peripheral neuropathies. These very encouraging results for benzotropine
484 deserve to lead to a study in humans in order to be able to address a problematic with clinical
485 relevance. The results of this clinical trial could lead to the exploration of benzotropine as a
486 potentially neuroprotective agent in other pathologies of the PNS.

487

488 **Competing interests:** Tânia Cristina Gonçalves was an employee of Sanofi (and a Sanofi
489 shareholder via participation/profit-sharing) when these studies were conducted. All other co-
490 authors declare no conflict of interest.

491 **Acknowledgments:** The authors would like to thank Dr. Pierre Billuart for his expertise in
492 perfusing the mice and kind advice. The authors are also very grateful to Dr. Thomas Guilbert for
493 having created a macro allowing us to systematically measure the G-ratios on the sections of
494 electron microscopy.

495

496 **Materials and Methods**

497 **Cell culture and treatments**

498 CT26 (mouse colon carcinoma) cells, purchased from the ATCC (CRL-2638), were grown in
499 Dulbecco's Modified Eagle Medium (Gibco, Sigma-Aldrich) with 10% FBS (Gibco, Sigma-
500 Aldrich), penicillin/streptomycin, and L-glutamine supplementation. N2a (mouse brain
501 neuroblastoma) cells, purchased from the ATCC (CCL-131), were grown in Eagle Minimum
502 Essential Medium supplemented with 10% FBS, penicillin/streptomycin, 2% sodium pyruvate, 1%
503 ciprofloxacin, non-essential amino acids, and L-glutamine supplementation.

504 **Animal models and treatments**

505 Five-week-old male BALB/cJRj mice were purchased from Janvier Laboratory (Le Genest Saint
506 Isle, France). All mice were housed in ventilated cages (n = 7 to 10 animals per cage) with sterile
507 food and water *ad libitum* and were exposed to a standard light cycle of 12 h on and 12 h off. All
508 experiments were performed in accordance with European and French institutional guidelines
509 (Directive 2010/63/EU, Ethics committee CEEA 34 – APAFIS authorization #8394).

510 **Model of oxaliplatin-induced peripheral neuropathies**

511 Both models of oxaliplatin-induced peripheral neuropathies, namely, the acute form and the chronic
512 form were induced by protocols with timeframes that were analogous to the clinical protocols
513 which results in the induction of either of these forms in patients, and were previously used in mice.

514 The acute form of oxaliplatin peripheral neuropathy was induced by daily low doses intraperitoneal
515 injections of oxaliplatin [Accord, 5 mg/mL IV solution, 3 mg/kg diluted in phosphate-buffered
516 saline (PBS 1X)] for 5 days followed by 5 days of rest, for 2 cycles^{68,80}. The chronic form of
517 oxaliplatin peripheral neuropathy mice was induced by intraperitoneal injections of first, oxaliplatin
518 (10 mg/kg diluted in PBS) once a week for 6-8 weeks^{68,81}. In both models of oxaliplatin-induced
519 peripheral neuropathies, benztropine was administered 5 days a week intraperitoneal injections (10
520 mg/kg diluted in PBS)²⁰, 6h after oxaliplatin injections.

521 **Model of streptozotocin-induced diabetic peripheral neuropathies**

522 Poor survival over the course of preliminary tests was observed with a 3-h food withdrawal before
523 and after a single dose of 200 mg/kg of Streptozotocin (STZ)⁸². This dose was therefore lowered to
524 180 mg/kg (dissolved in 10 mmol/L sodium citrate buffer, pH 4.5) with 3-h food fasting before and
525 after the injection. STZ was diluted to allow a final volume of 0.1 mL/10 g body weight for
526 intraperitoneal injections. One week after STZ injection, diabetes was confirmed by blood glucose
527 levels using a Cobas 8000 modular analyzer (Roche) in blood samples taken under isoflurane 2,5%
528 (Isovet, #ISO005, Centravet, Plancoët, France) from mice retro-orbital sinus. Mice with blood
529 glucose levels ≥ 12 mM were considered diabetic and included in the study²⁹. Benztropine was
530 administered 5 days a week intraperitoneal injections (10 mg/kg diluted in PBS)²⁰, 6h after
531 oxaliplatin injections.

532 **Behavioral studies**

533 Prior to baseline measurements for every behavioral test, mice underwent 2 weeks of acclimation
534 sessions with the specific training protocols to familiarize them with the experimental environments
535 and testing procedures, without probing with plastic fibers nor temperature setting. Before each
536 behavioral test, mice were allowed to acclimate to the experimental room for 10 minutes in their
537 home cages. Mice were only tested once on any given test day to avoid any possible stress,
538 anesthetic or tissue damage effects that could result from repeated exposure to the cold surface.

539 ***In vivo* cold hyperalgesia**

540 Mice from the acute model of oxaliplatin-induced peripheral neuropathies were subjected to weekly
541 tests for cold hyperalgesia. Mice were put on a cold/hot plate (Ugo Basile, Comerio, Italy) set at the
542 temperature of $2^{\circ}\text{C} \pm 0.2^{\circ}\text{C}$ ⁸³. The total number of brisk lifts from either hind paw or jumps,
543 considered as a painful response to cold, was counted simultaneously by two observers to ensure
544 accuracy and averaged for the two observers' counts. A maximal cut-off time of 5 minutes was
545 imposed to prevent tissue damage. Results are expressed as the mean \pm SEM of the observers'
546 counts.

547 ***In vivo* cold hypoesthesia**

548 Mice from the chronic model of oxaliplatin-induced peripheral neuropathies were subjected to
549 weekly tests for cold hypoesthesia which was evaluated using temperature settings previously
550 described⁶⁸. Briefly, mice were put on the cold/hot plate set at $4^{\circ}\text{C} \pm 0.2^{\circ}\text{C}$ for 5 minutes. Similar,
551 to the test assessing cold hyperalgesia, the total number of brisk lifts from either hind paw or jumps
552 was counted simultaneously by two observers to ensure accuracy and averaged for the two
553 observers' counts. Results are expressed as the mean \pm SEM of the observers' counts.

554 ***In vivo* tactile hypoesthesia**

555 Mice from both the chronic oxaliplatin-induced and the diabetic models underwent weekly tests for
556 mechanical allodynia with the von Frey method⁸⁴, a standardized protocol assessing tactile

557 sensitivity⁸⁵. A set of 20 monofilaments based on the Semmes Weinstein monofilament set was
558 used (Model: Bio-VF-M, Bioseb, USA/Canada). The Semmes Weinstein set of monofilaments
559 provides an approximate logarithmic scale of actual force, and a linear scale of perceived intensity.
560 Briefly, mice were put on a mesh grid, an enclosed by a clear plexiglass barrier with a top cover and
561 left to calm down for 5 minutes. After the settling phase, mice are motionless allowing the
562 experimenter to touch their hind paws with a flexible plastic fiber of a fixed diameter. The fiber is
563 pressed through the mesh against the plantar surface at a right angle. The force of application
564 increases as long as the investigator pushes the probe and until the fiber bends. The scale of force
565 used ranged from 0.008 to 1.400 g. The threshold to perception of probing was asserted to the
566 movement of pulling back of either hind paw. Based on observations on control animals (vehicle-
567 injected or non-diabetic mice), the end-point for testing was set when a fiber tended to raise the
568 entire limb rather than to buckle.

569 ***In vivo* hot hyperesthesia**

570 Mice from the diabetic model of peripheral neuropathies underwent a weekly assessment of thermal
571 hyperalgesia according to a previously published study protocol²⁹. The same equipment as for cold
572 sensitivity was used for this experiment. The plate was set at $55^{\circ}\text{C} \pm 0.2^{\circ}\text{C}$. Latency to hind paw
573 licking or jumping was recorded simultaneously by two observers with a timer and time to response
574 was averaged for the two counts. To prevent tissue damage a cutoff time of 30 seconds was
575 implemented.

576 ***In vivo* electrophysiological exploration of neuromuscular and sensory excitability**

577 The sensory and/or neuromuscular excitability was assessed *in vivo* on mice under isoflurane
578 (AErrane®) anesthesia by minimally invasive electrophysiological methods using the Qtrac©
579 software (Prof. H. Bostock, Institute of Neurology, London, England), as previously described⁸³.
580 Briefly, an anaesthetized mouse was placed on a heating pad to maintain body temperature (from
581 36.02 ± 0.06 to 36.13 ± 0.04 , $n = 85$) throughout the experiments to avoid non-specific
582 modifications of excitability variables.

583 For neuromuscular excitability exploration, electrical stimulation was delivered to the sciatic motor
584 nerve by means of surface electrodes, and the compound muscle action potential (CMAP) was
585 recorded using needle electrodes inserted into the plantar muscle. Each mouse was systematically
586 submitted to one session of excitability measurements (TRONDE protocol), which consisted of five
587 different excitability tests performed together: (C0) The stimulus-response relationship (*i.e.* the
588 CMAP amplitude as a function of the intensity of a 1-ms stimulation) evaluated notably both the
589 CMAP maximal amplitude and the stimulation intensity that had to be applied to evoke a CMAP of
590 50% maximal amplitude, giving information on the global neuromuscular excitability state. (C1)
591 The current-threshold relationship evaluated the threshold changes at the end of 200-ms
592 conditioning subthreshold depolarizing and hyperpolarizing currents ranging from 50 to 100%
593 thresholds, giving information on axonal accommodation capacities to depolarizations and
594 hyperpolarizations. (C2) The strength-duration relationship (*i.e.*, the intensity in relation to the
595 duration of a stimulus necessary to evoke a given amplitude of CMAP) evaluated the minimal
596 intensity of infinitely long duration stimulation necessary to evoke a CMAP (rheobase) and the
597 intensity duration of twice the rheobase stimulation necessary to evoke a CMAP (chronaxis), giving
598 information on the axonal resting potential at the nodal membrane. (C3) The threshold electrotonus
599 (*i.e.*, the threshold changes during and after 100-ms conditioning subthreshold depolarizing and
600 hyperpolarizing currents applied at $\pm 40\%$ thresholds) evaluated the electrotonic changes in
601 membrane potential, giving also information on axonal accommodation capacities to

602 depolarizations and hyperpolarizations. (C4) The recovery cycle (*i.e.*, the excitability changes that
603 occur following a CMAP) evaluated the refractory periods (during which membrane excitability is
604 either nil or markedly decreased) followed by the supernormal and late subnormal periods (during
605 which membrane excitability is increased and decreased, respectively). As a whole, more than thirty
606 variables were determined from these excitability tests and analyzed. Most of them provide specific
607 and complementary information on the density and functional state of ion channels, receptors and
608 pumps, as well as on the passive membrane properties of the neuromuscular system^{86,87}.

609 For sensory excitability exploration, the compound nerve action potential (CNAP) was recorded
610 using needle electrodes inserted into the base of the tail, in response to stimulation of the caudal
611 nerve applied at the distal part of the tail by means of surface electrodes. Each mouse was
612 systematically and only submitted to the first session of excitability measurements (TRONDE
613 protocol) to establish the stimulus-response relationship (*i.e.*, the CNAP amplitude as a function of
614 the intensity of a 1-ms stimulation) and thus, evaluate notably the CNAP maximal amplitude, the
615 stimulation intensity that had to be applied to evoke a CNAP of 50% maximal amplitude and the
616 latency measured from stimulation onset to peak amplitude, giving information on the global
617 sensory excitability state.

618 ***In vitro* electrophysiological exploration of sensory excitability**

619
620 *In vitro* electrophysiological exploration of sensory excitability was performed by recording the
621 action potential from primary cultures of mouse dorsal root ganglia (DRG) sensory neurons, using
622 the patch-clamp technique. After being removed from the spinal cord of euthanized adult female
623 Swiss mice (10-12 weeks of age and 28-32 g body weight, purchased from Janvier Elevage and
624 housed at the CEA animal facility), DRG were placed in iced-Ham's F-12 medium (Sigma-Aldrich,
625 Saint-Quentin Fallavier, France) and enzymatically dissociated with collagenase type IA (2 mg/mL;
626 Sigma-Aldrich) and dispase (5 mg/mL; Gibco, Thermo Fisher Scientific, Villebon-sur-Yvette,
627 France). Neurons were then plated on 12-mm glass coverslips placed in a 24-wells plate coated with
628 10 µg/mL of poly-D-lysine and 100 µg/mL of murin laminin (Sigma-Aldrich). The cells were
629 maintained in culture at 37°C (in 95% air and 5% CO₂) in Neurobasal A medium (Gibco)
630 containing horse serum (5%; Gibco), penicillin/streptomycin (47.64 U/mL; Gibco), nerve growth
631 factor (83.33 ng/mL; Sigma-Aldrich), N2 supplement (3.18x; Gibco), Dulbecco's PBS (1X) w/o
632 CaCl₂ and MgCl₂ (1.68%; Gibco), bovine serum albumin (16.83 µg/mL; Sigma-Aldrich),
633 corticosteron (214.85 nM; Sigma-Aldrich), T3 hormone (56.06 nM; Sigma-Aldrich) and L-
634 glutamine (1.90 mM; Sigma-Aldrich). Cytosine β-D-arabinofuranoside (2 µM; Sigma-Aldrich) was
635 added to the culture medium, 24 h later, to stop proliferation of satellite glial cells. Experiments
636 were carried out within 2 to 6 days after cell plating. The day of their use, the neurons plated on
637 coverslips were transferred, for a minimum of 30 min at 37°C prior to patch-clamp recordings, in
638 35-mm Petri dishes filled with a standard physiological medium of the following composition (in
639 mM): NaCl 134, KCl 3, CaCl₂ 1, MgCl₂ 1, D-glucose 20, and HEPES 20 (pH 7.35, adjusted with
640 NaOH), and then in the recording bath filled with the standard physiological medium.

641 Whole-cell patch-clamp experiments were performed under current-clamp condition, by using a
642 MultiClamp 700B integrating patch-clamp amplifier and the pClamp10.6 software (Molecular
643 Devices, Sunnyvale, CA, USA), as previously described⁸⁸. The signals, acquired at a 4-kHz sample
644 rate, were filtered at 2 kHz with a low-pass Bessel filter and digitized with the aid of a computer
645 equipped with an analog-to-digital converter (Digidata-1440A model; Molecular Devices). The
646 patch-clamp pipettes were filled with a medium composed of (in mM): KCl 134, NaCl 10, MgCl₂ 2,

647 EGTA 2, ATP-Na₂ 4, and HEPES 20 (pH 7.32, adjusted with KOH), and had 2.71 ± 0.25 M Ω
648 resistance (n = 18) in the standard physiological medium. A fast superfusion system allowed
649 changing the solution [standard physiological medium without or with oxaliplatin (25-50 μ M) alone
650 or oxaliplatin (25-50 μ M) plus benztropine (10 μ M)] around the recorded cell within a few seconds.
651 The experiments were carried out at constant room temperature (22°C). Action potentials were
652 elicited, at a frequency of 0.5 Hz, by 100-ms current test-pulses of -0.2 to 1 nA (in 0.1-nA
653 increments) applied 200 ms after 200-ms current pre-pulses of -0.1 nA (to check the membrane
654 passive properties of neurons, mainly membrane capacitance).

655 ***Ex vivo* confocal microscopy morphological study of sciatic nerves**

656 The experiments were carried out on single myelinated axons isolated from the sciatic nerves of
657 euthanized mice, as previously detailed⁸³. Briefly, sciatic nerve sections of about 2 cm in length
658 were removed from their sheaths, dissected, and fixed for 1h in PBS 1X with 2%
659 paraformaldehyde, then rinsed three times with PBS. Sciatic nerves were deposited on microscope
660 slides, myelinated axons were gently teased apart from the main trunk, and preparations were kept
661 at -20°C until use. Just before the experiments, sciatic nerves were rehydrated for about 1 h with a
662 standard physiological solution containing (in mM): NaCl 154, KCl 5, CaCl₂ 2, MgCl₂ 1, glucose
663 11, and HEPES 5 (pH 7.4, adjusted with NaOH. Preparations were then exposed for 30 min to the
664 fluorescent dye FM1-43 (Molecular Probes) dissolved in a standard physiological solution to stain
665 the plasma membranes of the myelinated axons, and washed with dye-free solution before imaging.
666 A Zeiss LSM 510 META (Carl Zeiss) multiphoton scanning confocal microscope, mounted on an
667 upright microscope and controlled with the manufacturer’s software and workstation, was used for
668 optical sectioning of myelinated axons and subsequent 3D high-resolution digital reconstruction of
669 their structure. Images were collected using a 63x oil-immersion objective with a 1.40 numerical
670 aperture (Zeiss Plan-Apochromat); following excitation of FM1-43 with the 488 nm wavelength
671 line of an Argon ion laser, and then digitized at 12-bit resolution into a 512 x 512 pixel array.
672 Images were then analyzed using the ImageJ software (National Institutes of Health - NIH).
673 Quantification of morphometric parameters of myelinated axons were performed by measuring the
674 internodal diameter, nodal diameter (D) and nodal length (L). Assuming the simplest geometry in
675 which a node of Ranvier approaches a cylinder, the nodal volume (V) was then determined as $V =$
676 $\pi L(D/2)^2$.

677 ***Ex vivo* electronic microscopy morphological study of sciatic nerves**

678 Mice were anesthetized by intraperitoneal injections of 100 mg/kg ketamine and 10 mg/kg xylazine
679 and then intracardially perfused with first, 0.1 M PBS, pH 7.4, for 8 min and then 4%
680 paraformaldehyde, 2.5% glutaraldehyde, and 0.1 M PBS, pH 7.4. Mice were euthanized after
681 complete rigidity of the lower limbs and liver (endpoint of the perfusion). Tissues were dissected
682 24h later and immersed in the fixative solution at 4°C for 72h, washed in PBS, post-fixed in 2%
683 osmium tetroxide, dehydrated in graded ethanol, and embedded in epoxy resin. Ultrathin sections
684 (50–90 nm) were cut on an ultramicrotome (8800 Ultratome III; LKB Bromma) and collected on
685 300-mesh nickel grids. Staining was performed on drops of 4% aqueous uranyl acetate, followed by
686 Reynolds lead citrate. Ultrastructural analyses were performed in a JEOL JEM-1011 electron
687 microscope and digitalized with Digital Micrograph software. G-ratios and axon diameters were
688 calculated with the ImageJ software (National Institutes of Health) and the plugin g-ratio version
689 3.2 (Plug-in and source code available online at <http://gratio.efil.de>) according to previously
690 published material⁸⁹. Diameters were calculated from enclosed areas, considering first, the
691 diameter of the axon without the myelin and dividing it by the diameter of the axon plus the myelin

692 sheaths surrounding it. The plugin allows for semi-automated analysis of randomly selected fibers
693 with both diameters being considered and automatically processed through the algorithm to
694 calculate the g-ratio. A minimum of 500 randomly selected axons were analyzed per experimental
695 group, with at least 3 mice per group.

696 ***Ex vivo* study of myelin protein content in sciatic nerves**

697 Nerves were extracted in lysis buffer containing a cocktail of proteinase and phosphatase inhibitors
698 using a glass homogenizer. Protein lysate samples (40g) were resolved on 10% SDS-PAGE gels
699 and transferred by electrophoresis to nitrocellulose membranes. The membranes were blocked for
700 non-specific binding sites at room temperature in TBS buffer containing 0.1% Tween 20 and 5%
701 nonfat dried milk for 1 h. The membranes were then incubated overnight at 4°C with a primary
702 antibody against MBP (1:500; Merck). Subsequently, the membranes were incubated with an anti-
703 rabbit IgG, horseradish peroxidase linked whole antibody from donkey (1:1000; GE Healthcare Life
704 Sciences NA934, Little Chalfont, UK) and subjected to ECL reagent treatment. After film exposure,
705 all membranes were washed and then incubated with a 1:50,000 dilution of mouse monoclonal anti-
706 actin-peroxidase antibody (Sigma Aldrich; Saint Louis, Missouri, USA) as previously described
707 ⁹⁰. The images were captured using a CCD camera (LAS3000 from Fujifilm), and the bands were
708 quantified using MultiGauge software from Fujifilm.

709 ***Ex vivo* study of cutaneous nerve fiber density**

710 Sections of skin from the hind paws of mice were preserved in buffered 4% formol (VWR
711 Chemicals, Labonord SAS, France) and immersed in successive baths of increasing concentrations
712 of ethanol (50%, 70%, 90%, 100%). Samples were then immersed in histosol before being fixed in
713 paraffin, kept at 4°C and cut into 6 µm-thick slices. Samples were then unwaxed in three successive
714 baths of histosol for 3 min and rehydrated in ethanol baths for 1 min each, starting with two baths of
715 pure ethanol followed with baths of 90%, 70% and 30% ethanol and two baths of H₂O. Slides were
716 then washed in PBS for 2 min before being immersed in citrate buffer at 95°C for 10 min. Samples
717 were washed in 3 baths of PBS of 5 min each. Samples were then permeabilized (PBS, 0.25%
718 Triton X-100) for 10 min before being rinsed in PBS in 3 baths of 5 min each and immersed in a
719 blocking solution (PBS, 10% goat serum, 1% BSA) for at least 180 min. Samples were further
720 incubated at 4°C overnight in the primary antibody (Abcam, ab10404, rabbit polyclonal to PGP9.5,
721 1:1000) before being rinsed in PBS in 3 baths of 5 min each before incubating in the secondary
722 antibody (Sigma, F9887, anti-rabbit IgG FITC-conjugate, 1:1000) at room temperature in the dark.
723 Prior to mounting (Thermo Scientific, Shandon Immuno-Mount), slides were washed with PBS in 3
724 baths of 5 min each. Images were collected using a Nikon Eclipse 80i microscope with a Nikon
725 PlanFluor 100x/1.30 oil-immersion DIC H/N2 objective.

726 ***Ex vivo* study of systemic inflammatory markers**

727 Blood samples were taken under isoflurane from the retro-orbital sinus immediately before
728 sacrifice, centrifuged at 10.000 rpm and 2°C. Sera were diluted (1:4) in ELISA/ELISPOT diluent
729 1X before being distributed on ELISA 96-well plates specific of IL-6 and Tumor necrosis factor
730 alpha (TNF-α; Mouse IL-6 ELISA Ready-SET-Go!® and Mouse TNF ELISA Ready-SET-Go!® -
731 eBioscience, San Diego, CA, USA). Concentrations were calculated from a standard curve
732 according to the manufacturer's protocol.

733 ***In vivo* study of antitumor activity of benztropine upon association with chemotherapy**

734 A total of 1.10⁶ viable CT26 cells, as determined by trypan blue staining, and resuspended in
735 DMEM were injected subcutaneously into the back of the mice. When tumors reached a mean size

736 of 200 to 500 mm³, animals were randomized and received a single weekly injection of either
737 oxaliplatin (10 mg/kg) or vehicle. Concomitantly, mice received vehicle or benztropine (10 mg/kg)
738 every day. Following randomization, tumor size was measured with a numeric caliper twice a week
739 for 3 weeks. In order to comply with ethical guidelines, tumor growth experiments were stopped
740 three weeks after the first oxaliplatin injection. Tumor volume was calculated as follows: TV (mm³)
741 = $(L \times W^2)/2$, where L is the longest and W the shortest radius of the tumor in millimeters. Results
742 are expressed as mean \pm SD of tumor volumes ($n = 7$ in each group).

743 **Viability and ROS assays**

744 All cells (2×10^4 per well) were seeded in 96-well plates (Sigma-Aldrich, Saint-Quentin Fallavier
745 France) and incubated for 24 h with 7.5 to 30 μ M of benztropine (Sigma-Aldrich, Saint-Quentin
746 Fallavier France) and treated with 0 to 100 μ M of oxaliplatin (Accord Healthcare Limited, Lille,
747 France). Cell viability was assessed by a crystal violet assay, and results are expressed as the mean
748 percentage of viable cells \pm SEM versus cells not exposed to oxaliplatin (100% viability). Cellular
749 production of ROS and reduced glutathione (GSH) were assessed by spectrofluorimetry with 2',7'-
750 dichlorodihydrofluorescein diacetate (H2DCFDA, #6883 Sigma-Aldrich, Saint-Quentin Fallavier
751 France) and monochlorobimane (#69899 Sigma-Aldrich), respectively⁶⁹.

752 **Statistical analysis**

753 Statistical analysis was performed using GraphPad Prism 5. Artwork, was also created using
754 GraphPad Prism 5, except for electrophysiological study artwork which was created using the
755 Qtrac© software. Differences between values were tested using the unpaired Student's t -test, two-
756 way ANOVA, or the nonparametric Mann-Whitney U test, depending on the equality of variances
757 estimated using Lilliefors test. They were considered significant when $p < 0.05$, p values being
758 denoted as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$; NS: non-significant.

759


760 **References**

- 761 1. Seretny, M. *et al.* Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A
762 systematic review and meta-analysis. *Pain* **155**, 2461–2470 (2014).
- 763 2. Brewer, J. R., Morrison, G., Dolan, M. E. & Fleming, G. F. Chemotherapy-induced peripheral neuropathy:
764 Current status and progress. *Gynecol. Oncol.* **140**, 176–183 (2016).
- 765 3. Grisold, W., Cavaletti, G. & Windebank, A. J. Peripheral neuropathies from chemotherapeutics and targeted
766 agents: diagnosis, treatment, and prevention. *Neuro-Oncol.* **14 Suppl 4**, iv45-54 (2012).
- 767 4. de Gramont, A. *et al.* Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in
768 advanced colorectal cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **18**, 2938–2947 (2000).
- 769 5. André, T. *et al.* Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N. Engl. J.*
770 *Med.* **350**, 2343–2351 (2004).
- 771 6. Wagner, A. D. *et al.* Chemotherapy for advanced gastric cancer. *Cochrane Database Syst. Rev.* **8**, CD004064
772 (2017).
- 773 7. Iqbal, A. & George, T. J. Randomized Clinical Trials in Colon and Rectal Cancer. *Surg. Oncol. Clin. N. Am.*
774 **26**, 689–704 (2017).
- 775 8. Loprinzi, C. L. *et al.* Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and
776 magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). *J. Clin. Oncol. Off. J. Am.*
777 *Soc. Clin. Oncol.* **32**, 997–1005 (2014).
- 778 9. Pulvers, J. N. & Marx, G. Factors associated with the development and severity of oxaliplatin-induced
779 peripheral neuropathy: a systematic review. *Asia Pac. J. Clin. Oncol.* (2017). doi:10.1111/ajco.12694
- 780 10. Cavaletti, G., Alberti, P. & Marmiroli, P. Chemotherapy-induced peripheral neurotoxicity in the era of
781 pharmacogenomics. *Lancet Oncol.* **12**, 1151–1161 (2011).
- 782 11. Bakogeorgos, M. & Georgoulas, V. Risk-reduction and treatment of chemotherapy-induced peripheral
783 neuropathy. *Expert Rev. Anticancer Ther.* **17**, 1045–1060 (2017).


- 784 12. Imai, S. *et al.* Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. *Sci. Rep.* **7**,
785 5947 (2017).
- 786 13. Carozzi, V. A., Canta, A. & Chiorazzi, A. Chemotherapy-induced peripheral neuropathy: What do we know
787 about mechanisms? *Neurosci. Lett.* **596**, 90–107 (2015).
- 788 14. Sima, A. A. F. & Zhang, W. Mechanisms of diabetic neuropathy: axon dysfunction. *Handb. Clin. Neurol.* **126**,
789 429–442 (2014).
- 790 15. Heinen, A., Lehmann, H. C. & Küry, P. Negative regulators of schwann cell differentiation—novel targets for
791 peripheral nerve therapies? *J. Clin. Immunol.* **33 Suppl 1**, S18–26 (2013).
- 792 16. Feldman, E. L., Bennett, D. L. H., Nave, K.-A. & Jensen, T. S. New Horizons in Diabetic Neuropathy:
793 Mechanisms, Bioenergetics, and Pain. *Neuron* **93**, 1296–1313 (2017).
- 794 17. Gonçalves, N. P. *et al.* Schwann cell interactions with axons and microvessels in diabetic neuropathy. *Nat.*
795 *Rev. Neurol.* **13**, 135–147 (2017).
- 796 18. Lehmann, H. C. & Höke, A. Schwann cells as a therapeutic target for peripheral neuropathies. *CNS Neurol.*
797 *Disord. Drug Targets* **9**, 801–806 (2010).
- 798 19. Gonçalves, N. P., Vægter, C. B. & Pallesen, L. T. Peripheral Glial Cells in the Development of Diabetic
799 Neuropathy. *Front. Neurol.* **9**, (2018).
- 800 20. Deshmukh, V. A. *et al.* A regenerative approach to the treatment of multiple sclerosis. *Nature* **502**, 327–332
801 (2013).
- 802 21. Caulfield, M. P. Muscarinic receptors—characterization, coupling and function. *Pharmacol. Ther.* **58**, 319–379
803 (1993).
- 804 22. Wess, J. *et al.* Muscarinic receptor subtypes mediating central and peripheral antinociception studied with
805 muscarinic receptor knockout mice: a review. *Life Sci.* **72**, 2047–2054 (2003).
- 806 23. Sittl, R., Carr, R. W., Schwarz, J. R. & Grafe, P. The Kv7 potassium channel activator flupirtine affects
807 clinical excitability parameters of myelinated axons in isolated rat sural nerve. *J. Peripher. Nerv. Syst. JPNS*
808 **15**, 63–72 (2010).
- 809 24. Fujii, T. Expression and Function of the Cholinergic System in Immune Cells. - PubMed - NCBI. 6;8:1085
810 (2017).
- 811 25. Kawashima, K. & Fujii, T. Extraneuronal cholinergic system in lymphocytes. *Pharmacol. Ther.* **86**, 29–48
812 (2000).
- 813 26. Cheng, K., Shang, A. C., Drachenberg, C. B., Zhan, M. & Raufman, J.-P. Differential expression of M3
814 muscarinic receptors in progressive colon neoplasia and metastasis. *Oncotarget* **8**, 21106–21114 (2017).
- 815 27. Spindel, E. R. Muscarinic Receptor Agonists and Antagonists: Effects on Cancer. *Handb. Exp. Pharmacol.*
816 451–468 (2012). doi:10.1007/978-3-642-23274-9_19
- 817 28. Yu, H. *et al.* Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes
818 gastric cancer cell proliferation. *Sci. Rep.* **7**, 40802 (2017).
- 819 29. Ulugol, A. *et al.* 5-HT7 receptor activation attenuates thermal hyperalgesia in streptozocin-induced diabetic
820 mice. *Pharmacol. Biochem. Behav.* **102**, 344–348 (2012).
- 821 30. Watson, J. C. & Dyck, P. J. B. Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom
822 Management. *Mayo Clin. Proc.* **90**, 940–951 (2015).
- 823 31. Mendell, J. Painful Sensory Neuropathy. *N. Engl. J. Med.* **Volume: 348 Issue 13 (2003)**, 13 (2003).
- 824 32. Doughty, C. T. & Seyedsadjadi, R. Approach to Peripheral Neuropathy for the Primary Care Clinician. *Am. J.*
825 *Med.* (2018). doi:10.1016/j.amjmed.2017.12.042
- 826 33. Vinik, A. I., Casellini, C. & Névoret, M.-L. Alternative Quantitative Tools in the Assessment of Diabetic
827 Peripheral and Autonomic Neuropathy. in *International Review of Neurobiology* (eds. Calcutt, N. A. &
828 Fernyhough, P.) **127**, 235–285 (Academic Press, 2016).
- 829 34. Adelsberger, H. *et al.* The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat
830 sensory neurons. *Eur. J. Pharmacol.* **406**, 25–32 (2000).
- 831 35. Webster, R. G., Brain, K. L., Wilson, R. H., Grem, J. L. & Vincent, A. Oxaliplatin induces hyperexcitability at
832 motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. *Br. J.*
833 *Pharmacol.* **146**, 1027–1039 (2005).
- 834 36. Benoit, E., Brienza, S. & Dubois, J. M. Oxaliplatin, an anticancer agent that affects both Na⁺ and K⁺ channels
835 in frog peripheral myelinated axons. *Gen. Physiol. Biophys.* **25**, 263–276 (2006).
- 836 37. Park, B., Kim, K., Rhee, D. & Pyo, S. The apoptotic effect of allicin in MCF-7 human breast cancer cells: role
837 for ATF3. *FASEB J.* **26**, 1b367–1b367 (2012).
- 838 38. Sittl, R. *et al.* Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel
839 subtype Na(V)1.6-resurgent and persistent current. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 6704–6709 (2012).

- 840 39. Deuis, J. R. *et al.* An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in
841 peripheral pain pathways. *Pain* **154**, 1749–1757 (2013).
- 842 40. Cantrell, A. R., Ma, J. Y., Scheuer, T. & Catterall, W. A. Muscarinic modulation of sodium current by
843 activation of protein kinase C in rat hippocampal neurons. *Neuron* **16**, 1019–1026 (1996).
- 844 41. Wu, D.-F. *et al.* PKC ϵ phosphorylation of the sodium channel NaV1.8 increases channel function and
845 produces mechanical hyperalgesia in mice. *J. Clin. Invest.* **122**, 1306–1315 (2012).
- 846 42. Laedermann, C. J., Abriel, H. & Decosterd, I. Post-translational modifications of voltage-gated sodium
847 channels in chronic pain syndromes. *Front. Pharmacol.* **6**, (2015).
- 848 43. Kamei, N. *et al.* Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage
849 recruitment and insulin resistance. *J. Biol. Chem.* **281**, 26602–26614 (2006).
- 850 44. Kagiava, A., Tsingotjidou, A., Emmanouilides, C. & Theophilidis, G. The effects of oxaliplatin, an anticancer
851 drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. *Neurotoxicology* **29**,
852 1100–1106 (2008).
- 853 45. Passmore, G. & Brown, D. Effects of M-channel modulators on peripheral excitability in rat hairy skin. *Soc.*
854 *Neurosci. Abstr* 681.8 (2007).
- 855 46. Lang, P. M., Fleckenstein, J., Passmore, G. M., Brown, D. A. & Grafe, P. Retigabine reduces the excitability
856 of unmyelinated peripheral human axons. *Neuropharmacology* **54**, 1271–1278 (2008).
- 857 47. Brown, D. A. & Passmore, G. M. Neural KCNQ (Kv7) channels. *Br. J. Pharmacol.* **156**, 1185–1195 (2009).
- 858 48. Loreti, S. *et al.* Rat Schwann cells express M1-M4 muscarinic receptor subtypes. *J. Neurosci. Res.* **84**, 97–105
859 (2006).
- 860 49. Fields, R. D., Dutta, D. J., Belgrad, J. & Robnett, M. Cholinergic signaling in myelination. *Glia* **65**, 687–698
861 (2017).
- 862 50. Rawlins, F. A. & Villegas, J. Autoradiographic localization of acetylcholine receptors in the Schwann cell
863 membrane of the squid nerve fiber. *J. Cell Biol.* **77**, 371–376 (1978).
- 864 51. Verdiyev, E. E., Allakhverdiyev, E. S. & Maksimov, G. V. Study of the Peripheral Nerve Fibers Myelin
865 Structure Changes during Activation of Schwann Cell Acetylcholine Receptors. *PloS One* **11**, e0158083
866 (2016).
- 867 52. Calcutt, N. A. *et al.* Selective antagonism of muscarinic receptors is neuroprotective in peripheral neuropathy.
868 *J. Clin. Invest.* **127**, 608–622 (2017).
- 869 53. Keswani, S. C. *et al.* Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons.
870 *Ann. Neurol.* **54**, 287–296 (2003).
- 871 54. Cunha, T. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. - PubMed -
872 NCBI. 1;102(5):1755-60 (2005).
- 873 55. Scholz, J. & Woolf, C. J. The neuropathic pain triad: neurons, immune cells and glia. *Nat. Neurosci.* **10**, 1361–
874 1368 (2007).
- 875 56. Flatters, S. J. L. & Bennett, G. J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral
876 neuropathy: evidence for mitochondrial dysfunction. *Pain* **122**, 245–257 (2006).
- 877 57. Verstappen, C. C. P., Heimans, J. J., Hoekman, K. & Postma, T. J. Neurotoxic complications of chemotherapy
878 in patients with cancer: clinical signs and optimal management. *Drugs* **63**, 1549–1563 (2003).
- 879 58. Marchand, F., Perretti, M. & McMahon, S. B. Role of the immune system in chronic pain. *Nat. Rev. Neurosci.*
880 **6**, 521–532 (2005).
- 881 59. Peters, C. M. *et al.* Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy
882 characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. *Exp. Neurol.*
883 **203**, 42–54 (2007).
- 884 60. Melemedjian, O. K. *et al.* Local translation and retrograde axonal transport of CREB regulates IL-6-induced
885 nociceptive plasticity. *Mol. Pain* **10**, 45 (2014).
- 886 61. Vazquez, E. *et al.* Spinal interleukin-6 is an amplifier of arthritic pain in the rat. *Arthritis Rheum.* **64**, 2233–
887 2242 (2012).
- 888 62. Starkweather, A. Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral
889 neuropathy in women after breast cancer treatment. *Nurs. Res. Pract.* **2010**, 281531 (2010).
- 890 63. Kellogg, A. P. *et al.* Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve
891 dysfunction and intraepidermal nerve fiber loss in experimental diabetes. *Diabetes* **56**, 2997–3005 (2007).
- 892 64. Shi, X., Chen, Y., Nadeem, L. & Xu, G. Beneficial effect of TNF- α inhibition on diabetic peripheral
893 neuropathy. *J. Neuroinflammation* **10**, 69 (2013).
- 894 65. Felton, J., Hu, S. & Raufman, J.-P. Targeting M3 Muscarinic Receptors for Colon Cancer Therapy. *Curr. Mol.*
895 *Pharmacol.* (2018). doi:10.2174/1874467211666180119115828

- 896 66.Urrunaga, N. H. *et al.* M1 muscarinic receptors modify oxidative stress response to acetaminophen-induced
897 acute liver injury. *Free Radic. Biol. Med.* **78**, 66–81 (2015).
- 898 67.Mangelus, M., Kroyter, A., Galron, R. & Sokolovsky, M. Reactive oxygen species regulate signaling pathways
899 induced by M1 muscarinic receptors in PC12M1 cells. *J. Neurochem.* **76**, 1701–1711 (2001).
- 900 68.Coriat, R. *et al.* Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. *J. Clin.*
901 *Invest.* **124**, 262–272 (2014).
- 902 69.Laurent, A. *et al.* Controlling tumor growth by modulating endogenous production of reactive oxygen species.
903 *Cancer Res.* **65**, 948–956 (2005).
- 904 70.Alexandre, J. *et al.* Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase
905 mimic mangafodipir. *J. Natl. Cancer Inst.* **98**, 236–244 (2006).
- 906 71.Morales, M.-C. *et al.* Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the
907 antineoplastic agent N-(4-hydroxyphenyl) retinamide. *Anticancer Res.* **25**, 1945–1951 (2005).
- 908 72.Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical
909 therapeutic approach? *Nat. Rev. Drug Discov.* **8**, 579–591 (2009).
- 910 73.González-Reyes, S., Guzmán-Beltrán, S., Medina-Campos, O. N. & Pedraza-Chaverri, J. Curcumin
911 pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary
912 cultures of cerebellar granule neurons of rats. *Oxid. Med. Cell. Longev.* **2013**, 801418 (2013).
- 913 74.Belrose, J. C., Xie, Y.-F., Gierszewski, L. J., MacDonald, J. F. & Jackson, M. F. Loss of glutathione
914 homeostasis associated with neuronal senescence facilitates TRPM2 channel activation in cultured
915 hippocampal pyramidal neurons. *Mol. Brain* **5**, 11 (2012).
- 916 75.Bains, J. S. & Shaw, C. A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-
917 mediated neuronal death. *Brain Res. Brain Res. Rev.* **25**, 335–358 (1997).
- 918 76.Sagara, M. *et al.* Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats
919 with N-acetylcysteine. *Diabetologia* **39**, 263–269 (1996).
- 920 77.Cascinu, S. *et al.* Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in
921 advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. *J. Clin. Oncol. Off. J. Am.*
922 *Soc. Clin. Oncol.* **20**, 3478–3483 (2002).
- 923 78.Lehky, T. J., Leonard, G. D., Wilson, R. H., Grem, J. L. & Floeter, M. K. Oxaliplatin-induced neurotoxicity:
924 acute hyperexcitability and chronic neuropathy. *Muscle Nerve* **29**, 387–392 (2004).
- 925 79.Renn, C. L. *et al.* Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-
926 based chemotherapy in mice. *Mol. Pain* **7**, 29 (2011).
- 927 80.Ta, L. E., Low, P. A. & Windebank, A. J. Mice with cisplatin and oxaliplatin-induced painful neuropathy
928 develop distinct early responses to thermal stimuli. *Mol. Pain* **5**, 9 (2009).
- 929 81.Toyama, S. *et al.* Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and
930 differential effects of a novel mitochondria-targeted antioxidant on the neuropathies. *Anesthesiology* **120**, 459–
931 473 (2014).
- 932 82.Jack, M. M., Ryals, J. M. & Wright, D. E. Protection from diabetes-induced peripheral sensory neuropathy--a
933 role for elevated glyoxalase I? *Exp. Neurol.* **234**, 62–69 (2012).
- 934 83.Cerles, O. *et al.* Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer
935 Therapeutic Response. *Mol. Cancer Ther.* **16**, 300–311 (2017).
- 936 84.Lopes, L. C. G. *et al.* Beyond weakness: Characterization of pain, sensory profile and conditioned pain
937 modulation in patients with motor neuron disease: A controlled study. *Eur. J. Pain Lond. Engl.* **22**, 72–83
938 (2018).
- 939 85.Miraucourt, L. S., Moisset, X., Dallel, R. & Voisin, D. L. Glycine Inhibitory Dysfunction Induces a
940 Selectively Dynamic, Morphine-Resistant, and Neurokinin 1 Receptor- Independent Mechanical Allodynia. *J.*
941 *Neurosci.* **29**, 2519–2527 (2009).
- 942 86.Kiernan, M. C., Burke, D., Andersen, K. V. & Bostock, H. Multiple measures of axonal excitability: a new
943 approach in clinical testing. *Muscle Nerve* **23**, 399–409 (2000).
- 944 87.Krishnan, A. V., Lin, C. S.-Y., Park, S. B. & Kiernan, M. C. Assessment of nerve excitability in toxic and
945 metabolic neuropathies. *J. Peripher. Nerv. Syst. JPNS* **13**, 7–26 (2008).
- 946 88.Schlumberger, S. *et al.* Permeability characteristics of cell-membrane pores induced by ostreolysin
947 A/pleurotolysin B, binary pore-forming proteins from the oyster mushroom. *FEBS Lett.* **588**, 35–40 (2014).
- 948 89.Goebbels, S. *et al.* Elevated Phosphatidylinositol 3,4,5-Trisphosphate in Glia Triggers Cell-Autonomous
949 Membrane Wrapping and Myelination. *J. Neurosci.* **30**, 8953–8964 (2010).
- 950 90.Liu, Z. *et al.* Specific marker expression and cell state of Schwann cells during culture in vitro. *PloS One* **10**,
951 e0123278 (2015).



Supplementary Figure 1. Benztropine prevents the *in vivo* effects induced by oxaliplatin on mouse neuromuscular excitability curves. Excitability curves (means \pm SD) were recorded at the plantar muscle in response to sciatic motor nerve stimulation of mice treated for 6 weeks with vehicle (black circles, $n = 18$), oxaliplatin (white circles, $n = 14$, left panels), oxaliplatin plus benztropine (white circles, $n = 10$, middle panels) or benztropine alone (white circles, $n = 13$, right panels). (C1) Current-threshold relationship [excitability modifications in response to depolarizing (up) and hyperpolarizing (down) currents], (C2) strength-duration relationship, (C3) threshold electrotonus in response to constant depolarizing (up) and hyperpolarizing (down) long-duration currents applied at sub-threshold intensity ($\pm 40\%$), and (C4) recovery cycle. Note the absence of effect of oxaliplatin plus benztropine and benztropine alone, *versus* vehicle, on excitability waveforms.



Supplementary Figure 2. Benztropine prevents the *in vivo* effects induced by diabetes on mouse neuromuscular excitability curves. Excitability curves (means \pm SD) were recorded at the plantar muscle in response to sciatic motor nerve stimulation of mice treated for 6 weeks with non-diabetic vehicle (black circles, n = 18), diabetic vehicle (white circles, n = 16, left panels), and diabetic benztropine (white circles, n = 14, right panels). (C1) Current-threshold relationship [excitability modifications in response to depolarizing (up) and hyperpolarizing (down) currents], (C2) strength-duration relationship, (C3) threshold electrotonus in response to constant depolarizing (up) and hyperpolarizing (down) long-duration currents applied at sub-threshold intensity (\pm 40%), and (C4) recovery cycle. Note the absence of effect of diabetic benztropine, *versus* non-diabetic vehicle, on excitability waveforms.

Supplementary Table 1. Benztropine prevents the *in vivo* effects induced by oxaliplatin and diabetes on mouse neuromuscular excitability variables. Variables (means ± SD) derived from excitability curves established from plantar muscle recordings in response to sciatic motor nerve stimulation of mice treated with vehicle (n = 18), oxaliplatin (n = 14), oxaliplatin plus benztropine (n = 10), diabetic vehicle (n = 16), diabetic benztropine (n = 14) or benztropine alone (n = 13) for 6 weeks.

	Vehicle	Oxaliplatin	Oxaliplatin + Benztropine	Diabetic Vehicle	Diabetic Benztropine	Benztropine
C0 06. Peak response (mV)	3.21 ± 1.11	4.24 ± 1.12*	2.87 ± 1.18	5.57 ± 1.10**	3.40 ± 1.19	2.85 ± 1.18
C0 19. Latency (ms)	3.07 ± 0.10	3.01 ± 0.12	3.16 ± 0.17	3.38 ± 0.08	3.06 ± 0.11	2.75 ± 0.08
C0 01. Stimulus (mA) for 50% max response	0.25 ± 0.05	0.18 ± 0.04***	0.22 ± 0.09	0.20 ± 0.06*	0.24 ± 0.04	0.32 ± 0.08
C0 05. Stimulus-response slope	3.23 ± 1.09	3.25 ± 1.15	3.30 ± 1.31	2.84 ± 1.12	3.06 ± 1.10	4.24 ± 1.17
C1 07. Resting slope	0.95 ± 0.05	0.96 ± 0.03	1.03 ± 0.18	0.95 ± 0.09	0.91 ± 0.05	1.15 ± 0.23
C1 08. Minimum slope	0.51 ± 0.03	0.30 ± 0.01*	0.63 ± 0.17	0.27 ± 0.01*	0.46 ± 0.07	0.37 ± 0.03
C1 28. Hyperpolarizing slope	1.63 ± 0.08	0.50 ± 0.03**	2.08 ± 1.06	0.44 ± 0.06**	1.62 ± 0.07	1.09 ± 1.00
C2 03. Strength-duration time constant (ms)	0.43 ± 0.02	0.45 ± 0.04	0.49 ± 0.06	0.43 ± 0.04	0.43 ± 0.03	0.37 ± 0.03
C2 04. Rheobase (mA)	0.16 ± 1.04	0.16 ± 1.07	0.14 ± 1.08	0.15 ± 1.08	0.17 ± 1.05	0.17 ± 1.07
C3 12. TE _d (10-20 ms)	47.97 ± 2.17	49.87 ± 1.52	43.66 ± 3.15	62.88 ± 2.86***	52.04 ± 2.97	41.98 ± 2.30
C3 25. TE _d (peak)	49.48 ± 2.05	50.15 ± 1.38	45.87 ± 2.79	62.49 ± 2.68**	52.52 ± 2.56	44.66 ± 1.78
C3 20. TE _d (40-60 ms)	36.81 ± 1.56	37.45 ± 1.06	32.17 ± 2.48	47.97 ± 2.39**	40.24 ± 2.30	31.77 ± 1.96
C3 21. TE _d (90-100 ms)	34.24 ± 1.63	34.68 ± 1.09	28.06 ± 3.22	40.16 ± 2.07*	34.65 ± 2.08	29.66 ± 1.83
C3 26. S ₂ accommodation	15.25 ± 1.20	15.48 ± 0.79	18.14 ± 1.71	22.33 ± 0.88***	17.87 ± 1.11	14.00 ± 0.93
C3 23. TE _d (undershoot)	-9.53 ± 1.03	-11.74 ± 0.78	-11.38 ± 1.29	-19.15 ± 1.39****	-13.61 ± 0.76**	-11.05 ± 0.89
C3 22. TE _h (10-20 ms)	-71.52 ± 3.91	-78.37 ± 1.77*	-73.64 ± 5.76	-79.42 ± 2.17	-72.19 ± 3.41	-67.96 ± 3.62
C3 30. TE _h (20-40 ms)	-81.21 ± 5.06	-92.88 ± 2.60*	-81.81 ± 7.49	-92.71 ± 3.07	-83.18 ± 5.18	-77.66 ± 4.64
C3 11. TE _h (90-100 ms)	-83.88 ± 8.32	-104.90 ± 4.42*	-81.59 ± 11.90	-110.20 ± 6.13*	-94.17 ± 7.78	-88.14 ± 6.24
C3 24. TE _h (overshoot)	9.16 ± 0.91	8.09 ± 0.76	9.25 ± 1.07	16.26 ± 1.50***	11.09 ± 1.07	6.34 ± 0.98
C4 32. Refractoriness at 2 ms (%)	22.60 ± 3.77	28.84 ± 3.25	18.69 ± 10.40	30.07 ± 3.44	15.07 ± 11.20	19.60 ± 3.27
C4 29. Refractoriness at 2.5 ms (%)	10.24 ± 3.13	12.77 ± 2.32	13.09 ± 8.23	13.47 ± 1.65	9.55 ± 8.56	9.31 ± 1.94
C4 34. Superexcitability at 5 ms (%)	-7.78 ± 1.35	-0.43 ± 1.33**	-3.95 ± 2.11	-3.10 ± 1.63*	-7.39 ± 3.46	-5.99 ± 1.02
C4 33. Superexcitability at 7 ms (%)	-4.81 ± 1.54	1.96 ± 0.99**	-0.74 ± 1.70	-1.31 ± 1.03*	-4.37 ± 2.38	-3.08 ± 1.14
C4 14. Subexcitability (%)	6.75 ± 0.72	6.30 ± 0.33	8.35 ± 1.93	6.19 ± 0.33	6.45 ± 0.82	6.09 ± 0.67

(C0) Stimulus-response relationship, (C1) current-threshold relationship, (C2) strength-duration relationship, (C3) threshold electrotonus in response to constant depolarizing (TE_d) and hyperpolarizing (TE_h) long-duration currents applied at sub-threshold intensity (± 40%), and (C4) recovery cycle. **p* < 0.05, ***p* < 0.01, ****p* < 0.001, and *****p* < 0.0001 *versus* vehicle (highlighted in grey). Note that, compared to vehicle; most if not all variables modified with oxaliplatin and diabetic vehicle remain unchanged with oxaliplatin plus benztropine, diabetic benztropine or benztropine alone.

Supplementary Table 2. Comparison of morphometric parameters. Mean values ± SD of morphometric parameters of single myelinated axons isolated from sciatic nerves of mice injected with vehicle, oxaliplatin, oxaliplatin plus benztropine or benztropine alone, for 6 weeks (137-206 axons from 4 different mice under each condition). **P* = 0.011-0.049, ***P* = 0.006 and ****P* < 0.0001 *versus* vehicle (highlighted in grey).

Morphometric parameters	Vehicle	Oxaliplatin	Oxaliplatin + Benztropine	Benztropine
Internodal diameter (Di, in μm)	7.19 ± 0.25	6.33 ± 0.20 **	7.71 ± 0.23	7.85 ± 0.21
Nodal diameter (D, in μm)	2.32 ± 0.08	2.62 ± 0.11 *	2.49 ± 0.11	2.49 ± 0.08
Nodal length (L, in μm)	1.03 ± 0.03	1.44 ± 0.06 ***	1.12 ± 0.03 *	1.16 ± 0.04 *
Nodal volume (V, in μm ³)	6.07 ± 0.44	15.06 ± 1.77 ***	8.51 ± 0.92 *	7.98 ± 0.82
D/Di	0.33 ± 0.01	0.40 ± 0.01 ***	0.33 ± 0.01	0.32 ± 0.01
L/Di	0.15 ± 0.01	0.23 ± 0.01 ***	0.18 ± 0.01	0.16 ± 0.01
V/Di	0.70 ± 0.04	1.67 ± 0.14 ***	0.89 ± 0.08 *	0.86 ± 0.06 *

Résumé des résultats obtenus

L'évaluation multimodale des propriétés d'excitabilité sensorielle, *in vivo* chez des souris anesthésiées ayant reçu des injections intrapéritonéales hebdomadaires d'oxaliplatine (10 mg/kg) pendant 6 semaines, révèle des modifications traduisant une hyperexcitabilité membranaire et une diminution de la vitesse de conduction nerveuse, ce qui suggère une réduction du nombre de fibres à conduction rapide ou une diminution de la densité et/ou du fonctionnement des canaux Na_v , et une modification de la dépendance vis-à-vis du potentiel de ces canaux. L'évaluation multimodale des propriétés d'excitabilité neuromusculaire, *in vivo* chez ces mêmes souris et chez des souris diabétiques (*i.e.* ayant subi une injection de 180 mg/kg de streptozotocine), révèle également des modifications compatibles avec une hyperexcitabilité membranaire et suggérant une modification de la dépendance vis-à-vis du potentiel des canaux Na_v ainsi qu'une diminution de la densité et/ou du fonctionnement des canaux K_v , sans que la vitesse de transmission neuromusculaire ne soit affectée. Ces modifications n'apparaissent pas chez des souris ayant subi des administrations conjointes d'oxaliplatine (10 mg/kg) et de benztropine (10 mg/kg) et sont considérablement réduites chez des souris diabétiques ayant subi des administrations de benztropine (10 mg/kg).

De plus, l'étude morphologique *ex vivo* des nerfs sciatiques isolés de souris ayant subi les injections d'oxaliplatine, par une exploration au microscope confocal, met en évidence une diminution du diamètre internodal des axones myélinisés, ce qui suggère fortement une perte préférentielle des fibres de gros diamètre, *i.e.* à conduction rapide (voir ci-dessus). Cette diminution du diamètre internodal est associée notamment à une augmentation de la longueur nodale, ce qui traduit une démyélinisation axonale. Cette démyélinisation axonale est confirmée par l'exploration au microscope électronique des nerfs sciatiques et par l'étude de l'expression de la protéine basique de la myéline (MBP pour "myelin basic protein") réalisées par l'équipe du Pr. Batteux. Ces altérations n'apparaissent pas ou sont considérablement réduites chez les souris ayant subi des administrations conjointes d'oxaliplatine et de benztropine.

Finalement, les effets de l'oxaliplatine et de la benztropine ont été également évalués *in vitro* sur les potentiels d'action enregistrés à partir de cultures primaires de neurones sensoriels de DRG de souris, à l'aide de la technique de patch clamp en configuration "cellule entière". Les modifications détectées en présence d'oxaliplatine (25-50 μ M) traduisent, là encore, une hyperexcitabilité membranaire: (i) un potentiel de repos membranaire moins négatif d'environ 20 mV (dépolarisation membranaire), (ii) une diminution de l'intensité du courant nécessaire pour évoquer un nombre accru de potentiels d'action répétitifs, et (iii) une diminution de l'amplitude maximale et une augmentation de la durée des phases ascendante et descendante des potentiels d'action. Ces

modifications, indiquant des altérations de la densité et/ou du fonctionnement des canaux Na_v et K_v , n'apparaissent pas en présence d'oxaliplatine (50 μ M) et de benztropine (10 μ M).

La neuroprotection conférée par la benztropine est associée à une expression plus faible de cytokines inflammatoires et à une diminution de la croissance tumorale expliquée, au moins en partie, par un déséquilibre des espèces réactives de l'oxygène dans les cellules tumorales (études réalisées par l'équipe du Pr. Batteux).

Conclusion

La benztropine, un inhibiteur des récepteurs muscariniques M1-M3 de l'acétylcholine, améliore les symptômes de neuropathies périphériques dues à la chimiothérapie (oxaliplatine) et au diabète, chez des modèles expérimentaux de souris, et augmente l'effet antitumoral de l'oxaliplatine. Ces résultats pourraient être à court terme transposables aux patients puisque la benztropine est actuellement indiquée pour traiter la maladie de Parkinson aux États-Unis et a donc déjà obtenu une autorisation de mise sur le marché par la FDA.

Titre : Evaluation multi-échelle de toxines de venins comme agents antinociceptifs potentiels

Mots clés : toxines de venins, antinociception, canaux sodium dépendants du potentiel, électrophysiologie

Résumé: L'objectif de ma thèse était d'identifier, comme agents antinociceptifs potentiels, des toxines de venins originales par leur séquence et/ou leur provenance. Dans cette optique, un criblage à haut débit de deux banques de venins a été réalisé par des méthodes électrophysiologiques de "patch-clamp" automatique, sur des lignées cellulaires exprimant le sous-type neuronal hNav1.7 de canaux sodium (*versus* celles exprimant le sous-type cardiaque hNav1.5), une cible antidouleur validée génétiquement et fortement exprimée au niveau des neurones sensoriels primaires des ganglions de la racine dorsale, premier support de la transmission du message nociceptif.

Le criblage de la première banque de venins (appartenant à Smartox Biotechnology) a permis l'identification et la caractérisation, par des approches structurales et fonctionnelles multi-échelles (de la cellule *in vitro* à l'organisme *in vivo*), de 2 peptides de venins d'araignées ayant des propriétés potentiellement antinociceptives :

(1) la cyriotoxine-1a du venin de *Cyriopagopus schioedtei*, dont les propriétés fonctionnelles sont proches de celles des peptides appartenant à la famille 1 des toxines d'araignées inhibant les canaux sodium, et (2) la poecitoxine-1a du venin de *Poecilotheria subfusca*, qui présente une meilleure affinité pour le sous-type hCa_v1.2 de canaux calcium que pour le sous-type hNa_v1.7. Nous avons également mené une étude de "structure-activité" afin d'améliorer le profil de sélectivité de la phlotoxine-1 d'une araignée *Phlogiellus*, connue pour son activité antinociceptive. Finalement, nous avons mis en évidence une interaction directe entre l'huwentoxine-IV, déjà connue comme agent antinociceptif potentiel, et le sous-type neuronal Na_v1.6, responsable d'effets neuromusculaires indésirables. Le criblage de la deuxième banque de venins (appartenant à SANOFI) a permis d'identifier des *hits* intéressants provenant de venins d'araignées et de scorpions non étudiés jusqu'à présent et ayant une séquence originale présentant peu d'homologie avec les séquences déjà connues.

Title : Multiscale evaluation of venom toxins as potential antinociceptive agents

Keywords : venom toxins, antinociception, voltage-dependent sodium channels, electrophysiology

Abstract: The aim of my thesis was to identify original venom toxins, by their sequence and/or origin, as potential antinociceptive agents. In this context, a high-throughput screening of two venom libraries was performed, by automated patch-clamp electrophysiology, on cell lines expressing the hNav1.7 neuronal subtype of sodium channels (*versus* those expressing the hNav1.5 cardiac subtype), a genetically-validated and strongly expressed pain target in the primary sensory neurons of dorsal root ganglia, the first support of nociceptive message transmission.

The screening of the first venom library (belonging to Smartox Biotechnology) allowed the identification and characterization, by structural and multiscale functional approaches (from the cell *in vitro* to the organism *in vivo*), of 2 peptides from spider venoms having potential antinociceptive properties : (1) cyriotoxin-1a from

Cyriopagopus schioedtei venom, whose functional properties are close to those of peptides belonging to family 1 of spider toxins inhibiting sodium channels, and (2) poecitoxin-1a from *Poecilotheria subfusca* venom, which has a better affinity for the hCa_v1.2 subtype of calcium channels than for the hNav1.7 subtype. We also conducted a "structure-activity" study to improve the selectivity profile of phlotoxin-1 from a *Phlogiellus* spider, known for its antinociceptive activity. Finally, we evidenced a direct interaction between huwentoxin-IV, already known as a potential antinociceptive agent, and the Na_v1.6 neuronal subtype which is the main cause of undesirable neuromuscular effects. The screening of the second venom library (belonging to SANOFI) allowed to identify interesting hits from spider and scorpion venoms, not studied until now, having an original sequence with little homology with already known sequences.

